@prefix ns1: <https://1145.am/db/> .
@prefix org: <http://www.w3.org/ns/org#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://1145.am/db/2231462/Leonard_Green___Partners_Lp> a org:Organization ;
    ns1:basedInLowRaw "NEW YORK" ;
    ns1:buyer <https://1145.am/db/2231462/Prospect_Medical_Holdings_Inc_Acquisition> ;
    ns1:documentDate "2010-08-18T15:34:49+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Shareholder Update: Investigation of Acquisition of Prospect Medical by Tripp Levy PLLC" ;
    ns1:documentURL <https://www.fiercehealthcare.com/healthcare/shareholder-update-investigation-acquisition-prospect-medical-by-tripp-levy-pllc> ;
    ns1:foundName "Leonard Green & Partners, L.P." ;
    ns1:name "Leonard Green & Partners, L.P." ;
    ns1:sameAsMedium <https://1145.am/db/1282379/Leonard_Green___Partners_Lp>,
        <https://1145.am/db/1282540/Leonard_Green___Partners_Lp>,
        <https://1145.am/db/1283645/Leonard_Green___Partners_Lp>,
        <https://1145.am/db/1283922/Leonard_Green___Partners_Lp>,
        <https://1145.am/db/1992597/Leonard_Green___Partners_Lp>,
        <https://1145.am/db/2023792/Leonard_Green___Partners_Lp>,
        <https://1145.am/db/2023851/Leonard_Green___Partners_Lp>,
        <https://1145.am/db/2231463/Leonard_Green___Partners_Lp>,
        <https://1145.am/db/2231466/Leonard_Green___Partners_Lp>,
        <https://1145.am/db/2267153/Leonard_Green___Partners>,
        <https://1145.am/db/226913/Leonard_Green___Partners_Lp>,
        <https://1145.am/db/417305/Leonard_Green___Partners>,
        <https://1145.am/db/422170/Leonard_Green___Partners_Lp>,
        <https://1145.am/db/425292/Leonard_Green___Partners_Lp>,
        <https://1145.am/db/426192/Leonard_Green___Partners_Lp>,
        <https://1145.am/db/443794/Leonard_Green___Partners_Lp>,
        <https://1145.am/db/443962/Leonard_Green___Partners>,
        <https://1145.am/db/444728/Leonard_Green___Partners_Lp>,
        <https://1145.am/db/446781/Leonard_Green___Partners_Lp>,
        <https://1145.am/db/447069/Leonard_Green___Partners_Lp>,
        <https://1145.am/db/547965/Leonard_Green___Partners>,
        <https://1145.am/db/661944/Leonard_Green___Partners_Lp>,
        <https://1145.am/db/800849/Leonard_Green___Partners> ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2231462/Tripp_Levy_Pllc> a org:Organization ;
    ns1:basedInHighGeoName "New York City" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5128581/about.rdf> ;
    ns1:basedInHighRaw "NEW YORK" ;
    ns1:documentDate "2010-08-18T15:34:49+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Shareholder Update: Investigation of Acquisition of Prospect Medical by Tripp Levy PLLC" ;
    ns1:documentURL <https://www.fiercehealthcare.com/healthcare/shareholder-update-investigation-acquisition-prospect-medical-by-tripp-levy-pllc> ;
    ns1:foundName "Tripp Levy PLLC" ;
    ns1:investor <https://1145.am/db/2231462/Prospect_Medical_Holdings_Inc_Acquisition> ;
    ns1:name "Tripp Levy PLLC" ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2235296/Fca_Venture_Partners> a org:Organization ;
    ns1:basedInLowRaw "Tenn" ;
    ns1:description "Venture capital" ;
    ns1:documentDate "2010-09-09T18:02:35+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Entrada Completes Series A Funding" ;
    ns1:documentURL <https://www.fiercehealthcare.com/healthcare/entrada-completes-series-a-funding> ;
    ns1:foundName "FCA Venture Partners" ;
    ns1:investor <https://1145.am/db/2235296/Investment_Entrada_Entrada_Silicon_Valley_Bank_Completed> ;
    ns1:name "FCA Venture Partners" ;
    ns1:sameAsHigh <https://1145.am/db/1592338/Fca_Venture_Partners>,
        <https://1145.am/db/1594929/Fca_Venture_Partners> ;
    ns1:sameAsMedium <https://1145.am/db/1239790/Fca_Venture_Partners>,
        <https://1145.am/db/221002/Fca_Venture_Partners> ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2235296/Silicon_Valley_Bank> a org:Organization ;
    ns1:basedInLowRaw "Tenn" ;
    ns1:documentDate "2010-09-09T18:02:35+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Entrada Completes Series A Funding" ;
    ns1:documentURL <https://www.fiercehealthcare.com/healthcare/entrada-completes-series-a-funding> ;
    ns1:foundName "Silicon Valley Bank" ;
    ns1:investor <https://1145.am/db/2235296/Investment_Entrada_Entrada_Silicon_Valley_Bank_Completed> ;
    ns1:name "Silicon Valley Bank" ;
    ns1:sameAsMedium <https://1145.am/db/1083805/Silicon_Valley_Bank>,
        <https://1145.am/db/1150348/Silicon_Valley_Bank>,
        <https://1145.am/db/1152132/Silicon_Valley_Bank>,
        <https://1145.am/db/1152410/Silicon_Valley_Bank>,
        <https://1145.am/db/1156520/Silicon_Valley_Bank>,
        <https://1145.am/db/1156858/Silicon_Valley_Bank>,
        <https://1145.am/db/1157082/Silicon_Valley_Bank>,
        <https://1145.am/db/1322428/Silicon_Valley_Bank>,
        <https://1145.am/db/1322978/Silicon_Valley_Bank>,
        <https://1145.am/db/1323008/Silicon_Valley_Bank>,
        <https://1145.am/db/1364929/Silicon_Valley_Bank>,
        <https://1145.am/db/1406733/Silicon_Valley_Bank>,
        <https://1145.am/db/1407485/Silicon_Valley_Bank>,
        <https://1145.am/db/1459745/Silicon_Valley_Bank>,
        <https://1145.am/db/1459827/Silicon_Valley_Bank>,
        <https://1145.am/db/1459870/Silicon_Valley_Bank>,
        <https://1145.am/db/1488514/Silicon_Valley_Bank>,
        <https://1145.am/db/1541570/Silicon_Valley_Bank>,
        <https://1145.am/db/1593099/Silicon_Valley_Bank>,
        <https://1145.am/db/1593638/Silicon_Valley_Bank>,
        <https://1145.am/db/1593923/Silicon_Valley_Bank>,
        <https://1145.am/db/1632797/Silicon_Valley_Bank>,
        <https://1145.am/db/1642059/Silicon_Valley_Bank>,
        <https://1145.am/db/1642619/Silicon_Valley_Bank>,
        <https://1145.am/db/1667921/Silicon_Valley_Bank>,
        <https://1145.am/db/1698574/Silicon_Valley_Bank>,
        <https://1145.am/db/1713202/Silicon_Valley_Bank>,
        <https://1145.am/db/1741357/Silicon_Valley_Bank>,
        <https://1145.am/db/1742374/Silicon_Valley_Bank>,
        <https://1145.am/db/1743415/Silicon_Valley_Bank>,
        <https://1145.am/db/1754583/Silicon_Valley_Bank>,
        <https://1145.am/db/1763293/Silicon_Valley_Bank>,
        <https://1145.am/db/1763925/Silicon_Valley_Bank>,
        <https://1145.am/db/1764096/Silicon_Valley_Bank>,
        <https://1145.am/db/1770095/Silicon_Valley_Bank>,
        <https://1145.am/db/1772737/Silicon_Valley_Bank>,
        <https://1145.am/db/1773924/Silicon_Valley_Bank>,
        <https://1145.am/db/1774323/Silicon_Valley_Bank>,
        <https://1145.am/db/1776688/Silicon_Valley_Bank>,
        <https://1145.am/db/1779266/Silicon_Valley_Bank>,
        <https://1145.am/db/1786720/Silicon_Valley_Bank>,
        <https://1145.am/db/1788937/Silicon_Valley_Bank>,
        <https://1145.am/db/1790917/Silicon_Valley_Bank>,
        <https://1145.am/db/1797945/Silicon_Valley_Bank>,
        <https://1145.am/db/1798154/Silicon_Valley_Bank>,
        <https://1145.am/db/1800466/Silicon_Valley_Bank>,
        <https://1145.am/db/1801332/Silicon_Valley_Bank>,
        <https://1145.am/db/1801801/Silicon_Valley_Bank>,
        <https://1145.am/db/1802212/Silicon_Valley_Bank>,
        <https://1145.am/db/1805339/Silicon_Valley_Bank>,
        <https://1145.am/db/1811789/Silicon_Valley_Bank>,
        <https://1145.am/db/1815709/Silicon_Valley_Bank>,
        <https://1145.am/db/1816776/Silicon_Valley_Bank>,
        <https://1145.am/db/1826128/Silicon_Valley_Bank>,
        <https://1145.am/db/1835585/Silicon_Valley_Bank>,
        <https://1145.am/db/1835823/Silicon_Valley_Bank>,
        <https://1145.am/db/1838850/Silicon_Valley_Bank>,
        <https://1145.am/db/1844083/Silicon_Valley_Bank>,
        <https://1145.am/db/1847903/Silicon_Valley_Bank>,
        <https://1145.am/db/1850081/Silicon_Valley_Bank>,
        <https://1145.am/db/1851311/Silicon_Valley_Bank>,
        <https://1145.am/db/1851910/Silicon_Valley_Bank>,
        <https://1145.am/db/1859520/Silicon_Valley_Bank>,
        <https://1145.am/db/1865990/Silicon_Valley_Bank>,
        <https://1145.am/db/1870276/Silicon_Valley_Bank>,
        <https://1145.am/db/1879085/Silicon_Valley_Bank>,
        <https://1145.am/db/1885748/Silicon_Valley_Bank>,
        <https://1145.am/db/1892674/Silicon_Valley_Bank>,
        <https://1145.am/db/1910560/Silicon_Valley_Bank>,
        <https://1145.am/db/1920478/Silicon_Valley_Bank>,
        <https://1145.am/db/1930908/Silicon_Valley_Bank>,
        <https://1145.am/db/1934634/Silicon_Valley_Bank_Uk_Limited>,
        <https://1145.am/db/1934658/Silicon_Valley_Bank>,
        <https://1145.am/db/1934735/Silicon_Valley_Bank>,
        <https://1145.am/db/1934736/Silicon_Valley_Bank>,
        <https://1145.am/db/1934742/Silicon_Valley_Bank_Uk>,
        <https://1145.am/db/1934843/Silicon_Valley_Bank>,
        <https://1145.am/db/1935125/Silicon_Valley_Bank>,
        <https://1145.am/db/1935154/Silicon_Valley_Bank>,
        <https://1145.am/db/1935871/Silicon_Valley_Bank>,
        <https://1145.am/db/1935994/Silicon_Valley_Bank>,
        <https://1145.am/db/1937022/Silicon_Valley_Bank>,
        <https://1145.am/db/1939035/Silicon_Valley_Bank>,
        <https://1145.am/db/1941577/Silicon_Valley_Bank>,
        <https://1145.am/db/1942037/Silicon_Valley_Bank>,
        <https://1145.am/db/1943030/Silicon_Valley_Bank>,
        <https://1145.am/db/1947358/Silicon_Valley_Bank>,
        <https://1145.am/db/1947401/Silicon_Valley_Bank>,
        <https://1145.am/db/1949094/Silicon_Valley_Bank>,
        <https://1145.am/db/1949839/Silicon_Valley_Bank>,
        <https://1145.am/db/1950157/Silicon_Valley_Bank>,
        <https://1145.am/db/1950194/Silicon_Valley_Bank>,
        <https://1145.am/db/1950239/Silicon_Valley_Bank>,
        <https://1145.am/db/1951636/Silicon_Valley_Bank>,
        <https://1145.am/db/1955045/Silicon_Valley_Bank>,
        <https://1145.am/db/2002123/Silicon_Valley_Bank>,
        <https://1145.am/db/2038928/Silicon_Valley_Bank>,
        <https://1145.am/db/2073939/Silicon_Valley_Bank>,
        <https://1145.am/db/2075411/Silicon_Valley_Bank>,
        <https://1145.am/db/2115567/Silicon_Valley_Bank>,
        <https://1145.am/db/2163392/Silicon_Valley_Bank>,
        <https://1145.am/db/2170076/Silicon_Valley_Bank>,
        <https://1145.am/db/2189022/Silicon_Valley_Bank>,
        <https://1145.am/db/2192716/Silicon_Valley_Bank>,
        <https://1145.am/db/2206103/Silicon_Valley_Bank>,
        <https://1145.am/db/2248746/Silicon_Valley_Bank>,
        <https://1145.am/db/2281936/Silicon_Valley_Bank>,
        <https://1145.am/db/2288016/Silicon_Valley_Bank>,
        <https://1145.am/db/2297263/Silicon_Valley_Bank>,
        <https://1145.am/db/2302085/Silicon_Valley_Bank>,
        <https://1145.am/db/2302707/Silicon_Valley_Bank>,
        <https://1145.am/db/2306687/Silicon_Valley_Bank>,
        <https://1145.am/db/2307820/Silicon_Valley_Bank>,
        <https://1145.am/db/2328616/Silicon_Valley_Bank>,
        <https://1145.am/db/2331928/Silicon_Valley_Bank>,
        <https://1145.am/db/2332435/Silicon_Valley_Bank>,
        <https://1145.am/db/2341774/Silicon_Valley_Bank>,
        <https://1145.am/db/2342734/Silicon_Valley_Bank>,
        <https://1145.am/db/2344593/Silicon_Valley_Bank>,
        <https://1145.am/db/2364404/Silicon_Valley_Bank>,
        <https://1145.am/db/2430644/Silicon_Valley_Bank>,
        <https://1145.am/db/2752043/Silicon_Valley_Bank>,
        <https://1145.am/db/2752829/Silicon_Valley_Bank>,
        <https://1145.am/db/366024/Silicon_Valley_Bank>,
        <https://1145.am/db/490152/Silicon_Valley_Bank>,
        <https://1145.am/db/490991/Silicon_Valley_Bank>,
        <https://1145.am/db/563676/Silicon_Valley_Bank>,
        <https://1145.am/db/596524/Silicon_Valley_Bank>,
        <https://1145.am/db/658338/Silicon_Valley_Bank>,
        <https://1145.am/db/714643/Silicon_Valley_Bank>,
        <https://1145.am/db/880050/Silicon_Valley_Bank>,
        <https://1145.am/db/941028/Silicon_Valley_Bank>,
        <https://1145.am/db/980498/Silicon_Valley_Bank>,
        <https://1145.am/db/996844/Silicon_Valley_Bank>,
        <https://1145.am/db/998845/Silicon_Valley_Bank> ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2235312/Altaris_Capital_Partners> a org:Organization ;
    ns1:buyer <https://1145.am/db/2235312/Brim_Holdings_Businesses_Acquisition> ;
    ns1:description "healthcare" ;
    ns1:documentDate "2010-09-10T14:02:57+00:00"^^xsd:dateTime ;
    ns1:documentTitle "IASIS Healthcare to Acquire Brim Holdings, Inc." ;
    ns1:documentURL <https://www.fiercehealthcare.com/healthcare/iasis-healthcare-to-acquire-brim-holdings-inc> ;
    ns1:foundName "Altaris Capital Partners" ;
    ns1:name "Altaris Capital Partners" ;
    ns1:sameAsHigh <https://1145.am/db/1537549/Amulet_Capital_Partners>,
        <https://1145.am/db/2322679/Amulet_Capital_Partners>,
        <https://1145.am/db/471415/Amulet_Capital_Partners_Ii>,
        <https://1145.am/db/935236/Amulet_Capital_Partners> ;
    ns1:sameAsMedium <https://1145.am/db/1084742/Altaris_Capital_Partners_Llc>,
        <https://1145.am/db/2295973/Altaris_Capital_Partners>,
        <https://1145.am/db/2296931/Altaris_Capital_Partners>,
        <https://1145.am/db/2298583/Altaris_Capital_Partners>,
        <https://1145.am/db/2327077/Altaris_Capital_Partners>,
        <https://1145.am/db/2334957/Altaris_Capital_Partners>,
        <https://1145.am/db/252316/Altaris_Capital_Partners>,
        <https://1145.am/db/2554838/Altaris_Capital_Partners>,
        <https://1145.am/db/2564219/Altaris_Capital_Partners>,
        <https://1145.am/db/2580057/Altaris_Capital_Partners>,
        <https://1145.am/db/495687/Altaris_Capital_Partners>,
        <https://1145.am/db/497819/Altaris_Capital_Partners>,
        <https://1145.am/db/708834/Altaris_Capital_Partners>,
        <https://1145.am/db/710146/Altaris_Capital_Partners>,
        <https://1145.am/db/80589/Altaris_Capital_Partners_Llc> ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2235312/Iasis_Healthcare> a org:Organization ;
    ns1:basedInHighGeoName "Franklin County" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/4623574/about.rdf> ;
    ns1:basedInHighRaw "FRANKLIN, Tenn." ;
    ns1:buyer <https://1145.am/db/2235312/Brim_Holdings_Businesses_Acquisition>,
        <https://1145.am/db/2235312/Pikes_Peak_Regional_Hospital_Acquisition> ;
    ns1:description "Healthcare" ;
    ns1:documentDate "2010-09-10T14:02:57+00:00"^^xsd:dateTime ;
    ns1:documentTitle "IASIS Healthcare to Acquire Brim Holdings, Inc." ;
    ns1:documentURL <https://www.fiercehealthcare.com/healthcare/iasis-healthcare-to-acquire-brim-holdings-inc> ;
    ns1:foundName "IASIS",
        "IASIS Healthcare" ;
    ns1:industry "Healthcare" ;
    ns1:name "IASIS Healthcare" ;
    ns1:sameAsHigh <https://1145.am/db/1027574/Iks_Health>,
        <https://1145.am/db/1028108/Iks_Health>,
        <https://1145.am/db/1330218/Imre>,
        <https://1145.am/db/1376913/Aiot_Health>,
        <https://1145.am/db/1580068/Akido>,
        <https://1145.am/db/176732/Health_Ipass>,
        <https://1145.am/db/1932959/Iks_Health>,
        <https://1145.am/db/2200414/Ims>,
        <https://1145.am/db/2206682/Ikasystems>,
        <https://1145.am/db/2228674/Ims_Health>,
        <https://1145.am/db/2229882/Ims_Health>,
        <https://1145.am/db/2232624/Iasis_Healthcare_Corporation>,
        <https://1145.am/db/2235982/Iasis_Healthcare>,
        <https://1145.am/db/2237582/Iasis_Healthcare®_Llc>,
        <https://1145.am/db/2240328/Iasis_Healthcare>,
        <https://1145.am/db/2241174/Ims_Health>,
        <https://1145.am/db/2242190/Ims_Health>,
        <https://1145.am/db/2243215/Iasis_Healthcare>,
        <https://1145.am/db/2244260/Iasis_Healthcare>,
        <https://1145.am/db/2245999/Iasis_Healthcare>,
        <https://1145.am/db/2251901/Iasis_Healthcare®_Llc>,
        <https://1145.am/db/2251918/Iasis_Healthcare>,
        <https://1145.am/db/2252334/Iasis_Healthcare>,
        <https://1145.am/db/2266528/Ims_Health>,
        <https://1145.am/db/2303640/Ims_Health_Incorporated>,
        <https://1145.am/db/2323941/Ims_Health>,
        <https://1145.am/db/2325871/Ims_Health>,
        <https://1145.am/db/2326751/Ims_Health>,
        <https://1145.am/db/2326752/Ims_Health>,
        <https://1145.am/db/2330040/Ims_Health>,
        <https://1145.am/db/2335130/Ims_Health>,
        <https://1145.am/db/2335132/Ims_Health>,
        <https://1145.am/db/2335171/Ims_Health>,
        <https://1145.am/db/2335172/Ims_Health>,
        <https://1145.am/db/2335395/Ims_Health>,
        <https://1145.am/db/2335397/Ims_Health>,
        <https://1145.am/db/2592241/Ims_Health>,
        <https://1145.am/db/331951/Imc>,
        <https://1145.am/db/346891/Imc>,
        <https://1145.am/db/348337/Imc>,
        <https://1145.am/db/747016/Healthsmart_International>,
        <https://1145.am/db/800954/Healthsmart_International> ;
    ns1:sameAsMedium <https://1145.am/db/2242437/Iasis_Healthcare®_Llc>,
        <https://1145.am/db/2242439/Iasis_Healthcare_Llc>,
        <https://1145.am/db/2242987/Iasis_Healthcare>,
        <https://1145.am/db/2245306/Iasis_Healthcare> ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2242173/Bronson_Healthcare_Group> a org:Organization ;
    ns1:basedInHighGeoName "Kalamazoo County" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/4997791/about.rdf> ;
    ns1:basedInHighRaw "Kalamazoo" ;
    ns1:basedInLowRaw "Novi, Mich" ;
    ns1:buyer <https://1145.am/db/2242173/Battle_Creek_Health_System_Share_Acquisition>,
        <https://1145.am/db/2242173/Share_Acquisition_Bronson_Healthcare_Group_Trinity_Health_Has_Not_Happened> ;
    ns1:description "health" ;
    ns1:documentDate "2010-12-15T17:57:28+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Merger will create new Michigan healthcare system" ;
    ns1:documentURL <https://www.fiercehealthcare.com/healthcare/merger-will-create-new-michigan-healthcare-system> ;
    ns1:foundName "Bronson",
        "Bronson Healthcare Group" ;
    ns1:industry "Healthcare",
        "health care" ;
    ns1:investor <https://1145.am/db/2242173/Battle_Creek_Health_System_Share_Acquisition>,
        <https://1145.am/db/2242173/Share_Investment_Bchs_Community_Partner_Bronson_Healthcare_Group_Has_Not_Happened> ;
    ns1:name "Bronson",
        "Bronson Healthcare Group" ;
    ns1:protagonist <https://1145.am/db/2242173/Stake_Merger_Battle_Creek_Health_System_Bronson_Healthcare_Group_Has_Not_Happened> ;
    ns1:sameAsHigh <https://1145.am/db/2252748/Bronson_Healthcare_Group> ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2288596/Eagle_Ventures> a org:Organization ;
    ns1:documentDate "2010-10-11T13:54:38+00:00"^^xsd:dateTime ;
    ns1:documentTitle "ALung, InfraReDx round up funding" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/alung-infraredx-round-up-funding> ;
    ns1:foundName "Eagle Ventures" ;
    ns1:investor <https://1145.am/db/2288596/Series_A_Investment_Alung_Eagle_Ventures_Completed> ;
    ns1:name "Eagle Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/2296603/Eagle_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2300746/Santé_Ventures> a org:Organization ;
    ns1:documentDate "2010-07-20T19:49:39+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Cancer Dx company Metamark rounds up $22M" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/cancer-dx-company-metamark-rounds-up-22m> ;
    ns1:foundName "Santé Ventures" ;
    ns1:investor <https://1145.am/db/2300746/Equity_Investment_Endostim_Santé_Ventures_Completed> ;
    ns1:name "Santé Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/1335370/Santé_Ventures>,
        <https://1145.am/db/1558876/Santé_Ventures>,
        <https://1145.am/db/2050386/Sante_Ventures>,
        <https://1145.am/db/2073480/Santé_Ventures>,
        <https://1145.am/db/2300218/Santé_Ventures>,
        <https://1145.am/db/2301736/Santé_Ventures>,
        <https://1145.am/db/2335675/Sante_Ventures>,
        <https://1145.am/db/2337106/Sante_Ventures>,
        <https://1145.am/db/2348967/Sante_Ventures>,
        <https://1145.am/db/494998/Santé_Ventures>,
        <https://1145.am/db/956417/Santé_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2300746/Series_B_Investment_Metamark_Genetics_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-07-20T19:49:39+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Cambridge, MA - based Metamark Genetics has raised $ 22 million in Series B funding." ;
    ns1:documentTitle "Cancer Dx company Metamark rounds up $22M" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/cancer-dx-company-metamark-rounds-up-22m> ;
    ns1:foundName "funding" ;
    ns1:name "funding" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2300746/Metamark_Genetics> ;
    ns1:targetDetails "Series B" ;
    ns1:valueRaw "$ 22 million" ;
    ns1:whereGeoName "Cambridge" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/4931972/about.rdf> ;
    ns1:whereRaw "Cambridge, MA" .

<https://1145.am/db/2341003/Vatera_Healthcare_Partners> a org:Organization ;
    ns1:basedInLowRaw "Calif" ;
    ns1:documentDate "2010-10-19T14:00:23+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Pearl Therapeutics Raises $69 Million Series C Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/pearl-therapeutics-raises-69-million-series-c-financing> ;
    ns1:foundName "Vatera Healthcare Partners" ;
    ns1:investor <https://1145.am/db/2341003/Series_C_Investment_5am_Ventures_Clarus_Ventures_New_Leaf_Venture_Partners_Pearl_Therapeutics_Inc_Vatera_Healthcare_Partners_Completed> ;
    ns1:name "Vatera Healthcare Partners" ;
    ns1:sameAsMedium <https://1145.am/db/2341005/Vatera_Healthcare>,
        <https://1145.am/db/2347397/Vatera_Healthcare_Partners_Llc>,
        <https://1145.am/db/2349120/Vatera_Healthcare_Partners>,
        <https://1145.am/db/2350011/Vatera_Healthcare_Partners>,
        <https://1145.am/db/2352277/Vatera_Healthcare_Partners>,
        <https://1145.am/db/2353256/Vatera_Healthcare_Partners>,
        <https://1145.am/db/2353260/Vatera_Healthcare_Partners>,
        <https://1145.am/db/2354004/Vatera_Healthcare_Partners>,
        <https://1145.am/db/2354009/Vatera_Healthcare_Partners_Llc>,
        <https://1145.am/db/2359662/Vatera_Healthcare_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2343041/Series_B_Equity_Investment_Dicerna_Pharmaceuticals_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-10-21T16:07:04+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Dicerna Pharmaceuticals Announces Second Close of Series B Financing.",
        "WATERTOWN, Mass., Oct 21, 2010 (BUSINESS WIRE) - Dicerna Pharmaceuticals, Inc. (Dicerna) , a second generation RNA interference (RNAi) company developing novel therapeutics utilizing its proprietary Dicer Substrate Technology (TM) and Dicer Substrate siRNA (DsiRNA) molecules, today announced a second closing of its Series B equity financing, securing an additional $ 4 million and bringing the total capital raised in this round to $ 29 million." ;
    ns1:documentTitle "Dicerna Pharmaceuticals Announces Second Close of Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/dicerna-pharmaceuticals-announces-second-close-of-series-b-financing> ;
    ns1:foundName "Financing",
        "financing" ;
    ns1:name "Financing",
        "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2343041/Dicerna_Pharmaceuticals> ;
    ns1:targetDetails "Series B",
        "equity" ;
    ns1:valueRaw "$ 29 million",
        "$ 4 million" ;
    ns1:when "2010-10-21T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "2010-Oct-21" ;
    ns1:whereGeoName "Watertown" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/4954611/about.rdf> ;
    ns1:whereRaw "WATERTOWN, Mass" .

<https://1145.am/db/2343058/Series_B_Investment_Dicerna_Pharmaceuticals_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-10-22T14:11:46+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Dicerna Pharmaceuticals Announces Second Close of Series B Financing; Securing Additional $ 4 Million.",
        "WATERTOWN, Mass.- (BUSINESS WIRE) - Dicerna Pharmaceuticals, Inc. (Dicerna) , a second generation RNA interference (RNAi) company developing novel therapeutics utilizing its proprietary Dicer Substrate TechnologyTM and Dicer Substrate siRNA (DsiRNA) molecules, today announced a second closing of its Series B equity financing, securing an additional $ 4 million and bringing the total capital raised in this round to $ 29 million." ;
    ns1:documentTitle "Dicerna Pharmaceuticals Announces Second Close of Series B Financing; Securing Additional $4 Million" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/dicerna-pharmaceuticals-announces-second-close-of-series-b-financing-securing-additional-4> ;
    ns1:foundName "Financing",
        "financing" ;
    ns1:name "Financing",
        "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2343058/Dicerna_Pharmaceuticals> ;
    ns1:targetDetails "Series B",
        "equity" ;
    ns1:valueRaw "$ 29 million",
        "$ 4 million",
        "Additional $ 4 Million" ;
    ns1:when "2010-10-21T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "10/21/2010" ;
    ns1:whereGeoName "Watertown" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/4954611/about.rdf> ;
    ns1:whereRaw "WATERTOWN, Mass" .

<https://1145.am/db/2343486/Dov_Pharmaceutical_Series_A_Investment> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-07-22T13:15:02+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Closes $ 24 Million Series A Financing and Completes Acquisition of DOV Pharmaceutical.",
        "Euthymics Bioscience, Inc. Closes $ 24 Million Series A Financing and Completes Acquisition of DOV Pharmaceutical." ;
    ns1:documentTitle "Euthymics Bioscience, Inc. Closes $24 Million Series A Financing and Completes Acquisition of DOV Pharmaceutical" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/euthymics-bioscience-inc-closes-24-million-series-a-financing-and-completes-acquisition-of> ;
    ns1:foundName "Acquisition" ;
    ns1:name "Acquisition" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2343486/Dov_Pharmaceutical> ;
    ns1:targetDetails "Series A" ;
    ns1:targetName "DOV Pharmaceutical" ;
    ns1:valueRaw "$ 24 Million" ;
    ns1:when "2010-07-22T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "2010-Jul-22" ;
    ns1:whereGeoName "Cambridge" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/4931972/about.rdf> ;
    ns1:whereRaw "CAMBRIDGE, Mass" .

<https://1145.am/db/2343486/Gbs_Venture_Partners> a org:Organization ;
    ns1:basedInLowRaw "Wisconsin" ;
    ns1:description "financing" ;
    ns1:documentDate "2010-07-22T13:15:02+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Euthymics Bioscience, Inc. Closes $24 Million Series A Financing and Completes Acquisition of DOV Pharmaceutical" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/euthymics-bioscience-inc-closes-24-million-series-a-financing-and-completes-acquisition-of> ;
    ns1:foundName "GBS Venture Partners" ;
    ns1:investor <https://1145.am/db/2343486/Series_A_Investment_Euthymics_Bioscience_Gbs_Venture_Partners_Hambrecht___Quist_Capital_Management_Novartis_Venture_Funds_State_Of_Wisconsin_Investment_Board_Completed> ;
    ns1:name "GBS Venture Partners" ;
    ns1:sameAsHigh <https://1145.am/db/2759458/Gobi_Partners_Gba> ;
    ns1:sameAsMedium <https://1145.am/db/1281079/Gbs_Venture_Partners>,
        <https://1145.am/db/1281647/Gbs_Venture_Partners>,
        <https://1145.am/db/2306568/Gbs_Venture_Partners>,
        <https://1145.am/db/2338527/Gbs_Venture_Partners>,
        <https://1145.am/db/2363535/Gbs_Venture_Partners>,
        <https://1145.am/db/2366133/Gbs_Venture_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2343486/Hambrecht___Quist_Capital_Management> a org:Organization ;
    ns1:basedInLowRaw "Wisconsin" ;
    ns1:description "investing" ;
    ns1:documentDate "2010-07-22T13:15:02+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Euthymics Bioscience, Inc. Closes $24 Million Series A Financing and Completes Acquisition of DOV Pharmaceutical" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/euthymics-bioscience-inc-closes-24-million-series-a-financing-and-completes-acquisition-of> ;
    ns1:foundName "Hambrecht & Quist Capital Management, LLC" ;
    ns1:investor <https://1145.am/db/2343486/Series_A_Investment_Euthymics_Bioscience_Gbs_Venture_Partners_Hambrecht___Quist_Capital_Management_Novartis_Venture_Funds_State_Of_Wisconsin_Investment_Board_Completed> ;
    ns1:name "Hambrecht & Quist Capital Management" ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2343486/State_Of_Wisconsin_Investment_Board> a org:Organization ;
    ns1:basedInLowRaw "Wisconsin" ;
    ns1:description "investing" ;
    ns1:documentDate "2010-07-22T13:15:02+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Euthymics Bioscience, Inc. Closes $24 Million Series A Financing and Completes Acquisition of DOV Pharmaceutical" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/euthymics-bioscience-inc-closes-24-million-series-a-financing-and-completes-acquisition-of> ;
    ns1:foundName "the State of Wisconsin Investment Board" ;
    ns1:investor <https://1145.am/db/2343486/Series_A_Investment_Euthymics_Bioscience_Gbs_Venture_Partners_Hambrecht___Quist_Capital_Management_Novartis_Venture_Funds_State_Of_Wisconsin_Investment_Board_Completed> ;
    ns1:name "State of Wisconsin Investment Board" ;
    ns1:sameAsHigh <https://1145.am/db/1794712/State_Of_Wisconsin_Investment_Board> ;
    ns1:sameAsMedium <https://1145.am/db/2356690/State_Of_Wisconsin_Investment_Board>,
        <https://1145.am/db/2369504/State_Of_Wisconsin_Investment_Board>,
        <https://1145.am/db/2556669/State_Of_Wisconsin_Investment_Board>,
        <https://1145.am/db/2583558/State_Of_Wisconsin_Investment_Board> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2343545/Alta_Partners_And_Tvm_Capital> a org:Organization ;
    ns1:basedInLowRaw "France" ;
    ns1:documentDate "2010-07-26T13:03:59+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Cerenis Therapeutics raises EUR 40 million in series C financingJean-Pierre Garnier appointed as non-executive director to the" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cerenis-therapeutics-raises-eur-40-million-series-c-financingjean-pierre-garnier-appointed> ;
    ns1:foundName "Alta Partners and TVM Capital" ;
    ns1:investor <https://1145.am/db/2343545/Series_C_Investment_Alta_Partners_And_Tvm_Capital_Cerenis_Therapeutics_Sa_Daiwa_Corporate_Investment_Edf_Ventures_Fund_For_Strategic_Investment_Healthcap_Orbimed_Sofinnova_Partners_Completed> ;
    ns1:name "Alta Partners and TVM Capital" ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2343545/Daiwa_Corporate_Investment> a org:Organization ;
    ns1:basedInLowRaw "France" ;
    ns1:documentDate "2010-07-26T13:03:59+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Cerenis Therapeutics raises EUR 40 million in series C financingJean-Pierre Garnier appointed as non-executive director to the" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cerenis-therapeutics-raises-eur-40-million-series-c-financingjean-pierre-garnier-appointed> ;
    ns1:foundName "DAIWA Corporate Investment" ;
    ns1:investor <https://1145.am/db/2343545/Series_C_Investment_Alta_Partners_And_Tvm_Capital_Cerenis_Therapeutics_Sa_Daiwa_Corporate_Investment_Edf_Ventures_Fund_For_Strategic_Investment_Healthcap_Orbimed_Sofinnova_Partners_Completed> ;
    ns1:name "DAIWA Corporate Investment" ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2343545/Edf_Ventures> a org:Organization ;
    ns1:basedInHighGeoName "Republic of France" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/3017382/about.rdf> ;
    ns1:basedInHighRaw "France" ;
    ns1:documentDate "2010-07-26T13:03:59+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Cerenis Therapeutics raises EUR 40 million in series C financingJean-Pierre Garnier appointed as non-executive director to the" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cerenis-therapeutics-raises-eur-40-million-series-c-financingjean-pierre-garnier-appointed> ;
    ns1:foundName "EDF Ventures" ;
    ns1:investor <https://1145.am/db/2343545/Series_C_Investment_Alta_Partners_And_Tvm_Capital_Cerenis_Therapeutics_Sa_Daiwa_Corporate_Investment_Edf_Ventures_Fund_For_Strategic_Investment_Healthcap_Orbimed_Sofinnova_Partners_Completed> ;
    ns1:name "EDF Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/2289616/Edf_Ventures>,
        <https://1145.am/db/2323243/Edf_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2343545/Fund_For_Strategic_Investment> a org:Organization ;
    ns1:basedInLowRaw "France" ;
    ns1:documentDate "2010-07-26T13:03:59+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Cerenis Therapeutics raises EUR 40 million in series C financingJean-Pierre Garnier appointed as non-executive director to the" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cerenis-therapeutics-raises-eur-40-million-series-c-financingjean-pierre-garnier-appointed> ;
    ns1:foundName "Fund for Strategic Investment",
        "for Strategic Investment" ;
    ns1:investor <https://1145.am/db/2343545/Series_C_Investment_Alta_Partners_And_Tvm_Capital_Cerenis_Therapeutics_Sa_Daiwa_Corporate_Investment_Edf_Ventures_Fund_For_Strategic_Investment_Healthcap_Orbimed_Sofinnova_Partners_Completed> ;
    ns1:name "Fund",
        "Fund for Strategic Investment" ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2343545/Healthcap> a org:Organization ;
    ns1:basedInHighGeoName "Ann Arbor" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/4984247/about.rdf> ;
    ns1:basedInHighRaw "Ann Arbor, MI, USA" ;
    ns1:documentDate "2010-07-26T13:03:59+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Cerenis Therapeutics raises EUR 40 million in series C financingJean-Pierre Garnier appointed as non-executive director to the" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cerenis-therapeutics-raises-eur-40-million-series-c-financingjean-pierre-garnier-appointed> ;
    ns1:foundName "HealthCap" ;
    ns1:investor <https://1145.am/db/2343545/Series_C_Investment_Alta_Partners_And_Tvm_Capital_Cerenis_Therapeutics_Sa_Daiwa_Corporate_Investment_Edf_Ventures_Fund_For_Strategic_Investment_Healthcap_Orbimed_Sofinnova_Partners_Completed> ;
    ns1:name "HealthCap" ;
    ns1:sameAsMedium <https://1145.am/db/1334395/Healthcap>,
        <https://1145.am/db/1669813/Healthcap>,
        <https://1145.am/db/2286782/Healthcap>,
        <https://1145.am/db/2291206/Healthcap>,
        <https://1145.am/db/2301093/Healthcap>,
        <https://1145.am/db/2315943/Healthcap>,
        <https://1145.am/db/2315957/Healthcap>,
        <https://1145.am/db/2336511/Healthcap>,
        <https://1145.am/db/2337599/Healthcap>,
        <https://1145.am/db/2342611/Healthcap>,
        <https://1145.am/db/2347822/Healthcap>,
        <https://1145.am/db/2354537/Healthcap>,
        <https://1145.am/db/2354540/Healthcap>,
        <https://1145.am/db/2357144/Healthcap>,
        <https://1145.am/db/2359562/Healthcap>,
        <https://1145.am/db/2364492/Healthcap>,
        <https://1145.am/db/2364517/Healthcap>,
        <https://1145.am/db/2368579/Healthcap> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2343545/Orbimed> a org:Organization ;
    ns1:basedInLowRaw "France" ;
    ns1:documentDate "2010-07-26T13:03:59+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Cerenis Therapeutics raises EUR 40 million in series C financingJean-Pierre Garnier appointed as non-executive director to the" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cerenis-therapeutics-raises-eur-40-million-series-c-financingjean-pierre-garnier-appointed> ;
    ns1:foundName "OrbiMed" ;
    ns1:investor <https://1145.am/db/2343545/Series_C_Investment_Alta_Partners_And_Tvm_Capital_Cerenis_Therapeutics_Sa_Daiwa_Corporate_Investment_Edf_Ventures_Fund_For_Strategic_Investment_Healthcap_Orbimed_Sofinnova_Partners_Completed> ;
    ns1:name "OrbiMed" ;
    ns1:sameAsMedium <https://1145.am/db/1004121/Orbimed>,
        <https://1145.am/db/1042080/Orbimed>,
        <https://1145.am/db/1086582/Orbimed>,
        <https://1145.am/db/1089269/Orbimed>,
        <https://1145.am/db/1140378/Orbimed>,
        <https://1145.am/db/1213048/Orbimed>,
        <https://1145.am/db/1334863/Orbimed>,
        <https://1145.am/db/1340338/Orbimed>,
        <https://1145.am/db/1426073/Orbimed>,
        <https://1145.am/db/1426943/Orbimed>,
        <https://1145.am/db/1608803/Orbimed>,
        <https://1145.am/db/1690914/Orbimed>,
        <https://1145.am/db/194149/Orbimed>,
        <https://1145.am/db/2032047/Orbimed>,
        <https://1145.am/db/2080575/Orbimed>,
        <https://1145.am/db/2151717/Orbimed>,
        <https://1145.am/db/2192716/Orbimed>,
        <https://1145.am/db/2198716/Orbimed>,
        <https://1145.am/db/2280770/Orbimed>,
        <https://1145.am/db/2281204/Orbimed>,
        <https://1145.am/db/2281272/Orbimed>,
        <https://1145.am/db/2283935/Orbimed>,
        <https://1145.am/db/2286207/Orbimed>,
        <https://1145.am/db/2286245/Orbimed>,
        <https://1145.am/db/2286541/Orbimed>,
        <https://1145.am/db/2288436/Orbimed>,
        <https://1145.am/db/2288529/Orbimed>,
        <https://1145.am/db/2290069/Orbimed>,
        <https://1145.am/db/2290337/Orbimed>,
        <https://1145.am/db/2290766/Orbimed>,
        <https://1145.am/db/2292284/Orbimed>,
        <https://1145.am/db/2293503/Orbimed>,
        <https://1145.am/db/2293508/Orbimed>,
        <https://1145.am/db/2293540/Orbimed>,
        <https://1145.am/db/2293893/Orbimed>,
        <https://1145.am/db/2295525/Orbimed>,
        <https://1145.am/db/2295713/Orbimed>,
        <https://1145.am/db/2297224/Orbimed>,
        <https://1145.am/db/2297507/Orbimed>,
        <https://1145.am/db/2297514/Orbimed>,
        <https://1145.am/db/2297930/Orbimed>,
        <https://1145.am/db/2298642/Orbimed>,
        <https://1145.am/db/2299411/Orbimed>,
        <https://1145.am/db/2299645/Orbimed>,
        <https://1145.am/db/2300061/Orbimed>,
        <https://1145.am/db/2300653/Orbimed>,
        <https://1145.am/db/2301464/Orbimed>,
        <https://1145.am/db/2304258/Orbimed>,
        <https://1145.am/db/2318134/Orbimed>,
        <https://1145.am/db/2323243/Orbimed>,
        <https://1145.am/db/2330389/Orbimed>,
        <https://1145.am/db/2335764/Orbimed>,
        <https://1145.am/db/2337043/Orbimed>,
        <https://1145.am/db/2337667/Orbimed>,
        <https://1145.am/db/2340942/Orbimed>,
        <https://1145.am/db/2341484/Orbimed>,
        <https://1145.am/db/2341487/Orbimed>,
        <https://1145.am/db/2344044/Orbimed>,
        <https://1145.am/db/2344045/Orbimed>,
        <https://1145.am/db/2347103/Orbimed>,
        <https://1145.am/db/2347885/Orbimed>,
        <https://1145.am/db/2348149/Orbimed>,
        <https://1145.am/db/2348857/Orbimed>,
        <https://1145.am/db/2349834/Orbimed>,
        <https://1145.am/db/2349838/Orbimed>,
        <https://1145.am/db/2350720/Orbimed>,
        <https://1145.am/db/2353515/Orbimed>,
        <https://1145.am/db/2355023/Orbimed>,
        <https://1145.am/db/2361337/Orbimed>,
        <https://1145.am/db/2362768/Orbimed>,
        <https://1145.am/db/236388/Orbimed>,
        <https://1145.am/db/2363947/Orbimed>,
        <https://1145.am/db/2368872/Orbimed>,
        <https://1145.am/db/2369135/Orbimed>,
        <https://1145.am/db/2369140/Orbimed>,
        <https://1145.am/db/2369202/Orbimed>,
        <https://1145.am/db/2369548/Orbimed>,
        <https://1145.am/db/2369982/Orbimed>,
        <https://1145.am/db/2369999/Orbimed>,
        <https://1145.am/db/2370208/Orbimed>,
        <https://1145.am/db/2370295/Orbimed>,
        <https://1145.am/db/2370694/Orbimed>,
        <https://1145.am/db/2370782/Orbimed>,
        <https://1145.am/db/2370799/Orbimed>,
        <https://1145.am/db/2371160/Orbimed>,
        <https://1145.am/db/2371163/Orbimed>,
        <https://1145.am/db/2547469/Orbimed>,
        <https://1145.am/db/2548437/Orbimed>,
        <https://1145.am/db/2718732/Orbimed>,
        <https://1145.am/db/2787561/Orbimed>,
        <https://1145.am/db/402604/Orbimed>,
        <https://1145.am/db/474852/Orbimed>,
        <https://1145.am/db/581662/Orbimed>,
        <https://1145.am/db/583614/Orbimed>,
        <https://1145.am/db/676857/Orbimed>,
        <https://1145.am/db/713335/Orbimed>,
        <https://1145.am/db/714498/Orbimed>,
        <https://1145.am/db/770684/Orbimed>,
        <https://1145.am/db/791742/Orbimed>,
        <https://1145.am/db/867907/Orbimed>,
        <https://1145.am/db/912732/Orbimed> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2343545/Sofinnova_Partners> a org:Organization ;
    ns1:basedInLowRaw "France" ;
    ns1:documentDate "2010-07-26T13:03:59+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Cerenis Therapeutics raises EUR 40 million in series C financingJean-Pierre Garnier appointed as non-executive director to the" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cerenis-therapeutics-raises-eur-40-million-series-c-financingjean-pierre-garnier-appointed> ;
    ns1:foundName "Sofinnova Partners" ;
    ns1:investor <https://1145.am/db/2343545/Series_C_Investment_Alta_Partners_And_Tvm_Capital_Cerenis_Therapeutics_Sa_Daiwa_Corporate_Investment_Edf_Ventures_Fund_For_Strategic_Investment_Healthcap_Orbimed_Sofinnova_Partners_Completed> ;
    ns1:name "Sofinnova Partners" ;
    ns1:sameAsMedium <https://1145.am/db/1039135/Sofinnova_Partners>,
        <https://1145.am/db/1054859/Sofinnova_Partners>,
        <https://1145.am/db/1112260/Sofinnova_Partners>,
        <https://1145.am/db/1113007/Sofinnova_Partners>,
        <https://1145.am/db/1118732/Sofinnova_Partners>,
        <https://1145.am/db/1196006/Sofinnova_Partners>,
        <https://1145.am/db/1196618/Sofinnova_Partners>,
        <https://1145.am/db/1199155/Sofinnova_Partners>,
        <https://1145.am/db/1419128/Sofinnova_Partners>,
        <https://1145.am/db/1490183/Sofinnova_Partners>,
        <https://1145.am/db/1490997/Sofinnova_Partners>,
        <https://1145.am/db/1583413/Sofinnova_Partners>,
        <https://1145.am/db/1584328/Sofinnova_Partners>,
        <https://1145.am/db/1618717/Sofinnova_Partners>,
        <https://1145.am/db/1619418/Sofinnova_Partners>,
        <https://1145.am/db/1707724/Sofinnova_Partners>,
        <https://1145.am/db/1722774/Sofinnova_Partners>,
        <https://1145.am/db/1735325/Sofinnova_Partners>,
        <https://1145.am/db/1773491/Sofinnova_Partners>,
        <https://1145.am/db/1802402/Sofinnova_Partners>,
        <https://1145.am/db/1876390/Sofinnova_Partners>,
        <https://1145.am/db/1892777/Sofinnova_Partners>,
        <https://1145.am/db/1919228/Sofinnova_Partners>,
        <https://1145.am/db/1928060/Sofinnova_Partners>,
        <https://1145.am/db/1975388/Sofinnova_Partners>,
        <https://1145.am/db/2066938/Sofinnova_Partners>,
        <https://1145.am/db/2075963/Sofinnova_Partners>,
        <https://1145.am/db/2109799/Sofinnova_Partners>,
        <https://1145.am/db/2152180/Sofinnova_Partners>,
        <https://1145.am/db/2153042/Sofinnova_Partners>,
        <https://1145.am/db/2153373/Sofinnova_Partners>,
        <https://1145.am/db/2155625/Sofinnova_Partners>,
        <https://1145.am/db/2280230/Sofinnova_Partners>,
        <https://1145.am/db/2282400/Sofinnova_Partners>,
        <https://1145.am/db/2282747/Sofinnova_Partners>,
        <https://1145.am/db/2286182/Sofinnova_Partners>,
        <https://1145.am/db/2286404/Sofinnova_Partners>,
        <https://1145.am/db/2288699/Sofinnova_Partners>,
        <https://1145.am/db/2291023/Sofinnova_Partners>,
        <https://1145.am/db/2291790/Sofinnova_Partners>,
        <https://1145.am/db/2294367/Sofinnova_Partners>,
        <https://1145.am/db/2294502/Sofinnova_Partners>,
        <https://1145.am/db/2297649/Sofinnova_Partners>,
        <https://1145.am/db/2298624/Sofinnova_Partners>,
        <https://1145.am/db/2298631/Sofinnova_Partners>,
        <https://1145.am/db/2298641/Sofinnova_Partners>,
        <https://1145.am/db/2299758/Sofinnova_Partners>,
        <https://1145.am/db/2302741/Sofinnova_Partners>,
        <https://1145.am/db/2302750/Sofinnova_Partners>,
        <https://1145.am/db/2303849/Sofinnova_Partners>,
        <https://1145.am/db/2306395/Sofinnova_Partners>,
        <https://1145.am/db/2317779/Sofinnova_Partners>,
        <https://1145.am/db/2321542/Sofinnova_Partners>,
        <https://1145.am/db/2322646/Sofinnova_Partners>,
        <https://1145.am/db/2323100/Sofinnova_Partners>,
        <https://1145.am/db/2323102/Sofinnova_Partners>,
        <https://1145.am/db/2323243/Sofinnova_Partners>,
        <https://1145.am/db/2324027/Sofinnova_Partners>,
        <https://1145.am/db/2324034/Sofinnova_Partners>,
        <https://1145.am/db/2325549/Sofinnova_Partners>,
        <https://1145.am/db/2327222/Sofinnova_Partners>,
        <https://1145.am/db/2328763/Sofinnova_Partners>,
        <https://1145.am/db/2328769/Sofinnova_Partners>,
        <https://1145.am/db/2328825/Sofinnova_Partners>,
        <https://1145.am/db/2329870/Sofinnova_Partners>,
        <https://1145.am/db/2330876/Sofinnova_Partners>,
        <https://1145.am/db/2335582/Sofinnova_Partners>,
        <https://1145.am/db/2335587/Sofinnova_Partners>,
        <https://1145.am/db/2336333/Sofinnova_Partners>,
        <https://1145.am/db/2336335/Sofinnova_Partners>,
        <https://1145.am/db/2339692/Sofinnova_Partners>,
        <https://1145.am/db/2343301/Sofinnova_Partners>,
        <https://1145.am/db/2349013/Sofinnova_Partners>,
        <https://1145.am/db/2349096/Sofinnova_Partners>,
        <https://1145.am/db/2354296/Sofinnova_Partners>,
        <https://1145.am/db/2355740/Sofinnova_Partners>,
        <https://1145.am/db/2355741/Sofinnova_Partners>,
        <https://1145.am/db/2355885/Sofinnova_Partners>,
        <https://1145.am/db/2356384/Sofinnova_Partners>,
        <https://1145.am/db/2358268/Sofinnova_Partners>,
        <https://1145.am/db/2358269/Sofinnova_Partners>,
        <https://1145.am/db/2359960/Sofinnova_Partners>,
        <https://1145.am/db/236357/Sofinnova_Partners>,
        <https://1145.am/db/2363593/Sofinnova_Partners>,
        <https://1145.am/db/2363597/Sofinnova_Partners>,
        <https://1145.am/db/2365826/Sofinnova_Partners>,
        <https://1145.am/db/2366303/Sofinnova_Partners>,
        <https://1145.am/db/2367549/Sofinnova_Partners>,
        <https://1145.am/db/2370118/Sofinnova_Partners>,
        <https://1145.am/db/2538923/Sofinnova_Partners>,
        <https://1145.am/db/2555540/Sofinnova_Partners>,
        <https://1145.am/db/2571050/Sofinnova_Partners>,
        <https://1145.am/db/2577022/Sofinnova_Partners>,
        <https://1145.am/db/2578627/Sofinnova_Partners>,
        <https://1145.am/db/2765863/Sofinnova_Partners>,
        <https://1145.am/db/2765866/Sofinnova_Partners>,
        <https://1145.am/db/2765873/Sofinnova_Partners>,
        <https://1145.am/db/530060/Sofinnova_Partners>,
        <https://1145.am/db/555385/Sofinnova_Partners>,
        <https://1145.am/db/577785/Sofinnova_Partners>,
        <https://1145.am/db/595282/Sofinnova_Partners>,
        <https://1145.am/db/602316/Sofinnova_Partners>,
        <https://1145.am/db/625791/Sofinnova_Partners>,
        <https://1145.am/db/695229/Sofinnova_Partners>,
        <https://1145.am/db/695704/Sofinnova_Partners>,
        <https://1145.am/db/798753/Sofinnova_Partners>,
        <https://1145.am/db/810584/Sofinnova_Partners>,
        <https://1145.am/db/955355/Sofinnova_Partners>,
        <https://1145.am/db/992046/Sofinnova_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2344565/Oxford_Finance_Corporation> a org:Organization ;
    ns1:basedInLowRaw "CALIF" ;
    ns1:documentDate "2010-07-27T18:54:24+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Tethys Raises $33 Million" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/tethys-raises-33-million-0> ;
    ns1:foundName "Oxford Finance" ;
    ns1:investor <https://1145.am/db/2344565/Working_Capital_Investment_Greenspring_Associates_Inc_Greenspring_Associates_Inc_Oxford_Finance_Corporation_Paul_Capital_Investments_Tethys_Bioscience_Completed> ;
    ns1:name "Oxford Finance Corporation" ;
    ns1:sameAsMedium <https://1145.am/db/1100295/Oxford_Finance_Llc>,
        <https://1145.am/db/1100492/Oxford_Finance_Llc>,
        <https://1145.am/db/1101340/Oxford_Finance_Llc>,
        <https://1145.am/db/1152410/Oxford_Finance_Llc>,
        <https://1145.am/db/1318713/Oxford_Finance_Llc>,
        <https://1145.am/db/1422452/Oxford_Finance_Llc>,
        <https://1145.am/db/1433740/Oxford_Finance_Llc>,
        <https://1145.am/db/1434127/Oxford_Finance_Llc>,
        <https://1145.am/db/1459745/Oxford_Finance_Llc>,
        <https://1145.am/db/1506328/Oxford_Finance_Llc>,
        <https://1145.am/db/1508005/Oxford_Finance_Llc>,
        <https://1145.am/db/188641/Oxford_Finance_Llc>,
        <https://1145.am/db/2003353/Oxford_Finance_Llc>,
        <https://1145.am/db/2069388/Oxford_Finance>,
        <https://1145.am/db/2199361/Oxford_Finance_Corporation>,
        <https://1145.am/db/2288016/Oxford_Finance>,
        <https://1145.am/db/2289940/Oxford_Finance>,
        <https://1145.am/db/2292812/Oxford_Finance>,
        <https://1145.am/db/2293047/Oxford_Finance>,
        <https://1145.am/db/2302085/Oxford_Finance_Corporation>,
        <https://1145.am/db/2302707/Oxford_Finance_Corporation>,
        <https://1145.am/db/2305927/Oxford_Finance_Corporation>,
        <https://1145.am/db/2306687/Oxford_Finance_Corporation>,
        <https://1145.am/db/2311101/Oxford_Finance_Corporation>,
        <https://1145.am/db/2317145/Oxford_Finance_Corporation>,
        <https://1145.am/db/2319430/Oxford_Finance>,
        <https://1145.am/db/2324337/Oxford_Finance_Corporation>,
        <https://1145.am/db/2327464/Oxford_Finance>,
        <https://1145.am/db/2328500/Oxford_Finance_Corporation>,
        <https://1145.am/db/2328511/Oxford_Finance_Corporation>,
        <https://1145.am/db/2328616/Oxford_Finance_Corporation>,
        <https://1145.am/db/2331928/Oxford_Finance_Corporation>,
        <https://1145.am/db/2341182/Oxford_Finance_Llc>,
        <https://1145.am/db/2346204/Oxford_Finance_Llc>,
        <https://1145.am/db/2348745/Oxford_Finance_Llc>,
        <https://1145.am/db/2358002/Oxford_Finance_Corporation>,
        <https://1145.am/db/2358116/Oxford_Finance_Llc>,
        <https://1145.am/db/2364404/Oxford_Finance_Corporation>,
        <https://1145.am/db/2365674/Oxford_Finance_Corporation>,
        <https://1145.am/db/2575677/Oxford_Finance>,
        <https://1145.am/db/2575679/Oxford_Finance>,
        <https://1145.am/db/2587375/Oxford_Finance>,
        <https://1145.am/db/520223/Oxford_Finance>,
        <https://1145.am/db/522518/Oxford_Finance>,
        <https://1145.am/db/593670/Oxford_Finance>,
        <https://1145.am/db/596524/Oxford_Finance_Llc>,
        <https://1145.am/db/604065/Oxford_Finance_Llc>,
        <https://1145.am/db/606420/Oxford_Finance_Llc>,
        <https://1145.am/db/704387/Oxford_Finance_Llc>,
        <https://1145.am/db/781786/Oxford_Finance>,
        <https://1145.am/db/815981/Oxford_Finance_Llc>,
        <https://1145.am/db/830736/Oxford_Finance_Llc>,
        <https://1145.am/db/847790/Oxford_Finance_Llc>,
        <https://1145.am/db/848458/Oxford_Finance_Llc>,
        <https://1145.am/db/928761/Oxford_Finance_Llc>,
        <https://1145.am/db/930408/Oxford_Finance_Llc>,
        <https://1145.am/db/955192/Oxford_Finance_Llc>,
        <https://1145.am/db/955875/Oxford_Finance_Llc> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2345142/Flemish_Agency> a org:Organization ;
    ns1:basedInHighGeoName "Mechelen" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2791538/about.rdf> ;
    ns1:basedInHighRaw "MECHELEN, BELGIUM" ;
    ns1:description "Innovation by Science and Technology" ;
    ns1:documentDate "2010-10-28T13:25:17+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Galapagos NV (GLPG.BR) Receives EUR 3.7 Million ($5.1 Million) Grant For Cystic Fibrosis Program" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/galapagos-nv-glpg-br-receives-eur-3-7-million-5-1-million-grant-for-cystic-fibrosis-program> ;
    ns1:foundName "agency" ;
    ns1:investor <https://1145.am/db/2345142/Investment_Flemish_Agency_Galapagos_Nv_Innovation_By_Science_And_Technology_Has_Not_Happened> ;
    ns1:name "Flemish agency" ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2345142/Innovation_By_Science_And_Technology> a org:Organization ;
    ns1:basedInHighGeoName "Mechelen" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2791538/about.rdf> ;
    ns1:basedInHighRaw "MECHELEN, BELGIUM" ;
    ns1:description "announcing new projects" ;
    ns1:documentDate "2010-10-28T13:25:17+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Galapagos NV (GLPG.BR) Receives EUR 3.7 Million ($5.1 Million) Grant For Cystic Fibrosis Program" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/galapagos-nv-glpg-br-receives-eur-3-7-million-5-1-million-grant-for-cystic-fibrosis-program> ;
    ns1:foundName "Innovation by Science and Technology" ;
    ns1:investor <https://1145.am/db/2345142/Investment_Flemish_Agency_Galapagos_Nv_Innovation_By_Science_And_Technology_Has_Not_Happened> ;
    ns1:name "Innovation by Science and Technology" ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2345603/Azimuth_Opportunity_Ltd> a org:Organization ;
    ns1:basedInLowRaw "SEATTLE" ;
    ns1:description "equity, debt and non-dilutive financing transactions" ;
    ns1:documentDate "2010-07-29T15:37:41+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Omeros Secures $40 Million Committed Equity Financing Facility" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/omeros-secures-40-million-committed-equity-financing-facility> ;
    ns1:foundName "Azimuth Opportunity, Ltd" ;
    ns1:investor <https://1145.am/db/2345603/Investment_Azimuth_Opportunity_Ltd_Omeros_Corporation_Has_Not_Happened> ;
    ns1:name "Azimuth Opportunity, Ltd" ;
    ns1:sameAsMedium <https://1145.am/db/2304214/Azimuth_Opportunity>,
        <https://1145.am/db/2304227/Azimuth_Opportunity>,
        <https://1145.am/db/2305020/Azimuth_Opportunity>,
        <https://1145.am/db/2308452/Azimuth_Opportunity_Ltd>,
        <https://1145.am/db/2345604/Azimuth_Opportunity> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2346187/Isar_Pharma_K_S> a org:Organization ;
    ns1:basedInLowRaw "Denmark",
        "Nordic Biotech Venture Fund II K/S" ;
    ns1:description "Investing" ;
    ns1:documentDate "2010-11-01T15:06:01+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Allon Completes U.S. $10 Million Financing Agreement with Nordic Biotech Entity" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/allon-completes-u-s-10-million-financing-agreement-nordic-biotech-entity> ;
    ns1:foundName "Isar Pharma K/S",
        "Isar Pharma K/S," ;
    ns1:industry "Pharma",
        "Pharmaceutical" ;
    ns1:investor <https://1145.am/db/2346187/Investment_Allon_Therapeutics_Inc_Allon_Therapeutics_Inc_Isar_Pharma_K_S_Nordic_Biotech_Venture_Fund_Ii_K_S_Completed>,
        <https://1145.am/db/2346187/Investment_Allon_Us_Isar_Pharma_K_S_Completed> ;
    ns1:name "Isar",
        "Isar Pharma K/S" ;
    ns1:sameAsHigh <https://1145.am/db/2056773/Igc_Pharma>,
        <https://1145.am/db/2131326/Insud_Pharma>,
        <https://1145.am/db/2301852/Idec>,
        <https://1145.am/db/2302731/Inimex_Pharmaceuticals_Inc>,
        <https://1145.am/db/2305879/Intas_Pharmaceuticals>,
        <https://1145.am/db/2306110/Intermune>,
        <https://1145.am/db/2309121/Inimex_Pharmaceuticals>,
        <https://1145.am/db/2311701/Intrexon>,
        <https://1145.am/db/2328604/Intas_Biopharmaceuticals>,
        <https://1145.am/db/2335645/Intrexon_Corporation>,
        <https://1145.am/db/2343789/Idenix_Pharmaceuticals>,
        <https://1145.am/db/2356196/Intermune>,
        <https://1145.am/db/2357704/Intermune>,
        <https://1145.am/db/2357705/Intermune>,
        <https://1145.am/db/2360248/Intermune>,
        <https://1145.am/db/2371047/Intermune>,
        <https://1145.am/db/2536445/Indchem_International>,
        <https://1145.am/db/2536447/Indchem_International>,
        <https://1145.am/db/2546153/Intas_Pharmaceuticals>,
        <https://1145.am/db/2559637/Intas>,
        <https://1145.am/db/2570023/Intas>,
        <https://1145.am/db/940935/Insud_Pharma> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2346187/Nordic_Biotech_Venture_Fund_Ii_K_S> a org:Organization ;
    ns1:basedInLowRaw "Nordic Biotech Venture Fund II K/S" ;
    ns1:documentDate "2010-11-01T15:06:01+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Allon Completes U.S. $10 Million Financing Agreement with Nordic Biotech Entity" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/allon-completes-u-s-10-million-financing-agreement-nordic-biotech-entity> ;
    ns1:foundName "Nordic Biotech Venture Fund II K/S" ;
    ns1:name "Nordic Biotech Venture Fund II K/S" ;
    ns1:participant <https://1145.am/db/2346187/Investment_Allon_Therapeutics_Inc_Allon_Therapeutics_Inc_Isar_Pharma_K_S_Nordic_Biotech_Venture_Fund_Ii_K_S_Completed> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2346644/Shire_Plc> a org:Organization ;
    ns1:basedInHighGeoName "Grand Duchy of Luxembourg" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2960313/about.rdf> ;
    ns1:basedInHighRaw "Luxembourg" ;
    ns1:description "Business",
        "discovering, developing and commercializing innovative treatments for GI conditions with a high unmet medical" ;
    ns1:documentDate "2010-08-03T13:01:54+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Shire Proposes to Expand Specialist Gastrointestinal Portfolio" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/shire-proposes-to-expand-specialist-gastrointestinal-portfolio> ;
    ns1:foundName "Shire",
        "Shire plc" ;
    ns1:industry "biopharmaceutical" ;
    ns1:investor <https://1145.am/db/2346644/Investment_Shire_Plc_Has_Not_Happened> ;
    ns1:name "Shire",
        "Shire plc" ;
    ns1:participant <https://1145.am/db/2346644/Movetis_Acquisition> ;
    ns1:sameAsHigh <https://1145.am/db/142937/Shire_Plc>,
        <https://1145.am/db/2155273/Shire>,
        <https://1145.am/db/2225348/Shire_Plc>,
        <https://1145.am/db/2225352/Shire_Plc>,
        <https://1145.am/db/2290932/Shire>,
        <https://1145.am/db/2291354/Shire>,
        <https://1145.am/db/2292991/Shire>,
        <https://1145.am/db/2296208/Shire>,
        <https://1145.am/db/2296243/Shire>,
        <https://1145.am/db/2298391/Shire>,
        <https://1145.am/db/2300483/Shire>,
        <https://1145.am/db/2302783/Shire_Limited>,
        <https://1145.am/db/2303789/Shire>,
        <https://1145.am/db/2305581/Shire_Plc>,
        <https://1145.am/db/2306762/Shire>,
        <https://1145.am/db/2310002/Shire>,
        <https://1145.am/db/2311383/Shire_Pharmaceuticals>,
        <https://1145.am/db/2311393/Shire_Pharmaceuticals_Group>,
        <https://1145.am/db/2314408/Shire_Limited>,
        <https://1145.am/db/2315296/Shire_Biochem>,
        <https://1145.am/db/2315308/Shire_Biochem_Inc>,
        <https://1145.am/db/2320137/Shire>,
        <https://1145.am/db/2320509/Shire>,
        <https://1145.am/db/2324621/Shire_Plc>,
        <https://1145.am/db/2326381/Shire_Plc>,
        <https://1145.am/db/2328189/Shire>,
        <https://1145.am/db/2328700/Shire_Laboratories>,
        <https://1145.am/db/2328788/Shire_Plc>,
        <https://1145.am/db/2331795/Shire_Plc>,
        <https://1145.am/db/2335641/Shire>,
        <https://1145.am/db/2336575/Shire>,
        <https://1145.am/db/2336581/Shire>,
        <https://1145.am/db/2336708/Shire>,
        <https://1145.am/db/2338009/Shire>,
        <https://1145.am/db/2338011/Shire>,
        <https://1145.am/db/2340575/Shire>,
        <https://1145.am/db/2341074/Shire>,
        <https://1145.am/db/2341522/Shire>,
        <https://1145.am/db/2341828/Shire_Plc>,
        <https://1145.am/db/2341829/Shire>,
        <https://1145.am/db/2341838/Shire>,
        <https://1145.am/db/2341902/Shire>,
        <https://1145.am/db/2342514/Shire>,
        <https://1145.am/db/2342570/Shire>,
        <https://1145.am/db/2344160/Shire>,
        <https://1145.am/db/2344202/Shire>,
        <https://1145.am/db/2344913/Shire>,
        <https://1145.am/db/2344914/Shire_Plc>,
        <https://1145.am/db/2344928/Shire_Plc>,
        <https://1145.am/db/2345238/Shire>,
        <https://1145.am/db/2345248/Shire_Plc>,
        <https://1145.am/db/2345825/Shire_Plc>,
        <https://1145.am/db/2345826/Shire_Plc>,
        <https://1145.am/db/2346202/Shire>,
        <https://1145.am/db/2346640/Shire>,
        <https://1145.am/db/2346646/Shire_Plc>,
        <https://1145.am/db/2346752/Shire_Plc>,
        <https://1145.am/db/2346863/Shire_Plc>,
        <https://1145.am/db/2347646/Shire_Plc>,
        <https://1145.am/db/2348661/Shire>,
        <https://1145.am/db/2348742/Shire>,
        <https://1145.am/db/2348750/Shire>,
        <https://1145.am/db/2351482/Shire>,
        <https://1145.am/db/2351483/Shire>,
        <https://1145.am/db/2351754/Shire>,
        <https://1145.am/db/2352906/Shire>,
        <https://1145.am/db/2354266/Shire_Llc>,
        <https://1145.am/db/2357032/Shire>,
        <https://1145.am/db/2357116/Shire>,
        <https://1145.am/db/2359634/Shire>,
        <https://1145.am/db/2360712/Shire_Board>,
        <https://1145.am/db/2361514/Shire_Plc>,
        <https://1145.am/db/2361641/Shire>,
        <https://1145.am/db/2364136/Shire_Plc>,
        <https://1145.am/db/2364149/Shire_Plc>,
        <https://1145.am/db/2364556/Shire>,
        <https://1145.am/db/2364813/Shire>,
        <https://1145.am/db/2365002/Shire_Plc>,
        <https://1145.am/db/2367132/Shire_Plc>,
        <https://1145.am/db/2367297/Shire>,
        <https://1145.am/db/2368862/Shire>,
        <https://1145.am/db/2369141/Shire>,
        <https://1145.am/db/2369949/Shire>,
        <https://1145.am/db/2370010/Shire>,
        <https://1145.am/db/2370189/Shire>,
        <https://1145.am/db/2370740/Shire>,
        <https://1145.am/db/2371519/Shire>,
        <https://1145.am/db/2537396/Shire>,
        <https://1145.am/db/2541146/Shire>,
        <https://1145.am/db/2544223/Shire>,
        <https://1145.am/db/2544459/Shire>,
        <https://1145.am/db/2544726/Shire>,
        <https://1145.am/db/2546262/Shire>,
        <https://1145.am/db/2546291/Shire>,
        <https://1145.am/db/2547036/Shire>,
        <https://1145.am/db/2547277/Shire>,
        <https://1145.am/db/2548051/Shire>,
        <https://1145.am/db/2548859/Shire>,
        <https://1145.am/db/2550985/Shire>,
        <https://1145.am/db/2552455/Shire>,
        <https://1145.am/db/2554294/Shire>,
        <https://1145.am/db/2556988/Shire>,
        <https://1145.am/db/2559769/Shire>,
        <https://1145.am/db/2561541/Shire>,
        <https://1145.am/db/2563175/Shire>,
        <https://1145.am/db/2564899/Shire>,
        <https://1145.am/db/2565613/Shire>,
        <https://1145.am/db/2569388/Shire>,
        <https://1145.am/db/2569952/Shire>,
        <https://1145.am/db/2570020/Shire>,
        <https://1145.am/db/2570036/Shire>,
        <https://1145.am/db/2570733/Shire_Plc>,
        <https://1145.am/db/2570807/Shire>,
        <https://1145.am/db/2571521/Shire>,
        <https://1145.am/db/2571526/Shire>,
        <https://1145.am/db/2572335/Shire>,
        <https://1145.am/db/2573463/Shire>,
        <https://1145.am/db/2573508/Shire>,
        <https://1145.am/db/2574443/Shire>,
        <https://1145.am/db/2574731/Shire>,
        <https://1145.am/db/2575259/Shire>,
        <https://1145.am/db/2576815/Shire>,
        <https://1145.am/db/2576959/Shire>,
        <https://1145.am/db/2577117/Shire>,
        <https://1145.am/db/2577652/Shire_Plc>,
        <https://1145.am/db/2578085/Shire_Plc>,
        <https://1145.am/db/2578086/So_Shire>,
        <https://1145.am/db/2578319/Shire>,
        <https://1145.am/db/2578503/Shire>,
        <https://1145.am/db/2578568/Shire>,
        <https://1145.am/db/2579035/Shire_Plc>,
        <https://1145.am/db/2580603/Shire>,
        <https://1145.am/db/2580620/Shire>,
        <https://1145.am/db/2580622/Shire>,
        <https://1145.am/db/2580747/Shire>,
        <https://1145.am/db/2581261/Shire>,
        <https://1145.am/db/2582265/Shire>,
        <https://1145.am/db/2583177/Shire>,
        <https://1145.am/db/2583662/Shire>,
        <https://1145.am/db/2584216/Shire>,
        <https://1145.am/db/2585066/Shire>,
        <https://1145.am/db/2586884/Shire>,
        <https://1145.am/db/2586889/Shire>,
        <https://1145.am/db/2587094/Shire>,
        <https://1145.am/db/2587511/Shire>,
        <https://1145.am/db/2588152/Shire>,
        <https://1145.am/db/2589981/Shire_Plc>,
        <https://1145.am/db/2591412/Shire>,
        <https://1145.am/db/2592333/Shire>,
        <https://1145.am/db/2592562/Shire>,
        <https://1145.am/db/2595190/Shire>,
        <https://1145.am/db/2595210/Shire>,
        <https://1145.am/db/2597158/Shire>,
        <https://1145.am/db/2598205/Shire>,
        <https://1145.am/db/2976/Shire> ;
    ns1:sameAsMedium <https://1145.am/db/2288537/Shire>,
        <https://1145.am/db/2293472/Shire>,
        <https://1145.am/db/2297066/Shire>,
        <https://1145.am/db/2332620/Shire>,
        <https://1145.am/db/2333419/Shire>,
        <https://1145.am/db/2336126/Shire_Plc>,
        <https://1145.am/db/2339117/Shire>,
        <https://1145.am/db/2339733/Shire_Plc>,
        <https://1145.am/db/2340560/Shire>,
        <https://1145.am/db/2340566/Shire_Plc>,
        <https://1145.am/db/2341068/Shire>,
        <https://1145.am/db/2344205/Shire>,
        <https://1145.am/db/2345096/Shire>,
        <https://1145.am/db/2346872/Shire_Plc>,
        <https://1145.am/db/2346879/Shire>,
        <https://1145.am/db/2347772/Shire>,
        <https://1145.am/db/2348523/Shire>,
        <https://1145.am/db/2348805/Shire>,
        <https://1145.am/db/2350265/Shire_Plc>,
        <https://1145.am/db/2351734/Shire_Llc>,
        <https://1145.am/db/2351737/Shire_Llc>,
        <https://1145.am/db/2353283/Shire_Plc>,
        <https://1145.am/db/2354277/Shire>,
        <https://1145.am/db/2356384/Shire>,
        <https://1145.am/db/2357487/Shire>,
        <https://1145.am/db/2359681/Shire>,
        <https://1145.am/db/2360712/Shire_Plc>,
        <https://1145.am/db/2361640/Shire_Plc>,
        <https://1145.am/db/2362744/Shire>,
        <https://1145.am/db/2365826/Shire_Plc>,
        <https://1145.am/db/2366303/Shire>,
        <https://1145.am/db/2368144/Shire>,
        <https://1145.am/db/2368885/Shire>,
        <https://1145.am/db/2368915/Shire>,
        <https://1145.am/db/2368936/Shire>,
        <https://1145.am/db/2369701/Shire>,
        <https://1145.am/db/2370358/Shire>,
        <https://1145.am/db/2370514/Shire>,
        <https://1145.am/db/2371522/Shire>,
        <https://1145.am/db/2539292/Shire>,
        <https://1145.am/db/2544434/Shire>,
        <https://1145.am/db/2547575/Shire_Plc>,
        <https://1145.am/db/2548805/Shire>,
        <https://1145.am/db/2548979/Shire>,
        <https://1145.am/db/2552180/Shire>,
        <https://1145.am/db/2554269/Shire>,
        <https://1145.am/db/2558927/Shire>,
        <https://1145.am/db/2566716/Shire>,
        <https://1145.am/db/2570363/Shire>,
        <https://1145.am/db/2572113/Shire_Plc>,
        <https://1145.am/db/2572559/Shire>,
        <https://1145.am/db/2575050/Shire>,
        <https://1145.am/db/2577114/Shire>,
        <https://1145.am/db/2577176/Shire_Plc>,
        <https://1145.am/db/2577793/Shire_Plc>,
        <https://1145.am/db/2579062/Shire_Plc>,
        <https://1145.am/db/2580279/Shire>,
        <https://1145.am/db/2583624/Shire_Plc>,
        <https://1145.am/db/2585132/Shire>,
        <https://1145.am/db/2586132/Shire>,
        <https://1145.am/db/2592336/Shire> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2347207/Investment_Zalicus_Inc_Zalicus_Inc_Has_Not_Happened> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-11-02T14:22:53+00:00"^^xsd:dateTime ;
    ns1:documentExtract "CAMBRIDGE, Mass.- (BUSINESS WIRE) - Zalicus Inc. (NASDAQ: ZLCS) , innovators in the treatment of pain and immuno-inflammatory disease, today announced that it has been awarded a $ 244,000 grant under the IRS Qualifying Therapeutic Discovery Project (QTDP) ." ;
    ns1:documentTitle "Zalicus Awarded $244,000 Therapeutic Discovery Project Grant" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/zalicus-awarded-244-000-therapeutic-discovery-project-grant> ;
    ns1:foundName "grant" ;
    ns1:name "grant" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "has not happened" ;
    ns1:target <https://1145.am/db/2347207/Synavive>,
        <https://1145.am/db/2347207/Zalicus_Inc> ;
    ns1:targetName "Synavive" ;
    ns1:valueRaw "$ 244,000" ;
    ns1:whereGeoName "Cambridge" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/4931972/about.rdf> ;
    ns1:whereRaw "CAMBRIDGE, Mass" .

<https://1145.am/db/2347626/Qiming_Ventures> a org:Organization ;
    ns1:description "investing" ;
    ns1:documentDate "2010-08-03T15:43:54+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Sangon & Bio Basic Inc. Closes $10 Million Round of Investment by Qiming Ventures" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/sangon-bio-basic-inc-closes-10-million-round-of-investment-by-qiming-ventures> ;
    ns1:foundName "Qiming Ventures" ;
    ns1:investor <https://1145.am/db/2347626/Investment_Qiming_Ventures_Sangon___Bio_Basic_Inc_Sangon_Biotech_Completed> ;
    ns1:name "Qiming Ventures" ;
    ns1:sameAsHigh <https://1145.am/db/1721480/Qiming_Venture_Partners>,
        <https://1145.am/db/1895556/Qiming_Ventures>,
        <https://1145.am/db/2198776/Qiming_Venture_Partners>,
        <https://1145.am/db/2298954/Qiming_Venture_Partners>,
        <https://1145.am/db/2549519/Qiming_Venture_Partners>,
        <https://1145.am/db/689223/Qiming_Venture_Partners>,
        <https://1145.am/db/734448/Qiming_Venture_Partners_Usa>,
        <https://1145.am/db/768063/Qiming_Venture_Partners_Usa> ;
    ns1:sameAsMedium <https://1145.am/db/2144250/Qiming_Ventures>,
        <https://1145.am/db/2369135/Qiming_Ventures>,
        <https://1145.am/db/2369140/Qiming_Ventures>,
        <https://1145.am/db/2547469/Qiming_Ventures>,
        <https://1145.am/db/2548437/Qiming_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2348232/Gedeon_Richter_Plc> a org:Organization ;
    ns1:basedInLowRaw "Germany" ;
    ns1:buyer <https://1145.am/db/2348232/Portfolio_Acquisition_Gedeon_Richter_Plc_Richter_Completed> ;
    ns1:description "pharmaceutical company" ;
    ns1:documentDate "2010-11-03T14:33:44+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Richter Acquires Grünenthal's Oral Contraceptive Portfolio" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/richter-acquires-gr%C3%BCnenthal-s-oral-contraceptive-portfolio> ;
    ns1:foundName "Gedeon Richter Plc" ;
    ns1:industry "pharmaceutical" ;
    ns1:name "Gedeon Richter Plc" ;
    ns1:sameAsHigh <https://1145.am/db/2341838/Richter>,
        <https://1145.am/db/2366906/Gedeon_Richter_Plc>,
        <https://1145.am/db/2366906/Richter>,
        <https://1145.am/db/2367100/Gedeon_Richter_Plc>,
        <https://1145.am/db/2559783/Richter_Gedeon>,
        <https://1145.am/db/2561426/Gedeon_Richter>,
        <https://1145.am/db/2575183/Richter>,
        <https://1145.am/db/2591540/Gedeon_Richter>,
        <https://1145.am/db/2596684/Gedeon_Richter>,
        <https://1145.am/db/92181/Gedeon_Richter> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2348674/Caxton_Advantage_Life_Sciences_Fund_Of_New_York> a org:Organization ;
    ns1:basedInHighGeoName "New York City" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5128581/about.rdf> ;
    ns1:basedInHighRaw "New York" ;
    ns1:description "Life Sciences" ;
    ns1:documentDate "2010-08-05T15:28:11+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Gemin X raises $8M for cancer R&D; Bruce Montgomery ready to open a new chapter in biotech career;" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/gemin-x-raises-8m-for-cancer-r-d-bruce-montgomery-ready-to-open-a-new-chapter-biotech> ;
    ns1:foundName "Caxton Advantage Life Sciences Fund of New York" ;
    ns1:investor <https://1145.am/db/2348674/Series_E_Investment_Caxton_Advantage_Life_Sciences_Fund_Of_New_York_Gemin_X_Pharmaceuticals_Sanderling_Venture_Partners_Completed> ;
    ns1:name "Caxton Advantage Life Sciences Fund of New York" ;
    ns1:sameAsHigh <https://1145.am/db/2303642/Caxton_Advantage_Life_Sciences_Fund>,
        <https://1145.am/db/2309809/Caxton_Advantage_Life_Sciences_Fund>,
        <https://1145.am/db/2314397/Caxton_Advantage_Life_Sciences_Fund>,
        <https://1145.am/db/2314400/Caxton_Advantage_Life_Sciences_Fund>,
        <https://1145.am/db/2331026/Caxton_Advantage_Life_Sciences_Fund>,
        <https://1145.am/db/2331047/Caxton_Advantage_Life_Sciences_Fund> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2348674/Sanderling_Venture_Partners> a org:Organization ;
    ns1:basedInHighGeoName "New York City" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5128581/about.rdf> ;
    ns1:basedInHighRaw "New York" ;
    ns1:documentDate "2010-08-05T15:28:11+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Gemin X raises $8M for cancer R&D; Bruce Montgomery ready to open a new chapter in biotech career;" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/gemin-x-raises-8m-for-cancer-r-d-bruce-montgomery-ready-to-open-a-new-chapter-biotech> ;
    ns1:foundName "Sanderling Venture Partners" ;
    ns1:investor <https://1145.am/db/2348674/Series_E_Investment_Caxton_Advantage_Life_Sciences_Fund_Of_New_York_Gemin_X_Pharmaceuticals_Sanderling_Venture_Partners_Completed> ;
    ns1:name "Sanderling Venture Partners" ;
    ns1:sameAsMedium <https://1145.am/db/2251983/Sanderling_Venture_Partners>,
        <https://1145.am/db/2343704/Sanderling_Venture_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2349753/Abingworth> a org:Organization ;
    ns1:basedInLowRaw "Mass" ;
    ns1:documentDate "2010-08-11T13:20:47+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Dicerna Closes $25 Million Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/dicerna-closes-25-million-series-b-financing> ;
    ns1:foundName "Abingworth" ;
    ns1:investor <https://1145.am/db/2349753/Series_B_Investment_Abingworth_Dicerna_Pharmaceuticals_Domain_Associates_Oxford_Bioscience_Partners_Skyline_Ventures_Completed> ;
    ns1:name "Abingworth" ;
    ns1:sameAsMedium <https://1145.am/db/1533327/Abingworth>,
        <https://1145.am/db/1533685/Abingworth>,
        <https://1145.am/db/1669813/Abingworth>,
        <https://1145.am/db/2198942/Abingworth>,
        <https://1145.am/db/2235767/Abingworth>,
        <https://1145.am/db/2281044/Abingworth>,
        <https://1145.am/db/2282263/Abingworth>,
        <https://1145.am/db/2284358/Abingworth>,
        <https://1145.am/db/2285674/Abingworth>,
        <https://1145.am/db/2286368/Abingworth>,
        <https://1145.am/db/2286541/Abingworth>,
        <https://1145.am/db/2288699/Abingworth>,
        <https://1145.am/db/2292721/Abingworth>,
        <https://1145.am/db/2293814/Abingworth>,
        <https://1145.am/db/2293845/Abingworth>,
        <https://1145.am/db/2294502/Abingworth>,
        <https://1145.am/db/2298306/Abingworth>,
        <https://1145.am/db/2299499/Abingworth>,
        <https://1145.am/db/2301901/Abingworth>,
        <https://1145.am/db/2303656/Abingworth>,
        <https://1145.am/db/2308925/Abingworth>,
        <https://1145.am/db/2308931/Abingworth>,
        <https://1145.am/db/2316391/Abingworth>,
        <https://1145.am/db/2316478/Abingworth>,
        <https://1145.am/db/2317934/Abingworth>,
        <https://1145.am/db/2318733/Abingworth>,
        <https://1145.am/db/2319412/Abingworth>,
        <https://1145.am/db/2319784/Abingworth>,
        <https://1145.am/db/2322012/Abingworth>,
        <https://1145.am/db/2324936/Abingworth_Llp>,
        <https://1145.am/db/2328502/Abingworth>,
        <https://1145.am/db/2328763/Abingworth>,
        <https://1145.am/db/2328769/Abingworth>,
        <https://1145.am/db/2331750/Abingworth>,
        <https://1145.am/db/2335701/Abingworth>,
        <https://1145.am/db/2335714/Abingworth>,
        <https://1145.am/db/2335928/Abingworth_Llp>,
        <https://1145.am/db/2337140/Abingworth>,
        <https://1145.am/db/2346293/Abingworth>,
        <https://1145.am/db/2348012/Abingworth_Llp>,
        <https://1145.am/db/2349233/Abingworth>,
        <https://1145.am/db/2352357/Abingworth>,
        <https://1145.am/db/2352361/Abingworth>,
        <https://1145.am/db/2358430/Abingworth>,
        <https://1145.am/db/2364517/Abingworth_Llp>,
        <https://1145.am/db/2368164/Abingworth>,
        <https://1145.am/db/2368251/Abingworth>,
        <https://1145.am/db/2370582/Abingworth>,
        <https://1145.am/db/2787528/Abingworth>,
        <https://1145.am/db/4142/Abingworth_Llp>,
        <https://1145.am/db/899382/Abingworth>,
        <https://1145.am/db/951050/Abingworth> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2349753/Oxford_Bioscience_Partners> a org:Organization ;
    ns1:basedInLowRaw "Mass" ;
    ns1:description "a second generation RNA interference (RNAi) company developing novel therapeutics" ;
    ns1:documentDate "2010-08-11T13:20:47+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Dicerna Closes $25 Million Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/dicerna-closes-25-million-series-b-financing> ;
    ns1:foundName "Oxford Bioscience Partners" ;
    ns1:investor <https://1145.am/db/2349753/Series_B_Investment_Abingworth_Dicerna_Pharmaceuticals_Domain_Associates_Oxford_Bioscience_Partners_Skyline_Ventures_Completed> ;
    ns1:name "Oxford Bioscience Partners" ;
    ns1:sameAsMedium <https://1145.am/db/2223193/Oxford_Bioscience_Partners>,
        <https://1145.am/db/2305609/Oxford_Bioscience_Partners>,
        <https://1145.am/db/2307644/Oxford_Bioscience_Partners>,
        <https://1145.am/db/2308887/Oxford_Bioscience_Partners>,
        <https://1145.am/db/2308925/Oxford_Bioscience_Partners>,
        <https://1145.am/db/2308931/Oxford_Bioscience_Partners>,
        <https://1145.am/db/2309845/Oxford_Bioscience_Partners>,
        <https://1145.am/db/2312435/Oxford_Bioscience_Partners>,
        <https://1145.am/db/2314492/Oxford_Bioscience_Partners>,
        <https://1145.am/db/2316823/Oxford_Bioscience_Partners>,
        <https://1145.am/db/2318656/Oxford_Bioscience_Partners>,
        <https://1145.am/db/2321097/Oxford_Bioscience_Partners>,
        <https://1145.am/db/2324159/Oxford_Bioscience_Partners>,
        <https://1145.am/db/2324289/Oxford_Bioscience_Partners>,
        <https://1145.am/db/2326551/Oxford_Bioscience_Partners>,
        <https://1145.am/db/2327379/Oxford_Bioscience_Partners>,
        <https://1145.am/db/2331639/Oxford_Bioscience_Partners>,
        <https://1145.am/db/2331988/Oxford_Bioscience_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2349753/Skyline_Ventures> a org:Organization ;
    ns1:basedInLowRaw "Mass" ;
    ns1:documentDate "2010-08-11T13:20:47+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Dicerna Closes $25 Million Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/dicerna-closes-25-million-series-b-financing> ;
    ns1:foundName "Skyline Ventures" ;
    ns1:investor <https://1145.am/db/2349753/Series_B_Investment_Abingworth_Dicerna_Pharmaceuticals_Domain_Associates_Oxford_Bioscience_Partners_Skyline_Ventures_Completed> ;
    ns1:name "Skyline Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/2300653/Skyline_Ventures>,
        <https://1145.am/db/2303098/Skyline_Ventures>,
        <https://1145.am/db/2303598/Skyline_Ventures>,
        <https://1145.am/db/2305791/Skyline_Ventures>,
        <https://1145.am/db/2308925/Skyline_Ventures>,
        <https://1145.am/db/2308931/Skyline_Ventures>,
        <https://1145.am/db/2313305/Skyline_Ventures>,
        <https://1145.am/db/2313306/Skyline_Ventures>,
        <https://1145.am/db/2337571/Skyline_Ventures>,
        <https://1145.am/db/2337577/Skyline_Ventures>,
        <https://1145.am/db/2340204/Skyline_Ventures>,
        <https://1145.am/db/2340207/Skyline_Ventures>,
        <https://1145.am/db/2353439/Skyline_Ventures>,
        <https://1145.am/db/2355586/Skyline_Ventures>,
        <https://1145.am/db/2359287/Skyline_Ventures>,
        <https://1145.am/db/2365296/Skyline_Ventures>,
        <https://1145.am/db/2546216/Skyline_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2350780/L_Capital_Partners> a org:Organization ;
    ns1:basedInLowRaw "N.C." ;
    ns1:description "financing" ;
    ns1:documentDate "2010-08-13T13:29:08+00:00"^^xsd:dateTime ;
    ns1:documentTitle "CeNeRx BioPharma Completes $13 Million Series C Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cenerx-biopharma-completes-13-million-series-c-financing> ;
    ns1:foundName "L Capital Partners" ;
    ns1:investor <https://1145.am/db/2350780/Series_C_Investment_Cenerx_Biopharma_Inc_L_Capital_Partners_Pappas_Ventures_Perseus_Soros_Biopharmaceutical_Fund_Completed> ;
    ns1:name "L Capital Partners" ;
    ns1:sameAsHigh <https://1145.am/db/2539913/L_Capital_Partners> ;
    ns1:sameAsMedium <https://1145.am/db/2328388/L_Capital_Partners>,
        <https://1145.am/db/2332753/L_Capital_Partners>,
        <https://1145.am/db/2350779/L_Capital_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2350780/Perseus_Soros_Biopharmaceutical_Fund> a org:Organization ;
    ns1:basedInLowRaw "N.C." ;
    ns1:description "Investing" ;
    ns1:documentDate "2010-08-13T13:29:08+00:00"^^xsd:dateTime ;
    ns1:documentTitle "CeNeRx BioPharma Completes $13 Million Series C Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cenerx-biopharma-completes-13-million-series-c-financing> ;
    ns1:foundName "Perseus Soros Biopharmaceutical Fund" ;
    ns1:investor <https://1145.am/db/2350780/Series_C_Investment_Cenerx_Biopharma_Inc_L_Capital_Partners_Pappas_Ventures_Perseus_Soros_Biopharmaceutical_Fund_Completed> ;
    ns1:name "Perseus Soros Biopharmaceutical Fund" ;
    ns1:sameAsHigh <https://1145.am/db/2352441/Perseus-Soros_Biopharmaceutical_Fund> ;
    ns1:sameAsMedium <https://1145.am/db/2350779/Perseus_Soros_Biopharmaceutical_Fund>,
        <https://1145.am/db/2352436/Perseus-Soros_Biopharmaceutical_Fund>,
        <https://1145.am/db/2352442/Perseus-Soros_Biopharmaceutical_Fund> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2350800/Bridge_Investment_Aryx_Aryx_Has_Not_Happened> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-08-16T15:22:55+00:00"^^xsd:dateTime ;
    ns1:documentExtract "FREMONT, Calif., Aug 16, 2010 (BUSINESS WIRE) - ARYx Therapeutics, Inc. (NASDAQ: ARYX) today announced that it has secured bridge financing to allow ARYx time and resources to potentially complete a transaction that could create significant value for stockholders." ;
    ns1:documentTitle "ARYx Therapeutics Secures Interim Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/aryx-therapeutics-secures-interim-financing> ;
    ns1:foundName "financing" ;
    ns1:name "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2350800/Aryx> ;
    ns1:targetDetails "bridge" ;
    ns1:when "2010-08-16T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "2010-Aug-16" ;
    ns1:whereGeoName "Fremont" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5350734/about.rdf> ;
    ns1:whereRaw "FREMONT, Calif" .

<https://1145.am/db/2352382/Vi_Partners> a org:Organization ;
    ns1:basedInLowRaw "Switzerland" ;
    ns1:description "venture capital firms in the biotech industry" ;
    ns1:documentDate "2010-11-12T14:21:30+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Delenex Therapeutics Secures CHF 13.5 Million Series A Venture Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/delenex-therapeutics-secures-chf-13-5-million-series-a-venture-financing> ;
    ns1:foundName "VI Partners" ;
    ns1:industry "biotech" ;
    ns1:investor <https://1145.am/db/2352382/Series_A_Investment_Biomedinvest_Delenex_Therapeutics_Ag_Hbm_Biocapital_Hbm_Bioventures_Sv_Life_Sciences_Vi_Partners_Completed> ;
    ns1:name "VI Partners" ;
    ns1:sameAsHigh <https://1145.am/db/2286372/Viela_Bio>,
        <https://1145.am/db/2351897/Virobay>,
        <https://1145.am/db/2356341/Vectura>,
        <https://1145.am/db/520279/Virica_Biotech_Inc>,
        <https://1145.am/db/522815/Virica_Biotech_Inc> ;
    ns1:sameAsMedium <https://1145.am/db/1386529/Vi_Partners>,
        <https://1145.am/db/1388463/Vi_Partners>,
        <https://1145.am/db/2154009/Vi_Partners>,
        <https://1145.am/db/2313124/Vi_Partners>,
        <https://1145.am/db/2313322/Vi_Partners>,
        <https://1145.am/db/2313438/Vi_Partners>,
        <https://1145.am/db/2322761/Vi_Partners>,
        <https://1145.am/db/2324792/Vi_Partners_Ag>,
        <https://1145.am/db/2339295/Vi_Partners>,
        <https://1145.am/db/2341792/Vi_Partners>,
        <https://1145.am/db/2341800/Vi_Partners>,
        <https://1145.am/db/2347574/Vi_Partners_Ag>,
        <https://1145.am/db/2352383/Vi_Partners>,
        <https://1145.am/db/2370979/Vi_Partners>,
        <https://1145.am/db/935322/Vi_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352414/Bessemer_Venture_Partners> a org:Organization ;
    ns1:basedInLowRaw "CAMBRIDGE" ;
    ns1:documentDate "2010-11-15T14:49:42+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Cerulean Pharma Inc. Closes $24 Million in Series C Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cerulean-pharma-inc-closes-24-million-series-c-financing> ;
    ns1:foundName "Bessemer Venture Partners" ;
    ns1:investor <https://1145.am/db/2352414/Series_C_Investment_Bessemer_Venture_Partners_Cerulean_Pharma_Inc_Lilly_Ventures_Lux_Capital_Polaris_Venture_Partners_Venrock_Completed> ;
    ns1:name "Bessemer Venture Partners" ;
    ns1:sameAsMedium <https://1145.am/db/1060146/Bessemer_Venture_Partners>,
        <https://1145.am/db/1061468/Bessemer_Venture_Partners>,
        <https://1145.am/db/1061911/Bessemer_Venture_Partners>,
        <https://1145.am/db/1064710/Bessemer_Venture_Partners>,
        <https://1145.am/db/1090262/Bessemer_Venture_Partners>,
        <https://1145.am/db/1140521/Bessemer_Venture_Partners>,
        <https://1145.am/db/1150887/Bessemer_Venture_Partners>,
        <https://1145.am/db/1153184/Bessemer_Venture_Partners>,
        <https://1145.am/db/1168925/Bessemer_Venture_Partners>,
        <https://1145.am/db/1171251/Bessemer_Venture_Partners>,
        <https://1145.am/db/1287496/Bessemer_Venture_Partners>,
        <https://1145.am/db/1297270/Bessemer_Venture_Partners>,
        <https://1145.am/db/1298072/Bessemer_Venture_Partners>,
        <https://1145.am/db/1311917/Bessemer_Venture_Partners>,
        <https://1145.am/db/1412727/Bessemer_Venture_Partners>,
        <https://1145.am/db/1445566/Bessemer_Venture_Partners>,
        <https://1145.am/db/1449740/Bessemer_Venture_Partners>,
        <https://1145.am/db/1480187/Bessemer_Venture_Partners>,
        <https://1145.am/db/1490295/Bessemer_Venture_Partners>,
        <https://1145.am/db/1667738/Bessemer_Venture_Partners>,
        <https://1145.am/db/1669991/Bessemer_Venture_Partners>,
        <https://1145.am/db/1697155/Bessemer_Venture_Partners>,
        <https://1145.am/db/1698509/Bessemer_Venture_Partners>,
        <https://1145.am/db/1703633/Bessemer_Venture_Partners>,
        <https://1145.am/db/1706697/Bessemer_Venture_Partners>,
        <https://1145.am/db/1707187/Bessemer_Venture_Partners>,
        <https://1145.am/db/1712471/Bessemer_Venture_Partners>,
        <https://1145.am/db/1717313/Bessemer_Venture_Partners>,
        <https://1145.am/db/1718800/Bessemer_Venture_Partners>,
        <https://1145.am/db/1723948/Bessemer_Venture_Partners>,
        <https://1145.am/db/1725530/Bessemer_Venture_Partners>,
        <https://1145.am/db/1726088/Bessemer_Venture_Partners>,
        <https://1145.am/db/1731036/Bessemer_Venture_Partners>,
        <https://1145.am/db/1735755/Bessemer_Venture_Partners>,
        <https://1145.am/db/1736811/Bessemer_Venture_Partners>,
        <https://1145.am/db/1742802/Bessemer_Venture_Partners>,
        <https://1145.am/db/1744158/Bessemer_Venture_Partners>,
        <https://1145.am/db/1744201/Bessemer_Venture_Partners>,
        <https://1145.am/db/1744656/Bessemer_Venture_Partners>,
        <https://1145.am/db/1744676/Bessemer_Venture_Partners>,
        <https://1145.am/db/1748765/Bessemer_Venture_Partners>,
        <https://1145.am/db/1749643/Bessemer_Venture_Partners>,
        <https://1145.am/db/1750217/Bessemer_Venture_Partners>,
        <https://1145.am/db/1751506/Bessemer_Venture_Partners>,
        <https://1145.am/db/1751790/Bessemer_Venture_Partners>,
        <https://1145.am/db/1751800/Bessemer_Venture_Partners>,
        <https://1145.am/db/1752609/Bessemer_Venture_Partners>,
        <https://1145.am/db/1756092/Bessemer_Venture_Partners>,
        <https://1145.am/db/1756150/Bessemer_Venture_Partners>,
        <https://1145.am/db/1756999/Bessemer_Venture_Partners>,
        <https://1145.am/db/1757845/Bessemer_Venture_Partners>,
        <https://1145.am/db/1758776/Bessemer_Venture_Partners>,
        <https://1145.am/db/1759851/Bessemer_Venture_Partners>,
        <https://1145.am/db/1759923/Bessemer_Venture_Partners>,
        <https://1145.am/db/1760213/Bessemer_Venture_Partners>,
        <https://1145.am/db/1762343/Bessemer_Venture_Partners>,
        <https://1145.am/db/1763433/Bessemer_Venture_Partners>,
        <https://1145.am/db/1763774/Bessemer_Venture_Partners>,
        <https://1145.am/db/1765092/Bessemer_Venture_Partners>,
        <https://1145.am/db/1765646/Bessemer_Venture_Partners>,
        <https://1145.am/db/1767075/Bessemer_Venture_Partners>,
        <https://1145.am/db/1771769/Bessemer_Venture_Partners>,
        <https://1145.am/db/1772047/Bessemer_Venture_Partners>,
        <https://1145.am/db/1772381/Bessemer_Venture_Partners>,
        <https://1145.am/db/1774323/Bessemer_Venture_Partners>,
        <https://1145.am/db/1775794/Bessemer_Venture_Partners>,
        <https://1145.am/db/1776988/Bessemer_Venture_Partners>,
        <https://1145.am/db/1778844/Bessemer_Venture_Partners>,
        <https://1145.am/db/1779320/Bessemer_Venture_Partners>,
        <https://1145.am/db/1779634/Bessemer_Venture_Partners>,
        <https://1145.am/db/1780998/Bessemer_Venture_Partners>,
        <https://1145.am/db/1795531/Bessemer_Venture_Partners>,
        <https://1145.am/db/1797945/Bessemer_Venture_Partners>,
        <https://1145.am/db/1800364/Bessemer_Venture_Partners>,
        <https://1145.am/db/1801088/Bessemer_Venture_Partners>,
        <https://1145.am/db/1802034/Bessemer_Venture_Partners>,
        <https://1145.am/db/1802590/Bessemer_Venture_Partners>,
        <https://1145.am/db/1802834/Bessemer_Venture_Partners>,
        <https://1145.am/db/1806684/Bessemer_Venture_Partners>,
        <https://1145.am/db/1808735/Bessemer_Venture_Partners>,
        <https://1145.am/db/1813337/Bessemer_Venture_Partners>,
        <https://1145.am/db/1813349/Bessemer_Venture_Partners>,
        <https://1145.am/db/1814014/Bessemer_Venture_Partners>,
        <https://1145.am/db/1816701/Bessemer_Venture_Partners>,
        <https://1145.am/db/1818326/Bessemer_Venture_Partners>,
        <https://1145.am/db/1818535/Bessemer_Venture_Partners>,
        <https://1145.am/db/1819651/Bessemer_Venture_Partners>,
        <https://1145.am/db/1820660/Bessemer_Venture_Partners>,
        <https://1145.am/db/1821929/Bessemer_Venture_Partners>,
        <https://1145.am/db/1823001/Bessemer_Venture_Partners>,
        <https://1145.am/db/1823415/Bessemer_Venture_Partners>,
        <https://1145.am/db/1825267/Bessemer_Venture_Partners>,
        <https://1145.am/db/1826794/Bessemer_Ventures_Partners>,
        <https://1145.am/db/1828092/Bessemer_Venture_Partners>,
        <https://1145.am/db/1833296/Bessemer_Venture_Partners>,
        <https://1145.am/db/1836250/Bessemer_Venture_Partners>,
        <https://1145.am/db/1838678/Bessemer_Venture_Partners>,
        <https://1145.am/db/1839990/Bessemer_Venture_Partners>,
        <https://1145.am/db/1843244/Bessemer_Venture_Partners>,
        <https://1145.am/db/1846957/Bessemer_Venture_Partners>,
        <https://1145.am/db/1847160/Bessemer_Venture_Partners>,
        <https://1145.am/db/1849046/Bessemer_Venture_Partners>,
        <https://1145.am/db/1849606/Bessemer_Venture_Partners>,
        <https://1145.am/db/1849746/Bessemer_Venture_Partners>,
        <https://1145.am/db/1850076/Bessemer_Venture_Partners>,
        <https://1145.am/db/1850727/Bessemer_Venture_Partners>,
        <https://1145.am/db/1851792/Bessemer_Venture_Partners>,
        <https://1145.am/db/1853292/Bessemer_Venture_Partners>,
        <https://1145.am/db/1856085/Bessemer_Venture_Partners>,
        <https://1145.am/db/1857212/Bessemer_Venture_Partners>,
        <https://1145.am/db/1857278/Bessemer_Venture_Partners>,
        <https://1145.am/db/1859331/Bessemer_Venture_Partners>,
        <https://1145.am/db/1860367/Bessemer_Venture_Partners>,
        <https://1145.am/db/1860406/Bessemer_Venture_Partners>,
        <https://1145.am/db/1860637/Bessemer_Venture_Partners>,
        <https://1145.am/db/1861518/Bessemer_Venture_Partners>,
        <https://1145.am/db/1866032/Bessemer_Venture_Partners>,
        <https://1145.am/db/1876003/Bessemer_Venture_Partners>,
        <https://1145.am/db/1883858/Bessemer_Venture_Partners>,
        <https://1145.am/db/1885320/Bessemer_Venture_Partners>,
        <https://1145.am/db/1885998/Bessemer_Venture_Partners>,
        <https://1145.am/db/1889732/Bessemer_Venture_Partners>,
        <https://1145.am/db/1892105/Bessemer_Venture_Partners>,
        <https://1145.am/db/1893502/Bessemer_Venture_Partners>,
        <https://1145.am/db/1898837/Bessemer_Venture_Partners>,
        <https://1145.am/db/1904197/Bessemer_Venture_Partners>,
        <https://1145.am/db/1910644/Bessemer_Venture_Partners>,
        <https://1145.am/db/1914189/Bessemer_Venture_Partners>,
        <https://1145.am/db/1917346/Bessemer_Venture_Partners>,
        <https://1145.am/db/1921374/Bessemer_Venture_Partners>,
        <https://1145.am/db/1921599/Bessemer_Venture_Partners>,
        <https://1145.am/db/1947303/Bessemer_Venture_Partners>,
        <https://1145.am/db/1954147/Bessemer_Venture_Partners>,
        <https://1145.am/db/2011521/Bessemer_Venture_Partners>,
        <https://1145.am/db/2013193/Bessemer_Venture_Partners>,
        <https://1145.am/db/2031790/Bessemer_Venture_Partners>,
        <https://1145.am/db/2043214/Bessemer_Venture_Partners>,
        <https://1145.am/db/2051110/Bessemer_Venture_Partners>,
        <https://1145.am/db/2059038/Bessemer_Venture_Partners>,
        <https://1145.am/db/2070098/Bessemer_Venture_Partners>,
        <https://1145.am/db/207823/Bessemer_Venture_Partners>,
        <https://1145.am/db/2125259/Bessemer_Venture_Partners>,
        <https://1145.am/db/2127786/Bessemer_Venture_Partners>,
        <https://1145.am/db/2141061/Bessemer_Venture_Partners>,
        <https://1145.am/db/2142825/Bessemer_Venture_Partners>,
        <https://1145.am/db/2173983/Bessemer_Venture_Partners>,
        <https://1145.am/db/2181016/Bessemer_Venture_Partners>,
        <https://1145.am/db/2194210/Bessemer_Venture_Partners>,
        <https://1145.am/db/2197248/Bessemer_Venture_Partners>,
        <https://1145.am/db/221321/Bessemer_Venture_Partners>,
        <https://1145.am/db/2236188/Bessemer_Venture_Partners>,
        <https://1145.am/db/2303250/Bessemer_Venture_Partners>,
        <https://1145.am/db/2303251/Bessemer_Venture_Partners>,
        <https://1145.am/db/2303257/Bessemer_Venture_Partners>,
        <https://1145.am/db/2303675/Bessemer_Venture_Partners>,
        <https://1145.am/db/2311551/Bessemer_Venture_Partners>,
        <https://1145.am/db/2316356/Bessemer_Venture_Partners>,
        <https://1145.am/db/2317918/Bessemer_Venture_Partners>,
        <https://1145.am/db/2324076/Bessemer_Venture_Partners>,
        <https://1145.am/db/2325326/Bessemer_Venture_Partners>,
        <https://1145.am/db/2338625/Bessemer_Venture_Partners>,
        <https://1145.am/db/2338633/Bessemer_Venture_Partners>,
        <https://1145.am/db/2339925/Bessemer_Venture_Partners>,
        <https://1145.am/db/2339926/Bessemer_Venture_Partners>,
        <https://1145.am/db/2348448/Bessemer_Venture_Partners>,
        <https://1145.am/db/2349437/Bessemer_Venture_Partners>,
        <https://1145.am/db/2351520/Bessemer_Venture_Partners>,
        <https://1145.am/db/2353404/Bessemer_Venture_Partners>,
        <https://1145.am/db/2353415/Bessemer_Venture_Partners>,
        <https://1145.am/db/2362871/Bessemer_Venture_Partners>,
        <https://1145.am/db/2363330/Bessemer_Venture_Partners>,
        <https://1145.am/db/2621506/Bessemer_Venture_Partners>,
        <https://1145.am/db/2677219/Bessemer_Venture_Partners>,
        <https://1145.am/db/2766437/Bessemer_Venture_Partners>,
        <https://1145.am/db/293891/Bessemer_Venture_Partners>,
        <https://1145.am/db/325080/Bessemer_Venture_Partners>,
        <https://1145.am/db/341984/Bessemer_Venture_Partners>,
        <https://1145.am/db/341990/Bessemer_Venture_Partners>,
        <https://1145.am/db/425262/Bessemer_Venture_Partners>,
        <https://1145.am/db/472389/Bessemer_Venture_Partners>,
        <https://1145.am/db/473354/Bessemer_Venture_Partners>,
        <https://1145.am/db/478025/Bessemer_Venture_Partners>,
        <https://1145.am/db/506309/Bessemer_Venture_Partners>,
        <https://1145.am/db/507249/Bessemer_Venture_Partners>,
        <https://1145.am/db/508115/Bessemer_Venture_Partners>,
        <https://1145.am/db/511072/Bessemer_Venture_Partners>,
        <https://1145.am/db/513305/Bessemer_Venture_Partners>,
        <https://1145.am/db/559318/Bessemer_Venture_Partners>,
        <https://1145.am/db/575249/Bessemer_Venture_Partners>,
        <https://1145.am/db/606291/Bessemer_Venture_Partners>,
        <https://1145.am/db/668230/Bessemer_Venture_Partners>,
        <https://1145.am/db/668965/Bessemer_Venture_Partners>,
        <https://1145.am/db/676869/Bessemer_Venture_Partners>,
        <https://1145.am/db/678140/Bessemer_Venture_Partners>,
        <https://1145.am/db/694924/Bessemer_Venture_Partners>,
        <https://1145.am/db/699860/Bessemer_Venture_Partners>,
        <https://1145.am/db/700171/Bessemer_Venture_Partners>,
        <https://1145.am/db/803541/Bessemer_Venture_Partners>,
        <https://1145.am/db/829118/Bessemer_Venture_Partners>,
        <https://1145.am/db/8314/Bessemer_Venture_Partners>,
        <https://1145.am/db/832264/Bessemer_Venture_Partners>,
        <https://1145.am/db/847157/Bessemer_Venture_Partners>,
        <https://1145.am/db/862760/Bessemer_Venture_Partners>,
        <https://1145.am/db/862851/Bessemer_Venture_Partners>,
        <https://1145.am/db/877618/Bessemer_Venture_Partners>,
        <https://1145.am/db/884806/Bessemer_Venture_Partners>,
        <https://1145.am/db/902390/Bessemer_Venture_Partners>,
        <https://1145.am/db/907582/Bessemer_Venture_Partners>,
        <https://1145.am/db/907975/Bessemer_Venture_Partners>,
        <https://1145.am/db/924505/Bessemer_Venture_Partners>,
        <https://1145.am/db/955858/Bessemer_Venture_Partners>,
        <https://1145.am/db/960320/Bessemer_Venture_Partners>,
        <https://1145.am/db/971418/Bessemer_Venture_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352414/Lilly_Ventures> a org:Organization ;
    ns1:basedInLowRaw "CAMBRIDGE, Mass" ;
    ns1:documentDate "2010-11-15T14:49:42+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Cerulean Pharma Inc. Closes $24 Million in Series C Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cerulean-pharma-inc-closes-24-million-series-c-financing> ;
    ns1:foundName "Lilly Ventures" ;
    ns1:investor <https://1145.am/db/2352414/Series_C_Investment_Bessemer_Venture_Partners_Cerulean_Pharma_Inc_Lilly_Ventures_Lux_Capital_Polaris_Venture_Partners_Venrock_Completed> ;
    ns1:name "Lilly Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/2301739/Lilly_Ventures>,
        <https://1145.am/db/2317455/Lilly_Ventures>,
        <https://1145.am/db/2318733/Lilly_Ventures>,
        <https://1145.am/db/2319777/Lilly_Ventures>,
        <https://1145.am/db/2320082/Lilly_Ventures>,
        <https://1145.am/db/2322022/Lilly_Ventures>,
        <https://1145.am/db/2322984/Lilly_Ventures>,
        <https://1145.am/db/2323003/Lilly_Ventures>,
        <https://1145.am/db/2324042/Lilly_Ventures>,
        <https://1145.am/db/2326222/Lilly_Ventures>,
        <https://1145.am/db/2327441/Lilly_Ventures>,
        <https://1145.am/db/2327442/Lilly_Ventures>,
        <https://1145.am/db/2332864/Lilly_Ventures>,
        <https://1145.am/db/2332868/Lilly_Ventures>,
        <https://1145.am/db/2336328/Lilly_Ventures>,
        <https://1145.am/db/2339666/Lilly_Ventures>,
        <https://1145.am/db/2340096/Lilly_Ventures>,
        <https://1145.am/db/2340942/Lilly_Ventures>,
        <https://1145.am/db/2343723/Lilly_Ventures>,
        <https://1145.am/db/2343724/Lilly_Ventures>,
        <https://1145.am/db/2347682/Lilly_Ventures>,
        <https://1145.am/db/2348448/Lilly_Ventures>,
        <https://1145.am/db/2353439/Lilly_Ventures>,
        <https://1145.am/db/2355586/Lilly_Ventures>,
        <https://1145.am/db/2356048/Lilly_Ventures>,
        <https://1145.am/db/2357676/Lilly_Ventures>,
        <https://1145.am/db/2357679/Lilly_Ventures>,
        <https://1145.am/db/2357682/Lilly_Ventures>,
        <https://1145.am/db/2361581/Lilly_Ventures>,
        <https://1145.am/db/2362715/Lilly_Ventures>,
        <https://1145.am/db/2363396/Lilly_Ventures>,
        <https://1145.am/db/2368240/Lilly_Ventures>,
        <https://1145.am/db/2368322/Lilly_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352414/Lux_Capital> a org:Organization ;
    ns1:basedInLowRaw "CAMBRIDGE" ;
    ns1:description "venture capital" ;
    ns1:documentDate "2010-11-15T14:49:42+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Cerulean Pharma Inc. Closes $24 Million in Series C Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cerulean-pharma-inc-closes-24-million-series-c-financing> ;
    ns1:foundName "Lux Capital" ;
    ns1:investor <https://1145.am/db/2352414/Series_C_Investment_Bessemer_Venture_Partners_Cerulean_Pharma_Inc_Lilly_Ventures_Lux_Capital_Polaris_Venture_Partners_Venrock_Completed> ;
    ns1:name "Lux Capital" ;
    ns1:sameAsHigh <https://1145.am/db/1119433/Lux_Capital>,
        <https://1145.am/db/1312926/Primavera_Capital_Group>,
        <https://1145.am/db/1407553/Lux_Capital>,
        <https://1145.am/db/1553919/Lux_Capital>,
        <https://1145.am/db/1555013/Lux_Capital>,
        <https://1145.am/db/1669908/Lux_Capital>,
        <https://1145.am/db/1697296/Lux_Capital>,
        <https://1145.am/db/1737151/Lux_Capital>,
        <https://1145.am/db/1761607/Lux_Capital>,
        <https://1145.am/db/1763354/Lux_Capital>,
        <https://1145.am/db/1782221/Lux_Capital>,
        <https://1145.am/db/1792186/Lux_Capital>,
        <https://1145.am/db/1796593/Lux_Capital>,
        <https://1145.am/db/1803458/Lux_Capital>,
        <https://1145.am/db/1808133/Lux_Capital>,
        <https://1145.am/db/1809178/Lux_Capital>,
        <https://1145.am/db/2284256/Lux_Capital>,
        <https://1145.am/db/2335750/Lux_Capital>,
        <https://1145.am/db/2337522/Lux_Capital>,
        <https://1145.am/db/2345439/Lux_Capital>,
        <https://1145.am/db/540507/Lux_Capital>,
        <https://1145.am/db/547564/Lurra_Capital>,
        <https://1145.am/db/684792/Lux_Capital>,
        <https://1145.am/db/747771/Lux_Capital>,
        <https://1145.am/db/765641/Lux_Capital>,
        <https://1145.am/db/935910/Lux_Capital>,
        <https://1145.am/db/936989/Lux_Capital>,
        <https://1145.am/db/940684/Lux_Capital> ;
    ns1:sameAsMedium <https://1145.am/db/1105217/Lux_Capital>,
        <https://1145.am/db/1106865/Lux_Capital>,
        <https://1145.am/db/1119661/Lux_Capital>,
        <https://1145.am/db/1122753/Lux_Capital>,
        <https://1145.am/db/1139654/Lux_Capital>,
        <https://1145.am/db/1143903/Lux_Capital>,
        <https://1145.am/db/1238486/Lux_Capital>,
        <https://1145.am/db/1285901/Lux_Capital>,
        <https://1145.am/db/1374025/Lux_Capital>,
        <https://1145.am/db/1375318/Lux_Capital>,
        <https://1145.am/db/1376203/Lux_Capital>,
        <https://1145.am/db/1536915/Lux_Capital>,
        <https://1145.am/db/1632690/Lux_Capital>,
        <https://1145.am/db/1734597/Lux_Capital>,
        <https://1145.am/db/1737409/Lux_Capital>,
        <https://1145.am/db/174200/Lux_Capital>,
        <https://1145.am/db/1743303/Lux_Capital>,
        <https://1145.am/db/1758194/Lux_Capital>,
        <https://1145.am/db/1762041/Lux_Capital>,
        <https://1145.am/db/1766887/Lux_Capital>,
        <https://1145.am/db/1777184/Lux_Capital>,
        <https://1145.am/db/1811725/Lux_Capital>,
        <https://1145.am/db/1815044/Lux_Capital>,
        <https://1145.am/db/1817051/Lux_Capital>,
        <https://1145.am/db/1818204/Lux_Capital>,
        <https://1145.am/db/1819710/Lux_Capital>,
        <https://1145.am/db/1827904/Lux_Capital>,
        <https://1145.am/db/1829422/Lux_Capital>,
        <https://1145.am/db/1838965/Lux_Capital>,
        <https://1145.am/db/1845217/Lux_Capital>,
        <https://1145.am/db/1846254/Lux_Capital>,
        <https://1145.am/db/1930816/Lux_Capital>,
        <https://1145.am/db/1932856/Lux_Capital>,
        <https://1145.am/db/2006781/Lux_Capital>,
        <https://1145.am/db/2138013/Lux_Capital>,
        <https://1145.am/db/2141058/Lux_Capital>,
        <https://1145.am/db/2178040/Lux_Capital>,
        <https://1145.am/db/2291716/Lux_Capital>,
        <https://1145.am/db/2291901/Lux_Capital>,
        <https://1145.am/db/2303675/Lux_Capital>,
        <https://1145.am/db/2304963/Lux_Capital>,
        <https://1145.am/db/2305327/Lux_Capital>,
        <https://1145.am/db/2328280/Lux_Capital>,
        <https://1145.am/db/2331549/Lux_Capital>,
        <https://1145.am/db/2335755/Lux_Capital>,
        <https://1145.am/db/2337571/Lux_Capital>,
        <https://1145.am/db/2337577/Lux_Capital>,
        <https://1145.am/db/2344256/Lux_Capital>,
        <https://1145.am/db/2345224/Lux_Capital>,
        <https://1145.am/db/2347102/Lux_Capital>,
        <https://1145.am/db/2348448/Lux_Capital>,
        <https://1145.am/db/2546216/Lux_Capital>,
        <https://1145.am/db/2633440/Lux_Capital>,
        <https://1145.am/db/2801014/Lux_Capital>,
        <https://1145.am/db/412847/Lux_Capital>,
        <https://1145.am/db/424834/Lux_Capital>,
        <https://1145.am/db/425188/Lux_Capital>,
        <https://1145.am/db/425281/Lux_Capital>,
        <https://1145.am/db/426160/Lux_Capital>,
        <https://1145.am/db/516176/Lux_Capital>,
        <https://1145.am/db/516613/Lux_Capital>,
        <https://1145.am/db/823763/Lux_Capital>,
        <https://1145.am/db/863878/Lux_Capital>,
        <https://1145.am/db/918904/Lux_Capital> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352414/Venrock> a org:Organization ;
    ns1:basedInLowRaw "CAMBRIDGE" ;
    ns1:documentDate "2010-11-15T14:49:42+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Cerulean Pharma Inc. Closes $24 Million in Series C Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cerulean-pharma-inc-closes-24-million-series-c-financing> ;
    ns1:foundName "Venrock" ;
    ns1:investor <https://1145.am/db/2352414/Series_C_Investment_Bessemer_Venture_Partners_Cerulean_Pharma_Inc_Lilly_Ventures_Lux_Capital_Polaris_Venture_Partners_Venrock_Completed> ;
    ns1:name "Venrock" ;
    ns1:sameAsMedium <https://1145.am/db/1263825/Venrock>,
        <https://1145.am/db/1700286/Venrock>,
        <https://1145.am/db/1718033/Venrock>,
        <https://1145.am/db/1719688/Venrock>,
        <https://1145.am/db/1735836/Venrock>,
        <https://1145.am/db/1736582/Venrock>,
        <https://1145.am/db/1746940/Venrock>,
        <https://1145.am/db/1750203/Venrock>,
        <https://1145.am/db/1757897/Venrock>,
        <https://1145.am/db/1758165/Venrock>,
        <https://1145.am/db/1793754/Venrock>,
        <https://1145.am/db/1796590/Venrock>,
        <https://1145.am/db/1801792/Venrock>,
        <https://1145.am/db/1821534/Venrock>,
        <https://1145.am/db/1828008/Venrock>,
        <https://1145.am/db/1829024/Venrock>,
        <https://1145.am/db/1830635/Venrock>,
        <https://1145.am/db/1834607/Venrock>,
        <https://1145.am/db/1835080/Venrock>,
        <https://1145.am/db/1846413/Venrock>,
        <https://1145.am/db/1848371/Venrock>,
        <https://1145.am/db/1856457/Venrock>,
        <https://1145.am/db/1870276/Venrock>,
        <https://1145.am/db/1870808/Venrock>,
        <https://1145.am/db/1877870/Venrock>,
        <https://1145.am/db/1881935/Venrock>,
        <https://1145.am/db/1889137/Venrock>,
        <https://1145.am/db/1891984/Venrock>,
        <https://1145.am/db/1895986/Venrock>,
        <https://1145.am/db/1903951/Venrock>,
        <https://1145.am/db/1911226/Venrock>,
        <https://1145.am/db/2242614/Venrock>,
        <https://1145.am/db/2282806/Venrock>,
        <https://1145.am/db/2290283/Venrock>,
        <https://1145.am/db/2291211/Venrock>,
        <https://1145.am/db/2291384/Venrock>,
        <https://1145.am/db/2296169/Venrock>,
        <https://1145.am/db/2296869/Venrock>,
        <https://1145.am/db/2298631/Venrock>,
        <https://1145.am/db/2299758/Venrock>,
        <https://1145.am/db/2303675/Venrock>,
        <https://1145.am/db/2307476/Venrock>,
        <https://1145.am/db/2317918/Venrock>,
        <https://1145.am/db/2326903/Venrock>,
        <https://1145.am/db/2327474/Venrock>,
        <https://1145.am/db/2328599/Venrock>,
        <https://1145.am/db/2331784/Venrock>,
        <https://1145.am/db/2335748/Venrock>,
        <https://1145.am/db/2338126/Venrock>,
        <https://1145.am/db/2338127/Venrock>,
        <https://1145.am/db/2339666/Venrock>,
        <https://1145.am/db/2340942/Venrock>,
        <https://1145.am/db/2345037/Venrock>,
        <https://1145.am/db/2345047/Venrock>,
        <https://1145.am/db/2348448/Venrock>,
        <https://1145.am/db/2348857/Venrock>,
        <https://1145.am/db/2349834/Venrock>,
        <https://1145.am/db/2350164/Venrock>,
        <https://1145.am/db/2350167/Venrock>,
        <https://1145.am/db/2356064/Venrock>,
        <https://1145.am/db/2358173/Venrock>,
        <https://1145.am/db/2359334/Venrock>,
        <https://1145.am/db/2360682/Venrock>,
        <https://1145.am/db/2366775/Venrock>,
        <https://1145.am/db/2366984/Venrock>,
        <https://1145.am/db/2368501/Venrock>,
        <https://1145.am/db/2370436/Venrock>,
        <https://1145.am/db/2371160/Venrock>,
        <https://1145.am/db/2371163/Venrock>,
        <https://1145.am/db/2538407/Venrock>,
        <https://1145.am/db/2569515/Venrock>,
        <https://1145.am/db/2569522/Venrock>,
        <https://1145.am/db/437679/Venrock>,
        <https://1145.am/db/676854/Venrock>,
        <https://1145.am/db/678071/Venrock>,
        <https://1145.am/db/773235/Venrock>,
        <https://1145.am/db/893359/Venrock>,
        <https://1145.am/db/894233/Venrock>,
        <https://1145.am/db/922552/Venrock>,
        <https://1145.am/db/923335/Venrock> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352805/Domain_Associates_Clarus_Ventures_Quaker_Bioventures> a org:Organization ;
    ns1:description "Investing" ;
    ns1:documentDate "2010-08-19T15:26:14+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Venture groups snap up $50M block of Achillion shares" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/venture-groups-snap-up-50m-block-of-achillion-shares> ;
    ns1:foundName "Domain Associates, Clarus Ventures, Quaker BioVentures" ;
    ns1:industry "Pharmaceuticals" ;
    ns1:investor <https://1145.am/db/2352805/Investment_Achillion_Pharmaceuticals_Domain_Associates_Clarus_Ventures_Quaker_Bioventures_Pappas_Ventures_Completed> ;
    ns1:name "Domain Associates, Clarus Ventures, Quaker BioVentures" ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352807/Enterprise_Partners> a org:Organization ;
    ns1:basedInLowRaw "Calif" ;
    ns1:description "financing" ;
    ns1:documentDate "2010-08-19T15:28:58+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Complete Genomics, Inc. Announces Completion of $39 Million Series E Financing and Addresses Illumina Patent Infringement Lawsui" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/complete-genomics-inc-announces-completion-of-39-million-series-e-financing-and-addresses> ;
    ns1:foundName "Enterprise Partners" ;
    ns1:investor <https://1145.am/db/2352807/Series_E_Investment_Complete_Genomics_Enterprise_Partners_Essex_Woodlands_Highland_Capital_Ovp_Venture_Partners_Orbimed_Advisors_Prospect_Venture_Partners_Sands_Capital_Completed> ;
    ns1:name "Enterprise Partners" ;
    ns1:sameAsMedium <https://1145.am/db/2352804/Enterprise_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352807/Essex_Woodlands> a org:Organization ;
    ns1:basedInLowRaw "Calif" ;
    ns1:description "financing" ;
    ns1:documentDate "2010-08-19T15:28:58+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Complete Genomics, Inc. Announces Completion of $39 Million Series E Financing and Addresses Illumina Patent Infringement Lawsui" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/complete-genomics-inc-announces-completion-of-39-million-series-e-financing-and-addresses> ;
    ns1:foundName "Essex Woodlands" ;
    ns1:investor <https://1145.am/db/2352807/Series_E_Investment_Complete_Genomics_Enterprise_Partners_Essex_Woodlands_Highland_Capital_Ovp_Venture_Partners_Orbimed_Advisors_Prospect_Venture_Partners_Sands_Capital_Completed> ;
    ns1:name "Essex Woodlands" ;
    ns1:sameAsMedium <https://1145.am/db/2295687/Essex_Woodlands>,
        <https://1145.am/db/2317201/Essex_Woodlands>,
        <https://1145.am/db/2322742/Essex_Woodlands>,
        <https://1145.am/db/2331820/Essex_Woodlands>,
        <https://1145.am/db/2349802/Essex_Woodlands>,
        <https://1145.am/db/2352804/Essex_Woodlands>,
        <https://1145.am/db/2366333/Essex_Woodlands>,
        <https://1145.am/db/2368062/Essex_Woodlands>,
        <https://1145.am/db/2578052/Essex_Woodlands> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352807/Highland_Capital> a org:Organization ;
    ns1:basedInLowRaw "Calif" ;
    ns1:description "financing" ;
    ns1:documentDate "2010-08-19T15:28:58+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Complete Genomics, Inc. Announces Completion of $39 Million Series E Financing and Addresses Illumina Patent Infringement Lawsui" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/complete-genomics-inc-announces-completion-of-39-million-series-e-financing-and-addresses> ;
    ns1:foundName "Highland Capital" ;
    ns1:investor <https://1145.am/db/2352807/Series_E_Investment_Complete_Genomics_Enterprise_Partners_Essex_Woodlands_Highland_Capital_Ovp_Venture_Partners_Orbimed_Advisors_Prospect_Venture_Partners_Sands_Capital_Completed> ;
    ns1:name "Highland Capital" ;
    ns1:sameAsHigh <https://1145.am/db/1716136/Highland_Capital_Partners>,
        <https://1145.am/db/1803787/Highland_Capital_Partners>,
        <https://1145.am/db/1824461/Highland_Partners>,
        <https://1145.am/db/1830368/Highland_Capital_Partners>,
        <https://1145.am/db/1846953/Highland_Capital_Partners>,
        <https://1145.am/db/1859069/Highland_Capital_Partners>,
        <https://1145.am/db/1860137/Highland_Capital_Partners>,
        <https://1145.am/db/1876439/Highland_Partners>,
        <https://1145.am/db/1890839/Highland_Capital_Partners>,
        <https://1145.am/db/2286842/Highland_Capital_Partners>,
        <https://1145.am/db/2343184/Highland_Capital_Partners>,
        <https://1145.am/db/2367199/Highland_Capital_Partners>,
        <https://1145.am/db/435534/Highlander_Partners>,
        <https://1145.am/db/437475/Highlander_Partners>,
        <https://1145.am/db/437517/Highlander_Partners>,
        <https://1145.am/db/438992/Highlander_Partners> ;
    ns1:sameAsMedium <https://1145.am/db/1785265/Highland_Capital>,
        <https://1145.am/db/1794342/Highland_Capital>,
        <https://1145.am/db/1821735/Highland_Capital>,
        <https://1145.am/db/1823415/Highland_Capital>,
        <https://1145.am/db/1830648/Highland_Capital>,
        <https://1145.am/db/1851727/Highland_Capital>,
        <https://1145.am/db/1881932/Highland_Capital>,
        <https://1145.am/db/1882301/Highland_Capital>,
        <https://1145.am/db/513897/Highland_Capital>,
        <https://1145.am/db/514151/Highland_Capital> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352807/Ovp_Venture_Partners> a org:Organization ;
    ns1:basedInLowRaw "Calif" ;
    ns1:description "financing" ;
    ns1:documentDate "2010-08-19T15:28:58+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Complete Genomics, Inc. Announces Completion of $39 Million Series E Financing and Addresses Illumina Patent Infringement Lawsui" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/complete-genomics-inc-announces-completion-of-39-million-series-e-financing-and-addresses> ;
    ns1:foundName "OVP Venture Partners" ;
    ns1:investor <https://1145.am/db/2352807/Series_E_Investment_Complete_Genomics_Enterprise_Partners_Essex_Woodlands_Highland_Capital_Ovp_Venture_Partners_Orbimed_Advisors_Prospect_Venture_Partners_Sands_Capital_Completed> ;
    ns1:name "OVP Venture Partners" ;
    ns1:sameAsHigh <https://1145.am/db/1798788/Openview_Venture_Partners>,
        <https://1145.am/db/2207716/Openview_Venture_Partners>,
        <https://1145.am/db/2347368/Ovp_Venture_Partners> ;
    ns1:sameAsMedium <https://1145.am/db/1907771/Ovp_Venture_Partners>,
        <https://1145.am/db/2302602/Ovp_Venture_Partners>,
        <https://1145.am/db/2302603/Ovp_Venture_Partners>,
        <https://1145.am/db/2326159/Ovp_Venture_Partners>,
        <https://1145.am/db/2329125/Ovp_Venture_Partners>,
        <https://1145.am/db/2329131/Ovp_Venture_Partners>,
        <https://1145.am/db/2345223/Ovp_Venture_Partners>,
        <https://1145.am/db/2345769/Ovp_Venture_Partners>,
        <https://1145.am/db/2352804/Ovp_Venture_Partners>,
        <https://1145.am/db/2354295/Ovp_Venture_Partners>,
        <https://1145.am/db/2366049/Ovp_Venture_Partners>,
        <https://1145.am/db/2366055/Ovp_Venture_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352807/Sands_Capital> a org:Organization ;
    ns1:basedInLowRaw "Calif" ;
    ns1:description "financing" ;
    ns1:documentDate "2010-08-19T15:28:58+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Complete Genomics, Inc. Announces Completion of $39 Million Series E Financing and Addresses Illumina Patent Infringement Lawsui" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/complete-genomics-inc-announces-completion-of-39-million-series-e-financing-and-addresses> ;
    ns1:foundName "Sands Capital" ;
    ns1:investor <https://1145.am/db/2352807/Series_E_Investment_Complete_Genomics_Enterprise_Partners_Essex_Woodlands_Highland_Capital_Ovp_Venture_Partners_Orbimed_Advisors_Prospect_Venture_Partners_Sands_Capital_Completed> ;
    ns1:name "Sands Capital" ;
    ns1:sameAsHigh <https://1145.am/db/1196006/Sands_Capital>,
        <https://1145.am/db/181664/Sands_Capital>,
        <https://1145.am/db/428602/Sands_Capital> ;
    ns1:sameAsMedium <https://1145.am/db/1083569/Sands_Capital>,
        <https://1145.am/db/1091121/Sands_Capital>,
        <https://1145.am/db/1091898/Sands_Capital>,
        <https://1145.am/db/1231536/Sands_Capital>,
        <https://1145.am/db/1320499/Sands_Capital>,
        <https://1145.am/db/1334895/Sands_Capital>,
        <https://1145.am/db/1573697/Sands_Capital>,
        <https://1145.am/db/1654589/Sands_Capital>,
        <https://1145.am/db/1728428/Sands_Capital>,
        <https://1145.am/db/1735850/Sands_Capital>,
        <https://1145.am/db/1741631/Sands_Capital>,
        <https://1145.am/db/1748549/Sands_Capital>,
        <https://1145.am/db/1749645/Sands_Capital>,
        <https://1145.am/db/1786720/Sands_Capital>,
        <https://1145.am/db/1823381/Sands_Capital>,
        <https://1145.am/db/1847505/Sands_Capital>,
        <https://1145.am/db/2093410/Sands_Capital>,
        <https://1145.am/db/2185936/Sands_Capital>,
        <https://1145.am/db/2195351/Sands_Capital>,
        <https://1145.am/db/2284412/Sands_Capital>,
        <https://1145.am/db/2352804/Sands_Capital>,
        <https://1145.am/db/336353/Sands_Capital>,
        <https://1145.am/db/387629/Sands_Capital>,
        <https://1145.am/db/425953/Sands_Capital>,
        <https://1145.am/db/487399/Sands_Capital>,
        <https://1145.am/db/586002/Sands_Capital>,
        <https://1145.am/db/604349/Sands_Capital>,
        <https://1145.am/db/606074/Sands_Capital> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352820/Novartis_Option_Fund> a org:Organization ;
    ns1:basedInLowRaw "Mass" ;
    ns1:description "The investment" ;
    ns1:documentDate "2010-08-20T13:33:44+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Anchor Therapeutics Nabs $10M for New Class of Peptide Drugs Against Hard Targets" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/anchor-therapeutics-nabs-10m-for-new-class-of-peptide-drugs-against-hard-targets> ;
    ns1:foundName "Novartis Option Fund",
        "the Novartis Option Fund" ;
    ns1:investor <https://1145.am/db/2352820/Series_B_Investment_Anchor_Therapeutics_Healthcare_Ventures_Novartis_Option_Fund_Tvm_Capital_Completed> ;
    ns1:name "Novartis Option Fund" ;
    ns1:sameAsHigh <https://1145.am/db/2301739/Novartis_Option_Fund>,
        <https://1145.am/db/2303656/Novartis_Option_Fund> ;
    ns1:sameAsMedium <https://1145.am/db/2301741/Novartis_Option_Fund>,
        <https://1145.am/db/2311570/Novartis_Option_Fund>,
        <https://1145.am/db/2316601/Novartis_Option_Fund>,
        <https://1145.am/db/2316605/Novartis_Option_Fund>,
        <https://1145.am/db/2322953/Novartis_Option_Fund>,
        <https://1145.am/db/2332748/Novartis_Option_Fund>,
        <https://1145.am/db/2352814/Novartis_Option_Fund> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2354899/Novo_Ventures> a org:Organization ;
    ns1:basedInLowRaw "SAN DIEGO" ;
    ns1:description "venture capital" ;
    ns1:documentDate "2010-08-30T13:07:55+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Otonomy Closes $38.5 Million Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/otonomy-closes-38-5-million-series-b-financing> ;
    ns1:foundName "Novo Ventures" ;
    ns1:investor <https://1145.am/db/2354899/Series_B_Investment_Domain_Associates_Novo_Ventures_Otonomy_Rivervest_Venture_Partners_Tpg_Biotech_Completed> ;
    ns1:name "Novo Ventures" ;
    ns1:sameAsHigh <https://1145.am/db/2309507/Novo_A_S>,
        <https://1145.am/db/2313143/Novo_Ventures>,
        <https://1145.am/db/2339295/Novo_Ventures>,
        <https://1145.am/db/2343966/Novo_Ventures>,
        <https://1145.am/db/2345268/Novo_A_S>,
        <https://1145.am/db/2364505/Novo_A_S>,
        <https://1145.am/db/2570481/Novo_Ventures>,
        <https://1145.am/db/2570483/Novo_Ventures> ;
    ns1:sameAsMedium <https://1145.am/db/2251548/Novo_Ventures>,
        <https://1145.am/db/2284476/Novo_Ventures>,
        <https://1145.am/db/2326903/Novo_Ventures>,
        <https://1145.am/db/2330664/Novo_Ventures>,
        <https://1145.am/db/2330668/Novo_Ventures>,
        <https://1145.am/db/2336221/Novo_Ventures>,
        <https://1145.am/db/2350044/Novo_Ventures>,
        <https://1145.am/db/2352508/Novo_Ventures>,
        <https://1145.am/db/2353098/Novo_Ventures>,
        <https://1145.am/db/2353588/Novo_Ventures>,
        <https://1145.am/db/2353598/Novo_Ventures>,
        <https://1145.am/db/2353608/Novo_Ventures>,
        <https://1145.am/db/2354296/Novo_Ventures>,
        <https://1145.am/db/2354903/Novo_Ventures>,
        <https://1145.am/db/2356124/Novo_Ventures>,
        <https://1145.am/db/2358496/Novo_Ventures>,
        <https://1145.am/db/2358502/Novo_Ventures>,
        <https://1145.am/db/2361065/Novo_Ventures>,
        <https://1145.am/db/2362533/Novo_Ventures>,
        <https://1145.am/db/2363510/Novo_Ventures>,
        <https://1145.am/db/2365103/Novo_Ventures>,
        <https://1145.am/db/2370694/Novo_Ventures>,
        <https://1145.am/db/2371165/Novo_Ventures>,
        <https://1145.am/db/2371166/Novo_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2354899/Rivervest_Venture_Partners> a org:Organization ;
    ns1:basedInLowRaw "SAN DIEGO" ;
    ns1:description "Venture Capital" ;
    ns1:documentDate "2010-08-30T13:07:55+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Otonomy Closes $38.5 Million Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/otonomy-closes-38-5-million-series-b-financing> ;
    ns1:foundName "RiverVest Venture Partners" ;
    ns1:investor <https://1145.am/db/2354899/Series_B_Investment_Domain_Associates_Novo_Ventures_Otonomy_Rivervest_Venture_Partners_Tpg_Biotech_Completed> ;
    ns1:name "RiverVest Venture Partners" ;
    ns1:sameAsHigh <https://1145.am/db/1065366/Riverstone_Holdings>,
        <https://1145.am/db/1153383/Bluestone_Venture_Partners>,
        <https://1145.am/db/1283038/Rivervest_Venture_Partners>,
        <https://1145.am/db/1735706/Waterman_Ventures>,
        <https://1145.am/db/1892105/River_Street_Management>,
        <https://1145.am/db/2151983/Waterman_Ventures>,
        <https://1145.am/db/2280492/Bluestone_Venture_Partners>,
        <https://1145.am/db/2294893/Rivervest_Venture_Partners>,
        <https://1145.am/db/2329550/Rivervest_Venture_Partners>,
        <https://1145.am/db/583798/Rivervest_Venture_Partners> ;
    ns1:sameAsMedium <https://1145.am/db/1669813/Rivervest_Venture_Partners>,
        <https://1145.am/db/2155730/Rivervest_Venture_Partners>,
        <https://1145.am/db/2286035/Rivervest_Venture_Partners>,
        <https://1145.am/db/2288553/Rivervest_Venture_Partners>,
        <https://1145.am/db/2294113/Rivervest_Venture_Partners>,
        <https://1145.am/db/2296631/Rivervest_Venture_Partners>,
        <https://1145.am/db/2299423/Rivervest_Venture_Partners>,
        <https://1145.am/db/2336221/Rivervest_Venture_Partners>,
        <https://1145.am/db/2337106/Rivervest_Venture_Partners>,
        <https://1145.am/db/2340887/Rivervest_Venture_Partners>,
        <https://1145.am/db/2350044/Rivervest_Venture_Partners>,
        <https://1145.am/db/2355274/Rivervest_Venture_Partners>,
        <https://1145.am/db/2356216/Rivervest_Venture_Partners>,
        <https://1145.am/db/2358496/Rivervest_Venture_Partners>,
        <https://1145.am/db/2358502/Rivervest_Venture_Partners>,
        <https://1145.am/db/2369916/Rivervest_Venture_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2354899/Tpg_Biotech> a org:Organization ;
    ns1:basedInLowRaw "SAN DIEGO" ;
    ns1:description "Biotech" ;
    ns1:documentDate "2010-08-30T13:07:55+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Otonomy Closes $38.5 Million Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/otonomy-closes-38-5-million-series-b-financing> ;
    ns1:foundName "TPG Biotech" ;
    ns1:investor <https://1145.am/db/2354899/Series_B_Investment_Domain_Associates_Novo_Ventures_Otonomy_Rivervest_Venture_Partners_Tpg_Biotech_Completed> ;
    ns1:name "TPG Biotech" ;
    ns1:sameAsHigh <https://1145.am/db/1863540/Tpg_Biotech> ;
    ns1:sameAsMedium <https://1145.am/db/1867543/Tpg_Biotech>,
        <https://1145.am/db/2299423/Tpg_Biotech>,
        <https://1145.am/db/2300337/Tpg_Biotech>,
        <https://1145.am/db/2302333/Tpg_Biotech>,
        <https://1145.am/db/2308700/Tpg_Biotech>,
        <https://1145.am/db/2336221/Tpg_Biotech>,
        <https://1145.am/db/2342557/Tpg_Biotech>,
        <https://1145.am/db/2342558/Tpg_Biotech>,
        <https://1145.am/db/2342724/Tpg_Biotech>,
        <https://1145.am/db/2344678/Tpg_Biotech>,
        <https://1145.am/db/2350044/Tpg_Biotech>,
        <https://1145.am/db/2351897/Tpg_Biotech>,
        <https://1145.am/db/2352508/Tpg_Biotech>,
        <https://1145.am/db/2353588/Tpg_Biotech>,
        <https://1145.am/db/2353608/Tpg_Biotech>,
        <https://1145.am/db/2353771/Tpg_Biotech>,
        <https://1145.am/db/2353789/Tpg_Biotech>,
        <https://1145.am/db/2354537/Tpg_Biotech>,
        <https://1145.am/db/2354903/Tpg_Biotech>,
        <https://1145.am/db/2358515/Tpg_Biotech>,
        <https://1145.am/db/2358888/Tpg_Biotech>,
        <https://1145.am/db/2359562/Tpg_Biotech>,
        <https://1145.am/db/2362457/Tpg_Biotech>,
        <https://1145.am/db/2364035/Tpg_Biotech>,
        <https://1145.am/db/2365868/Tpg_Biotech>,
        <https://1145.am/db/2368351/Tpg_Biotech>,
        <https://1145.am/db/316299/Tpg_Biotech> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2355511/Ipo_Biocancell_Therapeutics_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "ipo" ;
    ns1:documentDate "2010-11-23T15:57:00+00:00"^^xsd:dateTime ;
    ns1:documentExtract "> BioCancell Therapeutics says it raised $ 5.1 million from a public offering." ;
    ns1:documentTitle "Xention raises £8M; Maxygen distributes Codexis shares; Insurer counts costs of diabetes;" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/xention-raises-%C2%A38m-maxygen-distributes-codexis-shares-insurer-counts-costs-of-diabetes> ;
    ns1:foundName "public offering" ;
    ns1:name "public offering" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:valueRaw "$ 5.1 million" ;
    ns1:vendor <https://1145.am/db/2355511/Biocancell_Therapeutics> ;
    ns1:whereGeoName "United Kingdom of Great Britain and Northern Ireland" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/2635167/about.rdf> ;
    ns1:whereRaw "UK" .

<https://1145.am/db/2356567/Edmond_De_Rothschild_Investment_Partners> a org:Organization ;
    ns1:basedInLowRaw "Switzerland" ;
    ns1:description "investing" ;
    ns1:documentDate "2010-11-29T16:58:07+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Covagen closes Series A financing round with Seroba Kernel as lead investor" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/covagen-closes-series-a-financing-round-seroba-kernel-as-lead-investor> ;
    ns1:foundName "Edmond de Rothschild Investment Partners (EdRIP)" ;
    ns1:investor <https://1145.am/db/2356567/Series_A_Investment_Covagen_Edmond_De_Rothschild_Investment_Partners_Mp_Healthcare_Venture_Management_Inc_Mp_Healthcare_Venture_Management_Inc_Novartis_Venture_Fund_Seroba_Kernel_Life_Sciences_Ventech_Completed> ;
    ns1:name "Edmond de Rothschild Investment Partners" ;
    ns1:sameAsHigh <https://1145.am/db/1165283/Rothschild___Co>,
        <https://1145.am/db/1165370/Rothschild___Co>,
        <https://1145.am/db/1667613/Rothschild___Co>,
        <https://1145.am/db/1673944/Rothschild___Co>,
        <https://1145.am/db/2053586/Rothschild___Co>,
        <https://1145.am/db/2057230/Rothschild>,
        <https://1145.am/db/2297507/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2301096/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2313410/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2315279/De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2320503/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2325831/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2338196/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2358268/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2363941/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2605925/Rothschild>,
        <https://1145.am/db/2701527/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/289938/Rothschild___Co>,
        <https://1145.am/db/668085/Rothschild___Co>,
        <https://1145.am/db/936350/Rothschild___Co> ;
    ns1:sameAsMedium <https://1145.am/db/2289591/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2299423/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2301041/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2303210/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2303641/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2303642/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2303849/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2313401/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2336923/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2338023/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2338193/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2348331/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2350101/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2351191/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2351192/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2353607/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2353610/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2358269/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2358541/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2363938/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2367201/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2368740/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2369953/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2369982/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2369999/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2555540/Edmond_De_Rothschild_Investment_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2356567/Ventech> a org:Organization ;
    ns1:basedInLowRaw "Switzerland" ;
    ns1:description "investing" ;
    ns1:documentDate "2010-11-29T16:58:07+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Covagen closes Series A financing round with Seroba Kernel as lead investor" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/covagen-closes-series-a-financing-round-seroba-kernel-as-lead-investor> ;
    ns1:foundName "Ventech" ;
    ns1:investor <https://1145.am/db/2356567/Series_A_Investment_Covagen_Edmond_De_Rothschild_Investment_Partners_Mp_Healthcare_Venture_Management_Inc_Mp_Healthcare_Venture_Management_Inc_Novartis_Venture_Fund_Seroba_Kernel_Life_Sciences_Ventech_Completed> ;
    ns1:name "Ventech" ;
    ns1:sameAsHigh <https://1145.am/db/1811087/Ventech>,
        <https://1145.am/db/1838206/Ventech>,
        <https://1145.am/db/1894754/Ventech>,
        <https://1145.am/db/2356685/Ventech>,
        <https://1145.am/db/813478/Venturi_Partners>,
        <https://1145.am/db/814558/Venturi_Partners>,
        <https://1145.am/db/830052/Ventech> ;
    ns1:sameAsMedium <https://1145.am/db/1704141/Ventech>,
        <https://1145.am/db/1725598/Ventech>,
        <https://1145.am/db/1738448/Ventech>,
        <https://1145.am/db/1741357/Ventech>,
        <https://1145.am/db/1743481/Ventech>,
        <https://1145.am/db/1765401/Ventech>,
        <https://1145.am/db/1767974/Ventech>,
        <https://1145.am/db/1778401/Ventech>,
        <https://1145.am/db/1800466/Ventech>,
        <https://1145.am/db/1802167/Ventech>,
        <https://1145.am/db/1812656/Ventech>,
        <https://1145.am/db/1828915/Ventech>,
        <https://1145.am/db/1833939/Ventech>,
        <https://1145.am/db/1835236/Ventech>,
        <https://1145.am/db/1873872/Ventech>,
        <https://1145.am/db/1890664/Ventech>,
        <https://1145.am/db/1892120/Ventech>,
        <https://1145.am/db/1906801/Ventech>,
        <https://1145.am/db/2301770/Ventech>,
        <https://1145.am/db/2302541/Ventech>,
        <https://1145.am/db/2311395/Ventech>,
        <https://1145.am/db/2315532/Ventech>,
        <https://1145.am/db/2315547/Ventech>,
        <https://1145.am/db/2322162/Ventech>,
        <https://1145.am/db/2327638/Ventech>,
        <https://1145.am/db/2351312/Ventech>,
        <https://1145.am/db/2358233/Ventech>,
        <https://1145.am/db/2358246/Ventech>,
        <https://1145.am/db/2358747/Ventech>,
        <https://1145.am/db/2580665/Ventech>,
        <https://1145.am/db/2580671/Ventech>,
        <https://1145.am/db/2601004/Ventech>,
        <https://1145.am/db/447174/Ventech>,
        <https://1145.am/db/883525/Ventech> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2357622/Emerging_Healthcare_Solutions> a org:Organization ;
    ns1:basedInHighGeoName "Houston" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/4699066/about.rdf> ;
    ns1:basedInHighRaw "HOUSTON" ;
    ns1:buyer <https://1145.am/db/2357622/Celulas_Genetica_Acquisition> ;
    ns1:description "stem-cell technology acquisition and development" ;
    ns1:documentDate "2010-12-01T14:22:45+00:00"^^xsd:dateTime ;
    ns1:documentTitle "EHSI Acquires Stem Cell Biotech Firm Celulas Genetica" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/ehsi-acquires-stem-cell-biotech-firm-celulas-genetica> ;
    ns1:foundName "Emerging Healthcare Solutions, Inc" ;
    ns1:industry "biotechnology" ;
    ns1:investor <https://1145.am/db/2357622/Celulas_Genetica_Acquisition> ;
    ns1:name "Emerging Healthcare Solutions" ;
    ns1:sameAsHigh <https://1145.am/db/1608803/Access_Biotechnology> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2358030/KFW> a org:Organization ;
    ns1:basedInHighGeoName "Kreisfreie Stadt Bonn" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/3247450/about.rdf> ;
    ns1:basedInHighRaw "Bonn" ;
    ns1:description "financing" ;
    ns1:documentDate "2010-09-07T15:33:08+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Protagen Raises € 10.0 Million For Diagnostic Developments" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/protagen-raises-%E2%82%AC-10-0-million-for-diagnostic-developments> ;
    ns1:foundName "KfW, Bonn",
        "KfW, Bonn," ;
    ns1:investor <https://1145.am/db/2358030/Investment_Kfw_Mig_Fonds_Nrwbank_Protagen_Ag_S-Venture_Capital_Dortmund_Completed> ;
    ns1:name "KfW" ;
    ns1:sameAsHigh <https://1145.am/db/1754583/KFW>,
        <https://1145.am/db/2296701/KFW> ;
    ns1:sameAsMedium <https://1145.am/db/1115864/KFW>,
        <https://1145.am/db/1275433/KFW>,
        <https://1145.am/db/1291324/KFW>,
        <https://1145.am/db/1602418/KFW>,
        <https://1145.am/db/1667816/KFW>,
        <https://1145.am/db/1710755/KFW>,
        <https://1145.am/db/1853264/KFW>,
        <https://1145.am/db/1898197/KFW>,
        <https://1145.am/db/1911897/KFW>,
        <https://1145.am/db/2305628/KFW>,
        <https://1145.am/db/2347872/KFW>,
        <https://1145.am/db/2360425/KFW>,
        <https://1145.am/db/2440017/KFW>,
        <https://1145.am/db/2558803/KFW>,
        <https://1145.am/db/315335/KFW>,
        <https://1145.am/db/894768/KFW> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2358030/Mig_Fonds> a org:Organization ;
    ns1:basedInHighGeoName "Munich" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2867714/about.rdf> ;
    ns1:basedInHighRaw "Munich" ;
    ns1:documentDate "2010-09-07T15:33:08+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Protagen Raises € 10.0 Million For Diagnostic Developments" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/protagen-raises-%E2%82%AC-10-0-million-for-diagnostic-developments> ;
    ns1:foundName "MIG Fonds, Munich, S-Capital Dortmund" ;
    ns1:investor <https://1145.am/db/2358030/Investment_Kfw_Mig_Fonds_Nrwbank_Protagen_Ag_S-Venture_Capital_Dortmund_Completed> ;
    ns1:name "MIG Fonds" ;
    ns1:sameAsMedium <https://1145.am/db/1226523/Mig_Fonds>,
        <https://1145.am/db/1790558/Mig_Fonds>,
        <https://1145.am/db/2320151/Mig_Fonds>,
        <https://1145.am/db/2323559/Mig_Fonds>,
        <https://1145.am/db/2336188/Mig_Fonds>,
        <https://1145.am/db/2336339/Mig_Fond> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2358030/Nrwbank> a org:Organization ;
    ns1:basedInHighGeoName "Federal Republic of Germany" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2921044/about.rdf> ;
    ns1:basedInHighRaw "Germany" ;
    ns1:documentDate "2010-09-07T15:33:08+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Protagen Raises € 10.0 Million For Diagnostic Developments" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/protagen-raises-%E2%82%AC-10-0-million-for-diagnostic-developments> ;
    ns1:foundName "the NRW.BANK, Düsseldorf" ;
    ns1:investor <https://1145.am/db/2358030/Investment_Kfw_Mig_Fonds_Nrwbank_Protagen_Ag_S-Venture_Capital_Dortmund_Completed> ;
    ns1:name "NRW.BANK" ;
    ns1:sameAsMedium <https://1145.am/db/1443192/Nrwbank>,
        <https://1145.am/db/1444350/Nrwbank>,
        <https://1145.am/db/1786289/Nrwbank>,
        <https://1145.am/db/1909578/Nrw_Bank>,
        <https://1145.am/db/2305628/Nrwbank>,
        <https://1145.am/db/2314674/Nrwbank>,
        <https://1145.am/db/2322062/Nrw_Bank>,
        <https://1145.am/db/2338929/Nrw_Bank>,
        <https://1145.am/db/2341942/Nrwbank>,
        <https://1145.am/db/2360425/Nrwbank>,
        <https://1145.am/db/2364776/Nrwbank>,
        <https://1145.am/db/2365376/Nrwbank>,
        <https://1145.am/db/2537737/Nrwbank>,
        <https://1145.am/db/2558803/Nrwbank>,
        <https://1145.am/db/2569491/Nrwbank>,
        <https://1145.am/db/3450/Nrwbank>,
        <https://1145.am/db/545842/Nrwbank> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2358030/S-Venture_Capital_Dortmund> a org:Organization ;
    ns1:basedInHighGeoName "Federal Republic of Germany" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2921044/about.rdf> ;
    ns1:basedInHighRaw "Germany" ;
    ns1:documentDate "2010-09-07T15:33:08+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Protagen Raises € 10.0 Million For Diagnostic Developments" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/protagen-raises-%E2%82%AC-10-0-million-for-diagnostic-developments> ;
    ns1:foundName "S-Venture Capital Dortmund" ;
    ns1:investor <https://1145.am/db/2358030/Investment_Kfw_Mig_Fonds_Nrwbank_Protagen_Ag_S-Venture_Capital_Dortmund_Completed> ;
    ns1:name "S-Venture Capital Dortmund" ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2358031/Agechem_Venture_Fund> a org:Organization ;
    ns1:basedInLowRaw "QUEBEC" ;
    ns1:description "Investing" ;
    ns1:documentDate "2010-09-07T15:34:11+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Alethia Biotherapeutics Secures C$9.6 Million in Series A Financing to Fund Its Therapeutic Monoclonal Antibody Product Pipeline" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/alethia-biotherapeutics-secures-c-9-6-million-series-a-financing-to-fund-its-therapeutic> ;
    ns1:foundName "AgeChem Venture Fund" ;
    ns1:investor <https://1145.am/db/2358031/Series_A_Investment_Agechem_Venture_Fund_Alethia_Biotherapeutics_Inc_Bdc_Venture_Capital_Epicentre_Technologies_Corporation_Of_Wisconsin_Go_Capital_Completed> ;
    ns1:name "AgeChem Venture Fund" ;
    ns1:sameAsHigh <https://1145.am/db/2310073/Agechem_Venture_Fund_Cross_Creek_Capital>,
        <https://1145.am/db/2346534/Agechem_Venture_Fund>,
        <https://1145.am/db/2346542/Agechem_Venture_Fund>,
        <https://1145.am/db/2354752/Agechem_Venture_Fund> ;
    ns1:sameAsMedium <https://1145.am/db/2305729/Agechem_Venture_Fund>,
        <https://1145.am/db/2328030/Agechem_Venture_Fund_Lp>,
        <https://1145.am/db/2328034/Agechem_Venture_Fund_Lp>,
        <https://1145.am/db/2345002/Agechem_Venture_Fund>,
        <https://1145.am/db/2354770/Agechem_Venture_Fund>,
        <https://1145.am/db/2367046/Agechem_Venture_Fund>,
        <https://1145.am/db/2367047/Agechem_Venture_Fund>,
        <https://1145.am/db/2575232/Agechem_Venture_Fund> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2358031/Bdc_Venture_Capital> a org:Organization ;
    ns1:basedInLowRaw "QUEBEC" ;
    ns1:description "Investing" ;
    ns1:documentDate "2010-09-07T15:34:11+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Alethia Biotherapeutics Secures C$9.6 Million in Series A Financing to Fund Its Therapeutic Monoclonal Antibody Product Pipeline" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/alethia-biotherapeutics-secures-c-9-6-million-series-a-financing-to-fund-its-therapeutic> ;
    ns1:foundName "BDC Venture Capital" ;
    ns1:investor <https://1145.am/db/2358031/Series_A_Investment_Agechem_Venture_Fund_Alethia_Biotherapeutics_Inc_Bdc_Venture_Capital_Epicentre_Technologies_Corporation_Of_Wisconsin_Go_Capital_Completed> ;
    ns1:name "BDC Venture Capital" ;
    ns1:sameAsHigh <https://1145.am/db/1169025/Blu_Ventures>,
        <https://1145.am/db/1697910/Bdc_Venture_Capital>,
        <https://1145.am/db/1890839/Bdc_Venture_Capital>,
        <https://1145.am/db/2303098/Brookside_Capital>,
        <https://1145.am/db/2317961/Bdc_Venture_Capital>,
        <https://1145.am/db/435691/Blu_Ventures> ;
    ns1:sameAsMedium <https://1145.am/db/1729122/Bdc_Venture_Capital>,
        <https://1145.am/db/1828449/Bdc_Venture_Capital>,
        <https://1145.am/db/1830077/Bdc_Venture_Capital>,
        <https://1145.am/db/1852909/Bdc_Venture_Capital>,
        <https://1145.am/db/1906920/Bdc_Venture_Capital>,
        <https://1145.am/db/2163356/Bdc_Venture_Capital>,
        <https://1145.am/db/2293047/Bdc_Venture_Capital>,
        <https://1145.am/db/2318781/Bdc_Venture_Capital_Inc>,
        <https://1145.am/db/2318796/Bdc_Venture_Capital_Inc>,
        <https://1145.am/db/2333504/Bdc_Venture_Capital>,
        <https://1145.am/db/2333525/Bdc_Venture_Capital>,
        <https://1145.am/db/2344786/Bdc_Venture_Capital>,
        <https://1145.am/db/2345002/Bdc_Venture_Capital>,
        <https://1145.am/db/2355034/Bdc_Venture_Capital>,
        <https://1145.am/db/2355936/Bdc_Venture_Capital>,
        <https://1145.am/db/2355938/Bdc_Venture_Capital> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2358031/Epicentre_Technologies_Corporation_Of_Wisconsin> a org:Organization ;
    ns1:basedInLowRaw "QUEBEC" ;
    ns1:description "What is the typical occupation of the person or organization that Epicentre Technologies Corporation of Wisconsin is described" ;
    ns1:documentDate "2010-09-07T15:34:11+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Alethia Biotherapeutics Secures C$9.6 Million in Series A Financing to Fund Its Therapeutic Monoclonal Antibody Product Pipeline" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/alethia-biotherapeutics-secures-c-9-6-million-series-a-financing-to-fund-its-therapeutic> ;
    ns1:foundName "Epicentre Technologies Corporation of Wisconsin" ;
    ns1:investor <https://1145.am/db/2358031/Series_A_Investment_Agechem_Venture_Fund_Alethia_Biotherapeutics_Inc_Bdc_Venture_Capital_Epicentre_Technologies_Corporation_Of_Wisconsin_Go_Capital_Completed> ;
    ns1:name "Epicentre Technologies Corporation of Wisconsin" ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2358031/Go_Capital> a org:Organization ;
    ns1:basedInLowRaw "QUEBEC" ;
    ns1:description "venture capital" ;
    ns1:documentDate "2010-09-07T15:34:11+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Alethia Biotherapeutics Secures C$9.6 Million in Series A Financing to Fund Its Therapeutic Monoclonal Antibody Product Pipeline" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/alethia-biotherapeutics-secures-c-9-6-million-series-a-financing-to-fund-its-therapeutic> ;
    ns1:foundName "GO Capital" ;
    ns1:investor <https://1145.am/db/2358031/Series_A_Investment_Agechem_Venture_Fund_Alethia_Biotherapeutics_Inc_Bdc_Venture_Capital_Epicentre_Technologies_Corporation_Of_Wisconsin_Go_Capital_Completed> ;
    ns1:name "GO Capital" ;
    ns1:sameAsHigh <https://1145.am/db/1173960/Gopoint_Ventures>,
        <https://1145.am/db/1760355/Go-Ventures>,
        <https://1145.am/db/2301792/Bdc_Venture_Capital_With_Go_Capital> ;
    ns1:sameAsMedium <https://1145.am/db/2295712/Go_Capital>,
        <https://1145.am/db/2301320/Go_Capital>,
        <https://1145.am/db/2345002/Go_Capital> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2359104/BMS> a org:Organization ;
    ns1:basedInLowRaw "Boston" ;
    ns1:buyer <https://1145.am/db/2359104/Zymogenetics_Acquisition> ;
    ns1:documentDate "2010-09-09T16:17:38+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Ark restructures; Genentech sees promise in preclinical cancer therapy" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/ark-restructures-genentech-sees-promise-preclinical-cancer-therapy> ;
    ns1:foundName "BMS" ;
    ns1:industry "Biotech" ;
    ns1:name "BMS" ;
    ns1:sameAsHigh <https://1145.am/db/2098388/Abcam>,
        <https://1145.am/db/2280275/Aum_Biosciences>,
        <https://1145.am/db/2299388/BMS>,
        <https://1145.am/db/2325217/BMS>,
        <https://1145.am/db/2340432/BMS>,
        <https://1145.am/db/2350282/BMS>,
        <https://1145.am/db/247893/Abcam>,
        <https://1145.am/db/542747/Aum_Biosciences>,
        <https://1145.am/db/542753/Aum_Biosciences> ;
    ns1:sameAsMedium <https://1145.am/db/2152495/BMS>,
        <https://1145.am/db/2331819/BMS>,
        <https://1145.am/db/2362963/BMS>,
        <https://1145.am/db/2539308/BMS>,
        <https://1145.am/db/2539899/BMS>,
        <https://1145.am/db/2542218/BMS>,
        <https://1145.am/db/2542814/BMS> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2359104/Investment_Ark_Therapeutics_Has_Not_Happened> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-09-09T16:17:38+00:00"^^xsd:dateTime ;
    ns1:documentExtract "> London - based Ark Therapeutics has announced a restructuring and a refocus of its R & D program." ;
    ns1:documentTitle "Ark restructures; Genentech sees promise in preclinical cancer therapy" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/ark-restructures-genentech-sees-promise-preclinical-cancer-therapy> ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "has not happened" ;
    ns1:target <https://1145.am/db/2359104/Ark_Therapeutics> ;
    ns1:whereGeoName "London" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/2643743/about.rdf> ;
    ns1:whereRaw "London" .

<https://1145.am/db/2359104/Rhythm> a org:Organization ;
    ns1:basedInHighGeoName "Boston" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/4930956/about.rdf> ;
    ns1:basedInHighRaw "Boston" ;
    ns1:documentDate "2010-09-09T16:17:38+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Ark restructures; Genentech sees promise in preclinical cancer therapy" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/ark-restructures-genentech-sees-promise-preclinical-cancer-therapy> ;
    ns1:foundName "Rhythm" ;
    ns1:industry "Biotech" ;
    ns1:investor <https://1145.am/db/2359104/Zymogenetics_Acquisition> ;
    ns1:name "Rhythm" ;
    ns1:sameAsHigh <https://1145.am/db/2154422/Rhythm>,
        <https://1145.am/db/2358058/Rhythm>,
        <https://1145.am/db/2366509/Rhythm>,
        <https://1145.am/db/2366513/Rhythm>,
        <https://1145.am/db/2366514/Rhythm> ;
    ns1:sameAsMedium <https://1145.am/db/2286542/Rhythm>,
        <https://1145.am/db/2342242/Rhythm>,
        <https://1145.am/db/2351918/Rhythm>,
        <https://1145.am/db/2351943/Rhythm>,
        <https://1145.am/db/2352227/Rhythm>,
        <https://1145.am/db/2352235/Rhythm>,
        <https://1145.am/db/2359873/Rhythm>,
        <https://1145.am/db/2583133/Rhythm>,
        <https://1145.am/db/2592638/Rhythm> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2359125/Safeguard_Scientifics> a org:Organization ;
    ns1:basedInLowRaw "BOSTON" ;
    ns1:documentDate "2010-09-10T13:16:20+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Good Start Genetics, Inc. Raises $18 Million to Develop and Launch Sequencing-Based Pre-Pregnancy Genetic Screening Test" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/good-start-genetics-inc-raises-18-million-to-develop-and-launch-sequencing-based-pre> ;
    ns1:foundName "Safeguard Scientifics, Inc." ;
    ns1:investor <https://1145.am/db/2359125/Series_A_Investment_Good_Start_Genetics_Orbimed_Advisors_Sv_Life_Sciences_Safeguard_Scientifics_Completed> ;
    ns1:name "Safeguard Scientifics" ;
    ns1:sameAsMedium <https://1145.am/db/1232627/Safeguard_Scientifics>,
        <https://1145.am/db/1383287/Safeguard_Scientifics>,
        <https://1145.am/db/1801934/Safeguard_Scientifics>,
        <https://1145.am/db/1843216/Safeguard_Scientifics>,
        <https://1145.am/db/1855887/Safeguard_Scientifics>,
        <https://1145.am/db/1873156/Safeguard_Scientifics>,
        <https://1145.am/db/1914893/Safeguard_Scientifics>,
        <https://1145.am/db/2147446/Safeguard_Scientifics>,
        <https://1145.am/db/2182583/Safeguard_Scientifics>,
        <https://1145.am/db/2290453/Safeguard_Scientifics>,
        <https://1145.am/db/2291872/Safeguard_Scientifics>,
        <https://1145.am/db/2292039/Safeguard_Scientifics>,
        <https://1145.am/db/2295945/Safeguard_Scientifics>,
        <https://1145.am/db/2297604/Safeguard_Scientifics>,
        <https://1145.am/db/2298535/Safeguard_Scientifics>,
        <https://1145.am/db/2304598/Safeguard_Scientifics>,
        <https://1145.am/db/2304605/Safeguard_Scientifics_Inc>,
        <https://1145.am/db/2305443/Safeguard_Scientifics>,
        <https://1145.am/db/2305609/Safeguard_Scientifics>,
        <https://1145.am/db/2307837/Safeguard_Scientifics>,
        <https://1145.am/db/2316302/Safeguard_Scientifics>,
        <https://1145.am/db/2317455/Safeguard_Scientifics_Inc>,
        <https://1145.am/db/2319506/Safeguard_Scientifics>,
        <https://1145.am/db/2322984/Safeguard_Scientifics>,
        <https://1145.am/db/2323003/Safeguard_Scientifics>,
        <https://1145.am/db/2323336/Safeguard_Scientifics>,
        <https://1145.am/db/2325237/Safeguard_Scientifics>,
        <https://1145.am/db/2354706/Safeguard_Scientifics>,
        <https://1145.am/db/2436408/Safeguard_Scientifics_Inc>,
        <https://1145.am/db/2447203/Safeguard_Scientifics_Inc>,
        <https://1145.am/db/2576460/Safeguard_Scientifics> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2360174/Mediphase_Venture_Partners> a org:Organization ;
    ns1:basedInLowRaw "Calif" ;
    ns1:description "venture capital" ;
    ns1:documentDate "2010-09-13T14:04:48+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Relypsa Raises $70 Million in Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/relypsa-raises-70-million-series-b-financing> ;
    ns1:foundName "Mediphase Venture Partners" ;
    ns1:investor <https://1145.am/db/2360174/Series_B_Investment_5am_Ventures_Delphi_Ventures_Mediphase_Venture_Partners_New_Leaf_Venture_Partners_Orbimed_Advisors_Llc_Relypsa_Sprout_Group_Completed> ;
    ns1:name "Mediphase Venture Partners" ;
    ns1:sameAsHigh <https://1145.am/db/2302351/Meditor_Capital_Management>,
        <https://1145.am/db/2317919/Mediphase_Venture_Partners>,
        <https://1145.am/db/2327488/Mediphase_Venture_Partners>,
        <https://1145.am/db/2352436/Medimmune_Ventures>,
        <https://1145.am/db/2356420/Medimmune_Ventures>,
        <https://1145.am/db/2363460/Medimmune_Ventures> ;
    ns1:sameAsMedium <https://1145.am/db/2320082/Mediphase_Venture_Partners>,
        <https://1145.am/db/2324042/Mediphase_Venture_Partners>,
        <https://1145.am/db/2359287/Mediphase_Venture_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2360174/Sprout_Group> a org:Organization ;
    ns1:basedInLowRaw "Calif" ;
    ns1:documentDate "2010-09-13T14:04:48+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Relypsa Raises $70 Million in Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/relypsa-raises-70-million-series-b-financing> ;
    ns1:foundName "Sprout Group" ;
    ns1:investor <https://1145.am/db/2360174/Series_B_Investment_5am_Ventures_Delphi_Ventures_Mediphase_Venture_Partners_New_Leaf_Venture_Partners_Orbimed_Advisors_Llc_Relypsa_Sprout_Group_Completed> ;
    ns1:name "Sprout Group" ;
    ns1:sameAsMedium <https://1145.am/db/2305254/Sprout_Group>,
        <https://1145.am/db/2317467/Sprout_Group>,
        <https://1145.am/db/2317919/Sprout_Group>,
        <https://1145.am/db/2325378/Sprout_Group> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2360189/Boehringer_Ingelheim_Venture_Fund> a org:Organization ;
    ns1:basedInLowRaw "Switzerland" ;
    ns1:documentDate "2010-09-14T11:29:40+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Okairos Raises €16 Million in Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/okairos-raises-%E2%82%AC16-million-series-b-financing> ;
    ns1:foundName "Boehringer Ingelheim Venture Fund" ;
    ns1:investor <https://1145.am/db/2360189/Series_B_Investment_Boehringer_Ingelheim_Venture_Fund_Okairos_Versant_Ventures_Completed> ;
    ns1:name "Boehringer Ingelheim Venture Fund" ;
    ns1:sameAsMedium <https://1145.am/db/2017297/Boehringer_Ingelheim_Venture_Fund>,
        <https://1145.am/db/2152704/Boehringer_Ingelheim_Venture_Fund>,
        <https://1145.am/db/2155640/Boehringer_Ingelheim_Venture_Fund>,
        <https://1145.am/db/2287572/Boehringer_Ingelheim_Venture_Fund>,
        <https://1145.am/db/2290753/Boehringer_Ingelheim_Venture_Fund>,
        <https://1145.am/db/2290758/Boehringer_Ingelheim_Venture_Fund>,
        <https://1145.am/db/2299902/Boehringer_Ingelheim_Venture_Fund>,
        <https://1145.am/db/2299919/Boehringer_Ingelheim_Venture_Fund>,
        <https://1145.am/db/2301541/Boehringer_Ingelheim_Venture_Fund>,
        <https://1145.am/db/2327899/Boehringer_Ingelheim_Venture_Fund>,
        <https://1145.am/db/2338929/Boehringer_Ingelheim_Venture_Fund>,
        <https://1145.am/db/2341942/Boehringer_Ingelheim_Venture_Fund>,
        <https://1145.am/db/2349060/Boehringer_Ingelheim_Venture_Fund>,
        <https://1145.am/db/2349068/Boehringer_Ingelheim_Venture_Fund>,
        <https://1145.am/db/2353283/Boehringer_Ingelheim_Venture_Fund>,
        <https://1145.am/db/2353285/Boehringer_Ingelheim_Venture_Fund>,
        <https://1145.am/db/2360191/Boehringer_Ingelheim_Venture_Fund>,
        <https://1145.am/db/2363593/Boehringer_Ingelheim_Venture_Fund>,
        <https://1145.am/db/2363597/Boehringer_Ingelheim_Venture_Fund>,
        <https://1145.am/db/2370764/Boehringer_Ingelheim_Venture_Fund>,
        <https://1145.am/db/2569491/Boehringer_Ingelheim_Venture_Fund>,
        <https://1145.am/db/3450/Boehringer_Ingelheim_Venture_Fund>,
        <https://1145.am/db/545842/Boehringer_Ingelheim_Venture_Fund>,
        <https://1145.am/db/835104/Boehringer_Ingelheim_Venture_Fund>,
        <https://1145.am/db/873365/Boehringer_Ingelheim_Venture_Fund> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2360213/Pontifax_Funds> a org:Organization ;
    ns1:basedInLowRaw "N.J" ;
    ns1:documentDate "2010-09-14T14:43:18+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Arno Therapeutics Raises $15 Million in Private Placement To Advance Clinical Development of Oncology Compounds" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/arno-therapeutics-raises-15-million-private-placement-to-advance-clinical-development-of> ;
    ns1:foundName "Pontifax Funds" ;
    ns1:investor <https://1145.am/db/2360213/Securities_Investment_Arno_Therapeutics_Pontifax_Funds_Uta_Capital_Completed> ;
    ns1:name "Pontifax Funds" ;
    ns1:sameAsMedium <https://1145.am/db/2341621/Pontifax_Fund_Lp> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2360213/Uta_Capital> a org:Organization ;
    ns1:basedInLowRaw "N.J" ;
    ns1:description "financing" ;
    ns1:documentDate "2010-09-14T14:43:18+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Arno Therapeutics Raises $15 Million in Private Placement To Advance Clinical Development of Oncology Compounds" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/arno-therapeutics-raises-15-million-private-placement-to-advance-clinical-development-of> ;
    ns1:foundName "UTA Capital, LLC" ;
    ns1:investor <https://1145.am/db/2360213/Securities_Investment_Arno_Therapeutics_Pontifax_Funds_Uta_Capital_Completed> ;
    ns1:name "UTA Capital" ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2361809/Merieux_Developpement> a org:Organization ;
    ns1:basedInLowRaw "France" ;
    ns1:description "life sciences research" ;
    ns1:documentDate "2010-12-13T15:52:16+00:00"^^xsd:dateTime ;
    ns1:documentTitle "QuantaLife, Inc. Closes $17.2M Series B Financing to Accelerate Application Development for Its Droplet DigitalTM PCR Platform" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/quantalife-inc-closes-17-2m-series-b-financing-to-accelerate-application-development-for> ;
    ns1:foundName "Merieux Developpement" ;
    ns1:investor <https://1145.am/db/2361809/Series_B_Investment_Merieux_Developpement_Paladin_Capital_Group_Quantalife_Vital_Financial_Llc_Completed> ;
    ns1:name "Merieux Developpement" ;
    ns1:sameAsMedium <https://1145.am/db/2288936/Mérieux_Développement>,
        <https://1145.am/db/2337294/Mérieux_Développement>,
        <https://1145.am/db/2337976/Mérieux_Développement>,
        <https://1145.am/db/2344202/Merieux_Developpement>,
        <https://1145.am/db/2344205/Merieux_Developpement>,
        <https://1145.am/db/2348350/Merieux_Developpement>,
        <https://1145.am/db/2351734/Mérieux_Développement>,
        <https://1145.am/db/2354266/Mérieux_Développement>,
        <https://1145.am/db/2354277/Mérieux_Développement> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2361809/Paladin_Capital_Group> a org:Organization ;
    ns1:documentDate "2010-12-13T15:52:16+00:00"^^xsd:dateTime ;
    ns1:documentTitle "QuantaLife, Inc. Closes $17.2M Series B Financing to Accelerate Application Development for Its Droplet DigitalTM PCR Platform" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/quantalife-inc-closes-17-2m-series-b-financing-to-accelerate-application-development-for> ;
    ns1:foundName "Paladin Capital Group" ;
    ns1:investor <https://1145.am/db/2361809/Series_B_Investment_Merieux_Developpement_Paladin_Capital_Group_Quantalife_Vital_Financial_Llc_Completed> ;
    ns1:name "Paladin Capital Group" ;
    ns1:sameAsMedium <https://1145.am/db/1081263/Paladin_Capital_Group>,
        <https://1145.am/db/1082650/Paladin_Capital_Group>,
        <https://1145.am/db/1083634/Paladin_Capital_Group>,
        <https://1145.am/db/1084022/Paladin_Capital_Group>,
        <https://1145.am/db/1085646/Paladin_Capital_Group>,
        <https://1145.am/db/1578227/Paladin_Capital_Group>,
        <https://1145.am/db/1696377/Paladin_Capital_Group>,
        <https://1145.am/db/1714641/Paladin_Capital_Group>,
        <https://1145.am/db/1742878/Paladin_Capital_Group>,
        <https://1145.am/db/1759759/Paladin_Capital_Group>,
        <https://1145.am/db/1821944/Paladin_Capital_Group>,
        <https://1145.am/db/1829157/Paladin_Capital_Group>,
        <https://1145.am/db/2050221/Paladin_Capital_Group>,
        <https://1145.am/db/2061430/Paladin_Capital_Group>,
        <https://1145.am/db/2074979/Paladin_Capital_Group>,
        <https://1145.am/db/2296869/Paladin_Capital_Group>,
        <https://1145.am/db/2359655/Paladin_Capital_Group>,
        <https://1145.am/db/537839/Paladin_Capital_Group>,
        <https://1145.am/db/539602/Paladin_Capital_Group>,
        <https://1145.am/db/601202/Paladin_Capital_Group>,
        <https://1145.am/db/633695/Paladin_Capital_Group>,
        <https://1145.am/db/77901/Paladin_Capital_Group>,
        <https://1145.am/db/888513/Paladin_Capital_Group> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2361809/Vital_Financial_Llc> a org:Organization ;
    ns1:description "finance" ;
    ns1:documentDate "2010-12-13T15:52:16+00:00"^^xsd:dateTime ;
    ns1:documentTitle "QuantaLife, Inc. Closes $17.2M Series B Financing to Accelerate Application Development for Its Droplet DigitalTM PCR Platform" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/quantalife-inc-closes-17-2m-series-b-financing-to-accelerate-application-development-for> ;
    ns1:foundName "Vital Financial LLC" ;
    ns1:investor <https://1145.am/db/2361809/Series_B_Investment_Merieux_Developpement_Paladin_Capital_Group_Quantalife_Vital_Financial_Llc_Completed> ;
    ns1:name "Vital Financial LLC" ;
    ns1:sameAsMedium <https://1145.am/db/1827971/Vital_Financial>,
        <https://1145.am/db/2215928/Vital_Financial>,
        <https://1145.am/db/2224522/Vital_Financial>,
        <https://1145.am/db/2236817/Vital_Financial> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2362826/Royalty_Pharma> a org:Organization ;
    ns1:basedInLowRaw "SAN DIEGO" ;
    ns1:description "pharmaceutical company engaged in the development of innovative drugs to treat central nervous system (CNS) disorders" ;
    ns1:documentDate "2010-12-15T13:23:15+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Cypress Bioscience Agrees To Be Acquired by Ramius LLC and Royalty Pharma for $6.50 Per Share in Cash" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cypress-bioscience-agrees-to-be-acquired-by-ramius-llc-and-royalty-pharma-for-6-50-per> ;
    ns1:foundName "Royalty Pharma" ;
    ns1:industry "pharmaceutical" ;
    ns1:name "Royalty Pharma" ;
    ns1:participant <https://1145.am/db/2362826/Cypress_Bioscience_Acquisition> ;
    ns1:sameAsHigh <https://1145.am/db/1203801/Royalty_Pharma_Plc>,
        <https://1145.am/db/1205635/Royalty_Pharma_Plc>,
        <https://1145.am/db/1205649/Royalty_Pharma_Plc>,
        <https://1145.am/db/1413763/Royalty_Pharma>,
        <https://1145.am/db/1488570/Royalty_Pharma>,
        <https://1145.am/db/1629605/Royalty_Pharma>,
        <https://1145.am/db/1629663/Royalty_Pharma>,
        <https://1145.am/db/1945850/Royalty_Pharma>,
        <https://1145.am/db/2324936/Royalty_Pharma>,
        <https://1145.am/db/2324938/Royalty>,
        <https://1145.am/db/2327241/Drug_Royalty_Corporation>,
        <https://1145.am/db/2327241/Drug_Royalty_Lp_3>,
        <https://1145.am/db/2333503/Drug_Royalty_Corporation>,
        <https://1145.am/db/2333535/Drug_Royalty_Corporation>,
        <https://1145.am/db/2335881/Royalty_Pharma>,
        <https://1145.am/db/2339863/Royalty_Pharma>,
        <https://1145.am/db/2339892/Royalty_Pharma>,
        <https://1145.am/db/2340402/Royalty_Pharma>,
        <https://1145.am/db/2344874/Royalty_Pharma>,
        <https://1145.am/db/2349378/Royalty_Pharma>,
        <https://1145.am/db/2351144/Royalty_Pharma>,
        <https://1145.am/db/2354591/Royalty_Pharma>,
        <https://1145.am/db/2358734/Royalty_Pharma>,
        <https://1145.am/db/2359529/Royalty_Pharma>,
        <https://1145.am/db/2363656/Royalty_Pharma>,
        <https://1145.am/db/2364612/Royalty_Pharma>,
        <https://1145.am/db/2551579/Royalty_Pharma>,
        <https://1145.am/db/2576151/Royalty_Pharma>,
        <https://1145.am/db/2576156/Royalty_Pharma>,
        <https://1145.am/db/2584834/Royalty_Pharma>,
        <https://1145.am/db/2588718/Royalty_Pharma>,
        <https://1145.am/db/2591606/Royalty_Pharma> ;
    ns1:sameAsMedium <https://1145.am/db/1072726/Royalty_Pharma>,
        <https://1145.am/db/2335650/Royalty_Pharma>,
        <https://1145.am/db/2339086/Royalty_Pharma>,
        <https://1145.am/db/2339918/Royalty_Pharma>,
        <https://1145.am/db/2351145/Royalty_Pharma>,
        <https://1145.am/db/380916/Royalty_Pharma> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2364301/Bioventures_Investors> a org:Organization ;
    ns1:basedInLowRaw "Cayman" ;
    ns1:documentDate "2010-09-24T13:02:10+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Cylene Initiates Phase I Trial in Multiple Myeloma With CX-4945 Inhibitor of CK2 and Closes Accompanying Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cylene-initiates-phase-i-trial-multiple-myeloma-cx-4945-inhibitor-ck2-and-closes> ;
    ns1:foundName "BioVentures Investors" ;
    ns1:investor <https://1145.am/db/2364301/Investment_Bioventures_Investors_Cylene_Pharmaceuticals_Hbm_Bioventures_(cayman)_Ltd_Lilly_Ventures_Mitsui___Co_Morningside_Venture_Investments_Ltd_Novartis_Bioventure_Fund_Sanderling_Ventures_Completed> ;
    ns1:name "BioVentures Investors" ;
    ns1:sameAsMedium <https://1145.am/db/2298304/Bioventures_Investors>,
        <https://1145.am/db/2298869/Bioventures_Investors>,
        <https://1145.am/db/2322012/Bioventure_Investors>,
        <https://1145.am/db/2331988/Bioventures_Investors> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2364301/Hbm_Bioventures_(cayman)_Ltd> a org:Organization ;
    ns1:basedInLowRaw "Cayman" ;
    ns1:documentDate "2010-09-24T13:02:10+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Cylene Initiates Phase I Trial in Multiple Myeloma With CX-4945 Inhibitor of CK2 and Closes Accompanying Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cylene-initiates-phase-i-trial-multiple-myeloma-cx-4945-inhibitor-ck2-and-closes> ;
    ns1:foundName "HBM BioVentures (Cayman) Ltd." ;
    ns1:investor <https://1145.am/db/2364301/Investment_Bioventures_Investors_Cylene_Pharmaceuticals_Hbm_Bioventures_(cayman)_Ltd_Lilly_Ventures_Mitsui___Co_Morningside_Venture_Investments_Ltd_Novartis_Bioventure_Fund_Sanderling_Ventures_Completed> ;
    ns1:name "HBM BioVentures (Cayman) Ltd." ;
    ns1:sameAsMedium <https://1145.am/db/2331651/Hbm_Bioventures_(cayman)_Ltd>,
        <https://1145.am/db/2332868/Hbm_Bioventures_(cayman)_Ltd> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2364301/Lilly_Ventures_Mitsui___Co> a org:Organization ;
    ns1:basedInLowRaw "Japan" ;
    ns1:description "Investing" ;
    ns1:documentDate "2010-09-24T13:02:10+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Cylene Initiates Phase I Trial in Multiple Myeloma With CX-4945 Inhibitor of CK2 and Closes Accompanying Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cylene-initiates-phase-i-trial-multiple-myeloma-cx-4945-inhibitor-ck2-and-closes> ;
    ns1:foundName "Lilly Ventures, Mitsui & Co.",
        "Mitsui & Co." ;
    ns1:investor <https://1145.am/db/2364301/Investment_Bioventures_Investors_Cylene_Pharmaceuticals_Hbm_Bioventures_(cayman)_Ltd_Lilly_Ventures_Mitsui___Co_Morningside_Venture_Investments_Ltd_Novartis_Bioventure_Fund_Sanderling_Ventures_Completed> ;
    ns1:name "Lilly Ventures, Mitsui & Co.",
        "Mitsui & Co." ;
    ns1:sameAsHigh <https://1145.am/db/2294202/Lilly_Asia_Ventures>,
        <https://1145.am/db/2318733/Lilly_Ventures>,
        <https://1145.am/db/2319777/Lilly_Ventures>,
        <https://1145.am/db/2332868/Lilly_Ventures>,
        <https://1145.am/db/2347682/Lilly_Ventures>,
        <https://1145.am/db/2363396/Lilly_Ventures>,
        <https://1145.am/db/2543363/Lilly_Asia_Ventures>,
        <https://1145.am/db/434179/Lilly_Asia_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2364301/Morningside_Venture_Investments_Ltd> a org:Organization ;
    ns1:basedInLowRaw "Cayman" ;
    ns1:description "Investing" ;
    ns1:documentDate "2010-09-24T13:02:10+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Cylene Initiates Phase I Trial in Multiple Myeloma With CX-4945 Inhibitor of CK2 and Closes Accompanying Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cylene-initiates-phase-i-trial-multiple-myeloma-cx-4945-inhibitor-ck2-and-closes> ;
    ns1:foundName "Morningside Venture Investments Ltd" ;
    ns1:investor <https://1145.am/db/2364301/Investment_Bioventures_Investors_Cylene_Pharmaceuticals_Hbm_Bioventures_(cayman)_Ltd_Lilly_Ventures_Mitsui___Co_Morningside_Venture_Investments_Ltd_Novartis_Bioventure_Fund_Sanderling_Ventures_Completed> ;
    ns1:name "Morningside Venture Investments Ltd" ;
    ns1:sameAsHigh <https://1145.am/db/1779627/Morningside_Venture_Capital>,
        <https://1145.am/db/2280336/Morningside_Venture>,
        <https://1145.am/db/2287135/Morningside_Venture_Capital>,
        <https://1145.am/db/2365296/Morningside_Ventures>,
        <https://1145.am/db/2723277/Morning_Ventures>,
        <https://1145.am/db/606235/Morningside> ;
    ns1:sameAsMedium <https://1145.am/db/2295713/Morningside_Venture_Investments>,
        <https://1145.am/db/2302731/Morningside_Venture_Investments_Ltd>,
        <https://1145.am/db/2308329/Morningside_Venture_Investments_Limited>,
        <https://1145.am/db/2324671/Morningside_Venture_Investments>,
        <https://1145.am/db/2370018/Morningside_Venture_Investments>,
        <https://1145.am/db/2370022/Morningside_Venture_Investments> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2364301/Novartis_Bioventure_Fund> a org:Organization ;
    ns1:basedInLowRaw "Cayman" ;
    ns1:documentDate "2010-09-24T13:02:10+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Cylene Initiates Phase I Trial in Multiple Myeloma With CX-4945 Inhibitor of CK2 and Closes Accompanying Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cylene-initiates-phase-i-trial-multiple-myeloma-cx-4945-inhibitor-ck2-and-closes> ;
    ns1:foundName "Novartis BioVenture Fund",
        "Novartis BioVenture Fund," ;
    ns1:investor <https://1145.am/db/2364301/Investment_Bioventures_Investors_Cylene_Pharmaceuticals_Hbm_Bioventures_(cayman)_Ltd_Lilly_Ventures_Mitsui___Co_Morningside_Venture_Investments_Ltd_Novartis_Bioventure_Fund_Sanderling_Ventures_Completed> ;
    ns1:name "Novartis BioVenture Fund" ;
    ns1:sameAsMedium <https://1145.am/db/2306568/Novartis_Bioventure_Fund> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2365135/Chl_Medical_Partners> a org:Organization ;
    ns1:basedInLowRaw "GAITHERSBURG" ;
    ns1:description "financing" ;
    ns1:documentDate "2010-09-27T12:37:38+00:00"^^xsd:dateTime ;
    ns1:documentTitle "OpGen Completes $17 Million Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/opgen-completes-17-million-series-b-financing> ;
    ns1:foundName "CHL Medical Partners" ;
    ns1:investor <https://1145.am/db/2365135/Series_B_Equity_Investment_Chl_Medical_Partners_Highland_Capital_Partners_Mason_Wells_Biomedical_Opgen_Versant_Ventures_Jven_Capital_Completed> ;
    ns1:name "CHL Medical Partners" ;
    ns1:sameAsMedium <https://1145.am/db/2210939/Chl_Medical_Partners>,
        <https://1145.am/db/2242614/Chl_Medical_Partners>,
        <https://1145.am/db/2296169/Chl_Medical_Partners>,
        <https://1145.am/db/2305015/Chl_Medical_Partners>,
        <https://1145.am/db/2321097/Chl_Medical_Partners>,
        <https://1145.am/db/2325681/Chl_Medical_Partners>,
        <https://1145.am/db/2343184/Chl_Medical_Partners>,
        <https://1145.am/db/2343185/Chl_Medical_Partners>,
        <https://1145.am/db/2348484/Chl_Medical_Partners>,
        <https://1145.am/db/2365134/Chl_Medical_Partners>,
        <https://1145.am/db/2538407/Chl_Medical_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2365135/Jven_Capital> a org:Organization ;
    ns1:basedInLowRaw "GAITHERSBURG" ;
    ns1:description "financing" ;
    ns1:documentDate "2010-09-27T12:37:38+00:00"^^xsd:dateTime ;
    ns1:documentTitle "OpGen Completes $17 Million Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/opgen-completes-17-million-series-b-financing> ;
    ns1:foundName "jVen Capital" ;
    ns1:investor <https://1145.am/db/2365135/Series_B_Equity_Investment_Chl_Medical_Partners_Highland_Capital_Partners_Mason_Wells_Biomedical_Opgen_Versant_Ventures_Jven_Capital_Completed> ;
    ns1:name "jVen Capital" ;
    ns1:sameAsHigh <https://1145.am/db/1783265/Junli_Capital> ;
    ns1:sameAsMedium <https://1145.am/db/2087289/Jven_Capital>,
        <https://1145.am/db/2325681/Jven_Capital>,
        <https://1145.am/db/2343184/Jven_Capital>,
        <https://1145.am/db/2343185/Jven_Capital>,
        <https://1145.am/db/2365134/Jven_Capital> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2365135/Mason_Wells_Biomedical> a org:Organization ;
    ns1:basedInHighGeoName "Gaithersburg" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/4355843/about.rdf> ;
    ns1:basedInHighRaw "GAITHERSBURG, Md." ;
    ns1:documentDate "2010-09-27T12:37:38+00:00"^^xsd:dateTime ;
    ns1:documentTitle "OpGen Completes $17 Million Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/opgen-completes-17-million-series-b-financing> ;
    ns1:foundName "Mason Wells Biomedical" ;
    ns1:investor <https://1145.am/db/2365135/Series_B_Equity_Investment_Chl_Medical_Partners_Highland_Capital_Partners_Mason_Wells_Biomedical_Opgen_Versant_Ventures_Jven_Capital_Completed> ;
    ns1:name "Mason Wells Biomedical" ;
    ns1:sameAsMedium <https://1145.am/db/2365134/Mason_Wells_Biomedical> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2365138/Astellas_Venture_Management> a org:Organization ;
    ns1:basedInLowRaw "CAMBRIDGE" ;
    ns1:description "Investing in new companies" ;
    ns1:documentDate "2010-09-27T13:02:25+00:00"^^xsd:dateTime ;
    ns1:documentTitle "DecImmune Therapeutics Secures $3.2 Million in Development Funding" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/decimmune-therapeutics-secures-3-2-million-development-funding> ;
    ns1:foundName "Astellas Venture Management" ;
    ns1:investor <https://1145.am/db/2365138/Sbir_Investment_Amgen_Ventures_Astellas_Venture_Management_Decimmune_Therapeutics_Healthcare_Ventures_Has_Not_Happened> ;
    ns1:name "Astellas Venture Management" ;
    ns1:sameAsHigh <https://1145.am/db/1201200/Ascendant_Venture>,
        <https://1145.am/db/1340145/Astanor_Ventures>,
        <https://1145.am/db/1489698/Glasswing_Ventures>,
        <https://1145.am/db/1503058/Astellas_Venture_Management>,
        <https://1145.am/db/1898750/Ata_Ventures>,
        <https://1145.am/db/2293640/Arthur_Ventures>,
        <https://1145.am/db/512918/Dreamit_Ventures>,
        <https://1145.am/db/562996/Avantech_Ventures>,
        <https://1145.am/db/922417/Arthur_Ventures>,
        <https://1145.am/db/922596/Arthur_Ventures>,
        <https://1145.am/db/935242/Avalon_Ventures> ;
    ns1:sameAsMedium <https://1145.am/db/1150529/Astellas_Venture_Management_Llc>,
        <https://1145.am/db/1156304/Astellas_Venture_Management>,
        <https://1145.am/db/2073480/Astellas_Venture_Management>,
        <https://1145.am/db/2302731/Astellas_Venture_Management_Llc>,
        <https://1145.am/db/2318733/Astellas_Venture_Management>,
        <https://1145.am/db/2319777/Astellas_Venture_Management>,
        <https://1145.am/db/2320476/Astellas_Venture_Management>,
        <https://1145.am/db/2329125/Astellas_Venture_Management>,
        <https://1145.am/db/2329131/Astellas_Venture_Management>,
        <https://1145.am/db/2357858/Astellas_Venture_Management>,
        <https://1145.am/db/2358430/Astellas_Venture_Management>,
        <https://1145.am/db/2358657/Astellas_Venture_Management>,
        <https://1145.am/db/2362871/Astellas_Venture_Management>,
        <https://1145.am/db/2365748/Astellas_Venture_Management>,
        <https://1145.am/db/2370582/Astellas_Venture_Management> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2365138/National_Institutes_Of_Health> a org:Organization ;
    ns1:basedInLowRaw "CAMBRIDGE" ;
    ns1:description "Research" ;
    ns1:documentDate "2010-09-27T13:02:25+00:00"^^xsd:dateTime ;
    ns1:documentTitle "DecImmune Therapeutics Secures $3.2 Million in Development Funding" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/decimmune-therapeutics-secures-3-2-million-development-funding> ;
    ns1:foundName "National Institutes of Health" ;
    ns1:investor <https://1145.am/db/2365138/Sbir_Investment_Amgen_Ventures_Astellas_Venture_Management_Decimmune_Therapeutics_Healthcare_Ventures_Has_Not_Happened> ;
    ns1:name "National Institutes of Health" ;
    ns1:sameAsHigh <https://1145.am/db/1073190/National_Institutes_Of_Health>,
        <https://1145.am/db/1537336/National_Institutes_Of_Health>,
        <https://1145.am/db/1538786/National_Institutes_Of_Health>,
        <https://1145.am/db/1681434/Us_National_Institutes_Of_Health>,
        <https://1145.am/db/2008356/National_Institutes_Of_Health>,
        <https://1145.am/db/2076195/The_Us_National_Institutes_Of_Health>,
        <https://1145.am/db/2188087/National_Institutes_Of_Health>,
        <https://1145.am/db/2326358/National_Institutes_Of_Health>,
        <https://1145.am/db/2335075/National_Institutes_Of_Health>,
        <https://1145.am/db/2348929/National_Institutes_Of_Health>,
        <https://1145.am/db/2362040/National_Institutes_Of_Health>,
        <https://1145.am/db/2365186/National_Institutes_Of_Health>,
        <https://1145.am/db/525140/Us_National_Institutes_Of_Health>,
        <https://1145.am/db/866816/The_Foundation_For_The_National_Institutes_Of_Health> ;
    ns1:sameAsMedium <https://1145.am/db/1476783/National_Institutes_Of_Health>,
        <https://1145.am/db/2104077/National_Institutes_Of_Health>,
        <https://1145.am/db/2294124/National_Institutes_Of_Health>,
        <https://1145.am/db/2303846/National_Institutes_Of_Health>,
        <https://1145.am/db/2308694/The_National_Institutes_Of_Health>,
        <https://1145.am/db/520310/National_Institutes_Of_Health>,
        <https://1145.am/db/522957/National_Institutes_Of_Health> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2365171/Pfizer_Ventures> a org:Organization ;
    ns1:description "pharmaceuticals" ;
    ns1:documentDate "2010-09-28T13:45:54+00:00"^^xsd:dateTime ;
    ns1:documentTitle "TetraLogic Pharmaceuticals Expands Series C Financing with New Investor Pfizer Ventures with Investment of $5 Million Incrasing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/tetralogic-pharmaceuticals-expands-series-c-financing-new-investor-pfizer-ventures> ;
    ns1:foundName "Pfizer Ventures" ;
    ns1:industry "Pharmaceuticals" ;
    ns1:investor <https://1145.am/db/2365171/Series_C_Investment_Amgen_Ventures_Clarus_Ventures_Hatteras_Venture_Partners_Healthcare_Ventures_Latterell_Venture_Partners_Novitas_Capital_Pfizer_Ventures_Quaker_Bioventures_Tetralogic_Pharmaceuticals_Vertical_Group_Completed> ;
    ns1:name "Pfizer Ventures" ;
    ns1:sameAsHigh <https://1145.am/db/1018723/Pfizer_Inc>,
        <https://1145.am/db/1042002/Pfizer_Inc>,
        <https://1145.am/db/1045477/Pfizer_Inc>,
        <https://1145.am/db/1053698/Pfizer>,
        <https://1145.am/db/1065617/Pfizer_Inc>,
        <https://1145.am/db/1066444/Pfizer_Inc>,
        <https://1145.am/db/1097915/Pfizer>,
        <https://1145.am/db/1123210/Pfizer_Inc>,
        <https://1145.am/db/1124362/Pfizer_Inc>,
        <https://1145.am/db/1138594/Pfizer_Inc>,
        <https://1145.am/db/1146707/Pfizer>,
        <https://1145.am/db/1258904/Pfizer_Inc>,
        <https://1145.am/db/1260932/Pfizer_Inc>,
        <https://1145.am/db/1261278/Pfizer_Inc>,
        <https://1145.am/db/1262347/Pfizer_Inc>,
        <https://1145.am/db/1262354/Pfizer_Inc>,
        <https://1145.am/db/1262545/Pfizer_Inc>,
        <https://1145.am/db/1264461/Pfizer_Inc>,
        <https://1145.am/db/1264475/Pfizer_Inc>,
        <https://1145.am/db/1270781/Pfizer_Inc>,
        <https://1145.am/db/1271008/Pfizer>,
        <https://1145.am/db/1308148/Pfizer_Inc>,
        <https://1145.am/db/1308675/Pfizer_Inc>,
        <https://1145.am/db/1385939/Pfizer_Inc>,
        <https://1145.am/db/1390822/Pfizer_Inc>,
        <https://1145.am/db/1394279/Pfizer_Inc>,
        <https://1145.am/db/1395353/Pfizer_Inc>,
        <https://1145.am/db/1549114/Pfizer_Inc>,
        <https://1145.am/db/1550950/Pfizer_Inc>,
        <https://1145.am/db/1936001/Pfizer_Inc>,
        <https://1145.am/db/1936167/Pfizer_Inc>,
        <https://1145.am/db/2007025/Pfizer_Inc>,
        <https://1145.am/db/2007025/Pfizer_Investment_Enterprises_Pte_Ltd>,
        <https://1145.am/db/2009165/Pfizer_Inc>,
        <https://1145.am/db/2009856/Pfizer>,
        <https://1145.am/db/2057315/Pfizer>,
        <https://1145.am/db/2088776/Pfizer>,
        <https://1145.am/db/2119099/Pfizer>,
        <https://1145.am/db/2152862/Pfizer>,
        <https://1145.am/db/2221589/Pfizer>,
        <https://1145.am/db/2280707/Pfizer>,
        <https://1145.am/db/2280933/Pfizer>,
        <https://1145.am/db/2281629/Pfizer>,
        <https://1145.am/db/2284235/Pfizer>,
        <https://1145.am/db/2285463/Pfizer>,
        <https://1145.am/db/2285764/Pfizer>,
        <https://1145.am/db/2289503/Pfizer>,
        <https://1145.am/db/2293980/Pfizer>,
        <https://1145.am/db/2295427/Pfizer>,
        <https://1145.am/db/2296000/Pfizer>,
        <https://1145.am/db/2297455/Pfizer>,
        <https://1145.am/db/2297477/Pfizer>,
        <https://1145.am/db/2298256/Pfizer>,
        <https://1145.am/db/2304647/Pfizer>,
        <https://1145.am/db/2308656/Pfizer>,
        <https://1145.am/db/2308807/Pfizer>,
        <https://1145.am/db/2309065/Pfizer>,
        <https://1145.am/db/2310071/Pfizer_Inc>,
        <https://1145.am/db/2310072/Pfizer>,
        <https://1145.am/db/2310168/Pfizer>,
        <https://1145.am/db/2310241/Pfizer>,
        <https://1145.am/db/2311347/Pfizer>,
        <https://1145.am/db/2312314/Pfizer>,
        <https://1145.am/db/2312321/Pfizer_Inc>,
        <https://1145.am/db/2312995/Pfizer_Inc>,
        <https://1145.am/db/2313383/Pfizer_Inc>,
        <https://1145.am/db/2316517/Pfizer>,
        <https://1145.am/db/2316538/Pfizer_Inc>,
        <https://1145.am/db/2316843/Pfizer>,
        <https://1145.am/db/2317915/Pfizer>,
        <https://1145.am/db/2318922/Pfizer>,
        <https://1145.am/db/2322307/Pfizer>,
        <https://1145.am/db/2322620/Pfizer>,
        <https://1145.am/db/2322633/Pfizer_Inc>,
        <https://1145.am/db/2322733/Pfizer>,
        <https://1145.am/db/2322786/Pfizer>,
        <https://1145.am/db/2324155/Pfizer>,
        <https://1145.am/db/2325165/Pfizer_Inc>,
        <https://1145.am/db/2327506/Pfizer>,
        <https://1145.am/db/2327511/Pfizer_Inc>,
        <https://1145.am/db/2328712/Pfizer>,
        <https://1145.am/db/2329920/Pfizer_Inc>,
        <https://1145.am/db/2330817/Pfizer_Inc>,
        <https://1145.am/db/2330955/Pfizer>,
        <https://1145.am/db/2332552/Pfizer>,
        <https://1145.am/db/2332767/Pfizer_Ltd>,
        <https://1145.am/db/2334133/Pfizer_Inc>,
        <https://1145.am/db/2334165/Pfizer_Inc>,
        <https://1145.am/db/2335634/Pfizer>,
        <https://1145.am/db/2335717/Pfizer>,
        <https://1145.am/db/2336333/Pfizer>,
        <https://1145.am/db/2337788/Pfizer>,
        <https://1145.am/db/2339633/Pfizer_Inc>,
        <https://1145.am/db/2340055/Pfizer>,
        <https://1145.am/db/2340321/Pfizer_Inc>,
        <https://1145.am/db/2340324/Pfizer_Inc>,
        <https://1145.am/db/2340325/Pfizer_Inc>,
        <https://1145.am/db/2340331/Pfizer_Inc>,
        <https://1145.am/db/2342559/Pfizer_Inc>,
        <https://1145.am/db/2343237/Pfizer_Inc>,
        <https://1145.am/db/2343273/Pfizer_Inc>,
        <https://1145.am/db/2343344/Pfizer>,
        <https://1145.am/db/2343454/Pfizer_Inc>,
        <https://1145.am/db/2346602/Pfizer_Inc>,
        <https://1145.am/db/2347383/Pfizer_Inc>,
        <https://1145.am/db/2348510/Pfizer_Inc>,
        <https://1145.am/db/2351730/Pfizer_Inc>,
        <https://1145.am/db/2353039/Pfizer_Inc>,
        <https://1145.am/db/2353364/Pfizer>,
        <https://1145.am/db/2354370/Pfizer_Inc>,
        <https://1145.am/db/2355021/Pfizer>,
        <https://1145.am/db/2355025/Pfizer_Inc>,
        <https://1145.am/db/2355472/Pfizer_Inc>,
        <https://1145.am/db/2357232/Pfizer>,
        <https://1145.am/db/2357308/Pfizer_Inc>,
        <https://1145.am/db/2358128/Pfizer>,
        <https://1145.am/db/2359697/Pfizer>,
        <https://1145.am/db/2360633/Pfizer>,
        <https://1145.am/db/2360647/Pfizer_Inc>,
        <https://1145.am/db/2362439/Pfizer_Inc>,
        <https://1145.am/db/2362851/Pfizer_Inc>,
        <https://1145.am/db/2363446/Pfizer_Inc>,
        <https://1145.am/db/2363896/Pfizer>,
        <https://1145.am/db/2364087/Pfizer_Inc>,
        <https://1145.am/db/2369876/Pfizer>,
        <https://1145.am/db/2369909/Pfizer_Inc>,
        <https://1145.am/db/2370016/Pfizer>,
        <https://1145.am/db/2371512/Pfizer>,
        <https://1145.am/db/2507041/Pfizer>,
        <https://1145.am/db/2536358/Pfizer_Inc>,
        <https://1145.am/db/2536361/Pfizer_Inc>,
        <https://1145.am/db/2536362/Pfizer_Inc>,
        <https://1145.am/db/2536365/Pfizer_Inc>,
        <https://1145.am/db/2537054/Pfizer_Inc>,
        <https://1145.am/db/2537057/Pfizer_Inc>,
        <https://1145.am/db/2538568/Pfizer_Inc>,
        <https://1145.am/db/2538915/Pfizer_Inc>,
        <https://1145.am/db/2538924/Pfizer>,
        <https://1145.am/db/2539516/Pfizer>,
        <https://1145.am/db/2539787/Pfizer>,
        <https://1145.am/db/2541139/Pfizer_Inc>,
        <https://1145.am/db/2541721/Pfizer>,
        <https://1145.am/db/2542067/Pfizer_Inc>,
        <https://1145.am/db/2543533/Pfizer>,
        <https://1145.am/db/2543826/Pfizer>,
        <https://1145.am/db/2544074/Pfizer>,
        <https://1145.am/db/2545058/Pfizer>,
        <https://1145.am/db/2545634/Pfizer>,
        <https://1145.am/db/2546596/Pfizer>,
        <https://1145.am/db/2547000/Pfizer>,
        <https://1145.am/db/2548752/Pfizer>,
        <https://1145.am/db/2548986/Pfizer>,
        <https://1145.am/db/2549719/Pfizer>,
        <https://1145.am/db/2550445/Pfizer>,
        <https://1145.am/db/2550685/Pfizer>,
        <https://1145.am/db/2553974/Pfizer>,
        <https://1145.am/db/2554937/Pfizer>,
        <https://1145.am/db/2554938/Pfizer>,
        <https://1145.am/db/2555896/Pfizer>,
        <https://1145.am/db/2557603/Pfizer_Consumer_Health>,
        <https://1145.am/db/2558970/Pfizer>,
        <https://1145.am/db/2558971/Pfizer>,
        <https://1145.am/db/2559649/Pfizer>,
        <https://1145.am/db/2560282/Pfizer>,
        <https://1145.am/db/2560720/Pfizer>,
        <https://1145.am/db/2562102/Pfizer_Inc>,
        <https://1145.am/db/2562701/Pfizer>,
        <https://1145.am/db/2564032/Pfizer>,
        <https://1145.am/db/2568121/Pfizer>,
        <https://1145.am/db/2569378/Pfizer>,
        <https://1145.am/db/2570369/Pfizer_Inc>,
        <https://1145.am/db/2571798/Pfizer_Inc>,
        <https://1145.am/db/2572036/Pfizer>,
        <https://1145.am/db/2573245/Pfizer_Inc>,
        <https://1145.am/db/2573465/Pfizer_Inc>,
        <https://1145.am/db/2573466/Pfizer>,
        <https://1145.am/db/2573562/Pfizer>,
        <https://1145.am/db/2573707/Pfizer>,
        <https://1145.am/db/2574461/Pfizer_Inc>,
        <https://1145.am/db/2574687/Pfizer>,
        <https://1145.am/db/2574691/Pfizer_Inc>,
        <https://1145.am/db/2575139/Pfizer_Inc>,
        <https://1145.am/db/2575145/Pfizer_Inc>,
        <https://1145.am/db/2575320/Pfizer>,
        <https://1145.am/db/2575471/Pfizer>,
        <https://1145.am/db/2575505/Pfizer_Inc>,
        <https://1145.am/db/2575575/Pfizer>,
        <https://1145.am/db/2576330/Pfizer_Inc>,
        <https://1145.am/db/2577077/Pfizer>,
        <https://1145.am/db/2577258/Pfizer_Inc>,
        <https://1145.am/db/2579709/Pfizer_Inc>,
        <https://1145.am/db/2581331/Pfizer_Inc>,
        <https://1145.am/db/2581334/Pfizer_Inc>,
        <https://1145.am/db/2581339/Pfizer>,
        <https://1145.am/db/2581394/Pfizer>,
        <https://1145.am/db/2581661/Pfizer_Inc>,
        <https://1145.am/db/2582158/Pfizer_Inc>,
        <https://1145.am/db/2582160/Pfizer_Inc>,
        <https://1145.am/db/2582343/Pfizer_Inc>,
        <https://1145.am/db/2582879/Pfizer_Inc>,
        <https://1145.am/db/2583155/Pfizer_Inc>,
        <https://1145.am/db/2583163/Pfizer>,
        <https://1145.am/db/2583165/Pfizer_Inc>,
        <https://1145.am/db/2583172/Pfizer>,
        <https://1145.am/db/2583242/Pfizer_Inc>,
        <https://1145.am/db/2583783/Pfizer>,
        <https://1145.am/db/2584085/Pfizer_Inc>,
        <https://1145.am/db/2584258/Pfizer_Inc>,
        <https://1145.am/db/2584601/Pfizer_Inc>,
        <https://1145.am/db/2585700/Pfizer>,
        <https://1145.am/db/2585908/New_York-Pfizer_Inc>,
        <https://1145.am/db/2585908/Pfizer>,
        <https://1145.am/db/2585912/Pfizer>,
        <https://1145.am/db/2586034/Pfizer_Inc>,
        <https://1145.am/db/2586047/Pfizer_Inc>,
        <https://1145.am/db/2587673/Pfizer>,
        <https://1145.am/db/2588134/Pfizer_Inc>,
        <https://1145.am/db/2590549/Pfizer_Inc>,
        <https://1145.am/db/2590887/Pfizer>,
        <https://1145.am/db/2591081/Pfizer_Inc>,
        <https://1145.am/db/2591092/Pfizer_Inc>,
        <https://1145.am/db/2592980/Pfizer>,
        <https://1145.am/db/2592990/Pfizer_Inc>,
        <https://1145.am/db/2592992/Pfizer_Inc>,
        <https://1145.am/db/2593150/Pfizer>,
        <https://1145.am/db/2593886/Pfizer>,
        <https://1145.am/db/2593961/Pfizer_Inc>,
        <https://1145.am/db/2594268/Pfizer_Inc>,
        <https://1145.am/db/2594422/Pfizer>,
        <https://1145.am/db/2594489/Pfizer_Inc>,
        <https://1145.am/db/2594992/Pfizer>,
        <https://1145.am/db/2595320/Pfizer_Inc>,
        <https://1145.am/db/2595472/Pfizer>,
        <https://1145.am/db/2595499/Pfizer>,
        <https://1145.am/db/2596344/Pfizer>,
        <https://1145.am/db/2596754/Pfizer_Inc>,
        <https://1145.am/db/2596778/Pfizer>,
        <https://1145.am/db/2596874/Pfizer>,
        <https://1145.am/db/2596947/Pfizer>,
        <https://1145.am/db/2597173/Pfizer>,
        <https://1145.am/db/2597183/Pfizer_Inc>,
        <https://1145.am/db/2597643/Pfizer_Inc>,
        <https://1145.am/db/2597650/Pfizer>,
        <https://1145.am/db/2597712/Pfizer>,
        <https://1145.am/db/274660/Pfizer_Inc>,
        <https://1145.am/db/274739/Pfizer_Inc>,
        <https://1145.am/db/318295/Pfizer_Inc>,
        <https://1145.am/db/422378/Pfizer_Inc>,
        <https://1145.am/db/424190/Pfizer_Inc>,
        <https://1145.am/db/426841/Pfizer_Inc>,
        <https://1145.am/db/428975/Pfizer_Inc>,
        <https://1145.am/db/626832/Pfizer_Inc>,
        <https://1145.am/db/627349/Pfizer_Inc>,
        <https://1145.am/db/631317/Pfizer_Inc>,
        <https://1145.am/db/635031/Pfizer>,
        <https://1145.am/db/692994/Pfizer_Inc>,
        <https://1145.am/db/694224/Pfizer_Inc>,
        <https://1145.am/db/699199/Pfizer>,
        <https://1145.am/db/76007/Pfizer>,
        <https://1145.am/db/761748/Pfizer>,
        <https://1145.am/db/764460/Pfizer>,
        <https://1145.am/db/797138/Pfizer_Inc>,
        <https://1145.am/db/800318/Pfizer_Inc>,
        <https://1145.am/db/896566/Pfizer_Inc>,
        <https://1145.am/db/897457/Pfizer_Inc>,
        <https://1145.am/db/962899/Pfizer_Inc>,
        <https://1145.am/db/965490/Pfizer_Inc>,
        <https://1145.am/db/968220/Pfizer_Inc>,
        <https://1145.am/db/971984/Pfizer_Inc> ;
    ns1:sameAsMedium <https://1145.am/db/1156304/Pfizer_Ventures>,
        <https://1145.am/db/1334624/Pfizer_Ventures>,
        <https://1145.am/db/2154844/Pfizer_Ventures>,
        <https://1145.am/db/2325726/Pfizer_Ventures>,
        <https://1145.am/db/2340888/Pfizer_Ventures>,
        <https://1145.am/db/2341896/Pfizer_Ventures>,
        <https://1145.am/db/2365184/Pfizer_Ventures>,
        <https://1145.am/db/2369202/Pfizer_Ventures>,
        <https://1145.am/db/587045/Pfizer_Ventures>,
        <https://1145.am/db/591613/Pfizer_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2366187/Canaan_Partners> a org:Organization ;
    ns1:basedInLowRaw "N.J." ;
    ns1:description "venture capital" ;
    ns1:documentDate "2010-09-30T16:26:17+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Tobira Therapeutics Inc. Raises $31 Million in Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/tobira-therapeutics-inc-raises-31-million-series-b-financing> ;
    ns1:foundName "Canaan Partners" ;
    ns1:investor <https://1145.am/db/2366187/Series_B_Investment_Canaan_Partners_Domain_Associates_Frazier_Healthcare_Ventures_Montreux_Equity_Partners_Novo_A_S_Tobira_Therapeutics_Inc_Completed> ;
    ns1:name "Canaan Partners" ;
    ns1:sameAsHigh <https://1145.am/db/1043342/Canaan_Partners>,
        <https://1145.am/db/1427471/Potentum_Partners>,
        <https://1145.am/db/1695894/Canaan_Partners>,
        <https://1145.am/db/1697131/Canaan_Partners>,
        <https://1145.am/db/1724566/Canaan_Partners>,
        <https://1145.am/db/1735660/Forward_Partners>,
        <https://1145.am/db/1747333/Framework_Venture_Partners>,
        <https://1145.am/db/1770648/Canaan_Partners>,
        <https://1145.am/db/1776537/Partech_Partners>,
        <https://1145.am/db/1791628/Canaan_Partners>,
        <https://1145.am/db/1819543/Canaan_Partners>,
        <https://1145.am/db/1842466/Canaan_Partners>,
        <https://1145.am/db/1863401/Canaan_Partners>,
        <https://1145.am/db/1910644/Canaan_Partners>,
        <https://1145.am/db/2141055/Excell_Partners>,
        <https://1145.am/db/2297592/Canaan_Partners>,
        <https://1145.am/db/2301765/Canaan_Partners>,
        <https://1145.am/db/2309376/Canaan_Partners>,
        <https://1145.am/db/2309387/Canaan_Partners>,
        <https://1145.am/db/2351129/Canaan_Partners>,
        <https://1145.am/db/2355043/Canaan_Partners>,
        <https://1145.am/db/2355715/Canaan_Partners>,
        <https://1145.am/db/2363535/Canaan_Partners>,
        <https://1145.am/db/2370802/Canaan_Partners>,
        <https://1145.am/db/2370834/Canaan_Partners>,
        <https://1145.am/db/2583466/Canaan_Partners>,
        <https://1145.am/db/3043/Elsewhere_Partners>,
        <https://1145.am/db/645540/Envisioning_Partners>,
        <https://1145.am/db/935302/Framework_Venture_Partners> ;
    ns1:sameAsMedium <https://1145.am/db/146274/Canaan_Partners>,
        <https://1145.am/db/1696766/Canaan_Partners>,
        <https://1145.am/db/1702857/Canaan_Partners>,
        <https://1145.am/db/1711633/Canaan_Partners>,
        <https://1145.am/db/1734259/Canaan_Partners>,
        <https://1145.am/db/1741014/Canaan_Partners>,
        <https://1145.am/db/1741105/Canaan_Partners>,
        <https://1145.am/db/1741424/Canaan_Partners>,
        <https://1145.am/db/1749744/Canaan_Partners>,
        <https://1145.am/db/1754820/Canaan_Partners>,
        <https://1145.am/db/1768400/Canaan_Partners>,
        <https://1145.am/db/1792426/Canaan_Partners>,
        <https://1145.am/db/1793543/Canaan_Partners>,
        <https://1145.am/db/1796375/Canaan_Partners>,
        <https://1145.am/db/1814413/Canaan_Partners>,
        <https://1145.am/db/1827240/Canaan_Partners>,
        <https://1145.am/db/1829078/Canaan_Partners>,
        <https://1145.am/db/1829544/Canaan_Partners>,
        <https://1145.am/db/1836578/Canaan_Partners>,
        <https://1145.am/db/1845119/Canaan_Partners>,
        <https://1145.am/db/1852066/Canaan_Partners>,
        <https://1145.am/db/1858762/Canaan_Partners>,
        <https://1145.am/db/1866968/Canaan_Partners>,
        <https://1145.am/db/1894670/Canaan_Partners>,
        <https://1145.am/db/1897255/Canaan_Partners>,
        <https://1145.am/db/1900458/Canaan_Partners>,
        <https://1145.am/db/1906336/Canaan_Partners>,
        <https://1145.am/db/1907151/Canaan_Partners>,
        <https://1145.am/db/1907762/Canaan_Partners>,
        <https://1145.am/db/1919135/Canaan_Partners>,
        <https://1145.am/db/1920478/Canaan_Partners>,
        <https://1145.am/db/2164798/Canaan_Partners>,
        <https://1145.am/db/2164838/Canaan_Partners>,
        <https://1145.am/db/2210939/Canaan_Partners>,
        <https://1145.am/db/2238667/Canaan_Partners>,
        <https://1145.am/db/2287025/Canaan_Partners>,
        <https://1145.am/db/2287777/Canaan_Partners>,
        <https://1145.am/db/2298642/Canaan_Partners>,
        <https://1145.am/db/2304587/Canaan_Partners>,
        <https://1145.am/db/2304605/Canaan_Partners>,
        <https://1145.am/db/2306281/Canaan_Partners>,
        <https://1145.am/db/2308329/Canaan_Partners>,
        <https://1145.am/db/2313171/Canaan_Partners>,
        <https://1145.am/db/2320925/Canaan_Partners>,
        <https://1145.am/db/2322231/Canaan_Partners>,
        <https://1145.am/db/2329010/Canaan_Partners>,
        <https://1145.am/db/2329011/Canaan_Partners>,
        <https://1145.am/db/2329531/Canaan_Partners>,
        <https://1145.am/db/2332322/Canaan_Partners>,
        <https://1145.am/db/2337958/Canaan_Partners>,
        <https://1145.am/db/2337974/Canaan_Partners>,
        <https://1145.am/db/2346532/Canaan_Partners>,
        <https://1145.am/db/2347469/Canaan_Partners>,
        <https://1145.am/db/2351316/Canaan_Partners>,
        <https://1145.am/db/2351684/Canaan_Partners>,
        <https://1145.am/db/2353588/Canaan_Partners>,
        <https://1145.am/db/2353608/Canaan_Partners>,
        <https://1145.am/db/2355238/Canaan_Partners>,
        <https://1145.am/db/2358378/Canaan_Partners>,
        <https://1145.am/db/2359185/Canaan_Partners>,
        <https://1145.am/db/2360258/Canaan_Partners>,
        <https://1145.am/db/2360266/Canaan_Partners>,
        <https://1145.am/db/2360647/Canaan_Partners>,
        <https://1145.am/db/2365700/Canaan_Partners>,
        <https://1145.am/db/2366753/Canaan_Partners>,
        <https://1145.am/db/2368322/Canaan_Partners>,
        <https://1145.am/db/2368973/Canaan_Partners>,
        <https://1145.am/db/2368982/Canaan_Partners>,
        <https://1145.am/db/2370582/Canaan_Partners>,
        <https://1145.am/db/2572398/Canaan_Partners>,
        <https://1145.am/db/2635439/Canaan_Partners>,
        <https://1145.am/db/316299/Canaan_Partners>,
        <https://1145.am/db/319155/Canaan_Partners>,
        <https://1145.am/db/353476/Canaan_Partners>,
        <https://1145.am/db/411041/Canaan_Partners>,
        <https://1145.am/db/523179/Canaan_Partners>,
        <https://1145.am/db/564082/Canaan_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2366187/Frazier_Healthcare_Ventures> a org:Organization ;
    ns1:basedInLowRaw "N.J." ;
    ns1:description "Investing in healthcare" ;
    ns1:documentDate "2010-09-30T16:26:17+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Tobira Therapeutics Inc. Raises $31 Million in Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/tobira-therapeutics-inc-raises-31-million-series-b-financing> ;
    ns1:foundName "Frazier Healthcare Ventures" ;
    ns1:investor <https://1145.am/db/2366187/Series_B_Investment_Canaan_Partners_Domain_Associates_Frazier_Healthcare_Ventures_Montreux_Equity_Partners_Novo_A_S_Tobira_Therapeutics_Inc_Completed> ;
    ns1:name "Frazier Healthcare Ventures" ;
    ns1:sameAsHigh <https://1145.am/db/1244886/Frazier_Healthcare_Partners>,
        <https://1145.am/db/1245863/Frazier_Healthcare_Partners>,
        <https://1145.am/db/2152824/Frazier_Healthcare_Partners>,
        <https://1145.am/db/2196903/Frazier_Healthcare_Partners>,
        <https://1145.am/db/2278780/Frazier_Healthcare_Partners>,
        <https://1145.am/db/2307829/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2318577/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2330075/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2331784/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2338625/Frazier_Healthcare>,
        <https://1145.am/db/2342352/Frazier_Healthcare>,
        <https://1145.am/db/2346532/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2346542/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2351519/Frazier_Healthcare>,
        <https://1145.am/db/2356269/Frazier_Healthcare>,
        <https://1145.am/db/2365700/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2553555/Frazier_Healthcare>,
        <https://1145.am/db/2592685/Frazier_Healthcare>,
        <https://1145.am/db/505366/Frazier_Healthcare_Partners>,
        <https://1145.am/db/770024/Frazier_Healthcare_Partners> ;
    ns1:sameAsMedium <https://1145.am/db/1329605/Frazier_Healthcare_Partners>,
        <https://1145.am/db/1374146/Frazier_Healthcare_Partners>,
        <https://1145.am/db/1813040/Frazier_Healthcare_Partners>,
        <https://1145.am/db/2154276/Frazier_Healthcare_Partners>,
        <https://1145.am/db/2189855/Frazier_Healthcare>,
        <https://1145.am/db/2245812/Frazier_Healthcare>,
        <https://1145.am/db/2292109/Frazier_Healthcare>,
        <https://1145.am/db/2294202/Frazier_Healthcare_Partners>,
        <https://1145.am/db/2303250/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2303251/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2303257/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2305524/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2307824/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2308855/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2310795/Frazier_Healthcare>,
        <https://1145.am/db/2310798/Frazier_Healthcare>,
        <https://1145.am/db/2311551/Frazier_Healthcare>,
        <https://1145.am/db/2316391/Frazier_Healthcare>,
        <https://1145.am/db/2318274/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2318276/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2318635/Frazier_Healthcare>,
        <https://1145.am/db/2321216/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2325326/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2326430/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2327441/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2327442/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2330079/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2334616/Frazier_Healthcare>,
        <https://1145.am/db/2334622/Frazier_Healthcare>,
        <https://1145.am/db/2334624/Frazier_Healthcare>,
        <https://1145.am/db/2335675/Frazier_Healthcare>,
        <https://1145.am/db/2335743/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2336032/Frazier_Healthcare>,
        <https://1145.am/db/2337166/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2338633/Frazier_Healthcare>,
        <https://1145.am/db/2339925/Frazier_Healthcare>,
        <https://1145.am/db/2339926/Frazier_Healthcare>,
        <https://1145.am/db/2340204/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2340207/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2342629/Frazier_Healthcare>,
        <https://1145.am/db/2348754/Frazier_Healthcare>,
        <https://1145.am/db/2351520/Frazier_Healthcare>,
        <https://1145.am/db/2356306/Frazier_Healthcare>,
        <https://1145.am/db/2361549/Frazier_Healthcare>,
        <https://1145.am/db/2361551/Frazier_Healthcare>,
        <https://1145.am/db/2366700/Frazier_Healthcare>,
        <https://1145.am/db/2368333/Frazier_Healthcare>,
        <https://1145.am/db/2370761/Frazier_Healthcare_Partners>,
        <https://1145.am/db/2537423/Frazier_Healthcare>,
        <https://1145.am/db/2584561/Frazier_Healthcare_Partners>,
        <https://1145.am/db/490601/Frazier_Healthcare_Partners>,
        <https://1145.am/db/578056/Frazier_Healthcare_Partners>,
        <https://1145.am/db/578059/Frazier_Healthcare_Partners>,
        <https://1145.am/db/699981/Frazier_Healthcare_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2366187/Montreux_Equity_Partners> a org:Organization ;
    ns1:basedInLowRaw "Montreux" ;
    ns1:description "Investing" ;
    ns1:documentDate "2010-09-30T16:26:17+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Tobira Therapeutics Inc. Raises $31 Million in Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/tobira-therapeutics-inc-raises-31-million-series-b-financing> ;
    ns1:foundName "Montreux Equity Partners" ;
    ns1:investor <https://1145.am/db/2366187/Series_B_Investment_Canaan_Partners_Domain_Associates_Frazier_Healthcare_Ventures_Montreux_Equity_Partners_Novo_A_S_Tobira_Therapeutics_Inc_Completed> ;
    ns1:name "Montreux Equity Partners" ;
    ns1:sameAsHigh <https://1145.am/db/1133268/Montreux_Growth_Partners>,
        <https://1145.am/db/2305507/Montreux_Equity_Partners>,
        <https://1145.am/db/2305514/Montreux_Equity_Partners>,
        <https://1145.am/db/2364492/Montreux_Equity_Partners> ;
    ns1:sameAsMedium <https://1145.am/db/1798788/Montreux_Equity_Partners>,
        <https://1145.am/db/2294721/Montreux_Equity_Partners>,
        <https://1145.am/db/2300653/Montreux_Equity_Partners>,
        <https://1145.am/db/2317951/Montreux_Equity_Partners>,
        <https://1145.am/db/2365700/Montreux_Equity_Partners>,
        <https://1145.am/db/2590138/Montreux_Equity_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2366860/Apposite_Capital> a org:Organization ;
    ns1:basedInLowRaw "UK" ;
    ns1:description "private equity" ;
    ns1:documentDate "2010-10-06T13:04:22+00:00"^^xsd:dateTime ;
    ns1:documentTitle "New Leaf Venture Partners Invests in $35.4 (GBP 22.4) Million Series A Financing of Convergence Pharmaceuticals" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/new-leaf-venture-partners-invests-35-4-gbp-22-4-million-series-a-financing-of-convergence> ;
    ns1:foundName "Apposite Capital" ;
    ns1:industry "private equity" ;
    ns1:investor <https://1145.am/db/2366860/Series_A_Investment_Apposite_Capital_Convergence_Pharmaceuticals_New_Leaf_Venture_Partners_Sv_Life_Sciences_Has_Not_Happened>,
        <https://1145.am/db/2366860/Series_A_Investment_Apposite_Capital_New_Leaf_Venture_Partners_Sv_Life_Sciences_Completed> ;
    ns1:name "Apposite Capital" ;
    ns1:sameAsHigh <https://1145.am/db/1006024/Ven_Capital_Partners>,
        <https://1145.am/db/1066985/Dc_Capital_Partners_Management_Lp>,
        <https://1145.am/db/1333900/Auctus_Capital_Partners_Ag>,
        <https://1145.am/db/1459062/Resolute_Capital_Partners>,
        <https://1145.am/db/1461518/Resolute_Capital_Partners>,
        <https://1145.am/db/1828275/Idinvest_Partners>,
        <https://1145.am/db/2027054/Avem_Partners>,
        <https://1145.am/db/2361455/Accele_Venture_Partners>,
        <https://1145.am/db/245856/Intermediate_Capital_Group>,
        <https://1145.am/db/2589930/Avistal_Capital_Partners>,
        <https://1145.am/db/2603843/Cvf_Capital_Partners>,
        <https://1145.am/db/2647818/Cvc_Partners>,
        <https://1145.am/db/355174/Aquiline_Capital_Partners>,
        <https://1145.am/db/355266/Aquiline_Capital_Partners>,
        <https://1145.am/db/355273/Aquiline_Capital_Partners>,
        <https://1145.am/db/594547/Aquiline_Capital_Partners>,
        <https://1145.am/db/612252/Apposite_Capital_Llp>,
        <https://1145.am/db/766278/Dl_Capital_Partners>,
        <https://1145.am/db/962132/Prather_Capital_Partners> ;
    ns1:sameAsMedium <https://1145.am/db/2344507/Apposite_Capital_Llp>,
        <https://1145.am/db/2352436/Apposite_Capital_Llp>,
        <https://1145.am/db/2352441/Apposite_Capital>,
        <https://1145.am/db/2352442/Apposite_Capital_Llp>,
        <https://1145.am/db/2360415/Apposite_Capital> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2367130/Lurie_Investments> a org:Organization ;
    ns1:basedInLowRaw "SKOKIE, Ill." ;
    ns1:documentDate "2010-10-11T14:42:14+00:00"^^xsd:dateTime ;
    ns1:documentTitle "NanoInk closes $65 million financing led by Lurie Investments" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/nanoink-closes-65-million-financing-led-by-lurie-investments> ;
    ns1:foundName "LURIE INVESTMENTS",
        "Lurie Investments" ;
    ns1:investor <https://1145.am/db/2367130/Investment_Lurie_Investments_Nanoink_Has_Not_Happened> ;
    ns1:name "LURIE INVESTMENTS",
        "Lurie Investments" ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2367176/Investment_Excelimmune_Has_Not_Happened> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-07-07T15:32:24+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Excelimmune has won an SBIR grant to back its work on a treatment for Clostridium difficile infection.",
        "Woburn, MA - based Excelimmune has rounded up $ 4.5 million in new financing for its planned clinical development work on polyclonal antibodies." ;
    ns1:documentTitle "Excelimmune garners $4.5M in new financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/excelimmune-garners-4-5m-new-financing> ;
    ns1:foundName "financing",
        "won" ;
    ns1:name "financing",
        "won" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2367176/Excelimmune> ;
    ns1:valueRaw "$ 4.5 million",
        "$ 8.9 million" ;
    ns1:whereGeoName "Massachusetts" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6254926/about.rdf> ;
    ns1:whereRaw "Massachusetts" .

<https://1145.am/db/2367204/Mission_Bay_Capital> a org:Organization ;
    ns1:basedInLowRaw "SOUTH SAN FRANCISCO" ;
    ns1:description "venture capital" ;
    ns1:documentDate "2010-07-08T15:06:02+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Calithera Biosciences Closes $40 Million in Series A Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/calithera-biosciences-closes-40-million-series-a-financing> ;
    ns1:foundName "Mission Bay Capital" ;
    ns1:investor <https://1145.am/db/2367204/Series_A_Investment_Advanced_Technology_Ventures_Calithera_Biosciences_Delphi_Ventures_Mission_Bay_Capital_Morgenthaler_Ventures_Us_Venture_Partners_Completed> ;
    ns1:name "Mission Bay Capital" ;
    ns1:sameAsHigh <https://1145.am/db/1830084/Bay_Partners>,
        <https://1145.am/db/1836989/Bay_Partners>,
        <https://1145.am/db/1879250/Baytech_Venture_Capital>,
        <https://1145.am/db/2306568/Bay_City_Capital>,
        <https://1145.am/db/2357418/Bay_City_Capital>,
        <https://1145.am/db/2370208/Mission_Bay_Capital>,
        <https://1145.am/db/2583466/Bay_City_Capital> ;
    ns1:sameAsMedium <https://1145.am/db/2342925/Mission_Bay_Capital>,
        <https://1145.am/db/2342937/Mission_Bay_Capital>,
        <https://1145.am/db/2344017/Mission_Bay_Capital>,
        <https://1145.am/db/2355051/Mission_Bay_Capital>,
        <https://1145.am/db/2358430/Mission_Bay_Capital>,
        <https://1145.am/db/2367621/Mission_Bay_Capital> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2367204/Morgenthaler_Ventures> a org:Organization ;
    ns1:basedInLowRaw "SOUTH SAN FRANCISCO" ;
    ns1:documentDate "2010-07-08T15:06:02+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Calithera Biosciences Closes $40 Million in Series A Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/calithera-biosciences-closes-40-million-series-a-financing> ;
    ns1:foundName "Morgenthaler Ventures" ;
    ns1:investor <https://1145.am/db/2367204/Series_A_Investment_Advanced_Technology_Ventures_Calithera_Biosciences_Delphi_Ventures_Mission_Bay_Capital_Morgenthaler_Ventures_Us_Venture_Partners_Completed> ;
    ns1:name "Morgenthaler Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/1281079/Morgenthaler_Ventures>,
        <https://1145.am/db/1281647/Morgenthaler_Ventures>,
        <https://1145.am/db/1653506/Morgenthaler_Ventures>,
        <https://1145.am/db/1695894/Morgenthaler_Ventures>,
        <https://1145.am/db/1699268/Morgenthaler_Ventures>,
        <https://1145.am/db/1709168/Morgenthaler_Ventures>,
        <https://1145.am/db/1724566/Morgenthaler_Ventures>,
        <https://1145.am/db/1826128/Morgenthaler_Ventures>,
        <https://1145.am/db/1829487/Morgenthaler_Ventures>,
        <https://1145.am/db/1830084/Morgenthaler_Ventures>,
        <https://1145.am/db/1836989/Morgenthaler_Ventures>,
        <https://1145.am/db/1837117/Morgenthaler_Ventures>,
        <https://1145.am/db/1839836/Morgenthaler_Ventures>,
        <https://1145.am/db/1846752/Morgenthaler_Ventures>,
        <https://1145.am/db/1881748/Morgenthaler_Ventures>,
        <https://1145.am/db/1890157/Morgenthaler_Ventures>,
        <https://1145.am/db/2246579/Morgenthaler_Ventures>,
        <https://1145.am/db/2257512/Morgenthaler_Ventures>,
        <https://1145.am/db/2297408/Morgenthaler_Ventures>,
        <https://1145.am/db/2297592/Morgenthaler_Ventures>,
        <https://1145.am/db/2307644/Morgenthaler_Ventures>,
        <https://1145.am/db/2308142/Morgenthaler_Ventures>,
        <https://1145.am/db/2311069/Morgenthaler_Ventures>,
        <https://1145.am/db/2311075/Morgenthaler_Ventures>,
        <https://1145.am/db/2312192/Morgenthaler_Ventures>,
        <https://1145.am/db/2323586/Morgenthaler_Ventures>,
        <https://1145.am/db/2329524/Morgenthaler_Ventures>,
        <https://1145.am/db/2329531/Morgenthaler_Ventures>,
        <https://1145.am/db/2338251/Morgenthaler_Ventures>,
        <https://1145.am/db/2338254/Morgenthaler_Ventures>,
        <https://1145.am/db/2338373/Morgenthaler_Ventures>,
        <https://1145.am/db/2338703/Morgenthaler_Ventures>,
        <https://1145.am/db/2338704/Morgenthaler_Ventures>,
        <https://1145.am/db/2342925/Morgenthaler_Ventures>,
        <https://1145.am/db/2342937/Morgenthaler_Ventures>,
        <https://1145.am/db/2343202/Morgenthaler_Ventures>,
        <https://1145.am/db/2343210/Morgenthaler_Ventures>,
        <https://1145.am/db/2352207/Morgenthaler_Ventures>,
        <https://1145.am/db/2362553/Morgenthaler_Ventures>,
        <https://1145.am/db/2363510/Morgenthaler_Ventures>,
        <https://1145.am/db/2364939/Morgenthaler_Ventures>,
        <https://1145.am/db/2570481/Morgenthaler_Ventures>,
        <https://1145.am/db/2570483/Morgenthaler_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2367204/Us_Venture_Partners> a org:Organization ;
    ns1:basedInLowRaw "U.S." ;
    ns1:description "financing" ;
    ns1:documentDate "2010-07-08T15:06:02+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Calithera Biosciences Closes $40 Million in Series A Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/calithera-biosciences-closes-40-million-series-a-financing> ;
    ns1:foundName "U.S. Venture Partners" ;
    ns1:investor <https://1145.am/db/2367204/Series_A_Investment_Advanced_Technology_Ventures_Calithera_Biosciences_Delphi_Ventures_Mission_Bay_Capital_Morgenthaler_Ventures_Us_Venture_Partners_Completed> ;
    ns1:name "U.S. Venture Partners" ;
    ns1:sameAsHigh <https://1145.am/db/1147854/Us_Venture_Partners>,
        <https://1145.am/db/1701580/Us_Venture_Partners>,
        <https://1145.am/db/1796259/Us_Venture_Partners>,
        <https://1145.am/db/1845321/Us_Venture_Partners>,
        <https://1145.am/db/1870790/Us_Venture_Partners>,
        <https://1145.am/db/2050254/Us_Venture_Partners>,
        <https://1145.am/db/2319658/Us_Venture_Partners> ;
    ns1:sameAsMedium <https://1145.am/db/1418766/Us_Venture_Partners>,
        <https://1145.am/db/1454909/Us_Venture_Partners>,
        <https://1145.am/db/1681426/Us_Venture_Partners>,
        <https://1145.am/db/1697656/Us_Venture_Partners>,
        <https://1145.am/db/1710567/Us_Venture_Partners>,
        <https://1145.am/db/1712506/Us_Venture_Partners>,
        <https://1145.am/db/1718048/Us_Venture_Partners>,
        <https://1145.am/db/1725165/Us_Venture_Partners>,
        <https://1145.am/db/1737882/Us_Venture_Partners>,
        <https://1145.am/db/1748970/Us_Venture_Partners>,
        <https://1145.am/db/1758985/Us_Venture_Partners>,
        <https://1145.am/db/1763964/Us_Venture_Partners>,
        <https://1145.am/db/1771750/Us_Venture_Partners>,
        <https://1145.am/db/1787502/Us_Venture_Partners>,
        <https://1145.am/db/1797905/Us_Venture_Partners>,
        <https://1145.am/db/1812267/Us_Venture_Partners>,
        <https://1145.am/db/1831222/Us_Venture_Partners>,
        <https://1145.am/db/1834392/Us_Venture_Partners>,
        <https://1145.am/db/1842350/Us_Venture_Partners>,
        <https://1145.am/db/1842466/Us_Venture_Partners>,
        <https://1145.am/db/1844571/Us_Venture_Partners>,
        <https://1145.am/db/1845308/Us_Venture_Partners>,
        <https://1145.am/db/1845924/Us_Venture_Partners>,
        <https://1145.am/db/1846470/Us_Venture_Partners>,
        <https://1145.am/db/1847323/Us_Venture_Partners>,
        <https://1145.am/db/1851689/Us_Venture_Partners>,
        <https://1145.am/db/1852806/Us_Venture_Partners>,
        <https://1145.am/db/1863147/Us_Venture_Partners>,
        <https://1145.am/db/1864900/Us_Venture_Partners>,
        <https://1145.am/db/1867951/Us_Venture_Partners>,
        <https://1145.am/db/1871784/Us_Venture_Partners>,
        <https://1145.am/db/1877830/Us_Venture_Partners>,
        <https://1145.am/db/1879026/Us_Venture_Partners>,
        <https://1145.am/db/1884155/Us_Venture_Partners>,
        <https://1145.am/db/1895986/Us_Venture_Partners>,
        <https://1145.am/db/1915640/Us_Venture_Partners>,
        <https://1145.am/db/2150562/Us_Venture_Partners>,
        <https://1145.am/db/2192716/Us_Venture_Partners>,
        <https://1145.am/db/2257512/Us_Venture_Partners>,
        <https://1145.am/db/2278799/Us_Venture_Partners>,
        <https://1145.am/db/2279124/Us_Venture_Partners>,
        <https://1145.am/db/2288251/Us_Venture_Partners>,
        <https://1145.am/db/2288899/Us_Venture_Partners>,
        <https://1145.am/db/2293765/Us_Venture_Partners>,
        <https://1145.am/db/2299776/Us_Venture_Partners>,
        <https://1145.am/db/2301809/Us_Venture_Partners>,
        <https://1145.am/db/2343206/Us_Venture_Partners>,
        <https://1145.am/db/2357858/Us_Venture_Partners>,
        <https://1145.am/db/2358430/Us_Venture_Partners>,
        <https://1145.am/db/2645160/Us_Venture_Partners>,
        <https://1145.am/db/425262/Us_Venture_Partners>,
        <https://1145.am/db/838691/Us_Venture_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2367291/Cd_Ventures> a org:Organization ;
    ns1:basedInLowRaw "BERLIN" ;
    ns1:documentDate "2010-10-12T15:14:20+00:00"^^xsd:dateTime ;
    ns1:documentTitle "NOXXON Confirms Total Capital Raise of €35m" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/noxxon-confirms-total-capital-raise-of-%E2%82%AC35m> ;
    ns1:foundName "CD Ventures" ;
    ns1:investor <https://1145.am/db/2367291/Investment_Cd_Ventures_Noxxon_Pharma_Ag_Completed> ;
    ns1:name "CD Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/2369872/Cd_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2367364/Cpmg_Inc> a org:Organization ;
    ns1:basedInLowRaw "IRVING, Texas" ;
    ns1:documentDate "2010-07-12T12:27:59+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Reata Pharmaceuticals Completes $78 Million Equity Financing for Second Pivotal Trial of Bardoxolone Methyl" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/reata-pharmaceuticals-completes-78-million-equity-financing-for-second-pivotal-trial-of> ;
    ns1:foundName "CPMG, Inc." ;
    ns1:investor <https://1145.am/db/2367364/Investment_Cpmg_Inc_Novo_A_S_Reata_Pharmaceuticals_Completed> ;
    ns1:name "CPMG, Inc." ;
    ns1:sameAsMedium <https://1145.am/db/2050282/CPMG>,
        <https://1145.am/db/2068430/CPMG>,
        <https://1145.am/db/2296606/CPMG>,
        <https://1145.am/db/2325116/Cpmg_Inc> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2367475/Aravis_Ventures> a org:Organization ;
    ns1:basedInHighGeoName "Republic of Singapore" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/1880251/about.rdf> ;
    ns1:basedInHighRaw "Singapore" ;
    ns1:documentDate "2010-07-13T16:13:01+00:00"^^xsd:dateTime ;
    ns1:documentTitle "MerLion Pharmaceuticals Completes US$7 Million Series C" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/merlion-pharmaceuticals-completes-us-7-million-series-c> ;
    ns1:foundName "Aravis Ventures" ;
    ns1:investor <https://1145.am/db/2367475/Series_C_Investment_Aurelia_Private_Equity_Bio_*_One_Capital_Heidelbergcapital_Merlion_Pharmaceuticals_Pte_Ltd_Venture_Incubator_Completed> ;
    ns1:name "Aravis Ventures" ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2367475/Aurelia_Private_Equity> a org:Organization ;
    ns1:basedInLowRaw "Singapore" ;
    ns1:documentDate "2010-07-13T16:13:01+00:00"^^xsd:dateTime ;
    ns1:documentTitle "MerLion Pharmaceuticals Completes US$7 Million Series C" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/merlion-pharmaceuticals-completes-us-7-million-series-c> ;
    ns1:foundName "Aurelia Private Equity" ;
    ns1:investor <https://1145.am/db/2367475/Series_C_Investment_Aurelia_Private_Equity_Bio_*_One_Capital_Heidelbergcapital_Merlion_Pharmaceuticals_Pte_Ltd_Venture_Incubator_Completed> ;
    ns1:name "Aurelia Private Equity" ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2367475/Bio_*_One_Capital> a org:Organization ;
    ns1:basedInLowRaw "Singapore" ;
    ns1:documentDate "2010-07-13T16:13:01+00:00"^^xsd:dateTime ;
    ns1:documentTitle "MerLion Pharmaceuticals Completes US$7 Million Series C" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/merlion-pharmaceuticals-completes-us-7-million-series-c> ;
    ns1:foundName "Bio * One Capital" ;
    ns1:investor <https://1145.am/db/2367475/Series_C_Investment_Aurelia_Private_Equity_Bio_*_One_Capital_Heidelbergcapital_Merlion_Pharmaceuticals_Pte_Ltd_Venture_Incubator_Completed> ;
    ns1:name "Bio * One Capital" ;
    ns1:sameAsMedium <https://1145.am/db/2292138/Bio_*_One_Capital>,
        <https://1145.am/db/2301741/Bio_*_One_Capital>,
        <https://1145.am/db/2316674/Bio_*_One_Capital>,
        <https://1145.am/db/2317779/Bio_*_One_Capital>,
        <https://1145.am/db/2318828/Bio_*_One_Capital_Pte_Ltd>,
        <https://1145.am/db/2332771/Bio_*_One_Capital>,
        <https://1145.am/db/2363459/Bio_*_One_Capital>,
        <https://1145.am/db/2363460/Bio_*_One_Capital> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2367475/Heidelbergcapital> a org:Organization ;
    ns1:basedInLowRaw "Singapore" ;
    ns1:documentDate "2010-07-13T16:13:01+00:00"^^xsd:dateTime ;
    ns1:documentTitle "MerLion Pharmaceuticals Completes US$7 Million Series C" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/merlion-pharmaceuticals-completes-us-7-million-series-c> ;
    ns1:foundName "HeidelbergCapital" ;
    ns1:investor <https://1145.am/db/2367475/Series_C_Investment_Aurelia_Private_Equity_Bio_*_One_Capital_Heidelbergcapital_Merlion_Pharmaceuticals_Pte_Ltd_Venture_Incubator_Completed> ;
    ns1:name "HeidelbergCapital" ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2367475/Venture_Incubator> a org:Organization ;
    ns1:basedInLowRaw "Singapore" ;
    ns1:documentDate "2010-07-13T16:13:01+00:00"^^xsd:dateTime ;
    ns1:documentTitle "MerLion Pharmaceuticals Completes US$7 Million Series C" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/merlion-pharmaceuticals-completes-us-7-million-series-c> ;
    ns1:foundName "Venture Incubator" ;
    ns1:investor <https://1145.am/db/2367475/Series_C_Investment_Aurelia_Private_Equity_Bio_*_One_Capital_Heidelbergcapital_Merlion_Pharmaceuticals_Pte_Ltd_Venture_Incubator_Completed> ;
    ns1:name "Venture Incubator" ;
    ns1:sameAsMedium <https://1145.am/db/1792383/Venture_Incubator> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2367497/Alta_Partners> a org:Organization ;
    ns1:basedInLowRaw "Japan" ;
    ns1:description "financing" ;
    ns1:documentDate "2010-07-14T12:04:54+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Trevena Secures $35 Million in Series B Funding" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/trevena-secures-35-million-series-b-funding> ;
    ns1:foundName "Alta Partners" ;
    ns1:investor <https://1145.am/db/2367497/Series_B_Investment_Alta_Partners_Healthcare_Ventures_New_Enterprise_Associates_Polaris_Venture_Partners_Trevena_Yasuda_Enterprise_Development_Company_Completed> ;
    ns1:name "Alta Partners" ;
    ns1:sameAsHigh <https://1145.am/db/1063835/Altamont_Capital_Partners>,
        <https://1145.am/db/1156304/Alta_Partners>,
        <https://1145.am/db/2303810/Alta_Partners>,
        <https://1145.am/db/2307691/Alta_Partners>,
        <https://1145.am/db/2311011/Alta_Partners>,
        <https://1145.am/db/2328815/Alta_Partners>,
        <https://1145.am/db/2330075/Alta_Partners>,
        <https://1145.am/db/2346542/Alta_Partners>,
        <https://1145.am/db/2353439/Alta_Partners>,
        <https://1145.am/db/2366693/Alta_Partners>,
        <https://1145.am/db/979509/Alta_Partners> ;
    ns1:sameAsMedium <https://1145.am/db/1230022/Alta_Partners>,
        <https://1145.am/db/1333948/Altas_Partners>,
        <https://1145.am/db/1334727/Altas_Partners>,
        <https://1145.am/db/2303814/Alta_Partners>,
        <https://1145.am/db/2304769/Alta_Partners>,
        <https://1145.am/db/2304870/Alta_Partners>,
        <https://1145.am/db/2305729/Alta_Partners>,
        <https://1145.am/db/2305745/Alta_Partners>,
        <https://1145.am/db/2306281/Alta_Partners>,
        <https://1145.am/db/2306568/Alta_Partners>,
        <https://1145.am/db/2307682/Alta_Partners>,
        <https://1145.am/db/2307824/Alta_Partners>,
        <https://1145.am/db/2307829/Alta_Partners>,
        <https://1145.am/db/2308855/Alta_Partners>,
        <https://1145.am/db/2313143/Alta_Partners>,
        <https://1145.am/db/2313405/Alta_Partners>,
        <https://1145.am/db/2316391/Alta_Partners>,
        <https://1145.am/db/2318577/Alta_Partners>,
        <https://1145.am/db/2318635/Alta_Partners>,
        <https://1145.am/db/2322984/Alta_Partners>,
        <https://1145.am/db/2323003/Alta_Partners>,
        <https://1145.am/db/2323243/Alta_Partners>,
        <https://1145.am/db/2324012/Alta_Partners>,
        <https://1145.am/db/2324015/Alta_Partners>,
        <https://1145.am/db/2326176/Alta_Partners>,
        <https://1145.am/db/2326903/Alta_Partners>,
        <https://1145.am/db/2327441/Alta_Partners>,
        <https://1145.am/db/2327442/Alta_Partners>,
        <https://1145.am/db/2327677/Alta_Partners>,
        <https://1145.am/db/2330079/Alta_Partners>,
        <https://1145.am/db/2338126/Alta_Partners>,
        <https://1145.am/db/2338127/Alta_Partners>,
        <https://1145.am/db/2340887/Alta_Partners>,
        <https://1145.am/db/2341764/Alta_Partners>,
        <https://1145.am/db/2343547/Alta_Partners>,
        <https://1145.am/db/2344092/Alta_Partners>,
        <https://1145.am/db/2344100/Alta_Partners>,
        <https://1145.am/db/2351224/Alta_Partners>,
        <https://1145.am/db/2351897/Alta_Partners>,
        <https://1145.am/db/2352167/Alta_Partners>,
        <https://1145.am/db/2352170/Alta_Partners>,
        <https://1145.am/db/2352362/Alta_Partners>,
        <https://1145.am/db/2352831/Alta_Partners>,
        <https://1145.am/db/2353771/Alta_Partners>,
        <https://1145.am/db/2353789/Alta_Partners>,
        <https://1145.am/db/2354299/Alta_Partners>,
        <https://1145.am/db/2354307/Alta_Partners>,
        <https://1145.am/db/2354314/Alta_Partners>,
        <https://1145.am/db/2355183/Alta_Partners>,
        <https://1145.am/db/2355274/Alta_Partners>,
        <https://1145.am/db/2355586/Alta_Partners>,
        <https://1145.am/db/2356216/Alta_Partners>,
        <https://1145.am/db/2358496/Alta_Partners>,
        <https://1145.am/db/2358502/Alta_Partners>,
        <https://1145.am/db/2362565/Alta_Partners>,
        <https://1145.am/db/2362566/Alta_Partners>,
        <https://1145.am/db/2362902/Alta_Partners>,
        <https://1145.am/db/2362909/Alta_Partners>,
        <https://1145.am/db/2362910/Alta_Partners>,
        <https://1145.am/db/2363364/Alta_Partners>,
        <https://1145.am/db/2363510/Alta_Partners>,
        <https://1145.am/db/2365748/Alta_Partners>,
        <https://1145.am/db/2366700/Alta_Partners>,
        <https://1145.am/db/328387/Altas_Partners>,
        <https://1145.am/db/443962/Altas_Partners>,
        <https://1145.am/db/750997/Alta_Partners>,
        <https://1145.am/db/987929/Alta_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2367497/New_Enterprise_Associates> a org:Organization ;
    ns1:description "venture capital" ;
    ns1:documentDate "2010-07-14T12:04:54+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Trevena Secures $35 Million in Series B Funding" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/trevena-secures-35-million-series-b-funding> ;
    ns1:foundName "New Enterprise Associates" ;
    ns1:investor <https://1145.am/db/2367497/Series_B_Investment_Alta_Partners_Healthcare_Ventures_New_Enterprise_Associates_Polaris_Venture_Partners_Trevena_Yasuda_Enterprise_Development_Company_Completed> ;
    ns1:name "New Enterprise Associates" ;
    ns1:sameAsHigh <https://1145.am/db/1061564/Evonik_Venture_Capital>,
        <https://1145.am/db/1091201/New_Enterprise_Associates>,
        <https://1145.am/db/1115103/New_Enterprise_Associates>,
        <https://1145.am/db/1127410/New_Enterprise_Associates>,
        <https://1145.am/db/1169121/New_Enterprise_Associates>,
        <https://1145.am/db/1279264/New_Enterprise_Associates>,
        <https://1145.am/db/1281079/New_Enterprise_Associates>,
        <https://1145.am/db/1281647/New_Enterprise_Associates>,
        <https://1145.am/db/1427471/New_Enterprise_Associates>,
        <https://1145.am/db/1469165/New_Enterprise_Associates>,
        <https://1145.am/db/1653132/New_Enterprise_Associates>,
        <https://1145.am/db/1653506/New_Enterprise_Associates>,
        <https://1145.am/db/1654515/New_Enterprise_Associates>,
        <https://1145.am/db/1694448/New_Enterprise_Associates>,
        <https://1145.am/db/1718018/New_Enterprise_Associates>,
        <https://1145.am/db/1768899/Eventures>,
        <https://1145.am/db/1786672/Eventures>,
        <https://1145.am/db/1788268/New_Enterprise_Associates>,
        <https://1145.am/db/1788746/New_Enterprise_Associates>,
        <https://1145.am/db/1794202/New_Enterprise_Associates>,
        <https://1145.am/db/1801934/New_Enterprise_Associates>,
        <https://1145.am/db/1806644/Eventures>,
        <https://1145.am/db/1811114/New_Enterprise_Associates>,
        <https://1145.am/db/1825681/New_Enterprise_Associates>,
        <https://1145.am/db/1826275/New_Enterprise_Associates>,
        <https://1145.am/db/1845066/New_Enterprise_Associates>,
        <https://1145.am/db/1849986/New_Enterprise_Associates>,
        <https://1145.am/db/1860644/New_Enterprise_Associates>,
        <https://1145.am/db/1869421/New_Enterprise_Associates>,
        <https://1145.am/db/1883008/New_Enterprise_Associates>,
        <https://1145.am/db/1894602/New_Enterprise_Associates>,
        <https://1145.am/db/2153726/New_Enterprise_Associates>,
        <https://1145.am/db/2170734/Eventures>,
        <https://1145.am/db/2185936/New_Enterprise_Associates>,
        <https://1145.am/db/2280770/New_Enterprise_Associates>,
        <https://1145.am/db/2291315/New_Enterprise_Associates>,
        <https://1145.am/db/2305507/New_Enterprise_Associates>,
        <https://1145.am/db/2305610/New_Enterprise_Associates>,
        <https://1145.am/db/2323138/New_Enterprise_Associates>,
        <https://1145.am/db/2323845/New_Enterprise_Associates>,
        <https://1145.am/db/2326447/New_Enterprise_Associates>,
        <https://1145.am/db/2326893/New_Enterprise_Associates>,
        <https://1145.am/db/2336634/New_Enterprise_Associates>,
        <https://1145.am/db/2338086/New_Enterprise_Associates>,
        <https://1145.am/db/2339206/New_Enterprise_Associates>,
        <https://1145.am/db/2340224/New_Enterprise_Associates_Inc>,
        <https://1145.am/db/2341792/New_Enterprise_Associates>,
        <https://1145.am/db/2341800/New_Enterprise_Associates>,
        <https://1145.am/db/2341896/New_Enterprise_Associates>,
        <https://1145.am/db/2343773/New_Enterprise_Associates>,
        <https://1145.am/db/2346094/New_Enterprise_Associates>,
        <https://1145.am/db/2348024/New_Enterprise_Associates>,
        <https://1145.am/db/2355754/New_Enterprise_Associates>,
        <https://1145.am/db/2355885/New_Enterprise_Associates>,
        <https://1145.am/db/2356393/New_Enterprise_Associates>,
        <https://1145.am/db/2356395/New_Enterprise_Associates>,
        <https://1145.am/db/2361004/New_Enterprise_Associates>,
        <https://1145.am/db/2364422/New_Enterprise_Associates>,
        <https://1145.am/db/330761/Emv_Capital>,
        <https://1145.am/db/490907/Echelon_Capital>,
        <https://1145.am/db/676316/New_Enterprise_Associates>,
        <https://1145.am/db/680751/New_Enterprise_Associates>,
        <https://1145.am/db/893810/New_Enterprise_Associates>,
        <https://1145.am/db/918706/New_Enterprise_Associates>,
        <https://1145.am/db/936724/Efung_Capital>,
        <https://1145.am/db/961672/New_Enterprise_Associates> ;
    ns1:sameAsMedium <https://1145.am/db/1031040/New_Enterprise_Associates>,
        <https://1145.am/db/1115600/New_Enterprise_Associates>,
        <https://1145.am/db/1116035/New_Enterprise_Associates>,
        <https://1145.am/db/1116076/New_Enterprise_Associates>,
        <https://1145.am/db/1230022/New_Enterprise_Associates>,
        <https://1145.am/db/1233430/New_Enterprise_Associates>,
        <https://1145.am/db/1371086/New_Enterprise_Associates>,
        <https://1145.am/db/1422234/New_Enterprise_Associates>,
        <https://1145.am/db/1422725/New_Enterprise_Associates>,
        <https://1145.am/db/1571794/New_Enterprise_Associates>,
        <https://1145.am/db/1606686/New_Enterprise_Associates>,
        <https://1145.am/db/1696213/New_Enterprise_Associates>,
        <https://1145.am/db/1699877/New_Enterprise_Associates>,
        <https://1145.am/db/1701285/New_Enterprise_Associates>,
        <https://1145.am/db/1701411/New_Enterprise_Associates>,
        <https://1145.am/db/1701589/New_Enterprise_Associates>,
        <https://1145.am/db/1715860/New_Enterprise_Associates>,
        <https://1145.am/db/1717498/New_Enterprise_Associates>,
        <https://1145.am/db/1717968/New_Enterprise_Associates>,
        <https://1145.am/db/1718000/New_Enterprise_Associates>,
        <https://1145.am/db/1719370/New_Enterprise_Associates>,
        <https://1145.am/db/1719408/New_Enterprise_Associates>,
        <https://1145.am/db/1720645/New_Enterprise_Associates>,
        <https://1145.am/db/1721392/New_Enterprise_Associates>,
        <https://1145.am/db/1731944/New_Enterprise_Associates>,
        <https://1145.am/db/1738986/New_Enterprise_Associates>,
        <https://1145.am/db/1743570/New_Enterprise_Associates>,
        <https://1145.am/db/1743999/New_Enterprise_Associates>,
        <https://1145.am/db/1751207/New_Enterprise_Associates>,
        <https://1145.am/db/1753526/New_Enterprise_Associates>,
        <https://1145.am/db/1760464/New_Enterprise_Associates>,
        <https://1145.am/db/1761607/New_Enterprise_Associates>,
        <https://1145.am/db/1772584/New_Enterprise_Associates>,
        <https://1145.am/db/1777442/New_Enterprise_Associates>,
        <https://1145.am/db/1777542/New_Enterprise_Associates>,
        <https://1145.am/db/1783236/New_Enterprise_Associates>,
        <https://1145.am/db/1790370/New_Enterprise_Associates>,
        <https://1145.am/db/1790675/New_Enterprise_Associates>,
        <https://1145.am/db/1791343/New_Enterprise_Associates>,
        <https://1145.am/db/1792086/New_Enterprise_Associates>,
        <https://1145.am/db/1796249/New_Enterprise_Associates>,
        <https://1145.am/db/1798548/New_Enterprise_Associates>,
        <https://1145.am/db/1798774/New_Enterprise_Associates>,
        <https://1145.am/db/1801088/New_Enterprise_Associates>,
        <https://1145.am/db/1804355/New_Enterprise_Associates>,
        <https://1145.am/db/1811472/New_Enterprise_Associates>,
        <https://1145.am/db/1813288/New_Enterprise_Associates>,
        <https://1145.am/db/1816928/New_Enterprise_Associates>,
        <https://1145.am/db/1818535/New_Enterprise_Associates>,
        <https://1145.am/db/1819637/New_Enterprise_Associates>,
        <https://1145.am/db/1823697/New_Enterprise_Associates>,
        <https://1145.am/db/1823742/New_Enterprise_Associates>,
        <https://1145.am/db/1824558/New_Enterprise_Associates>,
        <https://1145.am/db/1826221/New_Enterprise_Associates>,
        <https://1145.am/db/1826446/New_Enterprise_Associates>,
        <https://1145.am/db/1827724/New_Enterprise_Associates>,
        <https://1145.am/db/1828072/New_Enterprise_Associates>,
        <https://1145.am/db/1828658/New_Enterprise_Associates>,
        <https://1145.am/db/1828979/New_Enterprise_Associates>,
        <https://1145.am/db/1829581/New_Enterprise_Associates_Inc>,
        <https://1145.am/db/1830382/New_Enterprise_Associates>,
        <https://1145.am/db/1830408/New_Enterprise_Associates>,
        <https://1145.am/db/1830873/New_Enterprise_Associates>,
        <https://1145.am/db/1831689/New_Enterprise_Associates>,
        <https://1145.am/db/1832186/New_Enterprise_Associates>,
        <https://1145.am/db/1835229/New_Enterprise_Associates>,
        <https://1145.am/db/1837877/New_Enterprise_Associates>,
        <https://1145.am/db/1838611/New_Enterprise_Associates>,
        <https://1145.am/db/1842035/New_Enterprise_Associates>,
        <https://1145.am/db/1845590/New_Enterprise_Associates>,
        <https://1145.am/db/1846607/New_Enterprise_Associates>,
        <https://1145.am/db/1848728/New_Enterprise_Associates>,
        <https://1145.am/db/1849310/New_Enterprise_Associates>,
        <https://1145.am/db/1851923/New_Enterprise_Associates>,
        <https://1145.am/db/1852048/New_Enterprise_Associates>,
        <https://1145.am/db/1853875/New_Enterprise_Associates>,
        <https://1145.am/db/1854098/New_Enterprise_Associates>,
        <https://1145.am/db/1859858/New_Enterprise_Associates>,
        <https://1145.am/db/1860804/New_Enterprise_Associates>,
        <https://1145.am/db/1875228/New_Enterprise_Associates>,
        <https://1145.am/db/1879023/New_Enterprise_Associates>,
        <https://1145.am/db/1879085/New_Enterprise_Associates>,
        <https://1145.am/db/1880677/New_Enterprise_Associates>,
        <https://1145.am/db/1885336/New_Enterprise_Associates>,
        <https://1145.am/db/1887711/New_Enterprise_Associates>,
        <https://1145.am/db/1889764/New_Enterprise_Associates>,
        <https://1145.am/db/1889877/New_Enterprise_Associates>,
        <https://1145.am/db/1889935/New_Enterprise_Associates>,
        <https://1145.am/db/1890000/New_Enterprise_Associates>,
        <https://1145.am/db/1891539/New_Enterprise_Associates>,
        <https://1145.am/db/1891961/New_Enterprise_Associates>,
        <https://1145.am/db/1893324/New_Enterprise_Associates>,
        <https://1145.am/db/1893352/New_Enterprise_Associates>,
        <https://1145.am/db/1910957/New_Enterprise_Associates>,
        <https://1145.am/db/1917393/New_Enterprise_Associates>,
        <https://1145.am/db/1919425/New_Enterprise_Associates>,
        <https://1145.am/db/1958068/New_Enterprise_Associates>,
        <https://1145.am/db/2028610/New_Enterprise_Associates>,
        <https://1145.am/db/2069394/New_Enterprise_Associates>,
        <https://1145.am/db/2151964/New_Enterprise_Associates>,
        <https://1145.am/db/2152126/New_Enterprise_Associates>,
        <https://1145.am/db/2152422/New_Enterprise_Associates>,
        <https://1145.am/db/2153373/New_Enterprise_Associates>,
        <https://1145.am/db/2155273/New_Enterprise_Associates>,
        <https://1145.am/db/217906/New_Enterprise_Associates>,
        <https://1145.am/db/2195351/New_Enterprise_Associates>,
        <https://1145.am/db/2196440/New_Enterprise_Associates>,
        <https://1145.am/db/2207324/New_Enterprise_Associates>,
        <https://1145.am/db/2233715/New_Enterprise_Associates>,
        <https://1145.am/db/2239029/New_Enterprise_Associates>,
        <https://1145.am/db/2282600/New_Enterprise_Associates>,
        <https://1145.am/db/2284358/New_Enterprise_Associates>,
        <https://1145.am/db/2287244/New_Enterprise_Associates>,
        <https://1145.am/db/2288979/New_Enterprise_Associates>,
        <https://1145.am/db/2292554/New_Enterprise_Associates>,
        <https://1145.am/db/2293793/New_Enterprise_Associates>,
        <https://1145.am/db/2294677/New_Enterprise_Associates>,
        <https://1145.am/db/2295964/New_Enterprise_Associates>,
        <https://1145.am/db/2296696/New_Enterprise_Associates>,
        <https://1145.am/db/2296810/New_Enterprise_Associates>,
        <https://1145.am/db/2297280/New_Enterprise_Associates>,
        <https://1145.am/db/2297471/New_Enterprise_Associates>,
        <https://1145.am/db/2297592/New_Enterprise_Associates>,
        <https://1145.am/db/2298167/New_Enterprise_Associates>,
        <https://1145.am/db/2298437/New_Enterprise_Associates>,
        <https://1145.am/db/2299411/New_Enterprise_Associates>,
        <https://1145.am/db/2300340/New_Enterprise_Associates>,
        <https://1145.am/db/2301461/New_Enterprise_Associates>,
        <https://1145.am/db/2301790/New_Enterprise_Associates>,
        <https://1145.am/db/2302449/New_Enterprise_Associates>,
        <https://1145.am/db/2303391/New_Enterprise_Associates>,
        <https://1145.am/db/2305256/New_Enterprise_Associates>,
        <https://1145.am/db/2305514/New_Enterprise_Associates>,
        <https://1145.am/db/2305611/New_Enterprise_Associates_Inc>,
        <https://1145.am/db/2305656/New_Enterprise_Associates>,
        <https://1145.am/db/2306163/New_Enterprise_Associates>,
        <https://1145.am/db/2306167/New_Enterprise_Associates>,
        <https://1145.am/db/2306705/New_Enterprise_Associates>,
        <https://1145.am/db/2307682/New_Enterprise_Associates>,
        <https://1145.am/db/2307691/New_Enterprise_Associates>,
        <https://1145.am/db/2309059/New_Enterprise_Associates>,
        <https://1145.am/db/2313401/New_Enterprise_Associates>,
        <https://1145.am/db/2313405/New_Enterprise_Associates>,
        <https://1145.am/db/2315049/New_Enterprise_Associates>,
        <https://1145.am/db/2316601/New_Enterprise_Associates>,
        <https://1145.am/db/2316605/New_Enterprise_Associates>,
        <https://1145.am/db/2317951/New_Enterprise_Associates>,
        <https://1145.am/db/2319399/New_Enterprise_Associates>,
        <https://1145.am/db/2319809/New_Enterprise_Associates>,
        <https://1145.am/db/2323563/New_Enterprise_Associates>,
        <https://1145.am/db/2323568/New_Enterprise_Associates>,
        <https://1145.am/db/2323682/New_Enterprise_Associates>,
        <https://1145.am/db/2323683/New_Enterprise_Associates>,
        <https://1145.am/db/2324289/New_Enterprise_Associates>,
        <https://1145.am/db/2326455/New_Enterprise_Associates>,
        <https://1145.am/db/2326571/New_Enterprise_Associates>,
        <https://1145.am/db/2328700/New_Enterprise_Associates>,
        <https://1145.am/db/2329246/New_Enterprise_Associates>,
        <https://1145.am/db/2331784/New_Enterprise_Associates>,
        <https://1145.am/db/2331852/New_Enterprise_Associates>,
        <https://1145.am/db/2331858/New_Enterprise_Associates>,
        <https://1145.am/db/2332445/New_Enterprise_Associates>,
        <https://1145.am/db/2332982/New_Enterprise_Associates>,
        <https://1145.am/db/2333119/New_Enterprise_Associates>,
        <https://1145.am/db/2334847/New_Enterprise_Associates>,
        <https://1145.am/db/2335837/New_Enterprise_Associates>,
        <https://1145.am/db/2336052/New_Enterprise_Associates>,
        <https://1145.am/db/2336391/New_Enterprise_Associates>,
        <https://1145.am/db/2337250/New_Enterprise_Associates>,
        <https://1145.am/db/2337254/New_Enterprise_Associates>,
        <https://1145.am/db/2337971/New_Enterprise_Associates>,
        <https://1145.am/db/2337972/New_Enterprise_Associates>,
        <https://1145.am/db/2339041/New_Enterprise_Associates>,
        <https://1145.am/db/2340888/New_Enterprise_Associates>,
        <https://1145.am/db/2340890/New_Enterprise_Associates>,
        <https://1145.am/db/2344507/New_Enterprise_Associates>,
        <https://1145.am/db/2348029/New_Enterprise_Associates>,
        <https://1145.am/db/2348042/New_Enterprise_Associates>,
        <https://1145.am/db/2348057/New_Enterprise_Associates>,
        <https://1145.am/db/2348066/New_Enterprise_Associates>,
        <https://1145.am/db/2348956/New_Enterprise_Associates>,
        <https://1145.am/db/2348967/New_Enterprise_Associates>,
        <https://1145.am/db/2349234/New_Enterprise_Associates>,
        <https://1145.am/db/2350164/New_Enterprise_Associates_Inc>,
        <https://1145.am/db/2350167/New_Enterprise_Associates>,
        <https://1145.am/db/2350231/New_Enterprise_Associates>,
        <https://1145.am/db/2350327/New_Enterprise_Associates>,
        <https://1145.am/db/2352899/New_Enterprise_Associates>,
        <https://1145.am/db/2355048/New_Enterprise_Associates>,
        <https://1145.am/db/2355531/New_Enterprise_Associates>,
        <https://1145.am/db/2355543/New_Enterprise_Associates>,
        <https://1145.am/db/2356048/New_Enterprise_Associates>,
        <https://1145.am/db/2356216/New_Enterprise_Associates>,
        <https://1145.am/db/2356391/New_Enterprise_Associates>,
        <https://1145.am/db/2356396/New_Enterprise_Associates>,
        <https://1145.am/db/2357144/New_Enterprise_Associates>,
        <https://1145.am/db/2357566/New_Enterprise_Associates>,
        <https://1145.am/db/2358225/New_Enterprise_Associates>,
        <https://1145.am/db/2358242/New_Enterprise_Associates>,
        <https://1145.am/db/2358506/New_Enterprise_Associates>,
        <https://1145.am/db/2358529/New_Enterprise_Associates>,
        <https://1145.am/db/2358640/New_Enterprise_Associates>,
        <https://1145.am/db/2358657/New_Enterprise_Associates>,
        <https://1145.am/db/2358658/New_Enterprise_Associates>,
        <https://1145.am/db/2358812/New_Enterprise_Associates>,
        <https://1145.am/db/2358883/New_Enterprise_Associates>,
        <https://1145.am/db/2359185/New_Enterprise_Associates>,
        <https://1145.am/db/2359873/New_Enterprise_Associates>,
        <https://1145.am/db/2359875/New_Enterprise_Associates>,
        <https://1145.am/db/2360682/New_Enterprise_Associates>,
        <https://1145.am/db/2360979/New_Enterprise_Associates>,
        <https://1145.am/db/2361005/New_Enterprise_Associates>,
        <https://1145.am/db/2365868/New_Enterprise_Associates_Inc>,
        <https://1145.am/db/2366775/New_Enterprise_Associates>,
        <https://1145.am/db/2366984/New_Enterprise_Associates>,
        <https://1145.am/db/2367678/New_Enterprise_Associates>,
        <https://1145.am/db/2367711/New_Enterprise_Associates>,
        <https://1145.am/db/2367714/New_Enterprise_Associates>,
        <https://1145.am/db/2369202/New_Enterprise_Associates>,
        <https://1145.am/db/2369785/New_Enterprise_Associates>,
        <https://1145.am/db/2369916/New_Enterprise_Associates>,
        <https://1145.am/db/2370094/New_Enterprise_Associates>,
        <https://1145.am/db/2370436/New_Enterprise_Associates>,
        <https://1145.am/db/2370782/New_Enterprise_Associates>,
        <https://1145.am/db/2370799/New_Enterprise_Associates>,
        <https://1145.am/db/2371165/New_Enterprise_Associates>,
        <https://1145.am/db/2371166/New_Enterprise_Associates>,
        <https://1145.am/db/2438933/New_Enterprise_Associates>,
        <https://1145.am/db/2443170/New_Enterprise_Associates>,
        <https://1145.am/db/2450551/New_Enterprise_Associates>,
        <https://1145.am/db/2454491/New_Enterprise_Associates>,
        <https://1145.am/db/2541350/New_Enterprise_Associates>,
        <https://1145.am/db/2552598/New_Enterprise_Associates>,
        <https://1145.am/db/2570481/New_Enterprise_Associates>,
        <https://1145.am/db/2570483/New_Enterprise_Associates>,
        <https://1145.am/db/2571149/New_Enterprise_Associates>,
        <https://1145.am/db/2580133/New_Enterprise_Associates>,
        <https://1145.am/db/2587938/New_Enterprise_Associates>,
        <https://1145.am/db/2636760/New_Enterprise_Associates>,
        <https://1145.am/db/301469/New_Enterprise_Associates>,
        <https://1145.am/db/303111/New_Enterprise_Associates>,
        <https://1145.am/db/522665/New_Enterprise_Associates>,
        <https://1145.am/db/525766/New_Enterprise_Associates>,
        <https://1145.am/db/563438/New_Enterprise_Associates>,
        <https://1145.am/db/580082/New_Enterprise_Associates_Inc>,
        <https://1145.am/db/661958/New_Enterprise_Associates>,
        <https://1145.am/db/714395/New_Enterprise_Associates>,
        <https://1145.am/db/849950/New_Enterprise_Associates> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2367497/Yasuda_Enterprise_Development_Company> a org:Organization ;
    ns1:basedInLowRaw "Japan" ;
    ns1:description "financing" ;
    ns1:documentDate "2010-07-14T12:04:54+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Trevena Secures $35 Million in Series B Funding" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/trevena-secures-35-million-series-b-funding> ;
    ns1:foundName "Yasuda Enterprise Development Company" ;
    ns1:investor <https://1145.am/db/2367497/Series_B_Investment_Alta_Partners_Healthcare_Ventures_New_Enterprise_Associates_Polaris_Venture_Partners_Trevena_Yasuda_Enterprise_Development_Company_Completed> ;
    ns1:name "Yasuda Enterprise Development Company" ;
    ns1:sameAsMedium <https://1145.am/db/2308148/Yasuda_Enterprise_Development>,
        <https://1145.am/db/2318781/Yasuda_Enterprise_Development>,
        <https://1145.am/db/2318796/Yasuda_Enterprise_Development>,
        <https://1145.am/db/2360004/Yasuda_Enterprise_Development_Corporation>,
        <https://1145.am/db/2360006/Yasuda_Enterprise_Development_Corporation> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2581397/Bausch___Lomb> a org:Organization ;
    ns1:buyer <https://1145.am/db/2581397/Acquisition_Bausch___Lomb_Has_Not_Happened>,
        <https://1145.am/db/2581397/Acquisition_Bausch___Lomb_Novartis_Stopped>,
        <https://1145.am/db/2581397/Alcon_Assets_Acquisition> ;
    ns1:documentDate "2010-08-17T14:53:50+00:00"^^xsd:dateTime ;
    ns1:documentTitle "FTC Order Protects Consumers in U.S. Market for Eye Care Drug Used in Cataract Surgery" ;
    ns1:documentURL <https://www.fiercepharma.com/pharma/ftc-order-protects-consumers-u-s-market-for-eye-care-drug-used-cataract-surgery> ;
    ns1:foundName "Bausch & Lomb",
        "Bausch & Lomb, Inc." ;
    ns1:name "Bausch & Lomb" ;
    ns1:sameAsMedium <https://1145.am/db/2292928/Bausch___Lomb>,
        <https://1145.am/db/2316851/Bausch___Lomb>,
        <https://1145.am/db/2318581/Bausch___Lomb>,
        <https://1145.am/db/2320333/Bausch___Lomb>,
        <https://1145.am/db/2330204/Bausch___Lomb>,
        <https://1145.am/db/2364718/Bausch_+_Lomb>,
        <https://1145.am/db/2569877/Bausch___Lomb>,
        <https://1145.am/db/2572466/Bausch___Lomb>,
        <https://1145.am/db/2582935/Bausch___Lomb>,
        <https://1145.am/db/2594316/Bausch___Lomb> ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2608966/Ridgemont_Equity_Partners> a org:Organization ;
    ns1:basedInLowRaw "Midwest" ;
    ns1:documentDate "2010-08-31T14:42:45+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Ridgemont Equity Partners buys big piece of United Private Networks" ;
    ns1:documentURL <https://www.fiercetelecom.com/telecom/ridgemont-equity-partners-buys-big-piece-united-private-networks> ;
    ns1:foundName "Ridgemont Equity Partners" ;
    ns1:investor <https://1145.am/db/2608966/United_Private_Networks_Stake_Investment> ;
    ns1:name "Ridgemont Equity Partners" ;
    ns1:sameAsMedium <https://1145.am/db/1340452/Ridgemont_Equity_Partners>,
        <https://1145.am/db/1386740/Ridgemont_Equity_Partners>,
        <https://1145.am/db/1618787/Ridgemont_Equity_Partners>,
        <https://1145.am/db/1619465/Ridgemont_Equity_Partners>,
        <https://1145.am/db/1659786/Ridgemont_Equity_Partners>,
        <https://1145.am/db/204108/Ridgemont_Equity_Partners>,
        <https://1145.am/db/2109892/Ridgemont_Equity_Partners>,
        <https://1145.am/db/2344192/Ridgemont_Equity_Partners>,
        <https://1145.am/db/2557024/Ridgemont_Equity_Partners>,
        <https://1145.am/db/2557028/Ridgemont_Equity_Partners>,
        <https://1145.am/db/2560288/Ridgemont_Equity_Partners>,
        <https://1145.am/db/2602669/Ridgemont_Equity_Partners>,
        <https://1145.am/db/2766777/Ridgemont_Equity_Partners>,
        <https://1145.am/db/402461/Ridgemont_Equity_Partners>,
        <https://1145.am/db/459469/Ridgemont_Equity_Partners>,
        <https://1145.am/db/540664/Ridgemont_Equity_Partners>,
        <https://1145.am/db/555969/Ridgemont_Equity_Partners>,
        <https://1145.am/db/556522/Ridgemont_Equity_Partners>,
        <https://1145.am/db/562507/Ridgemont_Equity_Partners>,
        <https://1145.am/db/607534/Ridgemont_Equity_Partners>,
        <https://1145.am/db/626692/Ridgemont_Equity_Partners>,
        <https://1145.am/db/668316/Ridgemont_Equity_Partners>,
        <https://1145.am/db/669407/Ridgemont_Equity_Partners>,
        <https://1145.am/db/745196/Ridgemont_Equity_Partners>,
        <https://1145.am/db/747982/Ridgemont_Equity_Partners>,
        <https://1145.am/db/853934/Ridgemont_Equity_Partners> ;
    ns1:sourceName "Fierce Telecom" .

<https://1145.am/db/2610482/Convergeone> a org:Organization ;
    ns1:basedInLowRaw "New York" ;
    ns1:buyer <https://1145.am/db/2610482/Juma_Technology_Acquisition> ;
    ns1:description "Value added solutions" ;
    ns1:documentDate "2010-09-27T13:40:32+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Iran accuses West of unleashing computer worm; U.S. law enforcement wants Internet regulatory change" ;
    ns1:documentURL <https://www.fiercetelecom.com/telecom/iran-accuses-west-unleashing-computer-worm-u-s-law-enforcement-wants-internet-regulatory> ;
    ns1:foundName "ConvergeOne" ;
    ns1:industry "telecommunications and IT systems integrator" ;
    ns1:name "ConvergeOne" ;
    ns1:sourceName "Fierce Telecom" .

<https://1145.am/db/2614889/Clec_Paetec> a org:Organization ;
    ns1:basedInLowRaw "and see this story." ;
    ns1:buyer <https://1145.am/db/2614889/One_Communications_Acquisition> ;
    ns1:description "telecom" ;
    ns1:documentDate "2010-12-09T15:41:28+00:00"^^xsd:dateTime ;
    ns1:documentTitle "EarthLink wraps up ITC^Deltacom acquisition" ;
    ns1:documentURL <https://www.fiercetelecom.com/telecom/earthlink-wraps-up-itc-deltacom-acquisition> ;
    ns1:foundName "CLEC Paetec" ;
    ns1:name "CLEC Paetec" ;
    ns1:sameAsMedium <https://1145.am/db/2607568/Clec_Paetec> ;
    ns1:sourceName "Fierce Telecom" .

<https://1145.am/db/2614889/Earthlink_Paetec> a org:Organization ;
    ns1:basedInLowRaw "United States" ;
    ns1:buyer <https://1145.am/db/2614889/One_Communications_Acquisition> ;
    ns1:description "and see this story." ;
    ns1:documentDate "2010-12-09T15:41:28+00:00"^^xsd:dateTime ;
    ns1:documentTitle "EarthLink wraps up ITC^Deltacom acquisition" ;
    ns1:documentURL <https://www.fiercetelecom.com/telecom/earthlink-wraps-up-itc-deltacom-acquisition> ;
    ns1:foundName "EarthLink",
        "Earthlink, Paetec" ;
    ns1:name "EarthLink",
        "Earthlink, Paetec" ;
    ns1:sourceName "Fierce Telecom" .

<https://1145.am/db/2614893/Ntelos> a org:Organization ;
    ns1:buyer <https://1145.am/db/2614893/Acquisition_One_Communications_Ntelos_Completed>,
        <https://1145.am/db/2614893/Fibernet_Acquisition> ;
    ns1:documentDate "2010-12-09T20:52:24+00:00"^^xsd:dateTime ;
    ns1:documentTitle "nTelos breaks up wireless and wireline holdings into separate units" ;
    ns1:documentURL <https://www.fiercetelecom.com/telecom/ntelos-breaks-up-wireless-and-wireline-holdings-into-separate-units> ;
    ns1:foundName "nTelos" ;
    ns1:name "nTelos" ;
    ns1:sameAsMedium <https://1145.am/db/2165039/Ntelos>,
        <https://1145.am/db/2599288/Ntelos>,
        <https://1145.am/db/2606667/Ntelos>,
        <https://1145.am/db/2607378/Ntelos>,
        <https://1145.am/db/2608212/Ntelos>,
        <https://1145.am/db/2609842/Ntelos>,
        <https://1145.am/db/2611165/Ntelos>,
        <https://1145.am/db/2612811/Ntelos>,
        <https://1145.am/db/2614189/Ntelos>,
        <https://1145.am/db/2614880/Ntelos>,
        <https://1145.am/db/2615361/Ntelos>,
        <https://1145.am/db/2654217/Ntelos>,
        <https://1145.am/db/2660320/Ntelos>,
        <https://1145.am/db/2664692/Ntelos>,
        <https://1145.am/db/2665774/Ntelos>,
        <https://1145.am/db/2681889/Ntelos> ;
    ns1:sourceName "Fierce Telecom" .

<https://1145.am/db/2614893/The_New_Wireline_Company_Holdings_Merger> a ns1:CorporateFinanceActivity ;
    ns1:activityType "ipo",
        "merger" ;
    ns1:documentDate "2010-12-09T20:52:24+00:00"^^xsd:dateTime ;
    ns1:documentExtract "nTelos (Nasdaq: NTLS) has decided that it's time to split up its wireless and wireline holdings by creating a separate, publicly traded company called \"The New Wireline Company .\"" ;
    ns1:documentTitle "nTelos breaks up wireless and wireline holdings into separate units" ;
    ns1:documentURL <https://www.fiercetelecom.com/telecom/ntelos-breaks-up-wireless-and-wireline-holdings-into-separate-units> ;
    ns1:foundName "creating",
        "split up" ;
    ns1:name "creating",
        "split up" ;
    ns1:sourceName "Fierce Telecom" ;
    ns1:status "has not happened" ;
    ns1:target <https://1145.am/db/2614893/The_New_Wireline_Company> ;
    ns1:targetDetails "holdings" ;
    ns1:targetName "The New Wireline Company" .

<https://1145.am/db/2614902/Lightower_Fiber_Networks> a org:Organization ;
    ns1:basedInLowRaw "N.Y",
        "United States" ;
    ns1:buyer <https://1145.am/db/2614902/Lexent_Metro_Connect_Acquisition>,
        <https://1145.am/db/2614902/Open_Access_Merger> ;
    ns1:description "Network services",
        "business" ;
    ns1:documentDate "2010-12-13T15:33:12+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Lightower acquires Open Access, increases Long Island fiber footprint" ;
    ns1:documentURL <https://www.fiercetelecom.com/telecom/lightower-acquires-open-access-increases-long-island-fiber-footprint> ;
    ns1:foundName "Lightower",
        "Lightower Fiber Networks" ;
    ns1:name "Lightower",
        "Lightower Fiber Networks" ;
    ns1:sameAsHigh <https://1145.am/db/2600842/Lightower_Fiber_Networks>,
        <https://1145.am/db/2603595/Lightower_Fiber_Networks>,
        <https://1145.am/db/2604552/Lightower_Fiber_Networks>,
        <https://1145.am/db/2612723/Lightower_Fiber_Networks>,
        <https://1145.am/db/2615526/Lightower_Fiber_Networks> ;
    ns1:sameAsMedium <https://1145.am/db/2602607/Lightower_Fiber_Networks>,
        <https://1145.am/db/2609734/Lightower_Fiber_Networks>,
        <https://1145.am/db/2614380/Lightower_Fiber_Networks>,
        <https://1145.am/db/2616286/Lightower_Fiber_Networks> ;
    ns1:sourceName "Fierce Telecom" .

<https://1145.am/db/2615618/Lightower> a org:Organization ;
    ns1:basedInHighGeoName "Long Island" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/3572005/about.rdf> ;
    ns1:basedInHighRaw "Long Island." ;
    ns1:buyer <https://1145.am/db/2615618/Acquisition_Lightower_Completed>,
        <https://1145.am/db/2615618/Lexent_Metro_Connect_Acquisition>,
        <https://1145.am/db/2615618/Merger_Lightower_Completed>,
        <https://1145.am/db/2615618/Open_Access_Acquisition> ;
    ns1:description "business" ;
    ns1:documentDate "2010-12-20T15:40:15+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Lightower secures $230 million credit from GE Capital" ;
    ns1:documentURL <https://www.fiercetelecom.com/telecom/lightower-secures-230-million-credit-from-ge-capital> ;
    ns1:foundName "Lightower" ;
    ns1:name "Lightower" ;
    ns1:sameAsMedium <https://1145.am/db/2602608/Lightower>,
        <https://1145.am/db/2602621/Lightower>,
        <https://1145.am/db/2602728/Lightower>,
        <https://1145.am/db/2603337/Lightower>,
        <https://1145.am/db/2606403/Lightower>,
        <https://1145.am/db/2609686/Lightower>,
        <https://1145.am/db/2613269/Lightower>,
        <https://1145.am/db/2614179/Lightower>,
        <https://1145.am/db/2616294/Lightower>,
        <https://1145.am/db/2618015/Lightower> ;
    ns1:sourceName "Fierce Telecom" .

<https://1145.am/db/2615628/Alinda_Capital_Partners> a org:Organization ;
    ns1:buyer <https://1145.am/db/2615628/Investment_Alinda_Capital_Partners_Dukenet_Communications_Completed>,
        <https://1145.am/db/2615628/Rcn_Corp_Acquisition> ;
    ns1:documentDate "2010-12-22T04:14:18+00:00"^^xsd:dateTime ;
    ns1:documentTitle "DukeNet becomes joint venture of Duke Energy and Alinda Capital" ;
    ns1:documentURL <https://www.fiercetelecom.com/telecom/dukenet-becomes-joint-venture-duke-energy-and-alinda-capital> ;
    ns1:foundName "Alinda",
        "Alinda Capital Partners" ;
    ns1:investor <https://1145.am/db/2615628/Investment_Alinda_Capital_Partners_Dukenet_Communications_Completed> ;
    ns1:name "Alinda",
        "Alinda Capital Partners" ;
    ns1:sameAsMedium <https://1145.am/db/735020/Alinda_Capital_Partners>,
        <https://1145.am/db/873317/Alinda_Capital_Partners> ;
    ns1:sourceName "Fierce Telecom" .

<https://1145.am/db/2651267/China_Development_Bank_Corporation> a org:Organization ;
    ns1:basedInLowRaw "China" ;
    ns1:description "financing" ;
    ns1:documentDate "2010-12-20T01:04:00+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Cash gives China vendors clout in India" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/cash-gives-china-vendors-clout-india> ;
    ns1:foundName "China Development Bank Corporation" ;
    ns1:name "China Development Bank Corporation" ;
    ns1:participant <https://1145.am/db/2651267/Investment_China_Development_Bank_Corporation_Reliance_Communications_Completed> ;
    ns1:sameAsMedium <https://1145.am/db/1959152/China_Development_Bank>,
        <https://1145.am/db/2676031/China_Development_Bank> ;
    ns1:sourceName "Fierce Wireless" .

<https://1145.am/db/2662465/Temasek_Holdings> a org:Organization ;
    ns1:basedInHighGeoName "Republic of Singapore" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/1880251/about.rdf> ;
    ns1:basedInHighRaw "Singapore" ;
    ns1:basedInLowRaw "China" ;
    ns1:description "investment" ;
    ns1:documentDate "2010-08-09T01:07:00+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Chinese firms become foreign takeover targets" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/chinese-firms-become-foreign-takeover-targets> ;
    ns1:foundName "Temasek",
        "Temasek Holdings" ;
    ns1:industry "information technology" ;
    ns1:investor <https://1145.am/db/2662465/Investment_Temasek_Holdings_Tudou_Completed> ;
    ns1:name "Temasek",
        "Temasek Holdings" ;
    ns1:sameAsHigh <https://1145.am/db/1042545/Temasek>,
        <https://1145.am/db/1066315/Temasek>,
        <https://1145.am/db/1066322/Temasek>,
        <https://1145.am/db/1066323/Temasek>,
        <https://1145.am/db/1066333/Temasek>,
        <https://1145.am/db/1067524/Temasek>,
        <https://1145.am/db/1067526/Temasek>,
        <https://1145.am/db/1067529/Temasek>,
        <https://1145.am/db/1067530/Temasek>,
        <https://1145.am/db/1185911/Temasek>,
        <https://1145.am/db/1187636/Temasek>,
        <https://1145.am/db/1355546/Temasek>,
        <https://1145.am/db/1356171/Temasek>,
        <https://1145.am/db/1371212/Temasek>,
        <https://1145.am/db/1447378/Temasek_Holdings>,
        <https://1145.am/db/1448485/Temasek>,
        <https://1145.am/db/1451743/Singapores_Temasek_Holdings>,
        <https://1145.am/db/1502825/Temasek_Holdings>,
        <https://1145.am/db/1648491/Temasek>,
        <https://1145.am/db/1668144/Temasek>,
        <https://1145.am/db/1734427/Temasek>,
        <https://1145.am/db/1734560/Temasek>,
        <https://1145.am/db/1734901/Temasek>,
        <https://1145.am/db/1742532/Temasek>,
        <https://1145.am/db/1744957/Temasek>,
        <https://1145.am/db/1755004/Temasek>,
        <https://1145.am/db/1755209/Temasek>,
        <https://1145.am/db/1766628/Temasek>,
        <https://1145.am/db/1777816/Temasek_Holdings>,
        <https://1145.am/db/1785263/Temasek>,
        <https://1145.am/db/1821833/Temasek>,
        <https://1145.am/db/1847010/Temasek>,
        <https://1145.am/db/1965165/Temasek>,
        <https://1145.am/db/2067811/Temasek>,
        <https://1145.am/db/2074897/Temasek>,
        <https://1145.am/db/2110114/Temasek>,
        <https://1145.am/db/2110248/Temasek>,
        <https://1145.am/db/2111428/Temasek>,
        <https://1145.am/db/2299918/Temasek>,
        <https://1145.am/db/2340305/Temasek>,
        <https://1145.am/db/2599246/Temasek_Holdings>,
        <https://1145.am/db/274611/Temasek_Holdings>,
        <https://1145.am/db/323290/Temasek>,
        <https://1145.am/db/342626/Temasek_Holdings>,
        <https://1145.am/db/372639/Temasek>,
        <https://1145.am/db/406679/Temasek>,
        <https://1145.am/db/406744/Temasek>,
        <https://1145.am/db/466426/Temasek>,
        <https://1145.am/db/588995/Temasek>,
        <https://1145.am/db/620653/Temasek>,
        <https://1145.am/db/684583/Temasek>,
        <https://1145.am/db/755411/Temasek>,
        <https://1145.am/db/782551/Temasek>,
        <https://1145.am/db/786455/Temasek>,
        <https://1145.am/db/817162/Temasek>,
        <https://1145.am/db/852005/Temasek>,
        <https://1145.am/db/882636/Temasek>,
        <https://1145.am/db/968382/Temasek>,
        <https://1145.am/db/973671/Temasek>,
        <https://1145.am/db/976348/Temasek> ;
    ns1:sameAsMedium <https://1145.am/db/1095671/Temasek_Holdings>,
        <https://1145.am/db/1113195/Temasek_Holdings>,
        <https://1145.am/db/1263680/Temasek_Holdings>,
        <https://1145.am/db/1473068/Temasek_Holdings>,
        <https://1145.am/db/1772843/Temasek_Holdings>,
        <https://1145.am/db/1785172/Temasek_Holdings>,
        <https://1145.am/db/1997182/Temasek_Holdings>,
        <https://1145.am/db/2028459/Temasek_Holdings>,
        <https://1145.am/db/228001/Temasek_Holdings>,
        <https://1145.am/db/2284769/Temasek_Holdings>,
        <https://1145.am/db/263686/Temasek_Holdings>,
        <https://1145.am/db/2664200/Temasek_Holdings>,
        <https://1145.am/db/2721743/Temasek_Holdings>,
        <https://1145.am/db/2757495/Temasek_Holdings>,
        <https://1145.am/db/342617/Temasek_Holdings>,
        <https://1145.am/db/386715/Temasek_Holdings>,
        <https://1145.am/db/386742/Temasek_Holdings>,
        <https://1145.am/db/386758/Temasek_Holdings>,
        <https://1145.am/db/575352/Temasek_Holdings>,
        <https://1145.am/db/603078/Temasek_Holdings>,
        <https://1145.am/db/701062/Temasek_Holdings>,
        <https://1145.am/db/778583/Temasek_Holdings>,
        <https://1145.am/db/785709/Temasek_Holdings>,
        <https://1145.am/db/799292/Temasek_Holdings> ;
    ns1:sourceName "Fierce Wireless" .

<https://1145.am/db/2666786/Hellenic_Telecoms_Control_Investment> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition",
        "investment" ;
    ns1:documentDate "2010-09-09T01:08:00+00:00"^^xsd:dateTime ;
    ns1:documentExtract "\" Deutsche Telekom is interested in acquiring full control of its Greek unit Hellenic Telecoms (OTE) , and while the Greek government does not want to sell its stake at such low prices, DT would like the government to allow it to buy shares on the market ,\" Vourloumis told Greek newspaper.",
        "Naftemporiki. \" Deutsche Telekom is interested in acquiring full control of its Greek unit Hellenic Telecoms (OTE) , and while the Greek government does not want to sell its stake at such low prices, DT would like the government to allow it to buy shares on the market ,\" Vourloumis told Greek newspaper." ;
    ns1:documentTitle "Deutsche Tel seeks OTE control" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/deutsche-tel-seeks-ote-control> ;
    ns1:foundName "acquiring" ;
    ns1:name "acquiring" ;
    ns1:sourceName "Fierce Wireless" ;
    ns1:status "has not happened" ;
    ns1:target <https://1145.am/db/2666786/Hellenic_Telecoms> ;
    ns1:targetDetails "control" ;
    ns1:targetName "Hellenic Telecoms" ;
    ns1:whereGeoName "Hellenic Republic" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/390903/about.rdf> ;
    ns1:whereRaw "Greece" .

<https://1145.am/db/2681334/Juniper_Networks> a org:Organization ;
    ns1:buyer <https://1145.am/db/2681334/Altor_Networks_Acquisition> ;
    ns1:description "networking" ;
    ns1:documentDate "2010-12-07T01:00:00+00:00"^^xsd:dateTime ;
    ns1:documentTitle "News In Brief: EC, Qualcomm, Cisco, TeliaSonera, Juniper Networks, Ofcom" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/news-brief-ec-qualcomm-cisco-teliasonera-juniper-networks-ofcom> ;
    ns1:foundName "Juniper Networks" ;
    ns1:name "Juniper Networks" ;
    ns1:sameAsHigh <https://1145.am/db/1156497/Juniper_Networks>,
        <https://1145.am/db/12106/Juniper_Networks>,
        <https://1145.am/db/1415461/Juniper_Networks>,
        <https://1145.am/db/1746652/Juniper_Networks>,
        <https://1145.am/db/1837776/Juniper_Networks>,
        <https://1145.am/db/1890208/Juniper_Networks>,
        <https://1145.am/db/2164116/Juniper_Networks>,
        <https://1145.am/db/2168474/Juniper_Networks>,
        <https://1145.am/db/2603185/Juniper_Networks>,
        <https://1145.am/db/2604780/Juniper_Networks>,
        <https://1145.am/db/2606080/Juniper_Networks>,
        <https://1145.am/db/2609658/Juniper_Networks>,
        <https://1145.am/db/2610239/Juniper_Networks>,
        <https://1145.am/db/2614479/Juniper_Networks>,
        <https://1145.am/db/2618821/Juniper_Networks>,
        <https://1145.am/db/2640355/Juniper_Networks>,
        <https://1145.am/db/2643132/Juniper_Networks>,
        <https://1145.am/db/2649816/Juniper_Networks>,
        <https://1145.am/db/2674061/Juniper_Networks>,
        <https://1145.am/db/829020/Juniper_Networks>,
        <https://1145.am/db/831938/Juniper_Networks> ;
    ns1:sameAsMedium <https://1145.am/db/1056689/Juniper_Networks>,
        <https://1145.am/db/1057269/Juniper_Networks>,
        <https://1145.am/db/1781378/Juniper_Networks>,
        <https://1145.am/db/1820590/Juniper_Networks>,
        <https://1145.am/db/2175704/Juniper_Networks>,
        <https://1145.am/db/2601017/Juniper_Networks>,
        <https://1145.am/db/2601174/Juniper_Networks>,
        <https://1145.am/db/2602101/Juniper_Networks>,
        <https://1145.am/db/2603130/Juniper_Networks>,
        <https://1145.am/db/2607285/Juniper_Networks>,
        <https://1145.am/db/2607408/Juniper_Networks>,
        <https://1145.am/db/2610089/Juniper_Networks>,
        <https://1145.am/db/2610336/Juniper_Networks>,
        <https://1145.am/db/2612014/Juniper_Networks>,
        <https://1145.am/db/2613676/Juniper_Networks>,
        <https://1145.am/db/2614452/Juniper_Networks>,
        <https://1145.am/db/2614877/Juniper_Networks>,
        <https://1145.am/db/2615970/Juniper_Networks>,
        <https://1145.am/db/2615980/Juniper_Networks>,
        <https://1145.am/db/2616680/Juniper_Networks>,
        <https://1145.am/db/2618217/Juniper_Networks>,
        <https://1145.am/db/2618628/Juniper_Networks>,
        <https://1145.am/db/2646073/Juniper_Networks>,
        <https://1145.am/db/2648954/Juniper_Networks>,
        <https://1145.am/db/2650682/Juniper_Networks>,
        <https://1145.am/db/2659072/Juniper_Networks>,
        <https://1145.am/db/2666215/Juniper_Networks> ;
    ns1:sourceName "Fierce Wireless" .

<https://1145.am/db/2203459/Picis_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition",
        "merger" ;
    ns1:documentDate "2010-07-22T14:00:07+00:00"^^xsd:dateTime ;
    ns1:documentExtract "EDEN PRAIRIE, Minn. & WAKEFIELD, Mass.- (BUSINESS WIRE) - Ingenix, a leading health information technology and services company, today announced it has signed a definitive merger agreement to acquire Picis®, Inc., a leading provider of health information solutions for the high-acuity areas of hospitals." ;
    ns1:documentTitle "Ingenix to Acquire Picis" ;
    ns1:documentURL <https://www.fiercehealthcare.com/it/ingenix-to-acquire-picis-0> ;
    ns1:foundName "acquire",
        "merger" ;
    ns1:name "acquire",
        "merger" ;
    ns1:sourceName "Fierce Healthcare" ;
    ns1:status "has not happened" ;
    ns1:target <https://1145.am/db/2203459/Picis> ;
    ns1:targetName "Picis" ;
    ns1:whereGeoName "Eden Prairie" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5025219/about.rdf> ;
    ns1:whereRaw "EDEN PRAIRIE, Minn." .

<https://1145.am/db/2203476/Picis_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition",
        "merger" ;
    ns1:documentDate "2010-07-26T18:43:07+00:00"^^xsd:dateTime ;
    ns1:documentExtract "EDEN PRAIRIE, Minn. and WAKEFIELD, Mass., July 22, 2010 - Ingenix, a leading health information technology and services company, today announced it has signed a definitive merger agreement to acquire Picis®, Inc., a leading provider of health information solutions for the high-acuity areas of hospitals." ;
    ns1:documentTitle "Ingenix to Acquire Picis" ;
    ns1:documentURL <https://www.fiercehealthcare.com/it/ingenix-to-acquire-picis> ;
    ns1:foundName "acquire",
        "merger" ;
    ns1:name "acquire",
        "merger" ;
    ns1:sourceName "Fierce Healthcare" ;
    ns1:status "has not happened" ;
    ns1:target <https://1145.am/db/2203476/Picis> ;
    ns1:targetName "Picis" ;
    ns1:whereGeoName "Eden Prairie" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5025219/about.rdf> ;
    ns1:whereRaw "EDEN PRAIRIE, Minn." .

<https://1145.am/db/2208806/Lore_Associates> a org:Organization ;
    ns1:basedInHighGeoName "Philadelphia" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/4560349/about.rdf> ;
    ns1:basedInHighRaw "Philadelphia" ;
    ns1:documentDate "2010-10-07T17:00:04+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Halfpenny Technologies Secures $2.6 Million in Capital Investment" ;
    ns1:documentURL <https://www.fiercehealthcare.com/it/halfpenny-technologies-secures-2-6-million-capital-investment> ;
    ns1:foundName "LORE Associates" ;
    ns1:investor <https://1145.am/db/2208806/Venture_Capital_Investment_Halfpenny_Technologies_Lore_Associates_Milestone_Venture_Partners_Osage_Venture_Partners_Completed> ;
    ns1:name "LORE Associates" ;
    ns1:sameAsMedium <https://1145.am/db/2215928/Lore_Associates>,
        <https://1145.am/db/2242500/Lore_Associates> ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2208806/Milestone_Venture_Partners> a org:Organization ;
    ns1:basedInHighGeoName "New York City" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5128581/about.rdf> ;
    ns1:basedInHighRaw "New York" ;
    ns1:documentDate "2010-10-07T17:00:04+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Halfpenny Technologies Secures $2.6 Million in Capital Investment" ;
    ns1:documentURL <https://www.fiercehealthcare.com/it/halfpenny-technologies-secures-2-6-million-capital-investment> ;
    ns1:foundName "Milestone Venture Partners" ;
    ns1:investor <https://1145.am/db/2208806/Venture_Capital_Investment_Halfpenny_Technologies_Lore_Associates_Milestone_Venture_Partners_Osage_Venture_Partners_Completed> ;
    ns1:name "Milestone Venture Partners" ;
    ns1:sameAsMedium <https://1145.am/db/1696744/Milestone_Venture_Partners>,
        <https://1145.am/db/1830147/Milestone_Venture_Partners>,
        <https://1145.am/db/1860145/Milestone_Venture_Partners>,
        <https://1145.am/db/1879055/Milestone_Venture_Partners>,
        <https://1145.am/db/2215928/Milestone_Venture_Partners>,
        <https://1145.am/db/2242500/Milestone_Venture_Partners> ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2208806/Osage_Venture_Partners> a org:Organization ;
    ns1:basedInHighGeoName "Pennsylvania" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/6254927/about.rdf> ;
    ns1:basedInHighRaw "Pennsylvania" ;
    ns1:documentDate "2010-10-07T17:00:04+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Halfpenny Technologies Secures $2.6 Million in Capital Investment" ;
    ns1:documentURL <https://www.fiercehealthcare.com/it/halfpenny-technologies-secures-2-6-million-capital-investment> ;
    ns1:foundName "Osage Venture Partners" ;
    ns1:investor <https://1145.am/db/2208806/Venture_Capital_Investment_Halfpenny_Technologies_Lore_Associates_Milestone_Venture_Partners_Osage_Venture_Partners_Completed> ;
    ns1:name "Osage Venture Partners" ;
    ns1:sameAsMedium <https://1145.am/db/1168922/Osage_Venture_Partners>,
        <https://1145.am/db/1171244/Osage_Venture_Partners>,
        <https://1145.am/db/1649262/Osage_Venture_Partners>,
        <https://1145.am/db/1649643/Osage_Venture_Partners>,
        <https://1145.am/db/1817564/Osage_Venture_Partners>,
        <https://1145.am/db/1857593/Osage_Venture_Partners>,
        <https://1145.am/db/1892698/Osage_Venture_Partners>,
        <https://1145.am/db/2215928/Osage_Venture_Partners>,
        <https://1145.am/db/2242500/Osage_Venture_Partners>,
        <https://1145.am/db/2284768/Osage_Venture_Partners>,
        <https://1145.am/db/2604027/Osage_Venture_Partners>,
        <https://1145.am/db/506560/Osage_Venture_Partners>,
        <https://1145.am/db/526025/Osage_Venture_Partners>,
        <https://1145.am/db/526046/Osage_Venture_Partners>,
        <https://1145.am/db/818090/Osage_Venture_Partners> ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2210943/Amicas> a org:Organization ;
    ns1:basedInLowRaw "CHICAGO" ;
    ns1:documentDate "2010-11-05T12:30:02+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Merge Healthcare Completes Exchange Offer" ;
    ns1:documentURL <https://www.fiercehealthcare.com/it/merge-healthcare-completes-exchange-offer> ;
    ns1:foundName "AMICAS" ;
    ns1:industry "healthcare IT solutions provider" ;
    ns1:name "AMICAS" ;
    ns1:sameAsMedium <https://1145.am/db/2227227/Amicas>,
        <https://1145.am/db/2228200/Amicas>,
        <https://1145.am/db/2228238/Amicas>,
        <https://1145.am/db/2242028/Amicas>,
        <https://1145.am/db/2250510/Amicas> ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2210943/Amicas_Senior_Secured_Notes_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition",
        "ipo" ;
    ns1:documentDate "2010-11-05T12:30:02+00:00"^^xsd:dateTime ;
    ns1:documentExtract "CHICAGO- (BUSINESS WIRE) - Merge Healthcare Incorporated (NASDAQ: MRGE) (\"Merge\" or the \"Company\") , a leading healthcare IT solutions provider, announced today that it has completed the exchange offer of its 11.75 % Senior Secured Notes due 2015 (the \"Old Notes\") ." ;
    ns1:documentTitle "Merge Healthcare Completes Exchange Offer" ;
    ns1:documentURL <https://www.fiercehealthcare.com/it/merge-healthcare-completes-exchange-offer> ;
    ns1:foundName "acquisition",
        "exchange offer" ;
    ns1:name "acquisition",
        "exchange offer" ;
    ns1:sourceName "Fierce Healthcare" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2210943/Amicas> ;
    ns1:targetDetails "Senior Secured Notes" ;
    ns1:targetName "AMICAS" ;
    ns1:vendor <https://1145.am/db/2210943/Merge_Healthcare_Incorporated> ;
    ns1:whenRaw "2010" .

<https://1145.am/db/2210943/Merge_Healthcare_Incorporated> a org:Organization ;
    ns1:basedInHighGeoName "Chicago" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/4887398/about.rdf> ;
    ns1:basedInHighRaw "Chicago" ;
    ns1:buyer <https://1145.am/db/2210943/Amicas_Senior_Secured_Notes_Acquisition> ;
    ns1:description "Healthcare IT solutions provider" ;
    ns1:documentDate "2010-11-05T12:30:02+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Merge Healthcare Completes Exchange Offer" ;
    ns1:documentURL <https://www.fiercehealthcare.com/it/merge-healthcare-completes-exchange-offer> ;
    ns1:foundName "Merge",
        "Merge Healthcare Incorporated" ;
    ns1:industry "healthcare IT solutions provider" ;
    ns1:name "Merge Healthcare Incorporated" ;
    ns1:sameAsHigh <https://1145.am/db/1355948/Change_Healthcare_Inc>,
        <https://1145.am/db/1357434/Change_Healthcare_Inc>,
        <https://1145.am/db/1794140/Merge_Healthcare>,
        <https://1145.am/db/2191010/Healthcare_Merger_Corp>,
        <https://1145.am/db/2208793/Merge_Healthcare>,
        <https://1145.am/db/2215743/Merge_Healthcare>,
        <https://1145.am/db/2217392/Merge_Healthcare>,
        <https://1145.am/db/2218232/Merge_Healthcare>,
        <https://1145.am/db/2220594/Merge_Healthcare_Incorporated>,
        <https://1145.am/db/2223856/Merge_Healthcare_Incorporated>,
        <https://1145.am/db/2227227/Merge_Healthcare>,
        <https://1145.am/db/2228200/Merge_Healthcare_Incorporated>,
        <https://1145.am/db/2228238/Merge_Healthcare>,
        <https://1145.am/db/2232213/Merge_Healthcare>,
        <https://1145.am/db/2247957/Merge_Healthcare_Incorporated>,
        <https://1145.am/db/2250510/Merge_Healthcare_Incorporated>,
        <https://1145.am/db/2251973/Merge_Healthcare_Incorporated>,
        <https://1145.am/db/2320562/Merge_Healthcare>,
        <https://1145.am/db/2326099/Merge_Healthcare>,
        <https://1145.am/db/2326226/Merge_Healthcare>,
        <https://1145.am/db/2365055/Merge_Healthcare_Incorporated> ;
    ns1:sameAsMedium <https://1145.am/db/2205410/Merge_Healthcare>,
        <https://1145.am/db/2266051/Merge_Healthcare> ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2227885/Picis_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition",
        "merger" ;
    ns1:documentDate "2010-07-22T14:02:01+00:00"^^xsd:dateTime ;
    ns1:documentExtract "EDEN PRAIRIE, Minn. & WAKEFIELD, Mass.- (BUSINESS WIRE) - Ingenix, a leading health information technology and services company, today announced it has signed a definitive merger agreement to acquire Picis®, Inc., a leading provider of health information solutions for the high-acuity areas of hospitals." ;
    ns1:documentTitle "Ingenix to Acquire Picis" ;
    ns1:documentURL <https://www.fiercehealthcare.com/practices/ingenix-to-acquire-picis> ;
    ns1:foundName "acquire",
        "merger" ;
    ns1:name "acquire",
        "merger" ;
    ns1:sourceName "Fierce Healthcare" ;
    ns1:status "has not happened" ;
    ns1:target <https://1145.am/db/2227885/Picis> ;
    ns1:targetName "Picis" ;
    ns1:whereGeoName "Eden Prairie" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5025219/about.rdf> ;
    ns1:whereRaw "EDEN PRAIRIE, Minn." .

<https://1145.am/db/2231462/Prospect_Medical_Holdings_Inc> a org:Organization ;
    ns1:basedInLowRaw "NEW YORK" ;
    ns1:documentDate "2010-08-18T15:34:49+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Shareholder Update: Investigation of Acquisition of Prospect Medical by Tripp Levy PLLC" ;
    ns1:documentURL <https://www.fiercehealthcare.com/healthcare/shareholder-update-investigation-acquisition-prospect-medical-by-tripp-levy-pllc> ;
    ns1:foundName "/quotes/comstock/15 *! pzz/quotes/nls/pzz",
        "Prospect Medical" ;
    ns1:name "Prospect Medical Holdings, Inc",
        "Prospect Medical Holdings, Inc." ;
    ns1:sameAsMedium <https://1145.am/db/1397562/Prospect_Medical_Holdings_Inc>,
        <https://1145.am/db/1397608/Prospect_Medical_Holdings>,
        <https://1145.am/db/1397811/Prospect_Medical_Holdings>,
        <https://1145.am/db/2180693/Prospect_Medical_Holdings>,
        <https://1145.am/db/2181039/Prospect_Medical_Holdings>,
        <https://1145.am/db/2181660/Prospect_Medical_Holdings>,
        <https://1145.am/db/2183724/Prospect_Medical_Holdings>,
        <https://1145.am/db/2185234/Prospect_Medical_Holdings>,
        <https://1145.am/db/2185237/Prospect_Medical_Holdings>,
        <https://1145.am/db/2231466/Prospect_Medical_Holdings>,
        <https://1145.am/db/2262305/Prospect_Medical_Holdings>,
        <https://1145.am/db/2267153/Prospect_Medical_Holdings>,
        <https://1145.am/db/2785780/Prospect_Medical_Holdings>,
        <https://1145.am/db/824837/Prospect_Medical_Holdings_Inc> ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2235296/Entrada> a org:Organization ;
    ns1:basedInHighGeoName "Nashville" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/4644585/about.rdf> ;
    ns1:basedInHighRaw "NASHVILLE, Tenn." ;
    ns1:description "health information technology" ;
    ns1:documentDate "2010-09-09T18:02:35+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Entrada Completes Series A Funding" ;
    ns1:documentURL <https://www.fiercehealthcare.com/healthcare/entrada-completes-series-a-funding> ;
    ns1:foundName "Entrada" ;
    ns1:industry "health information technology" ;
    ns1:name "Entrada" ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2235312/Brim_Holdings> a org:Organization ;
    ns1:basedInHighGeoName "Texarkana" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/4736096/about.rdf> ;
    ns1:basedInHighRaw "Texarkana, Texas" ;
    ns1:description "Healthcare" ;
    ns1:documentDate "2010-09-10T14:02:57+00:00"^^xsd:dateTime ;
    ns1:documentTitle "IASIS Healthcare to Acquire Brim Holdings, Inc." ;
    ns1:documentURL <https://www.fiercehealthcare.com/healthcare/iasis-healthcare-to-acquire-brim-holdings-inc> ;
    ns1:foundName "Brim Holdings",
        "Brim Holdings, Inc." ;
    ns1:industry "Healthcare" ;
    ns1:name "Brim Holdings" ;
    ns1:sameAsHigh <https://1145.am/db/2235982/Brim_Holdings>,
        <https://1145.am/db/2240328/Brim_Holdings>,
        <https://1145.am/db/2317417/Bbk_Holdings> ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2235312/Pikes_Peak_Regional_Hospital> a org:Organization ;
    ns1:basedInHighGeoName "Woodland Park" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5444689/about.rdf> ;
    ns1:basedInHighRaw "Woodland Park, Colorado" ;
    ns1:description "Healthcare" ;
    ns1:documentDate "2010-09-10T14:02:57+00:00"^^xsd:dateTime ;
    ns1:documentTitle "IASIS Healthcare to Acquire Brim Holdings, Inc." ;
    ns1:documentURL <https://www.fiercehealthcare.com/healthcare/iasis-healthcare-to-acquire-brim-holdings-inc> ;
    ns1:foundName "Pikes Peak Regional Hospital" ;
    ns1:industry "Healthcare" ;
    ns1:name "Pikes Peak Regional Hospital" ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2235312/Pikes_Peak_Regional_Hospital_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition" ;
    ns1:documentDate "2010-09-10T14:02:57+00:00"^^xsd:dateTime ;
    ns1:documentExtract "FRANKLIN, Tenn.- (BUSINESS WIRE) - IASIS Healthcare (\"IASIS\") today announced the signing of a definitive agreement to acquire Brim Holdings, Inc., which operates Wadley Regional Medical Center in Texarkana, Texas, and Pikes Peak Regional Hospital in Woodland Park, Colorado, in a cash-for-stock transaction valued at approximately $ 95 million, subject to customary closing conditions and working capital adjustments." ;
    ns1:documentTitle "IASIS Healthcare to Acquire Brim Holdings, Inc." ;
    ns1:documentURL <https://www.fiercehealthcare.com/healthcare/iasis-healthcare-to-acquire-brim-holdings-inc> ;
    ns1:foundName "acquire" ;
    ns1:name "acquire" ;
    ns1:sourceName "Fierce Healthcare" ;
    ns1:status "has not happened" ;
    ns1:target <https://1145.am/db/2235312/Pikes_Peak_Regional_Hospital> ;
    ns1:targetName "Pikes Peak Regional Hospital" ;
    ns1:valueRaw "approximately $ 95 million" ;
    ns1:whereGeoName "Colorado" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5417618/about.rdf> ;
    ns1:whereRaw "Colorado" .

<https://1145.am/db/2242173/Battle_Creek_Health_System> a org:Organization ;
    ns1:basedInHighGeoName "Michigan" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5001836/about.rdf> ;
    ns1:basedInHighRaw "Michigan" ;
    ns1:documentDate "2010-12-15T17:57:28+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Merger will create new Michigan healthcare system" ;
    ns1:documentURL <https://www.fiercehealthcare.com/healthcare/merger-will-create-new-michigan-healthcare-system> ;
    ns1:foundName "Battle Creek",
        "Battle Creek Health System in Michigan" ;
    ns1:industry "Healthcare",
        "health care" ;
    ns1:name "Battle Creek",
        "Battle Creek Health System" ;
    ns1:protagonist <https://1145.am/db/2242173/Stake_Merger_Battle_Creek_Health_System_Bronson_Healthcare_Group_Has_Not_Happened> ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2242173/Bchs_Community_Partner> a org:Organization ;
    ns1:basedInLowRaw "Novi, Mich" ;
    ns1:documentDate "2010-12-15T17:57:28+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Merger will create new Michigan healthcare system" ;
    ns1:documentURL <https://www.fiercehealthcare.com/healthcare/merger-will-create-new-michigan-healthcare-system> ;
    ns1:foundName "BCHS Community Partner" ;
    ns1:name "BCHS Community Partner" ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2242173/Share_Acquisition_Bronson_Healthcare_Group_Trinity_Health_Has_Not_Happened> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition" ;
    ns1:documentDate "2010-12-15T17:57:28+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Bronson will buy 51 percent of Battle Creek by buying the 50 percent share from Trinity Health of Novi, Mich., and 1 percent of the BCHS Community Partner holdings." ;
    ns1:documentTitle "Merger will create new Michigan healthcare system" ;
    ns1:documentURL <https://www.fiercehealthcare.com/healthcare/merger-will-create-new-michigan-healthcare-system> ;
    ns1:foundName "buying" ;
    ns1:name "buying" ;
    ns1:sourceName "Fierce Healthcare" ;
    ns1:status "has not happened" ;
    ns1:targetDetails "share" ;
    ns1:vendor <https://1145.am/db/2242173/Trinity_Health> ;
    ns1:whereGeoName "Michigan" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5001836/about.rdf> ;
    ns1:whereRaw "Michigan" .

<https://1145.am/db/2242173/Share_Investment_Bchs_Community_Partner_Bronson_Healthcare_Group_Has_Not_Happened> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-12-15T17:57:28+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Bronson will buy 51 percent of Battle Creek by buying the 50 percent share from Trinity Health of Novi, Mich., and 1 percent of the BCHS Community Partner holdings." ;
    ns1:documentTitle "Merger will create new Michigan healthcare system" ;
    ns1:documentURL <https://www.fiercehealthcare.com/healthcare/merger-will-create-new-michigan-healthcare-system> ;
    ns1:foundName "buy" ;
    ns1:name "buy" ;
    ns1:sourceName "Fierce Healthcare" ;
    ns1:status "has not happened" ;
    ns1:target <https://1145.am/db/2242173/Bchs_Community_Partner> ;
    ns1:targetDetails "share" ;
    ns1:whereGeoName "Michigan" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5001836/about.rdf> ;
    ns1:whereRaw "Michigan" .

<https://1145.am/db/2242500/Lore_Associates> a org:Organization ;
    ns1:basedInHighGeoName "Philadelphia" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/4560349/about.rdf> ;
    ns1:basedInHighRaw "Philadelphia" ;
    ns1:documentDate "2010-10-07T17:02:42+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Halfpenny Technologies Secures $2.6 Million in Capital Investment" ;
    ns1:documentURL <https://www.fiercehealthcare.com/healthcare/halfpenny-technologies-secures-2-6-million-capital-investment> ;
    ns1:foundName "LORE Associates" ;
    ns1:investor <https://1145.am/db/2242500/Venture_Capital_Investment_Halfpenny_Technologies_Lore_Associates_Milestone_Venture_Partners_Osage_Venture_Partners_Completed> ;
    ns1:name "LORE Associates" ;
    ns1:sameAsMedium <https://1145.am/db/2208806/Lore_Associates>,
        <https://1145.am/db/2215928/Lore_Associates> ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2242500/Milestone_Venture_Partners> a org:Organization ;
    ns1:basedInHighGeoName "New York City" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5128581/about.rdf> ;
    ns1:basedInHighRaw "New York" ;
    ns1:documentDate "2010-10-07T17:02:42+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Halfpenny Technologies Secures $2.6 Million in Capital Investment" ;
    ns1:documentURL <https://www.fiercehealthcare.com/healthcare/halfpenny-technologies-secures-2-6-million-capital-investment> ;
    ns1:foundName "Milestone Venture Partners" ;
    ns1:investor <https://1145.am/db/2242500/Venture_Capital_Investment_Halfpenny_Technologies_Lore_Associates_Milestone_Venture_Partners_Osage_Venture_Partners_Completed> ;
    ns1:name "Milestone Venture Partners" ;
    ns1:sameAsMedium <https://1145.am/db/1696744/Milestone_Venture_Partners>,
        <https://1145.am/db/1830147/Milestone_Venture_Partners>,
        <https://1145.am/db/1860145/Milestone_Venture_Partners>,
        <https://1145.am/db/1879055/Milestone_Venture_Partners>,
        <https://1145.am/db/2208806/Milestone_Venture_Partners>,
        <https://1145.am/db/2215928/Milestone_Venture_Partners> ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2242500/Osage_Venture_Partners> a org:Organization ;
    ns1:basedInHighGeoName "Pennsylvania" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/6254927/about.rdf> ;
    ns1:basedInHighRaw "Pennsylvania" ;
    ns1:documentDate "2010-10-07T17:02:42+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Halfpenny Technologies Secures $2.6 Million in Capital Investment" ;
    ns1:documentURL <https://www.fiercehealthcare.com/healthcare/halfpenny-technologies-secures-2-6-million-capital-investment> ;
    ns1:foundName "Osage Venture Partners" ;
    ns1:investor <https://1145.am/db/2242500/Venture_Capital_Investment_Halfpenny_Technologies_Lore_Associates_Milestone_Venture_Partners_Osage_Venture_Partners_Completed> ;
    ns1:name "Osage Venture Partners" ;
    ns1:sameAsMedium <https://1145.am/db/1168922/Osage_Venture_Partners>,
        <https://1145.am/db/1171244/Osage_Venture_Partners>,
        <https://1145.am/db/1649262/Osage_Venture_Partners>,
        <https://1145.am/db/1649643/Osage_Venture_Partners>,
        <https://1145.am/db/1817564/Osage_Venture_Partners>,
        <https://1145.am/db/1857593/Osage_Venture_Partners>,
        <https://1145.am/db/1892698/Osage_Venture_Partners>,
        <https://1145.am/db/2208806/Osage_Venture_Partners>,
        <https://1145.am/db/2215928/Osage_Venture_Partners>,
        <https://1145.am/db/2284768/Osage_Venture_Partners>,
        <https://1145.am/db/2604027/Osage_Venture_Partners>,
        <https://1145.am/db/506560/Osage_Venture_Partners>,
        <https://1145.am/db/526025/Osage_Venture_Partners>,
        <https://1145.am/db/526046/Osage_Venture_Partners>,
        <https://1145.am/db/818090/Osage_Venture_Partners> ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2250964/Picis_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition",
        "merger" ;
    ns1:documentDate "2010-07-22T14:01:39+00:00"^^xsd:dateTime ;
    ns1:documentExtract "EDEN PRAIRIE, Minn. & WAKEFIELD, Mass.- (BUSINESS WIRE) - Ingenix, a leading health information technology and services company, today announced it has signed a definitive merger agreement to acquire Picis®, Inc., a leading provider of health information solutions for the high-acuity areas of hospitals." ;
    ns1:documentTitle "Ingenix to Acquire Picis" ;
    ns1:documentURL <https://www.fiercehealthcare.com/healthcare/ingenix-to-acquire-picis-0> ;
    ns1:foundName "acquire",
        "merger" ;
    ns1:name "acquire",
        "merger" ;
    ns1:sourceName "Fierce Healthcare" ;
    ns1:status "has not happened" ;
    ns1:target <https://1145.am/db/2250964/Picis> ;
    ns1:targetName "Picis" ;
    ns1:whereGeoName "Eden Prairie" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5025219/about.rdf> ;
    ns1:whereRaw "EDEN PRAIRIE, Minn." .

<https://1145.am/db/2262219/Picis_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition",
        "merger" ;
    ns1:documentDate "2010-07-22T15:10:34+00:00"^^xsd:dateTime ;
    ns1:documentExtract "EDEN PRAIRIE, Minn. & WAKEFIELD, Mass.- (BUSINESS WIRE) - Ingenix, a leading health information technology and services company, today announced it has signed a definitive merger agreement to acquire Picis®, Inc., a leading provider of health information solutions for the high-acuity areas of hospitals." ;
    ns1:documentTitle "Ingenix to Acquire Picis" ;
    ns1:documentURL <https://www.fiercehealthcare.com/payer/ingenix-to-acquire-picis> ;
    ns1:foundName "acquire",
        "merger" ;
    ns1:name "acquire",
        "merger" ;
    ns1:sourceName "Fierce Healthcare" ;
    ns1:status "has not happened" ;
    ns1:target <https://1145.am/db/2262219/Picis> ;
    ns1:targetName "Picis" ;
    ns1:whereGeoName "Eden Prairie" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5025219/about.rdf> ;
    ns1:whereRaw "EDEN PRAIRIE, Minn." .

<https://1145.am/db/2288596/Alung> a org:Organization ;
    ns1:basedInHighGeoName "Pittsburgh" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5206379/about.rdf> ;
    ns1:basedInHighRaw "Pittsburgh" ;
    ns1:description "a devicemaker" ;
    ns1:documentDate "2010-10-11T13:54:38+00:00"^^xsd:dateTime ;
    ns1:documentTitle "ALung, InfraReDx round up funding" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/alung-infraredx-round-up-funding> ;
    ns1:foundName "ALung Technologies" ;
    ns1:name "ALung" ;
    ns1:sameAsMedium <https://1145.am/db/2291127/Alung> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2288596/Infraredx> a org:Organization ;
    ns1:basedInHighGeoName "Burlington" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/4931737/about.rdf> ;
    ns1:basedInHighRaw "Burlington, MA" ;
    ns1:description "medical" ;
    ns1:documentDate "2010-10-11T13:54:38+00:00"^^xsd:dateTime ;
    ns1:documentTitle "ALung, InfraReDx round up funding" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/alung-infraredx-round-up-funding> ;
    ns1:foundName "InfraReDx" ;
    ns1:industry "Medical" ;
    ns1:name "InfraReDx" ;
    ns1:sameAsHigh <https://1145.am/db/2290206/Infraredx>,
        <https://1145.am/db/2295214/Infraredx> ;
    ns1:sameAsMedium <https://1145.am/db/2291878/Infraredx>,
        <https://1145.am/db/2292321/Infraredx> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2288596/Investment_Infraredx_Sanderling_Ventures_Spacelabs_Medical_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-10-11T13:54:38+00:00"^^xsd:dateTime ;
    ns1:documentExtract "ALSO: Spacelabs Medical has landed a $ 13.5 million Defense Department contract for \"patient monitoring systems, related products and training on the devices ,\" according to Mass Device.",
        "PLUS: Burlington, MA - based InfraReDx has completed a $ 21 million equity financing with the help of Sanderling Ventures." ;
    ns1:documentTitle "ALung, InfraReDx round up funding" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/alung-infraredx-round-up-funding> ;
    ns1:foundName "financing" ;
    ns1:name "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2288596/Infraredx>,
        <https://1145.am/db/2288596/Spacelabs_Medical> ;
    ns1:targetDetails "equity" ;
    ns1:valueRaw "$ 13.5 million",
        "$ 21 million" ;
    ns1:whereGeoName "Pittsburgh" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5206379/about.rdf> ;
    ns1:whereRaw "Pittsburgh" .

<https://1145.am/db/2288596/Sanderling_Ventures> a org:Organization ;
    ns1:basedInLowRaw "Burlington, MA" ;
    ns1:description "venture capital" ;
    ns1:documentDate "2010-10-11T13:54:38+00:00"^^xsd:dateTime ;
    ns1:documentTitle "ALung, InfraReDx round up funding" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/alung-infraredx-round-up-funding> ;
    ns1:foundName "Sanderling Ventures" ;
    ns1:investor <https://1145.am/db/2288596/Investment_Infraredx_Sanderling_Ventures_Spacelabs_Medical_Completed> ;
    ns1:name "Sanderling Ventures" ;
    ns1:sameAsHigh <https://1145.am/db/1006252/Menlo_Ventures>,
        <https://1145.am/db/1006262/Com_Prelude_Ventures>,
        <https://1145.am/db/1006574/Integr8d_Capital>,
        <https://1145.am/db/1006880/Root_Ventures>,
        <https://1145.am/db/1007193/Capital_One_Ventures>,
        <https://1145.am/db/1007527/Integr8d_Capital>,
        <https://1145.am/db/1008085/Root_Ventures>,
        <https://1145.am/db/1008260/Servicenow_Ventures>,
        <https://1145.am/db/1010064/Greatpoint_Ventures>,
        <https://1145.am/db/1010064/Maverick_Ventures>,
        <https://1145.am/db/1010199/One9_Ventures>,
        <https://1145.am/db/102038/Allegion_Ventures>,
        <https://1145.am/db/102038/Pathbreaker_Ventures>,
        <https://1145.am/db/102038/West_Ventures>,
        <https://1145.am/db/1023252/Digitalbridge_Ventures>,
        <https://1145.am/db/1024247/Digitalbridge_Ventures>,
        <https://1145.am/db/1024483/Investbridge_Capital>,
        <https://1145.am/db/1026319/Able_Partners>,
        <https://1145.am/db/1034591/Valia_Ventures>,
        <https://1145.am/db/1041601/Kineo_Finance>,
        <https://1145.am/db/1042250/Kineo_Finance>,
        <https://1145.am/db/1043051/Sequoia_Capital>,
        <https://1145.am/db/1043259/Sequoia_Capital>,
        <https://1145.am/db/1043342/Root_Ventures>,
        <https://1145.am/db/1043516/Kineo_Finance>,
        <https://1145.am/db/1045242/Dipalo_Ventures>,
        <https://1145.am/db/1045384/Sequoia_Capital>,
        <https://1145.am/db/1051115/Dn_Capital>,
        <https://1145.am/db/1051644/Vestigo_Ventures>,
        <https://1145.am/db/1052155/Gate_Ventures>,
        <https://1145.am/db/1059993/Tera_Ventures>,
        <https://1145.am/db/1060146/Ulu_Ventures>,
        <https://1145.am/db/1061824/Bluebird_Ventures>,
        <https://1145.am/db/1061911/Ulu_Ventures>,
        <https://1145.am/db/1065366/Applied_Ventures_Llc>,
        <https://1145.am/db/1065544/Menlo_Ventures>,
        <https://1145.am/db/1066120/Crosslink_Capital>,
        <https://1145.am/db/1081175/Rse_Ventures>,
        <https://1145.am/db/1081490/Vinco_Ventures>,
        <https://1145.am/db/1081888/Ggv_Capital>,
        <https://1145.am/db/1082613/Rse_Ventures>,
        <https://1145.am/db/1082719/Dorilton_Ventures>,
        <https://1145.am/db/1082814/Cathexis_Ventures>,
        <https://1145.am/db/1082814/Promus_Ventures>,
        <https://1145.am/db/1082814/Type_One_Ventures>,
        <https://1145.am/db/1084014/Ret_Ventures>,
        <https://1145.am/db/1085867/Ret_Ventures>,
        <https://1145.am/db/1086604/Alerion_Ventures>,
        <https://1145.am/db/1086673/Wintrust_Ventures>,
        <https://1145.am/db/1089416/Nexo_Ventures>,
        <https://1145.am/db/1090643/Argon_Ventures>,
        <https://1145.am/db/1090643/Glasswing_Ventures>,
        <https://1145.am/db/1101244/Acequia_Capital>,
        <https://1145.am/db/1103270/Acequia_Capital>,
        <https://1145.am/db/1106082/Northpond_Ventures>,
        <https://1145.am/db/1106670/Sequoia_Capital>,
        <https://1145.am/db/1111505/Nissay_Capital>,
        <https://1145.am/db/1111505/Remiges_Ventures>,
        <https://1145.am/db/1112074/Nissay_Capital>,
        <https://1145.am/db/1112074/Remiges_Ventures>,
        <https://1145.am/db/1114979/Catapult_Ventures>,
        <https://1145.am/db/1115103/Northpond_Ventures>,
        <https://1145.am/db/1119456/Truist_Ventures>,
        <https://1145.am/db/1119699/Prelude_Ventures>,
        <https://1145.am/db/1120030/Morpheus_Ventures>,
        <https://1145.am/db/1120030/Point72_Ventures>,
        <https://1145.am/db/1120071/Morpheus_Ventures>,
        <https://1145.am/db/1120071/Point72_Ventures>,
        <https://1145.am/db/1122750/Prelude_Ventures>,
        <https://1145.am/db/1129561/Redbeard_Ventures>,
        <https://1145.am/db/1130744/Redbeard_Ventures>,
        <https://1145.am/db/1133003/Sequoia_Capital>,
        <https://1145.am/db/1134165/Boldstart_Ventures>,
        <https://1145.am/db/1136173/Boldstart_Ventures>,
        <https://1145.am/db/1137178/CRV>,
        <https://1145.am/db/1138154/Ggv_Capital>,
        <https://1145.am/db/1139703/Industry_Ventures>,
        <https://1145.am/db/1140286/Origin_Ventures>,
        <https://1145.am/db/1141736/Redpoint_Ventures>,
        <https://1145.am/db/1150154/Riv_Capital>,
        <https://1145.am/db/1150529/Astellas_Venture_Management_Llc>,
        <https://1145.am/db/1150529/Solasta_Ventures>,
        <https://1145.am/db/1151328/Index_Ventures>,
        <https://1145.am/db/1151736/True_Ventures>,
        <https://1145.am/db/1152929/Aperiamventures>,
        <https://1145.am/db/1153706/Index_Ventures>,
        <https://1145.am/db/1154242/True_Ventures>,
        <https://1145.am/db/1163139/Sentiero_Ventures>,
        <https://1145.am/db/1163139/Skyriver_Ventures>,
        <https://1145.am/db/1164299/Lavrock_Ventures>,
        <https://1145.am/db/1164299/Progress_Ventures>,
        <https://1145.am/db/1164688/Abstract_Ventures>,
        <https://1145.am/db/1164688/Spacecadet_Ventures>,
        <https://1145.am/db/1164845/Lavrock_Ventures>,
        <https://1145.am/db/1164845/Progress_Ventures>,
        <https://1145.am/db/1165515/G2_Group_Ventures>,
        <https://1145.am/db/1166154/Allos_Ventures>,
        <https://1145.am/db/1166957/Seedil_Ventures>,
        <https://1145.am/db/1168757/Accomplice_Ventures>,
        <https://1145.am/db/1169687/Artiman_Ventures>,
        <https://1145.am/db/1169687/J_Ventures>,
        <https://1145.am/db/1169687/Nd_Capital>,
        <https://1145.am/db/1169815/Accomplice_Ventures>,
        <https://1145.am/db/1170971/Equinor_Ventures>,
        <https://1145.am/db/1173428/Equinor_Ventures>,
        <https://1145.am/db/1175576/Divcowest_Ventures>,
        <https://1145.am/db/1175576/Point72_Ventures>,
        <https://1145.am/db/1175576/Signia_Ventures>,
        <https://1145.am/db/1176018/First_Star_Ventures>,
        <https://1145.am/db/1187600/Caymus_Equity_Partners_Llc>,
        <https://1145.am/db/11887/Adv>,
        <https://1145.am/db/1190097/Caymus_Equity_Partners_Llc>,
        <https://1145.am/db/1190127/Animo_Ventures>,
        <https://1145.am/db/1190127/Chaac_Ventures>,
        <https://1145.am/db/1190127/Ulu_Ventures>,
        <https://1145.am/db/1196068/Arthur_Ventures>,
        <https://1145.am/db/1196728/Greatpoint_Ventures>,
        <https://1145.am/db/1199177/Greatpoint_Ventures>,
        <https://1145.am/db/1199182/Boxone_Ventures>,
        <https://1145.am/db/1202673/Basecamp_Ventures>,
        <https://1145.am/db/1203180/Basecamp_Ventures>,
        <https://1145.am/db/1206820/Tenoneten_Ventures>,
        <https://1145.am/db/1208519/Tappanhill_Ventures>,
        <https://1145.am/db/1208749/Industry_Ventures>,
        <https://1145.am/db/1208749/Keshif_Ventures>,
        <https://1145.am/db/1208749/Tenoneten_Ventures>,
        <https://1145.am/db/1213076/Equinor_Ventures>,
        <https://1145.am/db/1213076/Scf_Ventures>,
        <https://1145.am/db/1213119/Nevcaut_Ventures>,
        <https://1145.am/db/1215930/Northpond_Ventures>,
        <https://1145.am/db/1219982/Soma_Ventures>,
        <https://1145.am/db/1221237/C2_Ventures>,
        <https://1145.am/db/1222789/Glasswing_Ventures>,
        <https://1145.am/db/1232497/Droia_Ventures>,
        <https://1145.am/db/1232497/Gv>,
        <https://1145.am/db/1233314/Citta_Capital>,
        <https://1145.am/db/1236549/Adit_Ventures>,
        <https://1145.am/db/1247755/Sinewave_Ventures>,
        <https://1145.am/db/1247761/Clear_Ventures>,
        <https://1145.am/db/1248631/Sinewave_Ventures>,
        <https://1145.am/db/1252447/Gaingels>,
        <https://1145.am/db/1256269/Ampd_Ventures_Inc>,
        <https://1145.am/db/1264028/K3_Ventures>,
        <https://1145.am/db/1264587/Index_Ventures>,
        <https://1145.am/db/1268150/Pender_Ventures>,
        <https://1145.am/db/1269968/Abstract_Ventures>,
        <https://1145.am/db/1272468/Launchpad_Capital>,
        <https://1145.am/db/1279264/Roosh_Ventures>,
        <https://1145.am/db/1281079/Morgenthaler_Ventures>,
        <https://1145.am/db/1281647/Morgenthaler_Ventures>,
        <https://1145.am/db/1282820/Agya_Ventures>,
        <https://1145.am/db/1286872/Morevc>,
        <https://1145.am/db/1287476/Felicis_Ventures>,
        <https://1145.am/db/1297417/Bitkraft_Ventures>,
        <https://1145.am/db/1299578/Seedtob_Capital>,
        <https://1145.am/db/1307620/Inventus_Capital_Partners>,
        <https://1145.am/db/1311917/Avid_Ventures>,
        <https://1145.am/db/1311917/Canapi_Ventures>,
        <https://1145.am/db/1322441/Solana_Ventures>,
        <https://1145.am/db/1326376/Dexcom_Ventures>,
        <https://1145.am/db/1329887/Peter_Nagar>,
        <https://1145.am/db/1331691/Pelion_Ventures>,
        <https://1145.am/db/1332798/Acrobator_Ventures>,
        <https://1145.am/db/1334186/First_Ascent_Ventures>,
        <https://1145.am/db/1334193/Version_One_Ventures>,
        <https://1145.am/db/1334395/Gv>,
        <https://1145.am/db/1334895/Soleus_Capital>,
        <https://1145.am/db/1335073/Yl_Ventures>,
        <https://1145.am/db/1335080/Dorilton_Ventures>,
        <https://1145.am/db/1344240/Neotribe_Ventures>,
        <https://1145.am/db/1352420/Vamos_Ventures>,
        <https://1145.am/db/1353145/Infinity_Ventures>,
        <https://1145.am/db/1362743/Cobalt_Ventures>,
        <https://1145.am/db/1373683/BGV>,
        <https://1145.am/db/1375916/J2_Ventures>,
        <https://1145.am/db/1376353/J2_Ventures>,
        <https://1145.am/db/1378599/Menlo_Ventures>,
        <https://1145.am/db/1381832/Northpond_Ventures>,
        <https://1145.am/db/1382787/Northpond_Ventures>,
        <https://1145.am/db/1383818/Newlin_Ventures>,
        <https://1145.am/db/1387557/Naventures>,
        <https://1145.am/db/138878/Metacartel_Ventures>,
        <https://1145.am/db/1398057/Owen_Van_Natta_Temaris___Associates>,
        <https://1145.am/db/1398917/Trousdale_Ventures>,
        <https://1145.am/db/1407553/Sequoia_Capital>,
        <https://1145.am/db/1407614/C2_Ventures>,
        <https://1145.am/db/1411289/Sequoia_Capital>,
        <https://1145.am/db/1411934/Riptide_Ventures>,
        <https://1145.am/db/1425749/Menlo_Ventures>,
        <https://1145.am/db/1425749/Se_Ventures>,
        <https://1145.am/db/1433429/Crosslink_Capital>,
        <https://1145.am/db/1445378/Mvp_Ventures>,
        <https://1145.am/db/1445935/Verissimo_Ventures>,
        <https://1145.am/db/1449316/+Nd_Capital>,
        <https://1145.am/db/1449740/Mistral_Ventures>,
        <https://1145.am/db/1452107/Abstract_Ventures>,
        <https://1145.am/db/1455216/Engage_Ventures>,
        <https://1145.am/db/1455616/Abstract_Ventures>,
        <https://1145.am/db/1463829/1sharpe_Ventures>,
        <https://1145.am/db/1467693/Preseed_Ventures>,
        <https://1145.am/db/1467892/M_Ventures>,
        <https://1145.am/db/1467932/Sequoia_Capital_Gv>,
        <https://1145.am/db/1468981/Preseed_Ventures>,
        <https://1145.am/db/1476448/Origin_Ventures>,
        <https://1145.am/db/1480152/True_Ventures>,
        <https://1145.am/db/1480651/Glasswing_Ventures>,
        <https://1145.am/db/1480989/Infinity_Ventures>,
        <https://1145.am/db/1481875/Infinity_Ventures>,
        <https://1145.am/db/1482705/Oif_Ventures>,
        <https://1145.am/db/1484103/Boxone_Ventures>,
        <https://1145.am/db/1484857/Iu_Ventures>,
        <https://1145.am/db/1488858/Alkeon_Capital>,
        <https://1145.am/db/1490126/Seedtob_Capital>,
        <https://1145.am/db/1490183/Sofinnova_Partners>,
        <https://1145.am/db/1490978/Seedtob_Capital>,
        <https://1145.am/db/1492889/Future_Ventures>,
        <https://1145.am/db/1492889/Radical_Ventures>,
        <https://1145.am/db/1494028/Alkeon_Capital>,
        <https://1145.am/db/1496360/Realist_Ventures>,
        <https://1145.am/db/1503768/Nevateam_Partners>,
        <https://1145.am/db/1508325/Aramco_Ventures>,
        <https://1145.am/db/1509462/F7_Ventures>,
        <https://1145.am/db/1512891/Acme_Capital>,
        <https://1145.am/db/1515109/Cmfg_Ventures>,
        <https://1145.am/db/1515916/Sequoia_Capital>,
        <https://1145.am/db/1520070/Menlo_Ventures>,
        <https://1145.am/db/1520070/Northpond_Ventures>,
        <https://1145.am/db/1520772/January_Ventures>,
        <https://1145.am/db/1537166/Catalio_Capital_Management>,
        <https://1145.am/db/1537970/Catalio_Capital_Management>,
        <https://1145.am/db/1541308/Panoramic_Ventures>,
        <https://1145.am/db/1541797/G1_Ventures>,
        <https://1145.am/db/1545833/Alerion_Ventures>,
        <https://1145.am/db/1545994/Noemis_Ventures>,
        <https://1145.am/db/1546945/Alerion_Ventures>,
        <https://1145.am/db/1546965/Citi_Ventures>,
        <https://1145.am/db/1546965/Truist_Ventures>,
        <https://1145.am/db/1547281/Noemis_Ventures>,
        <https://1145.am/db/1548592/Gopoint_Ventures>,
        <https://1145.am/db/1556397/Dnx_Ventures>,
        <https://1145.am/db/1556442/C16_Ventures>,
        <https://1145.am/db/1557877/Embark_Ventures>,
        <https://1145.am/db/1559824/Embark_Ventures>,
        <https://1145.am/db/1560704/Breaktrail_Ventures>,
        <https://1145.am/db/1563623/Amex_Ventures>,
        <https://1145.am/db/1564049/Amex_Ventures>,
        <https://1145.am/db/1571330/Seae_Ventures>,
        <https://1145.am/db/1571330/Venturesouth>,
        <https://1145.am/db/1572216/Seae_Ventures>,
        <https://1145.am/db/1572216/Venturesouth>,
        <https://1145.am/db/1574557/True_Ventures>,
        <https://1145.am/db/1574647/Vanterra_Ventures>,
        <https://1145.am/db/1575612/Interlace_Ventures>,
        <https://1145.am/db/1575612/Valia_Ventures>,
        <https://1145.am/db/1578178/N49p>,
        <https://1145.am/db/1578178/Naventures>,
        <https://1145.am/db/1578327/Crit_Ventures>,
        <https://1145.am/db/1578327/Nextview_Ventures>,
        <https://1145.am/db/1579770/Schams_Ventures>,
        <https://1145.am/db/1579792/Crit_Ventures>,
        <https://1145.am/db/1579792/Nextview_Ventures>,
        <https://1145.am/db/1580468/Cohort_Ventures>,
        <https://1145.am/db/1582024/Avalon_Ventures>,
        <https://1145.am/db/1582111/Forepont_Capital_Partners>,
        <https://1145.am/db/1583413/Navigare_Ventures>,
        <https://1145.am/db/1615195/Digitalis_Ventures>,
        <https://1145.am/db/1616990/Digitalis_Ventures>,
        <https://1145.am/db/1632002/Catalio_Capital_Management>,
        <https://1145.am/db/1632028/Catalio_Capital_Management>,
        <https://1145.am/db/1632131/Catalio_Capital_Management>,
        <https://1145.am/db/1632156/Catalio_Capital_Management>,
        <https://1145.am/db/1638640/1digi_Ventures>,
        <https://1145.am/db/1649691/Sequoia_Capital>,
        <https://1145.am/db/1653506/Ascendum_Capital>,
        <https://1145.am/db/1653506/Citta_Capital>,
        <https://1145.am/db/1653506/Morgenthaler_Ventures>,
        <https://1145.am/db/1664837/Civilization_Ventures>,
        <https://1145.am/db/1664948/Dreamit_Ventures>,
        <https://1145.am/db/1669908/Aviso_Ventures>,
        <https://1145.am/db/1670128/Primary_Ventures>,
        <https://1145.am/db/1676513/Connect_Ventures>,
        <https://1145.am/db/1685482/Lavrock_Ventures>,
        <https://1145.am/db/1690703/Arkam_Ventures>,
        <https://1145.am/db/1690703/Prosus_Ventures>,
        <https://1145.am/db/1691060/Veblen_Ventures>,
        <https://1145.am/db/1691364/Ts_Ventures>,
        <https://1145.am/db/1693592/Cventures>,
        <https://1145.am/db/1693668/Sunny_Side_Ventures>,
        <https://1145.am/db/1693981/Boldstart_Ventures>,
        <https://1145.am/db/1694241/True_Ventures>,
        <https://1145.am/db/1694301/Dn_Capital>,
        <https://1145.am/db/1694417/Sequoia_Capital>,
        <https://1145.am/db/1694448/Presidio_Ventures>,
        <https://1145.am/db/1694592/Credo_Ventures>,
        <https://1145.am/db/1694592/Susa_Ventures>,
        <https://1145.am/db/1694798/Udc_Ventures>,
        <https://1145.am/db/1694947/Intersouth_Partners>,
        <https://1145.am/db/1695849/Salesforce_Ventures>,
        <https://1145.am/db/1695885/True_Ventures>,
        <https://1145.am/db/1697044/Palomar_Ventures>,
        <https://1145.am/db/1697044/Sequoia_Capital>,
        <https://1145.am/db/1697373/Lerer_Ventures>,
        <https://1145.am/db/1697910/Entrepia_Ventures>,
        <https://1145.am/db/1697910/Innovacom>,
        <https://1145.am/db/1698516/Engage_Ventures>,
        <https://1145.am/db/1698516/Tyh_Ventures>,
        <https://1145.am/db/1698644/Inovia_Capital>,
        <https://1145.am/db/1699263/Contour_Venture_Partners>,
        <https://1145.am/db/1700565/Sequoia_Capital>,
        <https://1145.am/db/1700572/Contour_Venture_Partners>,
        <https://1145.am/db/1701414/Sequoia_Capital>,
        <https://1145.am/db/1702003/Ventures_West>,
        <https://1145.am/db/1702065/Kreos_Capital>,
        <https://1145.am/db/1702472/Chiratae_Ventures>,
        <https://1145.am/db/1702483/Sure_Ventures_Usvp>,
        <https://1145.am/db/1702517/Prime_Ventures>,
        <https://1145.am/db/1702871/Charles_River_Ventures>,
        <https://1145.am/db/1703120/Point72_Ventures>,
        <https://1145.am/db/1703551/People_Ventures>,
        <https://1145.am/db/1703907/T-Venture>,
        <https://1145.am/db/1704404/True_Ventures>,
        <https://1145.am/db/1704740/T-Venture>,
        <https://1145.am/db/1704842/Se_Ventures>,
        <https://1145.am/db/1704871/Yl_Ventures>,
        <https://1145.am/db/1705825/Ventures_Platform>,
        <https://1145.am/db/1707227/Schams_Ventures>,
        <https://1145.am/db/1707540/Prosus_Ventures>,
        <https://1145.am/db/1707567/Contour_Venture_Partners>,
        <https://1145.am/db/1707567/Reign_Ventures>,
        <https://1145.am/db/1707637/Resolute_Ventures>,
        <https://1145.am/db/1707736/Artiman_Ventures>,
        <https://1145.am/db/1708555/20vc>,
        <https://1145.am/db/1708903/Kaedan_Capital>,
        <https://1145.am/db/1709168/Morgenthaler_Ventures>,
        <https://1145.am/db/1710027/Contour_Venture_Partners>,
        <https://1145.am/db/1711208/Sequoia_Capital>,
        <https://1145.am/db/1711383/Aviso_Ventures>,
        <https://1145.am/db/1711383/Pelion_Ventures>,
        <https://1145.am/db/1711750/Index_Ventures>,
        <https://1145.am/db/1711790/CRV>,
        <https://1145.am/db/1711849/K20_Ventures>,
        <https://1145.am/db/1712471/Cervin_Ventures>,
        <https://1145.am/db/1713712/Grotech_Ventures>,
        <https://1145.am/db/1714098/Charles_River_Ventures>,
        <https://1145.am/db/1714148/Ulu_Ventures>,
        <https://1145.am/db/1714624/Abstract_Ventures>,
        <https://1145.am/db/1714630/January_Ventures>,
        <https://1145.am/db/1716124/Appian_Ventures>,
        <https://1145.am/db/1716168/Onset_Ventures>,
        <https://1145.am/db/1716667/Dag_Ventures>,
        <https://1145.am/db/1717317/Index_Ventures>,
        <https://1145.am/db/1718012/Dag_Ventures>,
        <https://1145.am/db/1718012/Presidio_Ventures>,
        <https://1145.am/db/1718018/Ggv_Capital>,
        <https://1145.am/db/1718081/Jafco_Ventures>,
        <https://1145.am/db/1718748/Truist_Ventures>,
        <https://1145.am/db/1718787/J_Ventures>,
        <https://1145.am/db/1719362/True_Ventures>,
        <https://1145.am/db/1719370/Bv_Capital>,
        <https://1145.am/db/1720145/Bessemer_Ventures>,
        <https://1145.am/db/1720182/Convivialité_Ventures>,
        <https://1145.am/db/1720441/Origin_Ventures>,
        <https://1145.am/db/1721171/Citi_Ventures>,
        <https://1145.am/db/1721392/Redpoint_Ventures>,
        <https://1145.am/db/1721393/Trinity_Ventures>,
        <https://1145.am/db/1721548/Ggv_Capital>,
        <https://1145.am/db/1721548/Menlo_Ventures>,
        <https://1145.am/db/1722252/Onset_Ventures>,
        <https://1145.am/db/1723165/Menlo_Ventures>,
        <https://1145.am/db/1723664/T-Venture>,
        <https://1145.am/db/1723932/Citi_Ventures>,
        <https://1145.am/db/1724979/Jafco_Ventures>,
        <https://1145.am/db/1724979/Sequoia_Capital>,
        <https://1145.am/db/1725680/Index_Ventures>,
        <https://1145.am/db/1726088/Zeev_Ventures>,
        <https://1145.am/db/1726121/Index_Ventures>,
        <https://1145.am/db/1726149/Index_Ventures>,
        <https://1145.am/db/1726544/Ei_Ventures>,
        <https://1145.am/db/1727288/Sozo_Ventures>,
        <https://1145.am/db/1728569/Redpoint_Ventures>,
        <https://1145.am/db/1729186/Catamount_Ventures>,
        <https://1145.am/db/1731187/Rho_Ventures>,
        <https://1145.am/db/1731419/Redpoint_Ventures>,
        <https://1145.am/db/1734104/Alpana_Ventures>,
        <https://1145.am/db/1734104/Highsage_Ventures>,
        <https://1145.am/db/1734728/Talis_Capital>,
        <https://1145.am/db/1735194/Eqt_Ventures>,
        <https://1145.am/db/1735248/Corigin_Ventures>,
        <https://1145.am/db/1735726/Nextview_Ventures>,
        <https://1145.am/db/1735755/Firebolt_Ventures>,
        <https://1145.am/db/1735774/Alpha4_Ventures>,
        <https://1145.am/db/1736136/Ggv_Capital>,
        <https://1145.am/db/1737278/Crosslink_Capital>,
        <https://1145.am/db/1737392/Moxxie_Ventures>,
        <https://1145.am/db/1737979/CRV>,
        <https://1145.am/db/1738162/3one4_Capital>,
        <https://1145.am/db/1738300/Chryscapital>,
        <https://1145.am/db/1738415/Capnamic_Ventures>,
        <https://1145.am/db/1738444/Prosus_Ventures>,
        <https://1145.am/db/1738776/Illuminate_Ventures>,
        <https://1145.am/db/1739022/Eventures>,
        <https://1145.am/db/1739042/Experior_Venture_Fund>,
        <https://1145.am/db/1739064/Jsw_Ventures>,
        <https://1145.am/db/1739106/Sequoia_Capital>,
        <https://1145.am/db/1739120/Sequoia_Capital>,
        <https://1145.am/db/1739285/Sequoia_Capital>,
        <https://1145.am/db/1739630/Redsea_Ventures>,
        <https://1145.am/db/1739719/Seedplus>,
        <https://1145.am/db/1739851/Signum_Capital>,
        <https://1145.am/db/1739909/Root_Ventures>,
        <https://1145.am/db/1739946/Dn_Capital>,
        <https://1145.am/db/1740077/3one4_Capital>,
        <https://1145.am/db/1740665/First_Bridge_Ventures>,
        <https://1145.am/db/1740832/J_Ventures>,
        <https://1145.am/db/1740832/Susa_Ventures>,
        <https://1145.am/db/1740859/Ggv_Capital>,
        <https://1145.am/db/1741357/Dn_Capital>,
        <https://1145.am/db/1741575/Addventure>,
        <https://1145.am/db/1741635/Zeev_Ventures>,
        <https://1145.am/db/1742267/Firebolt_Ventures>,
        <https://1145.am/db/1742267/Point72_Ventures>,
        <https://1145.am/db/1743271/Liil_Ventures>,
        <https://1145.am/db/1743348/Felicis_Ventures>,
        <https://1145.am/db/1743409/Dreamit_Ventures>,
        <https://1145.am/db/1743737/Regah_Ventures>,
        <https://1145.am/db/1744229/R7>,
        <https://1145.am/db/1744775/Point72_Ventures>,
        <https://1145.am/db/1744864/Sequoia_Capital>,
        <https://1145.am/db/1744922/Aglaé_Ventures>,
        <https://1145.am/db/1745326/Eqt_Ventures>,
        <https://1145.am/db/1745326/Lios_Ventures>,
        <https://1145.am/db/1745326/Prime_Ventures>,
        <https://1145.am/db/1745746/Garuda_Ventures>,
        <https://1145.am/db/1745746/Starling_Ventures>,
        <https://1145.am/db/1745920/Sequoia_Capital>,
        <https://1145.am/db/1747252/Citi_Ventures>,
        <https://1145.am/db/1747391/Sequoia_Capital>,
        <https://1145.am/db/1747400/Eqt_Ventures>,
        <https://1145.am/db/1747503/Brighteye_Ventures>,
        <https://1145.am/db/1747722/Shinhan_Capital>,
        <https://1145.am/db/1747943/Altai_Ventures>,
        <https://1145.am/db/1748417/Zeev_Ventures>,
        <https://1145.am/db/1749226/Dn_Capital>,
        <https://1145.am/db/1749425/Ac_Ventures>,
        <https://1145.am/db/1749651/Colle_Capital>,
        <https://1145.am/db/1749911/Khwarizmi_Ventures>,
        <https://1145.am/db/1750942/Celesta_Capital>,
        <https://1145.am/db/1750942/Chiratae_Ventures>,
        <https://1145.am/db/1751135/Inovia_Capital>,
        <https://1145.am/db/1751312/Abstract_Ventures>,
        <https://1145.am/db/1751361/Kreos_Capital>,
        <https://1145.am/db/1751506/Ggv_Capital>,
        <https://1145.am/db/1751551/Gaingels>,
        <https://1145.am/db/1751553/Canapi_Ventures>,
        <https://1145.am/db/1751743/Intudo_Ventures>,
        <https://1145.am/db/1751800/Morpheus_Ventures>,
        <https://1145.am/db/1751954/Novastar_Ventures>,
        <https://1145.am/db/1752102/Origin_Ventures>,
        <https://1145.am/db/1752403/Yl_Ventures>,
        <https://1145.am/db/1752998/Aglaé_Ventures>,
        <https://1145.am/db/1753704/Apex_Ventures>,
        <https://1145.am/db/1753721/Financial_Venture_Studio>,
        <https://1145.am/db/1753721/Resolute_Ventures>,
        <https://1145.am/db/1753745/2i_Ventures>,
        <https://1145.am/db/1754211/Citi_Ventures>,
        <https://1145.am/db/1754211/Menlo_Ventures>,
        <https://1145.am/db/1754242/Gsv_Ventures>,
        <https://1145.am/db/1754595/Global_Ventures>,
        <https://1145.am/db/1754595/Otg_Ventures>,
        <https://1145.am/db/1754751/Menlo_Ventures>,
        <https://1145.am/db/1754787/Letsventure>,
        <https://1145.am/db/1754997/Alkeon_Capital>,
        <https://1145.am/db/1755086/Kollective_Ventures>,
        <https://1145.am/db/1755278/Zeev_Ventures>,
        <https://1145.am/db/1755704/Promus_Ventures>,
        <https://1145.am/db/1755828/Future_Ventures>,
        <https://1145.am/db/1755860/Dg_Ventures>,
        <https://1145.am/db/1755860/Intudo_Ventures>,
        <https://1145.am/db/1756040/Altos_Ventures>,
        <https://1145.am/db/1756094/CRV>,
        <https://1145.am/db/1756141/Index_Ventures>,
        <https://1145.am/db/1756231/Kreos_Capital>,
        <https://1145.am/db/1756326/Neotribe_Ventures>,
        <https://1145.am/db/1756384/Abstract_Ventures>,
        <https://1145.am/db/1756384/Lightspeed_Ventures>,
        <https://1145.am/db/1756599/True_Ventures>,
        <https://1145.am/db/1757035/Vectr_Ventures>,
        <https://1145.am/db/1757365/Will_Ventures>,
        <https://1145.am/db/1757382/Gl_Ventures>,
        <https://1145.am/db/1757590/Kreos_Capital>,
        <https://1145.am/db/1757772/Lorimer_Ventures>,
        <https://1145.am/db/1758193/Tenoneten_Ventures>,
        <https://1145.am/db/1758193/Valia_Ventures>,
        <https://1145.am/db/1758313/Venture_Field>,
        <https://1145.am/db/1758622/Oca_Ventures>,
        <https://1145.am/db/1759048/Avid_Ventures>,
        <https://1145.am/db/1759048/Lightspeed_Ventures>,
        <https://1145.am/db/1759567/J_Ventures>,
        <https://1145.am/db/1759922/Verance_Capital>,
        <https://1145.am/db/1760383/True_Ventures>,
        <https://1145.am/db/1760520/Prologis_Ventures>,
        <https://1145.am/db/1760816/Index_Ventures>,
        <https://1145.am/db/1760984/Index_Ventures>,
        <https://1145.am/db/1760984/Sequoia_Capital>,
        <https://1145.am/db/1760985/Frontier_Ventures>,
        <https://1145.am/db/1761126/Redpoint_Ventures>,
        <https://1145.am/db/1761566/Index_Ventures>,
        <https://1145.am/db/1761607/Menlo_Ventures>,
        <https://1145.am/db/1761607/Sinewave_Ventures>,
        <https://1145.am/db/1761957/Alkeon_Capital>,
        <https://1145.am/db/1761999/Ggv_Capital>,
        <https://1145.am/db/1762031/Menlo_Ventures>,
        <https://1145.am/db/1762055/Altos_Ventures>,
        <https://1145.am/db/1762277/Ac_Ventures>,
        <https://1145.am/db/1762453/Line_Ventures>,
        <https://1145.am/db/1762561/Grotech_Ventures>,
        <https://1145.am/db/1762669/Creandum>,
        <https://1145.am/db/1762844/Signum_Capital>,
        <https://1145.am/db/1763356/Aglaé_Ventures>,
        <https://1145.am/db/1763371/Spacecadet_Ventures>,
        <https://1145.am/db/1763395/Idc_Ventures>,
        <https://1145.am/db/1763565/Felicis_Ventures>,
        <https://1145.am/db/1763774/Ggv_Capital>,
        <https://1145.am/db/1763795/Ventures_Platform>,
        <https://1145.am/db/1763795/Xyz_Ventures>,
        <https://1145.am/db/1763875/Golden_Gate_Ventures>,
        <https://1145.am/db/1764027/Menlo_Ventures>,
        <https://1145.am/db/1764255/Pathbreaker_Ventures>,
        <https://1145.am/db/1764255/Stageone_Ventures>,
        <https://1145.am/db/1764345/Talis_Capital>,
        <https://1145.am/db/1764527/Presidio_Ventures>,
        <https://1145.am/db/1764527/Yl_Ventures>,
        <https://1145.am/db/1765273/Adevinta_Ventures>,
        <https://1145.am/db/1765273/Venturefriends>,
        <https://1145.am/db/1765372/Irobot_Ventures>,
        <https://1145.am/db/1765377/Redpoint_Ventures>,
        <https://1145.am/db/1765550/Sequoia_Capital>,
        <https://1145.am/db/1765646/Amiti_Ventures>,
        <https://1145.am/db/1765673/Salesforce_Ventures>,
        <https://1145.am/db/1766091/Inreach_Ventures>,
        <https://1145.am/db/1766096/Borealis_Ventures>,
        <https://1145.am/db/1766096/Northpond_Ventures>,
        <https://1145.am/db/1766253/Redpoint_Ventures>,
        <https://1145.am/db/1766253/True_Ventures>,
        <https://1145.am/db/1766540/Industry_Ventures>,
        <https://1145.am/db/1766978/Rga_Ventures>,
        <https://1145.am/db/1768099/Eventures>,
        <https://1145.am/db/1768363/Golden_Gate_Ventures>,
        <https://1145.am/db/1768841/Sequoia_Capital>,
        <https://1145.am/db/1769188/Felicis_Ventures>,
        <https://1145.am/db/1770095/Crosslink_Capital>,
        <https://1145.am/db/1770139/Victress_Capital>,
        <https://1145.am/db/1770265/Techstars_Ventures>,
        <https://1145.am/db/1770372/Avalon_Ventures>,
        <https://1145.am/db/1770372/Korelya_Capital>,
        <https://1145.am/db/1770802/Sequoia_Capital>,
        <https://1145.am/db/1770982/Gv>,
        <https://1145.am/db/1770982/Index_Ventures>,
        <https://1145.am/db/1771011/Ggv_Capital>,
        <https://1145.am/db/1771548/Seekdource_Capital>,
        <https://1145.am/db/1771613/Creandum>,
        <https://1145.am/db/1771642/Felicis_Ventures>,
        <https://1145.am/db/1772004/Raed_Ventures>,
        <https://1145.am/db/1772004/Seed_Equity_Venture_Partners>,
        <https://1145.am/db/1772381/Altos_Ventures>,
        <https://1145.am/db/1772452/Connect_Ventures>,
        <https://1145.am/db/1773130/Capnamic_Ventures>,
        <https://1145.am/db/1773143/Venturefriends>,
        <https://1145.am/db/1773323/Crosslink_Capital>,
        <https://1145.am/db/1774348/True_Ventures>,
        <https://1145.am/db/1774535/Felicis_Ventures>,
        <https://1145.am/db/1774535/Susa_Ventures>,
        <https://1145.am/db/1774658/Gv>,
        <https://1145.am/db/1775965/Felicis_Ventures>,
        <https://1145.am/db/1776340/Ggv_Capital>,
        <https://1145.am/db/1776340/Menlo_Ventures>,
        <https://1145.am/db/1776537/Origin_Ventures>,
        <https://1145.am/db/1776537/Tekton_Ventures>,
        <https://1145.am/db/1776621/Redpoint_Ventures>,
        <https://1145.am/db/1777289/Dn_Capital>,
        <https://1145.am/db/1777563/Evolv_Ventures>,
        <https://1145.am/db/1777563/Ggv_Capital>,
        <https://1145.am/db/1777848/Industry_Ventures>,
        <https://1145.am/db/1778935/Oryzn_Capital>,
        <https://1145.am/db/1780024/Partech_Ventures>,
        <https://1145.am/db/1782098/Addventure>,
        <https://1145.am/db/1782221/Point72_Ventures>,
        <https://1145.am/db/1783189/Citi_Ventures>,
        <https://1145.am/db/1784644/Creathor_Ventures>,
        <https://1145.am/db/1784964/Clear_Ventures>,
        <https://1145.am/db/1785361/M_Ventures>,
        <https://1145.am/db/1786249/Redpoint_Ventures>,
        <https://1145.am/db/1786249/Resolute_Ventures>,
        <https://1145.am/db/1786663/Edenred_Capital_Partners>,
        <https://1145.am/db/1786663/Eqt_Ventures>,
        <https://1145.am/db/1787249/Kpn_Ventures>,
        <https://1145.am/db/1787342/Korelya_Capital>,
        <https://1145.am/db/1787536/Point72_Ventures>,
        <https://1145.am/db/1787791/True_Ventures>,
        <https://1145.am/db/1787886/True_Ventures>,
        <https://1145.am/db/1788328/Index_Ventures>,
        <https://1145.am/db/1788570/Sequoia_Capital>,
        <https://1145.am/db/1788726/Redbeat_Capital>,
        <https://1145.am/db/1789460/Eventures>,
        <https://1145.am/db/1789754/Advancit_Capital>,
        <https://1145.am/db/1790280/Arthur_Ventures>,
        <https://1145.am/db/1790399/Capnamic_Ventures>,
        <https://1145.am/db/1790574/Crosslink_Capital>,
        <https://1145.am/db/1790574/Red_Swan_Ventures>,
        <https://1145.am/db/1790574/Sherpa_Ventures>,
        <https://1145.am/db/1790641/Dn_Capital>,
        <https://1145.am/db/1790771/Redpoint_Ventures>,
        <https://1145.am/db/1790777/Connect_Ventures>,
        <https://1145.am/db/1791216/True_Ventures>,
        <https://1145.am/db/1791303/Index_Ventures>,
        <https://1145.am/db/1791628/Industry_Ventures>,
        <https://1145.am/db/1791838/Advancit_Capital>,
        <https://1145.am/db/1792186/Sequoia_Capital>,
        <https://1145.am/db/1792771/Softtechvc>,
        <https://1145.am/db/1792887/Kaedan_Capital>,
        <https://1145.am/db/1792887/Stageone_Ventures>,
        <https://1145.am/db/1794699/Ws_Ventures>,
        <https://1145.am/db/1794935/Intervest_Co_Ltd>,
        <https://1145.am/db/1795020/Redpoint_Ventures>,
        <https://1145.am/db/1795210/Sequoia_Capital>,
        <https://1145.am/db/1795469/Index_Ventures>,
        <https://1145.am/db/1795538/Skystar_Capital>,
        <https://1145.am/db/1796109/Contour_Venture_Partners>,
        <https://1145.am/db/1796593/Tenoneten_Ventures>,
        <https://1145.am/db/1796901/Red_Swan_Ventures>,
        <https://1145.am/db/1796922/Cagni_Ventures>,
        <https://1145.am/db/1797209/Kdwc_Ventures>,
        <https://1145.am/db/1797518/Sequoia_Capital>,
        <https://1145.am/db/1797899/Brave_Ventures>,
        <https://1145.am/db/1797999/Redpoint_Ventures>,
        <https://1145.am/db/1798568/Index_Ventures>,
        <https://1145.am/db/1799099/Inovia_Capital>,
        <https://1145.am/db/1799184/Ggv_Capital>,
        <https://1145.am/db/1800232/Index_Ventures>,
        <https://1145.am/db/1800929/Ventureast>,
        <https://1145.am/db/1802086/High_Line_Ventures>,
        <https://1145.am/db/1802227/Advancit_Capital>,
        <https://1145.am/db/1802288/Sequoia_Capital>,
        <https://1145.am/db/1802336/Capnamic_Ventures>,
        <https://1145.am/db/1804102/True_Ventures>,
        <https://1145.am/db/1804247/Holtzbrinck_Ventures>,
        <https://1145.am/db/1804476/Felicis_Ventures>,
        <https://1145.am/db/1804476/True_Ventures>,
        <https://1145.am/db/1804992/Talis_Capital>,
        <https://1145.am/db/1805389/Industry_Ventures>,
        <https://1145.am/db/1805604/Connect_Ventures>,
        <https://1145.am/db/1805604/Inreach_Ventures>,
        <https://1145.am/db/1806644/Sequoia_Capital>,
        <https://1145.am/db/1806739/Golden_Gate_Ventures>,
        <https://1145.am/db/1808047/Salesforce_Ventures>,
        <https://1145.am/db/1808505/Helion_Ventures>,
        <https://1145.am/db/1808723/Mindworks_Ventures>,
        <https://1145.am/db/1808735/Commonangels_Ventures>,
        <https://1145.am/db/1809007/Sequoia_Capital>,
        <https://1145.am/db/1809844/Real_Ventures>,
        <https://1145.am/db/1809862/Acequia_Capital>,
        <https://1145.am/db/1810384/Starstrike_Ventures>,
        <https://1145.am/db/1810710/Ia_Ventures>,
        <https://1145.am/db/1810714/Catalus_Capital>,
        <https://1145.am/db/1810769/Eventures>,
        <https://1145.am/db/1810769/Sequoia_Capital>,
        <https://1145.am/db/1811357/Index_Ventures>,
        <https://1145.am/db/1812233/Sequoia_Capital>,
        <https://1145.am/db/1812856/Exfinity_Ventures>,
        <https://1145.am/db/1813375/Creandum>,
        <https://1145.am/db/1813575/Ggv_Capital>,
        <https://1145.am/db/1813944/Menlo_Ventures>,
        <https://1145.am/db/1814064/Index_Ventures>,
        <https://1145.am/db/1814643/Corigin_Ventures>,
        <https://1145.am/db/1814643/Launchcapital>,
        <https://1145.am/db/1815038/Plus_Ventures>,
        <https://1145.am/db/1815507/Globis_Capital_Partners>,
        <https://1145.am/db/1815697/Cherubic_Ventures>,
        <https://1145.am/db/1815701/True_Ventures>,
        <https://1145.am/db/1815886/Teneleven_Ventures>,
        <https://1145.am/db/1816491/Grotech_Ventures>,
        <https://1145.am/db/1818174/Advancit_Capital>,
        <https://1145.am/db/1818876/Kreos_Capital>,
        <https://1145.am/db/1818901/Sequoia_Capital>,
        <https://1145.am/db/1819374/Rothenberg_Ventures>,
        <https://1145.am/db/1819387/Index_Ventures>,
        <https://1145.am/db/1820882/Inven_Capital>,
        <https://1145.am/db/1821174/Index_Ventures>,
        <https://1145.am/db/1821711/Winton_Ventures>,
        <https://1145.am/db/1821752/Sequoia_Capital>,
        <https://1145.am/db/1823162/True_Ventures>,
        <https://1145.am/db/1823217/Kdc_Ventures>,
        <https://1145.am/db/1823217/Nbm_Ventures>,
        <https://1145.am/db/1823684/Dcm_Ventures>,
        <https://1145.am/db/1823684/Idg_Ventures>,
        <https://1145.am/db/1824252/Allos_Ventures>,
        <https://1145.am/db/1824253/Trinity_Ventures>,
        <https://1145.am/db/1824944/True_Ventures>,
        <https://1145.am/db/1825465/Ben_Narasin>,
        <https://1145.am/db/1825713/Menlo_Ventures>,
        <https://1145.am/db/1825946/Lerer_Ventures>,
        <https://1145.am/db/1826265/Idg_Ventures>,
        <https://1145.am/db/1826648/True_Ventures>,
        <https://1145.am/db/1826922/Ggv_Capital>,
        <https://1145.am/db/1827021/Dag_Ventures>,
        <https://1145.am/db/1828036/Redpoint_Ventures>,
        <https://1145.am/db/1828092/Eden_Ventures>,
        <https://1145.am/db/1828251/Golden_Gate_Ventures>,
        <https://1145.am/db/1828455/Quotidien_Ventures>,
        <https://1145.am/db/1828658/Focus_Ventures>,
        <https://1145.am/db/1828663/Great_Oaks_Ventures>,
        <https://1145.am/db/1828663/Inovia_Capital>,
        <https://1145.am/db/1829257/Sequoia_Capital>,
        <https://1145.am/db/1829422/Felicis_Ventures>,
        <https://1145.am/db/1829422/Rothenberg_Ventures>,
        <https://1145.am/db/1829612/Lerer_Ventures>,
        <https://1145.am/db/1830502/Frontline_Ventures>,
        <https://1145.am/db/1830613/True_Ventures>,
        <https://1145.am/db/1830809/Numecent>,
        <https://1145.am/db/1830809/T-Ventures>,
        <https://1145.am/db/1830817/Charles_River_Ventures>,
        <https://1145.am/db/1831577/Artiman_Ventures>,
        <https://1145.am/db/1831577/Sofinnova_Ventures>,
        <https://1145.am/db/1831764/Sequoia_Capital>,
        <https://1145.am/db/1832038/True_Ventures>,
        <https://1145.am/db/1832316/Partech_Ventures>,
        <https://1145.am/db/1832316/Scentan_Ventures>,
        <https://1145.am/db/1832316/Startcaps_Ventures>,
        <https://1145.am/db/1832856/Grotech_Ventures>,
        <https://1145.am/db/1834224/Avalon_Ventures>,
        <https://1145.am/db/1834224/Orix_Ventures>,
        <https://1145.am/db/1834305/Charles_River_Ventures>,
        <https://1145.am/db/1834334/Altos_Ventures>,
        <https://1145.am/db/1834334/Baseline_Ventures>,
        <https://1145.am/db/1834334/Firebolt_Ventures>,
        <https://1145.am/db/1834334/Lazerow_Ventures>,
        <https://1145.am/db/1834520/Ben_Horowitz>,
        <https://1145.am/db/1834541/Avalon_Ventures>,
        <https://1145.am/db/1834708/Sherpa_Ventures>,
        <https://1145.am/db/1834965/Lerer_Ventures>,
        <https://1145.am/db/1835229/Lerer_Ventures>,
        <https://1145.am/db/1835229/Trinity_Ventures>,
        <https://1145.am/db/1835229/Xg_Ventures>,
        <https://1145.am/db/1835740/Lerer_Ventures>,
        <https://1145.am/db/1835749/Gree_Ventures>,
        <https://1145.am/db/1835825/Focus_Ventures>,
        <https://1145.am/db/1836984/Siemer_Ventures>,
        <https://1145.am/db/1836984/Tekton_Ventures>,
        <https://1145.am/db/1837741/Menlo_Ventures>,
        <https://1145.am/db/1838026/Plus_Ventures>,
        <https://1145.am/db/1840775/Ggv_Capital>,
        <https://1145.am/db/1840881/Felicis_Ventures>,
        <https://1145.am/db/1840881/Trinity_Ventures>,
        <https://1145.am/db/1841176/Lerer_Ventures>,
        <https://1145.am/db/1841176/True_Ventures>,
        <https://1145.am/db/1842402/Index_Ventures>,
        <https://1145.am/db/1842402/Redpoint_Ventures>,
        <https://1145.am/db/1842898/Grotech_Ventures>,
        <https://1145.am/db/1843003/Eventures>,
        <https://1145.am/db/1843003/Index_Ventures>,
        <https://1145.am/db/1843031/Index_Ventures>,
        <https://1145.am/db/1843449/Redpoint_Ventures>,
        <https://1145.am/db/1843602/Nextview_Ventures>,
        <https://1145.am/db/1843659/Sequoia_Capital>,
        <https://1145.am/db/1844143/Inovia_Capital>,
        <https://1145.am/db/1844472/Sequoia_Capital>,
        <https://1145.am/db/1844737/True_Ventures>,
        <https://1145.am/db/1844931/Charles_River_Ventures>,
        <https://1145.am/db/1845308/Ia_Ventures>,
        <https://1145.am/db/1845960/Lerer_Ventures>,
        <https://1145.am/db/1846254/Index_Ventures>,
        <https://1145.am/db/1846483/Inovia_Capital>,
        <https://1145.am/db/1847463/Prism_Ventureworks>,
        <https://1145.am/db/1847752/T-Venture>,
        <https://1145.am/db/1848523/Trinity_Ventures>,
        <https://1145.am/db/1849673/Inventure_Partners>,
        <https://1145.am/db/1849884/Index_Ventures>,
        <https://1145.am/db/1849949/Holtzbrinck_Ventures>,
        <https://1145.am/db/1850020/Sequoia_Capital>,
        <https://1145.am/db/1850668/True_Ventures>,
        <https://1145.am/db/1850989/Artiman_Ventures>,
        <https://1145.am/db/1850989/Sequoia_Capital>,
        <https://1145.am/db/1851035/Acequia_Capital>,
        <https://1145.am/db/1851035/Index_Ventures>,
        <https://1145.am/db/1851035/Redpoint_Ventures>,
        <https://1145.am/db/1851705/Promus_Ventures>,
        <https://1145.am/db/1851854/Partech_Ventures>,
        <https://1145.am/db/1851923/Dag_Ventures>,
        <https://1145.am/db/1852308/Plus_Ventures>,
        <https://1145.am/db/1852513/Quotidian_Ventures>,
        <https://1145.am/db/1852513/Trestle_Ventures>,
        <https://1145.am/db/1852556/Dave_Morin>,
        <https://1145.am/db/1852806/Redpoint_Ventures>,
        <https://1145.am/db/1852870/Golden_Gate_Ventures>,
        <https://1145.am/db/1852870/Siemer_Ventures>,
        <https://1145.am/db/1853417/Catamount_Ventures>,
        <https://1145.am/db/1853496/T-Ventures>,
        <https://1145.am/db/1854200/Ggv_Capital>,
        <https://1145.am/db/1854201/Charles_River_Ventures>,
        <https://1145.am/db/1854786/Eden_Ventures>,
        <https://1145.am/db/1854874/Crosslink_Capital>,
        <https://1145.am/db/1854874/Sherpa_Ventures>,
        <https://1145.am/db/1854874/Softtech>,
        <https://1145.am/db/1855353/Sequoia_Capital>,
        <https://1145.am/db/1855363/True_Ventures>,
        <https://1145.am/db/1855403/Rho_Ventures>,
        <https://1145.am/db/1855780/Bds_Ventures>,
        <https://1145.am/db/1855780/Ggv_Capital>,
        <https://1145.am/db/1856191/Creandum>,
        <https://1145.am/db/1856380/Softtech>,
        <https://1145.am/db/1856402/Sequoia_Capital>,
        <https://1145.am/db/1856457/Aeris_Capital>,
        <https://1145.am/db/1856616/Redpoint_Ventures>,
        <https://1145.am/db/1856834/Sequoia_Capital>,
        <https://1145.am/db/1857635/Rikard_Steiber>,
        <https://1145.am/db/1857659/Revolution_Ventures>,
        <https://1145.am/db/1857930/Inovia_Capital>,
        <https://1145.am/db/1857930/Version_One_Ventures>,
        <https://1145.am/db/1858323/Avalon_Ventures>,
        <https://1145.am/db/1858545/Sequoia_Capital>,
        <https://1145.am/db/1858592/Apex_Venture_Partners>,
        <https://1145.am/db/1858592/Origin_Ventures>,
        <https://1145.am/db/1858991/Capnamic_Ventures>,
        <https://1145.am/db/1859199/True_Ventures>,
        <https://1145.am/db/1859314/Version_One_Ventures>,
        <https://1145.am/db/1860163/Inovia_Capital>,
        <https://1145.am/db/1860345/Commonangels>,
        <https://1145.am/db/1860345/Launchcapital>,
        <https://1145.am/db/1861054/Sequoia_Capital>,
        <https://1145.am/db/1861355/Rho_Ventures>,
        <https://1145.am/db/1862590/Felicis_Ventures>,
        <https://1145.am/db/1862878/Mohr_Davidow_Ventures>,
        <https://1145.am/db/1863147/Apex_Venture_Partners>,
        <https://1145.am/db/1864601/Trinity_Ventures>,
        <https://1145.am/db/1864646/Inventus_Capital>,
        <https://1145.am/db/1865436/Sequoia_Capital>,
        <https://1145.am/db/1865480/Felicis_Ventures>,
        <https://1145.am/db/1865480/Sequoia_Capital>,
        <https://1145.am/db/1865480/Sherpalo_Ventures>,
        <https://1145.am/db/1866032/Launchcapital>,
        <https://1145.am/db/1866134/Embarcadero_Ventures>,
        <https://1145.am/db/1866134/Mohr_Davidow_Ventures>,
        <https://1145.am/db/1866155/Presidio_Ventures>,
        <https://1145.am/db/1867543/Mohr_Davidow_Ventures>,
        <https://1145.am/db/1867599/Cava_Capital>,
        <https://1145.am/db/1868107/Redpoint_Ventures>,
        <https://1145.am/db/1868109/Charles_River_Ventures>,
        <https://1145.am/db/1868178/True_Ventures>,
        <https://1145.am/db/1870015/Redpoint_Ventures>,
        <https://1145.am/db/1870465/Nextview_Ventures>,
        <https://1145.am/db/1871221/True_Ventures>,
        <https://1145.am/db/1871574/Redpoint_Ventures>,
        <https://1145.am/db/1871777/Charles_River_Ventures>,
        <https://1145.am/db/1871784/Charles_River_Ventures>,
        <https://1145.am/db/1871888/Charles_River_Ventures>,
        <https://1145.am/db/1873191/El_Dorado_Ventures>,
        <https://1145.am/db/1873680/Crosslink_Capital>,
        <https://1145.am/db/1873680/Lerer_Ventures>,
        <https://1145.am/db/1873680/Xg_Ventures>,
        <https://1145.am/db/1874749/True_Ventures>,
        <https://1145.am/db/1874937/Quotidian_Ventures>,
        <https://1145.am/db/1877243/Felicis_Ventures>,
        <https://1145.am/db/1877283/Northzone_Ventures>,
        <https://1145.am/db/1877473/True_Ventures>,
        <https://1145.am/db/1877642/Dag_Ventures>,
        <https://1145.am/db/1878620/Ggv_Capital>,
        <https://1145.am/db/1879279/High_Line_Ventures>,
        <https://1145.am/db/1879759/T-Venture>,
        <https://1145.am/db/1880679/Northzone_Ventures>,
        <https://1145.am/db/1881464/Ggv_Capital>,
        <https://1145.am/db/1881748/Morgenthaler_Ventures>,
        <https://1145.am/db/1882330/New_World_Ventures>,
        <https://1145.am/db/1882727/Charles_River_Ventures>,
        <https://1145.am/db/1882907/Starfish_Ventures>,
        <https://1145.am/db/1883568/Eden_Ventures>,
        <https://1145.am/db/1883572/Astutia_Ventures>,
        <https://1145.am/db/1886402/New_Atlantic_Ventures>,
        <https://1145.am/db/1886566/Sequoia_Capital>,
        <https://1145.am/db/1889394/Focus_Ventures>,
        <https://1145.am/db/1889629/Sequoia_Capital>,
        <https://1145.am/db/1890000/Lerer_Ventures>,
        <https://1145.am/db/1890122/East_Ventures>,
        <https://1145.am/db/1890133/Crosslink_Capital>,
        <https://1145.am/db/1890133/Dag_Ventures>,
        <https://1145.am/db/1890133/Focus_Ventures>,
        <https://1145.am/db/1890157/Morgenthaler_Ventures>,
        <https://1145.am/db/1890208/Menlo_Ventures>,
        <https://1145.am/db/1890619/Mohr_Davidow_Ventures>,
        <https://1145.am/db/1890839/Inovia_Capital>,
        <https://1145.am/db/1890903/Miven_Ventures>,
        <https://1145.am/db/1891615/Holtzbrinck_Ventures>,
        <https://1145.am/db/1891777/Mohr_Davidow_Ventures>,
        <https://1145.am/db/1891913/New_World_Ventures>,
        <https://1145.am/db/1891913/Oca_Ventures>,
        <https://1145.am/db/1891926/New_World_Ventures>,
        <https://1145.am/db/1892050/Charles_River_Ventures>,
        <https://1145.am/db/1892105/Crosscreek_Capital>,
        <https://1145.am/db/1892105/Industry_Ventures>,
        <https://1145.am/db/1892106/Altos_Ventures>,
        <https://1145.am/db/1892106/Illuminate_Ventures>,
        <https://1145.am/db/1892620/True_Ventures>,
        <https://1145.am/db/1892674/Appian_Ventures>,
        <https://1145.am/db/1892902/Crosslink_Capital>,
        <https://1145.am/db/1892955/Guy_Gamzu>,
        <https://1145.am/db/1895072/Nextview_Ventures>,
        <https://1145.am/db/1895951/Windward_Ventures>,
        <https://1145.am/db/1896159/Ia_Ventures>,
        <https://1145.am/db/1896185/Index_Ventures>,
        <https://1145.am/db/1896379/Index_Ventures>,
        <https://1145.am/db/1896379/Redpoint_Ventures>,
        <https://1145.am/db/1896419/True_Ventures>,
        <https://1145.am/db/1902330/Baseline_Ventures>,
        <https://1145.am/db/1905483/Industry_Ventures>,
        <https://1145.am/db/1905858/Index_Ventures>,
        <https://1145.am/db/1907771/Dag_Ventures>,
        <https://1145.am/db/1909430/Menlo_Ventures>,
        <https://1145.am/db/1909651/Revolution_Ventures>,
        <https://1145.am/db/1910694/True_Ventures>,
        <https://1145.am/db/1910922/Charles_River_Ventures>,
        <https://1145.am/db/1912684/Charles_River_Ventures>,
        <https://1145.am/db/1913863/Tl_Ventures>,
        <https://1145.am/db/1913874/Redpoint_Ventures>,
        <https://1145.am/db/1914220/Index_Ventures>,
        <https://1145.am/db/1915393/Mohr_Davidow_Ventures>,
        <https://1145.am/db/1915862/Dag_Ventures>,
        <https://1145.am/db/1915862/Focus_Ventures>,
        <https://1145.am/db/1919724/Dag_Ventures>,
        <https://1145.am/db/1920478/Dawntreader_Ventures>,
        <https://1145.am/db/1920837/Onset_Ventures>,
        <https://1145.am/db/1927817/Trm_Ventures>,
        <https://1145.am/db/1939926/Cobalt_Ventures>,
        <https://1145.am/db/1945479/Crosslink_Capital>,
        <https://1145.am/db/1947303/Cavallo_Ventures>,
        <https://1145.am/db/1947312/Boldstart_Ventures>,
        <https://1145.am/db/1952989/Singularity_Ventures>,
        <https://1145.am/db/1954147/Accomplice_Ventures>,
        <https://1145.am/db/1957179/Sozo_Ventures>,
        <https://1145.am/db/1958963/Prosus_Ventures>,
        <https://1145.am/db/1959001/Capital_Technology_Ventures>,
        <https://1145.am/db/1959001/Glasswing_Ventures>,
        <https://1145.am/db/1962819/Connetic_Ventures>,
        <https://1145.am/db/1967592/Firebolt_Ventures>,
        <https://1145.am/db/1967683/Dig_Ventures_Vine_Ventures>,
        <https://1145.am/db/1975490/Northview_Ventures>,
        <https://1145.am/db/1975547/Nanban_Ventures>,
        <https://1145.am/db/1975547/Sinewave_Ventures>,
        <https://1145.am/db/1986122/Menlo_Ventures>,
        <https://1145.am/db/1995926/Neotribe_Ventures>,
        <https://1145.am/db/1998196/Gni_Group_Ltd>,
        <https://1145.am/db/1999771/Servicenow_Ventures>,
        <https://1145.am/db/2004427/Convivialité_Ventures>,
        <https://1145.am/db/2005131/Wwventures>,
        <https://1145.am/db/2007132/Nventures>,
        <https://1145.am/db/2020041/Inovia_Capital>,
        <https://1145.am/db/2020041/TCV>,
        <https://1145.am/db/2023596/Salesforce_Ventures>,
        <https://1145.am/db/2025081/True_Ventures>,
        <https://1145.am/db/2029648/Sequoia_Capital>,
        <https://1145.am/db/2035454/Gv>,
        <https://1145.am/db/2036021/Clear_Ventures>,
        <https://1145.am/db/2038783/Sequoia_Capital>,
        <https://1145.am/db/2039177/Stellantis_Ventures>,
        <https://1145.am/db/2041480/Brunnur_Ventures>,
        <https://1145.am/db/2042858/Gv>,
        <https://1145.am/db/2044380/20sales>,
        <https://1145.am/db/2045587/Veritec_Ventures>,
        <https://1145.am/db/2050229/Nventures>,
        <https://1145.am/db/2050359/At_One_Ventures>,
        <https://1145.am/db/2051164/Aviso_Ventures>,
        <https://1145.am/db/2053027/Glasswing_Ventures>,
        <https://1145.am/db/2055707/Globis_Capital_Partners>,
        <https://1145.am/db/2056931/We_Ventures>,
        <https://1145.am/db/2060003/Crit_Ventures_100___100_Ventures>,
        <https://1145.am/db/2061278/Incisive_Ventures>,
        <https://1145.am/db/2061278/Volo_Ventures>,
        <https://1145.am/db/2063642/Clear_Bridge_Ventures>,
        <https://1145.am/db/2063967/Vsquared_Ventures>,
        <https://1145.am/db/2069147/Boldstart_Ventures>,
        <https://1145.am/db/2069147/Pelion_Ventures>,
        <https://1145.am/db/2069147/Salesforce_Ventures>,
        <https://1145.am/db/2069495/Intermountain_Ventures>,
        <https://1145.am/db/2069495/Northpond_Ventures>,
        <https://1145.am/db/2073129/Abstract_Ventures>,
        <https://1145.am/db/2073132/Idc_Ventures>,
        <https://1145.am/db/2073480/Astellas_Venture_Management>,
        <https://1145.am/db/2075625/Rocketship_Ventures>,
        <https://1145.am/db/2081180/S4s_Ventures>,
        <https://1145.am/db/2081674/Capital_One_Ventures>,
        <https://1145.am/db/2082068/Arctern_Ventures>,
        <https://1145.am/db/2082068/Prelude_Ventures>,
        <https://1145.am/db/2083987/Vanterra_Ventures>,
        <https://1145.am/db/2087289/Jven_Capital>,
        <https://1145.am/db/2087289/Northpond_Ventures>,
        <https://1145.am/db/2089206/Crescendo_Venture_Partners>,
        <https://1145.am/db/2093427/Yl_Ventures>,
        <https://1145.am/db/2093713/Yl_Ventures>,
        <https://1145.am/db/209861/Crosslink_Capital>,
        <https://1145.am/db/2100116/Epic_Ventures>,
        <https://1145.am/db/2107533/Globis_Capital_Partners>,
        <https://1145.am/db/2109529/Point72_Ventures>,
        <https://1145.am/db/2109799/Sofinnova_Partners>,
        <https://1145.am/db/2109932/Catalio_Capital_Management>,
        <https://1145.am/db/2109932/Epic_Ventures>,
        <https://1145.am/db/2109932/Intermountain_Ventures>,
        <https://1145.am/db/2109932/North_South_Ventures>,
        <https://1145.am/db/2116769/Celesta_Capital>,
        <https://1145.am/db/2116769/Chiratae_Ventures>,
        <https://1145.am/db/2123953/Amex_Ventures>,
        <https://1145.am/db/2123953/Industry_Ventures>,
        <https://1145.am/db/2123953/Infinity_Ventures>,
        <https://1145.am/db/2124766/P1_Ventures>,
        <https://1145.am/db/2125182/Nevcaut_Ventures>,
        <https://1145.am/db/2125182/Ulu_Ventures>,
        <https://1145.am/db/2125927/1984_Ventures>,
        <https://1145.am/db/2127882/Akkadian_Ventures>,
        <https://1145.am/db/2134989/Clear_Ventures>,
        <https://1145.am/db/2134989/Felicis_Ventures>,
        <https://1145.am/db/2141183/S_Ventures>,
        <https://1145.am/db/2141328/Connetic_Ventures>,
        <https://1145.am/db/2143438/Scorpio_Capital>,
        <https://1145.am/db/2147767/Catapult_Ventures>,
        <https://1145.am/db/2147767/Tenoneten_Ventures>,
        <https://1145.am/db/2151983/CRV>,
        <https://1145.am/db/2151983/Greatpoint_Ventures>,
        <https://1145.am/db/2155426/Brighteyes_Ventures>,
        <https://1145.am/db/2155625/Sofinnova_Partners>,
        <https://1145.am/db/2164121/Menlo_Ventures>,
        <https://1145.am/db/2169799/Nwise_Ventures>,
        <https://1145.am/db/217906/Sequoia_Capital>,
        <https://1145.am/db/2181016/Foresite_Capital>,
        <https://1145.am/db/2182443/Global_Ventures>,
        <https://1145.am/db/2183352/Optum_Ventures>,
        <https://1145.am/db/2186568/Frist_Cressey_Ventures>,
        <https://1145.am/db/2186568/Springrock_Ventures>,
        <https://1145.am/db/2186949/Greatpoint_Ventures_And_Cross_Creek>,
        <https://1145.am/db/2186949/Springrock_Ventures>,
        <https://1145.am/db/2190141/Link_Ventures>,
        <https://1145.am/db/2192636/TCV>,
        <https://1145.am/db/219311/Origin_Ventures>,
        <https://1145.am/db/2196875/Sequoia_Capital>,
        <https://1145.am/db/2208603/McKesson_Ventures>,
        <https://1145.am/db/2210557/True_Ventures>,
        <https://1145.am/db/221321/Ggv_Capital>,
        <https://1145.am/db/2214690/Idg_Ventures>,
        <https://1145.am/db/2254568/Felicis_Ventures>,
        <https://1145.am/db/2264763/True_Ventures>,
        <https://1145.am/db/2283006/Catalio_Capital_Management>,
        <https://1145.am/db/2283185/Catalio_Capital_Management>,
        <https://1145.am/db/2283185/Northpond_Ventures>,
        <https://1145.am/db/2284412/Soleus_Capital>,
        <https://1145.am/db/2286665/Shanda_Group>,
        <https://1145.am/db/2288209/Echelon_Ventures>,
        <https://1145.am/db/2291277/Foresite_Capital>,
        <https://1145.am/db/2293172/Prospect_Ventures>,
        <https://1145.am/db/2294202/Trinitas_Capital>,
        <https://1145.am/db/2294815/Foresite_Capital>,
        <https://1145.am/db/2295253/Arkitekt_Ventures>,
        <https://1145.am/db/2295539/Sofinnova_Ventures>,
        <https://1145.am/db/2296249/Proxima_Ventures>,
        <https://1145.am/db/2296869/Dcm_Ventures>,
        <https://1145.am/db/2297406/Sequoia_Capital>,
        <https://1145.am/db/2298897/Eshelman_Ventures>,
        <https://1145.am/db/2300254/Sequoia_Capital>,
        <https://1145.am/db/2302351/Rho_Ventures>,
        <https://1145.am/db/2302731/Astellas_Venture_Management_Llc>,
        <https://1145.am/db/2302750/Sofinnova_Partners>,
        <https://1145.am/db/2302897/Ventures_West_Capital>,
        <https://1145.am/db/2303098/Seaflower_Ventures>,
        <https://1145.am/db/2303581/Clarus_Ventures>,
        <https://1145.am/db/2304606/Prism_Ventureworks>,
        <https://1145.am/db/2304606/Sofinnova_Ventures>,
        <https://1145.am/db/2305745/Clarus_Ventures>,
        <https://1145.am/db/2305745/Sanderling_Ventures>,
        <https://1145.am/db/2306281/Sanderling_Ventures>,
        <https://1145.am/db/2306568/Cmea_Ventures>,
        <https://1145.am/db/2306568/Sofinnova_Ventures>,
        <https://1145.am/db/2309507/Rho_Ventures>,
        <https://1145.am/db/2309840/Index_Ventures>,
        <https://1145.am/db/2311069/Morgenthaler_Ventures>,
        <https://1145.am/db/2311069/Sofinnova_Ventures>,
        <https://1145.am/db/2312288/Pappas_Ventures>,
        <https://1145.am/db/2312792/Onset_Ventures>,
        <https://1145.am/db/2313322/Clarus_Ventures>,
        <https://1145.am/db/2313438/Clarus_Ventures>,
        <https://1145.am/db/2314380/Puretech_Ventures>,
        <https://1145.am/db/2314397/Pappas_Ventures>,
        <https://1145.am/db/2314397/Sofinnova_Ventures>,
        <https://1145.am/db/2314400/Pappas_Ventures>,
        <https://1145.am/db/2314400/Sofinnova_Ventures>,
        <https://1145.am/db/2314515/Apjohnventures>,
        <https://1145.am/db/2315754/Arcturus_Capital>,
        <https://1145.am/db/2317779/Index_Ventures>,
        <https://1145.am/db/2317779/Sofinnova_Partners>,
        <https://1145.am/db/2319777/Astellas_Venture_Management>,
        <https://1145.am/db/2321856/Ventures_West_Capital_Ltd>,
        <https://1145.am/db/2323785/Eshelman_Ventures>,
        <https://1145.am/db/2324195/Sofinnova_Ventures>,
        <https://1145.am/db/2325015/True_Ventures>,
        <https://1145.am/db/2325140/Index_Ventures>,
        <https://1145.am/db/2325257/Ventures_West>,
        <https://1145.am/db/2325337/Resolvyx>,
        <https://1145.am/db/2326080/Felicis_Ventures>,
        <https://1145.am/db/2326362/Nextech_Venture>,
        <https://1145.am/db/2326404/Intersouth_Partners>,
        <https://1145.am/db/2328585/Cmea_Ventures>,
        <https://1145.am/db/2329870/Sofinnova_Partners>,
        <https://1145.am/db/2330775/Fletcher_Spaght_Ventures>,
        <https://1145.am/db/2332748/Clarus_Ventures>,
        <https://1145.am/db/2335587/Sofinnova_Partners>,
        <https://1145.am/db/2338023/Cipla_Ventures>,
        <https://1145.am/db/2338196/Index_Ventures>,
        <https://1145.am/db/2338236/Sanderling_Ventures>,
        <https://1145.am/db/2338703/Wavepoint_Ventures>,
        <https://1145.am/db/2339206/Fletcher_Spaght_Ventures>,
        <https://1145.am/db/2340429/Mohr_Davidow_Ventures>,
        <https://1145.am/db/2341896/Sofinnova_Ventures>,
        <https://1145.am/db/2341942/High-Tech_Gründerfonds>,
        <https://1145.am/db/2342998/Sofinnova_Ventures>,
        <https://1145.am/db/2343184/Jven_Capital>,
        <https://1145.am/db/2345017/Venture_Investments>,
        <https://1145.am/db/2345268/Foresite_Capital>,
        <https://1145.am/db/2346300/High-Tech_Gründerfonds>,
        <https://1145.am/db/2346452/Aescap_Venture>,
        <https://1145.am/db/2346532/Pappas_Ventures>,
        <https://1145.am/db/2346978/Ventures_West_Capital>,
        <https://1145.am/db/2347571/Index_Ventures>,
        <https://1145.am/db/2347876/Clarus_Ventures>,
        <https://1145.am/db/2348618/Index_Ventures>,
        <https://1145.am/db/2349096/Sofinnova_Partners>,
        <https://1145.am/db/2349096/Sofinnova_Ventures>,
        <https://1145.am/db/2350004/Clarus_Ventures>,
        <https://1145.am/db/2350044/Avalon_Ventures>,
        <https://1145.am/db/2352436/Forward_Ventures>,
        <https://1145.am/db/2352831/Clarus_Ventures>,
        <https://1145.am/db/2356384/Sofinnova_Partners>,
        <https://1145.am/db/2357487/Savitr_Capital>,
        <https://1145.am/db/2358050/Sofinnova_Ventures>,
        <https://1145.am/db/2358657/Fletcher_Spaght_Ventures>,
        <https://1145.am/db/2358725/Sofinnova_Ventures>,
        <https://1145.am/db/2358747/Solon_Ventures>,
        <https://1145.am/db/2358812/Fletcher_Spaght_Ventures>,
        <https://1145.am/db/2359562/Pappas_Ventures>,
        <https://1145.am/db/2359960/Sofinnova_Partners>,
        <https://1145.am/db/2362638/Launchpad_Venture_Group>,
        <https://1145.am/db/2363460/Rho_Ventures>,
        <https://1145.am/db/2363854/Chrysalis_Ventures>,
        <https://1145.am/db/2364820/Fletcher_Spaght_Ventures>,
        <https://1145.am/db/2365103/Aescap_Venture>,
        <https://1145.am/db/2367675/Avalon_Ventures>,
        <https://1145.am/db/2369967/Foresite_Capital>,
        <https://1145.am/db/2370240/Clarus_Ventures>,
        <https://1145.am/db/2371160/Sofinnova_Ventures>,
        <https://1145.am/db/238282/Carnrite_Ventures>,
        <https://1145.am/db/2400536/Capital_One_Ventures>,
        <https://1145.am/db/2423653/Venturewell>,
        <https://1145.am/db/253438/Esplanade_Ventures>,
        <https://1145.am/db/254357/Ulu_Ventures>,
        <https://1145.am/db/2549491/Ktb_Ventures>,
        <https://1145.am/db/2552636/Morningside_Ventures>,
        <https://1145.am/db/2569491/High-Tech_Gründerfonds>,
        <https://1145.am/db/2570138/Sherpa_Ventures>,
        <https://1145.am/db/2570481/Morgenthaler_Ventures>,
        <https://1145.am/db/2570483/Morgenthaler_Ventures>,
        <https://1145.am/db/2577022/Sofinnova_Partners>,
        <https://1145.am/db/2577022/Sofinnova_Ventures>,
        <https://1145.am/db/2603254/Salesforce_Ventures>,
        <https://1145.am/db/2628424/Verana_Networks>,
        <https://1145.am/db/2628848/Neocarta_Ventures>,
        <https://1145.am/db/2635849/Mohr_Davidow_Ventures>,
        <https://1145.am/db/2638432/Nissay_Capital>,
        <https://1145.am/db/2641337/Promus_Ventures>,
        <https://1145.am/db/2641337/True_Ventures>,
        <https://1145.am/db/2654391/Biggell_Finance>,
        <https://1145.am/db/265532/Ulu_Ventures>,
        <https://1145.am/db/2702871/Inovia_Capital>,
        <https://1145.am/db/274170/G1_Ventures>,
        <https://1145.am/db/2754677/Golden_Gate_Ventures>,
        <https://1145.am/db/2765022/Garuda_Ventures>,
        <https://1145.am/db/2765030/Daniel_Ventures>,
        <https://1145.am/db/2765418/Rw3_Ventures>,
        <https://1145.am/db/2786411/Allegion_Ventures>,
        <https://1145.am/db/2788052/Rx_Ventures>,
        <https://1145.am/db/2790064/Novastar_Ventures>,
        <https://1145.am/db/2794396/Snowpoint_Ventures>,
        <https://1145.am/db/2797562/Menlo_Ventures>,
        <https://1145.am/db/283272/Salesforce_Ventures>,
        <https://1145.am/db/283607/Salesforce_Ventures>,
        <https://1145.am/db/293715/Signum_Capital>,
        <https://1145.am/db/293849/Felicis_Ventures>,
        <https://1145.am/db/293891/Ggv_Capital>,
        <https://1145.am/db/299738/Steadfast_Capital_Ventures>,
        <https://1145.am/db/306236/Index_Ventures>,
        <https://1145.am/db/319155/Bgv_Ventures>,
        <https://1145.am/db/323273/Index_Ventures>,
        <https://1145.am/db/341984/Salesforce_Ventures>,
        <https://1145.am/db/341984/Sequoia_Capital>,
        <https://1145.am/db/341990/Salesforce_Ventures>,
        <https://1145.am/db/341990/Sequoia_Capital>,
        <https://1145.am/db/343459/F7_Ventures>,
        <https://1145.am/db/346598/Salesforce_Ventures>,
        <https://1145.am/db/348442/Triventures>,
        <https://1145.am/db/348659/Launchpad_Capital>,
        <https://1145.am/db/361303/Sequoia_Capital>,
        <https://1145.am/db/364168/Alerion_Ventures>,
        <https://1145.am/db/367592/Gv>,
        <https://1145.am/db/367592/Sequoia_Capital>,
        <https://1145.am/db/388551/Vestigo_Ventures>,
        <https://1145.am/db/396305/Real_Ventures>,
        <https://1145.am/db/402103/1776_Ventures>,
        <https://1145.am/db/402701/January_Ventures>,
        <https://1145.am/db/403810/Riverstone_Ventures>,
        <https://1145.am/db/410322/Gv>,
        <https://1145.am/db/410473/Celesta_Capital>,
        <https://1145.am/db/410473/Lytical_Ventures_And_Nepenthe_Capital>,
        <https://1145.am/db/410529/Goodyear_Ventures>,
        <https://1145.am/db/411539/Zeev_Ventures>,
        <https://1145.am/db/412020/Defi_Ventures_Inc>,
        <https://1145.am/db/415322/CRV>,
        <https://1145.am/db/416041/Akkadian_Ventures>,
        <https://1145.am/db/416041/Signia_Ventures>,
        <https://1145.am/db/416041/Zeev_Ventures>,
        <https://1145.am/db/419489/Point72_Ventures>,
        <https://1145.am/db/424877/North_First_Ventures>,
        <https://1145.am/db/425262/Yl_Ventures>,
        <https://1145.am/db/425423/True_Ventures>,
        <https://1145.am/db/425973/Will_Ventures>,
        <https://1145.am/db/426615/Sequoia_Capital>,
        <https://1145.am/db/429179/C5_Capital>,
        <https://1145.am/db/430986/Cortado_Ventures>,
        <https://1145.am/db/434334/1up_Ventures>,
        <https://1145.am/db/435691/Klick_Ventures>,
        <https://1145.am/db/439819/Cavu_Ventures>,
        <https://1145.am/db/441319/Celesta_Capital>,
        <https://1145.am/db/444105/Exfinity_Ventures>,
        <https://1145.am/db/445365/Revolution_Ventures>,
        <https://1145.am/db/446341/Sinewave_Ventures>,
        <https://1145.am/db/455558/Intudo_Ventures>,
        <https://1145.am/db/457435/Alerce>,
        <https://1145.am/db/457435/Clin>,
        <https://1145.am/db/460454/Index_Ventures>,
        <https://1145.am/db/471253/Gv>,
        <https://1145.am/db/471436/Citi_Ventures>,
        <https://1145.am/db/471504/Canapi_Ventures>,
        <https://1145.am/db/473030/Highsage_Ventures>,
        <https://1145.am/db/474928/Susa_Ventures>,
        <https://1145.am/db/478049/Worldquant_Ventures>,
        <https://1145.am/db/479113/Index_Ventures>,
        <https://1145.am/db/479113/Menlo_Ventures>,
        <https://1145.am/db/485616/K3_Ventures>,
        <https://1145.am/db/486858/Gaingels>,
        <https://1145.am/db/486901/Gaingels>,
        <https://1145.am/db/488743/Salesforce_Ventures>,
        <https://1145.am/db/491130/Raiven_Capital>,
        <https://1145.am/db/491338/Raiven_Capital>,
        <https://1145.am/db/493560/Tyh_Ventures>,
        <https://1145.am/db/495912/Regah_Ventures>,
        <https://1145.am/db/506588/Trinity_Ventures>,
        <https://1145.am/db/508145/Sora_Finance>,
        <https://1145.am/db/508161/Sora_Finance>,
        <https://1145.am/db/510565/Epic_Ventures>,
        <https://1145.am/db/513305/Avid_Ventures>,
        <https://1145.am/db/513305/Canapi_Ventures>,
        <https://1145.am/db/513897/Rlc_Ventures>,
        <https://1145.am/db/514151/Rlc_Ventures>,
        <https://1145.am/db/516396/Acequia_Capital>,
        <https://1145.am/db/517213/Acequia_Capital>,
        <https://1145.am/db/523349/Osf_Ventures>,
        <https://1145.am/db/523776/Root_Ventures>,
        <https://1145.am/db/525285/Inventum_Ventures>,
        <https://1145.am/db/525285/Optima_Ventures>,
        <https://1145.am/db/526109/Ggv_Capital>,
        <https://1145.am/db/526175/Ridgeline_Ventures>,
        <https://1145.am/db/529812/Inventum_Ventures>,
        <https://1145.am/db/529812/Optima_Ventures>,
        <https://1145.am/db/532016/Id_Ventures>,
        <https://1145.am/db/539571/Origin_Ventures>,
        <https://1145.am/db/545843/Capital_One_Ventures>,
        <https://1145.am/db/545852/Boxone_Ventures>,
        <https://1145.am/db/545852/Panache_Ventures>,
        <https://1145.am/db/547770/BGV>,
        <https://1145.am/db/547944/BGV>,
        <https://1145.am/db/554552/Konvoy_Ventures>,
        <https://1145.am/db/555193/Illumina_Ventures>,
        <https://1145.am/db/555193/Technology_Venture_Partners>,
        <https://1145.am/db/556705/Congress_Ave_Ventures>,
        <https://1145.am/db/558005/Illumina_Ventures>,
        <https://1145.am/db/558005/Technology_Venture_Partners>,
        <https://1145.am/db/558877/Falabella_Ventures>,
        <https://1145.am/db/559220/Ulu_Ventures>,
        <https://1145.am/db/561662/Redpoint_Ventures>,
        <https://1145.am/db/561662/Vandelay_Ventures>,
        <https://1145.am/db/562745/Vinmar_Ventures>,
        <https://1145.am/db/563575/Celesta_Capital>,
        <https://1145.am/db/564008/D1_Ventures>,
        <https://1145.am/db/571769/Illumina_Ventures>,
        <https://1145.am/db/571769/M_Ventures>,
        <https://1145.am/db/572097/Menlo_Ventures>,
        <https://1145.am/db/572097/Teneleven_Ventures>,
        <https://1145.am/db/575249/TCV>,
        <https://1145.am/db/576186/Konvoy_Ventures>,
        <https://1145.am/db/577120/Index_Ventures>,
        <https://1145.am/db/586525/Tenoneten_Ventures>,
        <https://1145.am/db/587038/Coparion>,
        <https://1145.am/db/591566/Morningside_Ventures>,
        <https://1145.am/db/596145/Anorak_Ventures>,
        <https://1145.am/db/596564/Anorak_Ventures>,
        <https://1145.am/db/601455/Morningside_Ventures>,
        <https://1145.am/db/603725/Ignitexl_Ventures>,
        <https://1145.am/db/606074/Fiscus_Ventures>,
        <https://1145.am/db/606144/Ggv_Capital>,
        <https://1145.am/db/615337/Companyon_Ventures>,
        <https://1145.am/db/619284/Scf_Ventures>,
        <https://1145.am/db/619366/Capital_One_Ventures>,
        <https://1145.am/db/619736/Lightspeed_Ventures>,
        <https://1145.am/db/623178/Array_Ventures>,
        <https://1145.am/db/625791/Sofinnova_Partners>,
        <https://1145.am/db/626781/Dnx_Ventures>,
        <https://1145.am/db/627030/Launchpad_Capital>,
        <https://1145.am/db/628654/Prologis_Ventures>,
        <https://1145.am/db/633238/True_Ventures>,
        <https://1145.am/db/633869/Skywell_Capital_Partners>,
        <https://1145.am/db/633869/Stageone_Ventures>,
        <https://1145.am/db/640939/Ggv_Capital>,
        <https://1145.am/db/642123/Charles_River_Ventures>,
        <https://1145.am/db/642518/Network_Ventures>,
        <https://1145.am/db/643600/Vinco_Ventures>,
        <https://1145.am/db/648552/True_Ventures>,
        <https://1145.am/db/659010/Index_Ventures>,
        <https://1145.am/db/659675/Gv>,
        <https://1145.am/db/661747/Adit_Ventures>,
        <https://1145.am/db/661818/Index_Ventures>,
        <https://1145.am/db/665129/Ac_Ventures>,
        <https://1145.am/db/665776/Firstime_Ventures>,
        <https://1145.am/db/676217/Steelsky_Ventures>,
        <https://1145.am/db/676869/Ggv_Capital>,
        <https://1145.am/db/678140/Ggv_Capital>,
        <https://1145.am/db/678587/Lightshed_Ventures>,
        <https://1145.am/db/678593/Solana_Ventures>,
        <https://1145.am/db/687538/Kayyak_Ventures>,
        <https://1145.am/db/689460/True_Ventures>,
        <https://1145.am/db/694513/Authentic_Ventures>,
        <https://1145.am/db/694924/Avid_Ventures>,
        <https://1145.am/db/700171/Sequoia_Capital>,
        <https://1145.am/db/700327/Menlo_Ventures>,
        <https://1145.am/db/700877/Gaingels>,
        <https://1145.am/db/703983/Eqventure>,
        <https://1145.am/db/704489/Eqventure>,
        <https://1145.am/db/704753/Felicis_Ventures>,
        <https://1145.am/db/704753/Menlo_Ventures>,
        <https://1145.am/db/704793/Quidnet_Ventures>,
        <https://1145.am/db/704991/Gaingels>,
        <https://1145.am/db/709633/Connetic_Ventures>,
        <https://1145.am/db/726461/Contour_Ventures>,
        <https://1145.am/db/729628/Kyber_Ventures>,
        <https://1145.am/db/729628/Signum_Capital>,
        <https://1145.am/db/738920/Oca_Ventures>,
        <https://1145.am/db/738920/Susa_Ventures>,
        <https://1145.am/db/739538/Morpheus_Ventures>,
        <https://1145.am/db/739538/Oca_Ventures>,
        <https://1145.am/db/739538/Susa_Ventures>,
        <https://1145.am/db/747051/Tenoneten_Ventures>,
        <https://1145.am/db/747771/Ta_Ventures>,
        <https://1145.am/db/749147/1984_Ventures>,
        <https://1145.am/db/749147/Index_Ventures>,
        <https://1145.am/db/749209/1984_Ventures>,
        <https://1145.am/db/749209/Index_Ventures>,
        <https://1145.am/db/750305/Yl_Ventures>,
        <https://1145.am/db/750725/Vestigo_Ventures>,
        <https://1145.am/db/751176/Maverick_Ventures>,
        <https://1145.am/db/751176/Susa_Ventures>,
        <https://1145.am/db/751387/Menlo_Ventures>,
        <https://1145.am/db/753120/Sequoia_Capital>,
        <https://1145.am/db/753251/Savantus_Ventures>,
        <https://1145.am/db/753913/Brunnur_Ventures>,
        <https://1145.am/db/755844/Sequoia_Capital>,
        <https://1145.am/db/758206/Great_North_Ventures>,
        <https://1145.am/db/758206/Grotech_Ventures>,
        <https://1145.am/db/759749/Cava_Capital>,
        <https://1145.am/db/763083/Gaingels>,
        <https://1145.am/db/764875/Rev1_Ventures>,
        <https://1145.am/db/764896/Rev1_Ventures>,
        <https://1145.am/db/765216/True_Ventures>,
        <https://1145.am/db/768172/Gaingels>,
        <https://1145.am/db/768172/Type_One_Ventures>,
        <https://1145.am/db/768349/Salesforce_Ventures>,
        <https://1145.am/db/768852/Felicis_Ventures>,
        <https://1145.am/db/769568/Axon_Ventures>,
        <https://1145.am/db/772099/Array_Ventures>,
        <https://1145.am/db/773235/Prelude_Ventures>,
        <https://1145.am/db/773684/Fulgur_Ventures>,
        <https://1145.am/db/773794/Array_Ventures>,
        <https://1145.am/db/778025/Felicis_Ventures>,
        <https://1145.am/db/778423/Sentiero_Ventures>,
        <https://1145.am/db/779637/Felicis_Ventures>,
        <https://1145.am/db/779867/Genesis_Block_Ventures>,
        <https://1145.am/db/780272/East_Ventures>,
        <https://1145.am/db/780289/East_Ventures>,
        <https://1145.am/db/783431/Cathay_Venture_Inc>,
        <https://1145.am/db/784093/Boldstart_Ventures>,
        <https://1145.am/db/787806/Boldstart_Ventures>,
        <https://1145.am/db/788016/Boldstart_Ventures>,
        <https://1145.am/db/791505/Index_Ventures>,
        <https://1145.am/db/796250/Sp_Ventures>,
        <https://1145.am/db/796629/Index_Ventures>,
        <https://1145.am/db/797597/Lansdowne_Partners>,
        <https://1145.am/db/798095/Index_Ventures>,
        <https://1145.am/db/798753/Sofinnova_Partners>,
        <https://1145.am/db/800093/Sequoia_Capital>,
        <https://1145.am/db/800101/Gaingels>,
        <https://1145.am/db/803541/Credo_Ventures>,
        <https://1145.am/db/803541/Index_Ventures>,
        <https://1145.am/db/803541/Sequoia_Capital>,
        <https://1145.am/db/8045/Greatpoint_Ventures>,
        <https://1145.am/db/806828/Promus_Ventures>,
        <https://1145.am/db/806994/Companyon_Ventures>,
        <https://1145.am/db/807080/K3_Ventures>,
        <https://1145.am/db/808020/Starlight_Ventures>,
        <https://1145.am/db/808020/Valo_Ventures>,
        <https://1145.am/db/8146/Rev1_Ventures>,
        <https://1145.am/db/817162/Orbia_Ventures>,
        <https://1145.am/db/818444/1984_Ventures>,
        <https://1145.am/db/821135/Se_Ventures>,
        <https://1145.am/db/823763/Infinity_Ventures>,
        <https://1145.am/db/828716/Idc_Ventures>,
        <https://1145.am/db/829118/Salesforce_Ventures>,
        <https://1145.am/db/830571/Company_Ventures>,
        <https://1145.am/db/830689/Soleus_Capital>,
        <https://1145.am/db/832264/Salesforce_Ventures>,
        <https://1145.am/db/832573/Solasta_Ventures>,
        <https://1145.am/db/834864/Ggv_Capital>,
        <https://1145.am/db/834864/K3_Ventures>,
        <https://1145.am/db/836848/Technexus_Venture_Collaborative>,
        <https://1145.am/db/836908/Frontier_Ventures>,
        <https://1145.am/db/837034/Redpoint_Ventures>,
        <https://1145.am/db/838138/Root_Ventures>,
        <https://1145.am/db/838181/Sequoia_Capital>,
        <https://1145.am/db/838691/Crosslink_Capital>,
        <https://1145.am/db/847157/Signum_Capital>,
        <https://1145.am/db/847862/Wise_Ventures>,
        <https://1145.am/db/854001/Gv>,
        <https://1145.am/db/854589/Verance_Capital>,
        <https://1145.am/db/854654/Mrtnz_Ventures>,
        <https://1145.am/db/854795/Menlo_Ventures>,
        <https://1145.am/db/867865/Applied_Ventures>,
        <https://1145.am/db/868093/Cobro_Ventures>,
        <https://1145.am/db/869652/Forever_Ventures>,
        <https://1145.am/db/874394/Nextview_Ventures>,
        <https://1145.am/db/874394/True_Ventures>,
        <https://1145.am/db/880050/Crosslink_Capital>,
        <https://1145.am/db/881298/At_One_Ventures>,
        <https://1145.am/db/882723/At_One_Ventures>,
        <https://1145.am/db/884787/Foresite_Capital>,
        <https://1145.am/db/884787/Gv>,
        <https://1145.am/db/884787/Northpond_Ventures>,
        <https://1145.am/db/886445/Gv>,
        <https://1145.am/db/887062/Panoramic_Ventures>,
        <https://1145.am/db/889246/At_One_Ventures>,
        <https://1145.am/db/890271/Panoramic_Ventures>,
        <https://1145.am/db/891162/Emergingvc>,
        <https://1145.am/db/891162/Launchpad_Venture_Group>,
        <https://1145.am/db/903689/Vectr_Ventures>,
        <https://1145.am/db/904276/Nextview_Ventures>,
        <https://1145.am/db/906393/East_Ventures>,
        <https://1145.am/db/907844/Argon_Ventures>,
        <https://1145.am/db/907844/Glasswing_Ventures>,
        <https://1145.am/db/913422/Sequoia_Capital>,
        <https://1145.am/db/913678/Sandbridge_Capital>,
        <https://1145.am/db/919636/Menlo_Ventures>,
        <https://1145.am/db/921704/Scop_Ventures>,
        <https://1145.am/db/92200/Knoll_Ventures>,
        <https://1145.am/db/922066/Irrvrnt_Vc>,
        <https://1145.am/db/922192/Gv>,
        <https://1145.am/db/922498/Sozo_Ventures>,
        <https://1145.am/db/923723/Scop_Ventures>,
        <https://1145.am/db/928711/Frontline_Ventures>,
        <https://1145.am/db/934946/Ggv_Capital>,
        <https://1145.am/db/935046/Origin_Ventures>,
        <https://1145.am/db/935249/Victress_Capital>,
        <https://1145.am/db/935322/Alpana_Ventures>,
        <https://1145.am/db/935322/M_Ventures>,
        <https://1145.am/db/935796/Salesforce_Ventures>,
        <https://1145.am/db/935962/Digitalbridge_Ventures>,
        <https://1145.am/db/936045/Lpc_Ventures>,
        <https://1145.am/db/936057/Noemis_Ventures>,
        <https://1145.am/db/936154/Salesforce_Ventures>,
        <https://1145.am/db/936448/Ggv_Capital>,
        <https://1145.am/db/936862/Lool_Ventures>,
        <https://1145.am/db/936906/Neotribe_Ventures>,
        <https://1145.am/db/937210/Citi_Ventures>,
        <https://1145.am/db/937210/Firebolt_Ventures>,
        <https://1145.am/db/937460/Sequoia_Capital>,
        <https://1145.am/db/938108/Conti_Ventures>,
        <https://1145.am/db/938555/Digitalbridge_Ventures>,
        <https://1145.am/db/938586/Venturesouth>,
        <https://1145.am/db/938921/Redpoint_Ventures>,
        <https://1145.am/db/938975/Ggv_Capital>,
        <https://1145.am/db/939163/Goodyear_Ventures>,
        <https://1145.am/db/940740/Agnc_Ventures>,
        <https://1145.am/db/940913/True_Ventures>,
        <https://1145.am/db/941816/Radical_Ventures>,
        <https://1145.am/db/942825/Argon_Ventures>,
        <https://1145.am/db/946710/Citi_Ventures>,
        <https://1145.am/db/947238/Kyros_Ventures>,
        <https://1145.am/db/952434/Verissimo_Ventures>,
        <https://1145.am/db/955201/Gv>,
        <https://1145.am/db/960022/Verance_Capital>,
        <https://1145.am/db/961837/Sequoia_Capital>,
        <https://1145.am/db/962622/Sequoia_Capital>,
        <https://1145.am/db/970950/Ulu_Ventures>,
        <https://1145.am/db/971415/Altai_Ventures>,
        <https://1145.am/db/971450/Allon_Ventures>,
        <https://1145.am/db/971939/Formic_Ventures>,
        <https://1145.am/db/975114/Formic_Ventures>,
        <https://1145.am/db/979753/Menlo_Ventures>,
        <https://1145.am/db/980678/Menlo_Ventures>,
        <https://1145.am/db/984645/Vinco_Ventures>,
        <https://1145.am/db/987688/Brightspark_Ventures>,
        <https://1145.am/db/987700/Infinityvc>,
        <https://1145.am/db/988084/Abstract_Ventures>,
        <https://1145.am/db/988084/Blank_Ventures>,
        <https://1145.am/db/988318/Arthur_Ventures>,
        <https://1145.am/db/988482/Brightspark_Ventures>,
        <https://1145.am/db/988979/Infinityvc>,
        <https://1145.am/db/989392/Arthur_Ventures>,
        <https://1145.am/db/990085/Radical_Ventures>,
        <https://1145.am/db/995593/Raiven_Capital>,
        <https://1145.am/db/995737/Nuoyan_Capital>,
        <https://1145.am/db/996563/Raiven_Capital> ;
    ns1:sameAsMedium <https://1145.am/db/2228252/Sanderling_Ventures>,
        <https://1145.am/db/2273257/Sanderling_Ventures>,
        <https://1145.am/db/2289884/Sanderling_Ventures>,
        <https://1145.am/db/2299881/Sanderling_Ventures>,
        <https://1145.am/db/2305739/Sanderling_Ventures>,
        <https://1145.am/db/2318941/Sanderling_Ventures>,
        <https://1145.am/db/2323103/Sanderling_Ventures>,
        <https://1145.am/db/2327212/Sanderling_Ventures>,
        <https://1145.am/db/2327227/Sanderling_Ventures>,
        <https://1145.am/db/2327638/Sanderling_Ventures>,
        <https://1145.am/db/2338237/Sanderling_Ventures>,
        <https://1145.am/db/2346532/Sanderling_Ventures>,
        <https://1145.am/db/2346542/Sanderling_Ventures>,
        <https://1145.am/db/2347594/Sanderling_Ventures>,
        <https://1145.am/db/2352831/Sanderling_Ventures>,
        <https://1145.am/db/2364301/Sanderling_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2288596/Series_A_Investment_Alung_Eagle_Ventures_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-10-11T13:54:38+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Eagle Ventures has led a $ 14 million Series A financing round for Pittsburgh - based ALung Technologies." ;
    ns1:documentTitle "ALung, InfraReDx round up funding" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/alung-infraredx-round-up-funding> ;
    ns1:foundName "financing" ;
    ns1:name "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2288596/Alung> ;
    ns1:targetDetails "Series A" ;
    ns1:valueRaw "$ 14 million" ;
    ns1:whereGeoName "Pittsburgh" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5206379/about.rdf> ;
    ns1:whereRaw "Pittsburgh" .

<https://1145.am/db/2288596/Spacelabs_Medical> a org:Organization ;
    ns1:basedInLowRaw "United States" ;
    ns1:description "patient monitoring systems, related products and training on the devices" ;
    ns1:documentDate "2010-10-11T13:54:38+00:00"^^xsd:dateTime ;
    ns1:documentTitle "ALung, InfraReDx round up funding" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/alung-infraredx-round-up-funding> ;
    ns1:foundName "Spacelabs Medical" ;
    ns1:name "Spacelabs Medical" ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2300746/Barrx_Medical> a org:Organization ;
    ns1:basedInHighGeoName "California" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5332921/about.rdf> ;
    ns1:basedInHighRaw "California" ;
    ns1:description "Business" ;
    ns1:documentDate "2010-07-20T19:49:39+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Cancer Dx company Metamark rounds up $22M" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/cancer-dx-company-metamark-rounds-up-22m> ;
    ns1:foundName "BARRX Medical" ;
    ns1:industry "medical" ;
    ns1:name "BARRX Medical" ;
    ns1:sameAsHigh <https://1145.am/db/2295177/Barrx_Medical> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2300746/Endostim> a org:Organization ;
    ns1:description "medical device company" ;
    ns1:documentDate "2010-07-20T19:49:39+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Cancer Dx company Metamark rounds up $22M" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/cancer-dx-company-metamark-rounds-up-22m> ;
    ns1:foundName "ALSO: EndoStim",
        "EndoStim" ;
    ns1:industry "medical device" ;
    ns1:name "EndoStim" ;
    ns1:sameAsHigh <https://1145.am/db/1207291/Endostart>,
        <https://1145.am/db/1207973/Endostart>,
        <https://1145.am/db/1502437/Endoron_Medical>,
        <https://1145.am/db/1556435/Endogastric_Solutions>,
        <https://1145.am/db/2096505/Endologix>,
        <https://1145.am/db/2152621/Endogastric_Solutions>,
        <https://1145.am/db/606138/Endologix> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2300746/Equity_Investment_Endostim_Santé_Ventures_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-07-20T19:49:39+00:00"^^xsd:dateTime ;
    ns1:documentExtract "ALSO: EndoStim, a medical device company developing minimally invasive interventional therapies to treat gastrointestinal and urological neuro-muscular disorders, has raised $ 6 million in Series B equity financing." ;
    ns1:documentTitle "Cancer Dx company Metamark rounds up $22M" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/cancer-dx-company-metamark-rounds-up-22m> ;
    ns1:foundName "financing" ;
    ns1:name "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2300746/Endostim> ;
    ns1:targetDetails "Series B",
        "equity" ;
    ns1:valueRaw "$ 6 million" ;
    ns1:whereGeoName "Cambridge" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/4931972/about.rdf> ;
    ns1:whereRaw "Cambridge, MA" .

<https://1145.am/db/2300746/Highland_Capital_Partners> a org:Organization ;
    ns1:basedInHighGeoName "California" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5332921/about.rdf> ;
    ns1:basedInHighRaw "California" ;
    ns1:documentDate "2010-07-20T19:49:39+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Cancer Dx company Metamark rounds up $22M" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/cancer-dx-company-metamark-rounds-up-22m> ;
    ns1:foundName "Highland Capital Partners" ;
    ns1:investor <https://1145.am/db/2300746/Series_D_Investment_Barrx_Medical_Highland_Capital_Partners_Completed> ;
    ns1:name "Highland Capital Partners" ;
    ns1:sameAsMedium <https://1145.am/db/1706417/Highland_Capital_Partners>,
        <https://1145.am/db/1716136/Highland_Capital_Partners>,
        <https://1145.am/db/1803787/Highland_Capital_Partners>,
        <https://1145.am/db/1806906/Highland_Capital_Partners>,
        <https://1145.am/db/1819710/Highland_Capital_Partners>,
        <https://1145.am/db/1823612/Highland_Capital_Partners>,
        <https://1145.am/db/1824878/Highland_Capital_Partners>,
        <https://1145.am/db/1830368/Highland_Capital_Partners>,
        <https://1145.am/db/1833239/Highland_Capital_Partners>,
        <https://1145.am/db/1839990/Highland_Capital_Partners>,
        <https://1145.am/db/1846953/Highland_Capital_Partners>,
        <https://1145.am/db/1850246/Highland_Capital_Partners>,
        <https://1145.am/db/1852044/Highland_Capital_Partners>,
        <https://1145.am/db/1859069/Highland_Capital_Partners>,
        <https://1145.am/db/1860137/Highland_Capital_Partners>,
        <https://1145.am/db/1861342/Highland_Capital_Partners>,
        <https://1145.am/db/1866156/Highland_Capital_Partners>,
        <https://1145.am/db/1871777/Highland_Capital_Partners>,
        <https://1145.am/db/1874364/Highland_Capital_Partners>,
        <https://1145.am/db/1881478/Highland_Capital_Partners>,
        <https://1145.am/db/1881599/Highland_Capital_Partners>,
        <https://1145.am/db/1890839/Highland_Capital_Partners>,
        <https://1145.am/db/1900458/Highland_Capital_Partners>,
        <https://1145.am/db/1912062/Highland_Capital_Partners>,
        <https://1145.am/db/2249658/Highland_Capital_Partners>,
        <https://1145.am/db/2286842/Highland_Capital_Partners>,
        <https://1145.am/db/2300340/Highland_Capital_Partners>,
        <https://1145.am/db/2303548/Highland_Capital_Partners>,
        <https://1145.am/db/2303560/Highland_Capital_Partners>,
        <https://1145.am/db/2305015/Highland_Capital_Partners>,
        <https://1145.am/db/2325681/Highland_Capital_Partners>,
        <https://1145.am/db/2331700/Highland_Capital_Partners>,
        <https://1145.am/db/2343184/Highland_Capital_Partners>,
        <https://1145.am/db/2343185/Highland_Capital_Partners>,
        <https://1145.am/db/2364422/Highland_Capital_Partners>,
        <https://1145.am/db/2365134/Highland_Capital_Partners>,
        <https://1145.am/db/2365135/Highland_Capital_Partners>,
        <https://1145.am/db/2367199/Highland_Capital_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2300746/Metamark_Genetics> a org:Organization ;
    ns1:basedInHighGeoName "Cambridge" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/4931972/about.rdf> ;
    ns1:basedInHighRaw "Cambridge, MA" ;
    ns1:documentDate "2010-07-20T19:49:39+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Cancer Dx company Metamark rounds up $22M" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/cancer-dx-company-metamark-rounds-up-22m> ;
    ns1:foundName "Metamark Genetics" ;
    ns1:name "Metamark Genetics" ;
    ns1:sameAsMedium <https://1145.am/db/2289784/Metamark_Genetics>,
        <https://1145.am/db/2300736/Metamark_Genetics>,
        <https://1145.am/db/2346014/Metamark_Genetics>,
        <https://1145.am/db/2349272/Metamark_Genetics>,
        <https://1145.am/db/2351342/Metamark_Genetics>,
        <https://1145.am/db/2353228/Metamark_Genetics>,
        <https://1145.am/db/2367504/Metamark_Genetics_Inc>,
        <https://1145.am/db/2370268/Metamark_Genetics> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2300746/Series_D_Investment_Barrx_Medical_Highland_Capital_Partners_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-07-20T19:49:39+00:00"^^xsd:dateTime ;
    ns1:documentExtract "PLUS: California - based BARRX Medical has landed $ 15 million Series D financing in a round led by new investor Highland Capital Partners." ;
    ns1:documentTitle "Cancer Dx company Metamark rounds up $22M" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/cancer-dx-company-metamark-rounds-up-22m> ;
    ns1:foundName "financing" ;
    ns1:name "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2300746/Barrx_Medical> ;
    ns1:targetDetails "Series D" ;
    ns1:valueRaw "$ 15 million" ;
    ns1:whereGeoName "Cambridge" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/4931972/about.rdf> ;
    ns1:whereRaw "Cambridge, MA" .

<https://1145.am/db/2341003/5am_Ventures> a org:Organization ;
    ns1:basedInLowRaw "REDWOOD CITY, Calif." ;
    ns1:description "venture partner" ;
    ns1:documentDate "2010-10-19T14:00:23+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Pearl Therapeutics Raises $69 Million Series C Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/pearl-therapeutics-raises-69-million-series-c-financing> ;
    ns1:foundName "5AM Ventures" ;
    ns1:investor <https://1145.am/db/2341003/Series_C_Investment_5am_Ventures_Clarus_Ventures_New_Leaf_Venture_Partners_Pearl_Therapeutics_Inc_Vatera_Healthcare_Partners_Completed> ;
    ns1:name "5AM Ventures" ;
    ns1:sameAsHigh <https://1145.am/db/1157541/5am_Ventures>,
        <https://1145.am/db/1533327/5am_Ventures>,
        <https://1145.am/db/2283394/5am_Ventures>,
        <https://1145.am/db/2311595/5am_Ventures>,
        <https://1145.am/db/2322646/5am_Ventures>,
        <https://1145.am/db/2324195/5am_Ventures>,
        <https://1145.am/db/2330075/5_Am_Ventures>,
        <https://1145.am/db/2347885/5am_Ventures>,
        <https://1145.am/db/2348754/5am_Ventures>,
        <https://1145.am/db/2348857/5am_Ventures>,
        <https://1145.am/db/2351316/5am_Ventures>,
        <https://1145.am/db/2354296/5am_Ventures>,
        <https://1145.am/db/2371163/5am_Ventures>,
        <https://1145.am/db/509733/5am_Ventures> ;
    ns1:sameAsMedium <https://1145.am/db/1533685/5am_Ventures>,
        <https://1145.am/db/1608803/5am_Ventures>,
        <https://1145.am/db/1669813/5am_Ventures>,
        <https://1145.am/db/2152422/5am_Ventures>,
        <https://1145.am/db/2153726/5am_Ventures>,
        <https://1145.am/db/2153910/5am_Ventures>,
        <https://1145.am/db/2286204/5am_Ventures>,
        <https://1145.am/db/2286665/5am_Ventures>,
        <https://1145.am/db/2288016/5am_Ventures>,
        <https://1145.am/db/2298404/5am_Ventures>,
        <https://1145.am/db/2298642/5am_Ventures>,
        <https://1145.am/db/2306549/5am_Ventures>,
        <https://1145.am/db/2306551/5am_Ventures>,
        <https://1145.am/db/2306754/5am_Ventures>,
        <https://1145.am/db/2313985/5am_Ventures>,
        <https://1145.am/db/2317919/5am_Ventures>,
        <https://1145.am/db/2318733/5am_Ventures>,
        <https://1145.am/db/2319784/5am_Ventures>,
        <https://1145.am/db/2323210/5am_Ventures>,
        <https://1145.am/db/2323226/5am_Ventures>,
        <https://1145.am/db/2328146/5am_Ventures>,
        <https://1145.am/db/2328338/5am_Ventures>,
        <https://1145.am/db/2329778/5am_Ventures>,
        <https://1145.am/db/2332322/5am_Ventures>,
        <https://1145.am/db/2339885/5am_Ventures>,
        <https://1145.am/db/2339886/5am_Ventures>,
        <https://1145.am/db/2340344/5am_Ventures>,
        <https://1145.am/db/2340345/5am_Ventures>,
        <https://1145.am/db/2340348/5am_Ventures>,
        <https://1145.am/db/2342352/5am_Ventures>,
        <https://1145.am/db/2349120/5am_Ventures>,
        <https://1145.am/db/2349834/5am_Ventures>,
        <https://1145.am/db/2351683/5am_Ventures>,
        <https://1145.am/db/2351684/5am_Ventures>,
        <https://1145.am/db/2355238/5am_Ventures>,
        <https://1145.am/db/2357858/5am_Ventures>,
        <https://1145.am/db/2359401/5am_Ventures>,
        <https://1145.am/db/2359864/5am_Ventures>,
        <https://1145.am/db/2360174/5am_Ventures>,
        <https://1145.am/db/2360415/5am_Ventures>,
        <https://1145.am/db/2362475/5am_Ventures>,
        <https://1145.am/db/2362481/5am_Ventures>,
        <https://1145.am/db/2364492/5am_Ventures>,
        <https://1145.am/db/2367275/5am_Ventures>,
        <https://1145.am/db/2370609/5am_Ventures>,
        <https://1145.am/db/2371160/5am_Ventures>,
        <https://1145.am/db/2538476/5am_Ventures>,
        <https://1145.am/db/2569220/5am_Ventures>,
        <https://1145.am/db/2572398/5am_Ventures>,
        <https://1145.am/db/2587596/5am_Ventures>,
        <https://1145.am/db/2592685/5am_Ventures>,
        <https://1145.am/db/359190/5am_Ventures>,
        <https://1145.am/db/428737/5am_Ventures>,
        <https://1145.am/db/558016/5am_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2341003/Pearl_Therapeutics_Inc> a org:Organization ;
    ns1:basedInHighGeoName "Redwood City" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5386834/about.rdf> ;
    ns1:basedInHighRaw "REDWOOD CITY, Calif." ;
    ns1:description "developing clinically differentiated combination therapies for the treatment of highly prevalent chronic respiratory diseases" ;
    ns1:documentDate "2010-10-19T14:00:23+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Pearl Therapeutics Raises $69 Million Series C Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/pearl-therapeutics-raises-69-million-series-c-financing> ;
    ns1:foundName "Pearl Therapeutics",
        "Pearl Therapeutics Inc." ;
    ns1:industry "Healthcare" ;
    ns1:name "Pearl Therapeutics",
        "Pearl Therapeutics Inc." ;
    ns1:sameAsHigh <https://1145.am/db/2302085/Pearl_Therapeutics>,
        <https://1145.am/db/2303563/Upstart_Pearl_Therapeutics>,
        <https://1145.am/db/2303581/Pearl_Therapeutics>,
        <https://1145.am/db/2306754/Pearl_Therapeutics>,
        <https://1145.am/db/2311595/Pearl_Therapeutics>,
        <https://1145.am/db/2331041/Pearl_Therapeutics_Inc>,
        <https://1145.am/db/2340097/Pearl_Therapeutics>,
        <https://1145.am/db/2341005/Pearl_Therapeutics>,
        <https://1145.am/db/2349118/Pearl_Therapeutics>,
        <https://1145.am/db/2349120/Pearl_Therapeutics_Inc>,
        <https://1145.am/db/2349678/Pearl_Therapeutics>,
        <https://1145.am/db/2350681/Pearl_Therapeutics>,
        <https://1145.am/db/2354978/Pearl_Therapeutics>,
        <https://1145.am/db/2362667/Pearl_Therapeutics>,
        <https://1145.am/db/2362670/Pearl_Therapeutics>,
        <https://1145.am/db/2363750/Pearl_Therapeutics>,
        <https://1145.am/db/2580556/Pearl_Therapeutics> ;
    ns1:sameAsMedium <https://1145.am/db/2305724/Pearl_Therapeutics> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2342488/Alta_Biopharma> a org:Organization ;
    ns1:basedInLowRaw "Conn" ;
    ns1:description "Biopharma" ;
    ns1:documentDate "2010-07-21T12:57:52+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Cara Therapeutics Secures $15 Million Series D Financing to Continue Clinical Development of CR845" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cara-therapeutics-secures-15-million-series-d-financing-to-continue-clinical-development-0> ;
    ns1:foundName "Alta Biopharma" ;
    ns1:investor <https://1145.am/db/2342488/Series_D_Investment_Alta_Biopharma_Ascent_Biomedical_Ventures_Ct_Innovations_Cara_Therapeutics_Devon_Park_Bioventures_Healthcare_Private_Equity_Mvm_Life_Science_Partners_Mitsubishi_International_Corporation_Rho_Ventures_Completed> ;
    ns1:name "Alta Biopharma" ;
    ns1:sameAsHigh <https://1145.am/db/1118932/Pharnext_Sa>,
        <https://1145.am/db/1139562/Scholar_Rock>,
        <https://1145.am/db/1143776/Scholar_Rock>,
        <https://1145.am/db/1354671/Scholar_Rock>,
        <https://1145.am/db/1391799/Pharnext>,
        <https://1145.am/db/1470827/Novadip_Biosciences>,
        <https://1145.am/db/1472245/Novadip_Biosciences>,
        <https://1145.am/db/1483506/Pharnext_Sa>,
        <https://1145.am/db/1488522/Scholar_Rock>,
        <https://1145.am/db/1536041/Pharnext_Sa>,
        <https://1145.am/db/1664021/Scholar_Rock>,
        <https://1145.am/db/1965327/Scholar_Rock>,
        <https://1145.am/db/2141367/Dompé>,
        <https://1145.am/db/2301832/Abraxis_Bioscience_Inc>,
        <https://1145.am/db/2329776/Biogen_Idec>,
        <https://1145.am/db/2336300/Braasch_Biotech>,
        <https://1145.am/db/2342498/Alta_Biopharma>,
        <https://1145.am/db/2358301/Biogen_Idec>,
        <https://1145.am/db/2536602/DPX>,
        <https://1145.am/db/2542068/Ucb>,
        <https://1145.am/db/2545133/Ucb>,
        <https://1145.am/db/2557995/Jhl_Biotech>,
        <https://1145.am/db/2578126/Biovest_International_Inc>,
        <https://1145.am/db/2586550/Ucb>,
        <https://1145.am/db/676610/Greenwich_Lifesciences_Inc>,
        <https://1145.am/db/720091/Pardes_Biosciences> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2342488/Ascent_Biomedical_Ventures> a org:Organization ;
    ns1:basedInLowRaw "Conn" ;
    ns1:description "Investing" ;
    ns1:documentDate "2010-07-21T12:57:52+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Cara Therapeutics Secures $15 Million Series D Financing to Continue Clinical Development of CR845" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cara-therapeutics-secures-15-million-series-d-financing-to-continue-clinical-development-0> ;
    ns1:foundName "Ascent Biomedical Ventures" ;
    ns1:investor <https://1145.am/db/2342488/Series_D_Investment_Alta_Biopharma_Ascent_Biomedical_Ventures_Ct_Innovations_Cara_Therapeutics_Devon_Park_Bioventures_Healthcare_Private_Equity_Mvm_Life_Science_Partners_Mitsubishi_International_Corporation_Rho_Ventures_Completed> ;
    ns1:name "Ascent Biomedical Ventures" ;
    ns1:sameAsHigh <https://1145.am/db/2303810/Ascent_Biomedical_Ventures>,
        <https://1145.am/db/2303814/Ascent_Biomedical_Ventures>,
        <https://1145.am/db/2310031/Ascent_Biomedical_Ventures>,
        <https://1145.am/db/2324354/Ascent_Biomedical_Ventures>,
        <https://1145.am/db/2342498/Ascent_Biomedical_Ventures> ;
    ns1:sameAsMedium <https://1145.am/db/2364853/Ascent_Biomedical_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2342488/Ct_Innovations> a org:Organization ;
    ns1:basedInLowRaw "Conn" ;
    ns1:description "Investing" ;
    ns1:documentDate "2010-07-21T12:57:52+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Cara Therapeutics Secures $15 Million Series D Financing to Continue Clinical Development of CR845" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cara-therapeutics-secures-15-million-series-d-financing-to-continue-clinical-development-0> ;
    ns1:foundName "CT Innovations" ;
    ns1:investor <https://1145.am/db/2342488/Series_D_Investment_Alta_Biopharma_Ascent_Biomedical_Ventures_Ct_Innovations_Cara_Therapeutics_Devon_Park_Bioventures_Healthcare_Private_Equity_Mvm_Life_Science_Partners_Mitsubishi_International_Corporation_Rho_Ventures_Completed> ;
    ns1:name "CT Innovations" ;
    ns1:sameAsHigh <https://1145.am/db/2342498/Ct_Innovations> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2342488/Devon_Park_Bioventures_Healthcare_Private_Equity> a org:Organization ;
    ns1:basedInLowRaw "Conn" ;
    ns1:description "Investing" ;
    ns1:documentDate "2010-07-21T12:57:52+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Cara Therapeutics Secures $15 Million Series D Financing to Continue Clinical Development of CR845" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cara-therapeutics-secures-15-million-series-d-financing-to-continue-clinical-development-0> ;
    ns1:foundName "Devon Park BioVentures",
        "Devon Park BioVentures, Healthcare Private Equity",
        "Healthcare Private Equity" ;
    ns1:investor <https://1145.am/db/2342488/Series_D_Investment_Alta_Biopharma_Ascent_Biomedical_Ventures_Ct_Innovations_Cara_Therapeutics_Devon_Park_Bioventures_Healthcare_Private_Equity_Mvm_Life_Science_Partners_Mitsubishi_International_Corporation_Rho_Ventures_Completed> ;
    ns1:name "Devon Park BioVentures",
        "Devon Park BioVentures, Healthcare Private Equity",
        "Healthcare Private Equity" ;
    ns1:sameAsHigh <https://1145.am/db/2342498/Devon_Park_Bioventures_Healthcare_Private_Equity> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2342488/Mitsubishi_International_Corporation> a org:Organization ;
    ns1:basedInLowRaw "Conn" ;
    ns1:description "Investing" ;
    ns1:documentDate "2010-07-21T12:57:52+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Cara Therapeutics Secures $15 Million Series D Financing to Continue Clinical Development of CR845" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cara-therapeutics-secures-15-million-series-d-financing-to-continue-clinical-development-0> ;
    ns1:foundName "Mitsubishi International Corporation" ;
    ns1:investor <https://1145.am/db/2342488/Series_D_Investment_Alta_Biopharma_Ascent_Biomedical_Ventures_Ct_Innovations_Cara_Therapeutics_Devon_Park_Bioventures_Healthcare_Private_Equity_Mvm_Life_Science_Partners_Mitsubishi_International_Corporation_Rho_Ventures_Completed> ;
    ns1:name "Mitsubishi International Corporation" ;
    ns1:sameAsHigh <https://1145.am/db/1087083/Mitsubishi_Corp>,
        <https://1145.am/db/1762967/Mitsubishi_Capital_Corporation>,
        <https://1145.am/db/2302351/Mitsubishi_Ufj_Capital>,
        <https://1145.am/db/2303802/Mitsubishi_Ufj_Capital_Co_Ltd>,
        <https://1145.am/db/2303810/Mitsubishi_International_Corporation>,
        <https://1145.am/db/2303814/Mitsubishi_International_Corporation>,
        <https://1145.am/db/2307644/Mitsubishi_International_Corporation>,
        <https://1145.am/db/2310031/Mitsubishi_International_Corporation>,
        <https://1145.am/db/2314400/Mitsubishi_International_Corporation>,
        <https://1145.am/db/2342498/Mitsubishi_International_Corporation> ;
    ns1:sameAsMedium <https://1145.am/db/2314397/Mitsubishi_International_Corporation> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2342488/Mvm_Life_Science_Partners> a org:Organization ;
    ns1:basedInLowRaw "Conn" ;
    ns1:description "Life Science" ;
    ns1:documentDate "2010-07-21T12:57:52+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Cara Therapeutics Secures $15 Million Series D Financing to Continue Clinical Development of CR845" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cara-therapeutics-secures-15-million-series-d-financing-to-continue-clinical-development-0> ;
    ns1:foundName "MVM Life Science Partners" ;
    ns1:industry "Life Science" ;
    ns1:investor <https://1145.am/db/2342488/Series_D_Investment_Alta_Biopharma_Ascent_Biomedical_Ventures_Ct_Innovations_Cara_Therapeutics_Devon_Park_Bioventures_Healthcare_Private_Equity_Mvm_Life_Science_Partners_Mitsubishi_International_Corporation_Rho_Ventures_Completed> ;
    ns1:name "MVM Life Science Partners" ;
    ns1:sameAsHigh <https://1145.am/db/2303810/Mvm_Life_Science_Partners>,
        <https://1145.am/db/2303814/Mvm_Life_Science_Partners>,
        <https://1145.am/db/2324034/Mvm_Life_Science_Partners_Llp>,
        <https://1145.am/db/2324855/Mvm_Life_Science_Partners>,
        <https://1145.am/db/2342498/Mvm_Life_Science_Partners>,
        <https://1145.am/db/2345273/Mvm_Life_Sciences_Partners> ;
    ns1:sameAsMedium <https://1145.am/db/2312874/Mvm_Life_Science_Partners>,
        <https://1145.am/db/2312876/Mvm_Life_Science_Partners>,
        <https://1145.am/db/2324354/Mvm_Life_Science_Partners>,
        <https://1145.am/db/2325376/Mvm_Life_Science_Partners>,
        <https://1145.am/db/2325549/Mvm_Life_Science_Partners_Llp>,
        <https://1145.am/db/2327982/Mvm_Life_Science_Partners>,
        <https://1145.am/db/2332748/Mvm_Life_Science_Partners>,
        <https://1145.am/db/2364517/Mvm_Life_Science_Partners_Llp> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2342488/Rho_Ventures> a org:Organization ;
    ns1:basedInLowRaw "Conn" ;
    ns1:documentDate "2010-07-21T12:57:52+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Cara Therapeutics Secures $15 Million Series D Financing to Continue Clinical Development of CR845" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cara-therapeutics-secures-15-million-series-d-financing-to-continue-clinical-development-0> ;
    ns1:foundName "Rho Ventures" ;
    ns1:investor <https://1145.am/db/2342488/Series_D_Investment_Alta_Biopharma_Ascent_Biomedical_Ventures_Ct_Innovations_Cara_Therapeutics_Devon_Park_Bioventures_Healthcare_Private_Equity_Mvm_Life_Science_Partners_Mitsubishi_International_Corporation_Rho_Ventures_Completed> ;
    ns1:name "Rho Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/1706416/Rho_Ventures>,
        <https://1145.am/db/1710930/Rho_Ventures>,
        <https://1145.am/db/1712520/Rho_Ventures>,
        <https://1145.am/db/1731187/Rho_Ventures>,
        <https://1145.am/db/1786612/Rho_Ventures>,
        <https://1145.am/db/1826683/Rho_Ventures>,
        <https://1145.am/db/1834943/Rho_Ventures>,
        <https://1145.am/db/1855403/Rho_Ventures>,
        <https://1145.am/db/1860832/Rho_Ventures>,
        <https://1145.am/db/1861355/Rho_Ventures>,
        <https://1145.am/db/1866478/Rho_Ventures>,
        <https://1145.am/db/1872936/Rho_Ventures>,
        <https://1145.am/db/1886354/Rho_Ventures>,
        <https://1145.am/db/1886445/Rho_Ventures>,
        <https://1145.am/db/1890208/Rho_Ventures>,
        <https://1145.am/db/1891490/Rho_Ventures>,
        <https://1145.am/db/2159775/Rho_Ventures>,
        <https://1145.am/db/2234358/Rho_Ventures>,
        <https://1145.am/db/2300708/Rho_Ventures>,
        <https://1145.am/db/2302351/Rho_Ventures>,
        <https://1145.am/db/2309506/Rho_Ventures>,
        <https://1145.am/db/2309507/Rho_Ventures>,
        <https://1145.am/db/2323578/Rho_Ventures>,
        <https://1145.am/db/2337971/Rho_Ventures>,
        <https://1145.am/db/2337972/Rho_Ventures>,
        <https://1145.am/db/2339883/Rho_Ventures>,
        <https://1145.am/db/2342485/Rho_Ventures>,
        <https://1145.am/db/2342498/Rho_Ventures>,
        <https://1145.am/db/2362902/Rho_Ventures>,
        <https://1145.am/db/2362909/Rho_Ventures>,
        <https://1145.am/db/2362910/Rho_Ventures>,
        <https://1145.am/db/2363459/Rho_Ventures>,
        <https://1145.am/db/2363460/Rho_Ventures>,
        <https://1145.am/db/2364505/Rho_Ventures>,
        <https://1145.am/db/2364508/Rho_Ventures>,
        <https://1145.am/db/2587938/Rho_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2342498/Alta_Biopharma> a org:Organization ;
    ns1:basedInLowRaw "Conn" ;
    ns1:description "Biopharma" ;
    ns1:documentDate "2010-07-21T15:31:17+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Cara Therapeutics Secures $15 Million Series D Financing to Continue Clinical Development of CR845" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cara-therapeutics-secures-15-million-series-d-financing-to-continue-clinical-development-of> ;
    ns1:foundName "Alta Biopharma" ;
    ns1:investor <https://1145.am/db/2342498/Series_D_Investment_Alta_Biopharma_Ascent_Biomedical_Ventures_Ct_Innovations_Cara_Therapeutics_Devon_Park_Bioventures_Healthcare_Private_Equity_Mvm_Life_Science_Partners_Mitsubishi_International_Corporation_Rho_Ventures_Completed> ;
    ns1:name "Alta Biopharma" ;
    ns1:sameAsHigh <https://1145.am/db/1118932/Pharnext_Sa>,
        <https://1145.am/db/1139562/Scholar_Rock>,
        <https://1145.am/db/1143776/Scholar_Rock>,
        <https://1145.am/db/1354671/Scholar_Rock>,
        <https://1145.am/db/1391799/Pharnext>,
        <https://1145.am/db/1470827/Novadip_Biosciences>,
        <https://1145.am/db/1472245/Novadip_Biosciences>,
        <https://1145.am/db/1483506/Pharnext_Sa>,
        <https://1145.am/db/1488522/Scholar_Rock>,
        <https://1145.am/db/1536041/Pharnext_Sa>,
        <https://1145.am/db/1664021/Scholar_Rock>,
        <https://1145.am/db/1965327/Scholar_Rock>,
        <https://1145.am/db/2141367/Dompé>,
        <https://1145.am/db/2301832/Abraxis_Bioscience_Inc>,
        <https://1145.am/db/2329776/Biogen_Idec>,
        <https://1145.am/db/2336300/Braasch_Biotech>,
        <https://1145.am/db/2342488/Alta_Biopharma>,
        <https://1145.am/db/2358301/Biogen_Idec>,
        <https://1145.am/db/2536602/DPX>,
        <https://1145.am/db/2542068/Ucb>,
        <https://1145.am/db/2545133/Ucb>,
        <https://1145.am/db/2557995/Jhl_Biotech>,
        <https://1145.am/db/2578126/Biovest_International_Inc>,
        <https://1145.am/db/2586550/Ucb>,
        <https://1145.am/db/676610/Greenwich_Lifesciences_Inc>,
        <https://1145.am/db/720091/Pardes_Biosciences> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2342498/Ascent_Biomedical_Ventures> a org:Organization ;
    ns1:basedInLowRaw "Conn" ;
    ns1:description "Investing" ;
    ns1:documentDate "2010-07-21T15:31:17+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Cara Therapeutics Secures $15 Million Series D Financing to Continue Clinical Development of CR845" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cara-therapeutics-secures-15-million-series-d-financing-to-continue-clinical-development-of> ;
    ns1:foundName "Ascent Biomedical Ventures" ;
    ns1:investor <https://1145.am/db/2342498/Series_D_Investment_Alta_Biopharma_Ascent_Biomedical_Ventures_Ct_Innovations_Cara_Therapeutics_Devon_Park_Bioventures_Healthcare_Private_Equity_Mvm_Life_Science_Partners_Mitsubishi_International_Corporation_Rho_Ventures_Completed> ;
    ns1:name "Ascent Biomedical Ventures" ;
    ns1:sameAsHigh <https://1145.am/db/2303810/Ascent_Biomedical_Ventures>,
        <https://1145.am/db/2303814/Ascent_Biomedical_Ventures>,
        <https://1145.am/db/2310031/Ascent_Biomedical_Ventures>,
        <https://1145.am/db/2324354/Ascent_Biomedical_Ventures>,
        <https://1145.am/db/2342488/Ascent_Biomedical_Ventures> ;
    ns1:sameAsMedium <https://1145.am/db/2364853/Ascent_Biomedical_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2342498/Ct_Innovations> a org:Organization ;
    ns1:basedInLowRaw "Conn" ;
    ns1:description "Investing" ;
    ns1:documentDate "2010-07-21T15:31:17+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Cara Therapeutics Secures $15 Million Series D Financing to Continue Clinical Development of CR845" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cara-therapeutics-secures-15-million-series-d-financing-to-continue-clinical-development-of> ;
    ns1:foundName "CT Innovations" ;
    ns1:investor <https://1145.am/db/2342498/Series_D_Investment_Alta_Biopharma_Ascent_Biomedical_Ventures_Ct_Innovations_Cara_Therapeutics_Devon_Park_Bioventures_Healthcare_Private_Equity_Mvm_Life_Science_Partners_Mitsubishi_International_Corporation_Rho_Ventures_Completed> ;
    ns1:name "CT Innovations" ;
    ns1:sameAsHigh <https://1145.am/db/2342488/Ct_Innovations> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2342498/Devon_Park_Bioventures_Healthcare_Private_Equity> a org:Organization ;
    ns1:basedInLowRaw "Conn" ;
    ns1:description "Investing" ;
    ns1:documentDate "2010-07-21T15:31:17+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Cara Therapeutics Secures $15 Million Series D Financing to Continue Clinical Development of CR845" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cara-therapeutics-secures-15-million-series-d-financing-to-continue-clinical-development-of> ;
    ns1:foundName "Devon Park BioVentures",
        "Devon Park BioVentures, Healthcare Private Equity",
        "Healthcare Private Equity" ;
    ns1:investor <https://1145.am/db/2342498/Series_D_Investment_Alta_Biopharma_Ascent_Biomedical_Ventures_Ct_Innovations_Cara_Therapeutics_Devon_Park_Bioventures_Healthcare_Private_Equity_Mvm_Life_Science_Partners_Mitsubishi_International_Corporation_Rho_Ventures_Completed> ;
    ns1:name "Devon Park BioVentures",
        "Devon Park BioVentures, Healthcare Private Equity",
        "Healthcare Private Equity" ;
    ns1:sameAsHigh <https://1145.am/db/2342488/Devon_Park_Bioventures_Healthcare_Private_Equity> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2342498/Mitsubishi_International_Corporation> a org:Organization ;
    ns1:basedInLowRaw "Conn" ;
    ns1:description "Investing" ;
    ns1:documentDate "2010-07-21T15:31:17+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Cara Therapeutics Secures $15 Million Series D Financing to Continue Clinical Development of CR845" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cara-therapeutics-secures-15-million-series-d-financing-to-continue-clinical-development-of> ;
    ns1:foundName "Mitsubishi International Corporation" ;
    ns1:investor <https://1145.am/db/2342498/Series_D_Investment_Alta_Biopharma_Ascent_Biomedical_Ventures_Ct_Innovations_Cara_Therapeutics_Devon_Park_Bioventures_Healthcare_Private_Equity_Mvm_Life_Science_Partners_Mitsubishi_International_Corporation_Rho_Ventures_Completed> ;
    ns1:name "Mitsubishi International Corporation" ;
    ns1:sameAsHigh <https://1145.am/db/1087083/Mitsubishi_Corp>,
        <https://1145.am/db/1762967/Mitsubishi_Capital_Corporation>,
        <https://1145.am/db/2302351/Mitsubishi_Ufj_Capital>,
        <https://1145.am/db/2303802/Mitsubishi_Ufj_Capital_Co_Ltd>,
        <https://1145.am/db/2303810/Mitsubishi_International_Corporation>,
        <https://1145.am/db/2303814/Mitsubishi_International_Corporation>,
        <https://1145.am/db/2307644/Mitsubishi_International_Corporation>,
        <https://1145.am/db/2310031/Mitsubishi_International_Corporation>,
        <https://1145.am/db/2314400/Mitsubishi_International_Corporation>,
        <https://1145.am/db/2342488/Mitsubishi_International_Corporation> ;
    ns1:sameAsMedium <https://1145.am/db/2314397/Mitsubishi_International_Corporation> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2342498/Mvm_Life_Science_Partners> a org:Organization ;
    ns1:basedInLowRaw "Conn" ;
    ns1:description "Life Science" ;
    ns1:documentDate "2010-07-21T15:31:17+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Cara Therapeutics Secures $15 Million Series D Financing to Continue Clinical Development of CR845" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cara-therapeutics-secures-15-million-series-d-financing-to-continue-clinical-development-of> ;
    ns1:foundName "MVM Life Science Partners" ;
    ns1:industry "Life Science" ;
    ns1:investor <https://1145.am/db/2342498/Series_D_Investment_Alta_Biopharma_Ascent_Biomedical_Ventures_Ct_Innovations_Cara_Therapeutics_Devon_Park_Bioventures_Healthcare_Private_Equity_Mvm_Life_Science_Partners_Mitsubishi_International_Corporation_Rho_Ventures_Completed> ;
    ns1:name "MVM Life Science Partners" ;
    ns1:sameAsHigh <https://1145.am/db/2303810/Mvm_Life_Science_Partners>,
        <https://1145.am/db/2303814/Mvm_Life_Science_Partners>,
        <https://1145.am/db/2324034/Mvm_Life_Science_Partners_Llp>,
        <https://1145.am/db/2324855/Mvm_Life_Science_Partners>,
        <https://1145.am/db/2342488/Mvm_Life_Science_Partners>,
        <https://1145.am/db/2345273/Mvm_Life_Sciences_Partners> ;
    ns1:sameAsMedium <https://1145.am/db/2312874/Mvm_Life_Science_Partners>,
        <https://1145.am/db/2312876/Mvm_Life_Science_Partners>,
        <https://1145.am/db/2324354/Mvm_Life_Science_Partners>,
        <https://1145.am/db/2325376/Mvm_Life_Science_Partners>,
        <https://1145.am/db/2325549/Mvm_Life_Science_Partners_Llp>,
        <https://1145.am/db/2327982/Mvm_Life_Science_Partners>,
        <https://1145.am/db/2332748/Mvm_Life_Science_Partners>,
        <https://1145.am/db/2364517/Mvm_Life_Science_Partners_Llp> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2342498/Rho_Ventures> a org:Organization ;
    ns1:basedInLowRaw "Conn" ;
    ns1:documentDate "2010-07-21T15:31:17+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Cara Therapeutics Secures $15 Million Series D Financing to Continue Clinical Development of CR845" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cara-therapeutics-secures-15-million-series-d-financing-to-continue-clinical-development-of> ;
    ns1:foundName "Rho Ventures" ;
    ns1:investor <https://1145.am/db/2342498/Series_D_Investment_Alta_Biopharma_Ascent_Biomedical_Ventures_Ct_Innovations_Cara_Therapeutics_Devon_Park_Bioventures_Healthcare_Private_Equity_Mvm_Life_Science_Partners_Mitsubishi_International_Corporation_Rho_Ventures_Completed> ;
    ns1:name "Rho Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/1706416/Rho_Ventures>,
        <https://1145.am/db/1710930/Rho_Ventures>,
        <https://1145.am/db/1712520/Rho_Ventures>,
        <https://1145.am/db/1731187/Rho_Ventures>,
        <https://1145.am/db/1786612/Rho_Ventures>,
        <https://1145.am/db/1826683/Rho_Ventures>,
        <https://1145.am/db/1834943/Rho_Ventures>,
        <https://1145.am/db/1855403/Rho_Ventures>,
        <https://1145.am/db/1860832/Rho_Ventures>,
        <https://1145.am/db/1861355/Rho_Ventures>,
        <https://1145.am/db/1866478/Rho_Ventures>,
        <https://1145.am/db/1872936/Rho_Ventures>,
        <https://1145.am/db/1886354/Rho_Ventures>,
        <https://1145.am/db/1886445/Rho_Ventures>,
        <https://1145.am/db/1890208/Rho_Ventures>,
        <https://1145.am/db/1891490/Rho_Ventures>,
        <https://1145.am/db/2159775/Rho_Ventures>,
        <https://1145.am/db/2234358/Rho_Ventures>,
        <https://1145.am/db/2300708/Rho_Ventures>,
        <https://1145.am/db/2302351/Rho_Ventures>,
        <https://1145.am/db/2309506/Rho_Ventures>,
        <https://1145.am/db/2309507/Rho_Ventures>,
        <https://1145.am/db/2323578/Rho_Ventures>,
        <https://1145.am/db/2337971/Rho_Ventures>,
        <https://1145.am/db/2337972/Rho_Ventures>,
        <https://1145.am/db/2339883/Rho_Ventures>,
        <https://1145.am/db/2342485/Rho_Ventures>,
        <https://1145.am/db/2342488/Rho_Ventures>,
        <https://1145.am/db/2362902/Rho_Ventures>,
        <https://1145.am/db/2362909/Rho_Ventures>,
        <https://1145.am/db/2362910/Rho_Ventures>,
        <https://1145.am/db/2363459/Rho_Ventures>,
        <https://1145.am/db/2363460/Rho_Ventures>,
        <https://1145.am/db/2364505/Rho_Ventures>,
        <https://1145.am/db/2364508/Rho_Ventures>,
        <https://1145.am/db/2587938/Rho_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2343486/Dov_Pharmaceutical> a org:Organization ;
    ns1:basedInLowRaw "CAMBRIDGE, Mass" ;
    ns1:documentDate "2010-07-22T13:15:02+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Euthymics Bioscience, Inc. Closes $24 Million Series A Financing and Completes Acquisition of DOV Pharmaceutical" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/euthymics-bioscience-inc-closes-24-million-series-a-financing-and-completes-acquisition-of> ;
    ns1:foundName "DOV Pharmaceutical" ;
    ns1:industry "Pharmaceutical" ;
    ns1:name "DOV Pharmaceutical" ;
    ns1:sameAsHigh <https://1145.am/db/2343493/Dov_Pharmaceutical> ;
    ns1:sameAsMedium <https://1145.am/db/2318984/Dov_Pharmaceuticals> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2343486/Euthymics_Bioscience> a org:Organization ;
    ns1:description "developing next-generation antidepressants" ;
    ns1:documentDate "2010-07-22T13:15:02+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Euthymics Bioscience, Inc. Closes $24 Million Series A Financing and Completes Acquisition of DOV Pharmaceutical" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/euthymics-bioscience-inc-closes-24-million-series-a-financing-and-completes-acquisition-of> ;
    ns1:foundName "Euthymics Bioscience, Inc." ;
    ns1:industry "pharmaceutical" ;
    ns1:name "Euthymics Bioscience" ;
    ns1:sameAsHigh <https://1145.am/db/2343493/Euthymics_Bioscience> ;
    ns1:sameAsMedium <https://1145.am/db/2354828/Euthymics_Bioscience> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2343486/Novartis_Venture_Funds> a org:Organization ;
    ns1:description "financing" ;
    ns1:documentDate "2010-07-22T13:15:02+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Euthymics Bioscience, Inc. Closes $24 Million Series A Financing and Completes Acquisition of DOV Pharmaceutical" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/euthymics-bioscience-inc-closes-24-million-series-a-financing-and-completes-acquisition-of> ;
    ns1:foundName "Novartis Venture Funds" ;
    ns1:investor <https://1145.am/db/2343486/Series_A_Investment_Euthymics_Bioscience_Gbs_Venture_Partners_Hambrecht___Quist_Capital_Management_Novartis_Venture_Funds_State_Of_Wisconsin_Investment_Board_Completed> ;
    ns1:name "Novartis Venture Funds" ;
    ns1:sameAsHigh <https://1145.am/db/1340338/Novartis_Venture_Fund>,
        <https://1145.am/db/2153726/Novartis_Venture_Fund_And_Partners_Innovation_Fund>,
        <https://1145.am/db/2297795/Novartis_Venture_Funds>,
        <https://1145.am/db/2306568/Novartis_Bioventure_Fund>,
        <https://1145.am/db/2310907/Novartis_Venture_Fund>,
        <https://1145.am/db/2313438/Novartis_Venture_Fund>,
        <https://1145.am/db/2317737/Novartis_Venture_Fund>,
        <https://1145.am/db/2323228/Novartis_Venture_Fund>,
        <https://1145.am/db/2323683/The_Novartis_Venture_Fund>,
        <https://1145.am/db/2324255/Novartis_Bioventures>,
        <https://1145.am/db/2326222/Novartis_Venture_Fund>,
        <https://1145.am/db/2327256/Novartis_Venture_Fund>,
        <https://1145.am/db/2327442/Novartis_Venture_Fund>,
        <https://1145.am/db/2330711/Novartis_Venture_Fund>,
        <https://1145.am/db/2331343/Novartis_Venture_Funds>,
        <https://1145.am/db/2331751/Novartis_Venture_Fund>,
        <https://1145.am/db/2332658/Novartis_Venture_Fund>,
        <https://1145.am/db/2332659/Novartis_Venture_Fund>,
        <https://1145.am/db/2335764/Novartis_Venture_Funds>,
        <https://1145.am/db/2339196/Novartis_Venture_Fund>,
        <https://1145.am/db/2340344/Novartis_Venture_Fund>,
        <https://1145.am/db/2340345/Novartis_Venture_Fund>,
        <https://1145.am/db/2340615/Novartis>,
        <https://1145.am/db/2343966/Novartis_Venture_Funds>,
        <https://1145.am/db/2344045/Novartis_Venture_Fund>,
        <https://1145.am/db/2352203/Novartis_Venture_Fund>,
        <https://1145.am/db/2352204/Novartis_Venture_Fund>,
        <https://1145.am/db/2354770/Novartis_Bioventures>,
        <https://1145.am/db/2356393/Novartis_Venture_Fund>,
        <https://1145.am/db/2356395/Novartis_Venture_Fund>,
        <https://1145.am/db/2356567/Novartis_Venture_Fund>,
        <https://1145.am/db/2358725/Novartis_Venture_Funds>,
        <https://1145.am/db/2361588/Novartis_Venture_Funds>,
        <https://1145.am/db/2363907/Novartis_Venture_Funds>,
        <https://1145.am/db/2369548/Novartis_Venture_Fund>,
        <https://1145.am/db/2575232/Novartis_Bioventures>,
        <https://1145.am/db/509733/Novartis_Venture_Fund>,
        <https://1145.am/db/619955/Novartis>,
        <https://1145.am/db/623985/Novartis>,
        <https://1145.am/db/866508/Novartis_Venture_Fund> ;
    ns1:sameAsMedium <https://1145.am/db/1523031/Novartis_Venture_Fund>,
        <https://1145.am/db/207823/Novartis_Venture_Fund>,
        <https://1145.am/db/2152422/Novartis_Venture_Fund>,
        <https://1145.am/db/2247240/Novartis_Venture_Funds>,
        <https://1145.am/db/2289983/Novartis_Venture_Funds>,
        <https://1145.am/db/2292300/Novartis_Venture_Funds>,
        <https://1145.am/db/2292345/Novartis_Venture_Funds>,
        <https://1145.am/db/2298176/Novartis_Venture_Fund>,
        <https://1145.am/db/2307682/Novartis_Venture_Fund>,
        <https://1145.am/db/2310905/Novartis_Venture_Fund>,
        <https://1145.am/db/2315943/Novartis_Venture_Fund>,
        <https://1145.am/db/2315957/Novartis_Venture_Fund>,
        <https://1145.am/db/2323210/Novartis_Venture_Funds>,
        <https://1145.am/db/2323682/The_Novartis_Venture_Fund>,
        <https://1145.am/db/2327441/Novartis_Venture_Fund>,
        <https://1145.am/db/2331750/Novartis_Venture_Fund>,
        <https://1145.am/db/2336032/Novartis_Venture_Fund>,
        <https://1145.am/db/2336328/Novartis_Venture_Funds>,
        <https://1145.am/db/2337294/Novartis_Venture_Funds>,
        <https://1145.am/db/2337645/Novartis_Venture_Fund>,
        <https://1145.am/db/2338527/Novartis_Venture_Funds>,
        <https://1145.am/db/2339193/Novartis_Venture_Fund>,
        <https://1145.am/db/2340612/Novartis_Venture_Fund>,
        <https://1145.am/db/2340942/Novartis_Venture_Fund>,
        <https://1145.am/db/2343493/Novartis_Venture_Funds>,
        <https://1145.am/db/2348012/Novartis_Venture_Fund>,
        <https://1145.am/db/2348348/Novartis_Venture_Funds>,
        <https://1145.am/db/2348350/Novartis_Venture_Funds>,
        <https://1145.am/db/2351958/Novartis_Venture_Funds>,
        <https://1145.am/db/2351959/Novartis_Venture_Fund>,
        <https://1145.am/db/2352216/Novartis_Venture_Fund>,
        <https://1145.am/db/2353098/Novartis_Venture_Fund>,
        <https://1145.am/db/2356287/Novartis_Venture_Fund>,
        <https://1145.am/db/2356290/Novartis_Venture_Fund>,
        <https://1145.am/db/2356391/Novartis_Venture_Fund>,
        <https://1145.am/db/2358430/Novartis_Venture_Funds>,
        <https://1145.am/db/2358733/Novartis_Venture_Fund>,
        <https://1145.am/db/2362715/Novartis_Venture_Funds>,
        <https://1145.am/db/2363510/Novartis_Venture_Funds>,
        <https://1145.am/db/2367046/Novartis_Venture_Fund>,
        <https://1145.am/db/2551315/Novartis_Venture_Fund>,
        <https://1145.am/db/2570481/Novartis_Venture_Fund>,
        <https://1145.am/db/2570483/Novartis_Venture_Fund>,
        <https://1145.am/db/2578837/Novartis_Venture_Funds>,
        <https://1145.am/db/2592611/Novartis_Venture_Funds> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2344565/Greenspring_Associates_Inc> a org:Organization ;
    ns1:basedInLowRaw "CALIF" ;
    ns1:documentDate "2010-07-27T18:54:24+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Tethys Raises $33 Million" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/tethys-raises-33-million-0> ;
    ns1:foundName "Associates, Inc.",
        "Greenspring Associates, Inc." ;
    ns1:investor <https://1145.am/db/2344565/Working_Capital_Investment_Greenspring_Associates_Inc_Greenspring_Associates_Inc_Oxford_Finance_Corporation_Paul_Capital_Investments_Tethys_Bioscience_Completed> ;
    ns1:name "Associates, Inc.",
        "Greenspring Associates, Inc." ;
    ns1:sameAsMedium <https://1145.am/db/1737723/Greenspring_Associates>,
        <https://1145.am/db/1744228/Greenspring_Associates>,
        <https://1145.am/db/1751506/Greenspring_Associates>,
        <https://1145.am/db/1760148/Greenspring_Associates>,
        <https://1145.am/db/1760399/Greenspring_Associates>,
        <https://1145.am/db/1762479/Greenspring_Associates>,
        <https://1145.am/db/1784596/Greenspring_Associates>,
        <https://1145.am/db/1788142/Greenspring_Associates>,
        <https://1145.am/db/1798788/Greenspring_Associates>,
        <https://1145.am/db/1806644/Greenspring_Associates>,
        <https://1145.am/db/1810769/Greenspring_Associates>,
        <https://1145.am/db/1818011/Greenspring_Associates>,
        <https://1145.am/db/1823460/Greenspring_Associates>,
        <https://1145.am/db/1828087/Greenspring_Associates>,
        <https://1145.am/db/1854807/Greenspring_Associates>,
        <https://1145.am/db/1881490/Greenspring_Associates>,
        <https://1145.am/db/2170734/Greenspring_Associates>,
        <https://1145.am/db/2188661/Greenspring_Associates>,
        <https://1145.am/db/2246652/Greenspring_Associates>,
        <https://1145.am/db/2310796/Greenspring_Associates>,
        <https://1145.am/db/2345549/Greenspring_Associates_Inc>,
        <https://1145.am/db/2443170/Greenspring_Associates>,
        <https://1145.am/db/2537417/Greenspring_Associates>,
        <https://1145.am/db/2648036/Greenspring_Associates>,
        <https://1145.am/db/336270/Greenspring_Associates>,
        <https://1145.am/db/410473/Greenspring_Associates>,
        <https://1145.am/db/487425/Greenspring_Associates>,
        <https://1145.am/db/559318/Greenspring_Associates>,
        <https://1145.am/db/583208/Greenspring_Associates> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2344565/Paul_Capital_Investments> a org:Organization ;
    ns1:basedInLowRaw "CALIF." ;
    ns1:documentDate "2010-07-27T18:54:24+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Tethys Raises $33 Million" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/tethys-raises-33-million-0> ;
    ns1:foundName "Paul Capital Investments" ;
    ns1:investor <https://1145.am/db/2344565/Working_Capital_Investment_Greenspring_Associates_Inc_Greenspring_Associates_Inc_Oxford_Finance_Corporation_Paul_Capital_Investments_Tethys_Bioscience_Completed> ;
    ns1:name "Paul Capital Investments" ;
    ns1:sameAsMedium <https://1145.am/db/2345549/Paul_Capital_Investments> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2345142/Galapagos_Nv> a org:Organization ;
    ns1:basedInLowRaw "Brazil" ;
    ns1:description "Pharmaceuticals" ;
    ns1:documentDate "2010-10-28T13:25:17+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Galapagos NV (GLPG.BR) Receives EUR 3.7 Million ($5.1 Million) Grant For Cystic Fibrosis Program" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/galapagos-nv-glpg-br-receives-eur-3-7-million-5-1-million-grant-for-cystic-fibrosis-program> ;
    ns1:foundName "Galapagos NV" ;
    ns1:industry "Pharmaceutical" ;
    ns1:name "Galapagos NV" ;
    ns1:sameAsHigh <https://1145.am/db/2155491/Galapagos>,
        <https://1145.am/db/2280515/Galapagos>,
        <https://1145.am/db/2283386/Galapagos>,
        <https://1145.am/db/2293342/Galapagos_And_Morphosys>,
        <https://1145.am/db/2317659/Galapagos_Nv>,
        <https://1145.am/db/2317663/Galapagos_Nv>,
        <https://1145.am/db/2322804/Galapagos_Nv>,
        <https://1145.am/db/2323866/Galapagos_Nv>,
        <https://1145.am/db/2324079/Galapagos>,
        <https://1145.am/db/2326457/Galapagos_Nv>,
        <https://1145.am/db/2328685/Galapagos>,
        <https://1145.am/db/2340805/Galapagos_Nv>,
        <https://1145.am/db/2346966/Galapagos_Nv>,
        <https://1145.am/db/2348686/Galapagos_Nv>,
        <https://1145.am/db/2348693/Galapagos>,
        <https://1145.am/db/2352289/Galapagos>,
        <https://1145.am/db/2353371/Galapagos>,
        <https://1145.am/db/2357258/Galapagos>,
        <https://1145.am/db/2358175/Galapagos_Nv>,
        <https://1145.am/db/2362738/Galapagos_Nv>,
        <https://1145.am/db/2368741/Galapagos>,
        <https://1145.am/db/2789255/Galapagos>,
        <https://1145.am/db/438906/Galapagos_Nv>,
        <https://1145.am/db/787864/Galapagos_Nv>,
        <https://1145.am/db/788935/Galapagos_Nv> ;
    ns1:sameAsMedium <https://1145.am/db/1600134/Galapagos>,
        <https://1145.am/db/2286742/Galapagos>,
        <https://1145.am/db/2317595/Galapagos>,
        <https://1145.am/db/2324243/Galapagos_Nv>,
        <https://1145.am/db/2326206/Galapagos_Nv>,
        <https://1145.am/db/2326367/Galapagos_Nv>,
        <https://1145.am/db/2330408/Galapagos>,
        <https://1145.am/db/2336737/Galapagos_Nv>,
        <https://1145.am/db/2339774/Galapagos>,
        <https://1145.am/db/2348324/Galapagos_Nv>,
        <https://1145.am/db/2348325/Galapagos_Nv>,
        <https://1145.am/db/2351315/Galapagos>,
        <https://1145.am/db/2358042/Galapagos_Nv>,
        <https://1145.am/db/2358075/Galapagos_Nv>,
        <https://1145.am/db/2370259/Galapagos> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2345549/Greenspring_Associates_Inc> a org:Organization ;
    ns1:basedInLowRaw "CALIF",
        "CALIF." ;
    ns1:description "venture financing" ;
    ns1:documentDate "2010-07-28T14:41:46+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Tethys Raises $33 Million" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/tethys-raises-33-million> ;
    ns1:foundName "Greenspring Associates, Inc",
        "Greenspring Associates, Inc.",
        "Inc." ;
    ns1:investor <https://1145.am/db/2345549/Working_Capital_Loan_Investment_Greenspring_Associates_Inc_Paul_Capital_Investments_Tethys_Bioscience_Completed> ;
    ns1:name "Greenspring Associates",
        "Greenspring Associates, Inc." ;
    ns1:sameAsHigh <https://1145.am/db/1087544/Greentrail_Capital>,
        <https://1145.am/db/1739053/Greenoaks>,
        <https://1145.am/db/1754580/Greenoaks_Capital>,
        <https://1145.am/db/1755672/Greenoaks_Capital>,
        <https://1145.am/db/1758075/Greenoaks_Capital>,
        <https://1145.am/db/1766059/Greenoaks_Capital>,
        <https://1145.am/db/1770982/Greenoaks_Capital>,
        <https://1145.am/db/2143283/Gotham_Green_Partners>,
        <https://1145.am/db/2186048/Greenoaks_Capital>,
        <https://1145.am/db/487425/Greenspring_Associates>,
        <https://1145.am/db/694325/Green_Egg_Ventures> ;
    ns1:sameAsMedium <https://1145.am/db/1737723/Greenspring_Associates>,
        <https://1145.am/db/1744228/Greenspring_Associates>,
        <https://1145.am/db/1751506/Greenspring_Associates>,
        <https://1145.am/db/1760148/Greenspring_Associates>,
        <https://1145.am/db/1760399/Greenspring_Associates>,
        <https://1145.am/db/1762479/Greenspring_Associates>,
        <https://1145.am/db/1784596/Greenspring_Associates>,
        <https://1145.am/db/1788142/Greenspring_Associates>,
        <https://1145.am/db/1798788/Greenspring_Associates>,
        <https://1145.am/db/1806644/Greenspring_Associates>,
        <https://1145.am/db/1810769/Greenspring_Associates>,
        <https://1145.am/db/1818011/Greenspring_Associates>,
        <https://1145.am/db/1823460/Greenspring_Associates>,
        <https://1145.am/db/1828087/Greenspring_Associates>,
        <https://1145.am/db/1854807/Greenspring_Associates>,
        <https://1145.am/db/1881490/Greenspring_Associates>,
        <https://1145.am/db/2170734/Greenspring_Associates>,
        <https://1145.am/db/2188661/Greenspring_Associates>,
        <https://1145.am/db/2246652/Greenspring_Associates>,
        <https://1145.am/db/2310796/Greenspring_Associates>,
        <https://1145.am/db/2344565/Greenspring_Associates_Inc>,
        <https://1145.am/db/2443170/Greenspring_Associates>,
        <https://1145.am/db/2537417/Greenspring_Associates>,
        <https://1145.am/db/2648036/Greenspring_Associates>,
        <https://1145.am/db/336270/Greenspring_Associates>,
        <https://1145.am/db/410473/Greenspring_Associates>,
        <https://1145.am/db/559318/Greenspring_Associates>,
        <https://1145.am/db/583208/Greenspring_Associates> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2345549/Paul_Capital_Investments> a org:Organization ;
    ns1:basedInLowRaw "CALIF." ;
    ns1:documentDate "2010-07-28T14:41:46+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Tethys Raises $33 Million" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/tethys-raises-33-million> ;
    ns1:foundName "Paul Capital Investments" ;
    ns1:investor <https://1145.am/db/2345549/Working_Capital_Loan_Investment_Greenspring_Associates_Inc_Paul_Capital_Investments_Tethys_Bioscience_Completed> ;
    ns1:name "Paul Capital Investments" ;
    ns1:sameAsMedium <https://1145.am/db/2344565/Paul_Capital_Investments> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2345603/Investment_Azimuth_Opportunity_Ltd_Omeros_Corporation_Has_Not_Happened> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-07-29T15:37:41+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Omeros Secures $ 40 Million Committed Equity Financing Facility.",
        "SEATTLE, July 29 /PRNewswire-FirstCall/ - Omeros Corporation (Nasdaq: OMER) today announced that it has secured a committed equity financing facility under which it may sell up to $ 40 million of its shares of common stock to Azimuth Opportunity, Ltd. (the \"investor\") over a 24-month period." ;
    ns1:documentTitle "Omeros Secures $40 Million Committed Equity Financing Facility" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/omeros-secures-40-million-committed-equity-financing-facility> ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "has not happened" ;
    ns1:target <https://1145.am/db/2345603/Omeros_Corporation> ;
    ns1:valueRaw "$ 40 Million" ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "United States" .

<https://1145.am/db/2345603/Omeros_Corporation> a org:Organization ;
    ns1:basedInLowRaw "SEATTLE" ;
    ns1:description "equity, debt and non-dilutive financing transactions" ;
    ns1:documentDate "2010-07-29T15:37:41+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Omeros Secures $40 Million Committed Equity Financing Facility" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/omeros-secures-40-million-committed-equity-financing-facility> ;
    ns1:foundName "Omeros",
        "Omeros Corporation" ;
    ns1:name "Omeros",
        "Omeros Corporation" ;
    ns1:sameAsMedium <https://1145.am/db/1044548/Omeros_Corporation>,
        <https://1145.am/db/2340002/Omeros_Corporation>,
        <https://1145.am/db/2344891/Omeros_Corporation>,
        <https://1145.am/db/2345604/Omeros>,
        <https://1145.am/db/2345919/Omeros_Corporation>,
        <https://1145.am/db/2353442/Omeros_Corporation>,
        <https://1145.am/db/2358388/Omeros_Corporation>,
        <https://1145.am/db/2362762/Omeros_Corporation>,
        <https://1145.am/db/2364983/Omeros_Corporation>,
        <https://1145.am/db/2507234/Omeros_Corporation>,
        <https://1145.am/db/665867/Omeros_Corporation>,
        <https://1145.am/db/714051/Omeros_Corporation>,
        <https://1145.am/db/717072/Omeros_Corporation>,
        <https://1145.am/db/868684/Omeros_Corporation>,
        <https://1145.am/db/869140/Omeros_Corporation> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2346187/Allon_Therapeutics_Inc> a org:Organization ;
    ns1:basedInHighGeoName "Vancouver" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/6173331/about.rdf> ;
    ns1:basedInHighRaw "VANCOUVER, BRITISH COLUMBIA" ;
    ns1:basedInLowRaw "Canada" ;
    ns1:description "Pharmaceuticals",
        "pharmaceutical" ;
    ns1:documentDate "2010-11-01T15:06:01+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Allon Completes U.S. $10 Million Financing Agreement with Nordic Biotech Entity" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/allon-completes-u-s-10-million-financing-agreement-nordic-biotech-entity> ;
    ns1:foundName "Allon",
        "Allon Therapeutics Inc.",
        "Allon U." ;
    ns1:industry "Biotech",
        "Pharma" ;
    ns1:name "Allon",
        "Allon Therapeutics Inc." ;
    ns1:sameAsHigh <https://1145.am/db/2151922/Allogene_Therapeutics>,
        <https://1145.am/db/2320503/Allecra_Therapeutics> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2346187/Allon_Us> a org:Organization ;
    ns1:basedInLowRaw "U.S." ;
    ns1:documentDate "2010-11-01T15:06:01+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Allon Completes U.S. $10 Million Financing Agreement with Nordic Biotech Entity" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/allon-completes-u-s-10-million-financing-agreement-nordic-biotech-entity> ;
    ns1:foundName "Allon U.S." ;
    ns1:name "Allon U.S." ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2346187/Investment_Allon_Us_Isar_Pharma_K_S_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-11-01T15:06:01+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Isar Pharma K/S, has paid Allon U.S. $ 10 million (Cdn $ 10.2 million) in return for a convertible royalty and revenue obligation on davunetide." ;
    ns1:documentTitle "Allon Completes U.S. $10 Million Financing Agreement with Nordic Biotech Entity" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/allon-completes-u-s-10-million-financing-agreement-nordic-biotech-entity> ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2346187/Allon_Us> ;
    ns1:valueRaw "$ 10 million",
        "Cdn $ 10.2 million" ;
    ns1:whereGeoName "Vancouver" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6173331/about.rdf> ;
    ns1:whereRaw "VANCOUVER, BRITISH COLUMBIA" .

<https://1145.am/db/2346644/Investment_Shire_Plc_Has_Not_Happened> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-08-03T13:01:54+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Shire to Add Newly-Launched RESOLOR (R) and a Promising GI Pipeline to its GI Business Through Proposed Recommended Cash Acquisition of Movetis NV." ;
    ns1:documentTitle "Shire Proposes to Expand Specialist Gastrointestinal Portfolio" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/shire-proposes-to-expand-specialist-gastrointestinal-portfolio> ;
    ns1:foundName "Acquisition" ;
    ns1:name "Acquisition" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "has not happened" ;
    ns1:whereGeoName "Sherē Āwraja" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/328591/about.rdf> ;
    ns1:whereRaw "Shire" .

<https://1145.am/db/2346644/Movetis> a org:Organization ;
    ns1:basedInLowRaw "NV" ;
    ns1:description "research and development" ;
    ns1:documentDate "2010-08-03T13:01:54+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Shire Proposes to Expand Specialist Gastrointestinal Portfolio" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/shire-proposes-to-expand-specialist-gastrointestinal-portfolio> ;
    ns1:foundName "Movetis NV" ;
    ns1:industry "pharmaceutical" ;
    ns1:name "Movetis" ;
    ns1:sameAsHigh <https://1145.am/db/2346640/Movetis>,
        <https://1145.am/db/2346646/Movetis_Nv>,
        <https://1145.am/db/2551566/Moventig>,
        <https://1145.am/db/2551574/Moventig>,
        <https://1145.am/db/2588152/Movetis> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2346644/Movetis_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition",
        "merger" ;
    ns1:documentDate "2010-08-03T13:01:54+00:00"^^xsd:dateTime ;
    ns1:documentExtract "DUBLIN, August 3, 2010 /PRNewswire-FirstCall/ - - Proposed recommended cash acquisition of specialty gastrointestinal (GI) company Movetis NV for a fully diluted equity purchase price of EUR428 million in cash.",
        "Shire plc (LSE: SHP, NASDAQ: SHPGY) , the global specialty biopharmaceutical company, announces that a Luxembourg incorporated wholly - owned subsidiary of Shire plc will launch a voluntary public take over offer for all the shares in Movetis NV, the Belgium - based European specialty gastrointestinal (GI) company." ;
    ns1:documentTitle "Shire Proposes to Expand Specialist Gastrointestinal Portfolio" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/shire-proposes-to-expand-specialist-gastrointestinal-portfolio> ;
    ns1:foundName "acquisition",
        "public take over",
        "take over" ;
    ns1:name "acquisition",
        "public take over",
        "take over" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "has not happened" ;
    ns1:target <https://1145.am/db/2346644/Movetis> ;
    ns1:targetName "Movetis" ;
    ns1:valueRaw "EUR428 million" ;
    ns1:whereGeoName "Dublin" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/2964574/about.rdf> ;
    ns1:whereRaw "DUBLIN" .

<https://1145.am/db/2347207/Synavive> a org:Organization ;
    ns1:basedInHighGeoName "Cambridgeshire" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2653940/about.rdf> ;
    ns1:basedInHighRaw "CAMBRIDGE" ;
    ns1:description "rheumatoid arthritis" ;
    ns1:documentDate "2010-11-02T14:22:53+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Zalicus Awarded $244,000 Therapeutic Discovery Project Grant" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/zalicus-awarded-244-000-therapeutic-discovery-project-grant> ;
    ns1:foundName "Synavive" ;
    ns1:name "Synavive" ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2347207/Zalicus_Inc> a org:Organization ;
    ns1:basedInHighGeoName "Cambridge" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/4931972/about.rdf> ;
    ns1:basedInHighRaw "CAMBRIDGE, Mass." ;
    ns1:description "Pain and immuno-inflammatory disease" ;
    ns1:documentDate "2010-11-02T14:22:53+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Zalicus Awarded $244,000 Therapeutic Discovery Project Grant" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/zalicus-awarded-244-000-therapeutic-discovery-project-grant> ;
    ns1:foundName "Zalicus",
        "Zalicus Inc" ;
    ns1:name "Zalicus",
        "Zalicus Inc" ;
    ns1:sameAsMedium <https://1145.am/db/2347211/Zalicus>,
        <https://1145.am/db/2355286/Zalicus_Inc>,
        <https://1145.am/db/2364492/Zalicus> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2347626/Investment_Qiming_Ventures_Sangon___Bio_Basic_Inc_Sangon_Biotech_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-08-03T15:43:54+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Closes $ 10 Million Round of Investment by Qiming Ventures.",
        "SHANGHAI, Aug. 3 /PRNewswire-Asia/ - Sangon Biotech, a Shanghai based life science research service company, and Bio Basic Inc. (BBI) , a Toronto based life science research service company, announced today the completion of a $ 10 million round of funding from Qiming Ventures.",
        "Sangon & Bio Basic Inc. Closes $ 10 Million Round of Investment by Qiming Ventures." ;
    ns1:documentTitle "Sangon & Bio Basic Inc. Closes $10 Million Round of Investment by Qiming Ventures" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/sangon-bio-basic-inc-closes-10-million-round-of-investment-by-qiming-ventures> ;
    ns1:foundName "Investment",
        "funding" ;
    ns1:name "Investment",
        "funding" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2347626/Sangon_Biotech>,
        <https://1145.am/db/2347626/Sangon___Bio_Basic_Inc> ;
    ns1:valueRaw "$ 10 Million",
        "$ 10 million" ;
    ns1:when "2010-08-03T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "Aug. 3" ;
    ns1:whereGeoName "People’s Republic of China" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/1814991/about.rdf> ;
    ns1:whereRaw "China" .

<https://1145.am/db/2348232/Portfolio_Acquisition_Richter_Richter_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition" ;
    ns1:documentDate "2010-11-03T14:33:44+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Richter Acquires Grünenthal's Oral Contraceptive Portfolio." ;
    ns1:documentTitle "Richter Acquires Grünenthal's Oral Contraceptive Portfolio" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/richter-acquires-gr%C3%BCnenthal-s-oral-contraceptive-portfolio> ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:targetDetails "Portfolio" ;
    ns1:vendor <https://1145.am/db/2348232/Richter> ;
    ns1:when "2010-11-03T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "11/3/2010" .

<https://1145.am/db/2348674/Gemin_X_Pharmaceuticals> a org:Organization ;
    ns1:documentDate "2010-08-05T15:28:11+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Gemin X raises $8M for cancer R&D; Bruce Montgomery ready to open a new chapter in biotech career;" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/gemin-x-raises-8m-for-cancer-r-d-bruce-montgomery-ready-to-open-a-new-chapter-biotech> ;
    ns1:foundName "Gemin X Pharmaceuticals" ;
    ns1:industry "Pharmaceuticals" ;
    ns1:name "Gemin X Pharmaceuticals" ;
    ns1:sameAsHigh <https://1145.am/db/2251983/Gemin_X_Pharmaceuticals>,
        <https://1145.am/db/2303172/Gemin_X_Pharmaceuticals>,
        <https://1145.am/db/2305688/Gemin_X_Pharmaceuticals>,
        <https://1145.am/db/2305703/Gemin_X_Pharmaceuticals>,
        <https://1145.am/db/2338474/Gemin_X>,
        <https://1145.am/db/2339554/Gemmus_Pharma_Inc>,
        <https://1145.am/db/2343704/Gemin_X_Pharmaceuticals>,
        <https://1145.am/db/2343706/Gemin_X_Pharmaceuticals>,
        <https://1145.am/db/2358020/Gemin_X>,
        <https://1145.am/db/2358023/Gemin_X_Pharmaceuticals>,
        <https://1145.am/db/2589829/Gemmus_Pharma_Inc> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2349717/Hatteras_Venture_Partners> a org:Organization ;
    ns1:basedInLowRaw "Pa" ;
    ns1:documentDate "2010-08-10T15:41:02+00:00"^^xsd:dateTime ;
    ns1:documentTitle "TetraLogic Pharmaceuticals Completes $32 Million Series C Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/tetralogic-pharmaceuticals-completes-32-million-series-c-financing> ;
    ns1:foundName "Hatteras Venture Partners" ;
    ns1:investor <https://1145.am/db/2349717/Series_C_Investment_Amgen_Ventures_Clarus_Ventures_Hatteras_Venture_Partners_Healthcare_Ventures_Latterell_Venture_Partners_Novitas_Capital_Quaker_Bioventures_Tetralogic_Pharmaceuticals_Vertical_Group_Completed> ;
    ns1:name "Hatteras Venture Partners" ;
    ns1:sameAsMedium <https://1145.am/db/1115103/Hatteras_Venture_Partners>,
        <https://1145.am/db/1335370/Hatteras_Venture_Partners>,
        <https://1145.am/db/1464210/Hatteras_Venture_Partners>,
        <https://1145.am/db/1465033/Hatteras_Venture_Partners>,
        <https://1145.am/db/1565424/Hatteras_Venture_Partners>,
        <https://1145.am/db/1896251/Hatteras_Venture_Partners>,
        <https://1145.am/db/1957179/Hatteras_Venture_Partners>,
        <https://1145.am/db/2153141/Hatteras_Venture_Partners>,
        <https://1145.am/db/2224522/Hatteras_Venture_Partners>,
        <https://1145.am/db/2236817/Hatteras_Venture_Partners>,
        <https://1145.am/db/2284028/Hatteras_Venture_Partners>,
        <https://1145.am/db/2306163/Hatteras_Venture_Partners>,
        <https://1145.am/db/2315247/Hatteras_Venture_Partners>,
        <https://1145.am/db/2315248/Hatteras_Venture_Partners>,
        <https://1145.am/db/2319640/Hatteras_Venture_Partners>,
        <https://1145.am/db/2321694/Hatteras_Venture_Partners>,
        <https://1145.am/db/2323511/Hatteras_Venture_Partners>,
        <https://1145.am/db/2328194/Hatteras_Venture_Partners>,
        <https://1145.am/db/2328196/Hatteras_Venture_Partners>,
        <https://1145.am/db/2332459/Hatteras_Venture_Partners>,
        <https://1145.am/db/2339206/Hatteras_Venture_Partners>,
        <https://1145.am/db/2349722/Hatteras_Venture_Partners>,
        <https://1145.am/db/2351316/Hatteras_Venture_Partners>,
        <https://1145.am/db/2353640/Hatteras_Venture_Partners>,
        <https://1145.am/db/2353671/Hatteras_Venture_Partners>,
        <https://1145.am/db/2353674/Hatteras_Venture_Partners>,
        <https://1145.am/db/2354648/Hatteras_Venture_Partners>,
        <https://1145.am/db/2358640/Hatteras_Venture_Partners>,
        <https://1145.am/db/2358657/Hatteras_Venture_Partners>,
        <https://1145.am/db/2358658/Hatteras_Venture_Partners>,
        <https://1145.am/db/2358812/Hatteras_Venture_Partners>,
        <https://1145.am/db/2359452/Hatteras_Venture_Partners>,
        <https://1145.am/db/2360521/Hatteras_Venture_Partners>,
        <https://1145.am/db/2360526/Hatteras_Venture_Partners>,
        <https://1145.am/db/2363396/Hatteras_Venture_Partners>,
        <https://1145.am/db/2363442/Hatteras_Venture_Partners>,
        <https://1145.am/db/2364853/Hatteras_Venture_Partners>,
        <https://1145.am/db/2365171/Hatteras_Venture_Partners>,
        <https://1145.am/db/495996/Hatteras_Venture_Partners>,
        <https://1145.am/db/496377/Hatteras_Venture_Partners>,
        <https://1145.am/db/601404/Hatteras_Venture_Partners>,
        <https://1145.am/db/885068/Hatteras_Venture_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2349717/Latterell_Venture_Partners> a org:Organization ;
    ns1:basedInLowRaw "Pa" ;
    ns1:description "financing" ;
    ns1:documentDate "2010-08-10T15:41:02+00:00"^^xsd:dateTime ;
    ns1:documentTitle "TetraLogic Pharmaceuticals Completes $32 Million Series C Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/tetralogic-pharmaceuticals-completes-32-million-series-c-financing> ;
    ns1:foundName "Latterell Venture Partners" ;
    ns1:investor <https://1145.am/db/2349717/Series_C_Investment_Amgen_Ventures_Clarus_Ventures_Hatteras_Venture_Partners_Healthcare_Ventures_Latterell_Venture_Partners_Novitas_Capital_Quaker_Bioventures_Tetralogic_Pharmaceuticals_Vertical_Group_Completed> ;
    ns1:name "Latterell Venture Partners" ;
    ns1:sameAsHigh <https://1145.am/db/2308828/Latterell_Venture_Partners>,
        <https://1145.am/db/2308841/Latterell_Venture_Partners>,
        <https://1145.am/db/2319658/Latterell_Venture_Partners>,
        <https://1145.am/db/2319874/Latterell_Venture_Partners_Us_Venture_Partners>,
        <https://1145.am/db/2357487/Latterell_Venture_Partners>,
        <https://1145.am/db/2365171/Latterell_Venture_Partners> ;
    ns1:sameAsMedium <https://1145.am/db/2223193/Latterell_Venture_Partners>,
        <https://1145.am/db/2257512/Latterell_Venture_Partners>,
        <https://1145.am/db/2312120/Latterell_Venture_Partners>,
        <https://1145.am/db/2324226/Latterell_Venture_Partners>,
        <https://1145.am/db/2329531/Latterell_Venture_Partners>,
        <https://1145.am/db/2341068/Latterell_Venture_Partners>,
        <https://1145.am/db/2341074/Latterell_Venture_Partners>,
        <https://1145.am/db/2345568/Latterell_Venture_Partners>,
        <https://1145.am/db/2349722/Latterell_Venture_Partners>,
        <https://1145.am/db/2366693/Latterell_Venture_Partners>,
        <https://1145.am/db/2366700/Latterell_Venture_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2349717/Novitas_Capital> a org:Organization ;
    ns1:basedInLowRaw "Pa" ;
    ns1:description "financing" ;
    ns1:documentDate "2010-08-10T15:41:02+00:00"^^xsd:dateTime ;
    ns1:documentTitle "TetraLogic Pharmaceuticals Completes $32 Million Series C Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/tetralogic-pharmaceuticals-completes-32-million-series-c-financing> ;
    ns1:foundName "Novitas Capital" ;
    ns1:investor <https://1145.am/db/2349717/Series_C_Investment_Amgen_Ventures_Clarus_Ventures_Hatteras_Venture_Partners_Healthcare_Ventures_Latterell_Venture_Partners_Novitas_Capital_Quaker_Bioventures_Tetralogic_Pharmaceuticals_Vertical_Group_Completed> ;
    ns1:name "Novitas Capital" ;
    ns1:sameAsHigh <https://1145.am/db/2365171/Novitas_Capital> ;
    ns1:sameAsMedium <https://1145.am/db/2331048/Novitas_Capital>,
        <https://1145.am/db/2349722/Novitas_Capital>,
        <https://1145.am/db/2358271/Novitas_Capital>,
        <https://1145.am/db/2358272/Novitas_Capital>,
        <https://1145.am/db/2363475/Novitas_Capital> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2349717/Vertical_Group> a org:Organization ;
    ns1:basedInLowRaw "Pa" ;
    ns1:description "financing" ;
    ns1:documentDate "2010-08-10T15:41:02+00:00"^^xsd:dateTime ;
    ns1:documentTitle "TetraLogic Pharmaceuticals Completes $32 Million Series C Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/tetralogic-pharmaceuticals-completes-32-million-series-c-financing> ;
    ns1:foundName "the Vertical Group" ;
    ns1:investor <https://1145.am/db/2349717/Series_C_Investment_Amgen_Ventures_Clarus_Ventures_Hatteras_Venture_Partners_Healthcare_Ventures_Latterell_Venture_Partners_Novitas_Capital_Quaker_Bioventures_Tetralogic_Pharmaceuticals_Vertical_Group_Completed> ;
    ns1:name "Vertical Group" ;
    ns1:sameAsHigh <https://1145.am/db/2050254/Vertical_Group> ;
    ns1:sameAsMedium <https://1145.am/db/2278799/Vertical_Group>,
        <https://1145.am/db/2349722/Vertical_Group>,
        <https://1145.am/db/2365171/Vertical_Group> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352382/Biomedinvest> a org:Organization ;
    ns1:basedInLowRaw "Swiss" ;
    ns1:description "venture capital firms in the biotech industry" ;
    ns1:documentDate "2010-11-12T14:21:30+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Delenex Therapeutics Secures CHF 13.5 Million Series A Venture Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/delenex-therapeutics-secures-chf-13-5-million-series-a-venture-financing> ;
    ns1:foundName "BioMedInvest" ;
    ns1:investor <https://1145.am/db/2352382/Series_A_Investment_Biomedinvest_Delenex_Therapeutics_Ag_Hbm_Biocapital_Hbm_Bioventures_Sv_Life_Sciences_Vi_Partners_Completed> ;
    ns1:name "BioMedInvest" ;
    ns1:sameAsHigh <https://1145.am/db/1223133/Bioadvance>,
        <https://1145.am/db/1223149/Bioadvance>,
        <https://1145.am/db/1422234/Forbion_Ventures>,
        <https://1145.am/db/1422725/Forbion_Ventures>,
        <https://1145.am/db/1867543/Tpg_Biotech>,
        <https://1145.am/db/1926411/Bioqube_Ventures>,
        <https://1145.am/db/1990861/Bioqube_Ventures>,
        <https://1145.am/db/2060484/Healthtech_Capital>,
        <https://1145.am/db/2155146/Biomatics_Capital_Partners>,
        <https://1145.am/db/2280492/Biovision_Ventures>,
        <https://1145.am/db/2285038/Time_Bioventures>,
        <https://1145.am/db/2286671/Forbion>,
        <https://1145.am/db/2298954/Biossom_Investment_Management>,
        <https://1145.am/db/2298978/Advent_Life_Sciences>,
        <https://1145.am/db/2301741/Bio_*_One_Capital>,
        <https://1145.am/db/2301792/Fonds_Bio-Innovation_Sec>,
        <https://1145.am/db/2302351/Medimmune_Ventures>,
        <https://1145.am/db/2305587/Medimmune_Ventures>,
        <https://1145.am/db/2309840/Bio_Fund>,
        <https://1145.am/db/2310285/Medventure_Associates>,
        <https://1145.am/db/2313322/Biomedinvest>,
        <https://1145.am/db/2313322/Hbm_Bioventures>,
        <https://1145.am/db/2313401/Biogen_Idec_New_Ventures>,
        <https://1145.am/db/2313438/Biomedinvest>,
        <https://1145.am/db/2313438/Hbm_Biocapital>,
        <https://1145.am/db/2313438/Hbm_Bioventures>,
        <https://1145.am/db/2313438/Sv_Life_Sciences>,
        <https://1145.am/db/2314400/Hbm_Biocapital>,
        <https://1145.am/db/2314515/Sv_Life_Sciences>,
        <https://1145.am/db/2314573/Avlar_Bioventures>,
        <https://1145.am/db/2316709/Bioadvance_Ventures>,
        <https://1145.am/db/2317737/Mc_Life_Sciences_Ventures>,
        <https://1145.am/db/2317779/Bio_*_One_Capital>,
        <https://1145.am/db/2319360/Medimmune_Ventures>,
        <https://1145.am/db/2321097/Healthcare_Ventures>,
        <https://1145.am/db/2323785/Medimmune_Ventures>,
        <https://1145.am/db/2324015/Medsciences_Capital>,
        <https://1145.am/db/2324195/Lotus_Bioscience_Ventures>,
        <https://1145.am/db/2325831/Bb_Biotech>,
        <https://1145.am/db/2325831/Hbm_Bioventures>,
        <https://1145.am/db/2336109/Biomed_Ventures>,
        <https://1145.am/db/2338673/Hopen_Life_Science_Ventures>,
        <https://1145.am/db/2339295/Biomedinvest>,
        <https://1145.am/db/2345037/Biomed_Ventures>,
        <https://1145.am/db/2347571/Advent_Life_Sciences>,
        <https://1145.am/db/2352633/Advanced_Biotechnologies_Venture_Fund>,
        <https://1145.am/db/2354295/Biomed_Ventures>,
        <https://1145.am/db/2359240/Frontline_Bioventures>,
        <https://1145.am/db/2364853/Medimmune_Ventures>,
        <https://1145.am/db/2365171/Healthcare_Ventures>,
        <https://1145.am/db/2366049/Biomed_Ventures>,
        <https://1145.am/db/2366055/Biomed_Ventures>,
        <https://1145.am/db/2366133/Biopacificventures>,
        <https://1145.am/db/2368251/Sv_Life_Sciences>,
        <https://1145.am/db/2369916/Biomed_Ventures>,
        <https://1145.am/db/363714/Palliare>,
        <https://1145.am/db/564585/Bioqube_Ventures>,
        <https://1145.am/db/566971/Bioqube_Ventures>,
        <https://1145.am/db/684123/Biourja_Ventures>,
        <https://1145.am/db/938108/Bioeconomy_Capital>,
        <https://1145.am/db/971939/I___I_Biotech_Fund>,
        <https://1145.am/db/975114/I___I_Biotech_Fund> ;
    ns1:sameAsMedium <https://1145.am/db/2293270/Biomedinvest_Ag>,
        <https://1145.am/db/2298049/Biomedinvest_Ag>,
        <https://1145.am/db/2299180/Biomedinvest>,
        <https://1145.am/db/2307886/Biomedinvest_Ag>,
        <https://1145.am/db/2310922/Biomedinvest>,
        <https://1145.am/db/2318778/Biomedinvest>,
        <https://1145.am/db/2331946/Biomedinvest>,
        <https://1145.am/db/2332658/Biomedinvest>,
        <https://1145.am/db/2332659/Biomedinvest>,
        <https://1145.am/db/2337043/Biomedinvest>,
        <https://1145.am/db/2360125/Biomedinvest>,
        <https://1145.am/db/2360127/Biomedinvest> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352382/Delenex_Therapeutics_Ag> a org:Organization ;
    ns1:basedInHighGeoName "Switzerland" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2658434/about.rdf> ;
    ns1:basedInHighRaw "Switzerland" ;
    ns1:basedInLowRaw "Switzerland" ;
    ns1:description "Biotech" ;
    ns1:documentDate "2010-11-12T14:21:30+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Delenex Therapeutics Secures CHF 13.5 Million Series A Venture Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/delenex-therapeutics-secures-chf-13-5-million-series-a-venture-financing> ;
    ns1:foundName "Delenex Therapeutics",
        "Delenex Therapeutics AG" ;
    ns1:industry "biotech" ;
    ns1:name "Delenex Therapeutics",
        "Delenex Therapeutics AG" ;
    ns1:sameAsHigh <https://1145.am/db/2339296/Delenex_Therapeutics>,
        <https://1145.am/db/2559306/Delpharm> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352382/Hbm_Biocapital> a org:Organization ;
    ns1:basedInLowRaw "Swiss" ;
    ns1:description "venture capital firms in the biotech industry" ;
    ns1:documentDate "2010-11-12T14:21:30+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Delenex Therapeutics Secures CHF 13.5 Million Series A Venture Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/delenex-therapeutics-secures-chf-13-5-million-series-a-venture-financing> ;
    ns1:foundName "HBM BioCapital" ;
    ns1:industry "biotech" ;
    ns1:investor <https://1145.am/db/2352382/Series_A_Investment_Biomedinvest_Delenex_Therapeutics_Ag_Hbm_Biocapital_Hbm_Bioventures_Sv_Life_Sciences_Vi_Partners_Completed> ;
    ns1:name "HBM BioCapital" ;
    ns1:sameAsHigh <https://1145.am/db/2302994/Hbm_Bioventures>,
        <https://1145.am/db/2302995/Hbm_Bioventures>,
        <https://1145.am/db/2303121/Hbm_Bioventures>,
        <https://1145.am/db/2313322/Hbm_Biocapital>,
        <https://1145.am/db/2324255/Hbm_Bioventures>,
        <https://1145.am/db/2326176/Hbm_Bioventures>,
        <https://1145.am/db/2329550/Hbm_Bioventures>,
        <https://1145.am/db/2332864/Hbm_Bioventures>,
        <https://1145.am/db/2352382/Hbm_Bioventures> ;
    ns1:sameAsMedium <https://1145.am/db/2308422/Hbm_Biocapital_Lp>,
        <https://1145.am/db/2309368/Hbm_Biocapital_Lp>,
        <https://1145.am/db/2313438/Hbm_Biocapital>,
        <https://1145.am/db/2314397/Hbm_Biocapital>,
        <https://1145.am/db/2314400/Hbm_Biocapital>,
        <https://1145.am/db/2339295/Hbm_Biocapital> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352382/Hbm_Bioventures> a org:Organization ;
    ns1:basedInLowRaw "Swiss" ;
    ns1:description "venture capital firms in the biotech industry" ;
    ns1:documentDate "2010-11-12T14:21:30+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Delenex Therapeutics Secures CHF 13.5 Million Series A Venture Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/delenex-therapeutics-secures-chf-13-5-million-series-a-venture-financing> ;
    ns1:foundName "HBM BioVentures" ;
    ns1:industry "biotech" ;
    ns1:investor <https://1145.am/db/2352382/Series_A_Investment_Biomedinvest_Delenex_Therapeutics_Ag_Hbm_Biocapital_Hbm_Bioventures_Sv_Life_Sciences_Vi_Partners_Completed> ;
    ns1:name "HBM BioVentures" ;
    ns1:sameAsHigh <https://1145.am/db/1157465/Oragenics>,
        <https://1145.am/db/1158575/Oragenics>,
        <https://1145.am/db/1509809/Novigenix>,
        <https://1145.am/db/2078301/Oragenics>,
        <https://1145.am/db/2151717/Abcellera>,
        <https://1145.am/db/2152981/Vividion>,
        <https://1145.am/db/2154072/Caelum_Biosciences>,
        <https://1145.am/db/2280707/Dren_Bio>,
        <https://1145.am/db/2281936/Bioindustry_Association>,
        <https://1145.am/db/2288986/Novogen>,
        <https://1145.am/db/2290780/Medivir>,
        <https://1145.am/db/2291198/Novogen>,
        <https://1145.am/db/2292333/Biodesix>,
        <https://1145.am/db/2292843/Reviral>,
        <https://1145.am/db/2293654/Viventia>,
        <https://1145.am/db/2296000/Medivation>,
        <https://1145.am/db/2301648/Achillion>,
        <https://1145.am/db/2302994/Hbm_Bioventures>,
        <https://1145.am/db/2302995/Hbm_Bioventures>,
        <https://1145.am/db/2306118/Biovex_Inc>,
        <https://1145.am/db/2307654/Bioton_Sa>,
        <https://1145.am/db/2309865/Biovex_Inc>,
        <https://1145.am/db/2309872/Biovex>,
        <https://1145.am/db/2310072/Encysive>,
        <https://1145.am/db/2313322/Hbm_Biocapital>,
        <https://1145.am/db/2319956/Cytovance>,
        <https://1145.am/db/2322304/Biovex>,
        <https://1145.am/db/2322312/Biovex_Inc>,
        <https://1145.am/db/2323591/Promedior>,
        <https://1145.am/db/2324255/Hbm_Bioventures>,
        <https://1145.am/db/2326139/Biovex_Inc>,
        <https://1145.am/db/2326176/Hbm_Bioventures>,
        <https://1145.am/db/2327506/Esperion>,
        <https://1145.am/db/2331639/Bioprocessors_Corporation>,
        <https://1145.am/db/2341458/Coridon>,
        <https://1145.am/db/2343202/Promedior>,
        <https://1145.am/db/2344535/Biovex_Inc>,
        <https://1145.am/db/2345773/Exonhit>,
        <https://1145.am/db/2352382/Hbm_Biocapital>,
        <https://1145.am/db/2358297/Clal_Biotechnology>,
        <https://1145.am/db/2366924/Biovex_Inc>,
        <https://1145.am/db/2367150/Biovex_Inc>,
        <https://1145.am/db/2368688/Etubics_Corporation>,
        <https://1145.am/db/2369363/Volution>,
        <https://1145.am/db/2369703/Promedior>,
        <https://1145.am/db/2369982/Reviral>,
        <https://1145.am/db/2370423/Nuevolution_A_S>,
        <https://1145.am/db/2545426/Medivation>,
        <https://1145.am/db/2549151/Encysive>,
        <https://1145.am/db/2557249/Biontech>,
        <https://1145.am/db/2558655/Biondvax>,
        <https://1145.am/db/2565174/Biocon_Viatris>,
        <https://1145.am/db/2572695/Biovex_Inc>,
        <https://1145.am/db/411454/Ensysce>,
        <https://1145.am/db/679276/Biodesix_Inc> ;
    ns1:sameAsMedium <https://1145.am/db/2292772/Hbm_Bioventures>,
        <https://1145.am/db/2301790/Hbm_Bioventures>,
        <https://1145.am/db/2303121/Hbm_Bioventures>,
        <https://1145.am/db/2304335/Hbm_Bioventures>,
        <https://1145.am/db/2304340/Hbm_Bioventures>,
        <https://1145.am/db/2313322/Hbm_Bioventures>,
        <https://1145.am/db/2313438/Hbm_Bioventures>,
        <https://1145.am/db/2325831/Hbm_Bioventures>,
        <https://1145.am/db/2329550/Hbm_Bioventures>,
        <https://1145.am/db/2332864/Hbm_Bioventures>,
        <https://1145.am/db/2335700/Hbm_Bioventures>,
        <https://1145.am/db/2339295/Hbm_Bioventures>,
        <https://1145.am/db/2349301/Hbm_Bioventures_Ltd>,
        <https://1145.am/db/2353607/Hbm_Bioventures>,
        <https://1145.am/db/2353610/Hbm_Bioventures>,
        <https://1145.am/db/2365748/Hbm_Bioventures>,
        <https://1145.am/db/2584056/Hbm_Bioventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352414/Cerulean_Pharma_Inc> a org:Organization ;
    ns1:description "designing and developing nanopharmaceuticals" ;
    ns1:documentDate "2010-11-15T14:49:42+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Cerulean Pharma Inc. Closes $24 Million in Series C Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cerulean-pharma-inc-closes-24-million-series-c-financing> ;
    ns1:foundName "Cerulean Pharma Inc." ;
    ns1:industry "Pharmaceutical" ;
    ns1:name "Cerulean Pharma Inc." ;
    ns1:sameAsHigh <https://1145.am/db/1019870/Moderna>,
        <https://1145.am/db/1028098/A2pg>,
        <https://1145.am/db/1028744/Apnimed>,
        <https://1145.am/db/1029882/Apnimed>,
        <https://1145.am/db/1041428/Dr>,
        <https://1145.am/db/1042161/Wellgistics>,
        <https://1145.am/db/1042221/Wellgistics>,
        <https://1145.am/db/1096114/Astorg>,
        <https://1145.am/db/1096677/Astorg>,
        <https://1145.am/db/1138447/Apnimed>,
        <https://1145.am/db/1139445/Apnimed>,
        <https://1145.am/db/1152269/Alpha-5>,
        <https://1145.am/db/1163849/Productlife_Group>,
        <https://1145.am/db/1172760/Apexigen>,
        <https://1145.am/db/1215735/Astorg>,
        <https://1145.am/db/1219810/Prokidney_Corp>,
        <https://1145.am/db/1271008/Reviral_Ltd>,
        <https://1145.am/db/1272754/Prokidney_Corp>,
        <https://1145.am/db/1294637/LTS>,
        <https://1145.am/db/1307202/Leo_Pharma>,
        <https://1145.am/db/1309648/Achrom>,
        <https://1145.am/db/1323486/Glo_Pharma>,
        <https://1145.am/db/1374672/Sp_Industries>,
        <https://1145.am/db/1384852/Moderna_Inc>,
        <https://1145.am/db/1391799/Pharnext>,
        <https://1145.am/db/1454905/Aquestive>,
        <https://1145.am/db/1505021/Pharmaceutics_International_Inc>,
        <https://1145.am/db/1540522/Atec>,
        <https://1145.am/db/1541946/Abiomed>,
        <https://1145.am/db/1562763/Indivior>,
        <https://1145.am/db/1613904/Apnimed_Inc>,
        <https://1145.am/db/1615580/Apnimed>,
        <https://1145.am/db/1617770/Pharnext_Sa>,
        <https://1145.am/db/1648815/Indevr>,
        <https://1145.am/db/1681016/Enveric_Biosciences>,
        <https://1145.am/db/1745685/Drugstoc>,
        <https://1145.am/db/1838777/Medikly>,
        <https://1145.am/db/1936167/Reviral_Ltd>,
        <https://1145.am/db/1962783/Ora_Inc>,
        <https://1145.am/db/2039692/Rk_Pharma_Inc>,
        <https://1145.am/db/2051589/Ora_Inc>,
        <https://1145.am/db/2060641/Abionyx_Pharma>,
        <https://1145.am/db/2073336/Ose>,
        <https://1145.am/db/2132018/Solutions>,
        <https://1145.am/db/2139917/Leo_Pharma>,
        <https://1145.am/db/2151848/D___D_Pharmatech>,
        <https://1145.am/db/2152469/Sobi003>,
        <https://1145.am/db/2152499/Highchem>,
        <https://1145.am/db/2152633/Themis>,
        <https://1145.am/db/2152849/Therachon>,
        <https://1145.am/db/2152901/Abcellera>,
        <https://1145.am/db/2154166/Leo_Pharma>,
        <https://1145.am/db/2154252/Phoremost>,
        <https://1145.am/db/2155490/Enterome>,
        <https://1145.am/db/2155631/Achillion>,
        <https://1145.am/db/2155863/Therachon>,
        <https://1145.am/db/2212420/Cel-Sci_Corporation>,
        <https://1145.am/db/2235873/M3_Usa>,
        <https://1145.am/db/2244405/Seek>,
        <https://1145.am/db/2281535/Eqt_Life_Sciences>,
        <https://1145.am/db/2281676/Apnimed>,
        <https://1145.am/db/2283559/Oric>,
        <https://1145.am/db/2283918/Indivior>,
        <https://1145.am/db/2286215/Pandion>,
        <https://1145.am/db/2289550/Well>,
        <https://1145.am/db/2290753/Medivir>,
        <https://1145.am/db/2294621/Pharmaceutics_International>,
        <https://1145.am/db/2296235/Apexigen>,
        <https://1145.am/db/2297631/Clarient>,
        <https://1145.am/db/2298376/Caprion>,
        <https://1145.am/db/2301879/Magen_Biosciences>,
        <https://1145.am/db/2302863/Amri>,
        <https://1145.am/db/2303412/Hologic>,
        <https://1145.am/db/2303415/Amevive>,
        <https://1145.am/db/2303612/Intradigm_Corporation>,
        <https://1145.am/db/2303675/Cerulean_Pharma_Inc>,
        <https://1145.am/db/2303720/Covance>,
        <https://1145.am/db/2305572/Covance_Inc>,
        <https://1145.am/db/2305703/Pinnacle_Bioventures>,
        <https://1145.am/db/2306640/Atryn>,
        <https://1145.am/db/2306640/Leo_Pharma>,
        <https://1145.am/db/2306724/Dermatech_Pty_Ltd>,
        <https://1145.am/db/2306725/Prevalere_Life_Sciences_Inc>,
        <https://1145.am/db/2306946/Amatsigroup>,
        <https://1145.am/db/2307526/Bioserv_Corporation>,
        <https://1145.am/db/2307529/Bioserv>,
        <https://1145.am/db/2307714/GTCR>,
        <https://1145.am/db/2308069/Bionomics>,
        <https://1145.am/db/2308807/Etrials_Worldwide>,
        <https://1145.am/db/2309352/Epicept_Corporation>,
        <https://1145.am/db/2309696/Encap>,
        <https://1145.am/db/2309697/Encap>,
        <https://1145.am/db/2310799/Inventiv_Health>,
        <https://1145.am/db/2312191/Medigene_Ag>,
        <https://1145.am/db/2312788/Leo_Pharma>,
        <https://1145.am/db/2312797/Leo_Pharma_A_S>,
        <https://1145.am/db/2312994/Upm>,
        <https://1145.am/db/2313383/Companyâ€™>,
        <https://1145.am/db/2314613/Advent_International>,
        <https://1145.am/db/2315373/Nitromed>,
        <https://1145.am/db/2315424/Covance_Inc>,
        <https://1145.am/db/2316707/Catalyst_Pharmaceutical>,
        <https://1145.am/db/2316856/Viranative_Ab>,
        <https://1145.am/db/2317006/Amri>,
        <https://1145.am/db/2317060/Ception>,
        <https://1145.am/db/2317144/Leo_Pharma>,
        <https://1145.am/db/2317334/Aesica>,
        <https://1145.am/db/2317369/Relthy>,
        <https://1145.am/db/2320351/Prochieve>,
        <https://1145.am/db/2320947/Nitromed>,
        <https://1145.am/db/2321635/Celator>,
        <https://1145.am/db/2322824/Amri>,
        <https://1145.am/db/2322826/Amri>,
        <https://1145.am/db/2323790/Amri>,
        <https://1145.am/db/2323861/Amri>,
        <https://1145.am/db/2324112/Nitromed>,
        <https://1145.am/db/2324118/Rem_Medical_Corporation>,
        <https://1145.am/db/2324350/Celmed_Biosciences_Inc>,
        <https://1145.am/db/2324394/Amdl>,
        <https://1145.am/db/2324985/Amri>,
        <https://1145.am/db/2325553/Fidelity_Biosciences>,
        <https://1145.am/db/2327076/Amri>,
        <https://1145.am/db/2327088/Covance>,
        <https://1145.am/db/2327241/Preotact_(r)>,
        <https://1145.am/db/2327258/Biocon_Limited>,
        <https://1145.am/db/2327374/Diamedica_Inc>,
        <https://1145.am/db/2327424/Innopharm>,
        <https://1145.am/db/2328008/Epicept_Corporation>,
        <https://1145.am/db/2328318/Medpointe>,
        <https://1145.am/db/2328713/Sepracor>,
        <https://1145.am/db/2329333/Biopharma_Services_Inc>,
        <https://1145.am/db/2330808/Sepracor>,
        <https://1145.am/db/2331911/Clarient>,
        <https://1145.am/db/2332005/R___d>,
        <https://1145.am/db/2332200/Compendia_Bioscience>,
        <https://1145.am/db/2332920/Nastech>,
        <https://1145.am/db/2333644/Targent>,
        <https://1145.am/db/2334020/Accovion>,
        <https://1145.am/db/2336287/Biomotiv>,
        <https://1145.am/db/2336355/Correvio>,
        <https://1145.am/db/2336625/Biota>,
        <https://1145.am/db/2336998/Medivation_Inc>,
        <https://1145.am/db/2337028/Medivation>,
        <https://1145.am/db/2337078/Cerulean_Pharma_Inc>,
        <https://1145.am/db/2338888/Cerulean_Pharma>,
        <https://1145.am/db/2338939/Nuevolution_A_S>,
        <https://1145.am/db/2339816/Nuevolution_A_S>,
        <https://1145.am/db/2339997/(Appa)>,
        <https://1145.am/db/2340054/Amri>,
        <https://1145.am/db/2340115/Mission>,
        <https://1145.am/db/2340160/Intercell_Ag>,
        <https://1145.am/db/2340507/Rho>,
        <https://1145.am/db/2341572/Aesica>,
        <https://1145.am/db/2341869/Fidelity_Biosciences>,
        <https://1145.am/db/2341897/Fidelity_Biosciences>,
        <https://1145.am/db/2342581/Cerulean_Pharma_Inc>,
        <https://1145.am/db/2342628/Cerulean_Pharma_Inc>,
        <https://1145.am/db/2343325/Medivir>,
        <https://1145.am/db/2344595/Mabxience>,
        <https://1145.am/db/2347172/Medivir_Ab>,
        <https://1145.am/db/2347755/Leo_Pharma_Inc>,
        <https://1145.am/db/2348448/Cerulean_Pharma_Inc>,
        <https://1145.am/db/2348675/Signum_Biosciences>,
        <https://1145.am/db/2349050/Fidelity_Biosciences>,
        <https://1145.am/db/2349373/Asmacure>,
        <https://1145.am/db/2349740/Signum_Biosciences_Inc>,
        <https://1145.am/db/2349983/Leading_Biosciences_Inc>,
        <https://1145.am/db/2349990/Aesica>,
        <https://1145.am/db/2350847/Covance>,
        <https://1145.am/db/2351198/(Ptc)>,
        <https://1145.am/db/2351259/Biotime_Inc>,
        <https://1145.am/db/2353223/Medivation_Inc>,
        <https://1145.am/db/2355036/Moderna>,
        <https://1145.am/db/2355194/Moderna>,
        <https://1145.am/db/2356488/Cerulean_Pharma>,
        <https://1145.am/db/2358197/Biopharma_Services_Inc>,
        <https://1145.am/db/2358403/Pht_Corporation>,
        <https://1145.am/db/2358637/Eurand>,
        <https://1145.am/db/2358638/Eurand_Nv>,
        <https://1145.am/db/2358734/Prosidion>,
        <https://1145.am/db/2358953/Abgent>,
        <https://1145.am/db/2359025/Nectid>,
        <https://1145.am/db/2359113/Eurand_Nv>,
        <https://1145.am/db/2359380/Amri>,
        <https://1145.am/db/2359577/Geno>,
        <https://1145.am/db/2359670/Biotie>,
        <https://1145.am/db/2359951/Entremed>,
        <https://1145.am/db/2360371/Preglem>,
        <https://1145.am/db/2360702/Cominnex>,
        <https://1145.am/db/2360922/Nuevolution_A_S>,
        <https://1145.am/db/2361675/Amri>,
        <https://1145.am/db/2361747/Servier>,
        <https://1145.am/db/2361926/Pharm-Olam_International_Ltd>,
        <https://1145.am/db/2362453/Pharnext>,
        <https://1145.am/db/2362607/Abide_Therapeutics>,
        <https://1145.am/db/2363722/Moderna>,
        <https://1145.am/db/2363725/Moderna>,
        <https://1145.am/db/2367022/Fidelity_Biosciences>,
        <https://1145.am/db/2367023/Fidelity_Biosciences>,
        <https://1145.am/db/2367298/Amri>,
        <https://1145.am/db/2368106/Obseva>,
        <https://1145.am/db/2368242/Symic>,
        <https://1145.am/db/2368257/Almirall>,
        <https://1145.am/db/2368329/Amri>,
        <https://1145.am/db/2368332/Amri>,
        <https://1145.am/db/2368333/R___d>,
        <https://1145.am/db/2368601/Promosome>,
        <https://1145.am/db/2368824/Almirall_Inc>,
        <https://1145.am/db/2369042/Abide_Therapeutics>,
        <https://1145.am/db/2369128/Aegerion>,
        <https://1145.am/db/2369269/R___d>,
        <https://1145.am/db/2369446/Presage_Biosciences>,
        <https://1145.am/db/2369490/Medivation>,
        <https://1145.am/db/2369708/Promedior>,
        <https://1145.am/db/2370156/Pharming_Group_Nv>,
        <https://1145.am/db/2370164/Cerulean_Pharma_Inc>,
        <https://1145.am/db/2370265/Ose_Pharma>,
        <https://1145.am/db/2370267/Ose_Pharma>,
        <https://1145.am/db/2370437/MSD>,
        <https://1145.am/db/2370557/Cerulean_Pharma_Inc>,
        <https://1145.am/db/2370579/Arvinas>,
        <https://1145.am/db/2370659/Nuevolution>,
        <https://1145.am/db/2370828/Nuevolution>,
        <https://1145.am/db/2371158/Moderna>,
        <https://1145.am/db/2371408/Business_Management>,
        <https://1145.am/db/2536140/Scinopharm>,
        <https://1145.am/db/2536209/TPG>,
        <https://1145.am/db/2536305/Radient>,
        <https://1145.am/db/2536469/Agila_Specialties>,
        <https://1145.am/db/2536473/Encap>,
        <https://1145.am/db/2536575/G___w>,
        <https://1145.am/db/2536576/G___w>,
        <https://1145.am/db/2536612/Pharmaceutics_International_Inc>,
        <https://1145.am/db/2536776/Oramed>,
        <https://1145.am/db/2538112/Pharmedium>,
        <https://1145.am/db/2539816/P___R_Group>,
        <https://1145.am/db/2539858/Aesica>,
        <https://1145.am/db/2539890/Scinopharm>,
        <https://1145.am/db/2540218/Amri>,
        <https://1145.am/db/2540222/Amri>,
        <https://1145.am/db/2540931/Accucaps>,
        <https://1145.am/db/2540931/Pharmtek>,
        <https://1145.am/db/2541419/Amri>,
        <https://1145.am/db/2541469/Agila_Specialties>,
        <https://1145.am/db/2542113/Profectus_Biosciences>,
        <https://1145.am/db/2542472/Aesica>,
        <https://1145.am/db/2543530/Covance>,
        <https://1145.am/db/2544087/Univercells>,
        <https://1145.am/db/2544258/C___O_Pharmaceutical_Technology>,
        <https://1145.am/db/2544596/Bioton>,
        <https://1145.am/db/2545125/Ascendis_Health>,
        <https://1145.am/db/2545545/Agila_Specialties>,
        <https://1145.am/db/2546430/Bal_Pharma>,
        <https://1145.am/db/2546892/Aphena>,
        <https://1145.am/db/2547568/Amec>,
        <https://1145.am/db/2548137/Innopharm>,
        <https://1145.am/db/2548674/Sepracor>,
        <https://1145.am/db/2548840/Btcp_Pharma_Llc>,
        <https://1145.am/db/2549082/British_Company>,
        <https://1145.am/db/2549201/Rexall_Health>,
        <https://1145.am/db/2550632/Amri>,
        <https://1145.am/db/2550638/Amri>,
        <https://1145.am/db/2553761/Mabxience>,
        <https://1145.am/db/2553978/Bioverativ>,
        <https://1145.am/db/2554838/Amri>,
        <https://1145.am/db/2555168/Prokidney>,
        <https://1145.am/db/2555326/Leo_Pharma>,
        <https://1145.am/db/2556356/Medivation>,
        <https://1145.am/db/2556744/Leo_Pharma>,
        <https://1145.am/db/2557034/West_Pharmaceutical>,
        <https://1145.am/db/2557482/Idifarma>,
        <https://1145.am/db/2558133/Lifehealth>,
        <https://1145.am/db/2559160/West_Pharmaceutical>,
        <https://1145.am/db/2560277/Aesica>,
        <https://1145.am/db/2560277/Consort>,
        <https://1145.am/db/2560766/Accucaps>,
        <https://1145.am/db/2560808/Novamedica>,
        <https://1145.am/db/2561121/Bioserv>,
        <https://1145.am/db/2562459/Eurand>,
        <https://1145.am/db/2563255/MSD>,
        <https://1145.am/db/2563772/Apiject>,
        <https://1145.am/db/2564003/Leo_Pharma>,
        <https://1145.am/db/2564490/Accucaps>,
        <https://1145.am/db/2564490/Pharmtek>,
        <https://1145.am/db/2565613/Servier>,
        <https://1145.am/db/2566037/Almirall>,
        <https://1145.am/db/2566348/Indivior>,
        <https://1145.am/db/2566348/Opiant>,
        <https://1145.am/db/2568711/West_Pharmaceutical>,
        <https://1145.am/db/2569107/Almirall_Sa>,
        <https://1145.am/db/2569356/Leo_Pharma_Inc>,
        <https://1145.am/db/2569393/R___d>,
        <https://1145.am/db/2570064/Aegerion>,
        <https://1145.am/db/2570177/Oramed>,
        <https://1145.am/db/2572329/Incivo®>,
        <https://1145.am/db/2572567/Northera>,
        <https://1145.am/db/2573050/Amatsigroup>,
        <https://1145.am/db/2573913/TPG>,
        <https://1145.am/db/2575143/Almirall>,
        <https://1145.am/db/2576254/Fougera>,
        <https://1145.am/db/2576550/TPG>,
        <https://1145.am/db/2576923/Pharmgate>,
        <https://1145.am/db/2576925/Pharmgate>,
        <https://1145.am/db/2577894/Advance_Properties_Ood>,
        <https://1145.am/db/2578052/Advent_International>,
        <https://1145.am/db/2578052/United_Medical>,
        <https://1145.am/db/2578645/Almirall>,
        <https://1145.am/db/2578667/Almirall>,
        <https://1145.am/db/2578667/Fycompa>,
        <https://1145.am/db/2579211/Proximagen>,
        <https://1145.am/db/2581197/Irom_Pharmaceutical>,
        <https://1145.am/db/2581832/West>,
        <https://1145.am/db/2586253/United_Biosource_Corporation>,
        <https://1145.am/db/2586420/Acuform>,
        <https://1145.am/db/2587709/Pharmstandard>,
        <https://1145.am/db/2589178/Oriel>,
        <https://1145.am/db/2590195/Nectid>,
        <https://1145.am/db/2590489/Amatsigroup>,
        <https://1145.am/db/2590528/C___O_Pharmaceutical>,
        <https://1145.am/db/2590556/Nycomed_Us>,
        <https://1145.am/db/2590827/Affairs>,
        <https://1145.am/db/2591609/Pharmstandard>,
        <https://1145.am/db/2591622/Pharmstandard>,
        <https://1145.am/db/2593060/Inventiv_Health>,
        <https://1145.am/db/2593265/Leo_Pharma>,
        <https://1145.am/db/2594186/Agila_Specialties>,
        <https://1145.am/db/2594699/Osi>,
        <https://1145.am/db/2595688/Fougera>,
        <https://1145.am/db/2598181/Amri>,
        <https://1145.am/db/2739044/Moderna>,
        <https://1145.am/db/2791590/Civica>,
        <https://1145.am/db/295168/Orifarm>,
        <https://1145.am/db/317543/Productlife_Group>,
        <https://1145.am/db/423883/Sohm_Inc>,
        <https://1145.am/db/449041/Advent_International>,
        <https://1145.am/db/515764/Sohm_Inc>,
        <https://1145.am/db/561196/Pharnext_Sa>,
        <https://1145.am/db/618115/Sohm>,
        <https://1145.am/db/654792/Innobic>,
        <https://1145.am/db/676564/Alvotech>,
        <https://1145.am/db/716162/Pharnext_Sa>,
        <https://1145.am/db/806327/Pharma_Nobis_Llc>,
        <https://1145.am/db/807295/Pharma_Nobis_Llc>,
        <https://1145.am/db/834480/Pharnext_Sa>,
        <https://1145.am/db/835269/Grand_Pharmaceutical_Group_Limited>,
        <https://1145.am/db/837157/Leo_Pharma_Inc>,
        <https://1145.am/db/848323/Pharmaceutics_International_Inc>,
        <https://1145.am/db/872336/Sohm_Inc>,
        <https://1145.am/db/882142/Aim>,
        <https://1145.am/db/886663/Théa>,
        <https://1145.am/db/888994/Théa>,
        <https://1145.am/db/943000/Pharnext>,
        <https://1145.am/db/965490/Reviral_Ltd> ;
    ns1:sameAsMedium <https://1145.am/db/2291713/Cerulean_Pharma>,
        <https://1145.am/db/2301089/Cerulean_Pharma>,
        <https://1145.am/db/2303674/Cerulean_Pharma>,
        <https://1145.am/db/2312088/Cerulean_Pharma>,
        <https://1145.am/db/2338883/Cerulean_Pharma_Inc>,
        <https://1145.am/db/2342996/Cerulean_Pharma_Inc>,
        <https://1145.am/db/2345089/Cerulean_Pharma_Inc>,
        <https://1145.am/db/2348440/Cerulean_Pharma>,
        <https://1145.am/db/2357508/Cerulean_Pharma_Inc> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352414/Polaris_Venture_Partners> a org:Organization ;
    ns1:basedInLowRaw "CAMBRIDGE" ;
    ns1:description "venture capital" ;
    ns1:documentDate "2010-11-15T14:49:42+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Cerulean Pharma Inc. Closes $24 Million in Series C Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cerulean-pharma-inc-closes-24-million-series-c-financing> ;
    ns1:foundName "Polaris Venture Partners" ;
    ns1:investor <https://1145.am/db/2352414/Series_C_Investment_Bessemer_Venture_Partners_Cerulean_Pharma_Inc_Lilly_Ventures_Lux_Capital_Polaris_Venture_Partners_Venrock_Completed> ;
    ns1:name "Polaris Venture Partners" ;
    ns1:sameAsHigh <https://1145.am/db/1163164/Polaris_Partners>,
        <https://1145.am/db/1166225/Polaris_Partners>,
        <https://1145.am/db/127343/Polaris_Partners>,
        <https://1145.am/db/1340338/Polaris_Partners>,
        <https://1145.am/db/1406211/Polaris_Partners>,
        <https://1145.am/db/1412727/Polaris_Partners>,
        <https://1145.am/db/1545490/Polaris_Partners>,
        <https://1145.am/db/1701903/Polaris_Venture_Partners>,
        <https://1145.am/db/1796259/Polaris_Capital>,
        <https://1145.am/db/1803886/Polaris_Partners>,
        <https://1145.am/db/1845960/Polaris_Partners>,
        <https://1145.am/db/1854788/Polaris_Partners>,
        <https://1145.am/db/1870436/Polaris_Venture_Partners>,
        <https://1145.am/db/1877606/Polaris_Venture_Partners>,
        <https://1145.am/db/1885717/Polaris_Ventures>,
        <https://1145.am/db/1897450/Polaris_Venture_Partners>,
        <https://1145.am/db/1909651/Polaris_Venture_Partners>,
        <https://1145.am/db/1947183/Polaris_Partners>,
        <https://1145.am/db/2140474/Polaris_Capital_Management>,
        <https://1145.am/db/2174824/Polaris_Venture_Partners>,
        <https://1145.am/db/2181016/Polaris_Partners>,
        <https://1145.am/db/2187023/Polaris_Partners>,
        <https://1145.am/db/2194844/Polaris_Partners>,
        <https://1145.am/db/2196895/Polaris_Partners>,
        <https://1145.am/db/2223723/Polaris_Partners>,
        <https://1145.am/db/2292800/Polaris_Venture_Partners>,
        <https://1145.am/db/2303656/Polaris_Venture_Partners>,
        <https://1145.am/db/2303675/Polaris_Venture_Partners>,
        <https://1145.am/db/2315289/Polaris_Venture_Partners>,
        <https://1145.am/db/2317918/Polaris_Ventures>,
        <https://1145.am/db/2318310/Polaris_Partners>,
        <https://1145.am/db/2323586/Polaris_Venture_Partners>,
        <https://1145.am/db/2324431/Polaris_Venture_Partners>,
        <https://1145.am/db/2335531/Flagship_Ventures_Polaris_Partners>,
        <https://1145.am/db/2335750/Polaris_Partners>,
        <https://1145.am/db/2338373/Polaris_Venture_Partners>,
        <https://1145.am/db/2341599/Polaris_Partners>,
        <https://1145.am/db/2343467/Polaris_Ventures>,
        <https://1145.am/db/2354806/Polaris_Venture_Partners>,
        <https://1145.am/db/2354955/Polaris_Partners>,
        <https://1145.am/db/2365296/Polaris_Venture_Partners>,
        <https://1145.am/db/2365300/Polaris_Venture_Partners>,
        <https://1145.am/db/2367497/Polaris_Venture_Partners>,
        <https://1145.am/db/2368913/Polaris_Partners>,
        <https://1145.am/db/2369304/Polaris_Partners>,
        <https://1145.am/db/2369305/Polaris_Partners>,
        <https://1145.am/db/250010/Polaris_Partners>,
        <https://1145.am/db/364226/Polaris_Partners>,
        <https://1145.am/db/572097/Polaris_Partners>,
        <https://1145.am/db/612707/Polaris_Partners> ;
    ns1:sameAsMedium <https://1145.am/db/1708291/Polaris_Venture_Partners>,
        <https://1145.am/db/1830502/Polaris_Venture_Partners>,
        <https://1145.am/db/2302116/Polaris_Venture_Partners>,
        <https://1145.am/db/2313401/Polaris_Venture_Partners>,
        <https://1145.am/db/2313405/Polaris_Venture_Partners>,
        <https://1145.am/db/2314380/Polaris_Venture_Partners>,
        <https://1145.am/db/2331763/Polaris_Venture_Partners>,
        <https://1145.am/db/2337571/Polaris_Venture_Partners>,
        <https://1145.am/db/2337577/Polaris_Venture_Partners>,
        <https://1145.am/db/2339127/Polaris_Venture_Partners>,
        <https://1145.am/db/2339128/Polaris_Venture_Partners>,
        <https://1145.am/db/2342445/Polaris_Venture_Partners>,
        <https://1145.am/db/2342862/Polaris_Venture_Partners>,
        <https://1145.am/db/2343210/Polaris_Venture_Partners>,
        <https://1145.am/db/2344256/Polaris_Venture_Partners>,
        <https://1145.am/db/2345224/Polaris_Venture_Partners>,
        <https://1145.am/db/2347102/Polaris_Venture_Partners>,
        <https://1145.am/db/2348448/Polaris_Venture_Partners>,
        <https://1145.am/db/2350034/Polaris_Venture_Partners>,
        <https://1145.am/db/2366654/Polaris_Venture_Partners>,
        <https://1145.am/db/2440024/Polaris_Venture_Partners>,
        <https://1145.am/db/2450515/Polaris_Venture_Partners>,
        <https://1145.am/db/2546216/Polaris_Venture_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352807/Complete_Genomics> a org:Organization ;
    ns1:description "Biotechnology" ;
    ns1:documentDate "2010-08-19T15:28:58+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Complete Genomics, Inc. Announces Completion of $39 Million Series E Financing and Addresses Illumina Patent Infringement Lawsui" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/complete-genomics-inc-announces-completion-of-39-million-series-e-financing-and-addresses> ;
    ns1:foundName "Complete Genomics",
        "Complete Genomics, Inc." ;
    ns1:name "Complete Genomics" ;
    ns1:sameAsMedium <https://1145.am/db/2309490/Complete_Genomics>,
        <https://1145.am/db/2309491/Complete_Genomics_Inc>,
        <https://1145.am/db/2328257/Complete_Genomics>,
        <https://1145.am/db/2331148/Complete_Genomics>,
        <https://1145.am/db/2331149/Complete_Genomics>,
        <https://1145.am/db/2340834/Complete_Genomics>,
        <https://1145.am/db/2352804/Complete_Genomics>,
        <https://1145.am/db/2360068/Complete_Genomics>,
        <https://1145.am/db/2360069/Complete_Genomics>,
        <https://1145.am/db/2360075/Complete_Genomics>,
        <https://1145.am/db/2360628/Complete_Genomics>,
        <https://1145.am/db/2360631/Complete_Genomics>,
        <https://1145.am/db/2364122/Complete_Genomics> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352807/Prospect_Venture_Partners> a org:Organization ;
    ns1:basedInLowRaw "Calif" ;
    ns1:description "financing" ;
    ns1:documentDate "2010-08-19T15:28:58+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Complete Genomics, Inc. Announces Completion of $39 Million Series E Financing and Addresses Illumina Patent Infringement Lawsui" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/complete-genomics-inc-announces-completion-of-39-million-series-e-financing-and-addresses> ;
    ns1:foundName "Prospect Venture Partners" ;
    ns1:investor <https://1145.am/db/2352807/Series_E_Investment_Complete_Genomics_Enterprise_Partners_Essex_Woodlands_Highland_Capital_Ovp_Venture_Partners_Orbimed_Advisors_Prospect_Venture_Partners_Sands_Capital_Completed> ;
    ns1:name "Prospect Venture Partners" ;
    ns1:sameAsHigh <https://1145.am/db/1342399/Draft_Ventures>,
        <https://1145.am/db/2308758/Prospect_Venture_Partners>,
        <https://1145.am/db/2330712/Prospect_Venture_Partners>,
        <https://1145.am/db/2331754/Prospect_Venture_Partners>,
        <https://1145.am/db/2339883/Prospect_Venture_Partners> ;
    ns1:sameAsMedium <https://1145.am/db/2300697/Prospect_Venture_Partners>,
        <https://1145.am/db/2303219/Prospect_Venture_Partners>,
        <https://1145.am/db/2309506/Prospect_Venture_Partners>,
        <https://1145.am/db/2309507/Prospect_Venture_Partners>,
        <https://1145.am/db/2314964/Prospect_Venture_Partners>,
        <https://1145.am/db/2319809/Prospect_Venture_Partners>,
        <https://1145.am/db/2323578/Prospect_Venture_Partners>,
        <https://1145.am/db/2330852/Prospect_Venture_Partners>,
        <https://1145.am/db/2331868/Prospect_Venture_Partners>,
        <https://1145.am/db/2340224/Prospect_Venture_Partners>,
        <https://1145.am/db/2352804/Prospect_Venture_Partners>,
        <https://1145.am/db/2358234/Prospect_Venture_Partners>,
        <https://1145.am/db/2360004/Prospect_Venture_Partners>,
        <https://1145.am/db/2360006/Prospect_Venture_Partners>,
        <https://1145.am/db/2364505/Prospect_Venture_Partners>,
        <https://1145.am/db/2367442/Prospect_Venture_Partners>,
        <https://1145.am/db/2367448/Prospect_Venture_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352819/Series_B_Investment_Anchor_Therapeutics_Tvm_Capital_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-08-20T13:42:43+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Anchor Therapeutics has raised $ 10 million in the first close of what the company hopes will be a $ 30 million Series B round.",
        "Anchor Therapeutics, known until earlier this year as Ascent Therapeutics, plans to pursue Big Pharma licensing pacts and its goal of raising a $ 30 million Series B round." ;
    ns1:documentTitle "Anchor raises $10M, aims for more in Series B" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/anchor-raises-10m-aims-for-more-series-b> ;
    ns1:foundName "raised",
        "raising" ;
    ns1:name "raised",
        "raising" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2352819/Anchor_Therapeutics> ;
    ns1:targetDetails "Series B" ;
    ns1:valueRaw "$ 10 million",
        "$ 30 million" .

<https://1145.am/db/2352819/Tvm_Capital> a org:Organization ;
    ns1:description "TVM Capital, HealthCare Ventures and the Novartis Option Fund participated in the" ;
    ns1:documentDate "2010-08-20T13:42:43+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Anchor raises $10M, aims for more in Series B" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/anchor-raises-10m-aims-for-more-series-b> ;
    ns1:foundName "TV" ;
    ns1:investor <https://1145.am/db/2352819/Series_B_Investment_Anchor_Therapeutics_Tvm_Capital_Completed> ;
    ns1:name "TVM Capital" ;
    ns1:sameAsMedium <https://1145.am/db/1919300/Tvm_Capital>,
        <https://1145.am/db/2289349/Tvm_Capital>,
        <https://1145.am/db/2298846/Tvm_Capital>,
        <https://1145.am/db/2303598/Tvm_Capital>,
        <https://1145.am/db/2314674/Tvm_Capital>,
        <https://1145.am/db/2317779/Tvm_Capital>,
        <https://1145.am/db/2322531/Tvm_Capital>,
        <https://1145.am/db/2323243/Tvm_Capital>,
        <https://1145.am/db/2325366/Tvm_Capital>,
        <https://1145.am/db/2326376/Tvm_Capital>,
        <https://1145.am/db/2327406/Tvm_Capital>,
        <https://1145.am/db/2336126/Tvm_Capital>,
        <https://1145.am/db/2347977/Tvm_Capital>,
        <https://1145.am/db/2347983/Tvm_Capital>,
        <https://1145.am/db/2352814/Tvm_Capital>,
        <https://1145.am/db/2352820/Tvm_Capital>,
        <https://1145.am/db/2353522/Tvm_Capital>,
        <https://1145.am/db/2353525/Tvm_Capital>,
        <https://1145.am/db/2353607/Tvm_Capital>,
        <https://1145.am/db/2353610/Tvm_Capital>,
        <https://1145.am/db/2358268/Tvm_Capital>,
        <https://1145.am/db/2358269/Tvm_Capital>,
        <https://1145.am/db/2365103/Tvm_Capital>,
        <https://1145.am/db/2366539/Tvm_Capital>,
        <https://1145.am/db/2564563/Tvm_Capital> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352820/Tvm_Capital> a org:Organization ;
    ns1:basedInLowRaw "CAMBRIDGE" ;
    ns1:documentDate "2010-08-20T13:33:44+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Anchor Therapeutics Nabs $10M for New Class of Peptide Drugs Against Hard Targets" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/anchor-therapeutics-nabs-10m-for-new-class-of-peptide-drugs-against-hard-targets> ;
    ns1:foundName "TVM Capital" ;
    ns1:investor <https://1145.am/db/2352820/Series_B_Investment_Anchor_Therapeutics_Healthcare_Ventures_Novartis_Option_Fund_Tvm_Capital_Completed> ;
    ns1:name "TVM Capital" ;
    ns1:sameAsMedium <https://1145.am/db/1919300/Tvm_Capital>,
        <https://1145.am/db/2289349/Tvm_Capital>,
        <https://1145.am/db/2298846/Tvm_Capital>,
        <https://1145.am/db/2303598/Tvm_Capital>,
        <https://1145.am/db/2314674/Tvm_Capital>,
        <https://1145.am/db/2317779/Tvm_Capital>,
        <https://1145.am/db/2322531/Tvm_Capital>,
        <https://1145.am/db/2323243/Tvm_Capital>,
        <https://1145.am/db/2325366/Tvm_Capital>,
        <https://1145.am/db/2326376/Tvm_Capital>,
        <https://1145.am/db/2327406/Tvm_Capital>,
        <https://1145.am/db/2336126/Tvm_Capital>,
        <https://1145.am/db/2347977/Tvm_Capital>,
        <https://1145.am/db/2347983/Tvm_Capital>,
        <https://1145.am/db/2352814/Tvm_Capital>,
        <https://1145.am/db/2352819/Tvm_Capital>,
        <https://1145.am/db/2353522/Tvm_Capital>,
        <https://1145.am/db/2353525/Tvm_Capital>,
        <https://1145.am/db/2353607/Tvm_Capital>,
        <https://1145.am/db/2353610/Tvm_Capital>,
        <https://1145.am/db/2358268/Tvm_Capital>,
        <https://1145.am/db/2358269/Tvm_Capital>,
        <https://1145.am/db/2365103/Tvm_Capital>,
        <https://1145.am/db/2366539/Tvm_Capital>,
        <https://1145.am/db/2564563/Tvm_Capital> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2354899/Otonomy> a org:Organization ;
    ns1:description "Ear Disorders" ;
    ns1:documentDate "2010-08-30T13:07:55+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Otonomy Closes $38.5 Million Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/otonomy-closes-38-5-million-series-b-financing> ;
    ns1:foundName "Otonomy",
        "Otonomy, Inc." ;
    ns1:industry "Biotech" ;
    ns1:name "Otonomy" ;
    ns1:sameAsHigh <https://1145.am/db/2336221/Otonomy>,
        <https://1145.am/db/2341559/Otonomy>,
        <https://1145.am/db/2343026/Otonomy>,
        <https://1145.am/db/2350044/Otonomy>,
        <https://1145.am/db/2350269/Otonomy>,
        <https://1145.am/db/2354141/Otonomy>,
        <https://1145.am/db/2354903/Otonomy>,
        <https://1145.am/db/2355424/Otonomy>,
        <https://1145.am/db/2355432/Otonomy>,
        <https://1145.am/db/2358118/Otonomy>,
        <https://1145.am/db/2361455/Otologic_Pharmaceutics>,
        <https://1145.am/db/2362475/Otonomy>,
        <https://1145.am/db/2367852/Oticpharma_Inc>,
        <https://1145.am/db/2368855/Otic_Pharma_Ltd> ;
    ns1:sameAsMedium <https://1145.am/db/2360770/Otonomy> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2355511/Biocancell_Therapeutics> a org:Organization ;
    ns1:basedInLowRaw "United States" ;
    ns1:documentDate "2010-11-23T15:57:00+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Xention raises £8M; Maxygen distributes Codexis shares; Insurer counts costs of diabetes;" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/xention-raises-%C2%A38m-maxygen-distributes-codexis-shares-insurer-counts-costs-of-diabetes> ;
    ns1:foundName "BioCancell Therapeutics" ;
    ns1:name "BioCancell Therapeutics" ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2355511/Btg_International> a org:Organization ;
    ns1:basedInLowRaw "UK" ;
    ns1:description "Life Sciences" ;
    ns1:documentDate "2010-11-23T15:57:00+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Xention raises £8M; Maxygen distributes Codexis shares; Insurer counts costs of diabetes;" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/xention-raises-%C2%A38m-maxygen-distributes-codexis-shares-insurer-counts-costs-of-diabetes> ;
    ns1:foundName "BTG International" ;
    ns1:investor <https://1145.am/db/2355511/Series_D_Investment_Btg_International_Crédit_Agricole_Private_Equity_Forbion_Capital_Partners_Mvm_Seroba-Kernel_Life_Sciences_Ltd_Xention_Completed> ;
    ns1:name "BTG International" ;
    ns1:sameAsMedium <https://1145.am/db/2355512/Btg_International> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2355511/Crédit_Agricole_Private_Equity> a org:Organization ;
    ns1:basedInLowRaw "UK" ;
    ns1:description "Private Equity" ;
    ns1:documentDate "2010-11-23T15:57:00+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Xention raises £8M; Maxygen distributes Codexis shares; Insurer counts costs of diabetes;" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/xention-raises-%C2%A38m-maxygen-distributes-codexis-shares-insurer-counts-costs-of-diabetes> ;
    ns1:foundName "Crédit Agricole Private Equity" ;
    ns1:investor <https://1145.am/db/2355511/Series_D_Investment_Btg_International_Crédit_Agricole_Private_Equity_Forbion_Capital_Partners_Mvm_Seroba-Kernel_Life_Sciences_Ltd_Xention_Completed> ;
    ns1:name "Crédit Agricole Private Equity" ;
    ns1:sameAsHigh <https://1145.am/db/1724650/Crédit_Agricole_Private_Equity>,
        <https://1145.am/db/1921869/Crédit_Agricole_Private_Equity>,
        <https://1145.am/db/2295207/Crédit_Agricole_Private_Equity>,
        <https://1145.am/db/2309865/Credit_Agricole_Private_Equity>,
        <https://1145.am/db/2313401/Credit_Agricole_Private_Equity>,
        <https://1145.am/db/2326139/Credit_Agricole_Private_Equity>,
        <https://1145.am/db/2343244/Credit_Agricole_Private_Equity>,
        <https://1145.am/db/2355512/Crédit_Agricole_Private_Equity>,
        <https://1145.am/db/2361390/Crédit_Agricole_Private_Equity> ;
    ns1:sameAsMedium <https://1145.am/db/2291361/Crédit_Agricole_Private_Equity>,
        <https://1145.am/db/2293779/Credit_Agricole_Private_Equity>,
        <https://1145.am/db/2301966/Credit_Agricole_Private_Equity>,
        <https://1145.am/db/2309872/Credit_Agricole_Private_Equity>,
        <https://1145.am/db/2313410/Credit_Agricole_Private_Equity>,
        <https://1145.am/db/2326130/Credit_Agricole_Private_Equity>,
        <https://1145.am/db/2343250/Credit_Agricole_Private_Equity>,
        <https://1145.am/db/2346397/Crédit_Agricole_Private_Equity> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2355511/Forbion_Capital_Partners> a org:Organization ;
    ns1:basedInLowRaw "UK" ;
    ns1:description "private equity" ;
    ns1:documentDate "2010-11-23T15:57:00+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Xention raises £8M; Maxygen distributes Codexis shares; Insurer counts costs of diabetes;" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/xention-raises-%C2%A38m-maxygen-distributes-codexis-shares-insurer-counts-costs-of-diabetes> ;
    ns1:foundName "Forbion Capital Partners" ;
    ns1:investor <https://1145.am/db/2355511/Series_D_Investment_Btg_International_Crédit_Agricole_Private_Equity_Forbion_Capital_Partners_Mvm_Seroba-Kernel_Life_Sciences_Ltd_Xention_Completed> ;
    ns1:name "Forbion Capital Partners" ;
    ns1:sameAsHigh <https://1145.am/db/2301966/Forbion_Capital_Partners>,
        <https://1145.am/db/2309865/Forbion_Capital_Partners>,
        <https://1145.am/db/2320503/Forbion_Capital_Partners>,
        <https://1145.am/db/2329919/Forbion_Capital_Partners>,
        <https://1145.am/db/2336126/Forbion_Capital_Partners>,
        <https://1145.am/db/2339932/Forbion_Capital_Partners>,
        <https://1145.am/db/2357941/Forbion_Capital_Partners>,
        <https://1145.am/db/2361390/Forbion_Capital_Partners> ;
    ns1:sameAsMedium <https://1145.am/db/2223193/Forbion_Capital_Partners>,
        <https://1145.am/db/2288529/Forbion_Capital_Partners>,
        <https://1145.am/db/2295207/Forbion_Capital_Partners>,
        <https://1145.am/db/2296065/Forbion_Capital_Partners>,
        <https://1145.am/db/2309872/Forbion_Capital_Partners>,
        <https://1145.am/db/2313401/Forbion_Capital_Partners>,
        <https://1145.am/db/2313410/Forbion_Capital_Partners>,
        <https://1145.am/db/2313915/Forbion_Capital_Partners>,
        <https://1145.am/db/2318829/Forbion_Capital_Partners>,
        <https://1145.am/db/2323586/Forbion_Capital_Partners>,
        <https://1145.am/db/2327009/Forbion_Capital_Partners>,
        <https://1145.am/db/2328040/Forbion_Capital_Partners>,
        <https://1145.am/db/2328763/Forbion_Capital_Partners>,
        <https://1145.am/db/2328769/Forbion_Capital_Partners>,
        <https://1145.am/db/2338373/Forbion_Capital_Partners>,
        <https://1145.am/db/2338987/Forbion_Capital_Partners>,
        <https://1145.am/db/2339427/Forbion_Capital_Partners>,
        <https://1145.am/db/2339428/Forbion_Capital_Partners>,
        <https://1145.am/db/2339933/Forbion_Capital_Partners>,
        <https://1145.am/db/2341942/Forbion_Capital_Partners>,
        <https://1145.am/db/2343202/Forbion_Capital_Partners>,
        <https://1145.am/db/2343210/Forbion_Capital_Partners>,
        <https://1145.am/db/2343244/Forbion_Capital_Partners>,
        <https://1145.am/db/2346397/Forbion_Capital_Partners>,
        <https://1145.am/db/2348506/Forbion_Capital_Partners>,
        <https://1145.am/db/2348523/Forbion_Capital_Partners>,
        <https://1145.am/db/2350101/Forbion_Capital_Partners>,
        <https://1145.am/db/2352566/Forbion_Capital_Partners>,
        <https://1145.am/db/2355512/Forbion_Capital_Partners>,
        <https://1145.am/db/2356989/Forbion_Capital_Partners>,
        <https://1145.am/db/2357956/Forbion_Capital_Partners>,
        <https://1145.am/db/2359960/Forbion_Capital_Partners>,
        <https://1145.am/db/2360313/Forbion_Capital_Partners>,
        <https://1145.am/db/2360317/Forbion_Capital_Partners>,
        <https://1145.am/db/2363593/Forbion_Capital_Partners>,
        <https://1145.am/db/2363597/Forbion_Capital_Partners>,
        <https://1145.am/db/2366539/Forbion_Capital_Partners>,
        <https://1145.am/db/2369872/Forbion_Capital_Partners>,
        <https://1145.am/db/2370054/Forbion_Capital_Partners>,
        <https://1145.am/db/2370056/Forbion_Capital_Partners>,
        <https://1145.am/db/2538923/Forbion_Capital_Partners>,
        <https://1145.am/db/2569491/Forbion_Capital_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2355511/MVM> a org:Organization ;
    ns1:basedInLowRaw "UK" ;
    ns1:description "private equity" ;
    ns1:documentDate "2010-11-23T15:57:00+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Xention raises £8M; Maxygen distributes Codexis shares; Insurer counts costs of diabetes;" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/xention-raises-%C2%A38m-maxygen-distributes-codexis-shares-insurer-counts-costs-of-diabetes> ;
    ns1:foundName "MVM" ;
    ns1:investor <https://1145.am/db/2355511/Series_D_Investment_Btg_International_Crédit_Agricole_Private_Equity_Forbion_Capital_Partners_Mvm_Seroba-Kernel_Life_Sciences_Ltd_Xention_Completed> ;
    ns1:name "MVM" ;
    ns1:sameAsHigh <https://1145.am/db/1059981/Kline_Hill_Partners>,
        <https://1145.am/db/1060630/Kline_Hill_Partners>,
        <https://1145.am/db/1272809/Mpe_Partners>,
        <https://1145.am/db/1346131/Mpe_Partners>,
        <https://1145.am/db/1639270/McNally_Capital>,
        <https://1145.am/db/1737208/Crédit_Mutuel_Equity>,
        <https://1145.am/db/1744957/Multiples_Private_Equity>,
        <https://1145.am/db/1887816/Matrix_Partners>,
        <https://1145.am/db/2063103/Mre_Partners>,
        <https://1145.am/db/2107009/Cvc_Capital>,
        <https://1145.am/db/2300233/Mh>,
        <https://1145.am/db/242660/Mbk_Partners>,
        <https://1145.am/db/2649781/Jmc_Capital_Partners>,
        <https://1145.am/db/2721798/Mbk_Partners>,
        <https://1145.am/db/2737463/Mbk_Partners>,
        <https://1145.am/db/274697/Mbk_Partners>,
        <https://1145.am/db/289370/Cvc_Capital>,
        <https://1145.am/db/551409/Mpe_Partners>,
        <https://1145.am/db/619535/V_Lp>,
        <https://1145.am/db/710764/Mkh_Capital_Partners>,
        <https://1145.am/db/734440/Mpe_Partners>,
        <https://1145.am/db/905614/Imm> ;
    ns1:sameAsMedium <https://1145.am/db/113321/MVM>,
        <https://1145.am/db/2355512/MVM> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2355512/Btg_International> a org:Organization ;
    ns1:basedInLowRaw "UK" ;
    ns1:documentDate "2010-11-23T16:11:46+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Xention Raises £8 Million in Private Equity Placement" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/xention-raises-%C2%A38-million-private-equity-placement> ;
    ns1:foundName "BTG International" ;
    ns1:investor <https://1145.am/db/2355512/Series_D_Investment_Btg_International_Cambridge_Crédit_Agricole_Private_Equity_Forbion_Capital_Partners_Mvm_Seroba-Kernel_Life_Sciences_Ltd_Xention_Ltd_Xention_Ltd_Completed> ;
    ns1:name "BTG International" ;
    ns1:sameAsMedium <https://1145.am/db/2355511/Btg_International> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2355512/Cambridge> a org:Organization ;
    ns1:basedInHighGeoName "United Kingdom of Great Britain and Northern Ireland" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2635167/about.rdf> ;
    ns1:basedInHighRaw "UK" ;
    ns1:description "Life Sciences" ;
    ns1:documentDate "2010-11-23T16:11:46+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Xention Raises £8 Million in Private Equity Placement" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/xention-raises-%C2%A38-million-private-equity-placement> ;
    ns1:foundName "CAMBRIDGE, UK -" ;
    ns1:industry "biopharmaceutical" ;
    ns1:name "CAMBRIDGE" ;
    ns1:sameAsHigh <https://1145.am/db/2300524/Oxford_Biotherapeutics>,
        <https://1145.am/db/2309255/Oxford_Biotherapeutics>,
        <https://1145.am/db/2326903/Merlin_Biomed>,
        <https://1145.am/db/2336941/Oxford_Biotherapeutics>,
        <https://1145.am/db/2348153/Cambridge_Mass-Scifluor_Life_Sciences>,
        <https://1145.am/db/2585810/Oxford_Biotherapeutics> ;
    ns1:sameAsMedium <https://1145.am/db/2304164/Cambridge>,
        <https://1145.am/db/2348761/Cambridge>,
        <https://1145.am/db/2361443/Cambridge>,
        <https://1145.am/db/2542093/Cambridge>,
        <https://1145.am/db/890955/Cambridge> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2355512/Crédit_Agricole_Private_Equity> a org:Organization ;
    ns1:basedInLowRaw "CAMBRIDGE, UK" ;
    ns1:description "Private Equity" ;
    ns1:documentDate "2010-11-23T16:11:46+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Xention Raises £8 Million in Private Equity Placement" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/xention-raises-%C2%A38-million-private-equity-placement> ;
    ns1:foundName "Crédit Agricole Private Equity" ;
    ns1:investor <https://1145.am/db/2355512/Series_D_Investment_Btg_International_Cambridge_Crédit_Agricole_Private_Equity_Forbion_Capital_Partners_Mvm_Seroba-Kernel_Life_Sciences_Ltd_Xention_Ltd_Xention_Ltd_Completed> ;
    ns1:name "Crédit Agricole Private Equity" ;
    ns1:sameAsHigh <https://1145.am/db/1724650/Crédit_Agricole_Private_Equity>,
        <https://1145.am/db/1921869/Crédit_Agricole_Private_Equity>,
        <https://1145.am/db/2295207/Crédit_Agricole_Private_Equity>,
        <https://1145.am/db/2309865/Credit_Agricole_Private_Equity>,
        <https://1145.am/db/2313401/Credit_Agricole_Private_Equity>,
        <https://1145.am/db/2326139/Credit_Agricole_Private_Equity>,
        <https://1145.am/db/2343244/Credit_Agricole_Private_Equity>,
        <https://1145.am/db/2355511/Crédit_Agricole_Private_Equity>,
        <https://1145.am/db/2361390/Crédit_Agricole_Private_Equity> ;
    ns1:sameAsMedium <https://1145.am/db/2291361/Crédit_Agricole_Private_Equity>,
        <https://1145.am/db/2293779/Credit_Agricole_Private_Equity>,
        <https://1145.am/db/2301966/Credit_Agricole_Private_Equity>,
        <https://1145.am/db/2309872/Credit_Agricole_Private_Equity>,
        <https://1145.am/db/2313410/Credit_Agricole_Private_Equity>,
        <https://1145.am/db/2326130/Credit_Agricole_Private_Equity>,
        <https://1145.am/db/2343250/Credit_Agricole_Private_Equity>,
        <https://1145.am/db/2346397/Crédit_Agricole_Private_Equity> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2355512/Forbion_Capital_Partners> a org:Organization ;
    ns1:basedInLowRaw "UK" ;
    ns1:documentDate "2010-11-23T16:11:46+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Xention Raises £8 Million in Private Equity Placement" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/xention-raises-%C2%A38-million-private-equity-placement> ;
    ns1:foundName "Forbion Capital Partners" ;
    ns1:investor <https://1145.am/db/2355512/Series_D_Investment_Btg_International_Cambridge_Crédit_Agricole_Private_Equity_Forbion_Capital_Partners_Mvm_Seroba-Kernel_Life_Sciences_Ltd_Xention_Ltd_Xention_Ltd_Completed> ;
    ns1:name "Forbion Capital Partners" ;
    ns1:sameAsMedium <https://1145.am/db/2223193/Forbion_Capital_Partners>,
        <https://1145.am/db/2288529/Forbion_Capital_Partners>,
        <https://1145.am/db/2295207/Forbion_Capital_Partners>,
        <https://1145.am/db/2296065/Forbion_Capital_Partners>,
        <https://1145.am/db/2301966/Forbion_Capital_Partners>,
        <https://1145.am/db/2309865/Forbion_Capital_Partners>,
        <https://1145.am/db/2309872/Forbion_Capital_Partners>,
        <https://1145.am/db/2313401/Forbion_Capital_Partners>,
        <https://1145.am/db/2313410/Forbion_Capital_Partners>,
        <https://1145.am/db/2313915/Forbion_Capital_Partners>,
        <https://1145.am/db/2318829/Forbion_Capital_Partners>,
        <https://1145.am/db/2320503/Forbion_Capital_Partners>,
        <https://1145.am/db/2323586/Forbion_Capital_Partners>,
        <https://1145.am/db/2327009/Forbion_Capital_Partners>,
        <https://1145.am/db/2328040/Forbion_Capital_Partners>,
        <https://1145.am/db/2328763/Forbion_Capital_Partners>,
        <https://1145.am/db/2328769/Forbion_Capital_Partners>,
        <https://1145.am/db/2329919/Forbion_Capital_Partners>,
        <https://1145.am/db/2336126/Forbion_Capital_Partners>,
        <https://1145.am/db/2338373/Forbion_Capital_Partners>,
        <https://1145.am/db/2338987/Forbion_Capital_Partners>,
        <https://1145.am/db/2339427/Forbion_Capital_Partners>,
        <https://1145.am/db/2339428/Forbion_Capital_Partners>,
        <https://1145.am/db/2339932/Forbion_Capital_Partners>,
        <https://1145.am/db/2339933/Forbion_Capital_Partners>,
        <https://1145.am/db/2341942/Forbion_Capital_Partners>,
        <https://1145.am/db/2343202/Forbion_Capital_Partners>,
        <https://1145.am/db/2343210/Forbion_Capital_Partners>,
        <https://1145.am/db/2343244/Forbion_Capital_Partners>,
        <https://1145.am/db/2346397/Forbion_Capital_Partners>,
        <https://1145.am/db/2348506/Forbion_Capital_Partners>,
        <https://1145.am/db/2348523/Forbion_Capital_Partners>,
        <https://1145.am/db/2350101/Forbion_Capital_Partners>,
        <https://1145.am/db/2352566/Forbion_Capital_Partners>,
        <https://1145.am/db/2355511/Forbion_Capital_Partners>,
        <https://1145.am/db/2356989/Forbion_Capital_Partners>,
        <https://1145.am/db/2357941/Forbion_Capital_Partners>,
        <https://1145.am/db/2357956/Forbion_Capital_Partners>,
        <https://1145.am/db/2359960/Forbion_Capital_Partners>,
        <https://1145.am/db/2360313/Forbion_Capital_Partners>,
        <https://1145.am/db/2360317/Forbion_Capital_Partners>,
        <https://1145.am/db/2361390/Forbion_Capital_Partners>,
        <https://1145.am/db/2363593/Forbion_Capital_Partners>,
        <https://1145.am/db/2363597/Forbion_Capital_Partners>,
        <https://1145.am/db/2366539/Forbion_Capital_Partners>,
        <https://1145.am/db/2369872/Forbion_Capital_Partners>,
        <https://1145.am/db/2370054/Forbion_Capital_Partners>,
        <https://1145.am/db/2370056/Forbion_Capital_Partners>,
        <https://1145.am/db/2538923/Forbion_Capital_Partners>,
        <https://1145.am/db/2569491/Forbion_Capital_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2355512/MVM> a org:Organization ;
    ns1:basedInLowRaw "UK" ;
    ns1:documentDate "2010-11-23T16:11:46+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Xention Raises £8 Million in Private Equity Placement" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/xention-raises-%C2%A38-million-private-equity-placement> ;
    ns1:foundName "MVM" ;
    ns1:investor <https://1145.am/db/2355512/Series_D_Investment_Btg_International_Cambridge_Crédit_Agricole_Private_Equity_Forbion_Capital_Partners_Mvm_Seroba-Kernel_Life_Sciences_Ltd_Xention_Ltd_Xention_Ltd_Completed> ;
    ns1:name "MVM" ;
    ns1:sameAsMedium <https://1145.am/db/113321/MVM>,
        <https://1145.am/db/2355511/MVM> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2355512/Seroba-Kernel_Life_Sciences_Ltd> a org:Organization ;
    ns1:basedInLowRaw "UK" ;
    ns1:description "Investing" ;
    ns1:documentDate "2010-11-23T16:11:46+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Xention Raises £8 Million in Private Equity Placement" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/xention-raises-%C2%A38-million-private-equity-placement> ;
    ns1:foundName "Seroba-Kernel Life Sciences Ltd" ;
    ns1:investor <https://1145.am/db/2355512/Series_D_Investment_Btg_International_Cambridge_Crédit_Agricole_Private_Equity_Forbion_Capital_Partners_Mvm_Seroba-Kernel_Life_Sciences_Ltd_Xention_Ltd_Xention_Ltd_Completed> ;
    ns1:name "Seroba-Kernel Life Sciences Ltd" ;
    ns1:sameAsHigh <https://1145.am/db/2330255/Tilocor_Life_Science>,
        <https://1145.am/db/2331304/Tilocor_Life_Science> ;
    ns1:sameAsMedium <https://1145.am/db/2355511/Seroba-Kernel_Life_Sciences_Ltd> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2356567/Covagen> a org:Organization ;
    ns1:basedInHighGeoName "Switzerland" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2658434/about.rdf> ;
    ns1:basedInHighRaw "Switzerland" ;
    ns1:description "Life Sciences" ;
    ns1:documentDate "2010-11-29T16:58:07+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Covagen closes Series A financing round with Seroba Kernel as lead investor" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/covagen-closes-series-a-financing-round-seroba-kernel-as-lead-investor> ;
    ns1:foundName "Covagen" ;
    ns1:industry "Life Sciences" ;
    ns1:name "Covagen" ;
    ns1:sameAsHigh <https://1145.am/db/1243074/Covaris>,
        <https://1145.am/db/1244550/Covaris>,
        <https://1145.am/db/2312833/Covidien> ;
    ns1:sameAsMedium <https://1145.am/db/2338952/Covagen>,
        <https://1145.am/db/2349077/Covagen>,
        <https://1145.am/db/2350140/Covagen>,
        <https://1145.am/db/2360254/Covagen>,
        <https://1145.am/db/2360256/Covagen> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2356567/Novartis_Venture_Fund> a org:Organization ;
    ns1:basedInLowRaw "Zurich" ;
    ns1:description "investing" ;
    ns1:documentDate "2010-11-29T16:58:07+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Covagen closes Series A financing round with Seroba Kernel as lead investor" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/covagen-closes-series-a-financing-round-seroba-kernel-as-lead-investor> ;
    ns1:foundName "Novartis Venture Fund" ;
    ns1:investor <https://1145.am/db/2356567/Series_A_Investment_Covagen_Edmond_De_Rothschild_Investment_Partners_Mp_Healthcare_Venture_Management_Inc_Mp_Healthcare_Venture_Management_Inc_Novartis_Venture_Fund_Seroba_Kernel_Life_Sciences_Ventech_Completed> ;
    ns1:name "Novartis Venture Fund" ;
    ns1:sameAsHigh <https://1145.am/db/1340338/Novartis_Venture_Fund>,
        <https://1145.am/db/2153726/Novartis_Venture_Fund_And_Partners_Innovation_Fund>,
        <https://1145.am/db/2297795/Novartis_Venture_Funds>,
        <https://1145.am/db/2306568/Novartis_Bioventure_Fund>,
        <https://1145.am/db/2310907/Novartis_Venture_Fund>,
        <https://1145.am/db/2313438/Novartis_Venture_Fund>,
        <https://1145.am/db/2317737/Novartis_Venture_Fund>,
        <https://1145.am/db/2323228/Novartis_Venture_Fund>,
        <https://1145.am/db/2323683/The_Novartis_Venture_Fund>,
        <https://1145.am/db/2324255/Novartis_Bioventures>,
        <https://1145.am/db/2326222/Novartis_Venture_Fund>,
        <https://1145.am/db/2327256/Novartis_Venture_Fund>,
        <https://1145.am/db/2327442/Novartis_Venture_Fund>,
        <https://1145.am/db/2330711/Novartis_Venture_Fund>,
        <https://1145.am/db/2331343/Novartis_Venture_Funds>,
        <https://1145.am/db/2331751/Novartis_Venture_Fund>,
        <https://1145.am/db/2332658/Novartis_Venture_Fund>,
        <https://1145.am/db/2332659/Novartis_Venture_Fund>,
        <https://1145.am/db/2335764/Novartis_Venture_Funds>,
        <https://1145.am/db/2339196/Novartis_Venture_Fund>,
        <https://1145.am/db/2340344/Novartis_Venture_Fund>,
        <https://1145.am/db/2340345/Novartis_Venture_Fund>,
        <https://1145.am/db/2340615/Novartis>,
        <https://1145.am/db/2343486/Novartis_Venture_Funds>,
        <https://1145.am/db/2343966/Novartis_Venture_Funds>,
        <https://1145.am/db/2344045/Novartis_Venture_Fund>,
        <https://1145.am/db/2352203/Novartis_Venture_Fund>,
        <https://1145.am/db/2352204/Novartis_Venture_Fund>,
        <https://1145.am/db/2354770/Novartis_Bioventures>,
        <https://1145.am/db/2356393/Novartis_Venture_Fund>,
        <https://1145.am/db/2356395/Novartis_Venture_Fund>,
        <https://1145.am/db/2358725/Novartis_Venture_Funds>,
        <https://1145.am/db/2361588/Novartis_Venture_Funds>,
        <https://1145.am/db/2363907/Novartis_Venture_Funds>,
        <https://1145.am/db/2369548/Novartis_Venture_Fund>,
        <https://1145.am/db/2575232/Novartis_Bioventures>,
        <https://1145.am/db/509733/Novartis_Venture_Fund>,
        <https://1145.am/db/619955/Novartis>,
        <https://1145.am/db/623985/Novartis>,
        <https://1145.am/db/866508/Novartis_Venture_Fund> ;
    ns1:sameAsMedium <https://1145.am/db/1523031/Novartis_Venture_Fund>,
        <https://1145.am/db/207823/Novartis_Venture_Fund>,
        <https://1145.am/db/2152422/Novartis_Venture_Fund>,
        <https://1145.am/db/2247240/Novartis_Venture_Funds>,
        <https://1145.am/db/2289983/Novartis_Venture_Funds>,
        <https://1145.am/db/2292300/Novartis_Venture_Funds>,
        <https://1145.am/db/2292345/Novartis_Venture_Funds>,
        <https://1145.am/db/2298176/Novartis_Venture_Fund>,
        <https://1145.am/db/2307682/Novartis_Venture_Fund>,
        <https://1145.am/db/2310905/Novartis_Venture_Fund>,
        <https://1145.am/db/2315943/Novartis_Venture_Fund>,
        <https://1145.am/db/2315957/Novartis_Venture_Fund>,
        <https://1145.am/db/2323210/Novartis_Venture_Funds>,
        <https://1145.am/db/2323682/The_Novartis_Venture_Fund>,
        <https://1145.am/db/2327441/Novartis_Venture_Fund>,
        <https://1145.am/db/2331750/Novartis_Venture_Fund>,
        <https://1145.am/db/2336032/Novartis_Venture_Fund>,
        <https://1145.am/db/2336328/Novartis_Venture_Funds>,
        <https://1145.am/db/2337294/Novartis_Venture_Funds>,
        <https://1145.am/db/2337645/Novartis_Venture_Fund>,
        <https://1145.am/db/2338527/Novartis_Venture_Funds>,
        <https://1145.am/db/2339193/Novartis_Venture_Fund>,
        <https://1145.am/db/2340612/Novartis_Venture_Fund>,
        <https://1145.am/db/2340942/Novartis_Venture_Fund>,
        <https://1145.am/db/2343493/Novartis_Venture_Funds>,
        <https://1145.am/db/2348012/Novartis_Venture_Fund>,
        <https://1145.am/db/2348348/Novartis_Venture_Funds>,
        <https://1145.am/db/2348350/Novartis_Venture_Funds>,
        <https://1145.am/db/2351958/Novartis_Venture_Funds>,
        <https://1145.am/db/2351959/Novartis_Venture_Fund>,
        <https://1145.am/db/2352216/Novartis_Venture_Fund>,
        <https://1145.am/db/2353098/Novartis_Venture_Fund>,
        <https://1145.am/db/2356287/Novartis_Venture_Fund>,
        <https://1145.am/db/2356290/Novartis_Venture_Fund>,
        <https://1145.am/db/2356391/Novartis_Venture_Fund>,
        <https://1145.am/db/2358430/Novartis_Venture_Funds>,
        <https://1145.am/db/2358733/Novartis_Venture_Fund>,
        <https://1145.am/db/2362715/Novartis_Venture_Funds>,
        <https://1145.am/db/2363510/Novartis_Venture_Funds>,
        <https://1145.am/db/2367046/Novartis_Venture_Fund>,
        <https://1145.am/db/2551315/Novartis_Venture_Fund>,
        <https://1145.am/db/2570481/Novartis_Venture_Fund>,
        <https://1145.am/db/2570483/Novartis_Venture_Fund>,
        <https://1145.am/db/2578837/Novartis_Venture_Funds>,
        <https://1145.am/db/2592611/Novartis_Venture_Funds> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2356567/Seroba_Kernel_Life_Sciences> a org:Organization ;
    ns1:basedInHighGeoName "Dublin",
        "Switzerland" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2658434/about.rdf>,
        <https://sws.geonames.org/2964574/about.rdf> ;
    ns1:basedInHighRaw "Dublin, Ireland",
        "Switzerland" ;
    ns1:description "Life Sciences" ;
    ns1:documentDate "2010-11-29T16:58:07+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Covagen closes Series A financing round with Seroba Kernel as lead investor" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/covagen-closes-series-a-financing-round-seroba-kernel-as-lead-investor> ;
    ns1:foundName "Seroba Kernel",
        "Seroba Kernel Life Sciences" ;
    ns1:industry "Life Sciences" ;
    ns1:investor <https://1145.am/db/2356567/Series_A_Investment_Covagen_Edmond_De_Rothschild_Investment_Partners_Mp_Healthcare_Venture_Management_Inc_Mp_Healthcare_Venture_Management_Inc_Novartis_Venture_Fund_Seroba_Kernel_Life_Sciences_Ventech_Completed> ;
    ns1:name "Seroba Kernel",
        "Seroba Kernel Life Sciences" ;
    ns1:sameAsHigh <https://1145.am/db/1386529/Seroba_Life_Sciences>,
        <https://1145.am/db/2291361/Seroba_Kernel_Life_Sciences>,
        <https://1145.am/db/2301096/Seroba_Life_Sciences>,
        <https://1145.am/db/2301620/Seroba_Life_Sciences>,
        <https://1145.am/db/2330711/Seroba_Kernel_Life_Sciences>,
        <https://1145.am/db/2331751/Seroba_Kernel_Life_Sciences>,
        <https://1145.am/db/2338987/Seroba_Kernel_Life_Sciences>,
        <https://1145.am/db/2352203/Seroba_Kernel_Life_Sciences>,
        <https://1145.am/db/2352204/Seroba_Kernel_Life_Sciences>,
        <https://1145.am/db/2355511/Seroba-Kernel_Life_Sciences_Ltd>,
        <https://1145.am/db/2364510/Seroba_Kernel_Life_Sciences>,
        <https://1145.am/db/2364514/Seroba_Kernel_Life_Sciences>,
        <https://1145.am/db/2364518/Seroba_Kernel_Life_Sciences> ;
    ns1:sameAsMedium <https://1145.am/db/2331750/Seroba_Kernel_Life_Sciences>,
        <https://1145.am/db/2352216/Seroba_Kernel_Life_Sciences> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2357622/Celulas_Genetica> a org:Organization ;
    ns1:basedInHighGeoName "Republic of Panama" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/3703430/about.rdf> ;
    ns1:basedInHighRaw "Panama" ;
    ns1:description "stem-cell technology acquisition and development" ;
    ns1:documentDate "2010-12-01T14:22:45+00:00"^^xsd:dateTime ;
    ns1:documentTitle "EHSI Acquires Stem Cell Biotech Firm Celulas Genetica" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/ehsi-acquires-stem-cell-biotech-firm-celulas-genetica> ;
    ns1:foundName "Celulas Genetica" ;
    ns1:industry "biotechnology" ;
    ns1:name "Celulas Genetica" ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2357626/Angus_Mitchell> a org:Organization ;
    ns1:basedInLowRaw "SAN DIEGO" ;
    ns1:documentDate "2010-12-01T15:12:33+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Histogen Announces Completion of Series A Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/histogen-announces-completion-of-series-a-financing-0> ;
    ns1:foundName "Angus Mitchell" ;
    ns1:investor <https://1145.am/db/2357626/Series_A_Investment_Angus_Mitchell_Histogen_Leonard_Lavin_Lordship_Ventures_Secure_Medical_Completed> ;
    ns1:name "Angus Mitchell" ;
    ns1:sameAsMedium <https://1145.am/db/2357628/Angus_Mitchell> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2357626/Leonard_Lavin> a org:Organization ;
    ns1:basedInLowRaw "SAN DIEGO" ;
    ns1:documentDate "2010-12-01T15:12:33+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Histogen Announces Completion of Series A Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/histogen-announces-completion-of-series-a-financing-0> ;
    ns1:foundName "Leonard Lavin" ;
    ns1:investor <https://1145.am/db/2357626/Series_A_Investment_Angus_Mitchell_Histogen_Leonard_Lavin_Lordship_Ventures_Secure_Medical_Completed> ;
    ns1:name "Leonard Lavin" ;
    ns1:sameAsMedium <https://1145.am/db/2357628/Leonard_Lavin> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2357626/Lordship_Ventures> a org:Organization ;
    ns1:basedInLowRaw "SAN DIEGO" ;
    ns1:documentDate "2010-12-01T15:12:33+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Histogen Announces Completion of Series A Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/histogen-announces-completion-of-series-a-financing-0> ;
    ns1:foundName "Lordship Ventures" ;
    ns1:investor <https://1145.am/db/2357626/Series_A_Investment_Angus_Mitchell_Histogen_Leonard_Lavin_Lordship_Ventures_Secure_Medical_Completed> ;
    ns1:name "Lordship Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/2357628/Lordship_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2357626/Secure_Medical> a org:Organization ;
    ns1:basedInLowRaw "SAN DIEGO" ;
    ns1:documentDate "2010-12-01T15:12:33+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Histogen Announces Completion of Series A Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/histogen-announces-completion-of-series-a-financing-0> ;
    ns1:foundName "Secure Medical" ;
    ns1:investor <https://1145.am/db/2357626/Series_A_Investment_Angus_Mitchell_Histogen_Leonard_Lavin_Lordship_Ventures_Secure_Medical_Completed> ;
    ns1:name "Secure Medical" ;
    ns1:sameAsMedium <https://1145.am/db/2357628/Secure_Medical> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2357628/Angus_Mitchell> a org:Organization ;
    ns1:description "private investors" ;
    ns1:documentDate "2010-12-01T15:20:17+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Histogen Announces Completion of Series A Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/histogen-announces-completion-of-series-a-financing> ;
    ns1:foundName "Angus Mitchell" ;
    ns1:investor <https://1145.am/db/2357628/Series_A_Investment_Angus_Mitchell_Histogen_Leonard_Lavin_Lordship_Ventures_Secure_Medical_Completed> ;
    ns1:name "Angus Mitchell" ;
    ns1:sameAsMedium <https://1145.am/db/2357626/Angus_Mitchell> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2357628/Leonard_Lavin> a org:Organization ;
    ns1:description "private investors" ;
    ns1:documentDate "2010-12-01T15:20:17+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Histogen Announces Completion of Series A Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/histogen-announces-completion-of-series-a-financing> ;
    ns1:foundName "Leonard Lavin" ;
    ns1:investor <https://1145.am/db/2357628/Series_A_Investment_Angus_Mitchell_Histogen_Leonard_Lavin_Lordship_Ventures_Secure_Medical_Completed> ;
    ns1:name "Leonard Lavin" ;
    ns1:sameAsMedium <https://1145.am/db/2357626/Leonard_Lavin> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2357628/Lordship_Ventures> a org:Organization ;
    ns1:description "private investors" ;
    ns1:documentDate "2010-12-01T15:20:17+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Histogen Announces Completion of Series A Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/histogen-announces-completion-of-series-a-financing> ;
    ns1:foundName "Lordship Ventures" ;
    ns1:investor <https://1145.am/db/2357628/Series_A_Investment_Angus_Mitchell_Histogen_Leonard_Lavin_Lordship_Ventures_Secure_Medical_Completed> ;
    ns1:name "Lordship Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/2357626/Lordship_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2357628/Secure_Medical> a org:Organization ;
    ns1:description "private investors" ;
    ns1:documentDate "2010-12-01T15:20:17+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Histogen Announces Completion of Series A Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/histogen-announces-completion-of-series-a-financing> ;
    ns1:foundName "Secure Medical" ;
    ns1:investor <https://1145.am/db/2357628/Series_A_Investment_Angus_Mitchell_Histogen_Leonard_Lavin_Lordship_Ventures_Secure_Medical_Completed> ;
    ns1:name "Secure Medical" ;
    ns1:sameAsMedium <https://1145.am/db/2357626/Secure_Medical> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2358030/Protagen_Ag> a org:Organization ;
    ns1:basedInHighGeoName "Dortmund" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2935517/about.rdf> ;
    ns1:basedInHighRaw "Dortmund, Germany" ;
    ns1:description "Business" ;
    ns1:documentDate "2010-09-07T15:33:08+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Protagen Raises € 10.0 Million For Diagnostic Developments" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/protagen-raises-%E2%82%AC-10-0-million-for-diagnostic-developments> ;
    ns1:foundName "Protagen",
        "Protagen AG" ;
    ns1:name "Protagen",
        "Protagen AG" ;
    ns1:sameAsMedium <https://1145.am/db/2295226/Protagen>,
        <https://1145.am/db/2296346/Protagen>,
        <https://1145.am/db/2296354/Protagen>,
        <https://1145.am/db/2358026/Protagen_Ag> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2358031/Alethia_Biotherapeutics_Inc> a org:Organization ;
    ns1:basedInHighGeoName "Montréal" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/6077246/about.rdf> ;
    ns1:basedInHighRaw "Montreal" ;
    ns1:basedInLowRaw "Canada" ;
    ns1:description "Biopharmaceutical",
        "Biotherapeutics" ;
    ns1:documentDate "2010-09-07T15:34:11+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Alethia Biotherapeutics Secures C$9.6 Million in Series A Financing to Fund Its Therapeutic Monoclonal Antibody Product Pipeline" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/alethia-biotherapeutics-secures-c-9-6-million-series-a-financing-to-fund-its-therapeutic> ;
    ns1:foundName "Alethia",
        "Alethia Biotherapeutics",
        "Alethia Biotherapeutics Inc." ;
    ns1:industry "biopharmaceutical" ;
    ns1:name "Alethia Biotherapeutics",
        "Alethia Biotherapeutics Inc." ;
    ns1:sameAsHigh <https://1145.am/db/1650252/Iaso_Biotherapeutics>,
        <https://1145.am/db/2345002/Alethia_Biotherapeutics_Inc>,
        <https://1145.am/db/2358026/Alethia_Biotherapeutics>,
        <https://1145.am/db/478360/Iaso_Biotherapeutics> ;
    ns1:sameAsMedium <https://1145.am/db/2314578/Alethia_Biotherapeutics> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2358635/Collegium_Pharmaceutical> a org:Organization ;
    ns1:basedInHighGeoName "Cumberland" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5221703/about.rdf> ;
    ns1:basedInHighRaw "CUMBERLAND, R.I." ;
    ns1:buyer <https://1145.am/db/2358635/Onset_Therapeutics_Divestment> ;
    ns1:description "developing, manufacturing, acquiring and marketing a broad portfolio of innovative dermatology products" ;
    ns1:documentDate "2010-12-01T17:30:41+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Collegium Pharmaceutical Announces the Spin-out of Onset Therapeutics and the Launch of PreCision Dermatology Inc" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/collegium-pharmaceutical-announces-spin-out-of-onset-therapeutics-and-launch-of-precision> ;
    ns1:foundName "Collegium Pharmaceutical, Inc." ;
    ns1:industry "pharmaceutical" ;
    ns1:name "Collegium Pharmaceutical" ;
    ns1:sameAsHigh <https://1145.am/db/1336076/Nlc_Pharma>,
        <https://1145.am/db/2152744/Essa_Pharma>,
        <https://1145.am/db/2152756/Eusa_Pharma>,
        <https://1145.am/db/2155863/Glypharma>,
        <https://1145.am/db/2202776/Eusa_Pharma_Inc>,
        <https://1145.am/db/2284072/Alliance_Pharma>,
        <https://1145.am/db/2299131/Nmd_Pharma>,
        <https://1145.am/db/2302052/Antares_Pharma>,
        <https://1145.am/db/2303588/Eusa_Pharma_Inc>,
        <https://1145.am/db/2305488/Eusa_Pharma_Inc>,
        <https://1145.am/db/2306649/Eusa_Pharma_Inc>,
        <https://1145.am/db/2306885/U3_Pharma>,
        <https://1145.am/db/2306929/Mgi_Pharma>,
        <https://1145.am/db/2309040/Ista_Pharma>,
        <https://1145.am/db/2310483/Antares_Pharma>,
        <https://1145.am/db/2313509/Mgi_Pharma>,
        <https://1145.am/db/2315519/Eusa_Pharma>,
        <https://1145.am/db/2318600/Idm_Pharma>,
        <https://1145.am/db/2318606/Idm_Pharma>,
        <https://1145.am/db/2318984/Idm_Pharma>,
        <https://1145.am/db/2320110/Pharma_Pass_Ii>,
        <https://1145.am/db/2321910/Idm_Pharma>,
        <https://1145.am/db/2321912/Idm_Pharma>,
        <https://1145.am/db/2324112/Antares_Pharma>,
        <https://1145.am/db/2327512/Eusa_Pharma_Inc>,
        <https://1145.am/db/2329301/Penn_Pharma>,
        <https://1145.am/db/2331898/U3_Pharma_Ag>,
        <https://1145.am/db/2335807/Antares_Pharma>,
        <https://1145.am/db/2335971/Antares_Pharma>,
        <https://1145.am/db/2336879/Antares_Pharma>,
        <https://1145.am/db/2338428/Collegium_Pharmaceutical>,
        <https://1145.am/db/2338429/Collegium_Pharmaceutical>,
        <https://1145.am/db/2340204/Collegium_Pharmaceutical>,
        <https://1145.am/db/2340207/Collegium_Pharmaceutical>,
        <https://1145.am/db/2342825/Antares_Pharma>,
        <https://1145.am/db/2346313/Ucb_Pharma>,
        <https://1145.am/db/2347775/Antares_Pharma_Inc>,
        <https://1145.am/db/2348187/Eusa_Pharma>,
        <https://1145.am/db/2350273/Collegium_Pharmaceutical>,
        <https://1145.am/db/2352288/Collegium_Pharmaceutical>,
        <https://1145.am/db/2353565/Eusa_Pharma>,
        <https://1145.am/db/2355927/Eusa_Pharma>,
        <https://1145.am/db/2357116/Nps_Pharma>,
        <https://1145.am/db/2360875/Antares_Pharma>,
        <https://1145.am/db/2364528/Antares_Pharma>,
        <https://1145.am/db/2366405/Collegium_Pharmaceutical>,
        <https://1145.am/db/2367945/Collegium_Pharmaceutical_Inc>,
        <https://1145.am/db/2369052/Essa_Pharma_Inc>,
        <https://1145.am/db/2551477/Penn_Pharma>,
        <https://1145.am/db/2551505/Eusa_Pharma>,
        <https://1145.am/db/2551516/Penn_Pharma>,
        <https://1145.am/db/2553920/Antares_Pharma>,
        <https://1145.am/db/2555777/Steri-Pharma>,
        <https://1145.am/db/2557083/Collegium_Pharmaceutical>,
        <https://1145.am/db/2569599/Collegium_Pharmaceutical>,
        <https://1145.am/db/2569778/Eusa_Pharma>,
        <https://1145.am/db/2570482/Ra_Pharma>,
        <https://1145.am/db/2592696/Alliance_Pharma>,
        <https://1145.am/db/659107/Nlc_Pharma>,
        <https://1145.am/db/659216/Nlc_Pharma>,
        <https://1145.am/db/669589/Eusa_Pharma>,
        <https://1145.am/db/670217/Eusa_Pharma>,
        <https://1145.am/db/832408/Collegium_Pharmaceutical>,
        <https://1145.am/db/833269/Collegium_Pharmaceutical>,
        <https://1145.am/db/926227/Collegium_Pharmaceutical_Inc> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2358635/Onset_Therapeutics> a org:Organization ;
    ns1:basedInHighGeoName "Cumberland" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5221703/about.rdf> ;
    ns1:basedInHighRaw "CUMBERLAND, R.I." ;
    ns1:description "Dermatology" ;
    ns1:documentDate "2010-12-01T17:30:41+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Collegium Pharmaceutical Announces the Spin-out of Onset Therapeutics and the Launch of PreCision Dermatology Inc" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/collegium-pharmaceutical-announces-spin-out-of-onset-therapeutics-and-launch-of-precision> ;
    ns1:foundName "Onset Therapeutics, LLC" ;
    ns1:industry "pharmaceutical" ;
    ns1:name "Onset Therapeutics" ;
    ns1:sameAsMedium <https://1145.am/db/2303707/Onset_Therapeutics> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2358635/Onset_Therapeutics_Divestment> a ns1:CorporateFinanceActivity ;
    ns1:activityType "divestment",
        "division",
        "merger" ;
    ns1:documentDate "2010-12-01T17:30:41+00:00"^^xsd:dateTime ;
    ns1:documentExtract "CUMBERLAND, R.I.- (BUSINESS WIRE) -Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, announced today that it has completed the spin-out of Onset Therapeutics, LLC, its wholly owned subsidiary focused on the Dermatology market." ;
    ns1:documentTitle "Collegium Pharmaceutical Announces the Spin-out of Onset Therapeutics and the Launch of PreCision Dermatology Inc" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/collegium-pharmaceutical-announces-spin-out-of-onset-therapeutics-and-launch-of-precision> ;
    ns1:foundName "out",
        "spin",
        "spin-out" ;
    ns1:name "out",
        "spin",
        "spin-out" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2358635/Onset_Therapeutics> ;
    ns1:targetName "Onset Therapeutics" ;
    ns1:vendor <https://1145.am/db/2358635/Collegium_Pharmaceutical> ;
    ns1:whereGeoName "Cumberland" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5221703/about.rdf> ;
    ns1:whereRaw "CUMBERLAND, R.I." .

<https://1145.am/db/2359104/Ark_Therapeutics_Has_Not_Happened> a ns1:CorporateFinanceActivity ;
    ns1:documentDate "2010-09-09T16:17:38+00:00"^^xsd:dateTime ;
    ns1:documentExtract "> London - based Ark Therapeutics has announced a restructuring and a refocus of its R & D program." ;
    ns1:documentTitle "Ark restructures; Genentech sees promise in preclinical cancer therapy" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/ark-restructures-genentech-sees-promise-preclinical-cancer-therapy> ;
    ns1:foundName "restructuring" ;
    ns1:name "restructuring" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "has not happened" ;
    ns1:vendor <https://1145.am/db/2359104/Ark_Therapeutics> ;
    ns1:whereGeoName "London" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/2643743/about.rdf> ;
    ns1:whereRaw "London" .

<https://1145.am/db/2359125/Good_Start_Genetics> a org:Organization ;
    ns1:description "developing and launching sequencing - based pre-pregnancy genetic screening test" ;
    ns1:documentDate "2010-09-10T13:16:20+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Good Start Genetics, Inc. Raises $18 Million to Develop and Launch Sequencing-Based Pre-Pregnancy Genetic Screening Test" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/good-start-genetics-inc-raises-18-million-to-develop-and-launch-sequencing-based-pre> ;
    ns1:foundName "Good Start Genetics, Inc." ;
    ns1:name "Good Start Genetics" ;
    ns1:sameAsMedium <https://1145.am/db/2296069/Good_Start_Genetics>,
        <https://1145.am/db/2297604/Good_Start_Genetics>,
        <https://1145.am/db/2300074/Good_Start_Genetics> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2360174/5am_Ventures> a org:Organization ;
    ns1:basedInLowRaw "Calif" ;
    ns1:description "venture capital" ;
    ns1:documentDate "2010-09-13T14:04:48+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Relypsa Raises $70 Million in Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/relypsa-raises-70-million-series-b-financing> ;
    ns1:foundName "5AM Ventures" ;
    ns1:investor <https://1145.am/db/2360174/Series_B_Investment_5am_Ventures_Delphi_Ventures_Mediphase_Venture_Partners_New_Leaf_Venture_Partners_Orbimed_Advisors_Llc_Relypsa_Sprout_Group_Completed> ;
    ns1:name "5AM Ventures" ;
    ns1:sameAsHigh <https://1145.am/db/1307620/Z5_Capital>,
        <https://1145.am/db/1765721/5y_Capital>,
        <https://1145.am/db/2153910/5am_Ventures>,
        <https://1145.am/db/2286204/5am_Ventures>,
        <https://1145.am/db/2288016/5am_Ventures>,
        <https://1145.am/db/2318733/5am_Ventures>,
        <https://1145.am/db/2319784/5am_Ventures>,
        <https://1145.am/db/2329778/5am_Ventures>,
        <https://1145.am/db/2339886/5am_Ventures>,
        <https://1145.am/db/2359864/5am_Ventures>,
        <https://1145.am/db/2362475/5am_Ventures>,
        <https://1145.am/db/2592685/5am_Ventures> ;
    ns1:sameAsMedium <https://1145.am/db/1157541/5am_Ventures>,
        <https://1145.am/db/1533327/5am_Ventures>,
        <https://1145.am/db/1533685/5am_Ventures>,
        <https://1145.am/db/1608803/5am_Ventures>,
        <https://1145.am/db/1669813/5am_Ventures>,
        <https://1145.am/db/2152422/5am_Ventures>,
        <https://1145.am/db/2153726/5am_Ventures>,
        <https://1145.am/db/2283394/5am_Ventures>,
        <https://1145.am/db/2286665/5am_Ventures>,
        <https://1145.am/db/2298404/5am_Ventures>,
        <https://1145.am/db/2298642/5am_Ventures>,
        <https://1145.am/db/2306549/5am_Ventures>,
        <https://1145.am/db/2306551/5am_Ventures>,
        <https://1145.am/db/2306754/5am_Ventures>,
        <https://1145.am/db/2311595/5am_Ventures>,
        <https://1145.am/db/2313985/5am_Ventures>,
        <https://1145.am/db/2317919/5am_Ventures>,
        <https://1145.am/db/2322646/5am_Ventures>,
        <https://1145.am/db/2323210/5am_Ventures>,
        <https://1145.am/db/2323226/5am_Ventures>,
        <https://1145.am/db/2324195/5am_Ventures>,
        <https://1145.am/db/2328146/5am_Ventures>,
        <https://1145.am/db/2328338/5am_Ventures>,
        <https://1145.am/db/2332322/5am_Ventures>,
        <https://1145.am/db/2339885/5am_Ventures>,
        <https://1145.am/db/2340344/5am_Ventures>,
        <https://1145.am/db/2340345/5am_Ventures>,
        <https://1145.am/db/2340348/5am_Ventures>,
        <https://1145.am/db/2341003/5am_Ventures>,
        <https://1145.am/db/2342352/5am_Ventures>,
        <https://1145.am/db/2347885/5am_Ventures>,
        <https://1145.am/db/2348754/5am_Ventures>,
        <https://1145.am/db/2348857/5am_Ventures>,
        <https://1145.am/db/2349120/5am_Ventures>,
        <https://1145.am/db/2349834/5am_Ventures>,
        <https://1145.am/db/2351316/5am_Ventures>,
        <https://1145.am/db/2351683/5am_Ventures>,
        <https://1145.am/db/2351684/5am_Ventures>,
        <https://1145.am/db/2354296/5am_Ventures>,
        <https://1145.am/db/2355238/5am_Ventures>,
        <https://1145.am/db/2357858/5am_Ventures>,
        <https://1145.am/db/2359401/5am_Ventures>,
        <https://1145.am/db/2360415/5am_Ventures>,
        <https://1145.am/db/2362481/5am_Ventures>,
        <https://1145.am/db/2364492/5am_Ventures>,
        <https://1145.am/db/2367275/5am_Ventures>,
        <https://1145.am/db/2370609/5am_Ventures>,
        <https://1145.am/db/2371160/5am_Ventures>,
        <https://1145.am/db/2371163/5am_Ventures>,
        <https://1145.am/db/2538476/5am_Ventures>,
        <https://1145.am/db/2569220/5am_Ventures>,
        <https://1145.am/db/2572398/5am_Ventures>,
        <https://1145.am/db/2587596/5am_Ventures>,
        <https://1145.am/db/359190/5am_Ventures>,
        <https://1145.am/db/428737/5am_Ventures>,
        <https://1145.am/db/509733/5am_Ventures>,
        <https://1145.am/db/558016/5am_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2360174/Delphi_Ventures> a org:Organization ;
    ns1:basedInLowRaw "SANTA CLARA" ;
    ns1:description "venture capital" ;
    ns1:documentDate "2010-09-13T14:04:48+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Relypsa Raises $70 Million in Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/relypsa-raises-70-million-series-b-financing> ;
    ns1:foundName "Delphi Ventures" ;
    ns1:investor <https://1145.am/db/2360174/Series_B_Investment_5am_Ventures_Delphi_Ventures_Mediphase_Venture_Partners_New_Leaf_Venture_Partners_Orbimed_Advisors_Llc_Relypsa_Sprout_Group_Completed> ;
    ns1:name "Delphi Ventures" ;
    ns1:sameAsHigh <https://1145.am/db/1086604/Tdf_Ventures>,
        <https://1145.am/db/1147828/Sixthirty_Ventures>,
        <https://1145.am/db/1199050/Rre_Ventures>,
        <https://1145.am/db/1356216/Trestle_Partners>,
        <https://1145.am/db/1358977/Tlv_Partners>,
        <https://1145.am/db/1427471/Twm_Venture_Co>,
        <https://1145.am/db/1546965/Ttv_Capital>,
        <https://1145.am/db/1569853/Titan_Capital>,
        <https://1145.am/db/168364/Trog_Hawley_Capital>,
        <https://1145.am/db/1693922/Remus_Capital>,
        <https://1145.am/db/1700572/Rre_Ventures>,
        <https://1145.am/db/1703609/Ttv_Capital>,
        <https://1145.am/db/1711383/Knollwood_Capital>,
        <https://1145.am/db/1713710/Remus_Capital>,
        <https://1145.am/db/1717313/Titan_Capital>,
        <https://1145.am/db/1741365/Translink_Capital>,
        <https://1145.am/db/1743285/Redline_Capital>,
        <https://1145.am/db/1746842/Tlcom_Capital>,
        <https://1145.am/db/1750867/Ttv_Capital>,
        <https://1145.am/db/1753054/Tahoma_Ventures>,
        <https://1145.am/db/1757065/Ttv_Capital>,
        <https://1145.am/db/1761607/Trousdale_Capital>,
        <https://1145.am/db/1762653/Tlv_Partners>,
        <https://1145.am/db/1763847/Tq_Ventures>,
        <https://1145.am/db/1788126/Translink_Capital>,
        <https://1145.am/db/1790574/Rre_Ventures>,
        <https://1145.am/db/1790953/T5_Capital>,
        <https://1145.am/db/1794935/Rre_Ventures>,
        <https://1145.am/db/1794935/Translink_Capital>,
        <https://1145.am/db/1805165/Translink_Capital>,
        <https://1145.am/db/1813349/Rre_Ventures>,
        <https://1145.am/db/1820363/Rre_Ventures>,
        <https://1145.am/db/1845022/Translink_Capital>,
        <https://1145.am/db/1849600/Sevenventures>,
        <https://1145.am/db/1851689/Translink_Capital>,
        <https://1145.am/db/1853156/T5_Capital>,
        <https://1145.am/db/1854396/Ttv_Capital>,
        <https://1145.am/db/1882330/Rre_Ventures>,
        <https://1145.am/db/1890000/Rre_Ventures>,
        <https://1145.am/db/1892428/T-Venture_Holding>,
        <https://1145.am/db/1984721/Redmile_Group>,
        <https://1145.am/db/2063249/Tlv_Partners>,
        <https://1145.am/db/2069147/Knollwood_Capital>,
        <https://1145.am/db/2142825/Ttv_Capital>,
        <https://1145.am/db/2291818/Delphi_Ventures>,
        <https://1145.am/db/2300306/Delphi_Ventures>,
        <https://1145.am/db/2302333/Delphi_Ventures>,
        <https://1145.am/db/2306568/Delphi_Ventures>,
        <https://1145.am/db/2315943/Truffle_Capital>,
        <https://1145.am/db/2315957/Truffle_Capital>,
        <https://1145.am/db/2317467/Delphi_Ventures>,
        <https://1145.am/db/2317919/Delphi_Ventures>,
        <https://1145.am/db/2332658/Truffle_Capital>,
        <https://1145.am/db/2332659/Truffle_Capital>,
        <https://1145.am/db/2333504/Delphi_Ventures>,
        <https://1145.am/db/2338059/Teralys_Capital>,
        <https://1145.am/db/2343206/Delphi_Ventures>,
        <https://1145.am/db/2352508/Delphi_Ventures>,
        <https://1145.am/db/2362106/Redmile_Group>,
        <https://1145.am/db/2365679/Delphi_Ventures>,
        <https://1145.am/db/2367204/Delphi_Ventures>,
        <https://1145.am/db/254241/Tkc_Capital>,
        <https://1145.am/db/506560/Tdf_Ventures>,
        <https://1145.am/db/539638/Tdf_Ventures>,
        <https://1145.am/db/601455/Tlv_Partners>,
        <https://1145.am/db/669408/Tdf_Ventures>,
        <https://1145.am/db/759595/Redblue_Capital>,
        <https://1145.am/db/885068/Tt_Capital_Partners>,
        <https://1145.am/db/892831/Ttv_Capital>,
        <https://1145.am/db/904252/Trinity_Capital>,
        <https://1145.am/db/952434/Tdf_Ventures>,
        <https://1145.am/db/991859/Ttv_Capital> ;
    ns1:sameAsMedium <https://1145.am/db/1124122/Delphi_Ventures>,
        <https://1145.am/db/1718690/Delphi_Ventures>,
        <https://1145.am/db/2290453/Delphi_Ventures>,
        <https://1145.am/db/2292554/Delphi_Ventures>,
        <https://1145.am/db/2294721/Delphi_Ventures>,
        <https://1145.am/db/2299776/Delphi_Ventures>,
        <https://1145.am/db/2300293/Delphi_Ventures>,
        <https://1145.am/db/2300455/Delphi_Ventures>,
        <https://1145.am/db/2304340/Delphi_Ventures>,
        <https://1145.am/db/2308063/Delphi_Ventures>,
        <https://1145.am/db/2310285/Delphi_Ventures>,
        <https://1145.am/db/2319874/Delphi_Ventures>,
        <https://1145.am/db/2326571/Delphi_Ventures>,
        <https://1145.am/db/2333495/Delphi_Ventures>,
        <https://1145.am/db/2335700/Delphi_Ventures>,
        <https://1145.am/db/2359510/Delphi_Ventures>,
        <https://1145.am/db/2362553/Delphi_Ventures>,
        <https://1145.am/db/2443170/Delphi_Ventures>,
        <https://1145.am/db/2575044/Delphi_Ventures>,
        <https://1145.am/db/2584056/Delphi_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2360174/Relypsa> a org:Organization ;
    ns1:description "Pharmaceuticals" ;
    ns1:documentDate "2010-09-13T14:04:48+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Relypsa Raises $70 Million in Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/relypsa-raises-70-million-series-b-financing> ;
    ns1:foundName "Relypsa",
        "Relypsa, Inc." ;
    ns1:industry "biopharmaceutical" ;
    ns1:name "Relypsa" ;
    ns1:sameAsHigh <https://1145.am/db/2317919/Relypsa>,
        <https://1145.am/db/2335879/Relypsa>,
        <https://1145.am/db/2344671/Relypsa_Inc>,
        <https://1145.am/db/2347532/Relypsa_Inc>,
        <https://1145.am/db/2347537/Relypsa_Inc>,
        <https://1145.am/db/2353972/Relypsa_Inc>,
        <https://1145.am/db/2357402/Relypsa>,
        <https://1145.am/db/2357443/Relypsa>,
        <https://1145.am/db/2357502/Relypsa_Inc>,
        <https://1145.am/db/2360488/Relypsa>,
        <https://1145.am/db/2360659/Relypsa_Inc>,
        <https://1145.am/db/2360664/Relypsa>,
        <https://1145.am/db/2361474/Relypsa_Inc>,
        <https://1145.am/db/2363586/Relypsa>,
        <https://1145.am/db/2596405/Relypsa_Inc> ;
    ns1:sameAsMedium <https://1145.am/db/2300798/Relypsa>,
        <https://1145.am/db/2317903/Relypsa>,
        <https://1145.am/db/2323794/Relypsa>,
        <https://1145.am/db/2347540/Relypsa>,
        <https://1145.am/db/2355260/Relypsa>,
        <https://1145.am/db/2371094/Relypsa> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2360189/Okairos> a org:Organization ;
    ns1:basedInLowRaw "France" ;
    ns1:description "venture capital" ;
    ns1:documentDate "2010-09-14T11:29:40+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Okairos Raises €16 Million in Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/okairos-raises-%E2%82%AC16-million-series-b-financing> ;
    ns1:foundName "Okairos" ;
    ns1:industry "pharmaceutical" ;
    ns1:name "Okairos" ;
    ns1:sameAsHigh <https://1145.am/db/1064125/Okyo_Pharma>,
        <https://1145.am/db/1760000/Okta_Ventures>,
        <https://1145.am/db/1776988/Okera>,
        <https://1145.am/db/1959687/Okyo_Pharma>,
        <https://1145.am/db/2285108/Okyo_Pharma>,
        <https://1145.am/db/2348505/Okairos>,
        <https://1145.am/db/2359553/Okairos_Ag>,
        <https://1145.am/db/2360191/Okairos>,
        <https://1145.am/db/2558071/Okasa_Pharma>,
        <https://1145.am/db/2558071/Okasa_Private> ;
    ns1:sameAsMedium <https://1145.am/db/2307682/Okairos>,
        <https://1145.am/db/2360552/Okairos>,
        <https://1145.am/db/2360562/Okairos> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2360189/Versant_Ventures> a org:Organization ;
    ns1:basedInHighGeoName "Switzerland" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2658434/about.rdf> ;
    ns1:basedInHighRaw "Switzerland" ;
    ns1:documentDate "2010-09-14T11:29:40+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Okairos Raises €16 Million in Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/okairos-raises-%E2%82%AC16-million-series-b-financing> ;
    ns1:foundName "Versant Ventures" ;
    ns1:investor <https://1145.am/db/2360189/Series_B_Investment_Boehringer_Ingelheim_Venture_Fund_Okairos_Versant_Ventures_Completed> ;
    ns1:name "Versant Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/1540787/Versant_Ventures>,
        <https://1145.am/db/1541055/Versant_Ventures>,
        <https://1145.am/db/1571794/Versant_Ventures>,
        <https://1145.am/db/1928388/Versant_Ventures>,
        <https://1145.am/db/1975490/Versant_Ventures>,
        <https://1145.am/db/2069394/Versant_Ventures>,
        <https://1145.am/db/2110276/Versant_Ventures>,
        <https://1145.am/db/2151802/Versant_Ventures>,
        <https://1145.am/db/2154338/Versant_Ventures>,
        <https://1145.am/db/2154566/Versant_Ventures>,
        <https://1145.am/db/2281211/Versant_Ventures>,
        <https://1145.am/db/2287023/Versant_Ventures>,
        <https://1145.am/db/2288016/Versant_Ventures>,
        <https://1145.am/db/2290283/Versant_Ventures>,
        <https://1145.am/db/2291315/Versant_Ventures>,
        <https://1145.am/db/2291344/Versant_Ventures>,
        <https://1145.am/db/2293059/Versant_Ventures>,
        <https://1145.am/db/2293893/Versant_Ventures>,
        <https://1145.am/db/2294202/Versant_Ventures>,
        <https://1145.am/db/2296209/Versant_Ventures>,
        <https://1145.am/db/2298176/Versant_Ventures>,
        <https://1145.am/db/2299080/Versant_Ventures>,
        <https://1145.am/db/2299776/Versant_Ventures>,
        <https://1145.am/db/2300337/Versant_Ventures>,
        <https://1145.am/db/2303767/Versant_Ventures>,
        <https://1145.am/db/2304598/Versant_Ventures>,
        <https://1145.am/db/2304606/Versant_Ventures>,
        <https://1145.am/db/2304769/Versant_Ventures>,
        <https://1145.am/db/2305015/Versant_Ventures>,
        <https://1145.am/db/2308758/Versant_Ventures>,
        <https://1145.am/db/2310285/Versant_Ventures>,
        <https://1145.am/db/2310302/Versant_Ventures>,
        <https://1145.am/db/2311353/Versant_Ventures>,
        <https://1145.am/db/2313143/Versant_Ventures>,
        <https://1145.am/db/2317750/Versant_Ventures>,
        <https://1145.am/db/2317753/Versant_Ventures>,
        <https://1145.am/db/2318733/Versant_Ventures>,
        <https://1145.am/db/2319784/Versant_Ventures>,
        <https://1145.am/db/2322646/Versant_Ventures>,
        <https://1145.am/db/2323226/Versant_Ventures>,
        <https://1145.am/db/2324226/Versant_Ventures>,
        <https://1145.am/db/2325681/Versant_Ventures>,
        <https://1145.am/db/2326361/Versant_Ventures>,
        <https://1145.am/db/2326373/Versant_Ventures>,
        <https://1145.am/db/2326903/Versant_Ventures>,
        <https://1145.am/db/2330075/Versant_Ventures>,
        <https://1145.am/db/2330712/Versant_Ventures>,
        <https://1145.am/db/2330852/Versant_Ventures>,
        <https://1145.am/db/2331754/Versant_Ventures>,
        <https://1145.am/db/2331868/Versant_Ventures>,
        <https://1145.am/db/2335675/Versant_Ventures>,
        <https://1145.am/db/2335760/Versant_Ventures>,
        <https://1145.am/db/2339885/Versant_Ventures>,
        <https://1145.am/db/2339886/Versant_Ventures>,
        <https://1145.am/db/2342445/Versant_Ventures>,
        <https://1145.am/db/2343184/Versant_Ventures>,
        <https://1145.am/db/2343185/Versant_Ventures>,
        <https://1145.am/db/2343206/Versant_Ventures>,
        <https://1145.am/db/2343467/Versant_Ventures>,
        <https://1145.am/db/2343547/Versant_Ventures>,
        <https://1145.am/db/2343641/Versant_Ventures>,
        <https://1145.am/db/2343647/Versant_Ventures>,
        <https://1145.am/db/2344915/Versant_Ventures>,
        <https://1145.am/db/2344916/Versant_Ventures>,
        <https://1145.am/db/2344922/Versant_Ventures>,
        <https://1145.am/db/2344926/Versant_Ventures>,
        <https://1145.am/db/2345769/Versant_Ventures>,
        <https://1145.am/db/2347368/Versant_Ventures>,
        <https://1145.am/db/2348012/Versant_Ventures>,
        <https://1145.am/db/2348857/Versant_Ventures>,
        <https://1145.am/db/2349233/Versant_Ventures>,
        <https://1145.am/db/2349834/Versant_Ventures>,
        <https://1145.am/db/2350917/Versant_Ventures>,
        <https://1145.am/db/2351904/Versant_Ventures>,
        <https://1145.am/db/2354296/Versant_Ventures>,
        <https://1145.am/db/2360191/Versant_Ventures>,
        <https://1145.am/db/2360415/Versant_Ventures>,
        <https://1145.am/db/2362457/Versant_Ventures>,
        <https://1145.am/db/2362527/Versant_Ventures>,
        <https://1145.am/db/2362528/Versant_Ventures>,
        <https://1145.am/db/2362565/Versant_Ventures>,
        <https://1145.am/db/2362566/Versant_Ventures>,
        <https://1145.am/db/2364480/Versant_Ventures>,
        <https://1145.am/db/2365134/Versant_Ventures>,
        <https://1145.am/db/2365135/Versant_Ventures>,
        <https://1145.am/db/2367275/Versant_Ventures>,
        <https://1145.am/db/2368517/Versant_Ventures>,
        <https://1145.am/db/2370609/Versant_Ventures>,
        <https://1145.am/db/2370782/Versant_Ventures>,
        <https://1145.am/db/2370799/Versant_Ventures>,
        <https://1145.am/db/2371160/Versant_Ventures>,
        <https://1145.am/db/2371163/Versant_Ventures>,
        <https://1145.am/db/2541575/Versant_Ventures>,
        <https://1145.am/db/2584561/Versant_Ventures>,
        <https://1145.am/db/456081/Versant_Ventures>,
        <https://1145.am/db/488687/Versant_Ventures>,
        <https://1145.am/db/547640/Versant_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2360213/Arno_Therapeutics> a org:Organization ;
    ns1:description "Oncology" ;
    ns1:documentDate "2010-09-14T14:43:18+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Arno Therapeutics Raises $15 Million in Private Placement To Advance Clinical Development of Oncology Compounds" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/arno-therapeutics-raises-15-million-private-placement-to-advance-clinical-development-of> ;
    ns1:foundName "Arno Therapeutics",
        "Arno Therapeutics, Inc." ;
    ns1:industry "biopharmaceutical" ;
    ns1:name "Arno Therapeutics" ;
    ns1:sameAsHigh <https://1145.am/db/2213473/Arno_Therapeutics_Inc>,
        <https://1145.am/db/2320472/Aryx_Therapeutics_Inc>,
        <https://1145.am/db/2336844/Argos_Therapeutics_Inc>,
        <https://1145.am/db/2337706/Arno_Therapeutics>,
        <https://1145.am/db/2338254/Elcelyx_Therapeutics>,
        <https://1145.am/db/2342845/Argos_Therapeutics_Inc>,
        <https://1145.am/db/2345831/Arno_Therapeutics_Inc>,
        <https://1145.am/db/2346087/Argos_Therapeutics>,
        <https://1145.am/db/2347977/Argos_Therapeutics_Inc>,
        <https://1145.am/db/2350043/Elcelyx_Therapeutics>,
        <https://1145.am/db/2354125/Arno_Therapeutics>,
        <https://1145.am/db/2357648/Arno_Therapeutics>,
        <https://1145.am/db/2362563/Arno_Therapeutics>,
        <https://1145.am/db/2362564/Arno_Therapeutics>,
        <https://1145.am/db/2367611/Arog_Pharmaceuticals>,
        <https://1145.am/db/2370600/Argos_Therapeutics>,
        <https://1145.am/db/2370779/Elcelyx_Therapeutics>,
        <https://1145.am/db/2551380/Argos_Therapeutics_Inc>,
        <https://1145.am/db/2552553/Argos_Therapeutics>,
        <https://1145.am/db/2559208/Argos_Therapeutics>,
        <https://1145.am/db/2583770/Arno_Therapeutics>,
        <https://1145.am/db/588256/Arrevus>,
        <https://1145.am/db/677973/Arrakis_Therapeutics> ;
    ns1:sameAsMedium <https://1145.am/db/2360191/Arno_Therapeutics> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2360756/Medimmune_Ventures> a org:Organization ;
    ns1:basedInLowRaw "CAMBRIDGE" ;
    ns1:documentDate "2010-12-08T14:42:10+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Catabasis Pharmaceuticals Secures $14.5 Million Second Tranche in Series A Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/catabasis-pharmaceuticals-secures-14-5-million-second-tranche-series-a-financing> ;
    ns1:foundName "MedImmune Ventures" ;
    ns1:investor <https://1145.am/db/2360756/Series_A_Investment_Advanced_Technology_Ventures_Catabasis_Pharmaceuticals_Catabasis_Pharmaceuticals_Clarus_Ventures_Medimmune_Ventures_Sv_Life_Sciences_Completed> ;
    ns1:name "MedImmune Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/2302192/Medimmune_Ventures>,
        <https://1145.am/db/2302351/Medimmune_Ventures>,
        <https://1145.am/db/2305587/Medimmune_Ventures>,
        <https://1145.am/db/2314492/Medimmune_Ventures>,
        <https://1145.am/db/2316823/Medimmune_Ventures>,
        <https://1145.am/db/2317561/Medimmune_Ventures>,
        <https://1145.am/db/2317564/Medimmune_Ventures>,
        <https://1145.am/db/2317737/Medimmune_Ventures>,
        <https://1145.am/db/2318656/Medimmune_Ventures>,
        <https://1145.am/db/2318657/Medimmune_Ventures>,
        <https://1145.am/db/2319360/Medimmune_Ventures>,
        <https://1145.am/db/2322012/Medimmune_Ventures>,
        <https://1145.am/db/2322022/Medimmune_Ventures>,
        <https://1145.am/db/2322939/Medimmune_Ventures>,
        <https://1145.am/db/2323785/Medimmune_Ventures>,
        <https://1145.am/db/2324159/Medimmune_Ventures>,
        <https://1145.am/db/2324289/Medimmune_Ventures>,
        <https://1145.am/db/2327379/Medimmune_Ventures>,
        <https://1145.am/db/2330867/Medimmune_Ventures>,
        <https://1145.am/db/2336313/Medimmune_Ventures>,
        <https://1145.am/db/2342213/Medimmune_Ventures>,
        <https://1145.am/db/2343722/Medimmune_Ventures>,
        <https://1145.am/db/2343725/Medimmune_Ventures>,
        <https://1145.am/db/2343737/Medimmune_Ventures>,
        <https://1145.am/db/2346030/Medimmune_Ventures>,
        <https://1145.am/db/2347389/Medimmune_Ventures>,
        <https://1145.am/db/2350199/Medimmune_Ventures>,
        <https://1145.am/db/2352436/Medimmune_Ventures>,
        <https://1145.am/db/2352442/Medimmune_Ventures>,
        <https://1145.am/db/2356420/Medimmune_Ventures>,
        <https://1145.am/db/2360758/Medimmune_Ventures>,
        <https://1145.am/db/2362472/Medimmune_Ventures>,
        <https://1145.am/db/2363442/Medimmune_Ventures>,
        <https://1145.am/db/2363459/Medimmune_Ventures>,
        <https://1145.am/db/2363460/Medimmune_Ventures>,
        <https://1145.am/db/2364853/Medimmune_Ventures>,
        <https://1145.am/db/2551315/Medimmune_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2360758/Medimmune_Ventures> a org:Organization ;
    ns1:basedInLowRaw "CAMBRIDGE" ;
    ns1:documentDate "2010-12-08T14:23:07+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Catabasis Pharmaceuticals Secures $14.5 Million Second Tranche in Series A Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/catabasis-pharmaceuticals-secures-14-5-million-second-tranche-series-a-financing-0> ;
    ns1:foundName "MedImmune Ventures" ;
    ns1:investor <https://1145.am/db/2360758/Series_A_Investment_Advanced_Technology_Ventures_Catabasis_Pharmaceuticals_Catabasis_Pharmaceuticals_Clarus_Ventures_Medimmune_Ventures_Sv_Life_Sciences_Completed> ;
    ns1:name "MedImmune Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/2302192/Medimmune_Ventures>,
        <https://1145.am/db/2302351/Medimmune_Ventures>,
        <https://1145.am/db/2305587/Medimmune_Ventures>,
        <https://1145.am/db/2314492/Medimmune_Ventures>,
        <https://1145.am/db/2316823/Medimmune_Ventures>,
        <https://1145.am/db/2317561/Medimmune_Ventures>,
        <https://1145.am/db/2317564/Medimmune_Ventures>,
        <https://1145.am/db/2317737/Medimmune_Ventures>,
        <https://1145.am/db/2318656/Medimmune_Ventures>,
        <https://1145.am/db/2318657/Medimmune_Ventures>,
        <https://1145.am/db/2319360/Medimmune_Ventures>,
        <https://1145.am/db/2322012/Medimmune_Ventures>,
        <https://1145.am/db/2322022/Medimmune_Ventures>,
        <https://1145.am/db/2322939/Medimmune_Ventures>,
        <https://1145.am/db/2323785/Medimmune_Ventures>,
        <https://1145.am/db/2324159/Medimmune_Ventures>,
        <https://1145.am/db/2324289/Medimmune_Ventures>,
        <https://1145.am/db/2327379/Medimmune_Ventures>,
        <https://1145.am/db/2330867/Medimmune_Ventures>,
        <https://1145.am/db/2336313/Medimmune_Ventures>,
        <https://1145.am/db/2342213/Medimmune_Ventures>,
        <https://1145.am/db/2343722/Medimmune_Ventures>,
        <https://1145.am/db/2343725/Medimmune_Ventures>,
        <https://1145.am/db/2343737/Medimmune_Ventures>,
        <https://1145.am/db/2346030/Medimmune_Ventures>,
        <https://1145.am/db/2347389/Medimmune_Ventures>,
        <https://1145.am/db/2350199/Medimmune_Ventures>,
        <https://1145.am/db/2352436/Medimmune_Ventures>,
        <https://1145.am/db/2352442/Medimmune_Ventures>,
        <https://1145.am/db/2356420/Medimmune_Ventures>,
        <https://1145.am/db/2360756/Medimmune_Ventures>,
        <https://1145.am/db/2362472/Medimmune_Ventures>,
        <https://1145.am/db/2363442/Medimmune_Ventures>,
        <https://1145.am/db/2363459/Medimmune_Ventures>,
        <https://1145.am/db/2363460/Medimmune_Ventures>,
        <https://1145.am/db/2364853/Medimmune_Ventures>,
        <https://1145.am/db/2551315/Medimmune_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2361809/Quantalife> a org:Organization ;
    ns1:description "Biotechnology" ;
    ns1:documentDate "2010-12-13T15:52:16+00:00"^^xsd:dateTime ;
    ns1:documentTitle "QuantaLife, Inc. Closes $17.2M Series B Financing to Accelerate Application Development for Its Droplet DigitalTM PCR Platform" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/quantalife-inc-closes-17-2m-series-b-financing-to-accelerate-application-development-for> ;
    ns1:foundName "QuantaLife, Inc." ;
    ns1:industry "life sciences research" ;
    ns1:name "QuantaLife" ;
    ns1:sameAsHigh <https://1145.am/db/2053204/Quanthealth>,
        <https://1145.am/db/2357623/Quanterix_Corporation> ;
    ns1:sameAsMedium <https://1145.am/db/2361808/Quantalife> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2362826/Ramius_V___O_Acquisition_Llc> a org:Organization ;
    ns1:basedInLowRaw "SAN DIEGO",
        "SAN DIEGO & NEW YORK" ;
    ns1:buyer <https://1145.am/db/2362826/Cypress_Bioscience_Acquisition> ;
    ns1:description "mergers" ;
    ns1:documentDate "2010-12-15T13:23:15+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Cypress Bioscience Agrees To Be Acquired by Ramius LLC and Royalty Pharma for $6.50 Per Share in Cash" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cypress-bioscience-agrees-to-be-acquired-by-ramius-llc-and-royalty-pharma-for-6-50-per> ;
    ns1:foundName "Ramius LLC",
        "Ramius V & O Acquisition LLC",
        "Ramius and Royalty Pharma" ;
    ns1:industry "pharmaceutical" ;
    ns1:name "Ramius",
        "Ramius V & O Acquisition LLC" ;
    ns1:participant <https://1145.am/db/2362826/Cypress_Bioscience_Acquisition> ;
    ns1:protagonist <https://1145.am/db/2362826/Cypress_Bioscience_Acquisition> ;
    ns1:sameAsHigh <https://1145.am/db/2361775/Ramius_V___O_Acquisition_Llc> ;
    ns1:sameAsMedium <https://1145.am/db/2365163/Ramius_V___O_Acquisition_Llc> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2363262/At_Impf_Gmbh> a org:Organization ;
    ns1:description "Investing" ;
    ns1:documentDate "2010-09-21T11:15:34+00:00"^^xsd:dateTime ;
    ns1:documentTitle "immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/immatics-raises-eur54-million-to-advance-its-late-stage-clinical-therapeutic-cancer-0> ;
    ns1:foundName "AT Impf GmbH" ;
    ns1:investor <https://1145.am/db/2363262/Series_C_Investment_At_Impf_Gmbh_Mig_Wellington_Partners_Dievini_Hopp_Biotech_Holding_Immatics_Biotechnologies_Gmbh_Completed> ;
    ns1:name "AT Impf GmbH" ;
    ns1:sameAsHigh <https://1145.am/db/2351883/At_Impf_Gmbh>,
        <https://1145.am/db/2363274/At_Impf_Gmbh> ;
    ns1:sameAsMedium <https://1145.am/db/2351879/At_Impf_Gmbh>,
        <https://1145.am/db/2359443/At_Impf_Gmbh>,
        <https://1145.am/db/2363275/At_Impf_Gmbh>,
        <https://1145.am/db/2562086/At_Impf_Gmbh> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2363262/Dievini_Hopp_Biotech_Holding> a org:Organization ;
    ns1:basedInLowRaw "Germany" ;
    ns1:description "Investing" ;
    ns1:documentDate "2010-09-21T11:15:34+00:00"^^xsd:dateTime ;
    ns1:documentTitle "immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/immatics-raises-eur54-million-to-advance-its-late-stage-clinical-therapeutic-cancer-0> ;
    ns1:foundName "dievini Hopp Biotech holding" ;
    ns1:investor <https://1145.am/db/2363262/Series_C_Investment_At_Impf_Gmbh_Mig_Wellington_Partners_Dievini_Hopp_Biotech_Holding_Immatics_Biotechnologies_Gmbh_Completed> ;
    ns1:name "dievini Hopp Biotech holding" ;
    ns1:sameAsHigh <https://1145.am/db/2351879/Dievini_Hopp_Biotech_Holding>,
        <https://1145.am/db/2361079/Dievini_Hopp_Biotech_Holding>,
        <https://1145.am/db/2361082/Dievini_Hopp_Biotech_Holding>,
        <https://1145.am/db/2361094/Dievini_Hopp_Biotech_Holding>,
        <https://1145.am/db/2363274/Dievini_Hopp_Biotech_Holding>,
        <https://1145.am/db/2579135/Dievini_Hopp_Biotech_Holding> ;
    ns1:sameAsMedium <https://1145.am/db/2331155/Dievini_Hopp_Biotech_Holding>,
        <https://1145.am/db/2351883/Dievini_Hopp_Biotech_Holding>,
        <https://1145.am/db/2354625/Dievini_Hopp_Biotech_Holding_Gmbh___Co_Kg>,
        <https://1145.am/db/2359443/Dievini_Hopp_Biotech_Holding>,
        <https://1145.am/db/2363275/Dievini_Hopp_Biotech_Holding>,
        <https://1145.am/db/2368133/Dievini_Hopp_Biotech_Holding_Gmbh___Co_Kg>,
        <https://1145.am/db/2562086/Dievini_Hopp_Biotech_Holding> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2363262/Mig> a org:Organization ;
    ns1:basedInLowRaw "immatics biotechnologies GmbH" ;
    ns1:description "advised funds" ;
    ns1:documentDate "2010-09-21T11:15:34+00:00"^^xsd:dateTime ;
    ns1:documentTitle "immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/immatics-raises-eur54-million-to-advance-its-late-stage-clinical-therapeutic-cancer-0> ;
    ns1:foundName "MIG" ;
    ns1:industry "biopharmaceutical" ;
    ns1:investor <https://1145.am/db/2363262/Series_C_Investment_At_Impf_Gmbh_Mig_Wellington_Partners_Dievini_Hopp_Biotech_Holding_Immatics_Biotechnologies_Gmbh_Completed> ;
    ns1:name "MIG" ;
    ns1:sameAsHigh <https://1145.am/db/2307808/Mig_Verwaltungs_Ag>,
        <https://1145.am/db/2313124/Mig>,
        <https://1145.am/db/2359443/Mig-Advised_Funds>,
        <https://1145.am/db/2363274/Mig> ;
    ns1:sameAsMedium <https://1145.am/db/148899/Mig>,
        <https://1145.am/db/223442/Mig>,
        <https://1145.am/db/2307886/Mig_Ag>,
        <https://1145.am/db/2320154/Mig_Ag>,
        <https://1145.am/db/601573/Mig> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2363262/Wellington_Partners> a org:Organization ;
    ns1:description "financing" ;
    ns1:documentDate "2010-09-21T11:15:34+00:00"^^xsd:dateTime ;
    ns1:documentTitle "immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/immatics-raises-eur54-million-to-advance-its-late-stage-clinical-therapeutic-cancer-0> ;
    ns1:foundName "Wellington Partners" ;
    ns1:investor <https://1145.am/db/2363262/Series_C_Investment_At_Impf_Gmbh_Mig_Wellington_Partners_Dievini_Hopp_Biotech_Holding_Immatics_Biotechnologies_Gmbh_Completed> ;
    ns1:name "Wellington Partners" ;
    ns1:sameAsHigh <https://1145.am/db/2351879/Wellington_Partners>,
        <https://1145.am/db/2363274/Wellington_Partners>,
        <https://1145.am/db/2569491/Wellington_Partners> ;
    ns1:sameAsMedium <https://1145.am/db/1680280/Wellington_Partners>,
        <https://1145.am/db/1742188/Wellington_Partners>,
        <https://1145.am/db/1742782/Wellington_Partners>,
        <https://1145.am/db/1764682/Wellington_Partners>,
        <https://1145.am/db/1769525/Wellington_Partners>,
        <https://1145.am/db/1793936/Wellington_Partners>,
        <https://1145.am/db/1817949/Wellington_Partners>,
        <https://1145.am/db/1821883/Wellington_Partners>,
        <https://1145.am/db/1828037/Wellington_Partners>,
        <https://1145.am/db/1829991/Wellington_Partners>,
        <https://1145.am/db/1833958/Wellington_Partners>,
        <https://1145.am/db/1834220/Wellington_Partners>,
        <https://1145.am/db/1846466/Wellington_Partners>,
        <https://1145.am/db/1848420/Wellington_Partners>,
        <https://1145.am/db/1854186/Wellington_Partners>,
        <https://1145.am/db/1856207/Wellington_Partners>,
        <https://1145.am/db/1864259/Wellington_Partners>,
        <https://1145.am/db/1868569/Wellington_Partners>,
        <https://1145.am/db/1875469/Wellington_Partners>,
        <https://1145.am/db/1879760/Wellington_Partners>,
        <https://1145.am/db/1881652/Wellington_Partners>,
        <https://1145.am/db/1883959/Wellington_Partners>,
        <https://1145.am/db/1887703/Wellington_Partners>,
        <https://1145.am/db/1893512/Wellington_Partners>,
        <https://1145.am/db/1901284/Wellington_Partners>,
        <https://1145.am/db/1905277/Wellington_Partners>,
        <https://1145.am/db/2151950/Wellington_Partners>,
        <https://1145.am/db/2288440/Wellington_Partners>,
        <https://1145.am/db/2289349/Wellington_Partners>,
        <https://1145.am/db/2295712/Wellington_Partners>,
        <https://1145.am/db/2296842/Wellington_Partners>,
        <https://1145.am/db/2298846/Wellington_Partners>,
        <https://1145.am/db/2323700/Wellington_Partners>,
        <https://1145.am/db/2323705/Wellington_Partners>,
        <https://1145.am/db/2331736/Wellington_Partners>,
        <https://1145.am/db/2332658/Wellington_Partners>,
        <https://1145.am/db/2332659/Wellington_Partners>,
        <https://1145.am/db/2338929/Wellington_Partners>,
        <https://1145.am/db/2341942/Wellington_Partners>,
        <https://1145.am/db/2342582/Wellington_Partners>,
        <https://1145.am/db/2348331/Wellington_Partners>,
        <https://1145.am/db/2349301/Wellington_Partners>,
        <https://1145.am/db/2351191/Wellington_Partners>,
        <https://1145.am/db/2351192/Wellington_Partners>,
        <https://1145.am/db/2351312/Wellington_Partners>,
        <https://1145.am/db/2351883/Wellington_Partners>,
        <https://1145.am/db/2359443/Wellington_Partners>,
        <https://1145.am/db/2361113/Wellington_Partners>,
        <https://1145.am/db/2363275/Wellington_Partners>,
        <https://1145.am/db/2536547/Wellington_Partners>,
        <https://1145.am/db/2562086/Wellington_Partners>,
        <https://1145.am/db/2580665/Wellington_Partners>,
        <https://1145.am/db/530060/Wellington_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2363274/At_Impf_Gmbh> a org:Organization ;
    ns1:description "Investing" ;
    ns1:documentDate "2010-09-21T12:37:18+00:00"^^xsd:dateTime ;
    ns1:documentTitle "immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/immatics-raises-eur54-million-to-advance-its-late-stage-clinical-therapeutic-cancer-vaccine> ;
    ns1:foundName "AT Impf GmbH" ;
    ns1:investor <https://1145.am/db/2363274/Series_C_Investment_At_Impf_Gmbh_Mig_Wellington_Partners_Dievini_Hopp_Biotech_Holding_Immatics_Biotechnologies_Gmbh_Completed> ;
    ns1:name "AT Impf GmbH" ;
    ns1:sameAsHigh <https://1145.am/db/2351883/At_Impf_Gmbh>,
        <https://1145.am/db/2363262/At_Impf_Gmbh> ;
    ns1:sameAsMedium <https://1145.am/db/2351879/At_Impf_Gmbh>,
        <https://1145.am/db/2359443/At_Impf_Gmbh>,
        <https://1145.am/db/2363275/At_Impf_Gmbh>,
        <https://1145.am/db/2562086/At_Impf_Gmbh> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2363274/Dievini_Hopp_Biotech_Holding> a org:Organization ;
    ns1:basedInLowRaw "Germany" ;
    ns1:description "Investing" ;
    ns1:documentDate "2010-09-21T12:37:18+00:00"^^xsd:dateTime ;
    ns1:documentTitle "immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/immatics-raises-eur54-million-to-advance-its-late-stage-clinical-therapeutic-cancer-vaccine> ;
    ns1:foundName "dievini Hopp Biotech holding" ;
    ns1:investor <https://1145.am/db/2363274/Series_C_Investment_At_Impf_Gmbh_Mig_Wellington_Partners_Dievini_Hopp_Biotech_Holding_Immatics_Biotechnologies_Gmbh_Completed> ;
    ns1:name "dievini Hopp Biotech holding" ;
    ns1:sameAsHigh <https://1145.am/db/2351879/Dievini_Hopp_Biotech_Holding>,
        <https://1145.am/db/2361079/Dievini_Hopp_Biotech_Holding>,
        <https://1145.am/db/2361082/Dievini_Hopp_Biotech_Holding>,
        <https://1145.am/db/2361094/Dievini_Hopp_Biotech_Holding>,
        <https://1145.am/db/2363262/Dievini_Hopp_Biotech_Holding>,
        <https://1145.am/db/2579135/Dievini_Hopp_Biotech_Holding> ;
    ns1:sameAsMedium <https://1145.am/db/2331155/Dievini_Hopp_Biotech_Holding>,
        <https://1145.am/db/2351883/Dievini_Hopp_Biotech_Holding>,
        <https://1145.am/db/2354625/Dievini_Hopp_Biotech_Holding_Gmbh___Co_Kg>,
        <https://1145.am/db/2359443/Dievini_Hopp_Biotech_Holding>,
        <https://1145.am/db/2363275/Dievini_Hopp_Biotech_Holding>,
        <https://1145.am/db/2368133/Dievini_Hopp_Biotech_Holding_Gmbh___Co_Kg>,
        <https://1145.am/db/2562086/Dievini_Hopp_Biotech_Holding> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2363274/Mig> a org:Organization ;
    ns1:basedInLowRaw "immatics biotechnologies GmbH" ;
    ns1:description "advised funds" ;
    ns1:documentDate "2010-09-21T12:37:18+00:00"^^xsd:dateTime ;
    ns1:documentTitle "immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/immatics-raises-eur54-million-to-advance-its-late-stage-clinical-therapeutic-cancer-vaccine> ;
    ns1:foundName "MIG" ;
    ns1:industry "biopharmaceutical" ;
    ns1:investor <https://1145.am/db/2363274/Series_C_Investment_At_Impf_Gmbh_Mig_Wellington_Partners_Dievini_Hopp_Biotech_Holding_Immatics_Biotechnologies_Gmbh_Completed> ;
    ns1:name "MIG" ;
    ns1:sameAsHigh <https://1145.am/db/2307808/Mig_Verwaltungs_Ag>,
        <https://1145.am/db/2313124/Mig>,
        <https://1145.am/db/2359443/Mig-Advised_Funds>,
        <https://1145.am/db/2363262/Mig> ;
    ns1:sameAsMedium <https://1145.am/db/148899/Mig>,
        <https://1145.am/db/223442/Mig>,
        <https://1145.am/db/2307886/Mig_Ag>,
        <https://1145.am/db/2320154/Mig_Ag>,
        <https://1145.am/db/601573/Mig> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2363274/Wellington_Partners> a org:Organization ;
    ns1:description "financing" ;
    ns1:documentDate "2010-09-21T12:37:18+00:00"^^xsd:dateTime ;
    ns1:documentTitle "immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/immatics-raises-eur54-million-to-advance-its-late-stage-clinical-therapeutic-cancer-vaccine> ;
    ns1:foundName "Wellington Partners" ;
    ns1:investor <https://1145.am/db/2363274/Series_C_Investment_At_Impf_Gmbh_Mig_Wellington_Partners_Dievini_Hopp_Biotech_Holding_Immatics_Biotechnologies_Gmbh_Completed> ;
    ns1:name "Wellington Partners" ;
    ns1:sameAsHigh <https://1145.am/db/2351879/Wellington_Partners>,
        <https://1145.am/db/2363262/Wellington_Partners>,
        <https://1145.am/db/2569491/Wellington_Partners> ;
    ns1:sameAsMedium <https://1145.am/db/1680280/Wellington_Partners>,
        <https://1145.am/db/1742188/Wellington_Partners>,
        <https://1145.am/db/1742782/Wellington_Partners>,
        <https://1145.am/db/1764682/Wellington_Partners>,
        <https://1145.am/db/1769525/Wellington_Partners>,
        <https://1145.am/db/1793936/Wellington_Partners>,
        <https://1145.am/db/1817949/Wellington_Partners>,
        <https://1145.am/db/1821883/Wellington_Partners>,
        <https://1145.am/db/1828037/Wellington_Partners>,
        <https://1145.am/db/1829991/Wellington_Partners>,
        <https://1145.am/db/1833958/Wellington_Partners>,
        <https://1145.am/db/1834220/Wellington_Partners>,
        <https://1145.am/db/1846466/Wellington_Partners>,
        <https://1145.am/db/1848420/Wellington_Partners>,
        <https://1145.am/db/1854186/Wellington_Partners>,
        <https://1145.am/db/1856207/Wellington_Partners>,
        <https://1145.am/db/1864259/Wellington_Partners>,
        <https://1145.am/db/1868569/Wellington_Partners>,
        <https://1145.am/db/1875469/Wellington_Partners>,
        <https://1145.am/db/1879760/Wellington_Partners>,
        <https://1145.am/db/1881652/Wellington_Partners>,
        <https://1145.am/db/1883959/Wellington_Partners>,
        <https://1145.am/db/1887703/Wellington_Partners>,
        <https://1145.am/db/1893512/Wellington_Partners>,
        <https://1145.am/db/1901284/Wellington_Partners>,
        <https://1145.am/db/1905277/Wellington_Partners>,
        <https://1145.am/db/2151950/Wellington_Partners>,
        <https://1145.am/db/2288440/Wellington_Partners>,
        <https://1145.am/db/2289349/Wellington_Partners>,
        <https://1145.am/db/2295712/Wellington_Partners>,
        <https://1145.am/db/2296842/Wellington_Partners>,
        <https://1145.am/db/2298846/Wellington_Partners>,
        <https://1145.am/db/2323700/Wellington_Partners>,
        <https://1145.am/db/2323705/Wellington_Partners>,
        <https://1145.am/db/2331736/Wellington_Partners>,
        <https://1145.am/db/2332658/Wellington_Partners>,
        <https://1145.am/db/2332659/Wellington_Partners>,
        <https://1145.am/db/2338929/Wellington_Partners>,
        <https://1145.am/db/2341942/Wellington_Partners>,
        <https://1145.am/db/2342582/Wellington_Partners>,
        <https://1145.am/db/2348331/Wellington_Partners>,
        <https://1145.am/db/2349301/Wellington_Partners>,
        <https://1145.am/db/2351191/Wellington_Partners>,
        <https://1145.am/db/2351192/Wellington_Partners>,
        <https://1145.am/db/2351312/Wellington_Partners>,
        <https://1145.am/db/2351883/Wellington_Partners>,
        <https://1145.am/db/2359443/Wellington_Partners>,
        <https://1145.am/db/2361113/Wellington_Partners>,
        <https://1145.am/db/2363275/Wellington_Partners>,
        <https://1145.am/db/2536547/Wellington_Partners>,
        <https://1145.am/db/2562086/Wellington_Partners>,
        <https://1145.am/db/2580665/Wellington_Partners>,
        <https://1145.am/db/530060/Wellington_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2364249/Roche_Venture_Fund> a org:Organization ;
    ns1:basedInLowRaw "SANTA BARBARA" ;
    ns1:description "Biotechnology" ;
    ns1:documentDate "2010-09-23T11:06:41+00:00"^^xsd:dateTime ;
    ns1:documentTitle "CytomX Therapeutics Completes $30 Million Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cytomx-therapeutics-completes-30-million-series-b-financing-0> ;
    ns1:foundName "Roche Venture Fund" ;
    ns1:investor <https://1145.am/db/2364249/Series_B_Investment_Cytomx_Therapeutics_Roche_Venture_Fund_Third_Rock_Ventures_Completed> ;
    ns1:name "Roche Venture Fund" ;
    ns1:sameAsMedium <https://1145.am/db/2299180/Roche_($_Rhhby)_Venture_Fund>,
        <https://1145.am/db/2302731/Roche_Venture_Fund>,
        <https://1145.am/db/2306549/Roche_Venture_Fund>,
        <https://1145.am/db/2313985/Roche_Venture_Fund>,
        <https://1145.am/db/2317779/Roche_Venture_Fund>,
        <https://1145.am/db/2326222/Roche_Venture_Fund>,
        <https://1145.am/db/2327441/Roche_Venture_Fund>,
        <https://1145.am/db/2327442/Roche_Venture_Fund>,
        <https://1145.am/db/2330668/Roche_Venture_Fund>,
        <https://1145.am/db/2336328/Roche_Venture_Fund>,
        <https://1145.am/db/2336333/Roche_Venture_Fund>,
        <https://1145.am/db/2336335/Roche_Venture_Fund>,
        <https://1145.am/db/2337958/Roche_Venture_Fund>,
        <https://1145.am/db/2337974/Roche_Venture_Fund>,
        <https://1145.am/db/2343301/Roche_Venture_Fund>,
        <https://1145.am/db/2346534/Roche_Venture_Fund>,
        <https://1145.am/db/2349143/Roche_Venture_Fund>,
        <https://1145.am/db/2352203/Roche_Venture_Fund>,
        <https://1145.am/db/2352204/Roche_Venture_Fund>,
        <https://1145.am/db/2352216/Roche_Venture_Fund>,
        <https://1145.am/db/2352436/Roche_Venture_Fund>,
        <https://1145.am/db/2352442/Roche_Venture_Fund>,
        <https://1145.am/db/2355043/Roche_Venture_Fund>,
        <https://1145.am/db/2358496/Roche_Venture_Fund>,
        <https://1145.am/db/2358502/Roche_Venture_Fund>,
        <https://1145.am/db/2362533/Roche_Venture_Fund>,
        <https://1145.am/db/2362715/Roche_Venture_Fund>,
        <https://1145.am/db/2363396/Roche_Venture_Fund>,
        <https://1145.am/db/2364255/Roche_Venture_Fund>,
        <https://1145.am/db/2364283/Roche_Venture_Fund>,
        <https://1145.am/db/2365748/Roche_Venture_Fund>,
        <https://1145.am/db/2367549/Roche_Venture_Fund>,
        <https://1145.am/db/2370694/Roche_Venture_Fund>,
        <https://1145.am/db/2371169/Roche_Venture_Fund>,
        <https://1145.am/db/829447/Roche_Venture_Fund> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2364283/Roche_Venture_Fund> a org:Organization ;
    ns1:basedInLowRaw "Calif" ;
    ns1:documentDate "2010-09-23T16:24:58+00:00"^^xsd:dateTime ;
    ns1:documentTitle "CytomX Therapeutics Completes $30 Million Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cytomx-therapeutics-completes-30-million-series-b-financing> ;
    ns1:foundName "Roche Venture Fund" ;
    ns1:investor <https://1145.am/db/2364283/Series_B_Investment_Cytomx_Therapeutics_Roche_Venture_Fund_Third_Rock_Ventures_Completed> ;
    ns1:name "Roche Venture Fund" ;
    ns1:sameAsMedium <https://1145.am/db/2299180/Roche_($_Rhhby)_Venture_Fund>,
        <https://1145.am/db/2302731/Roche_Venture_Fund>,
        <https://1145.am/db/2306549/Roche_Venture_Fund>,
        <https://1145.am/db/2313985/Roche_Venture_Fund>,
        <https://1145.am/db/2317779/Roche_Venture_Fund>,
        <https://1145.am/db/2326222/Roche_Venture_Fund>,
        <https://1145.am/db/2327441/Roche_Venture_Fund>,
        <https://1145.am/db/2327442/Roche_Venture_Fund>,
        <https://1145.am/db/2330668/Roche_Venture_Fund>,
        <https://1145.am/db/2336328/Roche_Venture_Fund>,
        <https://1145.am/db/2336333/Roche_Venture_Fund>,
        <https://1145.am/db/2336335/Roche_Venture_Fund>,
        <https://1145.am/db/2337958/Roche_Venture_Fund>,
        <https://1145.am/db/2337974/Roche_Venture_Fund>,
        <https://1145.am/db/2343301/Roche_Venture_Fund>,
        <https://1145.am/db/2346534/Roche_Venture_Fund>,
        <https://1145.am/db/2349143/Roche_Venture_Fund>,
        <https://1145.am/db/2352203/Roche_Venture_Fund>,
        <https://1145.am/db/2352204/Roche_Venture_Fund>,
        <https://1145.am/db/2352216/Roche_Venture_Fund>,
        <https://1145.am/db/2352436/Roche_Venture_Fund>,
        <https://1145.am/db/2352442/Roche_Venture_Fund>,
        <https://1145.am/db/2355043/Roche_Venture_Fund>,
        <https://1145.am/db/2358496/Roche_Venture_Fund>,
        <https://1145.am/db/2358502/Roche_Venture_Fund>,
        <https://1145.am/db/2362533/Roche_Venture_Fund>,
        <https://1145.am/db/2362715/Roche_Venture_Fund>,
        <https://1145.am/db/2363396/Roche_Venture_Fund>,
        <https://1145.am/db/2364249/Roche_Venture_Fund>,
        <https://1145.am/db/2364255/Roche_Venture_Fund>,
        <https://1145.am/db/2365748/Roche_Venture_Fund>,
        <https://1145.am/db/2367549/Roche_Venture_Fund>,
        <https://1145.am/db/2370694/Roche_Venture_Fund>,
        <https://1145.am/db/2371169/Roche_Venture_Fund>,
        <https://1145.am/db/829447/Roche_Venture_Fund> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2364301/Cylene_Pharmaceuticals> a org:Organization ;
    ns1:basedInHighGeoName "San Diego County" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5391832/about.rdf> ;
    ns1:basedInHighRaw "SAN DIEGO" ;
    ns1:basedInLowRaw "Cayman" ;
    ns1:description "Pharmaceuticals",
        "clinical trials" ;
    ns1:documentDate "2010-09-24T13:02:10+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Cylene Initiates Phase I Trial in Multiple Myeloma With CX-4945 Inhibitor of CK2 and Closes Accompanying Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cylene-initiates-phase-i-trial-multiple-myeloma-cx-4945-inhibitor-ck2-and-closes> ;
    ns1:foundName "Cylene",
        "Cylene Pharmaceuticals, Inc." ;
    ns1:industry "Pharmaceuticals" ;
    ns1:name "Cylene",
        "Cylene Pharmaceuticals" ;
    ns1:sameAsHigh <https://1145.am/db/2330989/Cylene_Pharmaceuticals>,
        <https://1145.am/db/2332864/Cylene_Pharmaceuticals>,
        <https://1145.am/db/2332868/Cylene_Pharmaceuticals> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2364301/Sanderling_Ventures> a org:Organization ;
    ns1:basedInLowRaw "Cayman" ;
    ns1:documentDate "2010-09-24T13:02:10+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Cylene Initiates Phase I Trial in Multiple Myeloma With CX-4945 Inhibitor of CK2 and Closes Accompanying Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cylene-initiates-phase-i-trial-multiple-myeloma-cx-4945-inhibitor-ck2-and-closes> ;
    ns1:foundName "Sanderling Ventures" ;
    ns1:investor <https://1145.am/db/2364301/Investment_Bioventures_Investors_Cylene_Pharmaceuticals_Hbm_Bioventures_(cayman)_Ltd_Lilly_Ventures_Mitsui___Co_Morningside_Venture_Investments_Ltd_Novartis_Bioventure_Fund_Sanderling_Ventures_Completed> ;
    ns1:name "Sanderling Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/2228252/Sanderling_Ventures>,
        <https://1145.am/db/2273257/Sanderling_Ventures>,
        <https://1145.am/db/2288596/Sanderling_Ventures>,
        <https://1145.am/db/2289884/Sanderling_Ventures>,
        <https://1145.am/db/2299881/Sanderling_Ventures>,
        <https://1145.am/db/2305739/Sanderling_Ventures>,
        <https://1145.am/db/2305745/Sanderling_Ventures>,
        <https://1145.am/db/2306281/Sanderling_Ventures>,
        <https://1145.am/db/2318941/Sanderling_Ventures>,
        <https://1145.am/db/2323103/Sanderling_Ventures>,
        <https://1145.am/db/2327212/Sanderling_Ventures>,
        <https://1145.am/db/2327227/Sanderling_Ventures>,
        <https://1145.am/db/2327638/Sanderling_Ventures>,
        <https://1145.am/db/2338236/Sanderling_Ventures>,
        <https://1145.am/db/2338237/Sanderling_Ventures>,
        <https://1145.am/db/2346532/Sanderling_Ventures>,
        <https://1145.am/db/2346542/Sanderling_Ventures>,
        <https://1145.am/db/2347594/Sanderling_Ventures>,
        <https://1145.am/db/2352831/Sanderling_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2365135/Highland_Capital_Partners> a org:Organization ;
    ns1:basedInLowRaw "GAITHERSBURG" ;
    ns1:documentDate "2010-09-27T12:37:38+00:00"^^xsd:dateTime ;
    ns1:documentTitle "OpGen Completes $17 Million Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/opgen-completes-17-million-series-b-financing> ;
    ns1:foundName "Highland Capital Partners" ;
    ns1:investor <https://1145.am/db/2365135/Series_B_Equity_Investment_Chl_Medical_Partners_Highland_Capital_Partners_Mason_Wells_Biomedical_Opgen_Versant_Ventures_Jven_Capital_Completed> ;
    ns1:name "Highland Capital Partners" ;
    ns1:sameAsMedium <https://1145.am/db/1706417/Highland_Capital_Partners>,
        <https://1145.am/db/1716136/Highland_Capital_Partners>,
        <https://1145.am/db/1803787/Highland_Capital_Partners>,
        <https://1145.am/db/1806906/Highland_Capital_Partners>,
        <https://1145.am/db/1819710/Highland_Capital_Partners>,
        <https://1145.am/db/1823612/Highland_Capital_Partners>,
        <https://1145.am/db/1824878/Highland_Capital_Partners>,
        <https://1145.am/db/1830368/Highland_Capital_Partners>,
        <https://1145.am/db/1833239/Highland_Capital_Partners>,
        <https://1145.am/db/1839990/Highland_Capital_Partners>,
        <https://1145.am/db/1846953/Highland_Capital_Partners>,
        <https://1145.am/db/1850246/Highland_Capital_Partners>,
        <https://1145.am/db/1852044/Highland_Capital_Partners>,
        <https://1145.am/db/1859069/Highland_Capital_Partners>,
        <https://1145.am/db/1860137/Highland_Capital_Partners>,
        <https://1145.am/db/1861342/Highland_Capital_Partners>,
        <https://1145.am/db/1866156/Highland_Capital_Partners>,
        <https://1145.am/db/1871777/Highland_Capital_Partners>,
        <https://1145.am/db/1874364/Highland_Capital_Partners>,
        <https://1145.am/db/1881478/Highland_Capital_Partners>,
        <https://1145.am/db/1881599/Highland_Capital_Partners>,
        <https://1145.am/db/1890839/Highland_Capital_Partners>,
        <https://1145.am/db/1900458/Highland_Capital_Partners>,
        <https://1145.am/db/1912062/Highland_Capital_Partners>,
        <https://1145.am/db/2249658/Highland_Capital_Partners>,
        <https://1145.am/db/2286842/Highland_Capital_Partners>,
        <https://1145.am/db/2300340/Highland_Capital_Partners>,
        <https://1145.am/db/2300746/Highland_Capital_Partners>,
        <https://1145.am/db/2303548/Highland_Capital_Partners>,
        <https://1145.am/db/2303560/Highland_Capital_Partners>,
        <https://1145.am/db/2305015/Highland_Capital_Partners>,
        <https://1145.am/db/2325681/Highland_Capital_Partners>,
        <https://1145.am/db/2331700/Highland_Capital_Partners>,
        <https://1145.am/db/2343184/Highland_Capital_Partners>,
        <https://1145.am/db/2343185/Highland_Capital_Partners>,
        <https://1145.am/db/2364422/Highland_Capital_Partners>,
        <https://1145.am/db/2365134/Highland_Capital_Partners>,
        <https://1145.am/db/2367199/Highland_Capital_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2365135/Opgen> a org:Organization ;
    ns1:description "commercial phase genomics" ;
    ns1:documentDate "2010-09-27T12:37:38+00:00"^^xsd:dateTime ;
    ns1:documentTitle "OpGen Completes $17 Million Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/opgen-completes-17-million-series-b-financing> ;
    ns1:foundName "OpGen",
        "OpGen, Inc." ;
    ns1:name "OpGen" ;
    ns1:sameAsMedium <https://1145.am/db/1002574/Opgen>,
        <https://1145.am/db/1382901/Opgen>,
        <https://1145.am/db/1391249/Opgen>,
        <https://1145.am/db/1637266/Opgen>,
        <https://1145.am/db/2299682/Opgen>,
        <https://1145.am/db/2305015/Opgen>,
        <https://1145.am/db/2317269/Opgen>,
        <https://1145.am/db/2325681/Opgen>,
        <https://1145.am/db/2343184/Opgen>,
        <https://1145.am/db/2343185/Opgen>,
        <https://1145.am/db/2348194/Opgen>,
        <https://1145.am/db/2349191/Opgen>,
        <https://1145.am/db/2349200/Opgen>,
        <https://1145.am/db/2365134/Opgen>,
        <https://1145.am/db/558114/Opgen> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2365135/Versant_Ventures> a org:Organization ;
    ns1:basedInLowRaw "GAITHERSBURG, Md." ;
    ns1:description "financing" ;
    ns1:documentDate "2010-09-27T12:37:38+00:00"^^xsd:dateTime ;
    ns1:documentTitle "OpGen Completes $17 Million Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/opgen-completes-17-million-series-b-financing> ;
    ns1:foundName "Versant Ventures" ;
    ns1:investor <https://1145.am/db/2365135/Series_B_Equity_Investment_Chl_Medical_Partners_Highland_Capital_Partners_Mason_Wells_Biomedical_Opgen_Versant_Ventures_Jven_Capital_Completed> ;
    ns1:name "Versant Ventures" ;
    ns1:sameAsHigh <https://1145.am/db/1928388/Versant_Ventures>,
        <https://1145.am/db/1975490/Versant_Ventures>,
        <https://1145.am/db/2110276/Versant_Ventures>,
        <https://1145.am/db/2154566/Versant_Ventures>,
        <https://1145.am/db/2288016/Versant_Ventures>,
        <https://1145.am/db/2290283/Versant_Ventures>,
        <https://1145.am/db/2291315/Versant_Ventures>,
        <https://1145.am/db/2294202/Versant_Ventures>,
        <https://1145.am/db/2300337/Versant_Ventures>,
        <https://1145.am/db/2303767/Versant_Ventures>,
        <https://1145.am/db/2304606/Versant_Ventures>,
        <https://1145.am/db/2305015/Versant_Ventures>,
        <https://1145.am/db/2308758/Versant_Ventures>,
        <https://1145.am/db/2313143/Versant_Ventures>,
        <https://1145.am/db/2318934/Versant>,
        <https://1145.am/db/2319784/Versant_Ventures>,
        <https://1145.am/db/2326361/Versant_Ventures>,
        <https://1145.am/db/2326373/Versant_Ventures>,
        <https://1145.am/db/2330852/Versant_Ventures>,
        <https://1145.am/db/2331754/Versant_Ventures>,
        <https://1145.am/db/2331868/Versant_Ventures>,
        <https://1145.am/db/2339886/Versant_Ventures>,
        <https://1145.am/db/2343184/Versant_Ventures>,
        <https://1145.am/db/2344916/Versant_Ventures>,
        <https://1145.am/db/2345769/Versant_Ventures>,
        <https://1145.am/db/2348857/Versant_Ventures>,
        <https://1145.am/db/2349233/Versant_Ventures>,
        <https://1145.am/db/2350915/Versant_Venture_Capital_V_Lp>,
        <https://1145.am/db/2362527/Versant_Ventures>,
        <https://1145.am/db/2362566/Versant_Ventures>,
        <https://1145.am/db/2364480/Versant_Ventures>,
        <https://1145.am/db/2367275/Versant_Ventures>,
        <https://1145.am/db/2371163/Versant_Ventures>,
        <https://1145.am/db/547640/Versant_Ventures> ;
    ns1:sameAsMedium <https://1145.am/db/1540787/Versant_Ventures>,
        <https://1145.am/db/1541055/Versant_Ventures>,
        <https://1145.am/db/1571794/Versant_Ventures>,
        <https://1145.am/db/2069394/Versant_Ventures>,
        <https://1145.am/db/2151802/Versant_Ventures>,
        <https://1145.am/db/2154338/Versant_Ventures>,
        <https://1145.am/db/2281211/Versant_Ventures>,
        <https://1145.am/db/2287023/Versant_Ventures>,
        <https://1145.am/db/2291344/Versant_Ventures>,
        <https://1145.am/db/2293059/Versant_Ventures>,
        <https://1145.am/db/2293893/Versant_Ventures>,
        <https://1145.am/db/2296209/Versant_Ventures>,
        <https://1145.am/db/2298176/Versant_Ventures>,
        <https://1145.am/db/2299080/Versant_Ventures>,
        <https://1145.am/db/2299776/Versant_Ventures>,
        <https://1145.am/db/2304598/Versant_Ventures>,
        <https://1145.am/db/2304769/Versant_Ventures>,
        <https://1145.am/db/2310285/Versant_Ventures>,
        <https://1145.am/db/2310302/Versant_Ventures>,
        <https://1145.am/db/2311353/Versant_Ventures>,
        <https://1145.am/db/2317750/Versant_Ventures>,
        <https://1145.am/db/2317753/Versant_Ventures>,
        <https://1145.am/db/2318733/Versant_Ventures>,
        <https://1145.am/db/2322646/Versant_Ventures>,
        <https://1145.am/db/2323226/Versant_Ventures>,
        <https://1145.am/db/2324226/Versant_Ventures>,
        <https://1145.am/db/2325681/Versant_Ventures>,
        <https://1145.am/db/2326903/Versant_Ventures>,
        <https://1145.am/db/2330075/Versant_Ventures>,
        <https://1145.am/db/2330712/Versant_Ventures>,
        <https://1145.am/db/2335675/Versant_Ventures>,
        <https://1145.am/db/2335760/Versant_Ventures>,
        <https://1145.am/db/2339885/Versant_Ventures>,
        <https://1145.am/db/2342445/Versant_Ventures>,
        <https://1145.am/db/2343185/Versant_Ventures>,
        <https://1145.am/db/2343206/Versant_Ventures>,
        <https://1145.am/db/2343467/Versant_Ventures>,
        <https://1145.am/db/2343547/Versant_Ventures>,
        <https://1145.am/db/2343641/Versant_Ventures>,
        <https://1145.am/db/2343647/Versant_Ventures>,
        <https://1145.am/db/2344915/Versant_Ventures>,
        <https://1145.am/db/2344922/Versant_Ventures>,
        <https://1145.am/db/2344926/Versant_Ventures>,
        <https://1145.am/db/2347368/Versant_Ventures>,
        <https://1145.am/db/2348012/Versant_Ventures>,
        <https://1145.am/db/2349834/Versant_Ventures>,
        <https://1145.am/db/2350917/Versant_Ventures>,
        <https://1145.am/db/2351904/Versant_Ventures>,
        <https://1145.am/db/2354296/Versant_Ventures>,
        <https://1145.am/db/2360189/Versant_Ventures>,
        <https://1145.am/db/2360191/Versant_Ventures>,
        <https://1145.am/db/2360415/Versant_Ventures>,
        <https://1145.am/db/2362457/Versant_Ventures>,
        <https://1145.am/db/2362528/Versant_Ventures>,
        <https://1145.am/db/2362565/Versant_Ventures>,
        <https://1145.am/db/2365134/Versant_Ventures>,
        <https://1145.am/db/2368517/Versant_Ventures>,
        <https://1145.am/db/2370609/Versant_Ventures>,
        <https://1145.am/db/2370782/Versant_Ventures>,
        <https://1145.am/db/2370799/Versant_Ventures>,
        <https://1145.am/db/2371160/Versant_Ventures>,
        <https://1145.am/db/2541575/Versant_Ventures>,
        <https://1145.am/db/2584561/Versant_Ventures>,
        <https://1145.am/db/456081/Versant_Ventures>,
        <https://1145.am/db/488687/Versant_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2365138/Decimmune_Therapeutics> a org:Organization ;
    ns1:basedInHighGeoName "Cambridgeshire" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2653940/about.rdf> ;
    ns1:basedInHighRaw "CAMBRIDGE" ;
    ns1:description "Biomedical" ;
    ns1:documentDate "2010-09-27T13:02:25+00:00"^^xsd:dateTime ;
    ns1:documentTitle "DecImmune Therapeutics Secures $3.2 Million in Development Funding" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/decimmune-therapeutics-secures-3-2-million-development-funding> ;
    ns1:foundName "DecImmune Therapeutics" ;
    ns1:name "DecImmune Therapeutics" ;
    ns1:sameAsMedium <https://1145.am/db/2365136/Decimmune_Therapeutics> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2365157/Bristol-Myers_Squibb> a org:Organization ;
    ns1:basedInHighGeoName "New York City" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5128581/about.rdf> ;
    ns1:basedInHighRaw "NEW YORK" ;
    ns1:buyer <https://1145.am/db/2365157/Zymogenetics_Acquisition> ;
    ns1:description "Business" ;
    ns1:documentDate "2010-09-28T12:07:12+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Bristol-Myers Squibb Announces Expiration of Hart-Scott-Rodino Waiting Period for Acquisition of ZymoGenetics, Inc." ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/bristol-myers-squibb-announces-expiration-of-hart-scott-rodino-waiting-period-for-1> ;
    ns1:foundName "Bristol-Myers Squibb",
        "Bristol-Myers Squibb Company" ;
    ns1:name "Bristol-Myers Squibb" ;
    ns1:sameAsHigh <https://1145.am/db/1094472/Bristol_Myers_Squibb>,
        <https://1145.am/db/1105768/Bristol_Myers_Squibb>,
        <https://1145.am/db/1106082/Bristol_Myers_Squibb>,
        <https://1145.am/db/1108228/Bristol_Myers_Squibb>,
        <https://1145.am/db/1110114/Bristol_Myers_Squibb_Co>,
        <https://1145.am/db/1111460/Bristol_Myers_Squibb>,
        <https://1145.am/db/1111853/Bristol_Myers_Squibb>,
        <https://1145.am/db/1113358/Bristol-Myers_Squibb>,
        <https://1145.am/db/1113452/Bristol_Myers_Squibb>,
        <https://1145.am/db/1114073/Bristol_Myers_Squibb>,
        <https://1145.am/db/1137730/Bristol_Myers_Squibb>,
        <https://1145.am/db/1142305/Bristol_Myers_Squibb>,
        <https://1145.am/db/1183637/Bristol_Myers_Squibb>,
        <https://1145.am/db/1184320/Bristol_Myers_Squibb>,
        <https://1145.am/db/1281441/Bristol_Myers_Squibb>,
        <https://1145.am/db/1285047/Bristol_Myers_Squibb>,
        <https://1145.am/db/1288028/Bristol_Myers_Squibb>,
        <https://1145.am/db/1340338/Bristol_Myers_Squibb>,
        <https://1145.am/db/1536915/Bristol_Myers_Squibb>,
        <https://1145.am/db/1613666/Bristol_Myers_Squibb>,
        <https://1145.am/db/1983649/Bristol_Myers_Squibb>,
        <https://1145.am/db/1984876/Bristol_Myers_Squibb_Co>,
        <https://1145.am/db/2139540/Bristol-Myers_Squibb>,
        <https://1145.am/db/2140511/Bristol-Myers_Squibb_Company>,
        <https://1145.am/db/2155237/Bristol-Myers_Squibb>,
        <https://1145.am/db/2228329/Bristol-Myers_Squibb>,
        <https://1145.am/db/2279340/Bristol_Myers_Squibb>,
        <https://1145.am/db/2280782/Bristol_Myers_Squibb>,
        <https://1145.am/db/2283422/Bristol_Myers_Squibb>,
        <https://1145.am/db/2283468/Bristol_Myer_Squibb>,
        <https://1145.am/db/2284339/Bristol_Myers>,
        <https://1145.am/db/2284393/Bristol_Myers_Squibb>,
        <https://1145.am/db/2287082/Bristol_Myers_Squibb>,
        <https://1145.am/db/2289865/Bristol-Myers_Squibb>,
        <https://1145.am/db/2292710/Bristol-Myers_Squibb>,
        <https://1145.am/db/2299388/Bristol-Myers>,
        <https://1145.am/db/2299902/Bristol-Myers_Squibb>,
        <https://1145.am/db/2300768/Bristol-Myers>,
        <https://1145.am/db/2301227/Bristol-Myers_Squibb>,
        <https://1145.am/db/2301536/Bristol-Myers_Squibb>,
        <https://1145.am/db/2301687/Bristol-Myers_Squibb>,
        <https://1145.am/db/2302975/Bristol-Myers_Squibb>,
        <https://1145.am/db/2303034/Bristol-Myers_Squibb>,
        <https://1145.am/db/2303037/Bristol-Myers_Squibb>,
        <https://1145.am/db/2303791/Bristol-Myers_Squibb>,
        <https://1145.am/db/2307060/Bristol-Myers>,
        <https://1145.am/db/2307066/Bristol-Myers_Squibb>,
        <https://1145.am/db/2309929/Bristol-Myers_Squibb_Company>,
        <https://1145.am/db/2310002/Bristol-Myers_Squibb>,
        <https://1145.am/db/2312194/Bristol-Myers_Squibb>,
        <https://1145.am/db/2312220/Bristol-Myers_Squibb>,
        <https://1145.am/db/2312436/Bristol-Myers_Squibb>,
        <https://1145.am/db/2312783/Bristol-Myers>,
        <https://1145.am/db/2313397/Bristol-Myers_Squibb>,
        <https://1145.am/db/2314245/Bristol-Myers_Squibb>,
        <https://1145.am/db/2314447/Bristol-Myers_Squibb_Company>,
        <https://1145.am/db/2314979/Bristol-Myers_Squibb>,
        <https://1145.am/db/2319442/Bristol-Myers_Squibb>,
        <https://1145.am/db/2319838/Bristol-Myers_Squibb>,
        <https://1145.am/db/2320315/Bristol-Myers_Squibb>,
        <https://1145.am/db/2320316/Bristol-Myers_Squibb>,
        <https://1145.am/db/2320973/Bristol-Myers_Squibb_Company>,
        <https://1145.am/db/2321014/Bristol-Myers>,
        <https://1145.am/db/2321432/Bristol-Myers_Squibb>,
        <https://1145.am/db/2324209/Bristol-Myers_Squibb>,
        <https://1145.am/db/2325918/Bristol-Myers_Squibb>,
        <https://1145.am/db/2326610/Bristol-Myers_Squibb>,
        <https://1145.am/db/2328576/Bristol-Myers_Squibb>,
        <https://1145.am/db/2328577/Bristol-Myers_Squibb>,
        <https://1145.am/db/2329134/Bristol-Myers_Squibb>,
        <https://1145.am/db/2329655/Bristol-Myers_Squibb>,
        <https://1145.am/db/2331201/Bristol-Myers_Squibb_Company>,
        <https://1145.am/db/2331823/Bristol_Myers_Squibb>,
        <https://1145.am/db/2332660/Bristol_Myers_Squibb>,
        <https://1145.am/db/2332832/Bristol-Myers_Squibb>,
        <https://1145.am/db/2332836/Bristol-Myers_Squibb>,
        <https://1145.am/db/2333555/Bristol-Myers_Squibb>,
        <https://1145.am/db/2336234/Bristol-Myers_Squibb>,
        <https://1145.am/db/2336237/Bristol-Myers_Squibb>,
        <https://1145.am/db/2336386/Bristol-Myers_Squibb_Company>,
        <https://1145.am/db/2336564/Bristol-Myers>,
        <https://1145.am/db/2336870/Bristol-Myers_Squibb_Company>,
        <https://1145.am/db/2337743/Bristol-Myers_Squibb>,
        <https://1145.am/db/2337982/Bristol-Myers_Squibb>,
        <https://1145.am/db/2338000/Bristol-Myers_Squibbs>,
        <https://1145.am/db/2339534/Bristol-Myers_Squibb>,
        <https://1145.am/db/2339822/Bristol-Myers_Squibb_Company>,
        <https://1145.am/db/2340675/Bristol-Myers_Squibb>,
        <https://1145.am/db/2341602/Bristol-Myers_Squibb>,
        <https://1145.am/db/2341628/Bristol-Myers_Squibb_Company_(bmy)>,
        <https://1145.am/db/2341871/Bristol-Myers_Squibb>,
        <https://1145.am/db/2343626/Bristol-Myers_Squibb>,
        <https://1145.am/db/2343628/Bristol-Myers_Squibb>,
        <https://1145.am/db/2344043/Bristol-Myers_Squibb>,
        <https://1145.am/db/2344635/Bristol-Myers_Squibb>,
        <https://1145.am/db/2345436/Bristol-Myers_Squibb>,
        <https://1145.am/db/2347040/Bristol-Myers_Squibb>,
        <https://1145.am/db/2347449/Bristol-Myers_Squibb>,
        <https://1145.am/db/2348079/Bristol-Myers_Squibb>,
        <https://1145.am/db/2350453/Bristol-Myers_Squibb>,
        <https://1145.am/db/2351670/Bristol-Myers_Squibb>,
        <https://1145.am/db/2351689/Bristol-Myers_Squibb>,
        <https://1145.am/db/2351759/Bristol-Myers_Squibb>,
        <https://1145.am/db/2355667/Bristol-Myers_Squibb>,
        <https://1145.am/db/2357757/Bristol-Myers_Squibb>,
        <https://1145.am/db/2358038/Bristol-Myers_Squibb>,
        <https://1145.am/db/2358039/Bristol-Myers_Squibb>,
        <https://1145.am/db/2358044/Bristol-Myers_Squibb>,
        <https://1145.am/db/2359117/Bristol-Myers_Squibb>,
        <https://1145.am/db/2362965/Bristol-Myers_Squibb>,
        <https://1145.am/db/2362966/Bristol-Myers>,
        <https://1145.am/db/2364052/Bristol-Myers_Squibb>,
        <https://1145.am/db/2364740/Bristol-Myers_Squibb>,
        <https://1145.am/db/2364742/Bristol-Myers_Squibb>,
        <https://1145.am/db/2364743/Bristol-Myers_Squibb>,
        <https://1145.am/db/2365605/Bristol-Myers_Squibb>,
        <https://1145.am/db/2366402/Bristol-Myers_Squibb>,
        <https://1145.am/db/2367078/Bristol-Myers_Squibb>,
        <https://1145.am/db/2367082/Bristol-Myers_Squibb>,
        <https://1145.am/db/2367085/Bristol-Myers_Squibb>,
        <https://1145.am/db/2367182/Bristol-Myers_Squibb>,
        <https://1145.am/db/2367306/Bristol-Myers_Squibb>,
        <https://1145.am/db/2367562/Bristol-Myers_Squibb>,
        <https://1145.am/db/2367705/Bristol-Myers_Squibb_Company>,
        <https://1145.am/db/2368768/Bristol-Myers_Squibb_Company>,
        <https://1145.am/db/2368770/Bristol-Myers_Squibb>,
        <https://1145.am/db/2369703/Bristol-Myers_Squibb>,
        <https://1145.am/db/2369708/Bristol-Myers_Squibb>,
        <https://1145.am/db/2369710/Bristol-Myers_Squibb>,
        <https://1145.am/db/2370861/Bristol-Myers_Squibb>,
        <https://1145.am/db/2370990/Bristol-Myers_Squibb>,
        <https://1145.am/db/2371215/Bristol-Myers_Squibb>,
        <https://1145.am/db/2371285/Bristol-Myers_Squibb>,
        <https://1145.am/db/2509115/Bristol_Myers_Squibb>,
        <https://1145.am/db/2536960/Bristol-Myers_Squibb>,
        <https://1145.am/db/2537396/Bristol-Myers_Squibb>,
        <https://1145.am/db/2537448/Bristol-Myers_Squibb>,
        <https://1145.am/db/2539341/Bristol-Myers_Squibb>,
        <https://1145.am/db/2543185/Bristol-Myers_Squibb>,
        <https://1145.am/db/2543227/Bristol-Myers>,
        <https://1145.am/db/2544206/Bristol-Myers_Squibb>,
        <https://1145.am/db/2545052/Bristol-Myers_Squibb>,
        <https://1145.am/db/2546564/Bristol-Myers_Squibb>,
        <https://1145.am/db/2550394/Bristol-Myers_Squibb>,
        <https://1145.am/db/2553958/Bristol-Myers_Squibb>,
        <https://1145.am/db/2554303/Bristol-Myers_Squibb>,
        <https://1145.am/db/2558657/Bristol-Myers_Squibb>,
        <https://1145.am/db/2558664/Bristol-Myers_Squibb>,
        <https://1145.am/db/2558727/Bristol-Myers_Squibb>,
        <https://1145.am/db/2560287/Bristol-Myers_Squibb>,
        <https://1145.am/db/2562693/Bristol_Myers>,
        <https://1145.am/db/2563587/Bristol-Myers_Squibb>,
        <https://1145.am/db/2565218/Bristol-Myers_Squibb>,
        <https://1145.am/db/2565297/Bristol_Myers_Squibb>,
        <https://1145.am/db/2565318/Bristol_Myers>,
        <https://1145.am/db/2567124/Bristol-Myers_Squibb>,
        <https://1145.am/db/2569734/Bristol-Myers_Squibb>,
        <https://1145.am/db/2569735/Bristol-Myers_Squibb>,
        <https://1145.am/db/2572655/Bristol-Myers_Squibb_And_Otsuka>,
        <https://1145.am/db/2573375/Bristol-Myers_Squibb>,
        <https://1145.am/db/2573535/Bristol-Myers_Squibb>,
        <https://1145.am/db/2573593/Bristol-Myers_Squibb>,
        <https://1145.am/db/2575289/Bristol-Myers_Squibb>,
        <https://1145.am/db/2576086/Bristol-Myers>,
        <https://1145.am/db/2578540/Bristol-Myers_Squibb>,
        <https://1145.am/db/2580038/Bristol-Myers_Squibb>,
        <https://1145.am/db/2580053/Bristol-Myers_Squibb>,
        <https://1145.am/db/2581155/Bristol-Myers_Squibb>,
        <https://1145.am/db/2582116/Bristol-Myers_Squibb>,
        <https://1145.am/db/2582228/Bristol-Myers_Squibb_Company>,
        <https://1145.am/db/2583120/Bristol-Myers_Squibb>,
        <https://1145.am/db/2584317/Bristol-Myers_Squibb>,
        <https://1145.am/db/2584318/Bristol-Myers_Squibb>,
        <https://1145.am/db/2585238/Bristol-Myers_Squibb>,
        <https://1145.am/db/2585263/Bristol-Myers_Squibb>,
        <https://1145.am/db/2588614/Bristol-Myers_Squibb>,
        <https://1145.am/db/2588910/Bristol-Myers_Squibb>,
        <https://1145.am/db/2589029/Bristol-Myers_Squibb>,
        <https://1145.am/db/2589053/Bristol-Myers_Squibb>,
        <https://1145.am/db/2589142/Bristol-Myers_Squibb>,
        <https://1145.am/db/2589861/Bristol-Myers_Squibb>,
        <https://1145.am/db/2589921/Bristol-Myers_Squibb_Company>,
        <https://1145.am/db/2592024/Bristol-Myers_Squibb>,
        <https://1145.am/db/2592993/Bristol-Myers_Squibb>,
        <https://1145.am/db/2594370/Bristol-Myers_Squibb>,
        <https://1145.am/db/2595133/Bristol-Myers_Squibb>,
        <https://1145.am/db/2595615/Bristol-Myers_Squibb>,
        <https://1145.am/db/2595843/Bristol-Myers_Squibb_Company>,
        <https://1145.am/db/2595876/Bristol-Myers_Squibb>,
        <https://1145.am/db/2596107/Bristol-Myers_Squibb>,
        <https://1145.am/db/2596135/Bristol-Myers_Squibb>,
        <https://1145.am/db/2596137/Bristol-Myers_Squibb>,
        <https://1145.am/db/2596434/Bristol-Myers_Squibb>,
        <https://1145.am/db/2597274/Bristol-Myers_Squibb>,
        <https://1145.am/db/2598195/Bristol-Myers_Squibb>,
        <https://1145.am/db/2598626/Bristol-Myers_Squibb>,
        <https://1145.am/db/2598639/Bristol-Myers_Squibb>,
        <https://1145.am/db/2716207/Bristol_Myers_Squibb>,
        <https://1145.am/db/2786473/Bristol_Myers_Squibb>,
        <https://1145.am/db/2796875/Bristol_Myers_Squibb>,
        <https://1145.am/db/569732/Bristol_Myers_Squibb_Co>,
        <https://1145.am/db/768063/Bristol_Myers_Squibb>,
        <https://1145.am/db/815499/Bristol_Myers_Squibb>,
        <https://1145.am/db/831553/Bristol-Myers_Squibb>,
        <https://1145.am/db/833098/Bristol-Myers_Squibb> ;
    ns1:sameAsMedium <https://1145.am/db/1055530/Bristol_Myers_Squibb>,
        <https://1145.am/db/1057172/Bristol_Myers_Squibb>,
        <https://1145.am/db/1213113/Bristol_Myers_Squibb>,
        <https://1145.am/db/1219346/Bristol_Myers_Squibb>,
        <https://1145.am/db/1219817/Bristol_Myers_Squibb>,
        <https://1145.am/db/1318775/Bristol-Myers_Squibb>,
        <https://1145.am/db/1319026/Bristol-Myers_Squibb>,
        <https://1145.am/db/1822601/Bristol-Myers_Squibb>,
        <https://1145.am/db/2139444/Bristol_Myers_Squibb>,
        <https://1145.am/db/2153042/Bristol_Myers_Squibb>,
        <https://1145.am/db/2278861/Bristol_Myers_Squibb>,
        <https://1145.am/db/2279067/Bristol_Myers_Squibb>,
        <https://1145.am/db/2279854/Bristol_Myers_Squibb>,
        <https://1145.am/db/2279903/Bristol_Myers_Squibb>,
        <https://1145.am/db/2280925/Bristol_Myers_Squibb>,
        <https://1145.am/db/2284903/Bristol_Myers_Squibb>,
        <https://1145.am/db/2291777/Bristol-Myers_Squibb>,
        <https://1145.am/db/2292751/Bristol-Myers_Squibb>,
        <https://1145.am/db/2293175/Bristol-Myers_Squibb>,
        <https://1145.am/db/2295625/Bristol-Myers_Squibb>,
        <https://1145.am/db/2299941/Bristol-Myers_Squibb>,
        <https://1145.am/db/2301461/Bristol-Myers_Squibb>,
        <https://1145.am/db/2305254/Bristol-Myers_Squibb_Company>,
        <https://1145.am/db/2307968/Bristol-Myers_Squibb>,
        <https://1145.am/db/2308778/Bristol-Myers_Squibb>,
        <https://1145.am/db/2311150/Bristol-Myers_Squibb_Company>,
        <https://1145.am/db/2326568/Bristol-Myers_Squibb_Company>,
        <https://1145.am/db/2331819/Bristol-Myers_Squibb>,
        <https://1145.am/db/2336201/Bristol-Myers_Squibb>,
        <https://1145.am/db/2336567/Bristol-Myers_Squibb>,
        <https://1145.am/db/2345426/Bristol-Myers_Squibb>,
        <https://1145.am/db/2345774/Bristol-Myers_Squibb_Company>,
        <https://1145.am/db/2347038/Bristol-Myers_Squibb_Company>,
        <https://1145.am/db/2347466/Bristol-Myers_Squibb_Company>,
        <https://1145.am/db/2347486/Bristol-Myers_Squibb_Company>,
        <https://1145.am/db/2347488/Bristol-Myers_Squibb>,
        <https://1145.am/db/2348034/Bristol-Myers_Squibb>,
        <https://1145.am/db/2348351/Bristol-Myers_Squibb>,
        <https://1145.am/db/2352534/Bristol-Myers_Squibb>,
        <https://1145.am/db/2354567/Bristol-Myers_Squibb>,
        <https://1145.am/db/2354577/Bristol-Myers_Squibb>,
        <https://1145.am/db/2355669/Bristol-Myers_Squibb>,
        <https://1145.am/db/2356005/Bristol-Myers_Squibb>,
        <https://1145.am/db/2356340/Bristol-Myers_Squibb>,
        <https://1145.am/db/2358078/Bristol-Myers_Squibb>,
        <https://1145.am/db/2360289/Bristol-Myers_Squibb>,
        <https://1145.am/db/2360963/Bristol-Myers_Squibb_Company>,
        <https://1145.am/db/2364049/Bristol-Myers_Squibb>,
        <https://1145.am/db/2367569/Bristol-Myers_Squibb>,
        <https://1145.am/db/2368765/Bristol-Myers_Squibb>,
        <https://1145.am/db/2371186/Bristol-Myers_Squibb>,
        <https://1145.am/db/2536422/Bristol-Myers_Squibb>,
        <https://1145.am/db/2537500/Bristol-Myers_Squibb>,
        <https://1145.am/db/2537537/Bristol-Myers_Squibb>,
        <https://1145.am/db/2539308/Bristol-Myers_Squibb>,
        <https://1145.am/db/2543220/Bristol-Myers_Squibb>,
        <https://1145.am/db/2543236/Bristol-Myers_Squibb>,
        <https://1145.am/db/2543552/Bristol-Myers_Squibb>,
        <https://1145.am/db/2543648/Bristol-Myers_Squibb>,
        <https://1145.am/db/2543655/Bristol-Myers_Squibb>,
        <https://1145.am/db/2545023/Bristol-Myers_Squibb>,
        <https://1145.am/db/2550188/Bristol-Myers_Squibb>,
        <https://1145.am/db/2551883/Bristol-Myers_Squibb>,
        <https://1145.am/db/2554631/Bristol-Myers_Squibb>,
        <https://1145.am/db/2554897/Bristol-Myers_Squibb>,
        <https://1145.am/db/2555760/Bristol-Myers_Squibb>,
        <https://1145.am/db/2556543/Bristol-Myers_Squibb>,
        <https://1145.am/db/2557238/Bristol-Myers_Squibb>,
        <https://1145.am/db/2559407/Bristol-Myers_Squibb>,
        <https://1145.am/db/2560564/Bristol_Myers_Squibb>,
        <https://1145.am/db/2561325/Bristol-Myers_Squibb>,
        <https://1145.am/db/2562459/Bristol-Myers_Squibb>,
        <https://1145.am/db/2562503/Bristol-Myers_Squibb>,
        <https://1145.am/db/2563390/Bristol-Myers_Squibb>,
        <https://1145.am/db/2563889/Bristol-Myers_Squibb>,
        <https://1145.am/db/2564274/Bristol_Myers_Squibb>,
        <https://1145.am/db/2565258/Bristol-Myers_Squibb>,
        <https://1145.am/db/2566282/Bristol_Myers_Squibb>,
        <https://1145.am/db/2567006/Bristol-Myers_Squibb>,
        <https://1145.am/db/2567466/Bristol_Myers_Squibb>,
        <https://1145.am/db/2575176/Bristol-Myers_Squibb>,
        <https://1145.am/db/2578567/Bristol-Myers_Squibb>,
        <https://1145.am/db/2582111/Bristol-Myers_Squibb_Company>,
        <https://1145.am/db/2582120/Bristol-Myers_Squibb>,
        <https://1145.am/db/2592791/Bristol-Myers_Squibb_Company>,
        <https://1145.am/db/2594365/Bristol-Myers_Squibb>,
        <https://1145.am/db/2596128/Bristol-Myers_Squibb_Company>,
        <https://1145.am/db/2597935/Bristol-Myers_Squibb>,
        <https://1145.am/db/2598099/Bristol-Myers_Squibb>,
        <https://1145.am/db/2788420/Bristol_Myers_Squibb>,
        <https://1145.am/db/426688/Bristol_Myers_Squibb>,
        <https://1145.am/db/870410/Bristol-Myers_Squibb>,
        <https://1145.am/db/979509/Bristol_Myers_Squibb> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2365157/Hart-Scott-Rodino> a org:Organization ;
    ns1:basedInLowRaw "NEW YORK" ;
    ns1:buyer <https://1145.am/db/2365157/Zymogenetics_Acquisition> ;
    ns1:description "mergers and acquisitions" ;
    ns1:documentDate "2010-09-28T12:07:12+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Bristol-Myers Squibb Announces Expiration of Hart-Scott-Rodino Waiting Period for Acquisition of ZymoGenetics, Inc." ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/bristol-myers-squibb-announces-expiration-of-hart-scott-rodino-waiting-period-for-1> ;
    ns1:foundName "Hart-Scott-Rodino" ;
    ns1:name "Hart-Scott-Rodino" ;
    ns1:sameAsHigh <https://1145.am/db/2589142/Hart-Scott-Rodino> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2365157/Zeus_Acquisition_Corporation> a org:Organization ;
    ns1:basedInLowRaw "NEW YORK" ;
    ns1:buyer <https://1145.am/db/2365157/Zymogenetics_Acquisition> ;
    ns1:description "a cash tender offer" ;
    ns1:documentDate "2010-09-28T12:07:12+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Bristol-Myers Squibb Announces Expiration of Hart-Scott-Rodino Waiting Period for Acquisition of ZymoGenetics, Inc." ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/bristol-myers-squibb-announces-expiration-of-hart-scott-rodino-waiting-period-for-1> ;
    ns1:foundName "Zeus Acquisition Corporation" ;
    ns1:name "Zeus Acquisition Corporation" ;
    ns1:sameAsHigh <https://1145.am/db/2359117/Zeus_Acquisition_Corporation>,
        <https://1145.am/db/2367082/Zeus_Acquisition_Corporation>,
        <https://1145.am/db/2585263/Zeus_Acquisition_Corporation>,
        <https://1145.am/db/2589142/Zeus_Acquisition_Corporation> ;
    ns1:sameAsMedium <https://1145.am/db/2367085/Zeus_Acquisition_Corporation>,
        <https://1145.am/db/2592024/Zeus_Acquisition_Corporation> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2365163/Cypress_Bioscience_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition",
        "ipo" ;
    ns1:documentDate "2010-09-28T13:04:15+00:00"^^xsd:dateTime ;
    ns1:documentExtract "SAN DIEGO, CA, Sep 28, 2010 (MARKETWIRE via COMTEX) - Cypress Bioscience, Inc. (\"Cypress\" or the \"Company\") , a pharmaceutical company engaged in the development of innovative drugs to treat central nervous system (CNS) disorders, today announced that its Board of Directors has unanimously rejected the unsolicited tender offer by Ramius V & O Acquisition LLC to purchase all of the outstanding shares of Cypress for $ 4.25 per share in cash (\"the Ramius offer\") ." ;
    ns1:documentTitle "Cypress Bioscience Board of Directors Unanimously Rejects Ramius' Unsolicited Tender Offer" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cypress-bioscience-board-of-directors-unanimously-rejects-ramius-unsolicited-tender-offer> ;
    ns1:foundName "purchase",
        "tender" ;
    ns1:name "purchase",
        "tender" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "stopped" ;
    ns1:target <https://1145.am/db/2365163/Cypress_Bioscience> ;
    ns1:targetName "Cypress Bioscience" ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "United States" .

<https://1145.am/db/2365163/Ramius_V___O_Acquisition_Llc> a org:Organization ;
    ns1:basedInLowRaw "SAN DIEGO, CA" ;
    ns1:buyer <https://1145.am/db/2365163/Cypress_Bioscience_Acquisition> ;
    ns1:description "Buying and selling" ;
    ns1:documentDate "2010-09-28T13:04:15+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Cypress Bioscience Board of Directors Unanimously Rejects Ramius' Unsolicited Tender Offer" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cypress-bioscience-board-of-directors-unanimously-rejects-ramius-unsolicited-tender-offer> ;
    ns1:foundName "Ramius V & O Acquisition LLC" ;
    ns1:name "Ramius V & O Acquisition LLC" ;
    ns1:sameAsMedium <https://1145.am/db/2361775/Ramius_V___O_Acquisition_Llc>,
        <https://1145.am/db/2362826/Ramius_V___O_Acquisition_Llc> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2365171/Hatteras_Venture_Partners> a org:Organization ;
    ns1:basedInLowRaw "Pa" ;
    ns1:documentDate "2010-09-28T13:45:54+00:00"^^xsd:dateTime ;
    ns1:documentTitle "TetraLogic Pharmaceuticals Expands Series C Financing with New Investor Pfizer Ventures with Investment of $5 Million Incrasing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/tetralogic-pharmaceuticals-expands-series-c-financing-new-investor-pfizer-ventures> ;
    ns1:foundName "Hatteras Venture Partners" ;
    ns1:investor <https://1145.am/db/2365171/Series_C_Investment_Amgen_Ventures_Clarus_Ventures_Hatteras_Venture_Partners_Healthcare_Ventures_Latterell_Venture_Partners_Novitas_Capital_Pfizer_Ventures_Quaker_Bioventures_Tetralogic_Pharmaceuticals_Vertical_Group_Completed> ;
    ns1:name "Hatteras Venture Partners" ;
    ns1:sameAsMedium <https://1145.am/db/1115103/Hatteras_Venture_Partners>,
        <https://1145.am/db/1335370/Hatteras_Venture_Partners>,
        <https://1145.am/db/1464210/Hatteras_Venture_Partners>,
        <https://1145.am/db/1465033/Hatteras_Venture_Partners>,
        <https://1145.am/db/1565424/Hatteras_Venture_Partners>,
        <https://1145.am/db/1896251/Hatteras_Venture_Partners>,
        <https://1145.am/db/1957179/Hatteras_Venture_Partners>,
        <https://1145.am/db/2153141/Hatteras_Venture_Partners>,
        <https://1145.am/db/2224522/Hatteras_Venture_Partners>,
        <https://1145.am/db/2236817/Hatteras_Venture_Partners>,
        <https://1145.am/db/2284028/Hatteras_Venture_Partners>,
        <https://1145.am/db/2306163/Hatteras_Venture_Partners>,
        <https://1145.am/db/2315247/Hatteras_Venture_Partners>,
        <https://1145.am/db/2315248/Hatteras_Venture_Partners>,
        <https://1145.am/db/2319640/Hatteras_Venture_Partners>,
        <https://1145.am/db/2321694/Hatteras_Venture_Partners>,
        <https://1145.am/db/2323511/Hatteras_Venture_Partners>,
        <https://1145.am/db/2328194/Hatteras_Venture_Partners>,
        <https://1145.am/db/2328196/Hatteras_Venture_Partners>,
        <https://1145.am/db/2332459/Hatteras_Venture_Partners>,
        <https://1145.am/db/2339206/Hatteras_Venture_Partners>,
        <https://1145.am/db/2349717/Hatteras_Venture_Partners>,
        <https://1145.am/db/2349722/Hatteras_Venture_Partners>,
        <https://1145.am/db/2351316/Hatteras_Venture_Partners>,
        <https://1145.am/db/2353640/Hatteras_Venture_Partners>,
        <https://1145.am/db/2353671/Hatteras_Venture_Partners>,
        <https://1145.am/db/2353674/Hatteras_Venture_Partners>,
        <https://1145.am/db/2354648/Hatteras_Venture_Partners>,
        <https://1145.am/db/2358640/Hatteras_Venture_Partners>,
        <https://1145.am/db/2358657/Hatteras_Venture_Partners>,
        <https://1145.am/db/2358658/Hatteras_Venture_Partners>,
        <https://1145.am/db/2358812/Hatteras_Venture_Partners>,
        <https://1145.am/db/2359452/Hatteras_Venture_Partners>,
        <https://1145.am/db/2360521/Hatteras_Venture_Partners>,
        <https://1145.am/db/2360526/Hatteras_Venture_Partners>,
        <https://1145.am/db/2363396/Hatteras_Venture_Partners>,
        <https://1145.am/db/2363442/Hatteras_Venture_Partners>,
        <https://1145.am/db/2364853/Hatteras_Venture_Partners>,
        <https://1145.am/db/495996/Hatteras_Venture_Partners>,
        <https://1145.am/db/496377/Hatteras_Venture_Partners>,
        <https://1145.am/db/601404/Hatteras_Venture_Partners>,
        <https://1145.am/db/885068/Hatteras_Venture_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2365171/Latterell_Venture_Partners> a org:Organization ;
    ns1:basedInLowRaw "Pa" ;
    ns1:description "Series C financing" ;
    ns1:documentDate "2010-09-28T13:45:54+00:00"^^xsd:dateTime ;
    ns1:documentTitle "TetraLogic Pharmaceuticals Expands Series C Financing with New Investor Pfizer Ventures with Investment of $5 Million Incrasing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/tetralogic-pharmaceuticals-expands-series-c-financing-new-investor-pfizer-ventures> ;
    ns1:foundName "Latterell Venture Partners" ;
    ns1:investor <https://1145.am/db/2365171/Series_C_Investment_Amgen_Ventures_Clarus_Ventures_Hatteras_Venture_Partners_Healthcare_Ventures_Latterell_Venture_Partners_Novitas_Capital_Pfizer_Ventures_Quaker_Bioventures_Tetralogic_Pharmaceuticals_Vertical_Group_Completed> ;
    ns1:name "Latterell Venture Partners" ;
    ns1:sameAsHigh <https://1145.am/db/2308828/Latterell_Venture_Partners>,
        <https://1145.am/db/2308841/Latterell_Venture_Partners>,
        <https://1145.am/db/2319658/Latterell_Venture_Partners>,
        <https://1145.am/db/2319874/Latterell_Venture_Partners_Us_Venture_Partners>,
        <https://1145.am/db/2349717/Latterell_Venture_Partners>,
        <https://1145.am/db/2357487/Latterell_Venture_Partners> ;
    ns1:sameAsMedium <https://1145.am/db/2223193/Latterell_Venture_Partners>,
        <https://1145.am/db/2257512/Latterell_Venture_Partners>,
        <https://1145.am/db/2312120/Latterell_Venture_Partners>,
        <https://1145.am/db/2324226/Latterell_Venture_Partners>,
        <https://1145.am/db/2329531/Latterell_Venture_Partners>,
        <https://1145.am/db/2341068/Latterell_Venture_Partners>,
        <https://1145.am/db/2341074/Latterell_Venture_Partners>,
        <https://1145.am/db/2345568/Latterell_Venture_Partners>,
        <https://1145.am/db/2349722/Latterell_Venture_Partners>,
        <https://1145.am/db/2366693/Latterell_Venture_Partners>,
        <https://1145.am/db/2366700/Latterell_Venture_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2365171/Novitas_Capital> a org:Organization ;
    ns1:basedInLowRaw "Pa" ;
    ns1:description "Series C financing" ;
    ns1:documentDate "2010-09-28T13:45:54+00:00"^^xsd:dateTime ;
    ns1:documentTitle "TetraLogic Pharmaceuticals Expands Series C Financing with New Investor Pfizer Ventures with Investment of $5 Million Incrasing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/tetralogic-pharmaceuticals-expands-series-c-financing-new-investor-pfizer-ventures> ;
    ns1:foundName "Novitas Capital" ;
    ns1:investor <https://1145.am/db/2365171/Series_C_Investment_Amgen_Ventures_Clarus_Ventures_Hatteras_Venture_Partners_Healthcare_Ventures_Latterell_Venture_Partners_Novitas_Capital_Pfizer_Ventures_Quaker_Bioventures_Tetralogic_Pharmaceuticals_Vertical_Group_Completed> ;
    ns1:name "Novitas Capital" ;
    ns1:sameAsHigh <https://1145.am/db/2349717/Novitas_Capital> ;
    ns1:sameAsMedium <https://1145.am/db/2331048/Novitas_Capital>,
        <https://1145.am/db/2349722/Novitas_Capital>,
        <https://1145.am/db/2358271/Novitas_Capital>,
        <https://1145.am/db/2358272/Novitas_Capital>,
        <https://1145.am/db/2363475/Novitas_Capital> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2365171/Vertical_Group> a org:Organization ;
    ns1:basedInLowRaw "Pa" ;
    ns1:description "venture capital" ;
    ns1:documentDate "2010-09-28T13:45:54+00:00"^^xsd:dateTime ;
    ns1:documentTitle "TetraLogic Pharmaceuticals Expands Series C Financing with New Investor Pfizer Ventures with Investment of $5 Million Incrasing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/tetralogic-pharmaceuticals-expands-series-c-financing-new-investor-pfizer-ventures> ;
    ns1:foundName "the Vertical Group" ;
    ns1:investor <https://1145.am/db/2365171/Series_C_Investment_Amgen_Ventures_Clarus_Ventures_Hatteras_Venture_Partners_Healthcare_Ventures_Latterell_Venture_Partners_Novitas_Capital_Pfizer_Ventures_Quaker_Bioventures_Tetralogic_Pharmaceuticals_Vertical_Group_Completed> ;
    ns1:name "Vertical Group" ;
    ns1:sameAsHigh <https://1145.am/db/1927859/Vertical_Venture_Partners>,
        <https://1145.am/db/2319874/The_Vertical_Group>,
        <https://1145.am/db/2326486/The_Vertical_Group> ;
    ns1:sameAsMedium <https://1145.am/db/2050254/Vertical_Group>,
        <https://1145.am/db/2278799/Vertical_Group>,
        <https://1145.am/db/2349717/Vertical_Group>,
        <https://1145.am/db/2349722/Vertical_Group> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2366187/Novo_A_S> a org:Organization ;
    ns1:basedInLowRaw "MANALAPAN" ;
    ns1:description "Investing" ;
    ns1:documentDate "2010-09-30T16:26:17+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Tobira Therapeutics Inc. Raises $31 Million in Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/tobira-therapeutics-inc-raises-31-million-series-b-financing> ;
    ns1:foundName "Novo A/S" ;
    ns1:investor <https://1145.am/db/2366187/Series_B_Investment_Canaan_Partners_Domain_Associates_Frazier_Healthcare_Ventures_Montreux_Equity_Partners_Novo_A_S_Tobira_Therapeutics_Inc_Completed> ;
    ns1:name "Novo A/S" ;
    ns1:sameAsHigh <https://1145.am/db/1045411/Novo_Holdings_Gv>,
        <https://1145.am/db/1196006/Novo_Holdings_A_S>,
        <https://1145.am/db/146274/Novo_Holdings>,
        <https://1145.am/db/1618894/Novo_Holdings_A_S>,
        <https://1145.am/db/1619579/Novo_Holdings_A_S>,
        <https://1145.am/db/1648777/Novo_Holdings>,
        <https://1145.am/db/2011280/Novo_Holdings_A_S>,
        <https://1145.am/db/2154185/Novo_Holdings>,
        <https://1145.am/db/2288016/Novo_A_S>,
        <https://1145.am/db/2296065/Novo_Holdings_A_S>,
        <https://1145.am/db/2302994/Novo_A_S>,
        <https://1145.am/db/2302995/Novo_A_S>,
        <https://1145.am/db/2304340/Novo_A_S>,
        <https://1145.am/db/2311133/Novo_A_S>,
        <https://1145.am/db/2318733/Novo_A_S>,
        <https://1145.am/db/2319433/Novo_A_S>,
        <https://1145.am/db/2355183/Novo_A_S>,
        <https://1145.am/db/2356124/Novo_Ventures>,
        <https://1145.am/db/2365700/Novo_A_S>,
        <https://1145.am/db/802321/Novo_Holdings_A_S>,
        <https://1145.am/db/829447/Novo_Holdings> ;
    ns1:sameAsMedium <https://1145.am/db/1753148/Novo>,
        <https://1145.am/db/1754034/Novo>,
        <https://1145.am/db/2296606/Novo_A_S>,
        <https://1145.am/db/2298077/Novo_A_S>,
        <https://1145.am/db/2298277/Novo_A_S>,
        <https://1145.am/db/2299423/Novo_As>,
        <https://1145.am/db/2299645/Novo>,
        <https://1145.am/db/2300653/Novo_A_S>,
        <https://1145.am/db/2301290/Novo>,
        <https://1145.am/db/2301494/Novo_A_S>,
        <https://1145.am/db/2303767/Novo_A_S>,
        <https://1145.am/db/2304335/Novo_A_S>,
        <https://1145.am/db/2308758/Novo_A_S>,
        <https://1145.am/db/2309506/Novo_A_S>,
        <https://1145.am/db/2309507/Novo_A_S>,
        <https://1145.am/db/2311274/Novo>,
        <https://1145.am/db/2312120/Novo_A_S>,
        <https://1145.am/db/2314546/Novo_A_S>,
        <https://1145.am/db/2319236/Novo_A_S>,
        <https://1145.am/db/2319416/Novo_A_S>,
        <https://1145.am/db/2319784/Novo_A_S>,
        <https://1145.am/db/2321216/Novo_A_S>,
        <https://1145.am/db/2321861/Novo_A_S>,
        <https://1145.am/db/2321870/Novo_A_S>,
        <https://1145.am/db/2325116/Novo_A_S>,
        <https://1145.am/db/2329010/Novo_A_S>,
        <https://1145.am/db/2329011/Novo_A_S>,
        <https://1145.am/db/2329224/Novo_A_S>,
        <https://1145.am/db/2335700/Novo_A_S>,
        <https://1145.am/db/2338817/Novo_A_S>,
        <https://1145.am/db/2339692/Novo_A_S>,
        <https://1145.am/db/2340612/Novo_A_S>,
        <https://1145.am/db/2341934/Novo>,
        <https://1145.am/db/2342284/Novo_A_S>,
        <https://1145.am/db/2345268/Novo_A_S>,
        <https://1145.am/db/2345273/Novo_A_S>,
        <https://1145.am/db/2346452/Novo_A_S>,
        <https://1145.am/db/2349013/Novo_A_S>,
        <https://1145.am/db/2349048/Novo_A_S>,
        <https://1145.am/db/2349050/Novo_A_S>,
        <https://1145.am/db/2349406/Novo_A_S>,
        <https://1145.am/db/2353241/Novo_A_S>,
        <https://1145.am/db/2356861/Novo_A_S>,
        <https://1145.am/db/2356876/Novo_A_S>,
        <https://1145.am/db/2357109/Novo_A_S>,
        <https://1145.am/db/2358233/Novo_A_S>,
        <https://1145.am/db/2358246/Novo_As>,
        <https://1145.am/db/2358271/Novo_A_S>,
        <https://1145.am/db/2358272/Novo_A_S>,
        <https://1145.am/db/2358459/Novo>,
        <https://1145.am/db/2358464/Novo_A_S>,
        <https://1145.am/db/2358542/Novo_A_S>,
        <https://1145.am/db/2359510/Novo_A_S>,
        <https://1145.am/db/2359683/Novo_A_S>,
        <https://1145.am/db/2360562/Novo>,
        <https://1145.am/db/2361588/Novo_A_S>,
        <https://1145.am/db/2363535/Novo_A_S>,
        <https://1145.am/db/2364505/Novo_A_S>,
        <https://1145.am/db/2364508/Novo_A_S>,
        <https://1145.am/db/2365701/Novo_A_S>,
        <https://1145.am/db/2366333/Novo_A_S>,
        <https://1145.am/db/2367275/Novo_A_S>,
        <https://1145.am/db/2367364/Novo_A_S>,
        <https://1145.am/db/2367368/Novo_A_S>,
        <https://1145.am/db/2368297/Novo_A_S>,
        <https://1145.am/db/2368333/Novo_A_S>,
        <https://1145.am/db/2368572/Novo_A_S>,
        <https://1145.am/db/2543793/Novo>,
        <https://1145.am/db/2544115/Novo>,
        <https://1145.am/db/2552947/Novo>,
        <https://1145.am/db/2557027/Novo>,
        <https://1145.am/db/2581901/Novo_A_S>,
        <https://1145.am/db/2581902/Novo_A_S>,
        <https://1145.am/db/2584056/Novo_A_S>,
        <https://1145.am/db/360351/Novo>,
        <https://1145.am/db/751135/Novo> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2366187/Tobira_Therapeutics_Inc> a org:Organization ;
    ns1:description "developing and commercializing innovative antiviral compounds to treat HIV disease" ;
    ns1:documentDate "2010-09-30T16:26:17+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Tobira Therapeutics Inc. Raises $31 Million in Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/tobira-therapeutics-inc-raises-31-million-series-b-financing> ;
    ns1:foundName "Tobira Therapeutics Inc." ;
    ns1:industry "biopharmaceutical" ;
    ns1:name "Tobira Therapeutics Inc." ;
    ns1:sameAsHigh <https://1145.am/db/2335611/Tokai_Pharmaceuticals_Inc>,
        <https://1145.am/db/2337979/Tokai_Pharmaceuticals>,
        <https://1145.am/db/2343666/Tolero_Pharmaceuticals_Inc>,
        <https://1145.am/db/2345428/Tokai_Pharmaceuticals_Inc>,
        <https://1145.am/db/2350602/Tokai_Pharmaceuticals>,
        <https://1145.am/db/2351058/Tokai_Pharmaceuticals>,
        <https://1145.am/db/2351273/Tobira_Therapeutics>,
        <https://1145.am/db/2351601/Tokai_Pharmaceuticals>,
        <https://1145.am/db/2352911/Tobira_Therapeutics>,
        <https://1145.am/db/2353948/Tobira_Therapeutics>,
        <https://1145.am/db/2357071/Tolero_Pharmaceuticals>,
        <https://1145.am/db/2357147/Tobira_Therapeutics>,
        <https://1145.am/db/2357942/Tobira_Therapeutics>,
        <https://1145.am/db/2359017/Tobira_Therapeutics>,
        <https://1145.am/db/2360434/Tobira_Therapeutics>,
        <https://1145.am/db/2361296/Tokai_Pharmaceuticals>,
        <https://1145.am/db/2362186/Tobira_Therapeutics>,
        <https://1145.am/db/2362331/Tokai_Pharmaceuticals>,
        <https://1145.am/db/2365700/Tobira_Therapeutics_Inc>,
        <https://1145.am/db/2577197/Tobira_Therapeutics>,
        <https://1145.am/db/2594369/Tokai_Pharmaceuticals_Inc>,
        <https://1145.am/db/2597426/Tokai_Pharmaceuticals> ;
    ns1:sameAsMedium <https://1145.am/db/2306755/Tobira_Therapeutics>,
        <https://1145.am/db/2331623/Tobira_Therapeutics>,
        <https://1145.am/db/2351285/Tobira_Therapeutics>,
        <https://1145.am/db/2353638/Tobira_Therapeutics> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2366860/Convergence_Pharmaceuticals> a org:Organization ;
    ns1:basedInHighGeoName "Cambridgeshire" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2653940/about.rdf> ;
    ns1:basedInHighRaw "Cambridge, UK" ;
    ns1:description "pharmaceuticals" ;
    ns1:documentDate "2010-10-06T13:04:22+00:00"^^xsd:dateTime ;
    ns1:documentTitle "New Leaf Venture Partners Invests in $35.4 (GBP 22.4) Million Series A Financing of Convergence Pharmaceuticals" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/new-leaf-venture-partners-invests-35-4-gbp-22-4-million-series-a-financing-of-convergence> ;
    ns1:foundName "Convergence Pharmaceuticals" ;
    ns1:industry "Pharmaceuticals" ;
    ns1:name "Convergence Pharmaceuticals" ;
    ns1:sameAsHigh <https://1145.am/db/2357123/Convergence_Pharmaceuticals>,
        <https://1145.am/db/2357546/Convergence_Pharmaceuticals> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2366860/Series_A_Investment_New_Leaf_Venture_Partners_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-10-06T13:04:22+00:00"^^xsd:dateTime ;
    ns1:documentExtract "New Leaf Venture Partners Invests in $ 35.4 (GBP 22.4) Million Series A Financing of Convergence Pharmaceuticals." ;
    ns1:documentTitle "New Leaf Venture Partners Invests in $35.4 (GBP 22.4) Million Series A Financing of Convergence Pharmaceuticals" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/new-leaf-venture-partners-invests-35-4-gbp-22-4-million-series-a-financing-of-convergence> ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:targetDetails "Series A" ;
    ns1:valueRaw "$ 35.4",
        "GBP 22.4",
        "Million" ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "United States" .

<https://1145.am/db/2366953/Alnara_Pharmaceuticals> a org:Organization ;
    ns1:basedInHighGeoName "Cambridge" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/4931972/about.rdf> ;
    ns1:basedInHighRaw "CAMBRIDGE, Mass." ;
    ns1:description "developing protein therapeutics for the treatment of metabolic diseases" ;
    ns1:documentDate "2010-07-02T13:00:55+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Lilly to Acquire Alnara Pharmaceuticals" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/lilly-to-acquire-alnara-pharmaceuticals> ;
    ns1:foundName "Alnara",
        "Alnara Pharmaceuticals, Inc." ;
    ns1:industry "biotechnology" ;
    ns1:name "Alnara Pharmaceuticals" ;
    ns1:protagonist <https://1145.am/db/2366953/Alnara_Pharmaceuticals_Acquisition> ;
    ns1:sameAsHigh <https://1145.am/db/1105083/Pharmacyte_Biotech>,
        <https://1145.am/db/1106504/Pharmacyte_Biotech>,
        <https://1145.am/db/1194874/Emerald_Health_Pharmaceuticals_Inc>,
        <https://1145.am/db/1378519/Idera_Pharmaceuticals_Inc>,
        <https://1145.am/db/1401764/Pharmacyte_Biotech>,
        <https://1145.am/db/2009873/Ochre_Bio>,
        <https://1145.am/db/2110130/Allay_Therapeutics>,
        <https://1145.am/db/2303804/Access_Pharmaceuticals>,
        <https://1145.am/db/2314347/Momenta_Pharmaceuticals>,
        <https://1145.am/db/2336239/Vitae_Pharmaceuticals>,
        <https://1145.am/db/2340755/Conatus_Pharmaceuticals_Inc>,
        <https://1145.am/db/2341792/Edimer_Pharmaceuticals>,
        <https://1145.am/db/2342503/Alnara_Pharmaceuticals>,
        <https://1145.am/db/2343800/Sideris_Pharmaceuticals>,
        <https://1145.am/db/2348620/Diartis_Pharmaceuticals_Inc>,
        <https://1145.am/db/2349844/Apellis_Pharmaceuticals>,
        <https://1145.am/db/2352045/Costim_Pharmaceuticals_Inc>,
        <https://1145.am/db/2353647/Rxi_Pharmaceuticals_Corporation>,
        <https://1145.am/db/2360709/Conatus_Pharmaceuticals_Inc>,
        <https://1145.am/db/2363331/Momenta_Pharmaceuticals>,
        <https://1145.am/db/2365082/Aveo_Pharmaceuticals>,
        <https://1145.am/db/2365628/Rxi_Pharmaceuticals_Corporation>,
        <https://1145.am/db/2366102/Rxi_Pharmaceuticals_Corporation>,
        <https://1145.am/db/2366948/Alnara_Pharmaceuticals>,
        <https://1145.am/db/2367807/Conatus_Pharmaceuticals_Inc>,
        <https://1145.am/db/2368847/Vitae_Pharmaceuticals>,
        <https://1145.am/db/2572711/Alnara_Pharmaceuticals>,
        <https://1145.am/db/2575554/Alnara_Pharmaceuticals>,
        <https://1145.am/db/2579346/Momenta_Pharmaceuticals>,
        <https://1145.am/db/401518/Pharmacyte_Biotech>,
        <https://1145.am/db/405493/Pharmacyte_Biotech>,
        <https://1145.am/db/423412/Pharmacyte_Biotech>,
        <https://1145.am/db/424843/Pharmacyte_Biotech>,
        <https://1145.am/db/474783/Allay_Therapeutics>,
        <https://1145.am/db/739207/Allay_Therapeutics>,
        <https://1145.am/db/886466/Avm_Biotechnology> ;
    ns1:sameAsMedium <https://1145.am/db/2303250/Alnara_Pharmaceuticals>,
        <https://1145.am/db/2303251/Alnara_Pharmaceuticals_Inc>,
        <https://1145.am/db/2303257/Alnara_Pharmaceuticals>,
        <https://1145.am/db/2311551/Alnara_Pharmaceuticals>,
        <https://1145.am/db/2326883/Alnara_Pharmaceuticals>,
        <https://1145.am/db/2338633/Alnara_Pharmaceuticals> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2366953/Eli_Lilly_And_Company> a org:Organization ;
    ns1:basedInHighGeoName "Indianapolis" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/4259418/about.rdf> ;
    ns1:basedInHighRaw "INDIANAPOLIS" ;
    ns1:buyer <https://1145.am/db/2366953/Alnara_Pharmaceuticals_Acquisition> ;
    ns1:description "Pharmaceuticals" ;
    ns1:documentDate "2010-07-02T13:00:55+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Lilly to Acquire Alnara Pharmaceuticals" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/lilly-to-acquire-alnara-pharmaceuticals> ;
    ns1:foundName "Eli Lilly and Company" ;
    ns1:industry "Pharmaceuticals" ;
    ns1:name "Eli Lilly and Company" ;
    ns1:sameAsHigh <https://1145.am/db/1038901/Eli_Lilly_And_Company>,
        <https://1145.am/db/1072187/Eli_Lilly_And_Company>,
        <https://1145.am/db/1087869/Eli_Lilly_And_Company>,
        <https://1145.am/db/1133669/Boehringer_Ingelheim>,
        <https://1145.am/db/1135149/Boehringer_Ingelheim>,
        <https://1145.am/db/1217359/Eli_Lilly_And_Company>,
        <https://1145.am/db/1272276/Eli_Lilly_And_Company>,
        <https://1145.am/db/1272276/Lilly>,
        <https://1145.am/db/1340338/Eli_Lilly_And_Company>,
        <https://1145.am/db/1425255/Eli_Lilly_And_Company>,
        <https://1145.am/db/1428583/Eli_Lilly_And_Company>,
        <https://1145.am/db/1428583/Lilly>,
        <https://1145.am/db/1432746/Eli_Lilly>,
        <https://1145.am/db/1534004/Eli_Lilly_And_Company>,
        <https://1145.am/db/1534438/Eli_Lilly_And_Company>,
        <https://1145.am/db/1537106/Boehringer_Ingelheim>,
        <https://1145.am/db/1537985/Boehringer_Ingelheim>,
        <https://1145.am/db/1546070/Eli_Lilly_And_Company>,
        <https://1145.am/db/1553175/Eli_Lilly___Company>,
        <https://1145.am/db/1553459/Eli_Lilly___Company>,
        <https://1145.am/db/1594413/Boehringer_Ingelheim>,
        <https://1145.am/db/1663572/Eli_Lilly_And_Company>,
        <https://1145.am/db/174741/Eli_Lilly_And_Co>,
        <https://1145.am/db/1979697/Eli_Lilly>,
        <https://1145.am/db/1984558/Eli_Lilly_And_Company>,
        <https://1145.am/db/2043001/Eli_Lilly_And_Co>,
        <https://1145.am/db/2045539/Eli_Lilly_And_Company>,
        <https://1145.am/db/2053734/Eli_Lilly_And_Co>,
        <https://1145.am/db/2055009/Eli_Lilly_And_Company>,
        <https://1145.am/db/2058865/Eli_Lilly_And_Company>,
        <https://1145.am/db/2062260/Eli_Lilly>,
        <https://1145.am/db/2065629/Eli_Lilly_And_Company>,
        <https://1145.am/db/2134678/Eli_Lilly_And_Co>,
        <https://1145.am/db/2136466/Eli_Lilly_And_Co>,
        <https://1145.am/db/2139015/Eli_Lilly_And_Company>,
        <https://1145.am/db/2152172/Boehringer_Ingelheim>,
        <https://1145.am/db/2152174/Boehringer_Ingelheim>,
        <https://1145.am/db/2152285/Boehringer>,
        <https://1145.am/db/2154037/Eli_Lilly>,
        <https://1145.am/db/2154391/Eli_Lilly>,
        <https://1145.am/db/2154401/Boehringer_Ingelheim>,
        <https://1145.am/db/2155453/Lilly_Usa>,
        <https://1145.am/db/2281211/Eli_Lilly>,
        <https://1145.am/db/2282739/Eli_Lilly>,
        <https://1145.am/db/2282930/Eli_Lilly>,
        <https://1145.am/db/2283595/Eli_Lilly>,
        <https://1145.am/db/2284615/Lilly>,
        <https://1145.am/db/2285156/Eli_Lilly>,
        <https://1145.am/db/2285189/Eli_Lilly>,
        <https://1145.am/db/2285525/Eli_Lilly>,
        <https://1145.am/db/2286402/Eli_Lilly>,
        <https://1145.am/db/2286404/Eli_Lilly>,
        <https://1145.am/db/2286617/Eli_Lilly>,
        <https://1145.am/db/2286657/Boehringer_Ingelheim>,
        <https://1145.am/db/2286911/Eli_Lilly>,
        <https://1145.am/db/2286998/Eli_Lilly>,
        <https://1145.am/db/2287005/Eli_Lilly>,
        <https://1145.am/db/2288158/Eli_Lilly>,
        <https://1145.am/db/2290507/Boehringer_Ingelheim>,
        <https://1145.am/db/2290919/Boehringer_Ingelheim>,
        <https://1145.am/db/229232/Eli_Lilly>,
        <https://1145.am/db/2293168/Boehringer_Ingelheim>,
        <https://1145.am/db/2294118/Eli_Lilly>,
        <https://1145.am/db/2298022/Eli_Lilly>,
        <https://1145.am/db/2299157/Eli_Lilly>,
        <https://1145.am/db/2301879/Eli_Lilly_And_Company>,
        <https://1145.am/db/2302104/Eli_Lilly_And_Company>,
        <https://1145.am/db/2303974/Boehringer_Ingelheim_Gmbh>,
        <https://1145.am/db/2303980/Boehringer_Ingelheim>,
        <https://1145.am/db/2305497/Eli_Lilly>,
        <https://1145.am/db/2306173/Boehringer_Ingelheim>,
        <https://1145.am/db/2306807/Eli_Lilly_And_Company>,
        <https://1145.am/db/2307651/Eli_Lilly>,
        <https://1145.am/db/2309473/Eli_Lilly>,
        <https://1145.am/db/2309599/Eli_Lilly>,
        <https://1145.am/db/2313544/Boehringer_Ingelheim>,
        <https://1145.am/db/2314412/Eli_Lilly_And_Company>,
        <https://1145.am/db/2316092/Eli_Lilly>,
        <https://1145.am/db/2316549/Eli_Lilly>,
        <https://1145.am/db/2318248/Boehringer_Ingelheim>,
        <https://1145.am/db/2318587/Eli_Lilly>,
        <https://1145.am/db/2320006/Eli_Lilly>,
        <https://1145.am/db/2320338/Eli_Lilly>,
        <https://1145.am/db/2322619/Eli_Lilly_And_Company>,
        <https://1145.am/db/2323165/Eli_Lilly_And_Company>,
        <https://1145.am/db/2325525/Boehringer_Ingelheim>,
        <https://1145.am/db/2325557/Eli_Lilly_And_Company>,
        <https://1145.am/db/2326272/Lilly_Usa>,
        <https://1145.am/db/2327587/Eli_Lilly_And_Company>,
        <https://1145.am/db/2328527/Eli_Lilly>,
        <https://1145.am/db/2328554/Eli_Lilly_And_Company>,
        <https://1145.am/db/2328718/Eli_Lilly>,
        <https://1145.am/db/2329107/Lilly>,
        <https://1145.am/db/2329114/Eli_Lilly>,
        <https://1145.am/db/2329115/Lilly>,
        <https://1145.am/db/2334645/Eli_Lilly>,
        <https://1145.am/db/2335594/Eli_Lilly_And_Company>,
        <https://1145.am/db/2335703/Boehringer_Ingelheim>,
        <https://1145.am/db/2335705/Boehringer_Ingelheim>,
        <https://1145.am/db/2335908/Boehringer>,
        <https://1145.am/db/2336074/Eli_Lilly_And_Company>,
        <https://1145.am/db/2338059/Eli_Lilly>,
        <https://1145.am/db/2340948/Eli_Lilly>,
        <https://1145.am/db/2341481/Eli_Lilly>,
        <https://1145.am/db/2341496/Eli_Lilly>,
        <https://1145.am/db/2342503/Eli_Lilly_And_Company>,
        <https://1145.am/db/2343945/Eli_Lilly_And_Company>,
        <https://1145.am/db/2344800/Eli_Lilly_And_Company>,
        <https://1145.am/db/2344808/Eli_Lilly>,
        <https://1145.am/db/2344991/Eli_Lilly>,
        <https://1145.am/db/2345213/Eli_Lilly>,
        <https://1145.am/db/2345214/Eli_Lilly>,
        <https://1145.am/db/2346629/Novo_Nordisk_Eli_Lilly>,
        <https://1145.am/db/2349020/Eli_Lilly_And_Company>,
        <https://1145.am/db/2349300/Eli_Lilly_And_Company>,
        <https://1145.am/db/2352358/Eli_Lilly>,
        <https://1145.am/db/2353350/Eli_Lilly>,
        <https://1145.am/db/2354380/Boehringer_Ingelheim>,
        <https://1145.am/db/2354388/Boehringer_Ingelheim>,
        <https://1145.am/db/2354761/Eli_Lilly_And_Company>,
        <https://1145.am/db/2354853/Eli_Lilly_And_Company>,
        <https://1145.am/db/2359240/Eli_Lilly>,
        <https://1145.am/db/2360080/Boehringer_Ingelheim>,
        <https://1145.am/db/2360086/Boehringer_Ingelheim>,
        <https://1145.am/db/2361027/Eli_Lilly>,
        <https://1145.am/db/2363310/Eli_Lilly_And_Company_(lly)>,
        <https://1145.am/db/2364605/Eli_Lilly>,
        <https://1145.am/db/2364810/Boehringer_Ingelheim>,
        <https://1145.am/db/2365178/Eli_Lilly_And_Company>,
        <https://1145.am/db/2366948/Eli_Lilly_And_Company>,
        <https://1145.am/db/2366948/Lilly>,
        <https://1145.am/db/2366953/Lilly>,
        <https://1145.am/db/2367430/Boehringer_Ingelheim>,
        <https://1145.am/db/2368562/Eli_Lilly_And_Company>,
        <https://1145.am/db/2369000/Eli_Lilly_And_Company>,
        <https://1145.am/db/2370162/Eli_Lilly>,
        <https://1145.am/db/2370523/Boehringer>,
        <https://1145.am/db/2371016/Eli_Lilly>,
        <https://1145.am/db/2371058/Eli_Lilly_And_Company>,
        <https://1145.am/db/2371075/Eli_Lilly_And_Company>,
        <https://1145.am/db/2371075/Lilly>,
        <https://1145.am/db/2536400/Boehringer_Ingelheim>,
        <https://1145.am/db/2536960/Eli_Lilly>,
        <https://1145.am/db/2537335/Eli_Lilly_And_Company>,
        <https://1145.am/db/2537665/Eli_Lilly>,
        <https://1145.am/db/2537666/Eli_Lilly>,
        <https://1145.am/db/2537817/Eli_Lilly_And_Company>,
        <https://1145.am/db/2537826/Eli_Lilly_And_Company>,
        <https://1145.am/db/2539012/Boehringer_Ingelheim>,
        <https://1145.am/db/2539287/Eli_Lilly>,
        <https://1145.am/db/2539970/Eli_Lilly>,
        <https://1145.am/db/2540249/Boehringer_Ingelheim>,
        <https://1145.am/db/2541725/Boehringer_Ingelheim>,
        <https://1145.am/db/2543185/Eli_Lilly>,
        <https://1145.am/db/2545618/Eli_Lilly>,
        <https://1145.am/db/2546160/Boehringer_Ingelheim>,
        <https://1145.am/db/2546781/Boehringer_Ingelheim>,
        <https://1145.am/db/2547189/Boehringer_Ingelheim>,
        <https://1145.am/db/2549450/Eli_Lilly>,
        <https://1145.am/db/2550996/Eli_Lilly>,
        <https://1145.am/db/2551049/Eli_Lilly>,
        <https://1145.am/db/2551101/Eli_Lilly>,
        <https://1145.am/db/2553131/Boehringer_Ingelheim>,
        <https://1145.am/db/2553131/Eli_Lilly>,
        <https://1145.am/db/2553551/Eli_Lilly>,
        <https://1145.am/db/2553750/Boehringer_Ingelheim>,
        <https://1145.am/db/2554242/Boehringer_Ingelheim>,
        <https://1145.am/db/2554535/Boehringer_Ingelheim>,
        <https://1145.am/db/2555393/Boehringer_Ingelheim>,
        <https://1145.am/db/2555921/Boehringer_Ingelheim_Group_Of_Companies>,
        <https://1145.am/db/2555925/Boehringer_Ingelheim_Plant>,
        <https://1145.am/db/2556906/Eli_Lilly_And_Company>,
        <https://1145.am/db/2556969/Eli_Lilly>,
        <https://1145.am/db/2557861/Boehringer_Ingelheim>,
        <https://1145.am/db/2558025/Boehringer_Ingelheim>,
        <https://1145.am/db/2558026/Boehringer_Ingelheim>,
        <https://1145.am/db/2559125/Eli_Lilly_And_Company>,
        <https://1145.am/db/2560253/Boehringer_Ingelheim>,
        <https://1145.am/db/2560487/Eli_Lilly>,
        <https://1145.am/db/2560865/Boehringer_Ingelheim>,
        <https://1145.am/db/2561357/Eli_Lilly>,
        <https://1145.am/db/2561960/Eli_Lilly>,
        <https://1145.am/db/2562442/Eli_Lilly>,
        <https://1145.am/db/2562576/Eli_Lilly>,
        <https://1145.am/db/2564389/Eli_Lilly___Co>,
        <https://1145.am/db/2566845/Lilly>,
        <https://1145.am/db/2567343/Eli_Lilly>,
        <https://1145.am/db/2567800/Boehringer_Ingelheim>,
        <https://1145.am/db/2569425/Boehringer_Ingelheim>,
        <https://1145.am/db/2569829/Eli_Lilly>,
        <https://1145.am/db/2571316/Boehringer_Ingelheim>,
        <https://1145.am/db/2571525/Boehringer_Ingelheim>,
        <https://1145.am/db/2572312/Eli_Lilly_And_Company>,
        <https://1145.am/db/2572711/Eli_Lilly_And_Company>,
        <https://1145.am/db/2572711/Lilly>,
        <https://1145.am/db/2572957/Eli_Lilly_And_Company>,
        <https://1145.am/db/2573259/Boehringer_Ingelheim>,
        <https://1145.am/db/2573885/Eli_Lilly>,
        <https://1145.am/db/2574421/Boehringer_Ingelheim_Group_Of_Companies>,
        <https://1145.am/db/2575554/Eli_Lilly_And_Company>,
        <https://1145.am/db/2575575/Boehringer_Ingelheim>,
        <https://1145.am/db/2575909/Eli_Lilly>,
        <https://1145.am/db/2575972/Eli_Lilly>,
        <https://1145.am/db/2576086/Eli_Lilly>,
        <https://1145.am/db/2576171/Eli_Lilly_And_Company>,
        <https://1145.am/db/2576460/Eli_Lilly_And_Company>,
        <https://1145.am/db/2576462/Eli_Lilly_And_Company>,
        <https://1145.am/db/2576892/Eli_Lilly>,
        <https://1145.am/db/2576933/Eli_Lilly>,
        <https://1145.am/db/2576944/Eli_Lilly>,
        <https://1145.am/db/2577171/Eli_Lilly_And_Company>,
        <https://1145.am/db/2578048/Eli_Lilly_And_Company>,
        <https://1145.am/db/2578603/Eli_Lilly>,
        <https://1145.am/db/2578745/Boehringer_Ingelheim>,
        <https://1145.am/db/2578827/Boehringer>,
        <https://1145.am/db/2578874/Eli_Lilly>,
        <https://1145.am/db/2578876/Eli_Lilly_And_Company>,
        <https://1145.am/db/2580140/Boehringer_Ingelheim_And_Eli_Lilly>,
        <https://1145.am/db/2580383/Boehringer_Ingelheim>,
        <https://1145.am/db/2581257/Eli_Lilly_And_Company>,
        <https://1145.am/db/2581309/Boehringer_Ingelheim>,
        <https://1145.am/db/2581745/Eli_Lilly_And_Company>,
        <https://1145.am/db/2582681/Boehringer_Ingelheim>,
        <https://1145.am/db/2583703/Eli_Lilly>,
        <https://1145.am/db/2584135/Eli_Lilly>,
        <https://1145.am/db/2584766/Eli_Lilly_And_Company>,
        <https://1145.am/db/2585710/Eli_Lilly>,
        <https://1145.am/db/2586025/Lilly>,
        <https://1145.am/db/2586687/Eli_Lilly_And_Company>,
        <https://1145.am/db/2587099/Boehringer>,
        <https://1145.am/db/2587104/Boehringer_Ingelheim_Plant>,
        <https://1145.am/db/2587215/Eli_Lilly_And_Company>,
        <https://1145.am/db/2587605/Elanco>,
        <https://1145.am/db/2587605/Eli_Lilly>,
        <https://1145.am/db/2587690/Eli_Lilly_And_Company>,
        <https://1145.am/db/2587699/Eli_Lilly_And_Company>,
        <https://1145.am/db/2587853/Eli_Lilly_And_Company>,
        <https://1145.am/db/2589156/Eli_Lilly_And_Company>,
        <https://1145.am/db/2589535/Eli_Lilly>,
        <https://1145.am/db/2589700/Eli_Lilly>,
        <https://1145.am/db/2590071/Eli_Lilly_And_Company>,
        <https://1145.am/db/2590486/Eli_Lilly>,
        <https://1145.am/db/2590739/Boehringer_Ingelheim>,
        <https://1145.am/db/2590997/Eli_Lilly_And_Company>,
        <https://1145.am/db/2591001/Eli_Lilly>,
        <https://1145.am/db/2591708/Eli_Lilly_And_Company>,
        <https://1145.am/db/2592790/Boehringer_Ingelheim_Usa_Corporation>,
        <https://1145.am/db/2592924/Boehringer_Ingelheim>,
        <https://1145.am/db/2593232/Boehringer_Ingelheim>,
        <https://1145.am/db/2593463/Boehringer_Ingelheim>,
        <https://1145.am/db/2593780/Eli_Lilly>,
        <https://1145.am/db/2594262/Boehringer_Ingelheim>,
        <https://1145.am/db/2594485/Eli_Lilly_And_Company>,
        <https://1145.am/db/2594494/Eli_Lilly_And_Company>,
        <https://1145.am/db/2595226/Boehringer_Ingelheim>,
        <https://1145.am/db/2596644/Eli_Lilly_And_Company>,
        <https://1145.am/db/2597644/Eli_Lilly_And_Company>,
        <https://1145.am/db/2597855/Eli_Lilly_And_Company>,
        <https://1145.am/db/2598317/Eli_Lilly>,
        <https://1145.am/db/264619/Eli_Lilly_And_Co>,
        <https://1145.am/db/385093/Boehringer_Ingelheim>,
        <https://1145.am/db/461671/Eli_Lilly_And_Company>,
        <https://1145.am/db/768105/Eli_Lilly>,
        <https://1145.am/db/86786/Eli_Lilly_And_Co> ;
    ns1:sameAsMedium <https://1145.am/db/1121894/Eli_Lilly_And_Company>,
        <https://1145.am/db/2109798/Eli_Lilly_And_Company>,
        <https://1145.am/db/2279118/Eli_Lilly>,
        <https://1145.am/db/2280616/Eli_Lilly>,
        <https://1145.am/db/2286126/Eli_Lilly>,
        <https://1145.am/db/2286379/Eli_Lilly>,
        <https://1145.am/db/2304319/Eli_Lilly_And_Company>,
        <https://1145.am/db/2305501/Eli_Lilly_And_Company>,
        <https://1145.am/db/2310738/Eli_Lilly>,
        <https://1145.am/db/2315325/Eli_Lilly>,
        <https://1145.am/db/2317682/Eli_Lilly>,
        <https://1145.am/db/2325257/Eli_Lilly_And_Company>,
        <https://1145.am/db/2328522/Eli_Lilly>,
        <https://1145.am/db/2328633/Eli_Lilly>,
        <https://1145.am/db/2329915/Eli_Lilly_And_Company>,
        <https://1145.am/db/2349001/Eli_Lilly_And_Company>,
        <https://1145.am/db/2360338/Eli_Lilly>,
        <https://1145.am/db/2361510/Eli_Lilly>,
        <https://1145.am/db/2368321/Eli_Lilly_And_Company>,
        <https://1145.am/db/2560025/Eli_Lilly>,
        <https://1145.am/db/2562999/Eli_Lilly>,
        <https://1145.am/db/2569849/Eli_Lilly_And_Company>,
        <https://1145.am/db/2574950/Eli_Lilly>,
        <https://1145.am/db/2575947/Eli_Lilly>,
        <https://1145.am/db/2576858/Eli_Lilly___Co>,
        <https://1145.am/db/2576939/Eli_Lilly>,
        <https://1145.am/db/2581804/Eli_Lilly>,
        <https://1145.am/db/2585144/Eli_Lilly_And_Company>,
        <https://1145.am/db/2593456/Eli_Lilly_And_Company> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2366953/Lilly> a org:Organization ;
    ns1:basedInHighGeoName "Indianapolis" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/4259418/about.rdf> ;
    ns1:basedInHighRaw "INDIANAPOLIS" ;
    ns1:buyer <https://1145.am/db/2366953/Alnara_Pharmaceuticals_Acquisition> ;
    ns1:description "Pharmaceuticals" ;
    ns1:documentDate "2010-07-02T13:00:55+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Lilly to Acquire Alnara Pharmaceuticals" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/lilly-to-acquire-alnara-pharmaceuticals> ;
    ns1:foundName "Lilly" ;
    ns1:industry "Pharmaceuticals" ;
    ns1:name "Lilly" ;
    ns1:sameAsHigh <https://1145.am/db/1038901/Eli_Lilly_And_Company>,
        <https://1145.am/db/1087869/Eli_Lilly_And_Company>,
        <https://1145.am/db/1217359/Eli_Lilly_And_Company>,
        <https://1145.am/db/1272276/Eli_Lilly_And_Company>,
        <https://1145.am/db/1272276/Lilly>,
        <https://1145.am/db/1340338/Eli_Lilly_And_Company>,
        <https://1145.am/db/1425255/Eli_Lilly_And_Company>,
        <https://1145.am/db/1428583/Eli_Lilly_And_Company>,
        <https://1145.am/db/1428583/Lilly>,
        <https://1145.am/db/1432746/Eli_Lilly>,
        <https://1145.am/db/1534004/Eli_Lilly_And_Company>,
        <https://1145.am/db/1534438/Eli_Lilly_And_Company>,
        <https://1145.am/db/1553175/Eli_Lilly___Company>,
        <https://1145.am/db/1553459/Eli_Lilly___Company>,
        <https://1145.am/db/1663572/Eli_Lilly_And_Company>,
        <https://1145.am/db/174741/Eli_Lilly_And_Co>,
        <https://1145.am/db/1979697/Eli_Lilly>,
        <https://1145.am/db/1984558/Eli_Lilly_And_Company>,
        <https://1145.am/db/2045539/Eli_Lilly_And_Company>,
        <https://1145.am/db/2055009/Eli_Lilly_And_Company>,
        <https://1145.am/db/2058865/Eli_Lilly_And_Company>,
        <https://1145.am/db/2065629/Eli_Lilly_And_Company>,
        <https://1145.am/db/2134678/Eli_Lilly_And_Co>,
        <https://1145.am/db/2136466/Eli_Lilly_And_Co>,
        <https://1145.am/db/2139015/Eli_Lilly_And_Company>,
        <https://1145.am/db/2154391/Eli_Lilly>,
        <https://1145.am/db/2155453/Lilly_Usa>,
        <https://1145.am/db/2279118/Eli_Lilly>,
        <https://1145.am/db/2281211/Eli_Lilly>,
        <https://1145.am/db/2282739/Eli_Lilly>,
        <https://1145.am/db/2282930/Eli_Lilly>,
        <https://1145.am/db/2283595/Eli_Lilly>,
        <https://1145.am/db/2284615/Lilly>,
        <https://1145.am/db/2285156/Eli_Lilly>,
        <https://1145.am/db/2285525/Eli_Lilly>,
        <https://1145.am/db/2286126/Eli_Lilly>,
        <https://1145.am/db/2286379/Eli_Lilly>,
        <https://1145.am/db/2286402/Eli_Lilly>,
        <https://1145.am/db/2286404/Eli_Lilly>,
        <https://1145.am/db/2286911/Eli_Lilly>,
        <https://1145.am/db/2286998/Eli_Lilly>,
        <https://1145.am/db/2287005/Eli_Lilly>,
        <https://1145.am/db/2288158/Eli_Lilly>,
        <https://1145.am/db/229232/Eli_Lilly>,
        <https://1145.am/db/2294118/Eli_Lilly>,
        <https://1145.am/db/2298022/Eli_Lilly>,
        <https://1145.am/db/2299157/Eli_Lilly>,
        <https://1145.am/db/2300049/Lilly>,
        <https://1145.am/db/2301879/Eli_Lilly_And_Company>,
        <https://1145.am/db/2302104/Eli_Lilly_And_Company>,
        <https://1145.am/db/2302104/Lilly>,
        <https://1145.am/db/2305497/Eli_Lilly>,
        <https://1145.am/db/2305501/Eli_Lilly_And_Company>,
        <https://1145.am/db/2306807/Eli_Lilly_And_Company>,
        <https://1145.am/db/2306807/Lilly>,
        <https://1145.am/db/2307651/Eli_Lilly>,
        <https://1145.am/db/2309473/Eli_Lilly>,
        <https://1145.am/db/2316092/Eli_Lilly>,
        <https://1145.am/db/2316549/Eli_Lilly>,
        <https://1145.am/db/2317149/Lilly_Usa>,
        <https://1145.am/db/2320006/Eli_Lilly>,
        <https://1145.am/db/2320338/Eli_Lilly>,
        <https://1145.am/db/2323165/Eli_Lilly_And_Company>,
        <https://1145.am/db/2326272/Lilly_Usa>,
        <https://1145.am/db/2327587/Eli_Lilly_And_Company>,
        <https://1145.am/db/2328522/Eli_Lilly>,
        <https://1145.am/db/2328527/Eli_Lilly>,
        <https://1145.am/db/2328554/Eli_Lilly_And_Company>,
        <https://1145.am/db/2328718/Eli_Lilly>,
        <https://1145.am/db/2329107/Lilly>,
        <https://1145.am/db/2329114/Eli_Lilly>,
        <https://1145.am/db/2329115/Lilly>,
        <https://1145.am/db/2334645/Eli_Lilly>,
        <https://1145.am/db/2335594/Eli_Lilly_And_Company>,
        <https://1145.am/db/2336074/Eli_Lilly_And_Company>,
        <https://1145.am/db/2338059/Eli_Lilly>,
        <https://1145.am/db/2342503/Eli_Lilly_And_Company>,
        <https://1145.am/db/2343945/Eli_Lilly_And_Company>,
        <https://1145.am/db/2344800/Eli_Lilly_And_Company>,
        <https://1145.am/db/2344808/Eli_Lilly>,
        <https://1145.am/db/2344991/Eli_Lilly>,
        <https://1145.am/db/2345213/Eli_Lilly>,
        <https://1145.am/db/2345214/Eli_Lilly>,
        <https://1145.am/db/2346629/Novo_Nordisk_Eli_Lilly>,
        <https://1145.am/db/2349001/Eli_Lilly_And_Company>,
        <https://1145.am/db/2349020/Eli_Lilly_And_Company>,
        <https://1145.am/db/2349300/Eli_Lilly_And_Company>,
        <https://1145.am/db/2353350/Eli_Lilly>,
        <https://1145.am/db/2354761/Eli_Lilly_And_Company>,
        <https://1145.am/db/2354853/Eli_Lilly_And_Company>,
        <https://1145.am/db/2359240/Eli_Lilly>,
        <https://1145.am/db/2363310/Eli_Lilly_And_Company_(lly)>,
        <https://1145.am/db/2366948/Eli_Lilly_And_Company>,
        <https://1145.am/db/2366948/Lilly>,
        <https://1145.am/db/2366953/Eli_Lilly_And_Company>,
        <https://1145.am/db/2368562/Eli_Lilly_And_Company>,
        <https://1145.am/db/2369000/Eli_Lilly_And_Company>,
        <https://1145.am/db/2370162/Eli_Lilly>,
        <https://1145.am/db/2371016/Eli_Lilly>,
        <https://1145.am/db/2371058/Eli_Lilly_And_Company>,
        <https://1145.am/db/2371075/Eli_Lilly_And_Company>,
        <https://1145.am/db/2371075/Lilly>,
        <https://1145.am/db/2536960/Eli_Lilly>,
        <https://1145.am/db/2537335/Eli_Lilly_And_Company>,
        <https://1145.am/db/2537665/Eli_Lilly>,
        <https://1145.am/db/2537817/Eli_Lilly_And_Company>,
        <https://1145.am/db/2537826/Eli_Lilly_And_Company>,
        <https://1145.am/db/2539287/Eli_Lilly>,
        <https://1145.am/db/2539970/Eli_Lilly>,
        <https://1145.am/db/2543185/Eli_Lilly>,
        <https://1145.am/db/2543220/Lilly>,
        <https://1145.am/db/2545618/Eli_Lilly>,
        <https://1145.am/db/2546125/Lilly>,
        <https://1145.am/db/2549450/Eli_Lilly>,
        <https://1145.am/db/2550996/Eli_Lilly>,
        <https://1145.am/db/2551101/Eli_Lilly>,
        <https://1145.am/db/2551693/Lilly>,
        <https://1145.am/db/2553131/Eli_Lilly>,
        <https://1145.am/db/2553551/Eli_Lilly>,
        <https://1145.am/db/2556906/Eli_Lilly_And_Company>,
        <https://1145.am/db/2556969/Eli_Lilly>,
        <https://1145.am/db/2559125/Eli_Lilly_And_Company>,
        <https://1145.am/db/2560487/Eli_Lilly>,
        <https://1145.am/db/2562442/Eli_Lilly>,
        <https://1145.am/db/2564389/Eli_Lilly___Co>,
        <https://1145.am/db/2566845/Lilly>,
        <https://1145.am/db/2567343/Eli_Lilly>,
        <https://1145.am/db/2572312/Eli_Lilly_And_Company>,
        <https://1145.am/db/2572711/Eli_Lilly_And_Company>,
        <https://1145.am/db/2572711/Lilly>,
        <https://1145.am/db/2572957/Eli_Lilly_And_Company>,
        <https://1145.am/db/2573885/Eli_Lilly>,
        <https://1145.am/db/2574958/Lilly>,
        <https://1145.am/db/2575554/Eli_Lilly_And_Company>,
        <https://1145.am/db/2575909/Eli_Lilly>,
        <https://1145.am/db/2576171/Eli_Lilly_And_Company>,
        <https://1145.am/db/2576462/Eli_Lilly_And_Company>,
        <https://1145.am/db/2576892/Eli_Lilly>,
        <https://1145.am/db/2576933/Eli_Lilly>,
        <https://1145.am/db/2576944/Eli_Lilly>,
        <https://1145.am/db/2577171/Eli_Lilly_And_Company>,
        <https://1145.am/db/2578048/Eli_Lilly_And_Company>,
        <https://1145.am/db/2578874/Eli_Lilly>,
        <https://1145.am/db/2578876/Eli_Lilly_And_Company>,
        <https://1145.am/db/2580140/Boehringer_Ingelheim_And_Eli_Lilly>,
        <https://1145.am/db/2581257/Eli_Lilly_And_Company>,
        <https://1145.am/db/2581745/Eli_Lilly_And_Company>,
        <https://1145.am/db/2583703/Eli_Lilly>,
        <https://1145.am/db/2584766/Eli_Lilly_And_Company>,
        <https://1145.am/db/2585144/Eli_Lilly_And_Company>,
        <https://1145.am/db/2585710/Eli_Lilly>,
        <https://1145.am/db/2586025/Lilly>,
        <https://1145.am/db/2587215/Eli_Lilly_And_Company>,
        <https://1145.am/db/2587605/Elanco>,
        <https://1145.am/db/2587605/Eli_Lilly>,
        <https://1145.am/db/2587853/Eli_Lilly_And_Company>,
        <https://1145.am/db/2589223/Lilly>,
        <https://1145.am/db/2589535/Eli_Lilly>,
        <https://1145.am/db/2589700/Eli_Lilly>,
        <https://1145.am/db/2590071/Eli_Lilly_And_Company>,
        <https://1145.am/db/2590486/Eli_Lilly>,
        <https://1145.am/db/2590993/Lilly>,
        <https://1145.am/db/2590997/Eli_Lilly_And_Company>,
        <https://1145.am/db/2590999/Lilly>,
        <https://1145.am/db/2591001/Eli_Lilly>,
        <https://1145.am/db/2591708/Eli_Lilly_And_Company>,
        <https://1145.am/db/2593456/Eli_Lilly_And_Company>,
        <https://1145.am/db/2593780/Eli_Lilly>,
        <https://1145.am/db/2594485/Eli_Lilly_And_Company>,
        <https://1145.am/db/2594494/Eli_Lilly_And_Company>,
        <https://1145.am/db/2597644/Eli_Lilly_And_Company>,
        <https://1145.am/db/2597855/Eli_Lilly_And_Company>,
        <https://1145.am/db/264619/Eli_Lilly_And_Co>,
        <https://1145.am/db/2718315/Lilly>,
        <https://1145.am/db/768105/Eli_Lilly>,
        <https://1145.am/db/86786/Eli_Lilly_And_Co> ;
    ns1:sameAsMedium <https://1145.am/db/2283431/Lilly>,
        <https://1145.am/db/2305501/Lilly>,
        <https://1145.am/db/2329915/Lilly>,
        <https://1145.am/db/2360970/Lilly>,
        <https://1145.am/db/2543328/Lilly>,
        <https://1145.am/db/2592795/Lilly> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2367130/Investment_Lurie_Investments_Nanoink_Has_Not_Happened> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-10-11T14:42:14+00:00"^^xsd:dateTime ;
    ns1:documentExtract "NANOINK CLOSES $ 65 MILLION FINANCING LED BY LURIE INVESTMENTS.",
        "NanoInk, parent company of the NanoGuardian, NanoFabrication, NanoProfessor and NanoBioDiscovery Divisions announces a $ 65 million financing to further expand commercial activities.",
        "SKOKIE, Ill. - October 11, 2010 - NanoInk, Inc. ® announced today a $ 65 million financing led by Lurie Investments." ;
    ns1:documentTitle "NanoInk closes $65 million financing led by Lurie Investments" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/nanoink-closes-65-million-financing-led-by-lurie-investments> ;
    ns1:foundName "financing" ;
    ns1:name "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2367130/Nanoink> ;
    ns1:valueRaw "$ 65 MILLION",
        "$ 65 million" ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "United States" .

<https://1145.am/db/2367130/Nanoink> a org:Organization ;
    ns1:description "commercial activities" ;
    ns1:documentDate "2010-10-11T14:42:14+00:00"^^xsd:dateTime ;
    ns1:documentTitle "NanoInk closes $65 million financing led by Lurie Investments" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/nanoink-closes-65-million-financing-led-by-lurie-investments> ;
    ns1:foundName "NANOINK",
        "NanoInk",
        "NanoInk, Inc",
        "NanoInk, Inc. ®" ;
    ns1:industry "Nanotechnology" ;
    ns1:name "NanoInk",
        "Nanoink" ;
    ns1:sameAsHigh <https://1145.am/db/2003588/Nanosys> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2367176/Excelimmune> a org:Organization ;
    ns1:basedInHighGeoName "Woburn" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/4956032/about.rdf> ;
    ns1:basedInHighRaw "Woburn, MA" ;
    ns1:documentDate "2010-07-07T15:32:24+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Excelimmune garners $4.5M in new financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/excelimmune-garners-4-5m-new-financing> ;
    ns1:foundName "Excelimmune" ;
    ns1:name "Excelimmune" ;
    ns1:sameAsMedium <https://1145.am/db/2347290/Excelimmune>,
        <https://1145.am/db/2348277/Excelimmune>,
        <https://1145.am/db/2348278/Excelimmune>,
        <https://1145.am/db/2350508/Excelimmune> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2367203/Bionest_Partners_Finance> a org:Organization ;
    ns1:basedInLowRaw "France" ;
    ns1:description "Life Sciences" ;
    ns1:documentDate "2010-07-08T15:01:09+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Bionest Partners Finance Advises Poxel in a Serie A Financing of €16M" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/bionest-partners-finance-advises-poxel-a-serie-a-financing-of-%E2%82%AC16m> ;
    ns1:foundName "Bionest Partners Finance" ;
    ns1:industry "Life Sciences" ;
    ns1:name "Bionest Partners Finance" ;
    ns1:participant <https://1145.am/db/2367203/Investment_Poxel_Completed> ;
    ns1:sameAsHigh <https://1145.am/db/1054859/Sofinnova_Partners>,
        <https://1145.am/db/1070743/Novateur_Ventures>,
        <https://1145.am/db/1112260/Sofinnova_Partners>,
        <https://1145.am/db/1113007/Sofinnova_Partners>,
        <https://1145.am/db/1490183/Sofinnova_Partners>,
        <https://1145.am/db/1490997/Sofinnova_Partners>,
        <https://1145.am/db/1618717/Sofinnova_Partners>,
        <https://1145.am/db/1619418/Sofinnova_Partners>,
        <https://1145.am/db/1928060/Sofinnova_Partners>,
        <https://1145.am/db/1975388/Sofinnova_Partners>,
        <https://1145.am/db/2282410/Lumira_Ventures>,
        <https://1145.am/db/2324027/Sofinnova_Partners>,
        <https://1145.am/db/2341600/Clarus_Ventures>,
        <https://1145.am/db/2342624/Clarus_Ventures>,
        <https://1145.am/db/2342998/Sofinnova_Ventures>,
        <https://1145.am/db/2348857/Sofinnova_Ventures>,
        <https://1145.am/db/2349011/Sofinnova_Ventures_And_Novo_A_S>,
        <https://1145.am/db/2350855/Sofinnova_Ventures>,
        <https://1145.am/db/2355741/Sofinnova_Partners>,
        <https://1145.am/db/2356084/Clarus_Ventures>,
        <https://1145.am/db/2357105/Sofinnova_Ventures>,
        <https://1145.am/db/2367206/Bionest_Partners_Finance>,
        <https://1145.am/db/2371160/Sofinnova_Ventures>,
        <https://1145.am/db/2371163/Sofinnova_Ventures>,
        <https://1145.am/db/2550552/Lightstone_Ventures>,
        <https://1145.am/db/2765866/Sofinnova_Partners>,
        <https://1145.am/db/625791/Sofinnova_Partners>,
        <https://1145.am/db/695229/Sofinnova_Partners>,
        <https://1145.am/db/695704/Sofinnova_Partners>,
        <https://1145.am/db/992046/Sofinnova_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2367203/Investment_Poxel_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-07-08T15:01:09+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Bionest Partners Finance, a provider of advisory and management services to Life Sciences companies, announces today it had advised French company Poxel a spin-off of Merck Serono, in the achievement of a 16 million Euros",
        "PARIS & NEW YORK- (BUSINESS WIRE) - Advised by Bionest Partners Finance Poxel raises 16 million Euros through a prestigious syndicate led by Edmond de Rothschild Investment Partners." ;
    ns1:documentTitle "Bionest Partners Finance Advises Poxel in a Serie A Financing of €16M" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/bionest-partners-finance-advises-poxel-a-serie-a-financing-of-%E2%82%AC16m> ;
    ns1:foundName "raises",
        "spin-off" ;
    ns1:name "raises",
        "spin-off" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2367203/Merck_Serono>,
        <https://1145.am/db/2367203/Poxel> ;
    ns1:targetName "Poxel" ;
    ns1:valueRaw "16 million Euros",
        "19.7 million U.S." ;
    ns1:whereGeoName "Republic of France" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/3017382/about.rdf> ;
    ns1:whereRaw "Euros",
        "French" .

<https://1145.am/db/2367204/Calithera_Biosciences> a org:Organization ;
    ns1:description "developing novel cancer therapeutics" ;
    ns1:documentDate "2010-07-08T15:06:02+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Calithera Biosciences Closes $40 Million in Series A Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/calithera-biosciences-closes-40-million-series-a-financing> ;
    ns1:foundName "Calithera Biosciences" ;
    ns1:name "Calithera Biosciences" ;
    ns1:sameAsHigh <https://1145.am/db/2360451/Calithera_Biosciences>,
        <https://1145.am/db/2362553/Calithera_Biosciences> ;
    ns1:sameAsMedium <https://1145.am/db/2287873/Calithera_Biosciences>,
        <https://1145.am/db/2336826/Calithera_Biosciences_Inc>,
        <https://1145.am/db/2336828/Calithera_Biosciences>,
        <https://1145.am/db/2362552/Calithera_Biosciences>,
        <https://1145.am/db/595445/Calithera_Biosciences>,
        <https://1145.am/db/940723/Calithera_Biosciences> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2367204/Delphi_Ventures> a org:Organization ;
    ns1:basedInLowRaw "SOUTH SAN FRANCISCO" ;
    ns1:description "Venture Capital" ;
    ns1:documentDate "2010-07-08T15:06:02+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Calithera Biosciences Closes $40 Million in Series A Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/calithera-biosciences-closes-40-million-series-a-financing> ;
    ns1:foundName "Delphi Ventures" ;
    ns1:investor <https://1145.am/db/2367204/Series_A_Investment_Advanced_Technology_Ventures_Calithera_Biosciences_Delphi_Ventures_Mission_Bay_Capital_Morgenthaler_Ventures_Us_Venture_Partners_Completed> ;
    ns1:name "Delphi Ventures" ;
    ns1:sameAsHigh <https://1145.am/db/1086604/Tdf_Ventures>,
        <https://1145.am/db/1147828/Sixthirty_Ventures>,
        <https://1145.am/db/1199050/Rre_Ventures>,
        <https://1145.am/db/1356216/Trestle_Partners>,
        <https://1145.am/db/1358977/Tlv_Partners>,
        <https://1145.am/db/1427471/Twm_Venture_Co>,
        <https://1145.am/db/1546965/Ttv_Capital>,
        <https://1145.am/db/1569853/Titan_Capital>,
        <https://1145.am/db/168364/Trog_Hawley_Capital>,
        <https://1145.am/db/1693922/Remus_Capital>,
        <https://1145.am/db/1700572/Rre_Ventures>,
        <https://1145.am/db/1703609/Ttv_Capital>,
        <https://1145.am/db/1711383/Knollwood_Capital>,
        <https://1145.am/db/1713710/Remus_Capital>,
        <https://1145.am/db/1717313/Titan_Capital>,
        <https://1145.am/db/1741365/Translink_Capital>,
        <https://1145.am/db/1743285/Redline_Capital>,
        <https://1145.am/db/1746842/Tlcom_Capital>,
        <https://1145.am/db/1750867/Ttv_Capital>,
        <https://1145.am/db/1753054/Tahoma_Ventures>,
        <https://1145.am/db/1757065/Ttv_Capital>,
        <https://1145.am/db/1761607/Trousdale_Capital>,
        <https://1145.am/db/1762653/Tlv_Partners>,
        <https://1145.am/db/1763847/Tq_Ventures>,
        <https://1145.am/db/1788126/Translink_Capital>,
        <https://1145.am/db/1790574/Rre_Ventures>,
        <https://1145.am/db/1790953/T5_Capital>,
        <https://1145.am/db/1794935/Rre_Ventures>,
        <https://1145.am/db/1794935/Translink_Capital>,
        <https://1145.am/db/1805165/Translink_Capital>,
        <https://1145.am/db/1813349/Rre_Ventures>,
        <https://1145.am/db/1820363/Rre_Ventures>,
        <https://1145.am/db/1845022/Translink_Capital>,
        <https://1145.am/db/1849600/Sevenventures>,
        <https://1145.am/db/1851689/Translink_Capital>,
        <https://1145.am/db/1853156/T5_Capital>,
        <https://1145.am/db/1854396/Ttv_Capital>,
        <https://1145.am/db/1882330/Rre_Ventures>,
        <https://1145.am/db/1890000/Rre_Ventures>,
        <https://1145.am/db/1892428/T-Venture_Holding>,
        <https://1145.am/db/1984721/Redmile_Group>,
        <https://1145.am/db/2063249/Tlv_Partners>,
        <https://1145.am/db/2069147/Knollwood_Capital>,
        <https://1145.am/db/2142825/Ttv_Capital>,
        <https://1145.am/db/2291818/Delphi_Ventures>,
        <https://1145.am/db/2300306/Delphi_Ventures>,
        <https://1145.am/db/2302333/Delphi_Ventures>,
        <https://1145.am/db/2306568/Delphi_Ventures>,
        <https://1145.am/db/2315943/Truffle_Capital>,
        <https://1145.am/db/2315957/Truffle_Capital>,
        <https://1145.am/db/2317467/Delphi_Ventures>,
        <https://1145.am/db/2317919/Delphi_Ventures>,
        <https://1145.am/db/2332658/Truffle_Capital>,
        <https://1145.am/db/2332659/Truffle_Capital>,
        <https://1145.am/db/2333504/Delphi_Ventures>,
        <https://1145.am/db/2338059/Teralys_Capital>,
        <https://1145.am/db/2343206/Delphi_Ventures>,
        <https://1145.am/db/2352508/Delphi_Ventures>,
        <https://1145.am/db/2360174/Delphi_Ventures>,
        <https://1145.am/db/2362106/Redmile_Group>,
        <https://1145.am/db/2365679/Delphi_Ventures>,
        <https://1145.am/db/254241/Tkc_Capital>,
        <https://1145.am/db/506560/Tdf_Ventures>,
        <https://1145.am/db/539638/Tdf_Ventures>,
        <https://1145.am/db/601455/Tlv_Partners>,
        <https://1145.am/db/669408/Tdf_Ventures>,
        <https://1145.am/db/759595/Redblue_Capital>,
        <https://1145.am/db/885068/Tt_Capital_Partners>,
        <https://1145.am/db/892831/Ttv_Capital>,
        <https://1145.am/db/904252/Trinity_Capital>,
        <https://1145.am/db/952434/Tdf_Ventures>,
        <https://1145.am/db/991859/Ttv_Capital> ;
    ns1:sameAsMedium <https://1145.am/db/1124122/Delphi_Ventures>,
        <https://1145.am/db/1718690/Delphi_Ventures>,
        <https://1145.am/db/2290453/Delphi_Ventures>,
        <https://1145.am/db/2292554/Delphi_Ventures>,
        <https://1145.am/db/2294721/Delphi_Ventures>,
        <https://1145.am/db/2299776/Delphi_Ventures>,
        <https://1145.am/db/2300293/Delphi_Ventures>,
        <https://1145.am/db/2300455/Delphi_Ventures>,
        <https://1145.am/db/2304340/Delphi_Ventures>,
        <https://1145.am/db/2308063/Delphi_Ventures>,
        <https://1145.am/db/2310285/Delphi_Ventures>,
        <https://1145.am/db/2319874/Delphi_Ventures>,
        <https://1145.am/db/2326571/Delphi_Ventures>,
        <https://1145.am/db/2333495/Delphi_Ventures>,
        <https://1145.am/db/2335700/Delphi_Ventures>,
        <https://1145.am/db/2359510/Delphi_Ventures>,
        <https://1145.am/db/2362553/Delphi_Ventures>,
        <https://1145.am/db/2443170/Delphi_Ventures>,
        <https://1145.am/db/2575044/Delphi_Ventures>,
        <https://1145.am/db/2584056/Delphi_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2367206/Bionest_Partners_Finance> a org:Organization ;
    ns1:basedInLowRaw "French" ;
    ns1:description "Life Sciences" ;
    ns1:documentDate "2010-07-08T15:10:38+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Bionest Partners Finance Advises Poxel in a Series A Financing of EUR16M" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/bionest-partners-finance-advises-poxel-a-series-a-financing-of-eur16m> ;
    ns1:foundName "Bionest Partners Finance" ;
    ns1:industry "Life Sciences" ;
    ns1:name "Bionest Partners Finance" ;
    ns1:participant <https://1145.am/db/2367206/Investment_Poxel_Completed>,
        <https://1145.am/db/2367206/Merck_Serono_Investment> ;
    ns1:sameAsHigh <https://1145.am/db/1054859/Sofinnova_Partners>,
        <https://1145.am/db/1070743/Novateur_Ventures>,
        <https://1145.am/db/1112260/Sofinnova_Partners>,
        <https://1145.am/db/1113007/Sofinnova_Partners>,
        <https://1145.am/db/1490183/Sofinnova_Partners>,
        <https://1145.am/db/1490997/Sofinnova_Partners>,
        <https://1145.am/db/1618717/Sofinnova_Partners>,
        <https://1145.am/db/1619418/Sofinnova_Partners>,
        <https://1145.am/db/1928060/Sofinnova_Partners>,
        <https://1145.am/db/1975388/Sofinnova_Partners>,
        <https://1145.am/db/2282410/Lumira_Ventures>,
        <https://1145.am/db/2324027/Sofinnova_Partners>,
        <https://1145.am/db/2341600/Clarus_Ventures>,
        <https://1145.am/db/2342624/Clarus_Ventures>,
        <https://1145.am/db/2342998/Sofinnova_Ventures>,
        <https://1145.am/db/2348857/Sofinnova_Ventures>,
        <https://1145.am/db/2349011/Sofinnova_Ventures_And_Novo_A_S>,
        <https://1145.am/db/2350855/Sofinnova_Ventures>,
        <https://1145.am/db/2355741/Sofinnova_Partners>,
        <https://1145.am/db/2356084/Clarus_Ventures>,
        <https://1145.am/db/2357105/Sofinnova_Ventures>,
        <https://1145.am/db/2367203/Bionest_Partners_Finance>,
        <https://1145.am/db/2371160/Sofinnova_Ventures>,
        <https://1145.am/db/2371163/Sofinnova_Ventures>,
        <https://1145.am/db/2550552/Lightstone_Ventures>,
        <https://1145.am/db/2765866/Sofinnova_Partners>,
        <https://1145.am/db/625791/Sofinnova_Partners>,
        <https://1145.am/db/695229/Sofinnova_Partners>,
        <https://1145.am/db/695704/Sofinnova_Partners>,
        <https://1145.am/db/992046/Sofinnova_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2367206/Investment_Poxel_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-07-08T15:10:38+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Bionest Partners Finance, a provider of advisory and management services to Life Sciences companies, announces today it had advised French company Poxel a spin-off of Merck Serono, in the achievement of a 16 million Euros",
        "PARIS & NEW YORK, Jul 08, 2010 (BUSINESS WIRE) - Advised by Bionest Partners Finance Poxel raises 16 million Euros through a prestigious syndicate led by Edmond de Rothschild Investment Partners." ;
    ns1:documentTitle "Bionest Partners Finance Advises Poxel in a Series A Financing of EUR16M" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/bionest-partners-finance-advises-poxel-a-series-a-financing-of-eur16m> ;
    ns1:foundName "raises",
        "spin-off" ;
    ns1:name "raises",
        "spin-off" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2367206/Merck_Serono>,
        <https://1145.am/db/2367206/Poxel> ;
    ns1:targetName "Poxel" ;
    ns1:valueRaw "16 million Euros",
        "19.7 million U.S." ;
    ns1:whereGeoName "Republic of France" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/3017382/about.rdf> ;
    ns1:whereRaw "Euros",
        "French" .

<https://1145.am/db/2367206/Merck_Serono_Investment> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-07-08T15:10:38+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Bionest Partners Finance, a provider of advisory and management services to Life Sciences companies, announces today it had advised French company Poxel a spin-off of Merck Serono, in the achievement of a 16 million Euros" ;
    ns1:documentTitle "Bionest Partners Finance Advises Poxel in a Series A Financing of EUR16M" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/bionest-partners-finance-advises-poxel-a-series-a-financing-of-eur16m> ;
    ns1:foundName "spin-off" ;
    ns1:name "spin-off" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2367206/Merck_Serono> ;
    ns1:targetName "Merck Serono" ;
    ns1:valueRaw "16 million Euros",
        "19.7 million U.S. Dollars" ;
    ns1:whereGeoName "Republic of France" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/3017382/about.rdf> ;
    ns1:whereRaw "French" .

<https://1145.am/db/2367291/Investment_Cd_Ventures_Noxxon_Pharma_Ag_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-10-12T15:14:20+00:00"^^xsd:dateTime ;
    ns1:documentExtract "BERLIN - NOXXON Pharma AG (website) announced today that in addition to the financing of €33m which was recently announced on 27 May 2010 (see press release) , it has concluded a further capital raise of €2m which brings the total amount raised in this series D financing to €35m in aggregate.",
        "NOXXON Confirms Total Capital Raise of €35m." ;
    ns1:documentTitle "NOXXON Confirms Total Capital Raise of €35m" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/noxxon-confirms-total-capital-raise-of-%E2%82%AC35m> ;
    ns1:foundName "capital raise",
        "financing" ;
    ns1:name "capital raise",
        "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2367291/Noxxon_Pharma_Ag> ;
    ns1:valueRaw "€2m",
        "€33m",
        "€35m" ;
    ns1:when "2010-05-27T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "27 May 2010" ;
    ns1:whereRaw "NOXXON Confirms Total Capital Raise of €35m" .

<https://1145.am/db/2367291/Noxxon_Pharma_Ag> a org:Organization ;
    ns1:basedInHighGeoName "Berlin" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2950159/about.rdf> ;
    ns1:basedInHighRaw "BERLIN" ;
    ns1:documentDate "2010-10-12T15:14:20+00:00"^^xsd:dateTime ;
    ns1:documentTitle "NOXXON Confirms Total Capital Raise of €35m" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/noxxon-confirms-total-capital-raise-of-%E2%82%AC35m> ;
    ns1:foundName "BERLIN - NOXXON Pharma AG (website)",
        "NOXXON" ;
    ns1:industry "Pharma" ;
    ns1:name "NOXXON",
        "NOXXON Pharma AG" ;
    ns1:sameAsHigh <https://1145.am/db/2286719/Noema_Pharma>,
        <https://1145.am/db/2335769/Nogra_Pharma>,
        <https://1145.am/db/2335793/Noxxon_Pharma>,
        <https://1145.am/db/2351940/Noxxon_Pharma>,
        <https://1145.am/db/2355104/Noxxon_Pharma_Ag>,
        <https://1145.am/db/2355109/Noxxon_Pharma>,
        <https://1145.am/db/2358268/Noxxon_Pharma_Ag>,
        <https://1145.am/db/2366698/Noxxon_Pharma_Ag>,
        <https://1145.am/db/2371385/Noxxon>,
        <https://1145.am/db/2564713/Nobilus>,
        <https://1145.am/db/862915/Noema_Pharma> ;
    ns1:sameAsMedium <https://1145.am/db/1048117/Noxxon_Pharma_Nv>,
        <https://1145.am/db/1200218/Noxxon_Pharma_Nv>,
        <https://1145.am/db/217559/Noxxon_Pharma_Nv>,
        <https://1145.am/db/2358269/Noxxon_Pharma>,
        <https://1145.am/db/576203/Noxxon_Pharma_Nv>,
        <https://1145.am/db/618981/Noxxon_Pharma_Nv>,
        <https://1145.am/db/700611/Noxxon_Pharma_Nv>,
        <https://1145.am/db/790713/Noxxon_Pharma_Nv>,
        <https://1145.am/db/995823/Noxxon_Pharma_Nv> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2367364/Novo_A_S> a org:Organization ;
    ns1:basedInLowRaw "Denmark" ;
    ns1:documentDate "2010-07-12T12:27:59+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Reata Pharmaceuticals Completes $78 Million Equity Financing for Second Pivotal Trial of Bardoxolone Methyl" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/reata-pharmaceuticals-completes-78-million-equity-financing-for-second-pivotal-trial-of> ;
    ns1:foundName "Novo A/S" ;
    ns1:investor <https://1145.am/db/2367364/Investment_Cpmg_Inc_Novo_A_S_Reata_Pharmaceuticals_Completed> ;
    ns1:name "Novo A/S" ;
    ns1:sameAsMedium <https://1145.am/db/1753148/Novo>,
        <https://1145.am/db/1754034/Novo>,
        <https://1145.am/db/2288016/Novo_A_S>,
        <https://1145.am/db/2296606/Novo_A_S>,
        <https://1145.am/db/2298077/Novo_A_S>,
        <https://1145.am/db/2298277/Novo_A_S>,
        <https://1145.am/db/2299423/Novo_As>,
        <https://1145.am/db/2299645/Novo>,
        <https://1145.am/db/2300653/Novo_A_S>,
        <https://1145.am/db/2301290/Novo>,
        <https://1145.am/db/2301494/Novo_A_S>,
        <https://1145.am/db/2302994/Novo_A_S>,
        <https://1145.am/db/2302995/Novo_A_S>,
        <https://1145.am/db/2303767/Novo_A_S>,
        <https://1145.am/db/2304335/Novo_A_S>,
        <https://1145.am/db/2304340/Novo_A_S>,
        <https://1145.am/db/2308758/Novo_A_S>,
        <https://1145.am/db/2309506/Novo_A_S>,
        <https://1145.am/db/2309507/Novo_A_S>,
        <https://1145.am/db/2311133/Novo_A_S>,
        <https://1145.am/db/2311274/Novo>,
        <https://1145.am/db/2312120/Novo_A_S>,
        <https://1145.am/db/2314546/Novo_A_S>,
        <https://1145.am/db/2318733/Novo_A_S>,
        <https://1145.am/db/2319236/Novo_A_S>,
        <https://1145.am/db/2319416/Novo_A_S>,
        <https://1145.am/db/2319433/Novo_A_S>,
        <https://1145.am/db/2319784/Novo_A_S>,
        <https://1145.am/db/2321216/Novo_A_S>,
        <https://1145.am/db/2321861/Novo_A_S>,
        <https://1145.am/db/2321870/Novo_A_S>,
        <https://1145.am/db/2325116/Novo_A_S>,
        <https://1145.am/db/2329010/Novo_A_S>,
        <https://1145.am/db/2329011/Novo_A_S>,
        <https://1145.am/db/2329224/Novo_A_S>,
        <https://1145.am/db/2335700/Novo_A_S>,
        <https://1145.am/db/2338817/Novo_A_S>,
        <https://1145.am/db/2339692/Novo_A_S>,
        <https://1145.am/db/2340612/Novo_A_S>,
        <https://1145.am/db/2341934/Novo>,
        <https://1145.am/db/2342284/Novo_A_S>,
        <https://1145.am/db/2345268/Novo_A_S>,
        <https://1145.am/db/2345273/Novo_A_S>,
        <https://1145.am/db/2346452/Novo_A_S>,
        <https://1145.am/db/2349013/Novo_A_S>,
        <https://1145.am/db/2349048/Novo_A_S>,
        <https://1145.am/db/2349050/Novo_A_S>,
        <https://1145.am/db/2349406/Novo_A_S>,
        <https://1145.am/db/2353241/Novo_A_S>,
        <https://1145.am/db/2355183/Novo_A_S>,
        <https://1145.am/db/2356861/Novo_A_S>,
        <https://1145.am/db/2356876/Novo_A_S>,
        <https://1145.am/db/2357109/Novo_A_S>,
        <https://1145.am/db/2358233/Novo_A_S>,
        <https://1145.am/db/2358246/Novo_As>,
        <https://1145.am/db/2358271/Novo_A_S>,
        <https://1145.am/db/2358272/Novo_A_S>,
        <https://1145.am/db/2358459/Novo>,
        <https://1145.am/db/2358464/Novo_A_S>,
        <https://1145.am/db/2358542/Novo_A_S>,
        <https://1145.am/db/2359510/Novo_A_S>,
        <https://1145.am/db/2359683/Novo_A_S>,
        <https://1145.am/db/2360562/Novo>,
        <https://1145.am/db/2361588/Novo_A_S>,
        <https://1145.am/db/2363535/Novo_A_S>,
        <https://1145.am/db/2364505/Novo_A_S>,
        <https://1145.am/db/2364508/Novo_A_S>,
        <https://1145.am/db/2365700/Novo_A_S>,
        <https://1145.am/db/2365701/Novo_A_S>,
        <https://1145.am/db/2366187/Novo_A_S>,
        <https://1145.am/db/2366333/Novo_A_S>,
        <https://1145.am/db/2367275/Novo_A_S>,
        <https://1145.am/db/2367368/Novo_A_S>,
        <https://1145.am/db/2368297/Novo_A_S>,
        <https://1145.am/db/2368333/Novo_A_S>,
        <https://1145.am/db/2368572/Novo_A_S>,
        <https://1145.am/db/2543793/Novo>,
        <https://1145.am/db/2544115/Novo>,
        <https://1145.am/db/2552947/Novo>,
        <https://1145.am/db/2557027/Novo>,
        <https://1145.am/db/2581901/Novo_A_S>,
        <https://1145.am/db/2581902/Novo_A_S>,
        <https://1145.am/db/2584056/Novo_A_S>,
        <https://1145.am/db/360351/Novo>,
        <https://1145.am/db/751135/Novo> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2367364/Reata_Pharmaceuticals> a org:Organization ;
    ns1:description "Pharmaceuticals" ;
    ns1:documentDate "2010-07-12T12:27:59+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Reata Pharmaceuticals Completes $78 Million Equity Financing for Second Pivotal Trial of Bardoxolone Methyl" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/reata-pharmaceuticals-completes-78-million-equity-financing-for-second-pivotal-trial-of> ;
    ns1:foundName "Reata Pharmaceuticals",
        "Reata Pharmaceuticals, Inc." ;
    ns1:industry "Pharmaceuticals" ;
    ns1:name "Reata Pharmaceuticals" ;
    ns1:sameAsHigh <https://1145.am/db/172278/Recipharm>,
        <https://1145.am/db/2074741/Reata_Pharmaceuticals_Inc>,
        <https://1145.am/db/2100253/Reata_Pharmaceuticals_Inc>,
        <https://1145.am/db/213083/Recipharm>,
        <https://1145.am/db/2313448/Reata_Pharmaceuticals>,
        <https://1145.am/db/2334118/Recipharm>,
        <https://1145.am/db/2334606/Recipharm>,
        <https://1145.am/db/2337022/Recipharm_Pharmaceutical_Development_Ab>,
        <https://1145.am/db/2337166/Rempex_Pharmaceuticals>,
        <https://1145.am/db/2337242/Recipharm>,
        <https://1145.am/db/2338120/Rempex_Pharmaceuticals>,
        <https://1145.am/db/2338421/Recro_Pharma>,
        <https://1145.am/db/2339242/Recipharm>,
        <https://1145.am/db/2346119/Recipharm>,
        <https://1145.am/db/2356181/Recro_Pharma>,
        <https://1145.am/db/2367368/Reata_Pharmaceuticals>,
        <https://1145.am/db/2368365/Recro_Pharma>,
        <https://1145.am/db/2369512/Recipharm>,
        <https://1145.am/db/2371408/Recipharm>,
        <https://1145.am/db/2536596/Recro_Pharma>,
        <https://1145.am/db/2537635/Recipharm>,
        <https://1145.am/db/2539816/Recipharm>,
        <https://1145.am/db/2540958/Recipharm>,
        <https://1145.am/db/2543483/Recipharm>,
        <https://1145.am/db/2544071/Recipharm_Ab>,
        <https://1145.am/db/2544452/Recipharm>,
        <https://1145.am/db/2545962/Recipharm>,
        <https://1145.am/db/2546145/Recipharm>,
        <https://1145.am/db/2546157/Recipharm>,
        <https://1145.am/db/2547189/Recipharm>,
        <https://1145.am/db/2548220/Recipharm_Ab>,
        <https://1145.am/db/2548222/Recipharm>,
        <https://1145.am/db/2550420/Recipharm>,
        <https://1145.am/db/2552528/Recipharm>,
        <https://1145.am/db/2557799/Recipharm>,
        <https://1145.am/db/2560291/Recipharm>,
        <https://1145.am/db/2561326/Recipharm>,
        <https://1145.am/db/2561334/Recipharm>,
        <https://1145.am/db/2562556/Recipharm>,
        <https://1145.am/db/2568205/Reata_Pharmaceuticals>,
        <https://1145.am/db/2568375/Reata_Pharmaceuticals>,
        <https://1145.am/db/2569549/Recipharm>,
        <https://1145.am/db/2594032/Recipharm>,
        <https://1145.am/db/2765310/Reata_Pharmaceuticals>,
        <https://1145.am/db/406977/Recro_Pharma> ;
    ns1:sameAsMedium <https://1145.am/db/1195713/Reata_Pharmaceuticals_Inc>,
        <https://1145.am/db/1197114/Reata_Pharmaceuticals_Inc>,
        <https://1145.am/db/2035420/Reata_Pharmaceuticals_Inc>,
        <https://1145.am/db/2071248/Reata_Pharmaceuticals>,
        <https://1145.am/db/2325116/Reata_Pharmaceuticals> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2367448/Ninepoint_Medical> a org:Organization ;
    ns1:basedInHighGeoName "Cambridge" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/4931972/about.rdf> ;
    ns1:basedInHighRaw "Cambridge, Mass." ;
    ns1:description "medical" ;
    ns1:documentDate "2010-10-14T14:30:50+00:00"^^xsd:dateTime ;
    ns1:documentTitle "NinePoint Medical Completes $33 Million Series A Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/ninepoint-medical-completes-33-million-series-a-financing> ;
    ns1:foundName "NinePoint Medical",
        "NinePoint Medical, Inc." ;
    ns1:industry "medical" ;
    ns1:name "NinePoint Medical" ;
    ns1:sameAsHigh <https://1145.am/db/2298296/Ninepoint_Medical>,
        <https://1145.am/db/2367442/Ninepoint_Medical> ;
    ns1:sameAsMedium <https://1145.am/db/2298844/Ninepoint_Medical> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2367448/Prospect_Venture_Partners> a org:Organization ;
    ns1:basedInLowRaw "Mass" ;
    ns1:documentDate "2010-10-14T14:30:50+00:00"^^xsd:dateTime ;
    ns1:documentTitle "NinePoint Medical Completes $33 Million Series A Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/ninepoint-medical-completes-33-million-series-a-financing> ;
    ns1:foundName "Prospect Venture Partners" ;
    ns1:investor <https://1145.am/db/2367448/Series_A_Investment_Ninepoint_Medical_Prospect_Venture_Partners_Third_Rock_Ventures_Completed> ;
    ns1:name "Prospect Venture Partners" ;
    ns1:sameAsMedium <https://1145.am/db/2300697/Prospect_Venture_Partners>,
        <https://1145.am/db/2303219/Prospect_Venture_Partners>,
        <https://1145.am/db/2308758/Prospect_Venture_Partners>,
        <https://1145.am/db/2309506/Prospect_Venture_Partners>,
        <https://1145.am/db/2309507/Prospect_Venture_Partners>,
        <https://1145.am/db/2314964/Prospect_Venture_Partners>,
        <https://1145.am/db/2319809/Prospect_Venture_Partners>,
        <https://1145.am/db/2323578/Prospect_Venture_Partners>,
        <https://1145.am/db/2330712/Prospect_Venture_Partners>,
        <https://1145.am/db/2330852/Prospect_Venture_Partners>,
        <https://1145.am/db/2331754/Prospect_Venture_Partners>,
        <https://1145.am/db/2331868/Prospect_Venture_Partners>,
        <https://1145.am/db/2339883/Prospect_Venture_Partners>,
        <https://1145.am/db/2340224/Prospect_Venture_Partners>,
        <https://1145.am/db/2352804/Prospect_Venture_Partners>,
        <https://1145.am/db/2352807/Prospect_Venture_Partners>,
        <https://1145.am/db/2358234/Prospect_Venture_Partners>,
        <https://1145.am/db/2360004/Prospect_Venture_Partners>,
        <https://1145.am/db/2360006/Prospect_Venture_Partners>,
        <https://1145.am/db/2364505/Prospect_Venture_Partners>,
        <https://1145.am/db/2367442/Prospect_Venture_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2367475/Merlion_Pharmaceuticals_Pte_Ltd> a org:Organization ;
    ns1:basedInHighGeoName "Republic of Singapore" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/1880251/about.rdf> ;
    ns1:basedInHighRaw "Singapore" ;
    ns1:basedInLowRaw "US" ;
    ns1:description "Discovery and development of novel antiinfectives",
        "pharmaceuticals" ;
    ns1:documentDate "2010-07-13T16:13:01+00:00"^^xsd:dateTime ;
    ns1:documentTitle "MerLion Pharmaceuticals Completes US$7 Million Series C" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/merlion-pharmaceuticals-completes-us-7-million-series-c> ;
    ns1:foundName "MerLion Pharmaceuticals",
        "MerLion Pharmaceuticals Pte Ltd" ;
    ns1:industry "Pharmaceuticals",
        "pharmaceuticals" ;
    ns1:name "MerLion Pharmaceuticals",
        "MerLion Pharmaceuticals Pte Ltd" ;
    ns1:sameAsHigh <https://1145.am/db/2309990/Merlion_Pharmaceuticals>,
        <https://1145.am/db/2314546/Merlion_Pharmaceuticals>,
        <https://1145.am/db/2364373/N30_Pharmaceuticals> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2367497/Polaris_Venture_Partners> a org:Organization ;
    ns1:description "financing" ;
    ns1:documentDate "2010-07-14T12:04:54+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Trevena Secures $35 Million in Series B Funding" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/trevena-secures-35-million-series-b-funding> ;
    ns1:foundName "Polaris Venture Partners" ;
    ns1:investor <https://1145.am/db/2367497/Series_B_Investment_Alta_Partners_Healthcare_Ventures_New_Enterprise_Associates_Polaris_Venture_Partners_Trevena_Yasuda_Enterprise_Development_Company_Completed> ;
    ns1:name "Polaris Venture Partners" ;
    ns1:sameAsHigh <https://1145.am/db/1163164/Polaris_Partners>,
        <https://1145.am/db/1166225/Polaris_Partners>,
        <https://1145.am/db/127343/Polaris_Partners>,
        <https://1145.am/db/1340338/Polaris_Partners>,
        <https://1145.am/db/1406211/Polaris_Partners>,
        <https://1145.am/db/1412727/Polaris_Partners>,
        <https://1145.am/db/1545490/Polaris_Partners>,
        <https://1145.am/db/1701903/Polaris_Venture_Partners>,
        <https://1145.am/db/1796259/Polaris_Capital>,
        <https://1145.am/db/1803886/Polaris_Partners>,
        <https://1145.am/db/1845960/Polaris_Partners>,
        <https://1145.am/db/1854788/Polaris_Partners>,
        <https://1145.am/db/1870436/Polaris_Venture_Partners>,
        <https://1145.am/db/1877606/Polaris_Venture_Partners>,
        <https://1145.am/db/1885717/Polaris_Ventures>,
        <https://1145.am/db/1897450/Polaris_Venture_Partners>,
        <https://1145.am/db/1909651/Polaris_Venture_Partners>,
        <https://1145.am/db/1947183/Polaris_Partners>,
        <https://1145.am/db/2140474/Polaris_Capital_Management>,
        <https://1145.am/db/2174824/Polaris_Venture_Partners>,
        <https://1145.am/db/2181016/Polaris_Partners>,
        <https://1145.am/db/2187023/Polaris_Partners>,
        <https://1145.am/db/2194844/Polaris_Partners>,
        <https://1145.am/db/2196895/Polaris_Partners>,
        <https://1145.am/db/2223723/Polaris_Partners>,
        <https://1145.am/db/2292800/Polaris_Venture_Partners>,
        <https://1145.am/db/2303656/Polaris_Venture_Partners>,
        <https://1145.am/db/2303675/Polaris_Venture_Partners>,
        <https://1145.am/db/2315289/Polaris_Venture_Partners>,
        <https://1145.am/db/2317918/Polaris_Ventures>,
        <https://1145.am/db/2318310/Polaris_Partners>,
        <https://1145.am/db/2323586/Polaris_Venture_Partners>,
        <https://1145.am/db/2324431/Polaris_Venture_Partners>,
        <https://1145.am/db/2335531/Flagship_Ventures_Polaris_Partners>,
        <https://1145.am/db/2335750/Polaris_Partners>,
        <https://1145.am/db/2338373/Polaris_Venture_Partners>,
        <https://1145.am/db/2341599/Polaris_Partners>,
        <https://1145.am/db/2343467/Polaris_Ventures>,
        <https://1145.am/db/2352414/Polaris_Venture_Partners>,
        <https://1145.am/db/2354806/Polaris_Venture_Partners>,
        <https://1145.am/db/2354955/Polaris_Partners>,
        <https://1145.am/db/2365296/Polaris_Venture_Partners>,
        <https://1145.am/db/2365300/Polaris_Venture_Partners>,
        <https://1145.am/db/2368913/Polaris_Partners>,
        <https://1145.am/db/2369304/Polaris_Partners>,
        <https://1145.am/db/2369305/Polaris_Partners>,
        <https://1145.am/db/250010/Polaris_Partners>,
        <https://1145.am/db/364226/Polaris_Partners>,
        <https://1145.am/db/572097/Polaris_Partners>,
        <https://1145.am/db/612707/Polaris_Partners> ;
    ns1:sameAsMedium <https://1145.am/db/1708291/Polaris_Venture_Partners>,
        <https://1145.am/db/1830502/Polaris_Venture_Partners>,
        <https://1145.am/db/2302116/Polaris_Venture_Partners>,
        <https://1145.am/db/2313401/Polaris_Venture_Partners>,
        <https://1145.am/db/2313405/Polaris_Venture_Partners>,
        <https://1145.am/db/2314380/Polaris_Venture_Partners>,
        <https://1145.am/db/2331763/Polaris_Venture_Partners>,
        <https://1145.am/db/2337571/Polaris_Venture_Partners>,
        <https://1145.am/db/2337577/Polaris_Venture_Partners>,
        <https://1145.am/db/2339127/Polaris_Venture_Partners>,
        <https://1145.am/db/2339128/Polaris_Venture_Partners>,
        <https://1145.am/db/2342445/Polaris_Venture_Partners>,
        <https://1145.am/db/2342862/Polaris_Venture_Partners>,
        <https://1145.am/db/2343210/Polaris_Venture_Partners>,
        <https://1145.am/db/2344256/Polaris_Venture_Partners>,
        <https://1145.am/db/2345224/Polaris_Venture_Partners>,
        <https://1145.am/db/2347102/Polaris_Venture_Partners>,
        <https://1145.am/db/2348448/Polaris_Venture_Partners>,
        <https://1145.am/db/2350034/Polaris_Venture_Partners>,
        <https://1145.am/db/2366654/Polaris_Venture_Partners>,
        <https://1145.am/db/2440024/Polaris_Venture_Partners>,
        <https://1145.am/db/2450515/Polaris_Venture_Partners>,
        <https://1145.am/db/2546216/Polaris_Venture_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2367497/Trevena> a org:Organization ;
    ns1:description "Pharmaceuticals" ;
    ns1:documentDate "2010-07-14T12:04:54+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Trevena Secures $35 Million in Series B Funding" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/trevena-secures-35-million-series-b-funding> ;
    ns1:foundName "Trevena",
        "Trevena, Inc." ;
    ns1:industry "drug discovery" ;
    ns1:name "Trevena" ;
    ns1:sameAsHigh <https://1145.am/db/1242236/Trevena>,
        <https://1145.am/db/1365037/Trevi_Therapeutics_Inc>,
        <https://1145.am/db/1365617/Trevi_Therapeutics>,
        <https://1145.am/db/1501458/Trevi_Therapeutics>,
        <https://1145.am/db/2313401/Trevena>,
        <https://1145.am/db/2313405/Trevena_Inc>,
        <https://1145.am/db/2335617/Trevena>,
        <https://1145.am/db/2337850/Trevena>,
        <https://1145.am/db/2343747/Trevena>,
        <https://1145.am/db/2347943/Trevena>,
        <https://1145.am/db/2348765/Trevena>,
        <https://1145.am/db/2351276/Trevena_Inc>,
        <https://1145.am/db/2352307/Trevena>,
        <https://1145.am/db/2353149/Trevena_Inc_(trevena)>,
        <https://1145.am/db/2354166/Trevena_Inc_(trevena)>,
        <https://1145.am/db/2361459/Trevena>,
        <https://1145.am/db/2368464/Trevena>,
        <https://1145.am/db/2368687/Trevena>,
        <https://1145.am/db/401324/Trevi_Therapeutics>,
        <https://1145.am/db/515342/Trevi_Therapeutics>,
        <https://1145.am/db/941597/Trevena>,
        <https://1145.am/db/984622/Trevena> ;
    ns1:sameAsMedium <https://1145.am/db/2314821/Trevena_Inc>,
        <https://1145.am/db/2336284/Trevena>,
        <https://1145.am/db/2358391/Trevena>,
        <https://1145.am/db/2363626/Trevena> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2581397/Acquisition_Bausch___Lomb_Has_Not_Happened> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition" ;
    ns1:documentDate "2010-08-17T14:53:50+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Novartis Must Sell Assets to Bausch & Lomb After Acquiring Alcon." ;
    ns1:documentTitle "FTC Order Protects Consumers in U.S. Market for Eye Care Drug Used in Cataract Surgery" ;
    ns1:documentURL <https://www.fiercepharma.com/pharma/ftc-order-protects-consumers-u-s-market-for-eye-care-drug-used-cataract-surgery> ;
    ns1:foundName "Sell" ;
    ns1:name "Sell" ;
    ns1:sourceName "Fierce Pharma" ;
    ns1:status "has not happened" ;
    ns1:whereGeoName "Switzerland" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/2658434/about.rdf> ;
    ns1:whereRaw "Switzerland" .

<https://1145.am/db/2581397/Acquisition_Bausch___Lomb_Novartis_Stopped> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition" ;
    ns1:documentDate "2010-08-17T14:53:50+00:00"^^xsd:dateTime ;
    ns1:documentExtract "The settlement requires Novartis to sell its drug Miochol-E to Bausch & Lomb, Inc." ;
    ns1:documentTitle "FTC Order Protects Consumers in U.S. Market for Eye Care Drug Used in Cataract Surgery" ;
    ns1:documentURL <https://www.fiercepharma.com/pharma/ftc-order-protects-consumers-u-s-market-for-eye-care-drug-used-cataract-surgery> ;
    ns1:foundName "sell" ;
    ns1:name "sell" ;
    ns1:sourceName "Fierce Pharma" ;
    ns1:status "stopped" ;
    ns1:vendor <https://1145.am/db/2581397/Novartis> ;
    ns1:whereGeoName "Switzerland" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/2658434/about.rdf> ;
    ns1:whereRaw "Switzerland" .

<https://1145.am/db/2589142/Bristol-Myers_Squibb> a org:Organization ;
    ns1:basedInHighGeoName "New York City" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5128581/about.rdf> ;
    ns1:basedInHighRaw "NEW YORK" ;
    ns1:buyer <https://1145.am/db/2589142/Zymogenetics_Acquisition> ;
    ns1:description "Business" ;
    ns1:documentDate "2010-09-28T12:04:31+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Bristol-Myers Squibb Announces Expiration of Hart-Scott-Rodino Waiting Period for Acquisition of ZymoGenetics, Inc." ;
    ns1:documentURL <https://www.fiercepharma.com/pharma/bristol-myers-squibb-announces-expiration-of-hart-scott-rodino-waiting-period-for-2> ;
    ns1:foundName "Bristol-Myers Squibb",
        "Bristol-Myers Squibb Company" ;
    ns1:name "Bristol-Myers Squibb" ;
    ns1:sameAsHigh <https://1145.am/db/1094472/Bristol_Myers_Squibb>,
        <https://1145.am/db/1105768/Bristol_Myers_Squibb>,
        <https://1145.am/db/1106082/Bristol_Myers_Squibb>,
        <https://1145.am/db/1108228/Bristol_Myers_Squibb>,
        <https://1145.am/db/1110114/Bristol_Myers_Squibb_Co>,
        <https://1145.am/db/1111460/Bristol_Myers_Squibb>,
        <https://1145.am/db/1111853/Bristol_Myers_Squibb>,
        <https://1145.am/db/1113358/Bristol-Myers_Squibb>,
        <https://1145.am/db/1113452/Bristol_Myers_Squibb>,
        <https://1145.am/db/1114073/Bristol_Myers_Squibb>,
        <https://1145.am/db/1137730/Bristol_Myers_Squibb>,
        <https://1145.am/db/1142305/Bristol_Myers_Squibb>,
        <https://1145.am/db/1183637/Bristol_Myers_Squibb>,
        <https://1145.am/db/1184320/Bristol_Myers_Squibb>,
        <https://1145.am/db/1281441/Bristol_Myers_Squibb>,
        <https://1145.am/db/1285047/Bristol_Myers_Squibb>,
        <https://1145.am/db/1288028/Bristol_Myers_Squibb>,
        <https://1145.am/db/1340338/Bristol_Myers_Squibb>,
        <https://1145.am/db/1536915/Bristol_Myers_Squibb>,
        <https://1145.am/db/1613666/Bristol_Myers_Squibb>,
        <https://1145.am/db/1983649/Bristol_Myers_Squibb>,
        <https://1145.am/db/1984876/Bristol_Myers_Squibb_Co>,
        <https://1145.am/db/2139540/Bristol-Myers_Squibb>,
        <https://1145.am/db/2140511/Bristol-Myers_Squibb_Company>,
        <https://1145.am/db/2155237/Bristol-Myers_Squibb>,
        <https://1145.am/db/2228329/Bristol-Myers_Squibb>,
        <https://1145.am/db/2279340/Bristol_Myers_Squibb>,
        <https://1145.am/db/2280782/Bristol_Myers_Squibb>,
        <https://1145.am/db/2283422/Bristol_Myers_Squibb>,
        <https://1145.am/db/2283468/Bristol_Myer_Squibb>,
        <https://1145.am/db/2284339/Bristol_Myers>,
        <https://1145.am/db/2284393/Bristol_Myers_Squibb>,
        <https://1145.am/db/2287082/Bristol_Myers_Squibb>,
        <https://1145.am/db/2289865/Bristol-Myers_Squibb>,
        <https://1145.am/db/2292710/Bristol-Myers_Squibb>,
        <https://1145.am/db/2299388/Bristol-Myers>,
        <https://1145.am/db/2299902/Bristol-Myers_Squibb>,
        <https://1145.am/db/2300768/Bristol-Myers>,
        <https://1145.am/db/2301227/Bristol-Myers_Squibb>,
        <https://1145.am/db/2301536/Bristol-Myers_Squibb>,
        <https://1145.am/db/2301687/Bristol-Myers_Squibb>,
        <https://1145.am/db/2302975/Bristol-Myers_Squibb>,
        <https://1145.am/db/2303034/Bristol-Myers_Squibb>,
        <https://1145.am/db/2303037/Bristol-Myers_Squibb>,
        <https://1145.am/db/2303791/Bristol-Myers_Squibb>,
        <https://1145.am/db/2307060/Bristol-Myers>,
        <https://1145.am/db/2307066/Bristol-Myers_Squibb>,
        <https://1145.am/db/2309929/Bristol-Myers_Squibb_Company>,
        <https://1145.am/db/2310002/Bristol-Myers_Squibb>,
        <https://1145.am/db/2312194/Bristol-Myers_Squibb>,
        <https://1145.am/db/2312220/Bristol-Myers_Squibb>,
        <https://1145.am/db/2312436/Bristol-Myers_Squibb>,
        <https://1145.am/db/2312783/Bristol-Myers>,
        <https://1145.am/db/2313397/Bristol-Myers_Squibb>,
        <https://1145.am/db/2314245/Bristol-Myers_Squibb>,
        <https://1145.am/db/2314447/Bristol-Myers_Squibb_Company>,
        <https://1145.am/db/2314979/Bristol-Myers_Squibb>,
        <https://1145.am/db/2319442/Bristol-Myers_Squibb>,
        <https://1145.am/db/2319838/Bristol-Myers_Squibb>,
        <https://1145.am/db/2320315/Bristol-Myers_Squibb>,
        <https://1145.am/db/2320316/Bristol-Myers_Squibb>,
        <https://1145.am/db/2320973/Bristol-Myers_Squibb_Company>,
        <https://1145.am/db/2321014/Bristol-Myers>,
        <https://1145.am/db/2321432/Bristol-Myers_Squibb>,
        <https://1145.am/db/2324209/Bristol-Myers_Squibb>,
        <https://1145.am/db/2325918/Bristol-Myers_Squibb>,
        <https://1145.am/db/2326610/Bristol-Myers_Squibb>,
        <https://1145.am/db/2328576/Bristol-Myers_Squibb>,
        <https://1145.am/db/2328577/Bristol-Myers_Squibb>,
        <https://1145.am/db/2329134/Bristol-Myers_Squibb>,
        <https://1145.am/db/2329655/Bristol-Myers_Squibb>,
        <https://1145.am/db/2331201/Bristol-Myers_Squibb_Company>,
        <https://1145.am/db/2331823/Bristol_Myers_Squibb>,
        <https://1145.am/db/2332660/Bristol_Myers_Squibb>,
        <https://1145.am/db/2332832/Bristol-Myers_Squibb>,
        <https://1145.am/db/2332836/Bristol-Myers_Squibb>,
        <https://1145.am/db/2333555/Bristol-Myers_Squibb>,
        <https://1145.am/db/2336234/Bristol-Myers_Squibb>,
        <https://1145.am/db/2336237/Bristol-Myers_Squibb>,
        <https://1145.am/db/2336386/Bristol-Myers_Squibb_Company>,
        <https://1145.am/db/2336564/Bristol-Myers>,
        <https://1145.am/db/2336870/Bristol-Myers_Squibb_Company>,
        <https://1145.am/db/2337743/Bristol-Myers_Squibb>,
        <https://1145.am/db/2337982/Bristol-Myers_Squibb>,
        <https://1145.am/db/2338000/Bristol-Myers_Squibbs>,
        <https://1145.am/db/2339534/Bristol-Myers_Squibb>,
        <https://1145.am/db/2339822/Bristol-Myers_Squibb_Company>,
        <https://1145.am/db/2340675/Bristol-Myers_Squibb>,
        <https://1145.am/db/2341602/Bristol-Myers_Squibb>,
        <https://1145.am/db/2341628/Bristol-Myers_Squibb_Company_(bmy)>,
        <https://1145.am/db/2341871/Bristol-Myers_Squibb>,
        <https://1145.am/db/2343626/Bristol-Myers_Squibb>,
        <https://1145.am/db/2343628/Bristol-Myers_Squibb>,
        <https://1145.am/db/2344043/Bristol-Myers_Squibb>,
        <https://1145.am/db/2344635/Bristol-Myers_Squibb>,
        <https://1145.am/db/2345436/Bristol-Myers_Squibb>,
        <https://1145.am/db/2347040/Bristol-Myers_Squibb>,
        <https://1145.am/db/2347449/Bristol-Myers_Squibb>,
        <https://1145.am/db/2348079/Bristol-Myers_Squibb>,
        <https://1145.am/db/2350453/Bristol-Myers_Squibb>,
        <https://1145.am/db/2351670/Bristol-Myers_Squibb>,
        <https://1145.am/db/2351689/Bristol-Myers_Squibb>,
        <https://1145.am/db/2351759/Bristol-Myers_Squibb>,
        <https://1145.am/db/2355667/Bristol-Myers_Squibb>,
        <https://1145.am/db/2357757/Bristol-Myers_Squibb>,
        <https://1145.am/db/2358038/Bristol-Myers_Squibb>,
        <https://1145.am/db/2358039/Bristol-Myers_Squibb>,
        <https://1145.am/db/2358044/Bristol-Myers_Squibb>,
        <https://1145.am/db/2359117/Bristol-Myers_Squibb>,
        <https://1145.am/db/2362965/Bristol-Myers_Squibb>,
        <https://1145.am/db/2362966/Bristol-Myers>,
        <https://1145.am/db/2364052/Bristol-Myers_Squibb>,
        <https://1145.am/db/2364740/Bristol-Myers_Squibb>,
        <https://1145.am/db/2364742/Bristol-Myers_Squibb>,
        <https://1145.am/db/2364743/Bristol-Myers_Squibb>,
        <https://1145.am/db/2365157/Bristol-Myers_Squibb>,
        <https://1145.am/db/2365605/Bristol-Myers_Squibb>,
        <https://1145.am/db/2366402/Bristol-Myers_Squibb>,
        <https://1145.am/db/2367078/Bristol-Myers_Squibb>,
        <https://1145.am/db/2367082/Bristol-Myers_Squibb>,
        <https://1145.am/db/2367085/Bristol-Myers_Squibb>,
        <https://1145.am/db/2367182/Bristol-Myers_Squibb>,
        <https://1145.am/db/2367306/Bristol-Myers_Squibb>,
        <https://1145.am/db/2367562/Bristol-Myers_Squibb>,
        <https://1145.am/db/2367705/Bristol-Myers_Squibb_Company>,
        <https://1145.am/db/2368768/Bristol-Myers_Squibb_Company>,
        <https://1145.am/db/2368770/Bristol-Myers_Squibb>,
        <https://1145.am/db/2369703/Bristol-Myers_Squibb>,
        <https://1145.am/db/2369708/Bristol-Myers_Squibb>,
        <https://1145.am/db/2369710/Bristol-Myers_Squibb>,
        <https://1145.am/db/2370861/Bristol-Myers_Squibb>,
        <https://1145.am/db/2370990/Bristol-Myers_Squibb>,
        <https://1145.am/db/2371215/Bristol-Myers_Squibb>,
        <https://1145.am/db/2371285/Bristol-Myers_Squibb>,
        <https://1145.am/db/2509115/Bristol_Myers_Squibb>,
        <https://1145.am/db/2536960/Bristol-Myers_Squibb>,
        <https://1145.am/db/2537396/Bristol-Myers_Squibb>,
        <https://1145.am/db/2537448/Bristol-Myers_Squibb>,
        <https://1145.am/db/2539341/Bristol-Myers_Squibb>,
        <https://1145.am/db/2543185/Bristol-Myers_Squibb>,
        <https://1145.am/db/2543227/Bristol-Myers>,
        <https://1145.am/db/2544206/Bristol-Myers_Squibb>,
        <https://1145.am/db/2545052/Bristol-Myers_Squibb>,
        <https://1145.am/db/2546564/Bristol-Myers_Squibb>,
        <https://1145.am/db/2550394/Bristol-Myers_Squibb>,
        <https://1145.am/db/2553958/Bristol-Myers_Squibb>,
        <https://1145.am/db/2554303/Bristol-Myers_Squibb>,
        <https://1145.am/db/2558657/Bristol-Myers_Squibb>,
        <https://1145.am/db/2558664/Bristol-Myers_Squibb>,
        <https://1145.am/db/2558727/Bristol-Myers_Squibb>,
        <https://1145.am/db/2560287/Bristol-Myers_Squibb>,
        <https://1145.am/db/2562693/Bristol_Myers>,
        <https://1145.am/db/2563587/Bristol-Myers_Squibb>,
        <https://1145.am/db/2565218/Bristol-Myers_Squibb>,
        <https://1145.am/db/2565297/Bristol_Myers_Squibb>,
        <https://1145.am/db/2565318/Bristol_Myers>,
        <https://1145.am/db/2567124/Bristol-Myers_Squibb>,
        <https://1145.am/db/2569734/Bristol-Myers_Squibb>,
        <https://1145.am/db/2569735/Bristol-Myers_Squibb>,
        <https://1145.am/db/2572655/Bristol-Myers_Squibb_And_Otsuka>,
        <https://1145.am/db/2573375/Bristol-Myers_Squibb>,
        <https://1145.am/db/2573535/Bristol-Myers_Squibb>,
        <https://1145.am/db/2573593/Bristol-Myers_Squibb>,
        <https://1145.am/db/2575289/Bristol-Myers_Squibb>,
        <https://1145.am/db/2576086/Bristol-Myers>,
        <https://1145.am/db/2578540/Bristol-Myers_Squibb>,
        <https://1145.am/db/2580038/Bristol-Myers_Squibb>,
        <https://1145.am/db/2580053/Bristol-Myers_Squibb>,
        <https://1145.am/db/2581155/Bristol-Myers_Squibb>,
        <https://1145.am/db/2582116/Bristol-Myers_Squibb>,
        <https://1145.am/db/2582228/Bristol-Myers_Squibb_Company>,
        <https://1145.am/db/2583120/Bristol-Myers_Squibb>,
        <https://1145.am/db/2584317/Bristol-Myers_Squibb>,
        <https://1145.am/db/2584318/Bristol-Myers_Squibb>,
        <https://1145.am/db/2585238/Bristol-Myers_Squibb>,
        <https://1145.am/db/2585263/Bristol-Myers_Squibb>,
        <https://1145.am/db/2588614/Bristol-Myers_Squibb>,
        <https://1145.am/db/2588910/Bristol-Myers_Squibb>,
        <https://1145.am/db/2589029/Bristol-Myers_Squibb>,
        <https://1145.am/db/2589053/Bristol-Myers_Squibb>,
        <https://1145.am/db/2589861/Bristol-Myers_Squibb>,
        <https://1145.am/db/2589921/Bristol-Myers_Squibb_Company>,
        <https://1145.am/db/2592024/Bristol-Myers_Squibb>,
        <https://1145.am/db/2592993/Bristol-Myers_Squibb>,
        <https://1145.am/db/2594370/Bristol-Myers_Squibb>,
        <https://1145.am/db/2595133/Bristol-Myers_Squibb>,
        <https://1145.am/db/2595615/Bristol-Myers_Squibb>,
        <https://1145.am/db/2595843/Bristol-Myers_Squibb_Company>,
        <https://1145.am/db/2595876/Bristol-Myers_Squibb>,
        <https://1145.am/db/2596107/Bristol-Myers_Squibb>,
        <https://1145.am/db/2596135/Bristol-Myers_Squibb>,
        <https://1145.am/db/2596137/Bristol-Myers_Squibb>,
        <https://1145.am/db/2596434/Bristol-Myers_Squibb>,
        <https://1145.am/db/2597274/Bristol-Myers_Squibb>,
        <https://1145.am/db/2598195/Bristol-Myers_Squibb>,
        <https://1145.am/db/2598626/Bristol-Myers_Squibb>,
        <https://1145.am/db/2598639/Bristol-Myers_Squibb>,
        <https://1145.am/db/2716207/Bristol_Myers_Squibb>,
        <https://1145.am/db/2786473/Bristol_Myers_Squibb>,
        <https://1145.am/db/2796875/Bristol_Myers_Squibb>,
        <https://1145.am/db/569732/Bristol_Myers_Squibb_Co>,
        <https://1145.am/db/768063/Bristol_Myers_Squibb>,
        <https://1145.am/db/815499/Bristol_Myers_Squibb>,
        <https://1145.am/db/831553/Bristol-Myers_Squibb>,
        <https://1145.am/db/833098/Bristol-Myers_Squibb> ;
    ns1:sameAsMedium <https://1145.am/db/1055530/Bristol_Myers_Squibb>,
        <https://1145.am/db/1057172/Bristol_Myers_Squibb>,
        <https://1145.am/db/1213113/Bristol_Myers_Squibb>,
        <https://1145.am/db/1219346/Bristol_Myers_Squibb>,
        <https://1145.am/db/1219817/Bristol_Myers_Squibb>,
        <https://1145.am/db/1318775/Bristol-Myers_Squibb>,
        <https://1145.am/db/1319026/Bristol-Myers_Squibb>,
        <https://1145.am/db/1822601/Bristol-Myers_Squibb>,
        <https://1145.am/db/2139444/Bristol_Myers_Squibb>,
        <https://1145.am/db/2153042/Bristol_Myers_Squibb>,
        <https://1145.am/db/2278861/Bristol_Myers_Squibb>,
        <https://1145.am/db/2279067/Bristol_Myers_Squibb>,
        <https://1145.am/db/2279854/Bristol_Myers_Squibb>,
        <https://1145.am/db/2279903/Bristol_Myers_Squibb>,
        <https://1145.am/db/2280925/Bristol_Myers_Squibb>,
        <https://1145.am/db/2284903/Bristol_Myers_Squibb>,
        <https://1145.am/db/2291777/Bristol-Myers_Squibb>,
        <https://1145.am/db/2292751/Bristol-Myers_Squibb>,
        <https://1145.am/db/2293175/Bristol-Myers_Squibb>,
        <https://1145.am/db/2295625/Bristol-Myers_Squibb>,
        <https://1145.am/db/2299941/Bristol-Myers_Squibb>,
        <https://1145.am/db/2301461/Bristol-Myers_Squibb>,
        <https://1145.am/db/2305254/Bristol-Myers_Squibb_Company>,
        <https://1145.am/db/2307968/Bristol-Myers_Squibb>,
        <https://1145.am/db/2308778/Bristol-Myers_Squibb>,
        <https://1145.am/db/2311150/Bristol-Myers_Squibb_Company>,
        <https://1145.am/db/2326568/Bristol-Myers_Squibb_Company>,
        <https://1145.am/db/2331819/Bristol-Myers_Squibb>,
        <https://1145.am/db/2336201/Bristol-Myers_Squibb>,
        <https://1145.am/db/2336567/Bristol-Myers_Squibb>,
        <https://1145.am/db/2345426/Bristol-Myers_Squibb>,
        <https://1145.am/db/2345774/Bristol-Myers_Squibb_Company>,
        <https://1145.am/db/2347038/Bristol-Myers_Squibb_Company>,
        <https://1145.am/db/2347466/Bristol-Myers_Squibb_Company>,
        <https://1145.am/db/2347486/Bristol-Myers_Squibb_Company>,
        <https://1145.am/db/2347488/Bristol-Myers_Squibb>,
        <https://1145.am/db/2348034/Bristol-Myers_Squibb>,
        <https://1145.am/db/2348351/Bristol-Myers_Squibb>,
        <https://1145.am/db/2352534/Bristol-Myers_Squibb>,
        <https://1145.am/db/2354567/Bristol-Myers_Squibb>,
        <https://1145.am/db/2354577/Bristol-Myers_Squibb>,
        <https://1145.am/db/2355669/Bristol-Myers_Squibb>,
        <https://1145.am/db/2356005/Bristol-Myers_Squibb>,
        <https://1145.am/db/2356340/Bristol-Myers_Squibb>,
        <https://1145.am/db/2358078/Bristol-Myers_Squibb>,
        <https://1145.am/db/2360289/Bristol-Myers_Squibb>,
        <https://1145.am/db/2360963/Bristol-Myers_Squibb_Company>,
        <https://1145.am/db/2364049/Bristol-Myers_Squibb>,
        <https://1145.am/db/2367569/Bristol-Myers_Squibb>,
        <https://1145.am/db/2368765/Bristol-Myers_Squibb>,
        <https://1145.am/db/2371186/Bristol-Myers_Squibb>,
        <https://1145.am/db/2536422/Bristol-Myers_Squibb>,
        <https://1145.am/db/2537500/Bristol-Myers_Squibb>,
        <https://1145.am/db/2537537/Bristol-Myers_Squibb>,
        <https://1145.am/db/2539308/Bristol-Myers_Squibb>,
        <https://1145.am/db/2543220/Bristol-Myers_Squibb>,
        <https://1145.am/db/2543236/Bristol-Myers_Squibb>,
        <https://1145.am/db/2543552/Bristol-Myers_Squibb>,
        <https://1145.am/db/2543648/Bristol-Myers_Squibb>,
        <https://1145.am/db/2543655/Bristol-Myers_Squibb>,
        <https://1145.am/db/2545023/Bristol-Myers_Squibb>,
        <https://1145.am/db/2550188/Bristol-Myers_Squibb>,
        <https://1145.am/db/2551883/Bristol-Myers_Squibb>,
        <https://1145.am/db/2554631/Bristol-Myers_Squibb>,
        <https://1145.am/db/2554897/Bristol-Myers_Squibb>,
        <https://1145.am/db/2555760/Bristol-Myers_Squibb>,
        <https://1145.am/db/2556543/Bristol-Myers_Squibb>,
        <https://1145.am/db/2557238/Bristol-Myers_Squibb>,
        <https://1145.am/db/2559407/Bristol-Myers_Squibb>,
        <https://1145.am/db/2560564/Bristol_Myers_Squibb>,
        <https://1145.am/db/2561325/Bristol-Myers_Squibb>,
        <https://1145.am/db/2562459/Bristol-Myers_Squibb>,
        <https://1145.am/db/2562503/Bristol-Myers_Squibb>,
        <https://1145.am/db/2563390/Bristol-Myers_Squibb>,
        <https://1145.am/db/2563889/Bristol-Myers_Squibb>,
        <https://1145.am/db/2564274/Bristol_Myers_Squibb>,
        <https://1145.am/db/2565258/Bristol-Myers_Squibb>,
        <https://1145.am/db/2566282/Bristol_Myers_Squibb>,
        <https://1145.am/db/2567006/Bristol-Myers_Squibb>,
        <https://1145.am/db/2567466/Bristol_Myers_Squibb>,
        <https://1145.am/db/2575176/Bristol-Myers_Squibb>,
        <https://1145.am/db/2578567/Bristol-Myers_Squibb>,
        <https://1145.am/db/2582111/Bristol-Myers_Squibb_Company>,
        <https://1145.am/db/2582120/Bristol-Myers_Squibb>,
        <https://1145.am/db/2592791/Bristol-Myers_Squibb_Company>,
        <https://1145.am/db/2594365/Bristol-Myers_Squibb>,
        <https://1145.am/db/2596128/Bristol-Myers_Squibb_Company>,
        <https://1145.am/db/2597935/Bristol-Myers_Squibb>,
        <https://1145.am/db/2598099/Bristol-Myers_Squibb>,
        <https://1145.am/db/2788420/Bristol_Myers_Squibb>,
        <https://1145.am/db/426688/Bristol_Myers_Squibb>,
        <https://1145.am/db/870410/Bristol-Myers_Squibb>,
        <https://1145.am/db/979509/Bristol_Myers_Squibb> ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2589142/Hart-Scott-Rodino> a org:Organization ;
    ns1:basedInLowRaw "NEW YORK" ;
    ns1:buyer <https://1145.am/db/2589142/Zymogenetics_Acquisition> ;
    ns1:description "mergers and acquisitions" ;
    ns1:documentDate "2010-09-28T12:04:31+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Bristol-Myers Squibb Announces Expiration of Hart-Scott-Rodino Waiting Period for Acquisition of ZymoGenetics, Inc." ;
    ns1:documentURL <https://www.fiercepharma.com/pharma/bristol-myers-squibb-announces-expiration-of-hart-scott-rodino-waiting-period-for-2> ;
    ns1:foundName "Hart-Scott-Rodino" ;
    ns1:name "Hart-Scott-Rodino" ;
    ns1:sameAsHigh <https://1145.am/db/2365157/Hart-Scott-Rodino> ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2589142/Zeus_Acquisition_Corporation> a org:Organization ;
    ns1:basedInLowRaw "NEW YORK" ;
    ns1:buyer <https://1145.am/db/2589142/Zymogenetics_Acquisition> ;
    ns1:description "a cash tender offer" ;
    ns1:documentDate "2010-09-28T12:04:31+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Bristol-Myers Squibb Announces Expiration of Hart-Scott-Rodino Waiting Period for Acquisition of ZymoGenetics, Inc." ;
    ns1:documentURL <https://www.fiercepharma.com/pharma/bristol-myers-squibb-announces-expiration-of-hart-scott-rodino-waiting-period-for-2> ;
    ns1:foundName "Zeus Acquisition Corporation" ;
    ns1:name "Zeus Acquisition Corporation" ;
    ns1:sameAsHigh <https://1145.am/db/2359117/Zeus_Acquisition_Corporation>,
        <https://1145.am/db/2365157/Zeus_Acquisition_Corporation>,
        <https://1145.am/db/2367082/Zeus_Acquisition_Corporation>,
        <https://1145.am/db/2585263/Zeus_Acquisition_Corporation> ;
    ns1:sameAsMedium <https://1145.am/db/2367085/Zeus_Acquisition_Corporation>,
        <https://1145.am/db/2592024/Zeus_Acquisition_Corporation> ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2596014/Investment_Metro_Bank_Of_Harrisburg_Unilife_Corporation_Unilife_Corporation_Has_Not_Happened> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-10-28T13:18:28+00:00"^^xsd:dateTime ;
    ns1:documentExtract "LEWISBERRY, Pa., Oct. 21 /PRNewswire/ - Unilife Corporation (\"Unilife\" or \"Company\") (Nasdaq: UNIS, ASX: UNS) today announced that it has secured U.S. Government financial backing to support the construction of its new global headquarters and manufacturing facility in York, Pennsylvania." ;
    ns1:documentTitle "Unilife Secures U.S. Government Financial Backing for the Completion of New Global Headquarters and Manufacturing Facility" ;
    ns1:documentURL <https://www.fiercepharma.com/pharma/unilife-secures-u-s-government-financial-backing-for-completion-of-new-global-headquarters> ;
    ns1:sourceName "Fierce Pharma" ;
    ns1:status "has not happened" ;
    ns1:target <https://1145.am/db/2596014/Metro_Bank_Of_Harrisburg>,
        <https://1145.am/db/2596014/Unilife_Corporation> ;
    ns1:valueRaw "$ 10 million",
        "$ 18 million" ;
    ns1:whereGeoName "Pennsylvania" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6254927/about.rdf> ;
    ns1:whereRaw "Pennsylvania" .

<https://1145.am/db/2596014/Metro_Bank_Of_Harrisburg> a org:Organization ;
    ns1:basedInLowRaw "U.S." ;
    ns1:documentDate "2010-10-28T13:18:28+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Unilife Secures U.S. Government Financial Backing for the Completion of New Global Headquarters and Manufacturing Facility" ;
    ns1:documentURL <https://www.fiercepharma.com/pharma/unilife-secures-u-s-government-financial-backing-for-completion-of-new-global-headquarters> ;
    ns1:foundName "Metro Bank of Harrisburg" ;
    ns1:name "Metro Bank of Harrisburg" ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2596014/Unilife_Corporation> a org:Organization ;
    ns1:basedInHighGeoName "York County" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5220355/about.rdf> ;
    ns1:basedInHighRaw "York, Pennsylvania" ;
    ns1:description "Agriculture" ;
    ns1:documentDate "2010-10-28T13:18:28+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Unilife Secures U.S. Government Financial Backing for the Completion of New Global Headquarters and Manufacturing Facility" ;
    ns1:documentURL <https://www.fiercepharma.com/pharma/unilife-secures-u-s-government-financial-backing-for-completion-of-new-global-headquarters> ;
    ns1:foundName "Unilife",
        "Unilife Corporation" ;
    ns1:investor <https://1145.am/db/2596014/Investment_Metro_Bank_Of_Harrisburg_Unilife_Corporation_Unilife_Corporation_Has_Not_Happened> ;
    ns1:name "Unilife",
        "Unilife Corporation" ;
    ns1:sameAsMedium <https://1145.am/db/2293251/Unilife>,
        <https://1145.am/db/2337978/Unilife_Corporation>,
        <https://1145.am/db/2341168/Unilife_Corporation>,
        <https://1145.am/db/2358316/Unilife_Corporation>,
        <https://1145.am/db/2369619/Unilife_Corporation>,
        <https://1145.am/db/2370843/Unilife>,
        <https://1145.am/db/2573976/Unilife> ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2608966/Court_Square> a org:Organization ;
    ns1:buyer <https://1145.am/db/2608966/Fibertech_Acquisition> ;
    ns1:documentDate "2010-08-31T14:42:45+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Ridgemont Equity Partners buys big piece of United Private Networks" ;
    ns1:documentURL <https://www.fiercetelecom.com/telecom/ridgemont-equity-partners-buys-big-piece-united-private-networks> ;
    ns1:foundName "Court Square" ;
    ns1:name "Court Square" ;
    ns1:sameAsMedium <https://1145.am/db/2605285/Court_Square>,
        <https://1145.am/db/2608946/Court_Square>,
        <https://1145.am/db/2609709/Court_Square>,
        <https://1145.am/db/2611165/Court_Square>,
        <https://1145.am/db/2615628/Court_Square>,
        <https://1145.am/db/2618622/Court_Square> ;
    ns1:sourceName "Fierce Telecom" .

<https://1145.am/db/2608966/Fibertech_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition" ;
    ns1:documentDate "2010-08-31T14:42:45+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Fibertech sold to Court Square for $ 500 million.",
        "Over the past week, ABRY Partners completed its acquisition of RCN, while Court Square bought up regional fiber service provider Fibertech." ;
    ns1:documentTitle "Ridgemont Equity Partners buys big piece of United Private Networks" ;
    ns1:documentURL <https://www.fiercetelecom.com/telecom/ridgemont-equity-partners-buys-big-piece-united-private-networks> ;
    ns1:foundName "bought",
        "bought up" ;
    ns1:name "bought",
        "bought up" ;
    ns1:sourceName "Fierce Telecom" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2608966/Fibertech> ;
    ns1:targetName "Fibertech" ;
    ns1:valueRaw "$ 500 million" .

<https://1145.am/db/2608966/United_Private_Networks> a org:Organization ;
    ns1:basedInHighGeoName "Midwest" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/11887750/about.rdf> ;
    ns1:basedInHighRaw "Midwest" ;
    ns1:description "providing data communications networks and related services" ;
    ns1:documentDate "2010-08-31T14:42:45+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Ridgemont Equity Partners buys big piece of United Private Networks" ;
    ns1:documentURL <https://www.fiercetelecom.com/telecom/ridgemont-equity-partners-buys-big-piece-united-private-networks> ;
    ns1:foundName "United Private Networks" ;
    ns1:name "United Private Networks" ;
    ns1:sourceName "Fierce Telecom" .

<https://1145.am/db/2608966/United_Private_Networks_Stake_Investment> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-08-31T14:42:45+00:00"^^xsd:dateTime ;
    ns1:documentExtract "United Private Networks (UPN) , a Midwest - based regional fiber - based provider, has decided to put its trust in a larger partner Ridgemont Equity Partners which will acquire a majority stake in the company." ;
    ns1:documentTitle "Ridgemont Equity Partners buys big piece of United Private Networks" ;
    ns1:documentURL <https://www.fiercetelecom.com/telecom/ridgemont-equity-partners-buys-big-piece-united-private-networks> ;
    ns1:foundName "acquire" ;
    ns1:name "acquire" ;
    ns1:sourceName "Fierce Telecom" ;
    ns1:status "has not happened" ;
    ns1:target <https://1145.am/db/2608966/United_Private_Networks> ;
    ns1:targetDetails "stake" ;
    ns1:targetName "United Private Networks" ;
    ns1:whereGeoName "Midwest" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/11887750/about.rdf> ;
    ns1:whereRaw "Midwest" .

<https://1145.am/db/2610482/Juma_Technology> a org:Organization ;
    ns1:basedInHighGeoName "New York City" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5128581/about.rdf> ;
    ns1:basedInHighRaw "New York" ;
    ns1:description "telecommunications and IT systems integrator" ;
    ns1:documentDate "2010-09-27T13:40:32+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Iran accuses West of unleashing computer worm; U.S. law enforcement wants Internet regulatory change" ;
    ns1:documentURL <https://www.fiercetelecom.com/telecom/iran-accuses-west-unleashing-computer-worm-u-s-law-enforcement-wants-internet-regulatory> ;
    ns1:foundName "Juma Technology" ;
    ns1:industry "telecommunications and IT systems integrator" ;
    ns1:name "Juma Technology" ;
    ns1:sameAsMedium <https://1145.am/db/2617211/Juma_Technology_Corp> ;
    ns1:sourceName "Fierce Telecom" .

<https://1145.am/db/2610482/Peter_Aquino> a org:Organization ;
    ns1:basedInLowRaw "United States" ;
    ns1:documentDate "2010-09-27T13:40:32+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Iran accuses West of unleashing computer worm; U.S. law enforcement wants Internet regulatory change" ;
    ns1:documentURL <https://www.fiercetelecom.com/telecom/iran-accuses-west-unleashing-computer-worm-u-s-law-enforcement-wants-internet-regulatory> ;
    ns1:foundName "RCN" ;
    ns1:name "Peter Aquino" ;
    ns1:sourceName "Fierce Telecom" .

<https://1145.am/db/2610482/Peter_Aquino_Investment> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-09-27T13:40:32+00:00"^^xsd:dateTime ;
    ns1:documentExtract "> Peter Aquino, former president and CEO of RCN who departed after the company's acquisition by ABRY Partners, has been named to the board of directors at TiVo (Nasdaq: TIVO) , Multichannel News reports." ;
    ns1:documentTitle "Iran accuses West of unleashing computer worm; U.S. law enforcement wants Internet regulatory change" ;
    ns1:documentURL <https://www.fiercetelecom.com/telecom/iran-accuses-west-unleashing-computer-worm-u-s-law-enforcement-wants-internet-regulatory> ;
    ns1:foundName "acquisition" ;
    ns1:name "acquisition" ;
    ns1:sourceName "Fierce Telecom" ;
    ns1:status "has not happened" ;
    ns1:target <https://1145.am/db/2610482/Peter_Aquino> ;
    ns1:targetName "Peter Aquino" .

<https://1145.am/db/2614893/Acquisition_One_Communications_Ntelos_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition" ;
    ns1:documentDate "2010-12-09T20:52:24+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Over the past year, nTelos has been enhancing the reach of its wireline unit by acquiring a 2,200 fiber mile network from Allegheny Communications followed by its recently completed acquisition of FiberNet from One Communications." ;
    ns1:documentTitle "nTelos breaks up wireless and wireline holdings into separate units" ;
    ns1:documentURL <https://www.fiercetelecom.com/telecom/ntelos-breaks-up-wireless-and-wireline-holdings-into-separate-units> ;
    ns1:foundName "acquisition" ;
    ns1:name "acquisition" ;
    ns1:sourceName "Fierce Telecom" ;
    ns1:status "completed" ;
    ns1:vendor <https://1145.am/db/2614893/One_Communications> ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "United States" .

<https://1145.am/db/2614893/Allegheny_Communications> a org:Organization ;
    ns1:description "enhancing the reach of its wireline unit" ;
    ns1:documentDate "2010-12-09T20:52:24+00:00"^^xsd:dateTime ;
    ns1:documentTitle "nTelos breaks up wireless and wireline holdings into separate units" ;
    ns1:documentURL <https://www.fiercetelecom.com/telecom/ntelos-breaks-up-wireless-and-wireline-holdings-into-separate-units> ;
    ns1:foundName "Allegheny Communications" ;
    ns1:name "Allegheny Communications" ;
    ns1:sourceName "Fierce Telecom" .

<https://1145.am/db/2614893/Fibernet> a org:Organization ;
    ns1:description "enhancing the reach of its wireline unit" ;
    ns1:documentDate "2010-12-09T20:52:24+00:00"^^xsd:dateTime ;
    ns1:documentTitle "nTelos breaks up wireless and wireline holdings into separate units" ;
    ns1:documentURL <https://www.fiercetelecom.com/telecom/ntelos-breaks-up-wireless-and-wireline-holdings-into-separate-units> ;
    ns1:foundName "FiberNet" ;
    ns1:name "FiberNet" ;
    ns1:sameAsMedium <https://1145.am/db/2602608/Fibernet>,
        <https://1145.am/db/2607378/Fibernet>,
        <https://1145.am/db/2607883/Fibernet>,
        <https://1145.am/db/2608212/Fibernet>,
        <https://1145.am/db/2609450/Fibernet>,
        <https://1145.am/db/2609709/Fibernet>,
        <https://1145.am/db/2614189/Fibernet>,
        <https://1145.am/db/2614880/Fibernet> ;
    ns1:sourceName "Fierce Telecom" .

<https://1145.am/db/2614893/Fibernet_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition" ;
    ns1:documentDate "2010-12-09T20:52:24+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Over the past year, nTelos has been enhancing the reach of its wireline unit by acquiring a 2,200 fiber mile network from Allegheny Communications followed by its recently completed acquisition of FiberNet from One Communications." ;
    ns1:documentTitle "nTelos breaks up wireless and wireline holdings into separate units" ;
    ns1:documentURL <https://www.fiercetelecom.com/telecom/ntelos-breaks-up-wireless-and-wireline-holdings-into-separate-units> ;
    ns1:foundName "acquiring",
        "acquisition" ;
    ns1:name "acquiring",
        "acquisition" ;
    ns1:sourceName "Fierce Telecom" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2614893/Fibernet> ;
    ns1:targetName "FiberNet" ;
    ns1:vendor <https://1145.am/db/2614893/Allegheny_Communications>,
        <https://1145.am/db/2614893/One_Communications> .

<https://1145.am/db/2614893/The_New_Wireline_Company> a org:Organization ;
    ns1:basedInLowRaw "The New Wireline Company" ;
    ns1:documentDate "2010-12-09T20:52:24+00:00"^^xsd:dateTime ;
    ns1:documentTitle "nTelos breaks up wireless and wireline holdings into separate units" ;
    ns1:documentURL <https://www.fiercetelecom.com/telecom/ntelos-breaks-up-wireless-and-wireline-holdings-into-separate-units> ;
    ns1:foundName "The New Wireline Company" ;
    ns1:industry "service provider" ;
    ns1:name "The New Wireline Company" ;
    ns1:sourceName "Fierce Telecom" .

<https://1145.am/db/2614902/Lexent_Metro_Connect_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition",
        "merger" ;
    ns1:documentDate "2010-12-13T15:33:12+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Lightower adds Lexent Metro Connect to its acquisition cart.",
        "Lightower finishes up Lexent acquisition." ;
    ns1:documentTitle "Lightower acquires Open Access, increases Long Island fiber footprint" ;
    ns1:documentURL <https://www.fiercetelecom.com/telecom/lightower-acquires-open-access-increases-long-island-fiber-footprint> ;
    ns1:foundName "acquisition" ;
    ns1:name "acquisition" ;
    ns1:sourceName "Fierce Telecom" ;
    ns1:status "has not happened" ;
    ns1:target <https://1145.am/db/2614902/Lexent_Metro_Connect> ;
    ns1:targetName "Lexent",
        "Lexent Metro Connect" .

<https://1145.am/db/2614902/Open_Access_Merger> a ns1:CorporateFinanceActivity ;
    ns1:activityType "merger" ;
    ns1:documentDate "2010-12-13T15:33:12+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Lightower Fiber Networks is continuing its strategic Northeast region network purchase strategy this week with the acquisition of Farmingdale, N.Y. - based Open Access Inc." ;
    ns1:documentTitle "Lightower acquires Open Access, increases Long Island fiber footprint" ;
    ns1:documentURL <https://www.fiercetelecom.com/telecom/lightower-acquires-open-access-increases-long-island-fiber-footprint> ;
    ns1:foundName "acquisition" ;
    ns1:name "acquisition" ;
    ns1:sourceName "Fierce Telecom" ;
    ns1:status "has not happened" ;
    ns1:target <https://1145.am/db/2614902/Open_Access> ;
    ns1:targetName "Open Access" ;
    ns1:whereGeoName "Farmingdale" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5116931/about.rdf> ;
    ns1:whereRaw "Farmingdale, N.Y" .

<https://1145.am/db/2615618/Acquisition_Lightower_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition" ;
    ns1:documentDate "2010-12-20T15:40:15+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Lightower acquires Open Access, increases Long Island fiber footprint." ;
    ns1:documentTitle "Lightower secures $230 million credit from GE Capital" ;
    ns1:documentURL <https://www.fiercetelecom.com/telecom/lightower-secures-230-million-credit-from-ge-capital> ;
    ns1:sourceName "Fierce Telecom" ;
    ns1:status "completed" ;
    ns1:whereGeoName "Long Island" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/3572005/about.rdf> ;
    ns1:whereRaw "Long Island" .

<https://1145.am/db/2615618/Lexent_Metro_Connect_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition",
        "merger" ;
    ns1:documentDate "2010-12-20T15:40:15+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Lightower adds Lexent Metro Connect to its acquisition cart.",
        "Lightower finishes up Lexent acquisition." ;
    ns1:documentTitle "Lightower secures $230 million credit from GE Capital" ;
    ns1:documentURL <https://www.fiercetelecom.com/telecom/lightower-secures-230-million-credit-from-ge-capital> ;
    ns1:foundName "acquisition" ;
    ns1:name "acquisition" ;
    ns1:sourceName "Fierce Telecom" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2615618/Lexent_Metro_Connect> ;
    ns1:targetName "Lexent",
        "Lexent Metro Connect" .

<https://1145.am/db/2615618/Merger_Lightower_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "merger" ;
    ns1:documentDate "2010-12-20T15:40:15+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Lightower finishes up Lexent acquisition." ;
    ns1:documentTitle "Lightower secures $230 million credit from GE Capital" ;
    ns1:documentURL <https://www.fiercetelecom.com/telecom/lightower-secures-230-million-credit-from-ge-capital> ;
    ns1:foundName "acquisition" ;
    ns1:name "acquisition" ;
    ns1:sourceName "Fierce Telecom" ;
    ns1:status "completed" ;
    ns1:whereGeoName "Long Island" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/3572005/about.rdf> ;
    ns1:whereRaw "Long Island" .

<https://1145.am/db/2615618/Open_Access_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition" ;
    ns1:documentDate "2010-12-20T15:40:15+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Lightower acquires Open Access, increases Long Island fiber footprint." ;
    ns1:documentTitle "Lightower secures $230 million credit from GE Capital" ;
    ns1:documentURL <https://www.fiercetelecom.com/telecom/lightower-secures-230-million-credit-from-ge-capital> ;
    ns1:foundName "acquires" ;
    ns1:name "acquires" ;
    ns1:sourceName "Fierce Telecom" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2615618/Open_Access> ;
    ns1:targetName "Open Access" ;
    ns1:whereGeoName "Long Island" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/3572005/about.rdf> ;
    ns1:whereRaw "Long Island" .

<https://1145.am/db/2615628/Court_Square> a org:Organization ;
    ns1:buyer <https://1145.am/db/2615628/Fibertech_Acquisition> ;
    ns1:documentDate "2010-12-22T04:14:18+00:00"^^xsd:dateTime ;
    ns1:documentTitle "DukeNet becomes joint venture of Duke Energy and Alinda Capital" ;
    ns1:documentURL <https://www.fiercetelecom.com/telecom/dukenet-becomes-joint-venture-duke-energy-and-alinda-capital> ;
    ns1:foundName "Court Square" ;
    ns1:investor <https://1145.am/db/2615628/Fibertech_Acquisition> ;
    ns1:name "Court Square" ;
    ns1:sameAsMedium <https://1145.am/db/2605285/Court_Square>,
        <https://1145.am/db/2608946/Court_Square>,
        <https://1145.am/db/2608966/Court_Square>,
        <https://1145.am/db/2609709/Court_Square>,
        <https://1145.am/db/2611165/Court_Square>,
        <https://1145.am/db/2618622/Court_Square> ;
    ns1:sourceName "Fierce Telecom" .

<https://1145.am/db/2615628/Dukenet_Communications> a org:Organization ;
    ns1:documentDate "2010-12-22T04:14:18+00:00"^^xsd:dateTime ;
    ns1:documentTitle "DukeNet becomes joint venture of Duke Energy and Alinda Capital" ;
    ns1:documentURL <https://www.fiercetelecom.com/telecom/dukenet-becomes-joint-venture-duke-energy-and-alinda-capital> ;
    ns1:foundName "DukeNet",
        "DukeNet Communications" ;
    ns1:name "DukeNet",
        "DukeNet Communications" ;
    ns1:sourceName "Fierce Telecom" .

<https://1145.am/db/2651267/Investment_China_Development_Bank_Corporation_Reliance_Communications_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-12-20T01:04:00+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Reliance Communications, India's second largest cellco, has signed a financing deal worth $ 1.93 billion (€1.4 billion) with the China Development Bank Corporation (CDBC) , according to." ;
    ns1:documentTitle "Cash gives China vendors clout in India" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/cash-gives-china-vendors-clout-india> ;
    ns1:foundName "financing" ;
    ns1:name "financing" ;
    ns1:sourceName "Fierce Wireless" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2651267/Reliance_Communications> ;
    ns1:valueRaw "$ 1.93 billion",
        "€1.4 billion" ;
    ns1:whereGeoName "Republic of India" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/1269750/about.rdf> ;
    ns1:whereRaw "India" .

<https://1145.am/db/2651267/Reliance_Communications> a org:Organization ;
    ns1:basedInHighGeoName "Republic of India" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/1269750/about.rdf> ;
    ns1:basedInHighRaw "India" ;
    ns1:description "cellco" ;
    ns1:documentDate "2010-12-20T01:04:00+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Cash gives China vendors clout in India" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/cash-gives-china-vendors-clout-india> ;
    ns1:foundName "Reliance Communications" ;
    ns1:name "Reliance Communications" ;
    ns1:sameAsMedium <https://1145.am/db/2599695/Reliance_Communications>,
        <https://1145.am/db/2602851/Reliance_Communications>,
        <https://1145.am/db/2604389/Reliance_Communications>,
        <https://1145.am/db/2613036/Reliance_Communications>,
        <https://1145.am/db/2615464/Reliance_Communications>,
        <https://1145.am/db/2616538/Reliance_Communications>,
        <https://1145.am/db/2619115/Reliance_Communications>,
        <https://1145.am/db/2619461/Reliance_Communications>,
        <https://1145.am/db/2652021/Reliance_Communications>,
        <https://1145.am/db/2654362/Reliance_Communications>,
        <https://1145.am/db/2654379/Reliance_Communications>,
        <https://1145.am/db/2655260/Reliance_Communications>,
        <https://1145.am/db/2656193/Reliance_Communications>,
        <https://1145.am/db/2656688/Reliance_Communications>,
        <https://1145.am/db/2657177/Reliance_Communications>,
        <https://1145.am/db/2660246/Reliance_Communications>,
        <https://1145.am/db/2661624/Reliance_Communications>,
        <https://1145.am/db/2666757/Reliance_Communications>,
        <https://1145.am/db/2671276/Reliance_Communications>,
        <https://1145.am/db/2672420/Reliance_Communications>,
        <https://1145.am/db/2679588/Reliance_Communications>,
        <https://1145.am/db/2679961/Reliance_Communications>,
        <https://1145.am/db/2680835/Reliance_Communications>,
        <https://1145.am/db/2682257/Reliance_Communications> ;
    ns1:sourceName "Fierce Wireless" .

<https://1145.am/db/2662465/Investment_Temasek_Holdings_Tudou_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-08-09T01:07:00+00:00"^^xsd:dateTime ;
    ns1:documentExtract "China's information technology sector is becoming increasingly attractive to investors from developed nations, with Temasek taking a stake in video firm Tudou and Apple eyeing games developer Handseeing.",
        "Temasek Holdings, the investment arm of the Singapore government, last week made its first foray into the Chinese technology sector, tipping $ 35 million (€26 million) into online video company Tudou." ;
    ns1:documentTitle "Chinese firms become foreign takeover targets" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/chinese-firms-become-foreign-takeover-targets> ;
    ns1:foundName "taking",
        "tipping" ;
    ns1:name "taking",
        "tipping" ;
    ns1:sourceName "Fierce Wireless" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2662465/Tudou> ;
    ns1:targetDetails "stake" ;
    ns1:targetName "Tudou" ;
    ns1:valueRaw "$ 35 million",
        "€26 million" ;
    ns1:whereGeoName "People’s Republic of China",
        "Republic of Singapore" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/1814991/about.rdf>,
        <https://sws.geonames.org/1880251/about.rdf> ;
    ns1:whereRaw "China",
        "Singapore" .

<https://1145.am/db/2662465/Tudou> a org:Organization ;
    ns1:basedInHighGeoName "People’s Republic of China" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/1814991/about.rdf> ;
    ns1:basedInHighRaw "China" ;
    ns1:description "online video" ;
    ns1:documentDate "2010-08-09T01:07:00+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Chinese firms become foreign takeover targets" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/chinese-firms-become-foreign-takeover-targets> ;
    ns1:foundName "Tudou" ;
    ns1:industry "information technology" ;
    ns1:name "Tudou" ;
    ns1:sameAsHigh <https://1145.am/db/2678680/Tudou> ;
    ns1:sameAsMedium <https://1145.am/db/2654050/Tudou>,
        <https://1145.am/db/2668108/Tudou>,
        <https://1145.am/db/2674623/Tudou>,
        <https://1145.am/db/2676293/Tudou> ;
    ns1:sourceName "Fierce Wireless" .

<https://1145.am/db/2666786/Hellenic_Telecoms> a org:Organization ;
    ns1:basedInHighGeoName "Hellenic Republic" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/390903/about.rdf> ;
    ns1:basedInHighRaw "Greece" ;
    ns1:description "Business" ;
    ns1:documentDate "2010-09-09T01:08:00+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Deutsche Tel seeks OTE control" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/deutsche-tel-seeks-ote-control> ;
    ns1:foundName "Hellenic Telecoms" ;
    ns1:name "Hellenic Telecoms" ;
    ns1:sameAsHigh <https://1145.am/db/2606974/Hellenic_Telecommunications_Organization>,
        <https://1145.am/db/2660467/Hellenic_Telecommunications_Organisation>,
        <https://1145.am/db/2678410/Hellenic_Telecommunications_Organization> ;
    ns1:sameAsMedium <https://1145.am/db/2660472/Hellenic_Telecom> ;
    ns1:sourceName "Fierce Wireless" .

<https://1145.am/db/2681334/Altor_Networks> a org:Organization ;
    ns1:description "security technology" ;
    ns1:documentDate "2010-12-07T01:00:00+00:00"^^xsd:dateTime ;
    ns1:documentTitle "News In Brief: EC, Qualcomm, Cisco, TeliaSonera, Juniper Networks, Ofcom" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/news-brief-ec-qualcomm-cisco-teliasonera-juniper-networks-ofcom> ;
    ns1:foundName "Altor Networks" ;
    ns1:name "Altor Networks" ;
    ns1:sameAsMedium <https://1145.am/db/2614877/Altor_Networks> ;
    ns1:sourceName "Fierce Wireless" .

<https://1145.am/db/2681334/Altor_Networks_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition" ;
    ns1:documentDate "2010-12-07T01:00:00+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Juniper Networks has acquired virtualization Altor Networks for $ 95 million (€70.9 million) in cash." ;
    ns1:documentTitle "News In Brief: EC, Qualcomm, Cisco, TeliaSonera, Juniper Networks, Ofcom" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/news-brief-ec-qualcomm-cisco-teliasonera-juniper-networks-ofcom> ;
    ns1:foundName "acquired" ;
    ns1:name "acquired" ;
    ns1:sourceName "Fierce Wireless" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2681334/Altor_Networks> ;
    ns1:targetName "Altor Networks" ;
    ns1:valueRaw "$ 95 million",
        "€70.9 million" .

<https://1145.am/db/2681334/Investment_Teliasonera_Asia_Holding_Teliasonera_Asia_Holding_Has_Not_Happened> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-12-07T01:00:00+00:00"^^xsd:dateTime ;
    ns1:documentExtract "TeliaSonera will spend 1.1 billion kronor (€120 million) to TeliaSonera Asia Holding - owner of Ncell in Nepal and Applifone in Cambodia - to 75.45 % from 51 %." ;
    ns1:documentTitle "News In Brief: EC, Qualcomm, Cisco, TeliaSonera, Juniper Networks, Ofcom" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/news-brief-ec-qualcomm-cisco-teliasonera-juniper-networks-ofcom> ;
    ns1:foundName "spend" ;
    ns1:name "spend" ;
    ns1:sourceName "Fierce Wireless" ;
    ns1:status "has not happened" ;
    ns1:target <https://1145.am/db/2681334/Teliasonera_Asia_Holding> ;
    ns1:targetName "TeliaSonera Asia Holding" ;
    ns1:valueRaw "1.1 billion kronor",
        "€120 million" ;
    ns1:whereGeoName "Nepal" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/1282988/about.rdf> ;
    ns1:whereRaw "Nepal" .

<https://1145.am/db/2681334/Ncell> a org:Organization ;
    ns1:basedInHighGeoName "Nepal" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/1282988/about.rdf> ;
    ns1:basedInHighRaw "Nepal" ;
    ns1:description "Nepal" ;
    ns1:documentDate "2010-12-07T01:00:00+00:00"^^xsd:dateTime ;
    ns1:documentTitle "News In Brief: EC, Qualcomm, Cisco, TeliaSonera, Juniper Networks, Ofcom" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/news-brief-ec-qualcomm-cisco-teliasonera-juniper-networks-ofcom> ;
    ns1:foundName "Ncell" ;
    ns1:name "Ncell" ;
    ns1:sameAsMedium <https://1145.am/db/2666273/Ncell>,
        <https://1145.am/db/2671804/Ncell> ;
    ns1:sourceName "Fierce Wireless" .

<https://1145.am/db/2681334/Ncell_Stake_Investment> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-12-07T01:00:00+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Sweden'swill spend 1.1 billion kronor (€120 million) to increase its stake in- owner of Ncell in Nepal and Applifone in Cambodia - to 75.45 % from 51 %.",
        "TeliaSonera will spend 1.1 billion kronor (€120 million) to TeliaSonera Asia Holding - owner of Ncell in Nepal and Applifone in Cambodia - to 75.45 % from 51 %." ;
    ns1:documentTitle "News In Brief: EC, Qualcomm, Cisco, TeliaSonera, Juniper Networks, Ofcom" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/news-brief-ec-qualcomm-cisco-teliasonera-juniper-networks-ofcom> ;
    ns1:foundName "increase" ;
    ns1:name "increase" ;
    ns1:sourceName "Fierce Wireless" ;
    ns1:status "has not happened" ;
    ns1:target <https://1145.am/db/2681334/Ncell> ;
    ns1:targetDetails "stake" ;
    ns1:targetName "Ncell" ;
    ns1:valueRaw "1.1 billion kronor",
        "€120 million" ;
    ns1:whereGeoName "Nepal" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/1282988/about.rdf> ;
    ns1:whereRaw "Nepal" .

<https://1145.am/db/2681334/Teliasonera_Asia_Holding> a org:Organization ;
    ns1:basedInLowRaw "Nepal",
        "Sweden" ;
    ns1:documentDate "2010-12-07T01:00:00+00:00"^^xsd:dateTime ;
    ns1:documentTitle "News In Brief: EC, Qualcomm, Cisco, TeliaSonera, Juniper Networks, Ofcom" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/news-brief-ec-qualcomm-cisco-teliasonera-juniper-networks-ofcom> ;
    ns1:foundName "TeliaSonera",
        "TeliaSonera Asia Holding" ;
    ns1:investor <https://1145.am/db/2681334/Investment_Teliasonera_Asia_Holding_Teliasonera_Asia_Holding_Has_Not_Happened>,
        <https://1145.am/db/2681334/Ncell_Stake_Investment> ;
    ns1:name "TeliaSonera",
        "TeliaSonera Asia Holding" ;
    ns1:sourceName "Fierce Wireless" .

<https://1145.am/db/2208806/Halfpenny_Technologies> a org:Organization ;
    ns1:basedInHighGeoName "Blue Bell" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5180961/about.rdf> ;
    ns1:basedInHighRaw "BLUE BELL" ;
    ns1:description "a company" ;
    ns1:documentDate "2010-10-07T17:00:04+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Halfpenny Technologies Secures $2.6 Million in Capital Investment" ;
    ns1:documentURL <https://www.fiercehealthcare.com/it/halfpenny-technologies-secures-2-6-million-capital-investment> ;
    ns1:foundName "Halfpenny Technologies, Inc." ;
    ns1:name "Halfpenny Technologies" ;
    ns1:sameAsHigh <https://1145.am/db/2242500/Halfpenny_Technologies> ;
    ns1:sameAsMedium <https://1145.am/db/2210975/Halfpenny_Technologies>,
        <https://1145.am/db/2215928/Halfpenny_Technologies>,
        <https://1145.am/db/2244615/Halfpenny_Technologies> ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2231462/Prospect_Medical_Holdings_Inc_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition",
        "investment" ;
    ns1:documentDate "2010-08-18T15:34:49+00:00"^^xsd:dateTime ;
    ns1:documentExtract "NEW YORK, Aug 16, 2010 (BUSINESS WIRE) - Tripp Levy PLLC is investigating the proposed acquisition of Prospect Medical Holdings, Inc. /quotes/comstock/15 *! pzz/quotes/nls/pzz (PZZ 8.50, -0.03, -0.35 %) ." ;
    ns1:documentTitle "Shareholder Update: Investigation of Acquisition of Prospect Medical by Tripp Levy PLLC" ;
    ns1:documentURL <https://www.fiercehealthcare.com/healthcare/shareholder-update-investigation-acquisition-prospect-medical-by-tripp-levy-pllc> ;
    ns1:foundName "acquired",
        "acquisition" ;
    ns1:name "acquired",
        "acquisition" ;
    ns1:sourceName "Fierce Healthcare" ;
    ns1:status "has not happened" ;
    ns1:target <https://1145.am/db/2231462/Prospect_Medical_Holdings_Inc> ;
    ns1:targetName "Prospect Medical Holdings, Inc",
        "Prospect Medical Holdings, Inc." ;
    ns1:valueRaw "$ 363 million" ;
    ns1:whereGeoName "New York City" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5128581/about.rdf> ;
    ns1:whereRaw "NEW YORK" .

<https://1145.am/db/2235296/Investment_Entrada_Entrada_Silicon_Valley_Bank_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-09-09T18:02:35+00:00"^^xsd:dateTime ;
    ns1:documentExtract "NASHVILLE, Tenn.- (BUSINESS WIRE) - Entrada, a pioneer in health information technology for clinical documentation and data exchange, has received growth financing from two new partners." ;
    ns1:documentTitle "Entrada Completes Series A Funding" ;
    ns1:documentURL <https://www.fiercehealthcare.com/healthcare/entrada-completes-series-a-funding> ;
    ns1:foundName "financing",
        "investing" ;
    ns1:name "financing",
        "investing" ;
    ns1:sourceName "Fierce Healthcare" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2235296/Entrada> ;
    ns1:valueRaw "almost $ 3 million" ;
    ns1:whereGeoName "Nashville" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/4644585/about.rdf> ;
    ns1:whereRaw "NASHVILLE, Tenn" .

<https://1145.am/db/2235312/Brim_Holdings_Businesses_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition",
        "divestment" ;
    ns1:documentDate "2010-09-10T14:02:57+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Altaris Capital Partners, the current majority owner of Brim Holdings, will retain majority ownership of Brim's hospital management contract and health technology solutions businesses through a spin-out transaction, which is scheduled to take place just prior to the closing of IASIS' acquisition of Brim Holdings.",
        "FRANKLIN, Tenn.- (BUSINESS WIRE) - IASIS Healthcare (\"IASIS\") today announced the signing of a definitive agreement to acquire Brim Holdings, Inc., which operates Wadley Regional Medical Center in Texarkana, Texas, and Pikes Peak Regional Hospital in Woodland Park, Colorado, in a cash-for-stock transaction valued at approximately $ 95 million, subject to customary closing conditions and working capital adjustments.",
        "IASIS' acquisition of Brim Holdings is expected to close no later than the fourth calendar quarter of 2010." ;
    ns1:documentTitle "IASIS Healthcare to Acquire Brim Holdings, Inc." ;
    ns1:documentURL <https://www.fiercehealthcare.com/healthcare/iasis-healthcare-to-acquire-brim-holdings-inc> ;
    ns1:foundName "acquire",
        "acquisition",
        "spin-out" ;
    ns1:name "acquire",
        "acquisition",
        "spin-out" ;
    ns1:sourceName "Fierce Healthcare" ;
    ns1:status "has not happened" ;
    ns1:target <https://1145.am/db/2235312/Brim_Holdings> ;
    ns1:targetDetails "businesses" ;
    ns1:targetName "Brim Holdings" ;
    ns1:valueRaw "approximately $ 95 million" ;
    ns1:whereGeoName "Texarkana" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/4736096/about.rdf> ;
    ns1:whereRaw "Texarkana, Texas" .

<https://1145.am/db/2242173/Battle_Creek_Health_System_Share_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition",
        "investment" ;
    ns1:documentDate "2010-12-15T17:57:28+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Bronson will buy 51 percent of Battle Creek by buying the 50 percent share from Trinity Health of Novi, Mich., and 1 percent of the BCHS Community Partner holdings." ;
    ns1:documentTitle "Merger will create new Michigan healthcare system" ;
    ns1:documentURL <https://www.fiercehealthcare.com/healthcare/merger-will-create-new-michigan-healthcare-system> ;
    ns1:foundName "buy",
        "buying" ;
    ns1:name "buy",
        "buying" ;
    ns1:sourceName "Fierce Healthcare" ;
    ns1:status "has not happened" ;
    ns1:target <https://1145.am/db/2242173/Battle_Creek_Health_System>,
        <https://1145.am/db/2242173/Trinity_Health> ;
    ns1:targetDetails "share" ;
    ns1:targetName "Battle Creek" ;
    ns1:vendor <https://1145.am/db/2242173/Trinity_Health> ;
    ns1:whereGeoName "Michigan" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5001836/about.rdf> ;
    ns1:whereRaw "Michigan" .

<https://1145.am/db/2242173/Stake_Merger_Battle_Creek_Health_System_Bronson_Healthcare_Group_Has_Not_Happened> a ns1:CorporateFinanceActivity ;
    ns1:activityType "merger" ;
    ns1:documentDate "2010-12-15T17:57:28+00:00"^^xsd:dateTime ;
    ns1:documentExtract "After nearly 18 months at the negotiating table, Battle Creek Health System in Michigan announced it will create a new regional healthcare system with Kalamazoo - based Bronson Healthcare Group, which will hold a majority stake." ;
    ns1:documentTitle "Merger will create new Michigan healthcare system" ;
    ns1:documentURL <https://www.fiercehealthcare.com/healthcare/merger-will-create-new-michigan-healthcare-system> ;
    ns1:foundName "create" ;
    ns1:name "create" ;
    ns1:sourceName "Fierce Healthcare" ;
    ns1:status "has not happened" ;
    ns1:targetDetails "stake" ;
    ns1:whereGeoName "Michigan" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5001836/about.rdf> ;
    ns1:whereRaw "Michigan" .

<https://1145.am/db/2242500/Halfpenny_Technologies> a org:Organization ;
    ns1:basedInHighGeoName "Blue Bell" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5180961/about.rdf> ;
    ns1:basedInHighRaw "BLUE BELL" ;
    ns1:description "a company" ;
    ns1:documentDate "2010-10-07T17:02:42+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Halfpenny Technologies Secures $2.6 Million in Capital Investment" ;
    ns1:documentURL <https://www.fiercehealthcare.com/healthcare/halfpenny-technologies-secures-2-6-million-capital-investment> ;
    ns1:foundName "Halfpenny Technologies, Inc." ;
    ns1:name "Halfpenny Technologies" ;
    ns1:sameAsHigh <https://1145.am/db/2208806/Halfpenny_Technologies> ;
    ns1:sameAsMedium <https://1145.am/db/2210975/Halfpenny_Technologies>,
        <https://1145.am/db/2215928/Halfpenny_Technologies>,
        <https://1145.am/db/2244615/Halfpenny_Technologies> ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2341003/New_Leaf_Venture_Partners> a org:Organization ;
    ns1:basedInLowRaw "Calif" ;
    ns1:documentDate "2010-10-19T14:00:23+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Pearl Therapeutics Raises $69 Million Series C Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/pearl-therapeutics-raises-69-million-series-c-financing> ;
    ns1:foundName "New Leaf Venture Partners" ;
    ns1:investor <https://1145.am/db/2341003/Series_C_Investment_5am_Ventures_Clarus_Ventures_New_Leaf_Venture_Partners_Pearl_Therapeutics_Inc_Vatera_Healthcare_Partners_Completed> ;
    ns1:name "New Leaf Venture Partners" ;
    ns1:sameAsMedium <https://1145.am/db/1287338/New_Leaf_Venture_Partners>,
        <https://1145.am/db/1749104/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2151983/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2155668/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2208603/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2289585/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2293765/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2298642/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2300322/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2301824/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2301828/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2305507/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2305514/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2307682/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2311595/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2312792/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2315071/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2315932/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2315934/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2316674/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2317919/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2318656/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2318657/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2325326/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2325398/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2334479/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2334797/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2342925/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2342937/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2343298/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2345037/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2345047/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2346532/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2346542/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2347043/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2347571/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2347876/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2347878/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2348149/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2348618/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2349120/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2350164/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2350167/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2350491/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2352059/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2357356/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2359683/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2360174/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2361416/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2362736/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2362737/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2366860/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2569522/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2594141/New_Leaf_Venture_Partners>,
        <https://1145.am/db/425953/New_Leaf_Venture_Partners>,
        <https://1145.am/db/583528/New_Leaf_Venture_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2342488/Cara_Therapeutics> a org:Organization ;
    ns1:description "Pharmaceuticals" ;
    ns1:documentDate "2010-07-21T12:57:52+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Cara Therapeutics Secures $15 Million Series D Financing to Continue Clinical Development of CR845" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cara-therapeutics-secures-15-million-series-d-financing-to-continue-clinical-development-0> ;
    ns1:foundName "Cara Therapeutics",
        "Cara Therapeutics, Inc." ;
    ns1:industry "Pharmaceutical" ;
    ns1:name "Cara Therapeutics" ;
    ns1:sameAsHigh <https://1145.am/db/2154851/Caraway_Therapeutics>,
        <https://1145.am/db/2303810/Cara_Therapeutics>,
        <https://1145.am/db/2303814/Cara_Therapeutics>,
        <https://1145.am/db/2310020/Cara_Therapeutics>,
        <https://1145.am/db/2310031/Cara_Therapeutics>,
        <https://1145.am/db/2324354/Cara_Therapeutics>,
        <https://1145.am/db/2325376/Cara_Therapeutics>,
        <https://1145.am/db/2342498/Cara_Therapeutics>,
        <https://1145.am/db/2343561/Cara_Therapeutics> ;
    ns1:sameAsMedium <https://1145.am/db/2342485/Cara_Therapeutics> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2342498/Cara_Therapeutics> a org:Organization ;
    ns1:description "Pharmaceuticals" ;
    ns1:documentDate "2010-07-21T15:31:17+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Cara Therapeutics Secures $15 Million Series D Financing to Continue Clinical Development of CR845" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cara-therapeutics-secures-15-million-series-d-financing-to-continue-clinical-development-of> ;
    ns1:foundName "Cara Therapeutics",
        "Cara Therapeutics, Inc." ;
    ns1:industry "Pharmaceutical" ;
    ns1:name "Cara Therapeutics" ;
    ns1:sameAsHigh <https://1145.am/db/2154851/Caraway_Therapeutics>,
        <https://1145.am/db/2303810/Cara_Therapeutics>,
        <https://1145.am/db/2303814/Cara_Therapeutics>,
        <https://1145.am/db/2310020/Cara_Therapeutics>,
        <https://1145.am/db/2310031/Cara_Therapeutics>,
        <https://1145.am/db/2324354/Cara_Therapeutics>,
        <https://1145.am/db/2325376/Cara_Therapeutics>,
        <https://1145.am/db/2342488/Cara_Therapeutics>,
        <https://1145.am/db/2343561/Cara_Therapeutics> ;
    ns1:sameAsMedium <https://1145.am/db/2342485/Cara_Therapeutics> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2343545/Cerenis_Therapeutics_Sa> a org:Organization ;
    ns1:basedInHighGeoName "Republic of France" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/3017382/about.rdf> ;
    ns1:basedInHighRaw "France" ;
    ns1:basedInLowRaw "France" ;
    ns1:description "research and development of novel therapies based on the metabolism of HDL" ;
    ns1:documentDate "2010-07-26T13:03:59+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Cerenis Therapeutics raises EUR 40 million in series C financingJean-Pierre Garnier appointed as non-executive director to the" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cerenis-therapeutics-raises-eur-40-million-series-c-financingjean-pierre-garnier-appointed> ;
    ns1:foundName "Cerenis Therapeutics",
        "Cerenis Therapeutics SA" ;
    ns1:industry "biopharmaceutical" ;
    ns1:name "Cerenis Therapeutics",
        "Cerenis Therapeutics SA" ;
    ns1:sameAsHigh <https://1145.am/db/2319672/Ception_Therapeutics>,
        <https://1145.am/db/2321967/Ception_Therapeutics>,
        <https://1145.am/db/2321976/Ception_Therapeutics>,
        <https://1145.am/db/2333573/Ception_Therapeutics>,
        <https://1145.am/db/2333577/Ception_Therapeutics>,
        <https://1145.am/db/2341874/Celtaxsys>,
        <https://1145.am/db/2342041/Cerenis_Therapeutics>,
        <https://1145.am/db/2350780/Cenerx_Biopharma_Inc>,
        <https://1145.am/db/2355679/Cerus_Corporation>,
        <https://1145.am/db/2361506/Celsus_Therapeutics>,
        <https://1145.am/db/2539913/Cenerx_Biopharma>,
        <https://1145.am/db/730643/Cincor_Pharma>,
        <https://1145.am/db/741322/Cincor_Pharma> ;
    ns1:sameAsMedium <https://1145.am/db/2323243/Cerenis_Therapeutics>,
        <https://1145.am/db/2329568/Cerenis_Therapeutics>,
        <https://1145.am/db/2329570/Cerenis_Therapeutics_Sa>,
        <https://1145.am/db/2337658/Cerenis_Therapeutics>,
        <https://1145.am/db/2343534/Cerenis_Therapeutics> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2344565/Tethys_Bioscience> a org:Organization ;
    ns1:basedInHighGeoName "Emeryville" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5346462/about.rdf> ;
    ns1:basedInHighRaw "EMERYVILLE, CALIF." ;
    ns1:description "a privately held company" ;
    ns1:documentDate "2010-07-27T18:54:24+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Tethys Raises $33 Million" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/tethys-raises-33-million-0> ;
    ns1:foundName "Tethys Bioscience, Inc." ;
    ns1:name "Tethys Bioscience" ;
    ns1:sameAsMedium <https://1145.am/db/2311733/Tethys_Bioscience>,
        <https://1145.am/db/2326926/Tethys_Bioscience>,
        <https://1145.am/db/2326935/Tethys_Bioscience>,
        <https://1145.am/db/2345549/Tethys_Bioscience> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2345142/Investment_Flemish_Agency_Galapagos_Nv_Innovation_By_Science_And_Technology_Has_Not_Happened> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-10-28T13:25:17+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Galapagos NV (GLPG.BR) Receives EUR 3.7 Million ($ 5.1 Million) Grant For Cystic Fibrosis Program.",
        "MECHELEN, BELGIUM- (Marketwire - October 28, 2010) - Galapagos NV (Euronext: GLPG) announces today that it has been awarded a EUR3.7 million grant from the Flemish agency for Innovation by Science and Technology (IWT) ." ;
    ns1:documentTitle "Galapagos NV (GLPG.BR) Receives EUR 3.7 Million ($5.1 Million) Grant For Cystic Fibrosis Program" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/galapagos-nv-glpg-br-receives-eur-3-7-million-5-1-million-grant-for-cystic-fibrosis-program> ;
    ns1:foundName "grant" ;
    ns1:name "grant" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "has not happened" ;
    ns1:target <https://1145.am/db/2345142/Galapagos_Nv> ;
    ns1:valueRaw "$ 5.1 Million",
        "EUR 3.7 Million",
        "EUR3.7 million" ;
    ns1:whereGeoName "Federative Republic of Brazil" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/3469034/about.rdf> ;
    ns1:whereRaw "Brazil" .

<https://1145.am/db/2345549/Tethys_Bioscience> a org:Organization ;
    ns1:basedInHighGeoName "Emeryville" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5346462/about.rdf> ;
    ns1:basedInHighRaw "EMERYVILLE, CALIF." ;
    ns1:basedInLowRaw "United States" ;
    ns1:description "Bioscience" ;
    ns1:documentDate "2010-07-28T14:41:46+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Tethys Raises $33 Million" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/tethys-raises-33-million> ;
    ns1:foundName "Tethys",
        "Tethys Bioscience, Inc." ;
    ns1:name "Tethys",
        "Tethys Bioscience" ;
    ns1:sameAsHigh <https://1145.am/db/2326926/Tethys_Bioscience> ;
    ns1:sameAsMedium <https://1145.am/db/2311733/Tethys_Bioscience>,
        <https://1145.am/db/2326935/Tethys_Bioscience>,
        <https://1145.am/db/2344565/Tethys_Bioscience> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2345549/Working_Capital_Loan_Investment_Greenspring_Associates_Inc_Paul_Capital_Investments_Tethys_Bioscience_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-07-28T14:41:46+00:00"^^xsd:dateTime ;
    ns1:documentExtract "2010-Jul-22 - EMERYVILLE, CALIF., - July 21, 2010 - Tethys Bioscience, Inc., a privately held company, announced today that the company has recently raised $ 33 million, comprising $ 23 million of venture financing and a $ 10 million working capital loan.",
        "Tethys Raises $ 33 Million." ;
    ns1:documentTitle "Tethys Raises $33 Million" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/tethys-raises-33-million> ;
    ns1:foundName "Raises",
        "financing",
        "raised" ;
    ns1:name "Raises",
        "financing",
        "raised" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2345549/Tethys_Bioscience> ;
    ns1:targetDetails "venture",
        "working capital loan" ;
    ns1:valueRaw "$ 10 million",
        "$ 23 million",
        "$ 33 Million",
        "$ 33 million" ;
    ns1:when "2010-07-22T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "2010-Jul-22" ;
    ns1:whereGeoName "California" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5332921/about.rdf> ;
    ns1:whereRaw "CALIF" .

<https://1145.am/db/2346187/Investment_Allon_Therapeutics_Inc_Allon_Therapeutics_Inc_Isar_Pharma_K_S_Nordic_Biotech_Venture_Fund_Ii_K_S_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-11-01T15:06:01+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Isar Pharma K/S, has paid Allon U.S. $ 10 million (Cdn $ 10.2 million) in return for a convertible royalty and revenue obligation on davunetide.",
        "VANCOUVER, BRITISH COLUMBIA, Nov 01, 2010 (MARKETWIRE via COMTEX) - Allon Therapeutics Inc. announced today it has closed a financing agreement with Isar Pharma K/S (\"Isar\") , a wholly owned limited partnership of Nordic Biotech Venture Fund II K/S under which Allon has received U.S. $ 10 million to advance davunetide, Allon's lead neuroprotective drug candidate." ;
    ns1:documentTitle "Allon Completes U.S. $10 Million Financing Agreement with Nordic Biotech Entity" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/allon-completes-u-s-10-million-financing-agreement-nordic-biotech-entity> ;
    ns1:foundName "financing" ;
    ns1:name "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2346187/Allon_Therapeutics_Inc> ;
    ns1:valueRaw "$ 10 million",
        "Cdn $ 10.2 million",
        "U.S. $ 10 million" ;
    ns1:when "2010-11-01T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "Nov 01, 2010" ;
    ns1:whereGeoName "Vancouver" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6173331/about.rdf> ;
    ns1:whereRaw "VANCOUVER, BRITISH COLUMBIA" .

<https://1145.am/db/2347626/Sangon_Biotech> a org:Organization ;
    ns1:basedInHighGeoName "Shanghai" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/1796236/about.rdf> ;
    ns1:basedInHighRaw "Shanghai" ;
    ns1:description "Life science research" ;
    ns1:documentDate "2010-08-03T15:43:54+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Sangon & Bio Basic Inc. Closes $10 Million Round of Investment by Qiming Ventures" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/sangon-bio-basic-inc-closes-10-million-round-of-investment-by-qiming-ventures> ;
    ns1:foundName "Sangon Biotech" ;
    ns1:industry "life science research" ;
    ns1:name "Sangon Biotech" ;
    ns1:sameAsHigh <https://1145.am/db/2284827/Sangon_Biotech>,
        <https://1145.am/db/2347626/Sangon___Bio_Basic_Inc> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2347626/Sangon___Bio_Basic_Inc> a org:Organization ;
    ns1:basedInHighGeoName "Toronto" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/6167865/about.rdf> ;
    ns1:basedInHighRaw "Toronto" ;
    ns1:basedInLowRaw "China" ;
    ns1:description "Life science research" ;
    ns1:documentDate "2010-08-03T15:43:54+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Sangon & Bio Basic Inc. Closes $10 Million Round of Investment by Qiming Ventures" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/sangon-bio-basic-inc-closes-10-million-round-of-investment-by-qiming-ventures> ;
    ns1:foundName "Bio Basic Inc",
        "Sangon & Bio Basic Inc." ;
    ns1:industry "Life science research" ;
    ns1:name "Bio Basic Inc",
        "Sangon & Bio Basic Inc." ;
    ns1:sameAsHigh <https://1145.am/db/2284827/Sangon_Biotech>,
        <https://1145.am/db/2347626/Sangon_Biotech> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2348232/Portfolio_Acquisition_Gedeon_Richter_Plc_Richter_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition" ;
    ns1:documentDate "2010-11-03T14:33:44+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Gedeon Richter Plc (\"Richter\") today announces the Acquisition of Grünenthal GmbH's (\"Grünenthal\") oral contraceptive (OC) portfolio.",
        "Richter has purchased Grünenthal's OC business, including distribution and marketing rights in all markets worldwide where registration approvals have been granted." ;
    ns1:documentTitle "Richter Acquires Grünenthal's Oral Contraceptive Portfolio" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/richter-acquires-gr%C3%BCnenthal-s-oral-contraceptive-portfolio> ;
    ns1:foundName "Acquisition",
        "purchased" ;
    ns1:name "Acquisition",
        "purchased" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:targetDetails "business",
        "portfolio" ;
    ns1:valueRaw "EUR 236.5 million" ;
    ns1:vendor <https://1145.am/db/2348232/Richter> ;
    ns1:whereGeoName "Federal Republic of Germany" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/2921044/about.rdf> ;
    ns1:whereRaw "Germany" .

<https://1145.am/db/2348232/Richter> a org:Organization ;
    ns1:basedInHighGeoName "Federal Republic of Germany" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2921044/about.rdf> ;
    ns1:basedInHighRaw "Germany" ;
    ns1:buyer <https://1145.am/db/2348232/Portfolio_Acquisition_Gedeon_Richter_Plc_Richter_Completed>,
        <https://1145.am/db/2348232/Portfolio_Acquisition_Richter_Richter_Completed> ;
    ns1:description "pharmaceutical company",
        "sales and marketing" ;
    ns1:documentDate "2010-11-03T14:33:44+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Richter Acquires Grünenthal's Oral Contraceptive Portfolio" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/richter-acquires-gr%C3%BCnenthal-s-oral-contraceptive-portfolio> ;
    ns1:foundName "Grünenthal",
        "Grünenthal GmbH",
        "Richter" ;
    ns1:industry "pharmaceutical" ;
    ns1:name "Grünenthal",
        "Richter" ;
    ns1:sameAsHigh <https://1145.am/db/1204975/Gruenenthal>,
        <https://1145.am/db/1205186/Grünenthal>,
        <https://1145.am/db/2289865/Grünenthal>,
        <https://1145.am/db/2289873/Grünenthal>,
        <https://1145.am/db/2320482/Grunenthal_Gmbh>,
        <https://1145.am/db/2320527/Grünenthal_Group>,
        <https://1145.am/db/2359025/Grunenthal_Gmbh>,
        <https://1145.am/db/2363553/Agilux>,
        <https://1145.am/db/2367971/Grünenthal>,
        <https://1145.am/db/2367972/Grünenthal>,
        <https://1145.am/db/2541810/Grünenthal>,
        <https://1145.am/db/2544607/Grünenthal>,
        <https://1145.am/db/2547336/Grünenthal>,
        <https://1145.am/db/2547676/Grunenthal>,
        <https://1145.am/db/2550480/Gerresheimer_Ag>,
        <https://1145.am/db/2550484/Gerresheimer>,
        <https://1145.am/db/2561166/Gerresheimer>,
        <https://1145.am/db/2574825/Grünenthal_Group> ;
    ns1:sameAsMedium <https://1145.am/db/2596684/Grunenthal> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2348674/Series_E_Investment_Caxton_Advantage_Life_Sciences_Fund_Of_New_York_Gemin_X_Pharmaceuticals_Sanderling_Venture_Partners_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-08-05T15:28:11+00:00"^^xsd:dateTime ;
    ns1:documentExtract "> Gemin X Pharmaceuticals has raised $ 8 million in a Series E, which is earmarked to back its work on new cancer therapies." ;
    ns1:documentTitle "Gemin X raises $8M for cancer R&D; Bruce Montgomery ready to open a new chapter in biotech career;" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/gemin-x-raises-8m-for-cancer-r-d-bruce-montgomery-ready-to-open-a-new-chapter-biotech> ;
    ns1:foundName "raised" ;
    ns1:name "raised" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2348674/Gemin_X_Pharmaceuticals> ;
    ns1:targetDetails "Series E" ;
    ns1:valueRaw "$ 8 million" ;
    ns1:whereGeoName "New York City" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5128581/about.rdf> ;
    ns1:whereRaw "New York" .

<https://1145.am/db/2349717/Amgen_Ventures> a org:Organization ;
    ns1:basedInLowRaw "Pa" ;
    ns1:description "financing" ;
    ns1:documentDate "2010-08-10T15:41:02+00:00"^^xsd:dateTime ;
    ns1:documentTitle "TetraLogic Pharmaceuticals Completes $32 Million Series C Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/tetralogic-pharmaceuticals-completes-32-million-series-c-financing> ;
    ns1:foundName "Amgen Ventures" ;
    ns1:investor <https://1145.am/db/2349717/Series_C_Investment_Amgen_Ventures_Clarus_Ventures_Hatteras_Venture_Partners_Healthcare_Ventures_Latterell_Venture_Partners_Novitas_Capital_Quaker_Bioventures_Tetralogic_Pharmaceuticals_Vertical_Group_Completed> ;
    ns1:name "Amgen Ventures" ;
    ns1:sameAsHigh <https://1145.am/db/1065608/Amgen_Ventures>,
        <https://1145.am/db/1066448/Amgen_Ventures>,
        <https://1145.am/db/1168715/Amgen_Ventures>,
        <https://1145.am/db/1169697/Amgen_Ventures>,
        <https://1145.am/db/1503058/Amgen_Ventures>,
        <https://1145.am/db/2141183/Amgen_Ventures>,
        <https://1145.am/db/2197183/Amgen_Ventures>,
        <https://1145.am/db/2352203/Amgen_Ventures>,
        <https://1145.am/db/2352204/Amgen_Ventures>,
        <https://1145.am/db/2352350/Amgen_Ventures>,
        <https://1145.am/db/2353439/Amgen_Ventures>,
        <https://1145.am/db/2366693/Amgen_Ventures>,
        <https://1145.am/db/2366700/Amgen_Ventures>,
        <https://1145.am/db/2367740/Amgen_Ventures>,
        <https://1145.am/db/874503/Amgen_Ventures> ;
    ns1:sameAsMedium <https://1145.am/db/1018050/Amgen_Ventures>,
        <https://1145.am/db/1115103/Amgen_Ventures>,
        <https://1145.am/db/1116076/Amgen_Ventures>,
        <https://1145.am/db/1219346/Amgen_Ventures>,
        <https://1145.am/db/1219817/Amgen_Ventures>,
        <https://1145.am/db/1422234/Amgen_Ventures>,
        <https://1145.am/db/1422725/Amgen_Ventures>,
        <https://1145.am/db/2152096/Amgen_Ventures>,
        <https://1145.am/db/2280119/Amgen_Ventures>,
        <https://1145.am/db/2280896/Amgen_Ventures>,
        <https://1145.am/db/2284256/Amgen_Ventures>,
        <https://1145.am/db/2298167/Amgen_Ventures>,
        <https://1145.am/db/2315446/Amgen_Ventures>,
        <https://1145.am/db/2318635/Amgen_Ventures>,
        <https://1145.am/db/2320476/Amgen_Ventures>,
        <https://1145.am/db/2342629/Amgen_Ventures>,
        <https://1145.am/db/2344782/Amgen_Ventures>,
        <https://1145.am/db/2344926/Amgen_Ventures>,
        <https://1145.am/db/2345223/Amgen_Ventures>,
        <https://1145.am/db/2347469/Amgen_Ventures>,
        <https://1145.am/db/2349722/Amgen_Ventures>,
        <https://1145.am/db/2352216/Amgen_Ventures>,
        <https://1145.am/db/2352349/Amgen_Ventures>,
        <https://1145.am/db/2353524/Amgen_Ventures>,
        <https://1145.am/db/2353525/Amgen_Ventures>,
        <https://1145.am/db/2355586/Amgen_Ventures>,
        <https://1145.am/db/2356048/Amgen_Ventures>,
        <https://1145.am/db/2365138/Amgen_Ventures>,
        <https://1145.am/db/2365171/Amgen_Ventures>,
        <https://1145.am/db/2569831/Amgen_Ventures>,
        <https://1145.am/db/2570481/Amgen_Ventures>,
        <https://1145.am/db/2570483/Amgen_Ventures>,
        <https://1145.am/db/770366/Amgen_Ventures>,
        <https://1145.am/db/919784/Amgen_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2349717/Quaker_Bioventures> a org:Organization ;
    ns1:basedInLowRaw "Pa" ;
    ns1:description "Investing" ;
    ns1:documentDate "2010-08-10T15:41:02+00:00"^^xsd:dateTime ;
    ns1:documentTitle "TetraLogic Pharmaceuticals Completes $32 Million Series C Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/tetralogic-pharmaceuticals-completes-32-million-series-c-financing> ;
    ns1:foundName "Quaker BioVentures" ;
    ns1:investor <https://1145.am/db/2349717/Series_C_Investment_Amgen_Ventures_Clarus_Ventures_Hatteras_Venture_Partners_Healthcare_Ventures_Latterell_Venture_Partners_Novitas_Capital_Quaker_Bioventures_Tetralogic_Pharmaceuticals_Vertical_Group_Completed> ;
    ns1:name "Quaker BioVentures" ;
    ns1:sameAsHigh <https://1145.am/db/2302192/Quaker_Bioventures>,
        <https://1145.am/db/2309809/Quaker_Bioventures>,
        <https://1145.am/db/2312792/Quaker_Bioventures>,
        <https://1145.am/db/2320853/Quaker_Bioventures>,
        <https://1145.am/db/2332631/Quaker_Bioventures>,
        <https://1145.am/db/2340429/Quaker_Bioventures>,
        <https://1145.am/db/2365171/Quaker_Bioventures> ;
    ns1:sameAsMedium <https://1145.am/db/2217039/Quaker_Bioventures>,
        <https://1145.am/db/2291872/Quaker_Bioventures>,
        <https://1145.am/db/2303458/Quaker_Bioventures>,
        <https://1145.am/db/2303641/Quaker_Bioventures>,
        <https://1145.am/db/2303642/Quaker_Bioventures>,
        <https://1145.am/db/2305610/Quaker_Bioventures>,
        <https://1145.am/db/2305615/Quaker_Bioventures>,
        <https://1145.am/db/2305625/Quaker_Bioventures>,
        <https://1145.am/db/2310123/Quaker_Bioventures>,
        <https://1145.am/db/2311099/Quaker_Bioventures>,
        <https://1145.am/db/2317849/Quaker_Bioventures>,
        <https://1145.am/db/2317961/Quaker_Bioventures>,
        <https://1145.am/db/2319360/Quaker_Bioventures>,
        <https://1145.am/db/2320852/Quaker_Bioventures>,
        <https://1145.am/db/2330549/Quaker_Bioventures>,
        <https://1145.am/db/2332021/Quaker_Bioventures>,
        <https://1145.am/db/2332626/Quaker_Bioventures>,
        <https://1145.am/db/2340423/Quaker_Bioventures>,
        <https://1145.am/db/2349722/Quaker_Bioventures>,
        <https://1145.am/db/2352808/Quaker_Bioventures>,
        <https://1145.am/db/2355936/Quaker_Bioventures>,
        <https://1145.am/db/2355938/Quaker_Bioventures>,
        <https://1145.am/db/2363464/Quaker_Bioventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2349717/Tetralogic_Pharmaceuticals> a org:Organization ;
    ns1:description "Pharmaceuticals" ;
    ns1:documentDate "2010-08-10T15:41:02+00:00"^^xsd:dateTime ;
    ns1:documentTitle "TetraLogic Pharmaceuticals Completes $32 Million Series C Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/tetralogic-pharmaceuticals-completes-32-million-series-c-financing> ;
    ns1:foundName "TetraLogic Pharmaceuticals" ;
    ns1:industry "Pharmaceuticals" ;
    ns1:name "TetraLogic Pharmaceuticals" ;
    ns1:sameAsHigh <https://1145.am/db/2070596/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2308022/Tetralogic_Pharmaceuticals>,
        <https://1145.am/db/2311219/Tekmira_Pharmaceuticals>,
        <https://1145.am/db/2314563/Tekmira_Pharmaceuticals>,
        <https://1145.am/db/2319925/Tekmira_Pharmaceuticals_Corporation>,
        <https://1145.am/db/2323263/Teva_Europe>,
        <https://1145.am/db/2339763/Teva_Pharmaceutical>,
        <https://1145.am/db/2349722/Tetralogic_Pharmaceuticals>,
        <https://1145.am/db/2349999/Tetraphase_Pharmaceuticals_Inc>,
        <https://1145.am/db/2357275/Tetraphase_Pharmaceuticals>,
        <https://1145.am/db/2358420/Tekmira_Pharmaceuticals>,
        <https://1145.am/db/2365171/Tetralogic_Pharmaceuticals>,
        <https://1145.am/db/2368702/Teva>,
        <https://1145.am/db/2567583/Teva_Pharmaceuticals>,
        <https://1145.am/db/2578498/Teva_Pharmaceutical_Industries_Sanofi-Aventis>,
        <https://1145.am/db/2594786/Tekmira_Pharmaceuticals_Corporation>,
        <https://1145.am/db/2594787/Tekmira_Pharmaceuticals> ;
    ns1:sameAsMedium <https://1145.am/db/2346197/Tetralogic_Pharmaceuticals>,
        <https://1145.am/db/2346213/Tetralogic_Pharmaceuticals>,
        <https://1145.am/db/2346948/Tetralogic_Pharmaceuticals>,
        <https://1145.am/db/2352302/Tetralogic_Pharmaceuticals_Corporation>,
        <https://1145.am/db/2366291/Tetralogic_Pharmaceuticals> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2350780/Cenerx_Biopharma_Inc> a org:Organization ;
    ns1:basedInHighGeoName "North Carolina",
        "Park County",
        "Research",
        "Triangle" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2151718/about.rdf>,
        <https://sws.geonames.org/4482348/about.rdf>,
        <https://sws.geonames.org/4790025/about.rdf>,
        <https://sws.geonames.org/5834587/about.rdf> ;
    ns1:basedInHighRaw "RESEARCH TRIANGLE PARK, N.C." ;
    ns1:description "developing and commercializing innovative treatments for diseases of the central nervous system" ;
    ns1:documentDate "2010-08-13T13:29:08+00:00"^^xsd:dateTime ;
    ns1:documentTitle "CeNeRx BioPharma Completes $13 Million Series C Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cenerx-biopharma-completes-13-million-series-c-financing> ;
    ns1:foundName "CeNeRx BioPharma",
        "CeNeRx BioPharma, Inc." ;
    ns1:industry "Biopharmaceutical",
        "Pharmaceutical" ;
    ns1:name "CeNeRx BioPharma",
        "CeNeRx BioPharma, Inc." ;
    ns1:sameAsHigh <https://1145.am/db/2319672/Ception_Therapeutics>,
        <https://1145.am/db/2321967/Ception_Therapeutics>,
        <https://1145.am/db/2321976/Ception_Therapeutics>,
        <https://1145.am/db/2333573/Ception_Therapeutics>,
        <https://1145.am/db/2333577/Ception_Therapeutics>,
        <https://1145.am/db/2341874/Celtaxsys>,
        <https://1145.am/db/2342041/Cerenis_Therapeutics>,
        <https://1145.am/db/2343545/Cerenis_Therapeutics_Sa>,
        <https://1145.am/db/2355679/Cerus_Corporation>,
        <https://1145.am/db/2361506/Celsus_Therapeutics>,
        <https://1145.am/db/2539913/Cenerx_Biopharma>,
        <https://1145.am/db/730643/Cincor_Pharma>,
        <https://1145.am/db/741322/Cincor_Pharma> ;
    ns1:sameAsMedium <https://1145.am/db/2303294/Cenerx_Biopharma>,
        <https://1145.am/db/2314637/Cenerx_Biopharma>,
        <https://1145.am/db/2328388/Cenerx_Biopharma>,
        <https://1145.am/db/2332753/Cenerx_Biopharma>,
        <https://1145.am/db/2350779/Cenerx_Biopharma> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2350780/Pappas_Ventures> a org:Organization ;
    ns1:basedInLowRaw "N.C." ;
    ns1:documentDate "2010-08-13T13:29:08+00:00"^^xsd:dateTime ;
    ns1:documentTitle "CeNeRx BioPharma Completes $13 Million Series C Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cenerx-biopharma-completes-13-million-series-c-financing> ;
    ns1:foundName "Pappas Ventures" ;
    ns1:investor <https://1145.am/db/2350780/Series_C_Investment_Cenerx_Biopharma_Inc_L_Capital_Partners_Pappas_Ventures_Perseus_Soros_Biopharmaceutical_Fund_Completed> ;
    ns1:name "Pappas Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/2289229/Pappas_Ventures>,
        <https://1145.am/db/2305706/Pappas_Ventures>,
        <https://1145.am/db/2305713/Pappas_Ventures>,
        <https://1145.am/db/2308329/Pappas_Ventures>,
        <https://1145.am/db/2312277/Pappas_Ventures>,
        <https://1145.am/db/2312288/Pappas_Ventures>,
        <https://1145.am/db/2314397/Pappas_Ventures>,
        <https://1145.am/db/2314400/Pappas_Ventures>,
        <https://1145.am/db/2314492/Pappas_Ventures>,
        <https://1145.am/db/2319029/Pappas_Ventures>,
        <https://1145.am/db/2324289/Pappas_Ventures>,
        <https://1145.am/db/2328388/Pappas_Ventures>,
        <https://1145.am/db/2332753/Pappas_Ventures>,
        <https://1145.am/db/2341904/Pappas_Ventures>,
        <https://1145.am/db/2346532/Pappas_Ventures>,
        <https://1145.am/db/2346542/Pappas_Ventures>,
        <https://1145.am/db/2350779/Pappas_Ventures>,
        <https://1145.am/db/2352805/Pappas_Ventures>,
        <https://1145.am/db/2352808/Pappas_Ventures>,
        <https://1145.am/db/2354537/Pappas_Ventures>,
        <https://1145.am/db/2354540/Pappas_Ventures>,
        <https://1145.am/db/2355274/Pappas_Ventures>,
        <https://1145.am/db/2356216/Pappas_Ventures>,
        <https://1145.am/db/2359562/Pappas_Ventures>,
        <https://1145.am/db/2539913/Pappas_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2350800/Aryx> a org:Organization ;
    ns1:basedInHighGeoName "Fremont" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5350734/about.rdf> ;
    ns1:basedInHighRaw "FREMONT, Calif" ;
    ns1:description "pharmaceuticals" ;
    ns1:documentDate "2010-08-16T15:22:55+00:00"^^xsd:dateTime ;
    ns1:documentTitle "ARYx Therapeutics Secures Interim Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/aryx-therapeutics-secures-interim-financing> ;
    ns1:foundName "ARYx",
        "ARYx Therapeutics, Inc" ;
    ns1:name "ARYx" ;
    ns1:sameAsHigh <https://1145.am/db/1443334/Alcon>,
        <https://1145.am/db/1633105/Amryt>,
        <https://1145.am/db/1633172/Amryt>,
        <https://1145.am/db/1645224/Amryt>,
        <https://1145.am/db/1683116/Amryt>,
        <https://1145.am/db/1975641/Aditxt>,
        <https://1145.am/db/2303588/Innocoll_Inc>,
        <https://1145.am/db/2306705/Aryx>,
        <https://1145.am/db/2306946/Amatsigroup>,
        <https://1145.am/db/2313223/Accera>,
        <https://1145.am/db/2323188/Alcon>,
        <https://1145.am/db/2337999/Akorn>,
        <https://1145.am/db/2340926/Innocoll>,
        <https://1145.am/db/2341615/Forma>,
        <https://1145.am/db/2342626/Affinivax_Inc>,
        <https://1145.am/db/2537618/Adare_Pharmaceuticals>,
        <https://1145.am/db/2546317/Akorn>,
        <https://1145.am/db/2549982/Aimmune>,
        <https://1145.am/db/2553835/Impax>,
        <https://1145.am/db/2559177/Impax>,
        <https://1145.am/db/2559178/Impax>,
        <https://1145.am/db/2560987/Admedus>,
        <https://1145.am/db/2569024/Akorn_Inc>,
        <https://1145.am/db/2569509/Adare_Pharmaceuticals>,
        <https://1145.am/db/2572248/Agila_Specialties>,
        <https://1145.am/db/2581397/Alcon>,
        <https://1145.am/db/2584185/Impax>,
        <https://1145.am/db/2584538/Aduro>,
        <https://1145.am/db/2588918/Akorn>,
        <https://1145.am/db/2597135/Alcon>,
        <https://1145.am/db/566598/Acino> ;
    ns1:sameAsMedium <https://1145.am/db/2305656/Aryx>,
        <https://1145.am/db/2350788/Aryx>,
        <https://1145.am/db/2351796/Aryx>,
        <https://1145.am/db/2360349/Aryx> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352805/Achillion_Pharmaceuticals> a org:Organization ;
    ns1:description "clinical trial work on new hepatitis C drugs" ;
    ns1:documentDate "2010-08-19T15:26:14+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Venture groups snap up $50M block of Achillion shares" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/venture-groups-snap-up-50m-block-of-achillion-shares> ;
    ns1:foundName "Achillion Pharmaceuticals" ;
    ns1:industry "Pharmaceuticals" ;
    ns1:name "Achillion Pharmaceuticals" ;
    ns1:sameAsHigh <https://1145.am/db/101025/Scpharmaceuticals_Inc>,
        <https://1145.am/db/101329/Scpharmaceuticals_Inc>,
        <https://1145.am/db/1031042/Intomics>,
        <https://1145.am/db/1033561/Hs_Pharmaceuticals>,
        <https://1145.am/db/1054457/Elite_Pharmaceuticals_Inc>,
        <https://1145.am/db/1054503/Hs_Pharmaceuticals>,
        <https://1145.am/db/1061901/Pharmaessentia_Corporation>,
        <https://1145.am/db/1070158/Biognosys>,
        <https://1145.am/db/1079560/Satiogen_Pharmaceuticals>,
        <https://1145.am/db/1080385/Satiogen_Pharmaceuticals>,
        <https://1145.am/db/1092000/Adamis_Pharmaceuticals_Corporation>,
        <https://1145.am/db/11010/Progenics_Pharmaceuticals>,
        <https://1145.am/db/1104169/20045078>,
        <https://1145.am/db/1118439/Inmed_Pharmaceuticals_Inc>,
        <https://1145.am/db/1141704/Inmed_Pharmaceuticals>,
        <https://1145.am/db/1174705/Scpharmaceuticals_Inc>,
        <https://1145.am/db/1176480/X4_Pharmaceuticals_Inc>,
        <https://1145.am/db/1185008/TDV>,
        <https://1145.am/db/1186876/Cornerstone_Pharmaceuticals>,
        <https://1145.am/db/1198337/Recce_Pharmaceuticals_Ltd>,
        <https://1145.am/db/1216583/Inmed_Pharmaceuticals_Inc>,
        <https://1145.am/db/1291286/Vital_Pharmaceuticals_Inc>,
        <https://1145.am/db/1294499/Aerie_Pharmaceuticals>,
        <https://1145.am/db/1294506/Aerie_Pharmaceuticals>,
        <https://1145.am/db/1295948/Aerie_Pharmaceuticals>,
        <https://1145.am/db/1296487/Aerie_Pharmaceuticals>,
        <https://1145.am/db/1307419/X4_Pharmaceuticals>,
        <https://1145.am/db/1322957/Biosion>,
        <https://1145.am/db/1329779/Inmed_Pharmaceuticals_Inc>,
        <https://1145.am/db/1339033/Inmed_Pharmaceuticals_Inc>,
        <https://1145.am/db/1343020/Biocryst_Pharmaceuticals>,
        <https://1145.am/db/1370859/Bioivt>,
        <https://1145.am/db/1371279/Aerie_Pharmaceuticals_Inc>,
        <https://1145.am/db/1387773/Aspire_Pharma>,
        <https://1145.am/db/1390741/Nexus_Pharmaceuticals_Inc>,
        <https://1145.am/db/1409143/Scpharmaceuticals_Inc>,
        <https://1145.am/db/1417348/Aerie_Pharmaceuticals_Inc>,
        <https://1145.am/db/1417723/Altasciences>,
        <https://1145.am/db/1418572/Aerie_Pharmaceuticals_Inc>,
        <https://1145.am/db/1430057/Aerie_Pharmaceuticals_Inc>,
        <https://1145.am/db/1443334/Aerie_Pharmaceuticals_Inc>,
        <https://1145.am/db/1443968/Pharmajet®>,
        <https://1145.am/db/1445613/Pharmajet>,
        <https://1145.am/db/1487706/Phathom_Pharmaceuticals_Inc>,
        <https://1145.am/db/1497210/Indivior_Plc>,
        <https://1145.am/db/1497210/Opiant_Pharmaceuticals_Inc>,
        <https://1145.am/db/1497218/Indivior>,
        <https://1145.am/db/1497218/Opiant_Pharmaceuticals>,
        <https://1145.am/db/1500616/Indivior_Plc>,
        <https://1145.am/db/1500616/Opiant_Pharmaceuticals_Inc>,
        <https://1145.am/db/1502096/Indivior_Plc>,
        <https://1145.am/db/1502096/Opiant_Pharmaceuticals_Inc>,
        <https://1145.am/db/1505968/Escient_Pharmaceuticals>,
        <https://1145.am/db/1508407/Escient_Pharmaceuticals>,
        <https://1145.am/db/1515279/Inmed_Pharmaceuticals_Inc>,
        <https://1145.am/db/1520596/Aerie_Pharmaceuticals>,
        <https://1145.am/db/1520597/Aerie_Pharmaceuticals>,
        <https://1145.am/db/1521624/Scpharmaceuticals>,
        <https://1145.am/db/1521695/Aerie_Pharmaceuticals>,
        <https://1145.am/db/1521941/Inmed_Pharmaceuticals_Inc>,
        <https://1145.am/db/1523220/Scpharmaceuticals_Inc>,
        <https://1145.am/db/1533327/Escient_Pharmaceuticals>,
        <https://1145.am/db/1533685/Escient_Pharmaceuticals>,
        <https://1145.am/db/1537336/Pharmajet®>,
        <https://1145.am/db/1538786/Pharmajet>,
        <https://1145.am/db/1540449/Aerie_Pharmaceuticals>,
        <https://1145.am/db/1541946/Amunix_Pharmaceuticals>,
        <https://1145.am/db/1548955/Amunix_Pharmaceuticals>,
        <https://1145.am/db/1557072/Essential_Pharma>,
        <https://1145.am/db/1559882/X4_Pharmaceuticals_Inc>,
        <https://1145.am/db/1571078/Organon>,
        <https://1145.am/db/1585097/Scpharmaceuticals_Inc>,
        <https://1145.am/db/158742/Biogen_Inc>,
        <https://1145.am/db/1595580/Madrigal_Pharmaceuticals>,
        <https://1145.am/db/160543/Mymd_Pharmaceuticals_Inc>,
        <https://1145.am/db/1613688/Pharmalex>,
        <https://1145.am/db/1624479/Indivior_Plc>,
        <https://1145.am/db/1624479/Opiant_Pharmaceuticals_Inc>,
        <https://1145.am/db/1625532/Indivior_Plc>,
        <https://1145.am/db/1625532/Opiant_Pharmaceuticals_Inc>,
        <https://1145.am/db/1629605/Biogen>,
        <https://1145.am/db/1629663/Biogen>,
        <https://1145.am/db/1632411/Scipher_Medicine>,
        <https://1145.am/db/1632862/Scipher_Medicine>,
        <https://1145.am/db/1632868/Sovereign_Pharmaceuticals_Llc>,
        <https://1145.am/db/1661035/Biontech>,
        <https://1145.am/db/1680583/Infinity_Pharmaceuticals_Inc>,
        <https://1145.am/db/1687234/Infinity_Pharmaceuticals_Inc>,
        <https://1145.am/db/180589/Servier>,
        <https://1145.am/db/1955684/Eip_Pharma_Inc>,
        <https://1145.am/db/1979697/Amphastar_Pharmaceuticals>,
        <https://1145.am/db/2038168/Infinity_Pharmaceuticals_Inc>,
        <https://1145.am/db/2039291/Infinity_Pharmaceuticals_Inc>,
        <https://1145.am/db/2039678/Infinity_Pharmaceuticals_Inc>,
        <https://1145.am/db/2040011/Ferring_Pharmaceuticals>,
        <https://1145.am/db/2045820/Ferring_Pharmaceuticals>,
        <https://1145.am/db/2049603/Inova_Pharmaceuticals>,
        <https://1145.am/db/2056005/Infinity_Pharmaceuticals_Inc>,
        <https://1145.am/db/2056755/Infinity_Pharmaceuticals_Inc>,
        <https://1145.am/db/2061803/Infinity_Pharmaceuticals>,
        <https://1145.am/db/2062156/Infinity_Pharmaceuticals_Inc>,
        <https://1145.am/db/2066480/Infinity_Pharmaceuticals_Inc>,
        <https://1145.am/db/2071248/Biogen>,
        <https://1145.am/db/2074741/Biogen_Inc>,
        <https://1145.am/db/2092442/Leo_Pharma>,
        <https://1145.am/db/2093802/Meitheal_Pharmaceuticals>,
        <https://1145.am/db/2100253/Biogen_Inc>,
        <https://1145.am/db/2101006/Leo_Pharma_A_S>,
        <https://1145.am/db/2138834/Altasciences>,
        <https://1145.am/db/2151781/Aerie_Pharmaceuticals>,
        <https://1145.am/db/2152103/Am-Pharma>,
        <https://1145.am/db/2152434/Tetraphase_Pharmaceuticals>,
        <https://1145.am/db/2153727/Amunix_Pharmaceuticals>,
        <https://1145.am/db/2154019/Aerie_Pharmaceuticals>,
        <https://1145.am/db/2154118/Aerie_Pharmaceuticals>,
        <https://1145.am/db/2154527/The_Medicines_Company>,
        <https://1145.am/db/2154871/Ferring_Pharmaceuticals>,
        <https://1145.am/db/2155006/Medicines_Company>,
        <https://1145.am/db/2155312/Ferring_Pharmaceuticals>,
        <https://1145.am/db/2155622/Isa_Pharmaceuticals>,
        <https://1145.am/db/2155631/Achillion>,
        <https://1145.am/db/2155792/Ucb_Pharma>,
        <https://1145.am/db/2155798/Ucb_Pharma>,
        <https://1145.am/db/2155994/Aegerion_Pharmaceuticals>,
        <https://1145.am/db/2156002/Aegerion_Pharmaceuticals>,
        <https://1145.am/db/2198945/Millennium_Pharmaceuticals_Inc>,
        <https://1145.am/db/2201094/Pharmadeals_Ltd>,
        <https://1145.am/db/2204969/Organon_Biosciences>,
        <https://1145.am/db/2207034/Cequent_Pharmaceuticals>,
        <https://1145.am/db/221697/Gw_Pharmaceuticals>,
        <https://1145.am/db/2217819/Pharmacopeia>,
        <https://1145.am/db/221787/Gw_Pharmaceuticals>,
        <https://1145.am/db/2218929/Millennium_Pharmaceuticals>,
        <https://1145.am/db/2224859/Biologics>,
        <https://1145.am/db/2229191/Biologics>,
        <https://1145.am/db/2279276/Aerie_Pharmaceuticals>,
        <https://1145.am/db/2279648/Organon>,
        <https://1145.am/db/2280123/Casi_Pharmaceuticals>,
        <https://1145.am/db/2280153/Pharming>,
        <https://1145.am/db/2281547/Ferring_Pharmaceuticals>,
        <https://1145.am/db/2283570/Pherin_Pharmaceuticals>,
        <https://1145.am/db/2284358/Escient_Pharmaceuticals>,
        <https://1145.am/db/2285117/Immedica>,
        <https://1145.am/db/2285495/Bioivt>,
        <https://1145.am/db/2287224/Escient_Pharmaceuticals>,
        <https://1145.am/db/2287505/Achillion_Pharmaceuticals>,
        <https://1145.am/db/2287572/T3_Pharmaceuticals>,
        <https://1145.am/db/2288192/Servier>,
        <https://1145.am/db/2290842/X4_Pharmaceuticals>,
        <https://1145.am/db/2291791/Aerie_Pharmaceuticals>,
        <https://1145.am/db/2291914/Achillion_Pharmaceuticals>,
        <https://1145.am/db/2294547/Vitae_Pharmaceuticals>,
        <https://1145.am/db/2294570/Pharmatek>,
        <https://1145.am/db/2296094/Biogen>,
        <https://1145.am/db/2297534/Bio>,
        <https://1145.am/db/2298037/Ethicon>,
        <https://1145.am/db/2298627/Ferring_Pharmaceuticals>,
        <https://1145.am/db/2299414/Biogen>,
        <https://1145.am/db/2301089/Cerulean_Pharma>,
        <https://1145.am/db/2301346/Pharmaron>,
        <https://1145.am/db/2301718/Oncomed_Pharmaceuticals>,
        <https://1145.am/db/2301735/Idera_Pharmaceuticals>,
        <https://1145.am/db/2301764/Map_Pharmaceuticals_Inc>,
        <https://1145.am/db/2301798/Osi_Pharmaceuticals>,
        <https://1145.am/db/2302019/Oscient_Pharmaceuticals_Corporation>,
        <https://1145.am/db/2302275/Map_Pharmaceuticals>,
        <https://1145.am/db/2302426/Idera_Pharmaceuticals_Inc>,
        <https://1145.am/db/2302431/Infinity_Pharmaceuticals_Inc>,
        <https://1145.am/db/2302552/Am-Pharma>,
        <https://1145.am/db/2302574/Via_Pharmaceuticals>,
        <https://1145.am/db/2302579/Via_Pharmaceuticals>,
        <https://1145.am/db/2302587/Access_Pharmaceuticals>,
        <https://1145.am/db/2302658/Biotie>,
        <https://1145.am/db/2302707/Vitae_Pharmaceuticals>,
        <https://1145.am/db/2302774/Innovive_Pharmaceuticals>,
        <https://1145.am/db/2302779/Innovive_Pharmaceuticals>,
        <https://1145.am/db/2302890/Presidio_Pharmaceuticals>,
        <https://1145.am/db/2302897/Presidio_Pharmaceuticals>,
        <https://1145.am/db/2303022/Ore_Pharmaceuticals>,
        <https://1145.am/db/2303121/Locus_Pharmaceuticals>,
        <https://1145.am/db/2303131/Locus_Pharmaceuticals>,
        <https://1145.am/db/2303182/Pharmexa>,
        <https://1145.am/db/2303208/Ore_Pharmaceuticals>,
        <https://1145.am/db/2303426/Infinity_Pharmaceuticals>,
        <https://1145.am/db/2303674/Cerulean_Pharma>,
        <https://1145.am/db/2303792/Access_Pharmaceuticals>,
        <https://1145.am/db/2303934/Oncomed_Pharmaceuticals>,
        <https://1145.am/db/2303956/Prolexys_Pharmaceuticals>,
        <https://1145.am/db/2304044/Novamed_Pharmaceuticals_Inc>,
        <https://1145.am/db/2304097/Pharmaceutical_Product_Development>,
        <https://1145.am/db/2304135/Progenics_Pharmaceuticals>,
        <https://1145.am/db/2304610/Pharmos_Corp>,
        <https://1145.am/db/2304745/Critical_Pharmaceuticals>,
        <https://1145.am/db/2304831/Pharmion_Corporation>,
        <https://1145.am/db/2304934/Medicure>,
        <https://1145.am/db/2304985/Pharmaceutical_Product_Development_Llc>,
        <https://1145.am/db/2305742/Mh_Pharma_Uk>,
        <https://1145.am/db/2305834/Nps_Pharmaceuticals>,
        <https://1145.am/db/2305927/Entremed>,
        <https://1145.am/db/2305956/Presidio_Pharmaceuticals>,
        <https://1145.am/db/2306255/Biosante_Pharmaceuticals>,
        <https://1145.am/db/2306299/Verily>,
        <https://1145.am/db/2306641/Bioalliance_Pharma_Sa>,
        <https://1145.am/db/2306962/Pharmaron>,
        <https://1145.am/db/2307239/Pharmaxis_Ltd>,
        <https://1145.am/db/2307246/Pharmaxis>,
        <https://1145.am/db/2307254/Presidio_Pharmaceuticals>,
        <https://1145.am/db/2307651/Organon>,
        <https://1145.am/db/2307834/Savient_Pharmaceuticals>,
        <https://1145.am/db/2307871/Access_Pharmaceuticals>,
        <https://1145.am/db/2307894/Lev_Pharmaceuticals>,
        <https://1145.am/db/2307897/Oramed_Pharmaceuticals>,
        <https://1145.am/db/2308423/Adamas_Pharmaceuticals>,
        <https://1145.am/db/2308429/Adamas_Pharmaceuticals_Inc>,
        <https://1145.am/db/2308446/Pharmathene>,
        <https://1145.am/db/2308922/Lev_Pharmaceuticals>,
        <https://1145.am/db/2308964/Slate_Pharmaceuticals>,
        <https://1145.am/db/2309001/Biocon>,
        <https://1145.am/db/2309301/Inc>,
        <https://1145.am/db/2309923/Diasome_Pharmaceuticals>,
        <https://1145.am/db/2310002/Infinity_Pharmaceuticals>,
        <https://1145.am/db/2310002/Map_Pharmaceuticals>,
        <https://1145.am/db/2310045/Slate_Pharmaceuticals>,
        <https://1145.am/db/2310071/Encysive_Pharmaceuticals_Inc>,
        <https://1145.am/db/2310196/Symbollon_Pharmaceuticals>,
        <https://1145.am/db/2310200/Encysive_Pharmaceuticals>,
        <https://1145.am/db/2310219/Docpharma>,
        <https://1145.am/db/2310232/Genaissance_Pharmaceuticals>,
        <https://1145.am/db/2310471/Cornerstone_Pharmaceuticals>,
        <https://1145.am/db/2310473/Cornerstone_Pharmaceuticals_Inc>,
        <https://1145.am/db/2310476/Afferent_Pharmaceuticals>,
        <https://1145.am/db/2310480/Idera_Pharmaceuticals_Inc>,
        <https://1145.am/db/2310590/Adamas_Pharmaceuticals>,
        <https://1145.am/db/2310790/Pharmaceutical_Product_Development_Llc>,
        <https://1145.am/db/2310989/Savient_Pharmaceuticals_Inc>,
        <https://1145.am/db/2310993/Pharmaceutical_Research_And_Manufacturers_Of_America>,
        <https://1145.am/db/2311166/Proprius_Pharmaceuticals>,
        <https://1145.am/db/2311202/Nps_Pharmaceuticals_Inc>,
        <https://1145.am/db/2311217/Biosante_Pharmaceuticals>,
        <https://1145.am/db/2311264/Medicure>,
        <https://1145.am/db/2311726/Inc>,
        <https://1145.am/db/2312088/Cerulean_Pharma>,
        <https://1145.am/db/2312088/Infinity_Pharmaceuticals>,
        <https://1145.am/db/2312158/Biosante_Pharmaceuticals>,
        <https://1145.am/db/2312193/Ore_Pharmaceuticals_Inc>,
        <https://1145.am/db/2312257/The_Medicines_Company>,
        <https://1145.am/db/2312344/Oscient_Pharmaceuticals>,
        <https://1145.am/db/2312416/Vitae_Pharmaceuticals>,
        <https://1145.am/db/2312476/Nps_Pharmaceuticals>,
        <https://1145.am/db/2312479/Nps_Pharmaceuticals>,
        <https://1145.am/db/2313305/Tetraphase_Pharmaceuticals_Inc>,
        <https://1145.am/db/2313306/Tetraphase_Pharmaceuticals>,
        <https://1145.am/db/2313320/Biosante_Pharmaceuticals>,
        <https://1145.am/db/2313320/Ore_Pharmaceuticals>,
        <https://1145.am/db/2313323/Biosante_Pharmaceuticals>,
        <https://1145.am/db/2313324/Ore_Pharmaceuticals_Inc>,
        <https://1145.am/db/2313336/Sound_Pharmaceuticals>,
        <https://1145.am/db/2313487/Symbollon_Pharmaceuticals>,
        <https://1145.am/db/2313501/Bioalliance_Pharma>,
        <https://1145.am/db/2313527/Millennium_Pharmaceuticals>,
        <https://1145.am/db/2313528/Us_Pharmaceutical_Company>,
        <https://1145.am/db/2314217/Sciele_Pharma>,
        <https://1145.am/db/2314271/Biomarck_Pharmaceuticals_Ltd>,
        <https://1145.am/db/2314277/Biomarck_Pharmaceuticals>,
        <https://1145.am/db/2314317/Infinity_Pharmaceuticals_Inc>,
        <https://1145.am/db/2314375/Cornerstone_Pharmaceuticals_Inc>,
        <https://1145.am/db/2314474/Pharmion>,
        <https://1145.am/db/2314680/Pharming>,
        <https://1145.am/db/2314816/Biosante_Pharmaceuticals_Inc>,
        <https://1145.am/db/2314837/Biosante_Pharmaceuticals>,
        <https://1145.am/db/2315159/Research_Pharmaceutical_Services_Inc>,
        <https://1145.am/db/2315192/Pharmaceutical_Product_Development>,
        <https://1145.am/db/2315296/Oscient_Pharmaceuticals>,
        <https://1145.am/db/2315485/Polpharma>,
        <https://1145.am/db/2315571/Sciele_Pharma>,
        <https://1145.am/db/2315624/Oscient_Pharmaceuticals>,
        <https://1145.am/db/2315624/Pharmos>,
        <https://1145.am/db/2315925/Oramed_Pharmaceuticals>,
        <https://1145.am/db/2315941/Adamis_Pharmaceuticals_Corporation>,
        <https://1145.am/db/2316239/Pharmaceutical_Product_Development_Llc>,
        <https://1145.am/db/2316418/Pharmaventures_Ltd>,
        <https://1145.am/db/2316435/Pharmaventures_Ltd>,
        <https://1145.am/db/2316481/Osi_Pharmaceuticals>,
        <https://1145.am/db/2316660/Pharmacopeia>,
        <https://1145.am/db/2316684/Infinity_Pharmaceuticals>,
        <https://1145.am/db/2317337/Pharmaceutical_Product_Development_Llc>,
        <https://1145.am/db/2317344/Research_Pharmaceutical_Services>,
        <https://1145.am/db/2317635/Biocryst_Pharmaceuticals>,
        <https://1145.am/db/2317762/Pharmathene>,
        <https://1145.am/db/2317826/Anormed>,
        <https://1145.am/db/2317826/Millennium_Pharmaceuticals>,
        <https://1145.am/db/2317842/Oncomed_Pharmaceuticals>,
        <https://1145.am/db/2317895/Esprit_Pharma>,
        <https://1145.am/db/2317929/Oncomed_Pharmaceuticals>,
        <https://1145.am/db/2318105/Pharma_Inc>,
        <https://1145.am/db/2318114/Transdel_Pharmaceuticals_Inc>,
        <https://1145.am/db/2318248/Vitae_Pharmaceuticals>,
        <https://1145.am/db/2318285/Pht_Corporation>,
        <https://1145.am/db/2318469/Research_Pharmaceutical_Services>,
        <https://1145.am/db/2318554/Vitae_Pharmaceuticals>,
        <https://1145.am/db/2318574/Idera_Pharmaceuticals>,
        <https://1145.am/db/2318711/Specialty_Pharmaceuticals>,
        <https://1145.am/db/2318743/Pharmos_Corporation>,
        <https://1145.am/db/2318808/Pharmathene>,
        <https://1145.am/db/2318986/Corgentech>,
        <https://1145.am/db/2318994/Cornerstone_Biopharma>,
        <https://1145.am/db/2319208/Osi_Pharmaceuticals>,
        <https://1145.am/db/2319687/Advisys>,
        <https://1145.am/db/2319790/Pharmacyclics>,
        <https://1145.am/db/2319806/Satori_Pharmaceuticals>,
        <https://1145.am/db/2319809/Satori_Pharmaceuticals_Incorporated>,
        <https://1145.am/db/2319938/Del_Pharmaceuticals>,
        <https://1145.am/db/2319939/Progenics_Pharmaceuticals>,
        <https://1145.am/db/2320009/Map_Pharmaceuticals>,
        <https://1145.am/db/2320025/Am-Pharma>,
        <https://1145.am/db/2320025/Esprit_Pharma>,
        <https://1145.am/db/2320461/Infinity_Pharmaceuticals_Inc>,
        <https://1145.am/db/2320767/Via_Pharmaceuticals>,
        <https://1145.am/db/2320903/Cequent_Pharmaceuticals>,
        <https://1145.am/db/2320949/Medicines_Company>,
        <https://1145.am/db/2321148/Savient_Pharmaceuticals>,
        <https://1145.am/db/2321157/Access_Pharmaceuticals>,
        <https://1145.am/db/2321256/Nps_Pharmaceuticals>,
        <https://1145.am/db/2321409/Adamis_Pharmaceuticals_Corporation>,
        <https://1145.am/db/2321413/Adamis_Pharmaceuticals_Corporation>,
        <https://1145.am/db/2321565/2009-2010>,
        <https://1145.am/db/2321784/Acceliant>,
        <https://1145.am/db/2321860/Achillion_Pharmaceuticals>,
        <https://1145.am/db/2321861/Astion_Pharma>,
        <https://1145.am/db/2321871/Astion_Pharma>,
        <https://1145.am/db/2321899/Aegerion_Pharmaceuticals>,
        <https://1145.am/db/2322135/Millennium_Pharmaceuticals_Inc>,
        <https://1145.am/db/2322235/Pharmacopeia>,
        <https://1145.am/db/2322291/Polpharma>,
        <https://1145.am/db/2322481/Cornerstone_Pharmaceuticals_Inc>,
        <https://1145.am/db/2322632/Savient_Pharmaceuticals>,
        <https://1145.am/db/2322942/Cequent_Pharmaceuticals>,
        <https://1145.am/db/2322953/Cequent_Pharmaceuticals>,
        <https://1145.am/db/2323173/Pharmacopeia>,
        <https://1145.am/db/2323181/Millennium_Pharmaceuticals>,
        <https://1145.am/db/2323225/Arqule>,
        <https://1145.am/db/2323273/Pharmion_Corporation>,
        <https://1145.am/db/2323278/Pharmion>,
        <https://1145.am/db/2323358/Organon_Biosciences>,
        <https://1145.am/db/2324017/Encysive_Pharmaceuticals>,
        <https://1145.am/db/2324024/Presidio_Pharmaceuticals>,
        <https://1145.am/db/2324243/Arqule>,
        <https://1145.am/db/2324417/Biomimetic_Pharmaceuticals>,
        <https://1145.am/db/2324753/Biomarin_Pharmaceutical_Inc>,
        <https://1145.am/db/2324838/Biogen>,
        <https://1145.am/db/2325070/The_Medicines_Company>,
        <https://1145.am/db/2325074/The_Medicines_Company>,
        <https://1145.am/db/2325259/Pharmacopeia>,
        <https://1145.am/db/2325269/Pharmacopeia>,
        <https://1145.am/db/2325394/Pharmion>,
        <https://1145.am/db/2325725/Osi_Pharmaceuticals_Inc>,
        <https://1145.am/db/2326025/Research_Pharmaceutical_Services>,
        <https://1145.am/db/2326148/Encysive_Pharmaceuticals>,
        <https://1145.am/db/2326286/Idera_Pharmaceuticals>,
        <https://1145.am/db/2326403/Millennium_Pharmaceuticals>,
        <https://1145.am/db/2326466/Macromed>,
        <https://1145.am/db/2326474/Innovive_Pharmaceuticals>,
        <https://1145.am/db/2327241/Nps_Pharmaceuticals>,
        <https://1145.am/db/2327450/York_Pharma>,
        <https://1145.am/db/2327480/Transdel_Pharmaceuticals>,
        <https://1145.am/db/2327649/Pediamed_Pharmaceuticals>,
        <https://1145.am/db/2327849/Pharmacia_Corporation>,
        <https://1145.am/db/2328043/Madrigal_Pharmaceuticals>,
        <https://1145.am/db/2328220/Pharmaceutical_Product_Development>,
        <https://1145.am/db/2328222/Pharmaceutical_Product_Development_Llc>,
        <https://1145.am/db/2328616/Map_Pharmaceuticals>,
        <https://1145.am/db/2328650/Millennium_Pharmaceuticals>,
        <https://1145.am/db/2328729/Pediamed_Pharmaceuticals>,
        <https://1145.am/db/2328988/Cequent_Pharmaceuticals>,
        <https://1145.am/db/2328990/Mdrna>,
        <https://1145.am/db/2328996/Via_Pharmaceuticals>,
        <https://1145.am/db/2329309/Pharmaceutical_Product_Development_Llc>,
        <https://1145.am/db/2329643/Pharmaceuticals_Inc>,
        <https://1145.am/db/2329756/Provid_Pharmaceuticals>,
        <https://1145.am/db/2329814/Map_Pharmaceuticals>,
        <https://1145.am/db/2329816/Map_Pharmaceuticals>,
        <https://1145.am/db/2330057/Pharmathene>,
        <https://1145.am/db/2330086/Idera_Pharmaceuticals_Inc>,
        <https://1145.am/db/2330094/Idera_Pharmaceuticals>,
        <https://1145.am/db/2330207/Bioxell>,
        <https://1145.am/db/2330207/Cosmo_Pharmaceuticals>,
        <https://1145.am/db/2330534/Pharmion>,
        <https://1145.am/db/2330576/Biocryst_Pharmaceuticals>,
        <https://1145.am/db/2330667/Savient_Pharmaceuticals_Inc>,
        <https://1145.am/db/2330858/Provid_Pharmaceuticals_Inc>,
        <https://1145.am/db/2330880/Access_Pharmaceuticals>,
        <https://1145.am/db/2330880/Biocryst_Pharmaceuticals>,
        <https://1145.am/db/2330882/Proprius_Pharmaceuticals>,
        <https://1145.am/db/2330951/Oscient_Pharmaceuticals>,
        <https://1145.am/db/2330989/Millennium_Pharmaceuticals>,
        <https://1145.am/db/2331692/Biosante_Pharmaceuticals>,
        <https://1145.am/db/2331745/Elan_Pharmaceuticals>,
        <https://1145.am/db/2331756/Pro-Pharmaceuticals>,
        <https://1145.am/db/2331875/Bioalliance_Pharma>,
        <https://1145.am/db/2332473/Pharmaceutical_Product_Development_Llc>,
        <https://1145.am/db/2332596/Esprit_Pharma>,
        <https://1145.am/db/2332777/S_*_Bio>,
        <https://1145.am/db/2332974/Osi_Pharmaceuticals>,
        <https://1145.am/db/2332980/Pharmos_Corporation>,
        <https://1145.am/db/2333492/Access_Pharmaceuticals>,
        <https://1145.am/db/2333569/Ception>,
        <https://1145.am/db/2333624/Pharmos>,
        <https://1145.am/db/2334034/Pharmaceutical_Product_Development_Llc>,
        <https://1145.am/db/2334119/Pharmaceutical_Product_Development>,
        <https://1145.am/db/2334121/Pharmaceutical_Product_Development>,
        <https://1145.am/db/2334183/Idera_Pharmaceuticals>,
        <https://1145.am/db/2335077/Pharmaceutical_Product_Development_Llc>,
        <https://1145.am/db/2336040/Ferring_Pharmaceuticals>,
        <https://1145.am/db/2336041/Ferring_Pharmaceuticals>,
        <https://1145.am/db/2336160/Pharmaceutical_Product_Development>,
        <https://1145.am/db/2336293/Aprecia_Pharmaceuticals_Company>,
        <https://1145.am/db/2336378/Oramed_Pharmaceuticals_Inc>,
        <https://1145.am/db/2336442/Bionor_Pharma_Asa>,
        <https://1145.am/db/2336452/Pharmaxis_Ltd>,
        <https://1145.am/db/2336503/Aragon_Pharmaceuticals_Inc>,
        <https://1145.am/db/2336505/Aragon_Pharmaceuticals_Inc>,
        <https://1145.am/db/2336506/Aragon_Pharmaceuticals>,
        <https://1145.am/db/2336524/Aragon_Pharmaceuticals_Inc>,
        <https://1145.am/db/2336629/Biota_Pharmaceuticals>,
        <https://1145.am/db/2336934/Savient_Pharmaceuticals_Inc>,
        <https://1145.am/db/2337053/N30_Pharmaceuticals>,
        <https://1145.am/db/2337345/Conatus_Pharmaceuticals_Inc>,
        <https://1145.am/db/2337348/Cosmo_Pharmaceuticals_Spa>,
        <https://1145.am/db/2337547/Aragon_Pharmaceuticals_Inc>,
        <https://1145.am/db/2337928/Progenics_Pharmaceuticals_Inc>,
        <https://1145.am/db/2337986/Pharmagen_Inc>,
        <https://1145.am/db/2338120/The_Medicines_Company>,
        <https://1145.am/db/2338123/The_Medicines_Company>,
        <https://1145.am/db/2338390/Inmed_Pharmaceuticals_Inc>,
        <https://1145.am/db/2338401/Tetraphase_Pharmaceuticals>,
        <https://1145.am/db/2338430/Pharmacyclics>,
        <https://1145.am/db/2338551/Biosante_Pharmaceuticals_Inc>,
        <https://1145.am/db/2338735/Map_Pharmaceuticals>,
        <https://1145.am/db/2338877/Aerie_Pharmaceuticals>,
        <https://1145.am/db/2338883/Cerulean_Pharma_Inc>,
        <https://1145.am/db/2339019/Isa_Pharmaceuticals_Bv>,
        <https://1145.am/db/2339186/Biocryst_Pharmaceuticals>,
        <https://1145.am/db/2339570/Map_Pharmaceuticals>,
        <https://1145.am/db/2339718/Bioalliance_Pharma_Sa>,
        <https://1145.am/db/2339727/Pharmacyclics_Inc>,
        <https://1145.am/db/2339787/Pharmalink_Ab>,
        <https://1145.am/db/2339892/Pharmacyclics>,
        <https://1145.am/db/2339907/Biosante_Pharmaceuticals>,
        <https://1145.am/db/2339910/Biomed_Pharmaceuticals>,
        <https://1145.am/db/2339922/Pharmaform>,
        <https://1145.am/db/2339979/Theravance>,
        <https://1145.am/db/2340000/Aerie_Pharmaceuticals>,
        <https://1145.am/db/2340224/Satori_Pharmaceuticals>,
        <https://1145.am/db/2340291/Pharmasset>,
        <https://1145.am/db/2340373/Nps_Pharmaceuticals>,
        <https://1145.am/db/2340431/Savient_Pharmaceuticals>,
        <https://1145.am/db/2341523/Biocryst_Pharmaceuticals>,
        <https://1145.am/db/2341742/Research_Pharmaceutical_Services>,
        <https://1145.am/db/2341752/Biocryst_Pharmaceuticals_Inc>,
        <https://1145.am/db/2341998/Achillion_Pharmaceuticals>,
        <https://1145.am/db/2342192/Aragon_Pharmaceuticals>,
        <https://1145.am/db/2342224/Infinity_Pharmaceuticals_Inc>,
        <https://1145.am/db/2342225/Infinity_Pharmaceuticals_Inc>,
        <https://1145.am/db/2342469/Pharmadel>,
        <https://1145.am/db/2342687/Bioalliance_Pharma>,
        <https://1145.am/db/2342800/Pharmathene>,
        <https://1145.am/db/2342805/Pharmathene>,
        <https://1145.am/db/2342918/Pharmalink_Ab>,
        <https://1145.am/db/2343264/Pharmaceutical_Product_Development>,
        <https://1145.am/db/2343277/Pharmasset>,
        <https://1145.am/db/2343826/The_Medicines_Company>,
        <https://1145.am/db/2343837/Medicines_Co>,
        <https://1145.am/db/2343966/Thesan_Pharmaceuticals>,
        <https://1145.am/db/2344011/Inmed_Pharmaceuticals_Inc>,
        <https://1145.am/db/2344076/Transdel_Pharmaceuticals_Inc>,
        <https://1145.am/db/2344079/Map_Pharmaceuticals_Inc>,
        <https://1145.am/db/2344131/Pharmascience_Inc>,
        <https://1145.am/db/2344207/Entremed>,
        <https://1145.am/db/2344624/Pharmagen_Inc>,
        <https://1145.am/db/2344735/Aragon_Pharmaceuticals_Inc>,
        <https://1145.am/db/2344739/Aragon_Pharmaceuticals>,
        <https://1145.am/db/2344850/Elite_Pharmaceuticals_Inc>,
        <https://1145.am/db/2344939/Theravance>,
        <https://1145.am/db/2344955/Pharmaceutical_Product_Development>,
        <https://1145.am/db/2345106/Map_Pharmaceuticals>,
        <https://1145.am/db/2345474/Infinity_Pharmaceuticals_Inc>,
        <https://1145.am/db/2345902/Elite_Pharmaceuticals_Inc>,
        <https://1145.am/db/2346534/Conatus_Pharmaceuticals_Inc>,
        <https://1145.am/db/2346542/Conatus_Pharmaceuticals>,
        <https://1145.am/db/2346775/N30_Pharmaceuticals>,
        <https://1145.am/db/2346800/Satori_Pharmaceuticals_Incorporated>,
        <https://1145.am/db/2346807/Satori_Pharmaceuticals_Incorporated>,
        <https://1145.am/db/2346832/Vital_Science_Corp>,
        <https://1145.am/db/2346833/Vital_Science_Corp>,
        <https://1145.am/db/2346951/Biota_Pharmaceuticals_Inc>,
        <https://1145.am/db/2346964/Aerie_Pharmaceuticals>,
        <https://1145.am/db/2347127/Pharmacyte_Biotech>,
        <https://1145.am/db/2347169/Idera_Pharmaceuticals_Inc>,
        <https://1145.am/db/2347227/Aoxing_Pharmaceutical>,
        <https://1145.am/db/2347272/Pharmascience>,
        <https://1145.am/db/2347519/Pharmadeals_Ltd>,
        <https://1145.am/db/2347644/Aragon_Pharmaceuticals>,
        <https://1145.am/db/2347648/Pharminox_Limited>,
        <https://1145.am/db/2347659/Aragon_Pharmaceuticals>,
        <https://1145.am/db/2347982/Epicept>,
        <https://1145.am/db/2348329/Esperance_Pharmaceuticals>,
        <https://1145.am/db/2348506/Am-Pharma_Bv>,
        <https://1145.am/db/2348523/Am-Pharma_Bv>,
        <https://1145.am/db/2348763/Bioalliance_Pharma_Sa>,
        <https://1145.am/db/2348864/Vital_Science_Corp>,
        <https://1145.am/db/2349103/Biota_Pharmaceuticals>,
        <https://1145.am/db/2349111/Idera_Pharmaceuticals_Inc>,
        <https://1145.am/db/2349348/R-Pharm>,
        <https://1145.am/db/2349573/Biosante_Pharmaceuticals_Inc>,
        <https://1145.am/db/2349581/Biosante_Pharmaceuticals_Inc>,
        <https://1145.am/db/2349608/Biosante_Pharmaceuticals_Inc>,
        <https://1145.am/db/2349965/Idera_Pharmaceuticals_Inc>,
        <https://1145.am/db/2350147/Biota_Pharmaceuticals_Inc>,
        <https://1145.am/db/2350440/Ethicon>,
        <https://1145.am/db/2350852/Isa_Pharmaceuticals>,
        <https://1145.am/db/2351091/Biomotiv>,
        <https://1145.am/db/2351471/Mymetics_Corporation>,
        <https://1145.am/db/2351818/Biocon>,
        <https://1145.am/db/2352046/Costim_Pharmaceuticals>,
        <https://1145.am/db/2352165/Bio>,
        <https://1145.am/db/2352177/Theravance_Inc>,
        <https://1145.am/db/2352180/Pharmaceutical_Research_And_Manufacturers_Of_America>,
        <https://1145.am/db/2352333/Inmed_Pharmaceuticals_Inc>,
        <https://1145.am/db/2352538/Biota_Pharmaceuticals>,
        <https://1145.am/db/2352659/Nps_Pharmaceuticals>,
        <https://1145.am/db/2352784/Biosante_Pharmaceuticals>,
        <https://1145.am/db/2352808/Achillion_Pharmaceuticals_Inc>,
        <https://1145.am/db/2353006/Radient_Pharmaceuticals_Corporation>,
        <https://1145.am/db/2353093/Thesan_Pharmaceuticals>,
        <https://1145.am/db/2353098/Thesan_Pharmaceuticals>,
        <https://1145.am/db/2353101/Index_Pharmaceuticals>,
        <https://1145.am/db/2353254/Pharma_Inc>,
        <https://1145.am/db/2353262/Sound_Pharmaceuticals_Inc>,
        <https://1145.am/db/2353279/Biocryst_Pharmaceuticals_Inc>,
        <https://1145.am/db/2353279/Presidio_Pharmaceuticals_Inc>,
        <https://1145.am/db/2353326/Am-Pharma>,
        <https://1145.am/db/2353364/Am-Pharma>,
        <https://1145.am/db/2353651/Pharmathene>,
        <https://1145.am/db/2353668/Biotie>,
        <https://1145.am/db/2354002/N30_Pharmaceuticals>,
        <https://1145.am/db/2354062/Osi_Pharmaceuticals>,
        <https://1145.am/db/2354064/Osi_Pharmaceuticals>,
        <https://1145.am/db/2354083/Osi_Pharmaceuticals>,
        <https://1145.am/db/2354086/Osi_Pharmaceuticals>,
        <https://1145.am/db/2354124/Uk>,
        <https://1145.am/db/2354146/Aerie_Pharmaceuticals>,
        <https://1145.am/db/2354376/Aspireo_Pharmaceuticals>,
        <https://1145.am/db/2354380/Pharmaxis>,
        <https://1145.am/db/2354388/Pharmaxis>,
        <https://1145.am/db/2354402/Achillion_Pharmaceuticals>,
        <https://1145.am/db/2354406/Gw_Pharmaceuticals_Plc>,
        <https://1145.am/db/2354779/Achillion_Pharmaceuticals_Inc>,
        <https://1145.am/db/2354783/Achillion_Pharmaceuticals>,
        <https://1145.am/db/2354804/Medicis_Pharmaceutical_Corporation>,
        <https://1145.am/db/2354836/Progenics_Pharmaceuticals_Inc>,
        <https://1145.am/db/2354913/Bionor_Pharma_Asa>,
        <https://1145.am/db/2355099/Infinity_Pharmaceuticals>,
        <https://1145.am/db/2355109/Infinity_Pharmaceuticals>,
        <https://1145.am/db/2355324/Biota_Pharmaceuticals_Inc>,
        <https://1145.am/db/2355678/Oncomed_Pharmaceuticals>,
        <https://1145.am/db/2355721/Pharmaceutical_Product_Development>,
        <https://1145.am/db/2355884/Omthera_Pharmaceuticals>,
        <https://1145.am/db/2355885/Omthera_Pharmaceuticals>,
        <https://1145.am/db/2355941/Theratechnologies>,
        <https://1145.am/db/2355974/Aegerion_Pharmaceuticals>,
        <https://1145.am/db/2356294/Company>,
        <https://1145.am/db/2356294/Inc>,
        <https://1145.am/db/2356391/Infinity_Pharmaceuticals>,
        <https://1145.am/db/2356434/The_Medicines_Company>,
        <https://1145.am/db/2357329/Pharmalink_Ab>,
        <https://1145.am/db/2357333/Pharmalink>,
        <https://1145.am/db/2357423/Achillion_Pharmaceuticals_Inc>,
        <https://1145.am/db/2357456/Infinity_Pharmaceuticals_Inc>,
        <https://1145.am/db/2357636/Biocryst_Pharmaceuticals>,
        <https://1145.am/db/2358047/Entremed>,
        <https://1145.am/db/2358405/Pharmagen_Inc>,
        <https://1145.am/db/2358449/Nps_Pharmaceuticals_Inc>,
        <https://1145.am/db/2358479/Nps_Pharmaceuticals_Inc>,
        <https://1145.am/db/2358732/Osi_Pharmaceuticals>,
        <https://1145.am/db/2358877/Biocryst_Pharmaceuticals_Inc>,
        <https://1145.am/db/2359266/D-Pharm>,
        <https://1145.am/db/2359401/Scpharmaceuticals_Inc>,
        <https://1145.am/db/2359438/Aerie_Pharmaceuticals>,
        <https://1145.am/db/2359474/Oncomed_Pharmaceuticals>,
        <https://1145.am/db/2359517/Elite_Pharmaceuticals_Inc>,
        <https://1145.am/db/2359539/Omthera_Pharmaceuticals>,
        <https://1145.am/db/2359550/Achillion_Pharmaceuticals>,
        <https://1145.am/db/2359668/Cosmo_Pharmaceuticals>,
        <https://1145.am/db/2359882/Biotie>,
        <https://1145.am/db/2359926/Entremed>,
        <https://1145.am/db/2360155/Aegerion_Pharmaceuticals>,
        <https://1145.am/db/2360489/Medac_Pharma>,
        <https://1145.am/db/2360588/Achillion_Pharmaceuticals>,
        <https://1145.am/db/2360596/Achillion_Pharmaceuticals_Inc>,
        <https://1145.am/db/2360697/Medgenics>,
        <https://1145.am/db/2360739/Cosmo_Pharmaceuticals>,
        <https://1145.am/db/2360945/Entremed>,
        <https://1145.am/db/2361244/Aegerion_Pharmaceuticals>,
        <https://1145.am/db/2361516/Aerie_Pharmaceuticals_Inc>,
        <https://1145.am/db/2362378/Ferring_Pharmaceuticals>,
        <https://1145.am/db/2362456/Action_Pharma_A_S>,
        <https://1145.am/db/2362525/Horizon_Pharma>,
        <https://1145.am/db/2362593/Aerie_Pharmaceuticals_Inc>,
        <https://1145.am/db/2363186/Savient_Pharmaceuticals_Inc>,
        <https://1145.am/db/2363285/Phenex_Pharmaceuticals_Ag>,
        <https://1145.am/db/2363340/Aerie_Pharmaceuticals_Inc>,
        <https://1145.am/db/2363387/Afferent_Pharmaceuticals>,
        <https://1145.am/db/2363425/The_Medicines_Company>,
        <https://1145.am/db/2363433/The_Medicines_Company>,
        <https://1145.am/db/2363452/Pharmasum_Therapeutics_As>,
        <https://1145.am/db/2363530/Adamas_Pharmaceuticals_Inc>,
        <https://1145.am/db/2363801/Preglem>,
        <https://1145.am/db/2363955/Savient_Pharmaceuticals>,
        <https://1145.am/db/2364093/Biotie>,
        <https://1145.am/db/2364252/Nps_Pharmaceuticals>,
        <https://1145.am/db/2364274/S_*_Bio_Pte_Ltd>,
        <https://1145.am/db/2364276/S_*_Bio>,
        <https://1145.am/db/2364494/Bioalliance_Pharma_Sa>,
        <https://1145.am/db/2364495/Bioalliance_Pharma>,
        <https://1145.am/db/2364538/Afferent_Pharmaceuticals>,
        <https://1145.am/db/2364541/K-V_Pharmaceutical_Company>,
        <https://1145.am/db/2364585/Conatus_Pharmaceuticals_Inc>,
        <https://1145.am/db/2364593/Aragon_Pharmaceuticals>,
        <https://1145.am/db/2364601/Aragon_Pharmaceuticals>,
        <https://1145.am/db/2364774/Aegerion_Pharmaceuticals>,
        <https://1145.am/db/2364884/Entremed_Inc>,
        <https://1145.am/db/2365030/Gw_Pharmaceuticals_Plc>,
        <https://1145.am/db/2365098/Conatus_Pharmaceuticals_Inc>,
        <https://1145.am/db/2365224/Research_Pharmaceutical_Services>,
        <https://1145.am/db/2365423/Conatus_Pharmaceuticals_Inc>,
        <https://1145.am/db/2365450/Prismic_Pharmaceuticals>,
        <https://1145.am/db/2365724/Biosante_Pharmaceuticals_Inc>,
        <https://1145.am/db/2365763/Biosante_Pharmaceuticals>,
        <https://1145.am/db/2366139/Prism_Pharmaceuticals>,
        <https://1145.am/db/2366388/Biosante_Pharmaceuticals_Inc>,
        <https://1145.am/db/2366521/Novamed_Pharmaceuticals>,
        <https://1145.am/db/2366540/Prism_Pharmaceuticals>,
        <https://1145.am/db/2367021/Biotie>,
        <https://1145.am/db/2367070/Aegerion_Pharmaceuticals>,
        <https://1145.am/db/2367280/Tetraphase_Pharmaceuticals>,
        <https://1145.am/db/2367438/Biocryst_Pharmaceuticals>,
        <https://1145.am/db/2367483/Vitae_Pharmaceuticals>,
        <https://1145.am/db/2367496/Vitae_Pharmaceuticals>,
        <https://1145.am/db/2367951/Prismic_Pharmaceuticals>,
        <https://1145.am/db/2367962/Catalyst_Pharmaceuticals>,
        <https://1145.am/db/2368070/Afferent_Pharmaceuticals>,
        <https://1145.am/db/2368339/Tetraphase_Pharmaceuticals>,
        <https://1145.am/db/2368420/Intec_Pharma>,
        <https://1145.am/db/2368593/Bioquiddity_Incorporated>,
        <https://1145.am/db/2368632/Pharmacyclics>,
        <https://1145.am/db/2368739/Novartis_Pharmaceuticals>,
        <https://1145.am/db/2368826/Aegerion_Pharmaceuticals>,
        <https://1145.am/db/2369004/Biogen>,
        <https://1145.am/db/2369037/Aegerion_Pharmaceuticals>,
        <https://1145.am/db/2369126/Achillion_Pharmaceuticals>,
        <https://1145.am/db/2369144/Aegerion_Pharmaceuticals>,
        <https://1145.am/db/2369233/Biopharmx_Corporation>,
        <https://1145.am/db/2369402/Medicines_Company>,
        <https://1145.am/db/2369812/Aoxing_Pharmaceutical_Company>,
        <https://1145.am/db/2369931/Biogen>,
        <https://1145.am/db/2370022/Apellis_Pharmaceuticals>,
        <https://1145.am/db/2370078/Pharmaceutical_Product_Development>,
        <https://1145.am/db/2370082/Aerie_Pharmaceuticals>,
        <https://1145.am/db/2370089/Abide_Therapeutics>,
        <https://1145.am/db/2370399/Pharmamar>,
        <https://1145.am/db/2370637/Medgenics_Inc>,
        <https://1145.am/db/2370797/Pharmanest>,
        <https://1145.am/db/2370798/Pharmalink_Ab>,
        <https://1145.am/db/2370946/Biogen>,
        <https://1145.am/db/2371015/M_Pharma>,
        <https://1145.am/db/2371016/M_Pharma>,
        <https://1145.am/db/2371279/Biomunex_Pharmaceuticals>,
        <https://1145.am/db/2371491/Biopharmx_Corporation>,
        <https://1145.am/db/2536754/Oramed_Pharma>,
        <https://1145.am/db/2536756/Zao>,
        <https://1145.am/db/2537468/Pharmascience_Inc>,
        <https://1145.am/db/2538171/Biomeda_Group>,
        <https://1145.am/db/2538567/Upm_Pharmaceuticals>,
        <https://1145.am/db/2538861/Par_Pharmaceuticals>,
        <https://1145.am/db/2538901/The_Harvard_Drug_Group>,
        <https://1145.am/db/2539516/Par_Pharmaceuticals>,
        <https://1145.am/db/2539568/Zao>,
        <https://1145.am/db/2540193/Pharmanest>,
        <https://1145.am/db/2540449/Biocon>,
        <https://1145.am/db/2540951/Rytary>,
        <https://1145.am/db/2541039/Elan_Pharmaceuticals>,
        <https://1145.am/db/2541239/Pharmstar>,
        <https://1145.am/db/2541326/Advanced_Pharmaceutical>,
        <https://1145.am/db/2541717/Adamas_Pharmaceuticals>,
        <https://1145.am/db/2541810/British_Pharma>,
        <https://1145.am/db/2542218/Pharmacyclics>,
        <https://1145.am/db/2543839/British_Pharma>,
        <https://1145.am/db/2544111/Unique_Pharmaceuticals>,
        <https://1145.am/db/2544358/Mundipharma>,
        <https://1145.am/db/2544596/Polpharma>,
        <https://1145.am/db/2544679/Neopharma>,
        <https://1145.am/db/2544783/Citius_Pharmaceuticals>,
        <https://1145.am/db/2545143/Mundipharma>,
        <https://1145.am/db/2545411/Aoxing_Pharmaceutical_Company>,
        <https://1145.am/db/2546441/Intas_Pharmaceuticals>,
        <https://1145.am/db/2546529/Pharma_Tech_Industries>,
        <https://1145.am/db/2546629/Par_Pharmaceutical>,
        <https://1145.am/db/2547189/Sagent_Pharmaceuticals>,
        <https://1145.am/db/2547596/Par_Pharmaceuticals>,
        <https://1145.am/db/2548585/Par_Pharmaceuticals>,
        <https://1145.am/db/2548674/Sopharma>,
        <https://1145.am/db/2549477/Sagent_Pharmaceuticals>,
        <https://1145.am/db/2549520/Aoxing_Pharmaceutical_Company>,
        <https://1145.am/db/2549919/Pharmathen>,
        <https://1145.am/db/2550212/Aoxing_Pharmaceutical>,
        <https://1145.am/db/2550471/Pharmaform>,
        <https://1145.am/db/2550523/Pharmaron>,
        <https://1145.am/db/2550685/Upm_Pharmaceuticals>,
        <https://1145.am/db/2551427/Pharmablock_Sciences>,
        <https://1145.am/db/2551601/Infinity_Pharmaceuticals>,
        <https://1145.am/db/2552169/Alembic_Pharmaceuticals>,
        <https://1145.am/db/2552465/Medis>,
        <https://1145.am/db/2552641/Plethico_Pharmaceuticals>,
        <https://1145.am/db/2552642/Mankind_Pharmaceuticals>,
        <https://1145.am/db/2552746/Supreme_Pharmaceuticals_Inc>,
        <https://1145.am/db/2552794/Millennium_Pharmaceuticals>,
        <https://1145.am/db/2553276/Millennium_Pharmaceuticals>,
        <https://1145.am/db/2553512/Pharmax_Pharmaceuticals>,
        <https://1145.am/db/2553708/Pharmaceutical_Product_Development_Llc>,
        <https://1145.am/db/2554237/Intas_Pharmaceuticals>,
        <https://1145.am/db/2554810/Continuus_Pharmaceuticals>,
        <https://1145.am/db/2554814/Globalpharma>,
        <https://1145.am/db/2554858/Medicure_Usa_Inc>,
        <https://1145.am/db/2555338/Pharmacore>,
        <https://1145.am/db/2555890/Pharmalucence>,
        <https://1145.am/db/2555896/Pharmalucence>,
        <https://1145.am/db/2556805/Medicis_Pharmaceuticals>,
        <https://1145.am/db/2557303/Pharmaron>,
        <https://1145.am/db/2557538/Neopharma>,
        <https://1145.am/db/2558025/Pharmaxis>,
        <https://1145.am/db/2558026/Pharmaxis>,
        <https://1145.am/db/2558970/Biostar_Pharmaceuticals>,
        <https://1145.am/db/2559783/Polpharma>,
        <https://1145.am/db/2560083/Exemed_Pharmaceuticals>,
        <https://1145.am/db/2561100/Exemed_Pharmaceuticals>,
        <https://1145.am/db/2561312/Oxford_Pharmaceuticals>,
        <https://1145.am/db/2561438/Pharmacia___Upjohn>,
        <https://1145.am/db/2561978/Biomarin_Pharmaceuticals>,
        <https://1145.am/db/2562199/Novartis_Pharmaceuticals_Corporation>,
        <https://1145.am/db/2562446/Specialty_Pharmaceutical>,
        <https://1145.am/db/2562500/Millennium_Pharmaceuticals>,
        <https://1145.am/db/2563255/Active_Pharmaceutical_Ingredients>,
        <https://1145.am/db/2563497/Creo_Pharmaceuticals>,
        <https://1145.am/db/2563497/Polpharma>,
        <https://1145.am/db/2564196/Pharmaron>,
        <https://1145.am/db/2564713/C2_Pharma>,
        <https://1145.am/db/2567007/Opiant_Pharmaceuticals>,
        <https://1145.am/db/2567055/Sovereign_Pharmaceuticals>,
        <https://1145.am/db/2567283/The_Pharma_Giant>,
        <https://1145.am/db/2567438/Biogen>,
        <https://1145.am/db/2567651/Indivior>,
        <https://1145.am/db/2567651/Opiant_Pharmaceuticals>,
        <https://1145.am/db/2568205/Biogen>,
        <https://1145.am/db/2568375/Biogen>,
        <https://1145.am/db/2569165/Pharmacyclics>,
        <https://1145.am/db/2569187/Pharmacyclics>,
        <https://1145.am/db/2569370/Co>,
        <https://1145.am/db/2569679/Pharmaceuticals_Inc>,
        <https://1145.am/db/2569729/The_Medicines_Company>,
        <https://1145.am/db/2569952/Nps_Pharmaceuticals>,
        <https://1145.am/db/2570068/Aegerion_Pharmaceuticals>,
        <https://1145.am/db/2570289/Pharmacyclics>,
        <https://1145.am/db/2570419/Pharmacyclics>,
        <https://1145.am/db/2570449/Biocon>,
        <https://1145.am/db/2570741/Sagent_Pharmaceuticals>,
        <https://1145.am/db/2570807/Nps_Pharmaceuticals>,
        <https://1145.am/db/2570807/Pharmacyclics>,
        <https://1145.am/db/2570834/Phrma>,
        <https://1145.am/db/2572200/The_Medicines_Company>,
        <https://1145.am/db/2572870/Hi-Tech_Pharmaceuticals>,
        <https://1145.am/db/2573057/Aprecia_Pharmaceuticals_Company>,
        <https://1145.am/db/2573058/Aprecia_Pharmaceuticals>,
        <https://1145.am/db/2573147/Medicis_Pharmaceutical>,
        <https://1145.am/db/2573271/Physician_Therapeutics>,
        <https://1145.am/db/2573391/Url_Pharma>,
        <https://1145.am/db/2573392/Url_Pharma>,
        <https://1145.am/db/2573887/Biogen>,
        <https://1145.am/db/2574679/Aprecia_Pharmaceuticals>,
        <https://1145.am/db/2574891/Pharmacyclics>,
        <https://1145.am/db/2575222/Map_Pharmaceuticals>,
        <https://1145.am/db/2575242/Research_Pharmaceutical_Services_Inc>,
        <https://1145.am/db/2575462/Paras_Pharmaceuticals>,
        <https://1145.am/db/2575623/Inova_Pharmaceuticals>,
        <https://1145.am/db/2576205/Medicis_Pharmaceutical_Corporation>,
        <https://1145.am/db/2576967/Insight_Pharmaceuticals>,
        <https://1145.am/db/2577145/Medicis_Pharmaceutical>,
        <https://1145.am/db/2577259/Pharmaceutical_Product_Development>,
        <https://1145.am/db/2577419/Osi_Pharmaceuticals>,
        <https://1145.am/db/2577675/Biogen>,
        <https://1145.am/db/2577684/Biogen>,
        <https://1145.am/db/2577894/Huvepharma_Ad>,
        <https://1145.am/db/2577934/Pharmascience>,
        <https://1145.am/db/2578177/Nexus_Pharmaceuticals>,
        <https://1145.am/db/2578319/Cosmo_Pharmaceuticals>,
        <https://1145.am/db/2578473/Aa_Pharma>,
        <https://1145.am/db/2578481/Aa_Pharma_Inc>,
        <https://1145.am/db/2579147/Medicis_Pharmaceutical>,
        <https://1145.am/db/2579211/Eusa_Pharma>,
        <https://1145.am/db/2579538/Pharmaforce>,
        <https://1145.am/db/2580123/Savient_Pharmaceuticals>,
        <https://1145.am/db/2580479/Pharmaxis>,
        <https://1145.am/db/2581225/Inova_Pharmaceuticals>,
        <https://1145.am/db/2582110/Savient_Pharmaceuticals>,
        <https://1145.am/db/2582153/Ferring_Pharmaceuticals>,
        <https://1145.am/db/2582174/Pharmasset>,
        <https://1145.am/db/2582320/Savient_Pharmaceuticals>,
        <https://1145.am/db/2582677/Aegerion_Pharmaceuticals>,
        <https://1145.am/db/2583013/Aragon_Pharmaceuticals_Inc>,
        <https://1145.am/db/2583022/Url_Pharma>,
        <https://1145.am/db/2583220/Cosmo_Pharmaceuticals_Spa>,
        <https://1145.am/db/2583270/Pharmaswiss>,
        <https://1145.am/db/2583291/Savient_Pharmaceuticals>,
        <https://1145.am/db/2583352/Elite_Pharmaceuticals_Inc>,
        <https://1145.am/db/2583402/Osi_Pharmaceuticals>,
        <https://1145.am/db/2583414/Polpharma>,
        <https://1145.am/db/2583769/Biocryst_Pharmaceuticals>,
        <https://1145.am/db/2584209/Pharmaswiss_Sa>,
        <https://1145.am/db/2584226/Pharmaswiss_Sa>,
        <https://1145.am/db/2584250/Progenics_Pharmaceuticals>,
        <https://1145.am/db/2585281/Aegerion_Pharmaceuticals>,
        <https://1145.am/db/2585887/Pharma_Inc>,
        <https://1145.am/db/2586968/Progenics_Pharmaceuticals_Inc>,
        <https://1145.am/db/2587155/Millennium_Pharma>,
        <https://1145.am/db/2587616/Pharmaq>,
        <https://1145.am/db/2587696/R-Pharm>,
        <https://1145.am/db/2588049/Aegerion_Pharmaceuticals_Inc>,
        <https://1145.am/db/2588718/Pharmacyclics>,
        <https://1145.am/db/2588884/Map_Pharmaceuticals>,
        <https://1145.am/db/2589884/Map_Pharmaceuticals>,
        <https://1145.am/db/2590159/Osi_Pharmaceuticals_Inc>,
        <https://1145.am/db/2590195/Pro-Tect_Pharmaceuticals>,
        <https://1145.am/db/2590409/Biogen>,
        <https://1145.am/db/2590910/Savient_Pharmaceuticals>,
        <https://1145.am/db/2591540/Polpharma>,
        <https://1145.am/db/2591690/Medicis_Pharmaceutical>,
        <https://1145.am/db/2591938/Ferring_Pharmaceuticals>,
        <https://1145.am/db/2593142/Access_Pharmaceuticals>,
        <https://1145.am/db/2593573/Savient_Pharmaceuticals_Inc>,
        <https://1145.am/db/2594042/Oramed_Pharmaceuticals_Inc>,
        <https://1145.am/db/2594106/Paras_Pharmaceuticals>,
        <https://1145.am/db/2594116/Pharmerica>,
        <https://1145.am/db/2594602/Osi_Pharma>,
        <https://1145.am/db/2594798/Pharmerica>,
        <https://1145.am/db/2595190/Nps_Pharmaceuticals>,
        <https://1145.am/db/2595202/Aegerion_Pharmaceuticals>,
        <https://1145.am/db/2595210/Nps_Pharmaceuticals>,
        <https://1145.am/db/2595237/Emcure_Pharmaceuticals>,
        <https://1145.am/db/2595413/Osi_Pharmaceuticals_Inc>,
        <https://1145.am/db/2596054/Elite_Pharmaceuticals_Inc>,
        <https://1145.am/db/2596307/Savient_Pharmaceuticals>,
        <https://1145.am/db/2596356/Infinity_Pharmaceuticals_Inc>,
        <https://1145.am/db/2596369/Pharmadeals_Ltd>,
        <https://1145.am/db/2596818/Pharmasset>,
        <https://1145.am/db/2597158/Nps_Pharmaceuticals>,
        <https://1145.am/db/2597180/Prism_Pharmaceuticals>,
        <https://1145.am/db/2597622/Biosante_Pharmaceuticals_Inc>,
        <https://1145.am/db/2597935/Osi_Pharmaceuticals>,
        <https://1145.am/db/2598027/Nps_Pharmaceuticals>,
        <https://1145.am/db/2598099/Paras_Pharmaceuticals>,
        <https://1145.am/db/2598137/Biosante_Pharmaceuticals_Inc>,
        <https://1145.am/db/2598195/Pharmatech>,
        <https://1145.am/db/2598605/Oncomed_Pharmaceuticals>,
        <https://1145.am/db/2765310/Biogen>,
        <https://1145.am/db/281576/Mymd_Pharmaceuticals>,
        <https://1145.am/db/307255/Mymd_Pharmaceuticals_Inc>,
        <https://1145.am/db/324642/Mundipharma>,
        <https://1145.am/db/367137/Biomat>,
        <https://1145.am/db/378431/Pharmathen>,
        <https://1145.am/db/378464/Pharmathen>,
        <https://1145.am/db/378839/Adamis_Pharmaceuticals_Corporation>,
        <https://1145.am/db/380389/Diamedica_Therapeutics_Inc>,
        <https://1145.am/db/381068/Adamis_Pharmaceuticals_Corporation>,
        <https://1145.am/db/401218/Biocryst_Pharmaceuticals_Inc>,
        <https://1145.am/db/407888/Quoin_Pharmaceuticals>,
        <https://1145.am/db/410129/Catalyst_Pharmaceuticals_Inc>,
        <https://1145.am/db/427157/Adamis_Pharmaceuticals_Corporation>,
        <https://1145.am/db/431169/Pharmablock>,
        <https://1145.am/db/4491/Achillion_Pharmaceuticals_Inc>,
        <https://1145.am/db/452957/Aerie_Pharmaceuticals>,
        <https://1145.am/db/468221/Aerie_Pharmaceuticals>,
        <https://1145.am/db/481129/Biocon_Ltd>,
        <https://1145.am/db/485351/Aerie_Pharmaceuticals_Inc>,
        <https://1145.am/db/486302/Phathom_Pharmaceuticals>,
        <https://1145.am/db/487010/Scipher_Medicine>,
        <https://1145.am/db/488564/Aerie_Pharmaceuticals>,
        <https://1145.am/db/498367/Aspire_Pharma_Limited>,
        <https://1145.am/db/499171/Aspire_Pharma_Limited>,
        <https://1145.am/db/538112/Adamas_Pharmaceuticals_Inc>,
        <https://1145.am/db/538277/Adamas_Pharmaceuticals>,
        <https://1145.am/db/539267/Adamas_Pharmaceuticals>,
        <https://1145.am/db/540865/Adamas_Pharmaceuticals_Inc>,
        <https://1145.am/db/541731/Adamas_Pharmaceuticals_Inc>,
        <https://1145.am/db/541755/Adamas_Pharmaceuticals_Inc>,
        <https://1145.am/db/545583/Citius_Pharmaceuticals>,
        <https://1145.am/db/546391/Inmed_Pharmaceuticals_Inc>,
        <https://1145.am/db/549059/Adamas_Pharmaceuticals>,
        <https://1145.am/db/567789/Aprecia_Pharmaceuticals>,
        <https://1145.am/db/585607/Am-Pharma>,
        <https://1145.am/db/637582/The_Medicines_Co>,
        <https://1145.am/db/648300/Adamas_Pharmaceuticals>,
        <https://1145.am/db/662016/Prestige_Biopharma_Limited>,
        <https://1145.am/db/668495/Scipher_Medicine>,
        <https://1145.am/db/669775/Scipher_Medicine>,
        <https://1145.am/db/693128/Ascensus_Specialties>,
        <https://1145.am/db/700482/Novartis_Pharmaceuticals>,
        <https://1145.am/db/712037/Amunix_Pharmaceuticals>,
        <https://1145.am/db/712921/Mainpointe_Pharmaceuticals>,
        <https://1145.am/db/713105/Amunix_Pharmaceuticals_Inc>,
        <https://1145.am/db/713736/Aerie_Pharmaceuticals_Inc>,
        <https://1145.am/db/714923/Betterlife_Pharma_Inc>,
        <https://1145.am/db/715385/Aerie_Pharmaceuticals_Inc>,
        <https://1145.am/db/718008/Pharnext_Sa>,
        <https://1145.am/db/723883/Mymd_Pharmaceuticals>,
        <https://1145.am/db/724999/Mymd_Pharmaceuticals_Inc>,
        <https://1145.am/db/724999/Oramed_Pharmaceuticals_Inc>,
        <https://1145.am/db/734669/Escient_Pharmaceuticals>,
        <https://1145.am/db/742794/Hr®_Pharmaceuticals_Inc>,
        <https://1145.am/db/771062/Gw_Pharmaceuticals>,
        <https://1145.am/db/793071/Biogen_Inc>,
        <https://1145.am/db/835485/Pharmaessentia_Corporation>,
        <https://1145.am/db/854026/Aerie_Pharmaceuticals>,
        <https://1145.am/db/883896/Biontech>,
        <https://1145.am/db/884665/Pharmaceutical_Institute>,
        <https://1145.am/db/887575/Aprecia_Pharmaceuticals>,
        <https://1145.am/db/889331/Théa_Pharma>,
        <https://1145.am/db/912469/Aerie_Pharmaceuticals>,
        <https://1145.am/db/913730/Aerie_Pharmaceuticals>,
        <https://1145.am/db/922740/Grand_Pharma>,
        <https://1145.am/db/976867/Aprecia_Pharmaceuticals> ;
    ns1:sameAsMedium <https://1145.am/db/2369883/Achillion_Pharmaceuticals> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352805/Investment_Achillion_Pharmaceuticals_Domain_Associates_Clarus_Ventures_Quaker_Bioventures_Pappas_Ventures_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-08-19T15:26:14+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Achillion Pharmaceuticals is raising $ 50 million through the sale of its common shares to a slate of venture backers in a deal designed to fuel its clinical trial work on new hepatitis C drugs." ;
    ns1:documentTitle "Venture groups snap up $50M block of Achillion shares" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/venture-groups-snap-up-50m-block-of-achillion-shares> ;
    ns1:foundName "raising",
        "sale" ;
    ns1:name "raising",
        "sale" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2352805/Achillion_Pharmaceuticals> ;
    ns1:valueRaw "$ 50 million" ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "United States" .

<https://1145.am/db/2352805/Pappas_Ventures> a org:Organization ;
    ns1:description "venture backers" ;
    ns1:documentDate "2010-08-19T15:26:14+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Venture groups snap up $50M block of Achillion shares" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/venture-groups-snap-up-50m-block-of-achillion-shares> ;
    ns1:foundName "Pappas Ventures" ;
    ns1:investor <https://1145.am/db/2352805/Investment_Achillion_Pharmaceuticals_Domain_Associates_Clarus_Ventures_Quaker_Bioventures_Pappas_Ventures_Completed> ;
    ns1:name "Pappas Ventures" ;
    ns1:sameAsHigh <https://1145.am/db/2305706/Pappas_Ventures>,
        <https://1145.am/db/2539913/Pappas_Ventures> ;
    ns1:sameAsMedium <https://1145.am/db/2289229/Pappas_Ventures>,
        <https://1145.am/db/2305713/Pappas_Ventures>,
        <https://1145.am/db/2308329/Pappas_Ventures>,
        <https://1145.am/db/2312277/Pappas_Ventures>,
        <https://1145.am/db/2312288/Pappas_Ventures>,
        <https://1145.am/db/2314397/Pappas_Ventures>,
        <https://1145.am/db/2314400/Pappas_Ventures>,
        <https://1145.am/db/2314492/Pappas_Ventures>,
        <https://1145.am/db/2319029/Pappas_Ventures>,
        <https://1145.am/db/2324289/Pappas_Ventures>,
        <https://1145.am/db/2328388/Pappas_Ventures>,
        <https://1145.am/db/2332753/Pappas_Ventures>,
        <https://1145.am/db/2341904/Pappas_Ventures>,
        <https://1145.am/db/2346532/Pappas_Ventures>,
        <https://1145.am/db/2346542/Pappas_Ventures>,
        <https://1145.am/db/2350779/Pappas_Ventures>,
        <https://1145.am/db/2350780/Pappas_Ventures>,
        <https://1145.am/db/2352808/Pappas_Ventures>,
        <https://1145.am/db/2354537/Pappas_Ventures>,
        <https://1145.am/db/2354540/Pappas_Ventures>,
        <https://1145.am/db/2355274/Pappas_Ventures>,
        <https://1145.am/db/2356216/Pappas_Ventures>,
        <https://1145.am/db/2359562/Pappas_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352807/Orbimed_Advisors> a org:Organization ;
    ns1:basedInLowRaw "Calif" ;
    ns1:description "financing" ;
    ns1:documentDate "2010-08-19T15:28:58+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Complete Genomics, Inc. Announces Completion of $39 Million Series E Financing and Addresses Illumina Patent Infringement Lawsui" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/complete-genomics-inc-announces-completion-of-39-million-series-e-financing-and-addresses> ;
    ns1:foundName "OrbiMed Advisors" ;
    ns1:investor <https://1145.am/db/2352807/Series_E_Investment_Complete_Genomics_Enterprise_Partners_Essex_Woodlands_Highland_Capital_Ovp_Venture_Partners_Orbimed_Advisors_Prospect_Venture_Partners_Sands_Capital_Completed> ;
    ns1:name "OrbiMed Advisors" ;
    ns1:sameAsHigh <https://1145.am/db/1426073/Orbimed>,
        <https://1145.am/db/1426943/Orbimed>,
        <https://1145.am/db/1809007/Orbimed_Advisors>,
        <https://1145.am/db/2080575/Orbimed>,
        <https://1145.am/db/2303098/Orbimed_Advisors>,
        <https://1145.am/db/2325257/Orbimed_Advisors>,
        <https://1145.am/db/2350720/Orbimed>,
        <https://1145.am/db/2356420/Orbimed_Advisors>,
        <https://1145.am/db/2359468/Orbimed_Advisors>,
        <https://1145.am/db/428737/Orbimed_Advisors>,
        <https://1145.am/db/770684/Orbimed>,
        <https://1145.am/db/791742/Orbimed> ;
    ns1:sameAsMedium <https://1145.am/db/1665536/Orbimed_Advisors>,
        <https://1145.am/db/2198816/Orbimed_Advisors>,
        <https://1145.am/db/2245885/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2281230/Orbimed_Advisors>,
        <https://1145.am/db/2284506/Orbimed_Advisors>,
        <https://1145.am/db/2289056/Orbimed_Advisors>,
        <https://1145.am/db/2290078/Orbimed_Advisors>,
        <https://1145.am/db/2290200/Orbimed_Advisors>,
        <https://1145.am/db/2290444/Orbimed_Advisors>,
        <https://1145.am/db/2297604/Orbimed_Advisors>,
        <https://1145.am/db/2298956/Orbimed_Advisors>,
        <https://1145.am/db/2304242/Orbimed_Advisors>,
        <https://1145.am/db/2305656/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2306251/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2306705/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2309491/Orbimed_Advisors>,
        <https://1145.am/db/2310922/Orbimed_Advisors>,
        <https://1145.am/db/2312233/Orbimed_Advisors>,
        <https://1145.am/db/2317918/Orbimed_Advisors>,
        <https://1145.am/db/2318133/Orbimed_Advisors>,
        <https://1145.am/db/2318829/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2318832/Orbimed_Advisers>,
        <https://1145.am/db/2318851/Orbimed_Advisors>,
        <https://1145.am/db/2319338/Orbimed_Advisors>,
        <https://1145.am/db/2320914/Orbimed_Advisors>,
        <https://1145.am/db/2322345/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2324226/Orbimed_Advisors>,
        <https://1145.am/db/2325880/Orbimed_Advisors>,
        <https://1145.am/db/2328599/Orbimed_Advisors>,
        <https://1145.am/db/2328700/Orbimed_Advisors>,
        <https://1145.am/db/2329260/Orbimed_Advisors>,
        <https://1145.am/db/2330799/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2330920/Orbimed_Advisors>,
        <https://1145.am/db/2332120/Orbimed_Advisors>,
        <https://1145.am/db/2333495/Orbimed_Advisors>,
        <https://1145.am/db/2333504/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2333966/Orbimed_Advisors>,
        <https://1145.am/db/2335743/Orbimed_Advisors>,
        <https://1145.am/db/2336221/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2336503/Orbimed_Advisors>,
        <https://1145.am/db/2336505/Orbimed_Advisors>,
        <https://1145.am/db/2336524/Orbimed_Advisors>,
        <https://1145.am/db/2337166/Orbimed_Advisors>,
        <https://1145.am/db/2337250/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2337254/Orbimed_Advisors>,
        <https://1145.am/db/2339885/Orbimed_Advisors>,
        <https://1145.am/db/2339886/Orbimed_Advisors>,
        <https://1145.am/db/2342862/Orbimed_Advisors>,
        <https://1145.am/db/2342925/Orbimed_Advisors>,
        <https://1145.am/db/2342937/Orbimed_Advisors>,
        <https://1145.am/db/2343244/Orbimed_Advisors>,
        <https://1145.am/db/2344735/Orbimed_Advisors>,
        <https://1145.am/db/2344786/Orbimed_Advisors>,
        <https://1145.am/db/2345435/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2345453/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2345456/Orbimed_Advisors>,
        <https://1145.am/db/2346030/Orbimed_Advisors>,
        <https://1145.am/db/2350034/Orbimed_Advisors>,
        <https://1145.am/db/2350044/Orbimed_Advisors>,
        <https://1145.am/db/2352436/Orbimed_Advisors>,
        <https://1145.am/db/2352441/Orbimed_Advisors>,
        <https://1145.am/db/2352442/Orbimed_Advisors>,
        <https://1145.am/db/2352701/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2352804/Orbimed_Advisors>,
        <https://1145.am/db/2355034/Orbimed_Advisors>,
        <https://1145.am/db/2356297/Orbimed_Advisors>,
        <https://1145.am/db/2357253/Orbimed_Advisors>,
        <https://1145.am/db/2357256/Orbimed_Advisors>,
        <https://1145.am/db/2357858/Orbimed_Advisors>,
        <https://1145.am/db/2359125/Orbimed_Advisors>,
        <https://1145.am/db/2359864/Orbimed_Advisors>,
        <https://1145.am/db/2360174/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2361018/Orbimed_Advisors>,
        <https://1145.am/db/2361022/Orbimed_Advisors>,
        <https://1145.am/db/2361027/Orbimed_Advisors>,
        <https://1145.am/db/2362475/Orbimed_Advisors>,
        <https://1145.am/db/2362481/Orbimed_Advisors>,
        <https://1145.am/db/2363339/Orbimed_Advisors>,
        <https://1145.am/db/2365679/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2365868/Orbimed_Advisors>,
        <https://1145.am/db/2366519/Orbimed_Advisors>,
        <https://1145.am/db/2574232/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2583013/Orbimed_Advisors>,
        <https://1145.am/db/456081/Orbimed_Advisors>,
        <https://1145.am/db/456089/Orbimed_Advisors>,
        <https://1145.am/db/458377/Orbimed_Advisors>,
        <https://1145.am/db/674484/Orbimed_Advisors> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352808/Achillion_Pharmaceuticals_Inc> a org:Organization ;
    ns1:basedInHighGeoName "New Haven County" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/4839373/about.rdf> ;
    ns1:basedInHighRaw "NEW HAVEN, Conn." ;
    ns1:description "the discovery and development of small molecule drugs to combat the most challenging infectious diseases" ;
    ns1:documentDate "2010-08-19T15:35:59+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Achillion Announces Private Placement of $50 Million" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/achillion-announces-private-placement-of-50-million> ;
    ns1:foundName "! achn",
        "! achn/quotes/nls/achn",
        "Achillion Pharmaceuticals, Inc.",
        "Achillion'",
        "achn/quotes/nls",
        "achn/quotes/nls/achn" ;
    ns1:industry "Pharmaceuticals" ;
    ns1:investor <https://1145.am/db/2352808/Investment_Achillion_Pharmaceuticals_Inc_Clarus_Ventures_Domain_Associates_Pappas_Ventures_Quaker_Bioventures_Has_Not_Happened> ;
    ns1:name "Achillion Pharmaceuticals",
        "Achillion Pharmaceuticals, Inc." ;
    ns1:sameAsHigh <https://1145.am/db/101025/Scpharmaceuticals_Inc>,
        <https://1145.am/db/101329/Scpharmaceuticals_Inc>,
        <https://1145.am/db/1031042/Intomics>,
        <https://1145.am/db/1033561/Hs_Pharmaceuticals>,
        <https://1145.am/db/1054457/Elite_Pharmaceuticals_Inc>,
        <https://1145.am/db/1054503/Hs_Pharmaceuticals>,
        <https://1145.am/db/1061901/Pharmaessentia_Corporation>,
        <https://1145.am/db/1070158/Biognosys>,
        <https://1145.am/db/1079560/Satiogen_Pharmaceuticals>,
        <https://1145.am/db/1080385/Satiogen_Pharmaceuticals>,
        <https://1145.am/db/1092000/Adamis_Pharmaceuticals_Corporation>,
        <https://1145.am/db/11010/Progenics_Pharmaceuticals>,
        <https://1145.am/db/1104169/20045078>,
        <https://1145.am/db/1118439/Inmed_Pharmaceuticals_Inc>,
        <https://1145.am/db/1141704/Inmed_Pharmaceuticals>,
        <https://1145.am/db/1174705/Scpharmaceuticals_Inc>,
        <https://1145.am/db/1176480/X4_Pharmaceuticals_Inc>,
        <https://1145.am/db/1185008/TDV>,
        <https://1145.am/db/1186876/Cornerstone_Pharmaceuticals>,
        <https://1145.am/db/1198337/Recce_Pharmaceuticals_Ltd>,
        <https://1145.am/db/1216583/Inmed_Pharmaceuticals_Inc>,
        <https://1145.am/db/1291286/Vital_Pharmaceuticals_Inc>,
        <https://1145.am/db/1294499/Aerie_Pharmaceuticals>,
        <https://1145.am/db/1294506/Aerie_Pharmaceuticals>,
        <https://1145.am/db/1295948/Aerie_Pharmaceuticals>,
        <https://1145.am/db/1296487/Aerie_Pharmaceuticals>,
        <https://1145.am/db/1307419/X4_Pharmaceuticals>,
        <https://1145.am/db/1322957/Biosion>,
        <https://1145.am/db/1329779/Inmed_Pharmaceuticals_Inc>,
        <https://1145.am/db/1339033/Inmed_Pharmaceuticals_Inc>,
        <https://1145.am/db/1343020/Biocryst_Pharmaceuticals>,
        <https://1145.am/db/1370859/Bioivt>,
        <https://1145.am/db/1371279/Aerie_Pharmaceuticals_Inc>,
        <https://1145.am/db/1387773/Aspire_Pharma>,
        <https://1145.am/db/1390741/Nexus_Pharmaceuticals_Inc>,
        <https://1145.am/db/1409143/Scpharmaceuticals_Inc>,
        <https://1145.am/db/1417348/Aerie_Pharmaceuticals_Inc>,
        <https://1145.am/db/1417723/Altasciences>,
        <https://1145.am/db/1418572/Aerie_Pharmaceuticals_Inc>,
        <https://1145.am/db/1430057/Aerie_Pharmaceuticals_Inc>,
        <https://1145.am/db/1443334/Aerie_Pharmaceuticals_Inc>,
        <https://1145.am/db/1443968/Pharmajet®>,
        <https://1145.am/db/1445613/Pharmajet>,
        <https://1145.am/db/1487706/Phathom_Pharmaceuticals_Inc>,
        <https://1145.am/db/1497210/Indivior_Plc>,
        <https://1145.am/db/1497210/Opiant_Pharmaceuticals_Inc>,
        <https://1145.am/db/1497218/Indivior>,
        <https://1145.am/db/1497218/Opiant_Pharmaceuticals>,
        <https://1145.am/db/1500616/Indivior_Plc>,
        <https://1145.am/db/1500616/Opiant_Pharmaceuticals_Inc>,
        <https://1145.am/db/1502096/Indivior_Plc>,
        <https://1145.am/db/1502096/Opiant_Pharmaceuticals_Inc>,
        <https://1145.am/db/1505968/Escient_Pharmaceuticals>,
        <https://1145.am/db/1508407/Escient_Pharmaceuticals>,
        <https://1145.am/db/1515279/Inmed_Pharmaceuticals_Inc>,
        <https://1145.am/db/1520596/Aerie_Pharmaceuticals>,
        <https://1145.am/db/1520597/Aerie_Pharmaceuticals>,
        <https://1145.am/db/1521624/Scpharmaceuticals>,
        <https://1145.am/db/1521695/Aerie_Pharmaceuticals>,
        <https://1145.am/db/1521941/Inmed_Pharmaceuticals_Inc>,
        <https://1145.am/db/1523220/Scpharmaceuticals_Inc>,
        <https://1145.am/db/1533327/Escient_Pharmaceuticals>,
        <https://1145.am/db/1533685/Escient_Pharmaceuticals>,
        <https://1145.am/db/1537336/Pharmajet®>,
        <https://1145.am/db/1538786/Pharmajet>,
        <https://1145.am/db/1540449/Aerie_Pharmaceuticals>,
        <https://1145.am/db/1541946/Amunix_Pharmaceuticals>,
        <https://1145.am/db/1548955/Amunix_Pharmaceuticals>,
        <https://1145.am/db/1557072/Essential_Pharma>,
        <https://1145.am/db/1559882/X4_Pharmaceuticals_Inc>,
        <https://1145.am/db/1571078/Organon>,
        <https://1145.am/db/1585097/Scpharmaceuticals_Inc>,
        <https://1145.am/db/158742/Biogen_Inc>,
        <https://1145.am/db/1595580/Madrigal_Pharmaceuticals>,
        <https://1145.am/db/160543/Mymd_Pharmaceuticals_Inc>,
        <https://1145.am/db/1613688/Pharmalex>,
        <https://1145.am/db/1624479/Indivior_Plc>,
        <https://1145.am/db/1624479/Opiant_Pharmaceuticals_Inc>,
        <https://1145.am/db/1625532/Indivior_Plc>,
        <https://1145.am/db/1625532/Opiant_Pharmaceuticals_Inc>,
        <https://1145.am/db/1629605/Biogen>,
        <https://1145.am/db/1629663/Biogen>,
        <https://1145.am/db/1632411/Scipher_Medicine>,
        <https://1145.am/db/1632862/Scipher_Medicine>,
        <https://1145.am/db/1632868/Sovereign_Pharmaceuticals_Llc>,
        <https://1145.am/db/1661035/Biontech>,
        <https://1145.am/db/1680583/Infinity_Pharmaceuticals_Inc>,
        <https://1145.am/db/1687234/Infinity_Pharmaceuticals_Inc>,
        <https://1145.am/db/180589/Servier>,
        <https://1145.am/db/1955684/Eip_Pharma_Inc>,
        <https://1145.am/db/1979697/Amphastar_Pharmaceuticals>,
        <https://1145.am/db/2038168/Infinity_Pharmaceuticals_Inc>,
        <https://1145.am/db/2039291/Infinity_Pharmaceuticals_Inc>,
        <https://1145.am/db/2039678/Infinity_Pharmaceuticals_Inc>,
        <https://1145.am/db/2040011/Ferring_Pharmaceuticals>,
        <https://1145.am/db/2045820/Ferring_Pharmaceuticals>,
        <https://1145.am/db/2049603/Inova_Pharmaceuticals>,
        <https://1145.am/db/2056005/Infinity_Pharmaceuticals_Inc>,
        <https://1145.am/db/2056755/Infinity_Pharmaceuticals_Inc>,
        <https://1145.am/db/2061803/Infinity_Pharmaceuticals>,
        <https://1145.am/db/2062156/Infinity_Pharmaceuticals_Inc>,
        <https://1145.am/db/2066480/Infinity_Pharmaceuticals_Inc>,
        <https://1145.am/db/2071248/Biogen>,
        <https://1145.am/db/2074741/Biogen_Inc>,
        <https://1145.am/db/2092442/Leo_Pharma>,
        <https://1145.am/db/2093802/Meitheal_Pharmaceuticals>,
        <https://1145.am/db/2100253/Biogen_Inc>,
        <https://1145.am/db/2101006/Leo_Pharma_A_S>,
        <https://1145.am/db/2138834/Altasciences>,
        <https://1145.am/db/2151781/Aerie_Pharmaceuticals>,
        <https://1145.am/db/2152103/Am-Pharma>,
        <https://1145.am/db/2152434/Tetraphase_Pharmaceuticals>,
        <https://1145.am/db/2153727/Amunix_Pharmaceuticals>,
        <https://1145.am/db/2154019/Aerie_Pharmaceuticals>,
        <https://1145.am/db/2154118/Aerie_Pharmaceuticals>,
        <https://1145.am/db/2154527/The_Medicines_Company>,
        <https://1145.am/db/2154871/Ferring_Pharmaceuticals>,
        <https://1145.am/db/2155006/Medicines_Company>,
        <https://1145.am/db/2155312/Ferring_Pharmaceuticals>,
        <https://1145.am/db/2155622/Isa_Pharmaceuticals>,
        <https://1145.am/db/2155792/Ucb_Pharma>,
        <https://1145.am/db/2155798/Ucb_Pharma>,
        <https://1145.am/db/2155994/Aegerion_Pharmaceuticals>,
        <https://1145.am/db/2156002/Aegerion_Pharmaceuticals>,
        <https://1145.am/db/2198945/Millennium_Pharmaceuticals_Inc>,
        <https://1145.am/db/2201094/Pharmadeals_Ltd>,
        <https://1145.am/db/2204969/Organon_Biosciences>,
        <https://1145.am/db/2207034/Cequent_Pharmaceuticals>,
        <https://1145.am/db/221697/Gw_Pharmaceuticals>,
        <https://1145.am/db/2217819/Pharmacopeia>,
        <https://1145.am/db/221787/Gw_Pharmaceuticals>,
        <https://1145.am/db/2218929/Millennium_Pharmaceuticals>,
        <https://1145.am/db/2224859/Biologics>,
        <https://1145.am/db/2229191/Biologics>,
        <https://1145.am/db/2279276/Aerie_Pharmaceuticals>,
        <https://1145.am/db/2279648/Organon>,
        <https://1145.am/db/2280123/Casi_Pharmaceuticals>,
        <https://1145.am/db/2280153/Pharming>,
        <https://1145.am/db/2281547/Ferring_Pharmaceuticals>,
        <https://1145.am/db/2283570/Pherin_Pharmaceuticals>,
        <https://1145.am/db/2284358/Escient_Pharmaceuticals>,
        <https://1145.am/db/2285117/Immedica>,
        <https://1145.am/db/2285495/Bioivt>,
        <https://1145.am/db/2287224/Escient_Pharmaceuticals>,
        <https://1145.am/db/2287505/Achillion_Pharmaceuticals>,
        <https://1145.am/db/2287572/T3_Pharmaceuticals>,
        <https://1145.am/db/2288192/Servier>,
        <https://1145.am/db/2290842/X4_Pharmaceuticals>,
        <https://1145.am/db/2291791/Aerie_Pharmaceuticals>,
        <https://1145.am/db/2291914/Achillion_Pharmaceuticals>,
        <https://1145.am/db/2294547/Vitae_Pharmaceuticals>,
        <https://1145.am/db/2294570/Pharmatek>,
        <https://1145.am/db/2296094/Biogen>,
        <https://1145.am/db/2297534/Bio>,
        <https://1145.am/db/2298037/Ethicon>,
        <https://1145.am/db/2298627/Ferring_Pharmaceuticals>,
        <https://1145.am/db/2299414/Biogen>,
        <https://1145.am/db/2301089/Cerulean_Pharma>,
        <https://1145.am/db/2301346/Pharmaron>,
        <https://1145.am/db/2301718/Oncomed_Pharmaceuticals>,
        <https://1145.am/db/2301735/Idera_Pharmaceuticals>,
        <https://1145.am/db/2301764/Map_Pharmaceuticals_Inc>,
        <https://1145.am/db/2301798/Osi_Pharmaceuticals>,
        <https://1145.am/db/2302019/Oscient_Pharmaceuticals_Corporation>,
        <https://1145.am/db/2302275/Map_Pharmaceuticals>,
        <https://1145.am/db/2302426/Idera_Pharmaceuticals_Inc>,
        <https://1145.am/db/2302431/Infinity_Pharmaceuticals_Inc>,
        <https://1145.am/db/2302552/Am-Pharma>,
        <https://1145.am/db/2302574/Via_Pharmaceuticals>,
        <https://1145.am/db/2302579/Via_Pharmaceuticals>,
        <https://1145.am/db/2302587/Access_Pharmaceuticals>,
        <https://1145.am/db/2302658/Biotie>,
        <https://1145.am/db/2302707/Vitae_Pharmaceuticals>,
        <https://1145.am/db/2302774/Innovive_Pharmaceuticals>,
        <https://1145.am/db/2302779/Innovive_Pharmaceuticals>,
        <https://1145.am/db/2302890/Presidio_Pharmaceuticals>,
        <https://1145.am/db/2302897/Presidio_Pharmaceuticals>,
        <https://1145.am/db/2303022/Ore_Pharmaceuticals>,
        <https://1145.am/db/2303121/Locus_Pharmaceuticals>,
        <https://1145.am/db/2303131/Locus_Pharmaceuticals>,
        <https://1145.am/db/2303182/Pharmexa>,
        <https://1145.am/db/2303208/Ore_Pharmaceuticals>,
        <https://1145.am/db/2303426/Infinity_Pharmaceuticals>,
        <https://1145.am/db/2303674/Cerulean_Pharma>,
        <https://1145.am/db/2303792/Access_Pharmaceuticals>,
        <https://1145.am/db/2303934/Oncomed_Pharmaceuticals>,
        <https://1145.am/db/2303956/Prolexys_Pharmaceuticals>,
        <https://1145.am/db/2304044/Novamed_Pharmaceuticals_Inc>,
        <https://1145.am/db/2304097/Pharmaceutical_Product_Development>,
        <https://1145.am/db/2304135/Progenics_Pharmaceuticals>,
        <https://1145.am/db/2304610/Pharmos_Corp>,
        <https://1145.am/db/2304745/Critical_Pharmaceuticals>,
        <https://1145.am/db/2304831/Pharmion_Corporation>,
        <https://1145.am/db/2304934/Medicure>,
        <https://1145.am/db/2304985/Pharmaceutical_Product_Development_Llc>,
        <https://1145.am/db/2305742/Mh_Pharma_Uk>,
        <https://1145.am/db/2305834/Nps_Pharmaceuticals>,
        <https://1145.am/db/2305927/Entremed>,
        <https://1145.am/db/2305956/Presidio_Pharmaceuticals>,
        <https://1145.am/db/2306255/Biosante_Pharmaceuticals>,
        <https://1145.am/db/2306299/Verily>,
        <https://1145.am/db/2306641/Bioalliance_Pharma_Sa>,
        <https://1145.am/db/2306962/Pharmaron>,
        <https://1145.am/db/2307239/Pharmaxis_Ltd>,
        <https://1145.am/db/2307246/Pharmaxis>,
        <https://1145.am/db/2307254/Presidio_Pharmaceuticals>,
        <https://1145.am/db/2307651/Organon>,
        <https://1145.am/db/2307834/Savient_Pharmaceuticals>,
        <https://1145.am/db/2307871/Access_Pharmaceuticals>,
        <https://1145.am/db/2307894/Lev_Pharmaceuticals>,
        <https://1145.am/db/2307897/Oramed_Pharmaceuticals>,
        <https://1145.am/db/2308423/Adamas_Pharmaceuticals>,
        <https://1145.am/db/2308429/Adamas_Pharmaceuticals_Inc>,
        <https://1145.am/db/2308446/Pharmathene>,
        <https://1145.am/db/2308922/Lev_Pharmaceuticals>,
        <https://1145.am/db/2308964/Slate_Pharmaceuticals>,
        <https://1145.am/db/2309001/Biocon>,
        <https://1145.am/db/2309301/Inc>,
        <https://1145.am/db/2309923/Diasome_Pharmaceuticals>,
        <https://1145.am/db/2310002/Infinity_Pharmaceuticals>,
        <https://1145.am/db/2310002/Map_Pharmaceuticals>,
        <https://1145.am/db/2310045/Slate_Pharmaceuticals>,
        <https://1145.am/db/2310071/Encysive_Pharmaceuticals_Inc>,
        <https://1145.am/db/2310196/Symbollon_Pharmaceuticals>,
        <https://1145.am/db/2310200/Encysive_Pharmaceuticals>,
        <https://1145.am/db/2310219/Docpharma>,
        <https://1145.am/db/2310232/Genaissance_Pharmaceuticals>,
        <https://1145.am/db/2310471/Cornerstone_Pharmaceuticals>,
        <https://1145.am/db/2310473/Cornerstone_Pharmaceuticals_Inc>,
        <https://1145.am/db/2310476/Afferent_Pharmaceuticals>,
        <https://1145.am/db/2310480/Idera_Pharmaceuticals_Inc>,
        <https://1145.am/db/2310590/Adamas_Pharmaceuticals>,
        <https://1145.am/db/2310790/Pharmaceutical_Product_Development_Llc>,
        <https://1145.am/db/2310989/Savient_Pharmaceuticals_Inc>,
        <https://1145.am/db/2310993/Pharmaceutical_Research_And_Manufacturers_Of_America>,
        <https://1145.am/db/2311166/Proprius_Pharmaceuticals>,
        <https://1145.am/db/2311202/Nps_Pharmaceuticals_Inc>,
        <https://1145.am/db/2311217/Biosante_Pharmaceuticals>,
        <https://1145.am/db/2311264/Medicure>,
        <https://1145.am/db/2311726/Inc>,
        <https://1145.am/db/2312088/Cerulean_Pharma>,
        <https://1145.am/db/2312088/Infinity_Pharmaceuticals>,
        <https://1145.am/db/2312158/Biosante_Pharmaceuticals>,
        <https://1145.am/db/2312193/Ore_Pharmaceuticals_Inc>,
        <https://1145.am/db/2312257/The_Medicines_Company>,
        <https://1145.am/db/2312344/Oscient_Pharmaceuticals>,
        <https://1145.am/db/2312416/Vitae_Pharmaceuticals>,
        <https://1145.am/db/2312476/Nps_Pharmaceuticals>,
        <https://1145.am/db/2312479/Nps_Pharmaceuticals>,
        <https://1145.am/db/2313305/Tetraphase_Pharmaceuticals_Inc>,
        <https://1145.am/db/2313306/Tetraphase_Pharmaceuticals>,
        <https://1145.am/db/2313320/Biosante_Pharmaceuticals>,
        <https://1145.am/db/2313320/Ore_Pharmaceuticals>,
        <https://1145.am/db/2313323/Biosante_Pharmaceuticals>,
        <https://1145.am/db/2313324/Ore_Pharmaceuticals_Inc>,
        <https://1145.am/db/2313336/Sound_Pharmaceuticals>,
        <https://1145.am/db/2313487/Symbollon_Pharmaceuticals>,
        <https://1145.am/db/2313501/Bioalliance_Pharma>,
        <https://1145.am/db/2313527/Millennium_Pharmaceuticals>,
        <https://1145.am/db/2313528/Us_Pharmaceutical_Company>,
        <https://1145.am/db/2314217/Sciele_Pharma>,
        <https://1145.am/db/2314271/Biomarck_Pharmaceuticals_Ltd>,
        <https://1145.am/db/2314277/Biomarck_Pharmaceuticals>,
        <https://1145.am/db/2314317/Infinity_Pharmaceuticals_Inc>,
        <https://1145.am/db/2314375/Cornerstone_Pharmaceuticals_Inc>,
        <https://1145.am/db/2314474/Pharmion>,
        <https://1145.am/db/2314680/Pharming>,
        <https://1145.am/db/2314816/Biosante_Pharmaceuticals_Inc>,
        <https://1145.am/db/2314837/Biosante_Pharmaceuticals>,
        <https://1145.am/db/2315159/Research_Pharmaceutical_Services_Inc>,
        <https://1145.am/db/2315192/Pharmaceutical_Product_Development>,
        <https://1145.am/db/2315296/Oscient_Pharmaceuticals>,
        <https://1145.am/db/2315485/Polpharma>,
        <https://1145.am/db/2315571/Sciele_Pharma>,
        <https://1145.am/db/2315624/Oscient_Pharmaceuticals>,
        <https://1145.am/db/2315624/Pharmos>,
        <https://1145.am/db/2315925/Oramed_Pharmaceuticals>,
        <https://1145.am/db/2315941/Adamis_Pharmaceuticals_Corporation>,
        <https://1145.am/db/2316239/Pharmaceutical_Product_Development_Llc>,
        <https://1145.am/db/2316418/Pharmaventures_Ltd>,
        <https://1145.am/db/2316435/Pharmaventures_Ltd>,
        <https://1145.am/db/2316481/Osi_Pharmaceuticals>,
        <https://1145.am/db/2316660/Pharmacopeia>,
        <https://1145.am/db/2316684/Infinity_Pharmaceuticals>,
        <https://1145.am/db/2317337/Pharmaceutical_Product_Development_Llc>,
        <https://1145.am/db/2317344/Research_Pharmaceutical_Services>,
        <https://1145.am/db/2317635/Biocryst_Pharmaceuticals>,
        <https://1145.am/db/2317762/Pharmathene>,
        <https://1145.am/db/2317826/Anormed>,
        <https://1145.am/db/2317826/Millennium_Pharmaceuticals>,
        <https://1145.am/db/2317842/Oncomed_Pharmaceuticals>,
        <https://1145.am/db/2317895/Esprit_Pharma>,
        <https://1145.am/db/2317929/Oncomed_Pharmaceuticals>,
        <https://1145.am/db/2318105/Pharma_Inc>,
        <https://1145.am/db/2318114/Transdel_Pharmaceuticals_Inc>,
        <https://1145.am/db/2318248/Vitae_Pharmaceuticals>,
        <https://1145.am/db/2318285/Pht_Corporation>,
        <https://1145.am/db/2318469/Research_Pharmaceutical_Services>,
        <https://1145.am/db/2318554/Vitae_Pharmaceuticals>,
        <https://1145.am/db/2318574/Idera_Pharmaceuticals>,
        <https://1145.am/db/2318711/Specialty_Pharmaceuticals>,
        <https://1145.am/db/2318743/Pharmos_Corporation>,
        <https://1145.am/db/2318808/Pharmathene>,
        <https://1145.am/db/2318986/Corgentech>,
        <https://1145.am/db/2318994/Cornerstone_Biopharma>,
        <https://1145.am/db/2319208/Osi_Pharmaceuticals>,
        <https://1145.am/db/2319687/Advisys>,
        <https://1145.am/db/2319790/Pharmacyclics>,
        <https://1145.am/db/2319806/Satori_Pharmaceuticals>,
        <https://1145.am/db/2319809/Satori_Pharmaceuticals_Incorporated>,
        <https://1145.am/db/2319938/Del_Pharmaceuticals>,
        <https://1145.am/db/2319939/Progenics_Pharmaceuticals>,
        <https://1145.am/db/2320009/Map_Pharmaceuticals>,
        <https://1145.am/db/2320025/Am-Pharma>,
        <https://1145.am/db/2320025/Esprit_Pharma>,
        <https://1145.am/db/2320461/Infinity_Pharmaceuticals_Inc>,
        <https://1145.am/db/2320767/Via_Pharmaceuticals>,
        <https://1145.am/db/2320903/Cequent_Pharmaceuticals>,
        <https://1145.am/db/2320949/Medicines_Company>,
        <https://1145.am/db/2321148/Savient_Pharmaceuticals>,
        <https://1145.am/db/2321157/Access_Pharmaceuticals>,
        <https://1145.am/db/2321256/Nps_Pharmaceuticals>,
        <https://1145.am/db/2321409/Adamis_Pharmaceuticals_Corporation>,
        <https://1145.am/db/2321413/Adamis_Pharmaceuticals_Corporation>,
        <https://1145.am/db/2321565/2009-2010>,
        <https://1145.am/db/2321784/Acceliant>,
        <https://1145.am/db/2321860/Achillion_Pharmaceuticals>,
        <https://1145.am/db/2321861/Astion_Pharma>,
        <https://1145.am/db/2321871/Astion_Pharma>,
        <https://1145.am/db/2321899/Aegerion_Pharmaceuticals>,
        <https://1145.am/db/2322135/Millennium_Pharmaceuticals_Inc>,
        <https://1145.am/db/2322235/Pharmacopeia>,
        <https://1145.am/db/2322291/Polpharma>,
        <https://1145.am/db/2322481/Cornerstone_Pharmaceuticals_Inc>,
        <https://1145.am/db/2322632/Savient_Pharmaceuticals>,
        <https://1145.am/db/2322942/Cequent_Pharmaceuticals>,
        <https://1145.am/db/2322953/Cequent_Pharmaceuticals>,
        <https://1145.am/db/2323173/Pharmacopeia>,
        <https://1145.am/db/2323181/Millennium_Pharmaceuticals>,
        <https://1145.am/db/2323225/Arqule>,
        <https://1145.am/db/2323273/Pharmion_Corporation>,
        <https://1145.am/db/2323278/Pharmion>,
        <https://1145.am/db/2323358/Organon_Biosciences>,
        <https://1145.am/db/2324017/Encysive_Pharmaceuticals>,
        <https://1145.am/db/2324024/Presidio_Pharmaceuticals>,
        <https://1145.am/db/2324243/Arqule>,
        <https://1145.am/db/2324417/Biomimetic_Pharmaceuticals>,
        <https://1145.am/db/2324753/Biomarin_Pharmaceutical_Inc>,
        <https://1145.am/db/2324838/Biogen>,
        <https://1145.am/db/2325070/The_Medicines_Company>,
        <https://1145.am/db/2325074/The_Medicines_Company>,
        <https://1145.am/db/2325259/Pharmacopeia>,
        <https://1145.am/db/2325269/Pharmacopeia>,
        <https://1145.am/db/2325394/Pharmion>,
        <https://1145.am/db/2325725/Osi_Pharmaceuticals_Inc>,
        <https://1145.am/db/2326025/Research_Pharmaceutical_Services>,
        <https://1145.am/db/2326148/Encysive_Pharmaceuticals>,
        <https://1145.am/db/2326286/Idera_Pharmaceuticals>,
        <https://1145.am/db/2326403/Millennium_Pharmaceuticals>,
        <https://1145.am/db/2326466/Macromed>,
        <https://1145.am/db/2326474/Innovive_Pharmaceuticals>,
        <https://1145.am/db/2327241/Nps_Pharmaceuticals>,
        <https://1145.am/db/2327450/York_Pharma>,
        <https://1145.am/db/2327480/Transdel_Pharmaceuticals>,
        <https://1145.am/db/2327649/Pediamed_Pharmaceuticals>,
        <https://1145.am/db/2327849/Pharmacia_Corporation>,
        <https://1145.am/db/2328043/Madrigal_Pharmaceuticals>,
        <https://1145.am/db/2328220/Pharmaceutical_Product_Development>,
        <https://1145.am/db/2328222/Pharmaceutical_Product_Development_Llc>,
        <https://1145.am/db/2328616/Map_Pharmaceuticals>,
        <https://1145.am/db/2328650/Millennium_Pharmaceuticals>,
        <https://1145.am/db/2328729/Pediamed_Pharmaceuticals>,
        <https://1145.am/db/2328988/Cequent_Pharmaceuticals>,
        <https://1145.am/db/2328990/Mdrna>,
        <https://1145.am/db/2328996/Via_Pharmaceuticals>,
        <https://1145.am/db/2329309/Pharmaceutical_Product_Development_Llc>,
        <https://1145.am/db/2329643/Pharmaceuticals_Inc>,
        <https://1145.am/db/2329756/Provid_Pharmaceuticals>,
        <https://1145.am/db/2329814/Map_Pharmaceuticals>,
        <https://1145.am/db/2329816/Map_Pharmaceuticals>,
        <https://1145.am/db/2330057/Pharmathene>,
        <https://1145.am/db/2330086/Idera_Pharmaceuticals_Inc>,
        <https://1145.am/db/2330094/Idera_Pharmaceuticals>,
        <https://1145.am/db/2330207/Bioxell>,
        <https://1145.am/db/2330207/Cosmo_Pharmaceuticals>,
        <https://1145.am/db/2330534/Pharmion>,
        <https://1145.am/db/2330576/Biocryst_Pharmaceuticals>,
        <https://1145.am/db/2330667/Savient_Pharmaceuticals_Inc>,
        <https://1145.am/db/2330858/Provid_Pharmaceuticals_Inc>,
        <https://1145.am/db/2330880/Access_Pharmaceuticals>,
        <https://1145.am/db/2330880/Biocryst_Pharmaceuticals>,
        <https://1145.am/db/2330882/Proprius_Pharmaceuticals>,
        <https://1145.am/db/2330951/Oscient_Pharmaceuticals>,
        <https://1145.am/db/2330989/Millennium_Pharmaceuticals>,
        <https://1145.am/db/2331692/Biosante_Pharmaceuticals>,
        <https://1145.am/db/2331745/Elan_Pharmaceuticals>,
        <https://1145.am/db/2331756/Pro-Pharmaceuticals>,
        <https://1145.am/db/2331875/Bioalliance_Pharma>,
        <https://1145.am/db/2332473/Pharmaceutical_Product_Development_Llc>,
        <https://1145.am/db/2332596/Esprit_Pharma>,
        <https://1145.am/db/2332777/S_*_Bio>,
        <https://1145.am/db/2332974/Osi_Pharmaceuticals>,
        <https://1145.am/db/2332980/Pharmos_Corporation>,
        <https://1145.am/db/2333492/Access_Pharmaceuticals>,
        <https://1145.am/db/2333569/Ception>,
        <https://1145.am/db/2333624/Pharmos>,
        <https://1145.am/db/2334034/Pharmaceutical_Product_Development_Llc>,
        <https://1145.am/db/2334119/Pharmaceutical_Product_Development>,
        <https://1145.am/db/2334121/Pharmaceutical_Product_Development>,
        <https://1145.am/db/2334183/Idera_Pharmaceuticals>,
        <https://1145.am/db/2335077/Pharmaceutical_Product_Development_Llc>,
        <https://1145.am/db/2336040/Ferring_Pharmaceuticals>,
        <https://1145.am/db/2336041/Ferring_Pharmaceuticals>,
        <https://1145.am/db/2336160/Pharmaceutical_Product_Development>,
        <https://1145.am/db/2336293/Aprecia_Pharmaceuticals_Company>,
        <https://1145.am/db/2336378/Oramed_Pharmaceuticals_Inc>,
        <https://1145.am/db/2336442/Bionor_Pharma_Asa>,
        <https://1145.am/db/2336452/Pharmaxis_Ltd>,
        <https://1145.am/db/2336503/Aragon_Pharmaceuticals_Inc>,
        <https://1145.am/db/2336505/Aragon_Pharmaceuticals_Inc>,
        <https://1145.am/db/2336506/Aragon_Pharmaceuticals>,
        <https://1145.am/db/2336524/Aragon_Pharmaceuticals_Inc>,
        <https://1145.am/db/2336629/Biota_Pharmaceuticals>,
        <https://1145.am/db/2336934/Savient_Pharmaceuticals_Inc>,
        <https://1145.am/db/2337053/N30_Pharmaceuticals>,
        <https://1145.am/db/2337345/Conatus_Pharmaceuticals_Inc>,
        <https://1145.am/db/2337348/Cosmo_Pharmaceuticals_Spa>,
        <https://1145.am/db/2337547/Aragon_Pharmaceuticals_Inc>,
        <https://1145.am/db/2337928/Progenics_Pharmaceuticals_Inc>,
        <https://1145.am/db/2337986/Pharmagen_Inc>,
        <https://1145.am/db/2338120/The_Medicines_Company>,
        <https://1145.am/db/2338123/The_Medicines_Company>,
        <https://1145.am/db/2338390/Inmed_Pharmaceuticals_Inc>,
        <https://1145.am/db/2338401/Tetraphase_Pharmaceuticals>,
        <https://1145.am/db/2338430/Pharmacyclics>,
        <https://1145.am/db/2338551/Biosante_Pharmaceuticals_Inc>,
        <https://1145.am/db/2338735/Map_Pharmaceuticals>,
        <https://1145.am/db/2338877/Aerie_Pharmaceuticals>,
        <https://1145.am/db/2338883/Cerulean_Pharma_Inc>,
        <https://1145.am/db/2339019/Isa_Pharmaceuticals_Bv>,
        <https://1145.am/db/2339186/Biocryst_Pharmaceuticals>,
        <https://1145.am/db/2339570/Map_Pharmaceuticals>,
        <https://1145.am/db/2339718/Bioalliance_Pharma_Sa>,
        <https://1145.am/db/2339727/Pharmacyclics_Inc>,
        <https://1145.am/db/2339787/Pharmalink_Ab>,
        <https://1145.am/db/2339892/Pharmacyclics>,
        <https://1145.am/db/2339907/Biosante_Pharmaceuticals>,
        <https://1145.am/db/2339910/Biomed_Pharmaceuticals>,
        <https://1145.am/db/2339922/Pharmaform>,
        <https://1145.am/db/2339979/Theravance>,
        <https://1145.am/db/2340000/Aerie_Pharmaceuticals>,
        <https://1145.am/db/2340224/Satori_Pharmaceuticals>,
        <https://1145.am/db/2340291/Pharmasset>,
        <https://1145.am/db/2340373/Nps_Pharmaceuticals>,
        <https://1145.am/db/2340431/Savient_Pharmaceuticals>,
        <https://1145.am/db/2341523/Biocryst_Pharmaceuticals>,
        <https://1145.am/db/2341742/Research_Pharmaceutical_Services>,
        <https://1145.am/db/2341752/Biocryst_Pharmaceuticals_Inc>,
        <https://1145.am/db/2341998/Achillion_Pharmaceuticals>,
        <https://1145.am/db/2342192/Aragon_Pharmaceuticals>,
        <https://1145.am/db/2342224/Infinity_Pharmaceuticals_Inc>,
        <https://1145.am/db/2342225/Infinity_Pharmaceuticals_Inc>,
        <https://1145.am/db/2342469/Pharmadel>,
        <https://1145.am/db/2342687/Bioalliance_Pharma>,
        <https://1145.am/db/2342800/Pharmathene>,
        <https://1145.am/db/2342805/Pharmathene>,
        <https://1145.am/db/2342918/Pharmalink_Ab>,
        <https://1145.am/db/2343264/Pharmaceutical_Product_Development>,
        <https://1145.am/db/2343277/Pharmasset>,
        <https://1145.am/db/2343826/The_Medicines_Company>,
        <https://1145.am/db/2343837/Medicines_Co>,
        <https://1145.am/db/2343966/Thesan_Pharmaceuticals>,
        <https://1145.am/db/2344011/Inmed_Pharmaceuticals_Inc>,
        <https://1145.am/db/2344076/Transdel_Pharmaceuticals_Inc>,
        <https://1145.am/db/2344079/Map_Pharmaceuticals_Inc>,
        <https://1145.am/db/2344131/Pharmascience_Inc>,
        <https://1145.am/db/2344207/Entremed>,
        <https://1145.am/db/2344624/Pharmagen_Inc>,
        <https://1145.am/db/2344735/Aragon_Pharmaceuticals_Inc>,
        <https://1145.am/db/2344739/Aragon_Pharmaceuticals>,
        <https://1145.am/db/2344850/Elite_Pharmaceuticals_Inc>,
        <https://1145.am/db/2344939/Theravance>,
        <https://1145.am/db/2344955/Pharmaceutical_Product_Development>,
        <https://1145.am/db/2345106/Map_Pharmaceuticals>,
        <https://1145.am/db/2345474/Infinity_Pharmaceuticals_Inc>,
        <https://1145.am/db/2345902/Elite_Pharmaceuticals_Inc>,
        <https://1145.am/db/2346534/Conatus_Pharmaceuticals_Inc>,
        <https://1145.am/db/2346542/Conatus_Pharmaceuticals>,
        <https://1145.am/db/2346775/N30_Pharmaceuticals>,
        <https://1145.am/db/2346800/Satori_Pharmaceuticals_Incorporated>,
        <https://1145.am/db/2346807/Satori_Pharmaceuticals_Incorporated>,
        <https://1145.am/db/2346832/Vital_Science_Corp>,
        <https://1145.am/db/2346833/Vital_Science_Corp>,
        <https://1145.am/db/2346951/Biota_Pharmaceuticals_Inc>,
        <https://1145.am/db/2346964/Aerie_Pharmaceuticals>,
        <https://1145.am/db/2347127/Pharmacyte_Biotech>,
        <https://1145.am/db/2347169/Idera_Pharmaceuticals_Inc>,
        <https://1145.am/db/2347227/Aoxing_Pharmaceutical>,
        <https://1145.am/db/2347272/Pharmascience>,
        <https://1145.am/db/2347519/Pharmadeals_Ltd>,
        <https://1145.am/db/2347644/Aragon_Pharmaceuticals>,
        <https://1145.am/db/2347648/Pharminox_Limited>,
        <https://1145.am/db/2347659/Aragon_Pharmaceuticals>,
        <https://1145.am/db/2347982/Epicept>,
        <https://1145.am/db/2348329/Esperance_Pharmaceuticals>,
        <https://1145.am/db/2348506/Am-Pharma_Bv>,
        <https://1145.am/db/2348523/Am-Pharma_Bv>,
        <https://1145.am/db/2348763/Bioalliance_Pharma_Sa>,
        <https://1145.am/db/2348864/Vital_Science_Corp>,
        <https://1145.am/db/2349103/Biota_Pharmaceuticals>,
        <https://1145.am/db/2349111/Idera_Pharmaceuticals_Inc>,
        <https://1145.am/db/2349348/R-Pharm>,
        <https://1145.am/db/2349573/Biosante_Pharmaceuticals_Inc>,
        <https://1145.am/db/2349581/Biosante_Pharmaceuticals_Inc>,
        <https://1145.am/db/2349608/Biosante_Pharmaceuticals_Inc>,
        <https://1145.am/db/2349965/Idera_Pharmaceuticals_Inc>,
        <https://1145.am/db/2350147/Biota_Pharmaceuticals_Inc>,
        <https://1145.am/db/2350440/Ethicon>,
        <https://1145.am/db/2350852/Isa_Pharmaceuticals>,
        <https://1145.am/db/2351091/Biomotiv>,
        <https://1145.am/db/2351471/Mymetics_Corporation>,
        <https://1145.am/db/2351818/Biocon>,
        <https://1145.am/db/2352046/Costim_Pharmaceuticals>,
        <https://1145.am/db/2352165/Bio>,
        <https://1145.am/db/2352177/Theravance_Inc>,
        <https://1145.am/db/2352180/Pharmaceutical_Research_And_Manufacturers_Of_America>,
        <https://1145.am/db/2352333/Inmed_Pharmaceuticals_Inc>,
        <https://1145.am/db/2352538/Biota_Pharmaceuticals>,
        <https://1145.am/db/2352659/Nps_Pharmaceuticals>,
        <https://1145.am/db/2352784/Biosante_Pharmaceuticals>,
        <https://1145.am/db/2352805/Achillion_Pharmaceuticals>,
        <https://1145.am/db/2353006/Radient_Pharmaceuticals_Corporation>,
        <https://1145.am/db/2353093/Thesan_Pharmaceuticals>,
        <https://1145.am/db/2353098/Thesan_Pharmaceuticals>,
        <https://1145.am/db/2353101/Index_Pharmaceuticals>,
        <https://1145.am/db/2353254/Pharma_Inc>,
        <https://1145.am/db/2353262/Sound_Pharmaceuticals_Inc>,
        <https://1145.am/db/2353279/Biocryst_Pharmaceuticals_Inc>,
        <https://1145.am/db/2353279/Presidio_Pharmaceuticals_Inc>,
        <https://1145.am/db/2353326/Am-Pharma>,
        <https://1145.am/db/2353364/Am-Pharma>,
        <https://1145.am/db/2353651/Pharmathene>,
        <https://1145.am/db/2353668/Biotie>,
        <https://1145.am/db/2354002/N30_Pharmaceuticals>,
        <https://1145.am/db/2354062/Osi_Pharmaceuticals>,
        <https://1145.am/db/2354064/Osi_Pharmaceuticals>,
        <https://1145.am/db/2354083/Osi_Pharmaceuticals>,
        <https://1145.am/db/2354086/Osi_Pharmaceuticals>,
        <https://1145.am/db/2354124/Uk>,
        <https://1145.am/db/2354146/Aerie_Pharmaceuticals>,
        <https://1145.am/db/2354376/Aspireo_Pharmaceuticals>,
        <https://1145.am/db/2354380/Pharmaxis>,
        <https://1145.am/db/2354388/Pharmaxis>,
        <https://1145.am/db/2354402/Achillion_Pharmaceuticals>,
        <https://1145.am/db/2354406/Gw_Pharmaceuticals_Plc>,
        <https://1145.am/db/2354779/Achillion_Pharmaceuticals_Inc>,
        <https://1145.am/db/2354783/Achillion_Pharmaceuticals>,
        <https://1145.am/db/2354804/Medicis_Pharmaceutical_Corporation>,
        <https://1145.am/db/2354836/Progenics_Pharmaceuticals_Inc>,
        <https://1145.am/db/2354913/Bionor_Pharma_Asa>,
        <https://1145.am/db/2355099/Infinity_Pharmaceuticals>,
        <https://1145.am/db/2355109/Infinity_Pharmaceuticals>,
        <https://1145.am/db/2355324/Biota_Pharmaceuticals_Inc>,
        <https://1145.am/db/2355678/Oncomed_Pharmaceuticals>,
        <https://1145.am/db/2355721/Pharmaceutical_Product_Development>,
        <https://1145.am/db/2355884/Omthera_Pharmaceuticals>,
        <https://1145.am/db/2355885/Omthera_Pharmaceuticals>,
        <https://1145.am/db/2355941/Theratechnologies>,
        <https://1145.am/db/2355974/Aegerion_Pharmaceuticals>,
        <https://1145.am/db/2356294/Company>,
        <https://1145.am/db/2356294/Inc>,
        <https://1145.am/db/2356391/Infinity_Pharmaceuticals>,
        <https://1145.am/db/2356434/The_Medicines_Company>,
        <https://1145.am/db/2357329/Pharmalink_Ab>,
        <https://1145.am/db/2357333/Pharmalink>,
        <https://1145.am/db/2357423/Achillion_Pharmaceuticals_Inc>,
        <https://1145.am/db/2357456/Infinity_Pharmaceuticals_Inc>,
        <https://1145.am/db/2357636/Biocryst_Pharmaceuticals>,
        <https://1145.am/db/2358047/Entremed>,
        <https://1145.am/db/2358405/Pharmagen_Inc>,
        <https://1145.am/db/2358449/Nps_Pharmaceuticals_Inc>,
        <https://1145.am/db/2358479/Nps_Pharmaceuticals_Inc>,
        <https://1145.am/db/2358732/Osi_Pharmaceuticals>,
        <https://1145.am/db/2358877/Biocryst_Pharmaceuticals_Inc>,
        <https://1145.am/db/2359266/D-Pharm>,
        <https://1145.am/db/2359401/Scpharmaceuticals_Inc>,
        <https://1145.am/db/2359438/Aerie_Pharmaceuticals>,
        <https://1145.am/db/2359474/Oncomed_Pharmaceuticals>,
        <https://1145.am/db/2359517/Elite_Pharmaceuticals_Inc>,
        <https://1145.am/db/2359539/Omthera_Pharmaceuticals>,
        <https://1145.am/db/2359550/Achillion_Pharmaceuticals>,
        <https://1145.am/db/2359668/Cosmo_Pharmaceuticals>,
        <https://1145.am/db/2359882/Biotie>,
        <https://1145.am/db/2359926/Entremed>,
        <https://1145.am/db/2360155/Aegerion_Pharmaceuticals>,
        <https://1145.am/db/2360489/Medac_Pharma>,
        <https://1145.am/db/2360588/Achillion_Pharmaceuticals>,
        <https://1145.am/db/2360596/Achillion_Pharmaceuticals_Inc>,
        <https://1145.am/db/2360697/Medgenics>,
        <https://1145.am/db/2360739/Cosmo_Pharmaceuticals>,
        <https://1145.am/db/2360945/Entremed>,
        <https://1145.am/db/2361244/Aegerion_Pharmaceuticals>,
        <https://1145.am/db/2361516/Aerie_Pharmaceuticals_Inc>,
        <https://1145.am/db/2362378/Ferring_Pharmaceuticals>,
        <https://1145.am/db/2362456/Action_Pharma_A_S>,
        <https://1145.am/db/2362525/Horizon_Pharma>,
        <https://1145.am/db/2362593/Aerie_Pharmaceuticals_Inc>,
        <https://1145.am/db/2363186/Savient_Pharmaceuticals_Inc>,
        <https://1145.am/db/2363285/Phenex_Pharmaceuticals_Ag>,
        <https://1145.am/db/2363340/Aerie_Pharmaceuticals_Inc>,
        <https://1145.am/db/2363387/Afferent_Pharmaceuticals>,
        <https://1145.am/db/2363425/The_Medicines_Company>,
        <https://1145.am/db/2363433/The_Medicines_Company>,
        <https://1145.am/db/2363452/Pharmasum_Therapeutics_As>,
        <https://1145.am/db/2363530/Adamas_Pharmaceuticals_Inc>,
        <https://1145.am/db/2363801/Preglem>,
        <https://1145.am/db/2363955/Savient_Pharmaceuticals>,
        <https://1145.am/db/2364093/Biotie>,
        <https://1145.am/db/2364252/Nps_Pharmaceuticals>,
        <https://1145.am/db/2364274/S_*_Bio_Pte_Ltd>,
        <https://1145.am/db/2364276/S_*_Bio>,
        <https://1145.am/db/2364494/Bioalliance_Pharma_Sa>,
        <https://1145.am/db/2364495/Bioalliance_Pharma>,
        <https://1145.am/db/2364538/Afferent_Pharmaceuticals>,
        <https://1145.am/db/2364541/K-V_Pharmaceutical_Company>,
        <https://1145.am/db/2364585/Conatus_Pharmaceuticals_Inc>,
        <https://1145.am/db/2364593/Aragon_Pharmaceuticals>,
        <https://1145.am/db/2364601/Aragon_Pharmaceuticals>,
        <https://1145.am/db/2364774/Aegerion_Pharmaceuticals>,
        <https://1145.am/db/2364884/Entremed_Inc>,
        <https://1145.am/db/2365030/Gw_Pharmaceuticals_Plc>,
        <https://1145.am/db/2365098/Conatus_Pharmaceuticals_Inc>,
        <https://1145.am/db/2365224/Research_Pharmaceutical_Services>,
        <https://1145.am/db/2365423/Conatus_Pharmaceuticals_Inc>,
        <https://1145.am/db/2365450/Prismic_Pharmaceuticals>,
        <https://1145.am/db/2365724/Biosante_Pharmaceuticals_Inc>,
        <https://1145.am/db/2365763/Biosante_Pharmaceuticals>,
        <https://1145.am/db/2366139/Prism_Pharmaceuticals>,
        <https://1145.am/db/2366388/Biosante_Pharmaceuticals_Inc>,
        <https://1145.am/db/2366521/Novamed_Pharmaceuticals>,
        <https://1145.am/db/2366540/Prism_Pharmaceuticals>,
        <https://1145.am/db/2367021/Biotie>,
        <https://1145.am/db/2367070/Aegerion_Pharmaceuticals>,
        <https://1145.am/db/2367280/Tetraphase_Pharmaceuticals>,
        <https://1145.am/db/2367438/Biocryst_Pharmaceuticals>,
        <https://1145.am/db/2367483/Vitae_Pharmaceuticals>,
        <https://1145.am/db/2367496/Vitae_Pharmaceuticals>,
        <https://1145.am/db/2367951/Prismic_Pharmaceuticals>,
        <https://1145.am/db/2367962/Catalyst_Pharmaceuticals>,
        <https://1145.am/db/2368070/Afferent_Pharmaceuticals>,
        <https://1145.am/db/2368339/Tetraphase_Pharmaceuticals>,
        <https://1145.am/db/2368420/Intec_Pharma>,
        <https://1145.am/db/2368593/Bioquiddity_Incorporated>,
        <https://1145.am/db/2368632/Pharmacyclics>,
        <https://1145.am/db/2368739/Novartis_Pharmaceuticals>,
        <https://1145.am/db/2368826/Aegerion_Pharmaceuticals>,
        <https://1145.am/db/2369004/Biogen>,
        <https://1145.am/db/2369037/Aegerion_Pharmaceuticals>,
        <https://1145.am/db/2369126/Achillion_Pharmaceuticals>,
        <https://1145.am/db/2369144/Aegerion_Pharmaceuticals>,
        <https://1145.am/db/2369233/Biopharmx_Corporation>,
        <https://1145.am/db/2369402/Medicines_Company>,
        <https://1145.am/db/2369812/Aoxing_Pharmaceutical_Company>,
        <https://1145.am/db/2369931/Biogen>,
        <https://1145.am/db/2370022/Apellis_Pharmaceuticals>,
        <https://1145.am/db/2370078/Pharmaceutical_Product_Development>,
        <https://1145.am/db/2370082/Aerie_Pharmaceuticals>,
        <https://1145.am/db/2370089/Abide_Therapeutics>,
        <https://1145.am/db/2370399/Pharmamar>,
        <https://1145.am/db/2370637/Medgenics_Inc>,
        <https://1145.am/db/2370797/Pharmanest>,
        <https://1145.am/db/2370798/Pharmalink_Ab>,
        <https://1145.am/db/2370946/Biogen>,
        <https://1145.am/db/2371015/M_Pharma>,
        <https://1145.am/db/2371016/M_Pharma>,
        <https://1145.am/db/2371279/Biomunex_Pharmaceuticals>,
        <https://1145.am/db/2371491/Biopharmx_Corporation>,
        <https://1145.am/db/2536754/Oramed_Pharma>,
        <https://1145.am/db/2536756/Zao>,
        <https://1145.am/db/2537468/Pharmascience_Inc>,
        <https://1145.am/db/2538171/Biomeda_Group>,
        <https://1145.am/db/2538567/Upm_Pharmaceuticals>,
        <https://1145.am/db/2538861/Par_Pharmaceuticals>,
        <https://1145.am/db/2538901/The_Harvard_Drug_Group>,
        <https://1145.am/db/2539516/Par_Pharmaceuticals>,
        <https://1145.am/db/2539568/Zao>,
        <https://1145.am/db/2540193/Pharmanest>,
        <https://1145.am/db/2540449/Biocon>,
        <https://1145.am/db/2540951/Rytary>,
        <https://1145.am/db/2541039/Elan_Pharmaceuticals>,
        <https://1145.am/db/2541239/Pharmstar>,
        <https://1145.am/db/2541326/Advanced_Pharmaceutical>,
        <https://1145.am/db/2541717/Adamas_Pharmaceuticals>,
        <https://1145.am/db/2541810/British_Pharma>,
        <https://1145.am/db/2542218/Pharmacyclics>,
        <https://1145.am/db/2543839/British_Pharma>,
        <https://1145.am/db/2544111/Unique_Pharmaceuticals>,
        <https://1145.am/db/2544358/Mundipharma>,
        <https://1145.am/db/2544596/Polpharma>,
        <https://1145.am/db/2544679/Neopharma>,
        <https://1145.am/db/2544783/Citius_Pharmaceuticals>,
        <https://1145.am/db/2545143/Mundipharma>,
        <https://1145.am/db/2545411/Aoxing_Pharmaceutical_Company>,
        <https://1145.am/db/2546441/Intas_Pharmaceuticals>,
        <https://1145.am/db/2546529/Pharma_Tech_Industries>,
        <https://1145.am/db/2546629/Par_Pharmaceutical>,
        <https://1145.am/db/2547189/Sagent_Pharmaceuticals>,
        <https://1145.am/db/2547596/Par_Pharmaceuticals>,
        <https://1145.am/db/2548585/Par_Pharmaceuticals>,
        <https://1145.am/db/2548674/Sopharma>,
        <https://1145.am/db/2549477/Sagent_Pharmaceuticals>,
        <https://1145.am/db/2549520/Aoxing_Pharmaceutical_Company>,
        <https://1145.am/db/2549919/Pharmathen>,
        <https://1145.am/db/2550212/Aoxing_Pharmaceutical>,
        <https://1145.am/db/2550471/Pharmaform>,
        <https://1145.am/db/2550523/Pharmaron>,
        <https://1145.am/db/2550685/Upm_Pharmaceuticals>,
        <https://1145.am/db/2551427/Pharmablock_Sciences>,
        <https://1145.am/db/2551601/Infinity_Pharmaceuticals>,
        <https://1145.am/db/2552169/Alembic_Pharmaceuticals>,
        <https://1145.am/db/2552465/Medis>,
        <https://1145.am/db/2552641/Plethico_Pharmaceuticals>,
        <https://1145.am/db/2552642/Mankind_Pharmaceuticals>,
        <https://1145.am/db/2552746/Supreme_Pharmaceuticals_Inc>,
        <https://1145.am/db/2552794/Millennium_Pharmaceuticals>,
        <https://1145.am/db/2553276/Millennium_Pharmaceuticals>,
        <https://1145.am/db/2553512/Pharmax_Pharmaceuticals>,
        <https://1145.am/db/2553708/Pharmaceutical_Product_Development_Llc>,
        <https://1145.am/db/2554237/Intas_Pharmaceuticals>,
        <https://1145.am/db/2554810/Continuus_Pharmaceuticals>,
        <https://1145.am/db/2554814/Globalpharma>,
        <https://1145.am/db/2554858/Medicure_Usa_Inc>,
        <https://1145.am/db/2555338/Pharmacore>,
        <https://1145.am/db/2555890/Pharmalucence>,
        <https://1145.am/db/2555896/Pharmalucence>,
        <https://1145.am/db/2556805/Medicis_Pharmaceuticals>,
        <https://1145.am/db/2557303/Pharmaron>,
        <https://1145.am/db/2557538/Neopharma>,
        <https://1145.am/db/2558025/Pharmaxis>,
        <https://1145.am/db/2558026/Pharmaxis>,
        <https://1145.am/db/2558970/Biostar_Pharmaceuticals>,
        <https://1145.am/db/2559783/Polpharma>,
        <https://1145.am/db/2560083/Exemed_Pharmaceuticals>,
        <https://1145.am/db/2561100/Exemed_Pharmaceuticals>,
        <https://1145.am/db/2561312/Oxford_Pharmaceuticals>,
        <https://1145.am/db/2561438/Pharmacia___Upjohn>,
        <https://1145.am/db/2561978/Biomarin_Pharmaceuticals>,
        <https://1145.am/db/2562199/Novartis_Pharmaceuticals_Corporation>,
        <https://1145.am/db/2562446/Specialty_Pharmaceutical>,
        <https://1145.am/db/2562500/Millennium_Pharmaceuticals>,
        <https://1145.am/db/2563255/Active_Pharmaceutical_Ingredients>,
        <https://1145.am/db/2563497/Creo_Pharmaceuticals>,
        <https://1145.am/db/2563497/Polpharma>,
        <https://1145.am/db/2564196/Pharmaron>,
        <https://1145.am/db/2564713/C2_Pharma>,
        <https://1145.am/db/2567007/Opiant_Pharmaceuticals>,
        <https://1145.am/db/2567055/Sovereign_Pharmaceuticals>,
        <https://1145.am/db/2567283/The_Pharma_Giant>,
        <https://1145.am/db/2567438/Biogen>,
        <https://1145.am/db/2567651/Indivior>,
        <https://1145.am/db/2567651/Opiant_Pharmaceuticals>,
        <https://1145.am/db/2568205/Biogen>,
        <https://1145.am/db/2568375/Biogen>,
        <https://1145.am/db/2569165/Pharmacyclics>,
        <https://1145.am/db/2569187/Pharmacyclics>,
        <https://1145.am/db/2569370/Co>,
        <https://1145.am/db/2569679/Pharmaceuticals_Inc>,
        <https://1145.am/db/2569729/The_Medicines_Company>,
        <https://1145.am/db/2569952/Nps_Pharmaceuticals>,
        <https://1145.am/db/2570068/Aegerion_Pharmaceuticals>,
        <https://1145.am/db/2570289/Pharmacyclics>,
        <https://1145.am/db/2570419/Pharmacyclics>,
        <https://1145.am/db/2570449/Biocon>,
        <https://1145.am/db/2570741/Sagent_Pharmaceuticals>,
        <https://1145.am/db/2570807/Nps_Pharmaceuticals>,
        <https://1145.am/db/2570807/Pharmacyclics>,
        <https://1145.am/db/2570834/Phrma>,
        <https://1145.am/db/2572200/The_Medicines_Company>,
        <https://1145.am/db/2572870/Hi-Tech_Pharmaceuticals>,
        <https://1145.am/db/2573057/Aprecia_Pharmaceuticals_Company>,
        <https://1145.am/db/2573058/Aprecia_Pharmaceuticals>,
        <https://1145.am/db/2573147/Medicis_Pharmaceutical>,
        <https://1145.am/db/2573271/Physician_Therapeutics>,
        <https://1145.am/db/2573391/Url_Pharma>,
        <https://1145.am/db/2573392/Url_Pharma>,
        <https://1145.am/db/2573887/Biogen>,
        <https://1145.am/db/2574679/Aprecia_Pharmaceuticals>,
        <https://1145.am/db/2574891/Pharmacyclics>,
        <https://1145.am/db/2575222/Map_Pharmaceuticals>,
        <https://1145.am/db/2575242/Research_Pharmaceutical_Services_Inc>,
        <https://1145.am/db/2575462/Paras_Pharmaceuticals>,
        <https://1145.am/db/2575623/Inova_Pharmaceuticals>,
        <https://1145.am/db/2576205/Medicis_Pharmaceutical_Corporation>,
        <https://1145.am/db/2576967/Insight_Pharmaceuticals>,
        <https://1145.am/db/2577145/Medicis_Pharmaceutical>,
        <https://1145.am/db/2577259/Pharmaceutical_Product_Development>,
        <https://1145.am/db/2577419/Osi_Pharmaceuticals>,
        <https://1145.am/db/2577675/Biogen>,
        <https://1145.am/db/2577684/Biogen>,
        <https://1145.am/db/2577894/Huvepharma_Ad>,
        <https://1145.am/db/2577934/Pharmascience>,
        <https://1145.am/db/2578177/Nexus_Pharmaceuticals>,
        <https://1145.am/db/2578319/Cosmo_Pharmaceuticals>,
        <https://1145.am/db/2578473/Aa_Pharma>,
        <https://1145.am/db/2578481/Aa_Pharma_Inc>,
        <https://1145.am/db/2579147/Medicis_Pharmaceutical>,
        <https://1145.am/db/2579211/Eusa_Pharma>,
        <https://1145.am/db/2579538/Pharmaforce>,
        <https://1145.am/db/2580123/Savient_Pharmaceuticals>,
        <https://1145.am/db/2580479/Pharmaxis>,
        <https://1145.am/db/2581225/Inova_Pharmaceuticals>,
        <https://1145.am/db/2582110/Savient_Pharmaceuticals>,
        <https://1145.am/db/2582153/Ferring_Pharmaceuticals>,
        <https://1145.am/db/2582174/Pharmasset>,
        <https://1145.am/db/2582320/Savient_Pharmaceuticals>,
        <https://1145.am/db/2582677/Aegerion_Pharmaceuticals>,
        <https://1145.am/db/2583013/Aragon_Pharmaceuticals_Inc>,
        <https://1145.am/db/2583022/Url_Pharma>,
        <https://1145.am/db/2583220/Cosmo_Pharmaceuticals_Spa>,
        <https://1145.am/db/2583270/Pharmaswiss>,
        <https://1145.am/db/2583291/Savient_Pharmaceuticals>,
        <https://1145.am/db/2583352/Elite_Pharmaceuticals_Inc>,
        <https://1145.am/db/2583402/Osi_Pharmaceuticals>,
        <https://1145.am/db/2583414/Polpharma>,
        <https://1145.am/db/2583769/Biocryst_Pharmaceuticals>,
        <https://1145.am/db/2584209/Pharmaswiss_Sa>,
        <https://1145.am/db/2584226/Pharmaswiss_Sa>,
        <https://1145.am/db/2584250/Progenics_Pharmaceuticals>,
        <https://1145.am/db/2585281/Aegerion_Pharmaceuticals>,
        <https://1145.am/db/2585887/Pharma_Inc>,
        <https://1145.am/db/2586968/Progenics_Pharmaceuticals_Inc>,
        <https://1145.am/db/2587155/Millennium_Pharma>,
        <https://1145.am/db/2587616/Pharmaq>,
        <https://1145.am/db/2587696/R-Pharm>,
        <https://1145.am/db/2588049/Aegerion_Pharmaceuticals_Inc>,
        <https://1145.am/db/2588718/Pharmacyclics>,
        <https://1145.am/db/2588884/Map_Pharmaceuticals>,
        <https://1145.am/db/2589884/Map_Pharmaceuticals>,
        <https://1145.am/db/2590159/Osi_Pharmaceuticals_Inc>,
        <https://1145.am/db/2590195/Pro-Tect_Pharmaceuticals>,
        <https://1145.am/db/2590409/Biogen>,
        <https://1145.am/db/2590910/Savient_Pharmaceuticals>,
        <https://1145.am/db/2591540/Polpharma>,
        <https://1145.am/db/2591690/Medicis_Pharmaceutical>,
        <https://1145.am/db/2591938/Ferring_Pharmaceuticals>,
        <https://1145.am/db/2593142/Access_Pharmaceuticals>,
        <https://1145.am/db/2593573/Savient_Pharmaceuticals_Inc>,
        <https://1145.am/db/2594042/Oramed_Pharmaceuticals_Inc>,
        <https://1145.am/db/2594106/Paras_Pharmaceuticals>,
        <https://1145.am/db/2594116/Pharmerica>,
        <https://1145.am/db/2594602/Osi_Pharma>,
        <https://1145.am/db/2594798/Pharmerica>,
        <https://1145.am/db/2595190/Nps_Pharmaceuticals>,
        <https://1145.am/db/2595202/Aegerion_Pharmaceuticals>,
        <https://1145.am/db/2595210/Nps_Pharmaceuticals>,
        <https://1145.am/db/2595237/Emcure_Pharmaceuticals>,
        <https://1145.am/db/2595413/Osi_Pharmaceuticals_Inc>,
        <https://1145.am/db/2596054/Elite_Pharmaceuticals_Inc>,
        <https://1145.am/db/2596307/Savient_Pharmaceuticals>,
        <https://1145.am/db/2596356/Infinity_Pharmaceuticals_Inc>,
        <https://1145.am/db/2596369/Pharmadeals_Ltd>,
        <https://1145.am/db/2596818/Pharmasset>,
        <https://1145.am/db/2597158/Nps_Pharmaceuticals>,
        <https://1145.am/db/2597180/Prism_Pharmaceuticals>,
        <https://1145.am/db/2597622/Biosante_Pharmaceuticals_Inc>,
        <https://1145.am/db/2597935/Osi_Pharmaceuticals>,
        <https://1145.am/db/2598027/Nps_Pharmaceuticals>,
        <https://1145.am/db/2598099/Paras_Pharmaceuticals>,
        <https://1145.am/db/2598137/Biosante_Pharmaceuticals_Inc>,
        <https://1145.am/db/2598195/Pharmatech>,
        <https://1145.am/db/2598605/Oncomed_Pharmaceuticals>,
        <https://1145.am/db/2765310/Biogen>,
        <https://1145.am/db/281576/Mymd_Pharmaceuticals>,
        <https://1145.am/db/307255/Mymd_Pharmaceuticals_Inc>,
        <https://1145.am/db/324642/Mundipharma>,
        <https://1145.am/db/367137/Biomat>,
        <https://1145.am/db/378431/Pharmathen>,
        <https://1145.am/db/378464/Pharmathen>,
        <https://1145.am/db/378839/Adamis_Pharmaceuticals_Corporation>,
        <https://1145.am/db/380389/Diamedica_Therapeutics_Inc>,
        <https://1145.am/db/381068/Adamis_Pharmaceuticals_Corporation>,
        <https://1145.am/db/401218/Biocryst_Pharmaceuticals_Inc>,
        <https://1145.am/db/407888/Quoin_Pharmaceuticals>,
        <https://1145.am/db/410129/Catalyst_Pharmaceuticals_Inc>,
        <https://1145.am/db/427157/Adamis_Pharmaceuticals_Corporation>,
        <https://1145.am/db/431169/Pharmablock>,
        <https://1145.am/db/4491/Achillion_Pharmaceuticals_Inc>,
        <https://1145.am/db/452957/Aerie_Pharmaceuticals>,
        <https://1145.am/db/468221/Aerie_Pharmaceuticals>,
        <https://1145.am/db/481129/Biocon_Ltd>,
        <https://1145.am/db/485351/Aerie_Pharmaceuticals_Inc>,
        <https://1145.am/db/486302/Phathom_Pharmaceuticals>,
        <https://1145.am/db/487010/Scipher_Medicine>,
        <https://1145.am/db/488564/Aerie_Pharmaceuticals>,
        <https://1145.am/db/498367/Aspire_Pharma_Limited>,
        <https://1145.am/db/499171/Aspire_Pharma_Limited>,
        <https://1145.am/db/538112/Adamas_Pharmaceuticals_Inc>,
        <https://1145.am/db/538277/Adamas_Pharmaceuticals>,
        <https://1145.am/db/539267/Adamas_Pharmaceuticals>,
        <https://1145.am/db/540865/Adamas_Pharmaceuticals_Inc>,
        <https://1145.am/db/541731/Adamas_Pharmaceuticals_Inc>,
        <https://1145.am/db/541755/Adamas_Pharmaceuticals_Inc>,
        <https://1145.am/db/545583/Citius_Pharmaceuticals>,
        <https://1145.am/db/546391/Inmed_Pharmaceuticals_Inc>,
        <https://1145.am/db/549059/Adamas_Pharmaceuticals>,
        <https://1145.am/db/567789/Aprecia_Pharmaceuticals>,
        <https://1145.am/db/585607/Am-Pharma>,
        <https://1145.am/db/637582/The_Medicines_Co>,
        <https://1145.am/db/648300/Adamas_Pharmaceuticals>,
        <https://1145.am/db/662016/Prestige_Biopharma_Limited>,
        <https://1145.am/db/668495/Scipher_Medicine>,
        <https://1145.am/db/669775/Scipher_Medicine>,
        <https://1145.am/db/693128/Ascensus_Specialties>,
        <https://1145.am/db/700482/Novartis_Pharmaceuticals>,
        <https://1145.am/db/712037/Amunix_Pharmaceuticals>,
        <https://1145.am/db/712921/Mainpointe_Pharmaceuticals>,
        <https://1145.am/db/713105/Amunix_Pharmaceuticals_Inc>,
        <https://1145.am/db/713736/Aerie_Pharmaceuticals_Inc>,
        <https://1145.am/db/714923/Betterlife_Pharma_Inc>,
        <https://1145.am/db/715385/Aerie_Pharmaceuticals_Inc>,
        <https://1145.am/db/718008/Pharnext_Sa>,
        <https://1145.am/db/723883/Mymd_Pharmaceuticals>,
        <https://1145.am/db/724999/Mymd_Pharmaceuticals_Inc>,
        <https://1145.am/db/724999/Oramed_Pharmaceuticals_Inc>,
        <https://1145.am/db/734669/Escient_Pharmaceuticals>,
        <https://1145.am/db/742794/Hr®_Pharmaceuticals_Inc>,
        <https://1145.am/db/771062/Gw_Pharmaceuticals>,
        <https://1145.am/db/793071/Biogen_Inc>,
        <https://1145.am/db/835485/Pharmaessentia_Corporation>,
        <https://1145.am/db/854026/Aerie_Pharmaceuticals>,
        <https://1145.am/db/883896/Biontech>,
        <https://1145.am/db/884665/Pharmaceutical_Institute>,
        <https://1145.am/db/887575/Aprecia_Pharmaceuticals>,
        <https://1145.am/db/889331/Théa_Pharma>,
        <https://1145.am/db/912469/Aerie_Pharmaceuticals>,
        <https://1145.am/db/913730/Aerie_Pharmaceuticals>,
        <https://1145.am/db/922740/Grand_Pharma>,
        <https://1145.am/db/976867/Aprecia_Pharmaceuticals> ;
    ns1:sameAsMedium <https://1145.am/db/2369883/Achillion_Pharmaceuticals> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352808/Pappas_Ventures> a org:Organization ;
    ns1:basedInLowRaw "Conn" ;
    ns1:documentDate "2010-08-19T15:35:59+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Achillion Announces Private Placement of $50 Million" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/achillion-announces-private-placement-of-50-million> ;
    ns1:foundName "Pappas Ventures" ;
    ns1:investor <https://1145.am/db/2352808/Investment_Achillion_Pharmaceuticals_Inc_Clarus_Ventures_Domain_Associates_Pappas_Ventures_Quaker_Bioventures_Has_Not_Happened> ;
    ns1:name "Pappas Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/2289229/Pappas_Ventures>,
        <https://1145.am/db/2305706/Pappas_Ventures>,
        <https://1145.am/db/2305713/Pappas_Ventures>,
        <https://1145.am/db/2308329/Pappas_Ventures>,
        <https://1145.am/db/2312277/Pappas_Ventures>,
        <https://1145.am/db/2312288/Pappas_Ventures>,
        <https://1145.am/db/2314397/Pappas_Ventures>,
        <https://1145.am/db/2314400/Pappas_Ventures>,
        <https://1145.am/db/2314492/Pappas_Ventures>,
        <https://1145.am/db/2319029/Pappas_Ventures>,
        <https://1145.am/db/2324289/Pappas_Ventures>,
        <https://1145.am/db/2328388/Pappas_Ventures>,
        <https://1145.am/db/2332753/Pappas_Ventures>,
        <https://1145.am/db/2341904/Pappas_Ventures>,
        <https://1145.am/db/2346532/Pappas_Ventures>,
        <https://1145.am/db/2346542/Pappas_Ventures>,
        <https://1145.am/db/2350779/Pappas_Ventures>,
        <https://1145.am/db/2350780/Pappas_Ventures>,
        <https://1145.am/db/2352805/Pappas_Ventures>,
        <https://1145.am/db/2354537/Pappas_Ventures>,
        <https://1145.am/db/2354540/Pappas_Ventures>,
        <https://1145.am/db/2355274/Pappas_Ventures>,
        <https://1145.am/db/2356216/Pappas_Ventures>,
        <https://1145.am/db/2359562/Pappas_Ventures>,
        <https://1145.am/db/2539913/Pappas_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352808/Quaker_Bioventures> a org:Organization ;
    ns1:basedInLowRaw "Conn" ;
    ns1:documentDate "2010-08-19T15:35:59+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Achillion Announces Private Placement of $50 Million" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/achillion-announces-private-placement-of-50-million> ;
    ns1:foundName "Quaker BioVentures" ;
    ns1:investor <https://1145.am/db/2352808/Investment_Achillion_Pharmaceuticals_Inc_Clarus_Ventures_Domain_Associates_Pappas_Ventures_Quaker_Bioventures_Has_Not_Happened> ;
    ns1:name "Quaker BioVentures" ;
    ns1:sameAsMedium <https://1145.am/db/2217039/Quaker_Bioventures>,
        <https://1145.am/db/2291872/Quaker_Bioventures>,
        <https://1145.am/db/2302192/Quaker_Bioventures>,
        <https://1145.am/db/2303458/Quaker_Bioventures>,
        <https://1145.am/db/2303641/Quaker_Bioventures>,
        <https://1145.am/db/2303642/Quaker_Bioventures>,
        <https://1145.am/db/2305610/Quaker_Bioventures>,
        <https://1145.am/db/2305615/Quaker_Bioventures>,
        <https://1145.am/db/2305625/Quaker_Bioventures>,
        <https://1145.am/db/2309809/Quaker_Bioventures>,
        <https://1145.am/db/2310123/Quaker_Bioventures>,
        <https://1145.am/db/2311099/Quaker_Bioventures>,
        <https://1145.am/db/2312792/Quaker_Bioventures>,
        <https://1145.am/db/2317849/Quaker_Bioventures>,
        <https://1145.am/db/2317961/Quaker_Bioventures>,
        <https://1145.am/db/2319360/Quaker_Bioventures>,
        <https://1145.am/db/2320852/Quaker_Bioventures>,
        <https://1145.am/db/2320853/Quaker_Bioventures>,
        <https://1145.am/db/2330549/Quaker_Bioventures>,
        <https://1145.am/db/2332021/Quaker_Bioventures>,
        <https://1145.am/db/2332626/Quaker_Bioventures>,
        <https://1145.am/db/2332631/Quaker_Bioventures>,
        <https://1145.am/db/2340423/Quaker_Bioventures>,
        <https://1145.am/db/2340429/Quaker_Bioventures>,
        <https://1145.am/db/2349717/Quaker_Bioventures>,
        <https://1145.am/db/2349722/Quaker_Bioventures>,
        <https://1145.am/db/2355936/Quaker_Bioventures>,
        <https://1145.am/db/2355938/Quaker_Bioventures>,
        <https://1145.am/db/2363464/Quaker_Bioventures>,
        <https://1145.am/db/2365171/Quaker_Bioventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352819/Anchor_Therapeutics> a org:Organization ;
    ns1:description "Big Pharma" ;
    ns1:documentDate "2010-08-20T13:42:43+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Anchor raises $10M, aims for more in Series B" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/anchor-raises-10m-aims-for-more-series-b> ;
    ns1:foundName "Anchor Therapeutics" ;
    ns1:name "Anchor Therapeutics" ;
    ns1:sameAsHigh <https://1145.am/db/2278861/Century_Therapeutics> ;
    ns1:sameAsMedium <https://1145.am/db/2352814/Anchor_Therapeutics>,
        <https://1145.am/db/2352820/Anchor_Therapeutics> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352820/Anchor_Therapeutics> a org:Organization ;
    ns1:description "Pharmaceuticals" ;
    ns1:documentDate "2010-08-20T13:33:44+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Anchor Therapeutics Nabs $10M for New Class of Peptide Drugs Against Hard Targets" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/anchor-therapeutics-nabs-10m-for-new-class-of-peptide-drugs-against-hard-targets> ;
    ns1:foundName "Anchor Therapeutics" ;
    ns1:industry "pharmaceutical" ;
    ns1:name "Anchor Therapeutics" ;
    ns1:sameAsHigh <https://1145.am/db/2302019/Cornerstone_Therapeutics_Inc_Unit>,
        <https://1145.am/db/2303902/Cornerstone_Biopharma_Holdings>,
        <https://1145.am/db/2319710/Cornerstone_Therapeutics>,
        <https://1145.am/db/2328524/Cornerstone_Biopharma_Holdings>,
        <https://1145.am/db/2328568/Cornerstone_Biopharma_Holdings>,
        <https://1145.am/db/2352814/Anchor_Therapeutics> ;
    ns1:sameAsMedium <https://1145.am/db/2352819/Anchor_Therapeutics> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2355511/Seroba-Kernel_Life_Sciences_Ltd> a org:Organization ;
    ns1:basedInLowRaw "UK" ;
    ns1:description "Life Sciences" ;
    ns1:documentDate "2010-11-23T15:57:00+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Xention raises £8M; Maxygen distributes Codexis shares; Insurer counts costs of diabetes;" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/xention-raises-%C2%A38m-maxygen-distributes-codexis-shares-insurer-counts-costs-of-diabetes> ;
    ns1:foundName "Seroba-Kernel Life Sciences Ltd" ;
    ns1:industry "Life Sciences" ;
    ns1:investor <https://1145.am/db/2355511/Series_D_Investment_Btg_International_Crédit_Agricole_Private_Equity_Forbion_Capital_Partners_Mvm_Seroba-Kernel_Life_Sciences_Ltd_Xention_Completed> ;
    ns1:name "Seroba-Kernel Life Sciences Ltd" ;
    ns1:sameAsHigh <https://1145.am/db/1386529/Seroba_Life_Sciences>,
        <https://1145.am/db/2291361/Seroba_Kernel_Life_Sciences>,
        <https://1145.am/db/2301096/Seroba_Life_Sciences>,
        <https://1145.am/db/2301620/Seroba_Life_Sciences>,
        <https://1145.am/db/2330711/Seroba_Kernel_Life_Sciences>,
        <https://1145.am/db/2331751/Seroba_Kernel_Life_Sciences>,
        <https://1145.am/db/2338987/Seroba_Kernel_Life_Sciences>,
        <https://1145.am/db/2352203/Seroba_Kernel_Life_Sciences>,
        <https://1145.am/db/2352204/Seroba_Kernel_Life_Sciences>,
        <https://1145.am/db/2356567/Seroba_Kernel_Life_Sciences>,
        <https://1145.am/db/2364510/Seroba_Kernel_Life_Sciences>,
        <https://1145.am/db/2364514/Seroba_Kernel_Life_Sciences>,
        <https://1145.am/db/2364518/Seroba_Kernel_Life_Sciences> ;
    ns1:sameAsMedium <https://1145.am/db/2355512/Seroba-Kernel_Life_Sciences_Ltd> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2355511/Xention> a org:Organization ;
    ns1:basedInHighGeoName "United Kingdom of Great Britain and Northern Ireland" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2635167/about.rdf> ;
    ns1:basedInHighRaw "UK" ;
    ns1:description "pharmaceutical" ;
    ns1:documentDate "2010-11-23T15:57:00+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Xention raises £8M; Maxygen distributes Codexis shares; Insurer counts costs of diabetes;" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/xention-raises-%C2%A38m-maxygen-distributes-codexis-shares-insurer-counts-costs-of-diabetes> ;
    ns1:foundName "Xention" ;
    ns1:industry "Life Sciences" ;
    ns1:name "Xention" ;
    ns1:sameAsHigh <https://1145.am/db/1616500/Xoma_Corporation>,
        <https://1145.am/db/1755936/Xtalpi>,
        <https://1145.am/db/1775616/Xtalpi>,
        <https://1145.am/db/2304438/Xoma_Corporation>,
        <https://1145.am/db/2337949/Xoma_Corporation>,
        <https://1145.am/db/2337975/Xoma_Corporation>,
        <https://1145.am/db/2357461/Xoma_Corporation>,
        <https://1145.am/db/2565747/Xellia_Pharmaceuticals>,
        <https://1145.am/db/2569102/Xellia_Pharmaceuticals>,
        <https://1145.am/db/2587925/Xoma_Corporation>,
        <https://1145.am/db/2598467/Xoma>,
        <https://1145.am/db/435583/Xeris_Pharmaceuticals>,
        <https://1145.am/db/437663/Xeris_Pharmaceuticals>,
        <https://1145.am/db/457769/Xeris_Pharmaceuticals>,
        <https://1145.am/db/472420/Xeris_Pharmaceuticals>,
        <https://1145.am/db/473440/Xeris_Pharmaceuticals>,
        <https://1145.am/db/529337/Xeris_Pharmaceuticals_Inc> ;
    ns1:sameAsMedium <https://1145.am/db/2355512/Xention_Ltd>,
        <https://1145.am/db/2356903/Xention> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2355512/Xention_Ltd> a org:Organization ;
    ns1:basedInHighGeoName "Cambridgeshire" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2653940/about.rdf> ;
    ns1:basedInHighRaw "CAMBRIDGE",
        "CAMBRIDGE, UK" ;
    ns1:description "Discovery and development of ion channel-modulating drugs" ;
    ns1:documentDate "2010-11-23T16:11:46+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Xention Raises £8 Million in Private Equity Placement" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/xention-raises-%C2%A38-million-private-equity-placement> ;
    ns1:foundName "XENTION LTD",
        "Xention" ;
    ns1:industry "biopharmaceutical" ;
    ns1:name "XENTION LTD",
        "Xention" ;
    ns1:sameAsHigh <https://1145.am/db/1327786/Xencor>,
        <https://1145.am/db/1328640/Xencor>,
        <https://1145.am/db/1982692/Xencor>,
        <https://1145.am/db/2284393/Xencor>,
        <https://1145.am/db/2302427/Xencor>,
        <https://1145.am/db/2343207/Xcellerex>,
        <https://1145.am/db/2352880/Xencor>,
        <https://1145.am/db/2354356/Xencor>,
        <https://1145.am/db/2356094/Xeris_Pharmaceuticals>,
        <https://1145.am/db/2370644/Xtl_Biopharmaceuticals_Ltd>,
        <https://1145.am/db/2549625/Xcenda>,
        <https://1145.am/db/2550429/Xcellerex>,
        <https://1145.am/db/2766464/Xencor>,
        <https://1145.am/db/437663/Xeris_Pharmaceuticals>,
        <https://1145.am/db/496816/Xeris_Pharmaceuticals_Inc>,
        <https://1145.am/db/605920/Xeris_Pharmaceuticals_Inc>,
        <https://1145.am/db/639494/Xencor>,
        <https://1145.am/db/730509/Xeris_Biopharma_Holdings>,
        <https://1145.am/db/731708/Xeris_Biopharma_Holdings>,
        <https://1145.am/db/888059/Xeris_Biopharma_Holdings>,
        <https://1145.am/db/889927/Xeris_Biopharma_Holdings>,
        <https://1145.am/db/969962/Xontogeny>,
        <https://1145.am/db/976545/Xontogeny> ;
    ns1:sameAsMedium <https://1145.am/db/2355511/Xention>,
        <https://1145.am/db/2356903/Xention> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2357622/Celulas_Genetica_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition",
        "investment" ;
    ns1:documentDate "2010-12-01T14:22:45+00:00"^^xsd:dateTime ;
    ns1:documentExtract "HOUSTON- (BUSINESS WIRE) - Emerging Healthcare Solutions, Inc. (Pink Sheets: EHSI) today announced its acquisition of Celulas Genetica, a biotechnology firm based in Panama." ;
    ns1:documentTitle "EHSI Acquires Stem Cell Biotech Firm Celulas Genetica" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/ehsi-acquires-stem-cell-biotech-firm-celulas-genetica> ;
    ns1:foundName "acquisition",
        "purchased" ;
    ns1:name "acquisition",
        "purchased" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2357622/Celulas_Genetica> ;
    ns1:targetName "Celulas Genetica" ;
    ns1:whereGeoName "Republic of Panama" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/3703430/about.rdf> ;
    ns1:whereRaw "Panama" .

<https://1145.am/db/2357626/Histogen> a org:Organization ;
    ns1:description "regenerative medicine" ;
    ns1:documentDate "2010-12-01T15:12:33+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Histogen Announces Completion of Series A Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/histogen-announces-completion-of-series-a-financing-0> ;
    ns1:foundName "Histogen",
        "Histogen, Inc." ;
    ns1:industry "regenerative medicine" ;
    ns1:name "Histogen" ;
    ns1:sameAsHigh <https://1145.am/db/2292194/Histogenics>,
        <https://1145.am/db/2295860/Histogenics>,
        <https://1145.am/db/2336102/Histogenics_Corporation>,
        <https://1145.am/db/2336109/Histogenics_Corporation>,
        <https://1145.am/db/2336311/Histogenics_Corporation>,
        <https://1145.am/db/2357628/Histogen>,
        <https://1145.am/db/2363710/Histogenics_Corporation>,
        <https://1145.am/db/2364581/Histogenics>,
        <https://1145.am/db/2368340/Histogenics_Corporation> ;
    ns1:sameAsMedium <https://1145.am/db/1200838/Histogen_Inc>,
        <https://1145.am/db/1616609/Histogen_Inc>,
        <https://1145.am/db/2357625/Histogen>,
        <https://1145.am/db/607132/Histogen_Inc>,
        <https://1145.am/db/712076/Histogen_Inc>,
        <https://1145.am/db/932778/Histogen_Inc> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2357628/Histogen> a org:Organization ;
    ns1:basedInHighGeoName "San Diego County" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5391832/about.rdf> ;
    ns1:basedInHighRaw "San Diego, CA" ;
    ns1:description "regenerative medicine" ;
    ns1:documentDate "2010-12-01T15:20:17+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Histogen Announces Completion of Series A Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/histogen-announces-completion-of-series-a-financing> ;
    ns1:foundName "Histogen",
        "Histogen, Inc." ;
    ns1:industry "regenerative medicine" ;
    ns1:name "Histogen" ;
    ns1:sameAsHigh <https://1145.am/db/2292194/Histogenics>,
        <https://1145.am/db/2295860/Histogenics>,
        <https://1145.am/db/2336102/Histogenics_Corporation>,
        <https://1145.am/db/2336109/Histogenics_Corporation>,
        <https://1145.am/db/2336311/Histogenics_Corporation>,
        <https://1145.am/db/2357626/Histogen>,
        <https://1145.am/db/2363710/Histogenics_Corporation>,
        <https://1145.am/db/2364581/Histogenics>,
        <https://1145.am/db/2368340/Histogenics_Corporation> ;
    ns1:sameAsMedium <https://1145.am/db/1200838/Histogen_Inc>,
        <https://1145.am/db/1616609/Histogen_Inc>,
        <https://1145.am/db/2357625/Histogen>,
        <https://1145.am/db/607132/Histogen_Inc>,
        <https://1145.am/db/712076/Histogen_Inc>,
        <https://1145.am/db/932778/Histogen_Inc> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2359104/Ark_Therapeutics> a org:Organization ;
    ns1:basedInHighGeoName "London" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2643743/about.rdf> ;
    ns1:basedInHighRaw "London" ;
    ns1:description "R & D" ;
    ns1:documentDate "2010-09-09T16:17:38+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Ark restructures; Genentech sees promise in preclinical cancer therapy" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/ark-restructures-genentech-sees-promise-preclinical-cancer-therapy> ;
    ns1:foundName "Ark",
        "Ark Therapeutics" ;
    ns1:name "Ark",
        "Ark Therapeutics" ;
    ns1:protagonist <https://1145.am/db/2359104/Ark_Therapeutics_Has_Not_Happened> ;
    ns1:sameAsHigh <https://1145.am/db/2286730/Sage_Therapeutics> ;
    ns1:sameAsMedium <https://1145.am/db/2559797/Ark_Therapeutics> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2359104/Zymogenetics_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition",
        "investment" ;
    ns1:documentDate "2010-09-09T16:17:38+00:00"^^xsd:dateTime ;
    ns1:documentExtract "@ FierceBiotech: BMS forges $ 885M deal to buy ZymoGenetics." ;
    ns1:documentTitle "Ark restructures; Genentech sees promise in preclinical cancer therapy" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/ark-restructures-genentech-sees-promise-preclinical-cancer-therapy> ;
    ns1:foundName "buy",
        "expands" ;
    ns1:name "buy",
        "expands" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2359104/Zymogenetics> ;
    ns1:targetName "ZymoGenetics" ;
    ns1:valueRaw "$ 40M",
        "$ 885M" ;
    ns1:whereGeoName "Boston" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/4930956/about.rdf> ;
    ns1:whereRaw "Boston" .

<https://1145.am/db/2359125/Orbimed_Advisors> a org:Organization ;
    ns1:basedInLowRaw "BOSTON" ;
    ns1:documentDate "2010-09-10T13:16:20+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Good Start Genetics, Inc. Raises $18 Million to Develop and Launch Sequencing-Based Pre-Pregnancy Genetic Screening Test" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/good-start-genetics-inc-raises-18-million-to-develop-and-launch-sequencing-based-pre> ;
    ns1:foundName "OrbiMed Advisors" ;
    ns1:investor <https://1145.am/db/2359125/Series_A_Investment_Good_Start_Genetics_Orbimed_Advisors_Sv_Life_Sciences_Safeguard_Scientifics_Completed> ;
    ns1:name "OrbiMed Advisors" ;
    ns1:sameAsMedium <https://1145.am/db/1665536/Orbimed_Advisors>,
        <https://1145.am/db/1809007/Orbimed_Advisors>,
        <https://1145.am/db/2198816/Orbimed_Advisors>,
        <https://1145.am/db/2245885/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2281230/Orbimed_Advisors>,
        <https://1145.am/db/2284506/Orbimed_Advisors>,
        <https://1145.am/db/2289056/Orbimed_Advisors>,
        <https://1145.am/db/2290078/Orbimed_Advisors>,
        <https://1145.am/db/2290200/Orbimed_Advisors>,
        <https://1145.am/db/2290444/Orbimed_Advisors>,
        <https://1145.am/db/2297604/Orbimed_Advisors>,
        <https://1145.am/db/2298956/Orbimed_Advisors>,
        <https://1145.am/db/2303098/Orbimed_Advisors>,
        <https://1145.am/db/2304242/Orbimed_Advisors>,
        <https://1145.am/db/2305656/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2306251/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2306705/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2309491/Orbimed_Advisors>,
        <https://1145.am/db/2310922/Orbimed_Advisors>,
        <https://1145.am/db/2312233/Orbimed_Advisors>,
        <https://1145.am/db/2317918/Orbimed_Advisors>,
        <https://1145.am/db/2318133/Orbimed_Advisors>,
        <https://1145.am/db/2318829/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2318832/Orbimed_Advisers>,
        <https://1145.am/db/2318851/Orbimed_Advisors>,
        <https://1145.am/db/2319338/Orbimed_Advisors>,
        <https://1145.am/db/2320914/Orbimed_Advisors>,
        <https://1145.am/db/2322345/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2324226/Orbimed_Advisors>,
        <https://1145.am/db/2325257/Orbimed_Advisors>,
        <https://1145.am/db/2325880/Orbimed_Advisors>,
        <https://1145.am/db/2328599/Orbimed_Advisors>,
        <https://1145.am/db/2328700/Orbimed_Advisors>,
        <https://1145.am/db/2329260/Orbimed_Advisors>,
        <https://1145.am/db/2330799/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2330920/Orbimed_Advisors>,
        <https://1145.am/db/2332120/Orbimed_Advisors>,
        <https://1145.am/db/2333495/Orbimed_Advisors>,
        <https://1145.am/db/2333504/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2333966/Orbimed_Advisors>,
        <https://1145.am/db/2335743/Orbimed_Advisors>,
        <https://1145.am/db/2336221/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2336503/Orbimed_Advisors>,
        <https://1145.am/db/2336505/Orbimed_Advisors>,
        <https://1145.am/db/2336524/Orbimed_Advisors>,
        <https://1145.am/db/2337166/Orbimed_Advisors>,
        <https://1145.am/db/2337250/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2337254/Orbimed_Advisors>,
        <https://1145.am/db/2339885/Orbimed_Advisors>,
        <https://1145.am/db/2339886/Orbimed_Advisors>,
        <https://1145.am/db/2342862/Orbimed_Advisors>,
        <https://1145.am/db/2342925/Orbimed_Advisors>,
        <https://1145.am/db/2342937/Orbimed_Advisors>,
        <https://1145.am/db/2343244/Orbimed_Advisors>,
        <https://1145.am/db/2344735/Orbimed_Advisors>,
        <https://1145.am/db/2344786/Orbimed_Advisors>,
        <https://1145.am/db/2345435/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2345453/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2345456/Orbimed_Advisors>,
        <https://1145.am/db/2346030/Orbimed_Advisors>,
        <https://1145.am/db/2350034/Orbimed_Advisors>,
        <https://1145.am/db/2350044/Orbimed_Advisors>,
        <https://1145.am/db/2352436/Orbimed_Advisors>,
        <https://1145.am/db/2352441/Orbimed_Advisors>,
        <https://1145.am/db/2352442/Orbimed_Advisors>,
        <https://1145.am/db/2352701/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2352804/Orbimed_Advisors>,
        <https://1145.am/db/2352807/Orbimed_Advisors>,
        <https://1145.am/db/2355034/Orbimed_Advisors>,
        <https://1145.am/db/2356297/Orbimed_Advisors>,
        <https://1145.am/db/2356420/Orbimed_Advisors>,
        <https://1145.am/db/2357253/Orbimed_Advisors>,
        <https://1145.am/db/2357256/Orbimed_Advisors>,
        <https://1145.am/db/2357858/Orbimed_Advisors>,
        <https://1145.am/db/2359468/Orbimed_Advisors>,
        <https://1145.am/db/2359864/Orbimed_Advisors>,
        <https://1145.am/db/2360174/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2361018/Orbimed_Advisors>,
        <https://1145.am/db/2361022/Orbimed_Advisors>,
        <https://1145.am/db/2361027/Orbimed_Advisors>,
        <https://1145.am/db/2362475/Orbimed_Advisors>,
        <https://1145.am/db/2362481/Orbimed_Advisors>,
        <https://1145.am/db/2363339/Orbimed_Advisors>,
        <https://1145.am/db/2365679/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2365868/Orbimed_Advisors>,
        <https://1145.am/db/2366519/Orbimed_Advisors>,
        <https://1145.am/db/2574232/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2583013/Orbimed_Advisors>,
        <https://1145.am/db/428737/Orbimed_Advisors>,
        <https://1145.am/db/456081/Orbimed_Advisors>,
        <https://1145.am/db/456089/Orbimed_Advisors>,
        <https://1145.am/db/458377/Orbimed_Advisors>,
        <https://1145.am/db/674484/Orbimed_Advisors> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2360174/New_Leaf_Venture_Partners> a org:Organization ;
    ns1:basedInLowRaw "SANTA CLARA" ;
    ns1:description "venture capital" ;
    ns1:documentDate "2010-09-13T14:04:48+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Relypsa Raises $70 Million in Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/relypsa-raises-70-million-series-b-financing> ;
    ns1:foundName "New Leaf Venture Partners" ;
    ns1:investor <https://1145.am/db/2360174/Series_B_Investment_5am_Ventures_Delphi_Ventures_Mediphase_Venture_Partners_New_Leaf_Venture_Partners_Orbimed_Advisors_Llc_Relypsa_Sprout_Group_Completed> ;
    ns1:name "New Leaf Venture Partners" ;
    ns1:sameAsHigh <https://1145.am/db/1749104/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2151983/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2182517/New_Mountain_Capital>,
        <https://1145.am/db/2301824/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2305507/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2312792/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2325326/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2325398/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2334797/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2342925/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2342937/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2343298/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2347043/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2347571/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2347876/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2348618/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2359683/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2361416/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2362737/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2594141/New_Leaf_Venture_Partners> ;
    ns1:sameAsMedium <https://1145.am/db/1287338/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2155668/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2208603/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2289585/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2293765/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2298642/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2300322/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2301828/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2305514/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2307682/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2311595/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2315071/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2315932/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2315934/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2316674/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2317919/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2318656/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2318657/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2334479/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2341003/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2345037/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2345047/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2346532/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2346542/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2347878/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2348149/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2349120/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2350164/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2350167/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2350491/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2352059/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2357356/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2362736/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2366860/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2569522/New_Leaf_Venture_Partners>,
        <https://1145.am/db/425953/New_Leaf_Venture_Partners>,
        <https://1145.am/db/583528/New_Leaf_Venture_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2360174/Orbimed_Advisors_Llc> a org:Organization ;
    ns1:basedInHighGeoName "Santa Clara" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/3537906/about.rdf> ;
    ns1:basedInHighRaw "SANTA CLARA" ;
    ns1:basedInLowRaw "SANTA CLARA" ;
    ns1:documentDate "2010-09-13T14:04:48+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Relypsa Raises $70 Million in Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/relypsa-raises-70-million-series-b-financing> ;
    ns1:foundName "OrbiMed Advisors, LLC",
        "OrbiMed Advisors, LLC," ;
    ns1:investor <https://1145.am/db/2360174/Series_B_Investment_5am_Ventures_Delphi_Ventures_Mediphase_Venture_Partners_New_Leaf_Venture_Partners_Orbimed_Advisors_Llc_Relypsa_Sprout_Group_Completed> ;
    ns1:name "OrbiMed Advisors",
        "OrbiMed Advisors, LLC" ;
    ns1:sameAsMedium <https://1145.am/db/1665536/Orbimed_Advisors>,
        <https://1145.am/db/1809007/Orbimed_Advisors>,
        <https://1145.am/db/2198816/Orbimed_Advisors>,
        <https://1145.am/db/2245885/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2281230/Orbimed_Advisors>,
        <https://1145.am/db/2284506/Orbimed_Advisors>,
        <https://1145.am/db/2289056/Orbimed_Advisors>,
        <https://1145.am/db/2290078/Orbimed_Advisors>,
        <https://1145.am/db/2290200/Orbimed_Advisors>,
        <https://1145.am/db/2290444/Orbimed_Advisors>,
        <https://1145.am/db/2297604/Orbimed_Advisors>,
        <https://1145.am/db/2298956/Orbimed_Advisors>,
        <https://1145.am/db/2303098/Orbimed_Advisors>,
        <https://1145.am/db/2304242/Orbimed_Advisors>,
        <https://1145.am/db/2305656/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2306251/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2306705/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2309491/Orbimed_Advisors>,
        <https://1145.am/db/2310922/Orbimed_Advisors>,
        <https://1145.am/db/2312233/Orbimed_Advisors>,
        <https://1145.am/db/2317918/Orbimed_Advisors>,
        <https://1145.am/db/2318133/Orbimed_Advisors>,
        <https://1145.am/db/2318829/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2318832/Orbimed_Advisers>,
        <https://1145.am/db/2318851/Orbimed_Advisors>,
        <https://1145.am/db/2319338/Orbimed_Advisors>,
        <https://1145.am/db/2320914/Orbimed_Advisors>,
        <https://1145.am/db/2322345/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2324226/Orbimed_Advisors>,
        <https://1145.am/db/2325257/Orbimed_Advisors>,
        <https://1145.am/db/2325880/Orbimed_Advisors>,
        <https://1145.am/db/2328599/Orbimed_Advisors>,
        <https://1145.am/db/2328700/Orbimed_Advisors>,
        <https://1145.am/db/2329260/Orbimed_Advisors>,
        <https://1145.am/db/2330799/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2330920/Orbimed_Advisors>,
        <https://1145.am/db/2332120/Orbimed_Advisors>,
        <https://1145.am/db/2333495/Orbimed_Advisors>,
        <https://1145.am/db/2333504/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2333966/Orbimed_Advisors>,
        <https://1145.am/db/2335743/Orbimed_Advisors>,
        <https://1145.am/db/2336221/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2336503/Orbimed_Advisors>,
        <https://1145.am/db/2336505/Orbimed_Advisors>,
        <https://1145.am/db/2336524/Orbimed_Advisors>,
        <https://1145.am/db/2337166/Orbimed_Advisors>,
        <https://1145.am/db/2337250/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2337254/Orbimed_Advisors>,
        <https://1145.am/db/2339885/Orbimed_Advisors>,
        <https://1145.am/db/2339886/Orbimed_Advisors>,
        <https://1145.am/db/2342862/Orbimed_Advisors>,
        <https://1145.am/db/2342925/Orbimed_Advisors>,
        <https://1145.am/db/2342937/Orbimed_Advisors>,
        <https://1145.am/db/2343244/Orbimed_Advisors>,
        <https://1145.am/db/2344735/Orbimed_Advisors>,
        <https://1145.am/db/2344786/Orbimed_Advisors>,
        <https://1145.am/db/2345435/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2345453/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2345456/Orbimed_Advisors>,
        <https://1145.am/db/2346030/Orbimed_Advisors>,
        <https://1145.am/db/2350034/Orbimed_Advisors>,
        <https://1145.am/db/2350044/Orbimed_Advisors>,
        <https://1145.am/db/2352436/Orbimed_Advisors>,
        <https://1145.am/db/2352441/Orbimed_Advisors>,
        <https://1145.am/db/2352442/Orbimed_Advisors>,
        <https://1145.am/db/2352701/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2352804/Orbimed_Advisors>,
        <https://1145.am/db/2352807/Orbimed_Advisors>,
        <https://1145.am/db/2355034/Orbimed_Advisors>,
        <https://1145.am/db/2356297/Orbimed_Advisors>,
        <https://1145.am/db/2356420/Orbimed_Advisors>,
        <https://1145.am/db/2357253/Orbimed_Advisors>,
        <https://1145.am/db/2357256/Orbimed_Advisors>,
        <https://1145.am/db/2357858/Orbimed_Advisors>,
        <https://1145.am/db/2359125/Orbimed_Advisors>,
        <https://1145.am/db/2359468/Orbimed_Advisors>,
        <https://1145.am/db/2359864/Orbimed_Advisors>,
        <https://1145.am/db/2361018/Orbimed_Advisors>,
        <https://1145.am/db/2361022/Orbimed_Advisors>,
        <https://1145.am/db/2361027/Orbimed_Advisors>,
        <https://1145.am/db/2362475/Orbimed_Advisors>,
        <https://1145.am/db/2362481/Orbimed_Advisors>,
        <https://1145.am/db/2363339/Orbimed_Advisors>,
        <https://1145.am/db/2365679/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2365868/Orbimed_Advisors>,
        <https://1145.am/db/2366519/Orbimed_Advisors>,
        <https://1145.am/db/2574232/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2583013/Orbimed_Advisors>,
        <https://1145.am/db/428737/Orbimed_Advisors>,
        <https://1145.am/db/456081/Orbimed_Advisors>,
        <https://1145.am/db/456089/Orbimed_Advisors>,
        <https://1145.am/db/458377/Orbimed_Advisors>,
        <https://1145.am/db/674484/Orbimed_Advisors> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2360189/Series_B_Investment_Boehringer_Ingelheim_Venture_Fund_Okairos_Versant_Ventures_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-09-14T11:29:40+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Basel, Switzerland - September 14, 2010 - Okairos today announced the completion of a Series B private financing round totaling €16 million.",
        "Okairos Raises €16 Million in Series B Financing." ;
    ns1:documentTitle "Okairos Raises €16 Million in Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/okairos-raises-%E2%82%AC16-million-series-b-financing> ;
    ns1:foundName "financing" ;
    ns1:name "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2360189/Okairos> ;
    ns1:targetDetails "Series B" ;
    ns1:valueRaw "€16 Million",
        "€16 million" ;
    ns1:when "2010-09-14T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "September 14, 2010" ;
    ns1:whereGeoName "Switzerland" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/2658434/about.rdf> ;
    ns1:whereRaw "Switzerland" .

<https://1145.am/db/2360213/Securities_Investment_Arno_Therapeutics_Pontifax_Funds_Uta_Capital_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-09-14T14:43:18+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Arno Therapeutics Raises $ 15 Million in Private Placement To Advance Clinical Development of Oncology Compounds.",
        "PARSIPPANY, N.J.- (BUSINESS WIRE) -Arno Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing oncology therapeutics, today announced that it has closed a private placement of its securities resulting in gross proceeds to the company of over $ 15 million." ;
    ns1:documentTitle "Arno Therapeutics Raises $15 Million in Private Placement To Advance Clinical Development of Oncology Compounds" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/arno-therapeutics-raises-15-million-private-placement-to-advance-clinical-development-of> ;
    ns1:foundName "Placement",
        "private placement" ;
    ns1:name "Placement",
        "private placement" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2360213/Arno_Therapeutics> ;
    ns1:targetDetails "securities" ;
    ns1:valueRaw "$ 15 Million",
        "over $ 15 million" ;
    ns1:when "2010-09-14T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "9/14/2010" ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "United States" .

<https://1145.am/db/2360756/Advanced_Technology_Ventures> a org:Organization ;
    ns1:basedInLowRaw "CAMBRIDGE" ;
    ns1:documentDate "2010-12-08T14:42:10+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Catabasis Pharmaceuticals Secures $14.5 Million Second Tranche in Series A Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/catabasis-pharmaceuticals-secures-14-5-million-second-tranche-series-a-financing> ;
    ns1:foundName "Advanced Technology Ventures" ;
    ns1:investor <https://1145.am/db/2360756/Series_A_Investment_Advanced_Technology_Ventures_Catabasis_Pharmaceuticals_Catabasis_Pharmaceuticals_Clarus_Ventures_Medimmune_Ventures_Sv_Life_Sciences_Completed> ;
    ns1:name "Advanced Technology Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/1800080/Advanced_Technology_Ventures>,
        <https://1145.am/db/1830593/Advanced_Technology_Ventures>,
        <https://1145.am/db/1850376/Advanced_Technology_Ventures>,
        <https://1145.am/db/1854846/Advanced_Technology_Ventures>,
        <https://1145.am/db/1861352/Advanced_Technology_Ventures>,
        <https://1145.am/db/1872490/Advanced_Technology_Ventures>,
        <https://1145.am/db/2287777/Advanced_Technology_Ventures>,
        <https://1145.am/db/2291818/Advanced_Technology_Ventures>,
        <https://1145.am/db/2300322/Advanced_Technology_Ventures>,
        <https://1145.am/db/2316391/Advanced_Technology_Ventures>,
        <https://1145.am/db/2317467/Advanced_Technology_Ventures>,
        <https://1145.am/db/2317918/Advanced_Technology_Ventures>,
        <https://1145.am/db/2319874/Advanced_Technology_Ventures>,
        <https://1145.am/db/2322012/Advanced_Technology_Ventures>,
        <https://1145.am/db/2322022/Advanced_Technology_Ventures>,
        <https://1145.am/db/2328599/Advanced_Technology_Ventures>,
        <https://1145.am/db/2336313/Advanced_Technology_Ventures>,
        <https://1145.am/db/2338703/Advanced_Technology_Ventures>,
        <https://1145.am/db/2338704/Advanced_Technology_Ventures>,
        <https://1145.am/db/2341904/Advanced_Technology_Ventures>,
        <https://1145.am/db/2343722/Advanced_Technology_Ventures>,
        <https://1145.am/db/2343737/Advanced_Technology_Ventures>,
        <https://1145.am/db/2347389/Advanced_Technology_Ventures>,
        <https://1145.am/db/2360758/Advanced_Technology_Ventures>,
        <https://1145.am/db/2362553/Advanced_Technology_Ventures>,
        <https://1145.am/db/2362871/Advanced_Technology_Ventures>,
        <https://1145.am/db/2364939/Advanced_Technology_Ventures>,
        <https://1145.am/db/2367204/Advanced_Technology_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2360756/Catabasis_Pharmaceuticals> a org:Organization ;
    ns1:basedInHighGeoName "Cambridge" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/4931972/about.rdf> ;
    ns1:basedInHighRaw "CAMBRIDGE, Mass." ;
    ns1:description "a biopharmaceutical company" ;
    ns1:documentDate "2010-12-08T14:42:10+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Catabasis Pharmaceuticals Secures $14.5 Million Second Tranche in Series A Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/catabasis-pharmaceuticals-secures-14-5-million-second-tranche-series-a-financing> ;
    ns1:foundName "Catabasis",
        "Catabasis Pharmaceuticals" ;
    ns1:industry "biopharmaceutical" ;
    ns1:name "Catabasis Pharmaceuticals" ;
    ns1:sameAsHigh <https://1145.am/db/2336296/Catabasis_Pharmaceuticals_Inc>,
        <https://1145.am/db/2336303/Catabasis_Pharmaceuticals>,
        <https://1145.am/db/2343722/Catabasis_Pharmaceuticals>,
        <https://1145.am/db/2343725/Catabasis_Pharmaceuticals>,
        <https://1145.am/db/2343737/Catabasis_Pharmaceuticals>,
        <https://1145.am/db/2347389/Catabasis_Pharmaceuticals>,
        <https://1145.am/db/2347773/Catabasis_Pharmaceuticals>,
        <https://1145.am/db/2353371/Catabasis_Pharmaceuticals>,
        <https://1145.am/db/2353463/Catabasis_Pharmaceuticals>,
        <https://1145.am/db/2354134/Catabasis_Pharmaceuticals_Inc>,
        <https://1145.am/db/2360758/Catabasis_Pharmaceuticals>,
        <https://1145.am/db/2364972/Catabasis_Pharmaceuticals>,
        <https://1145.am/db/2367443/Catabasis_Pharmaceuticals>,
        <https://1145.am/db/2580881/Catabasis_Pharmaceuticals> ;
    ns1:sameAsMedium <https://1145.am/db/2336313/Catabasis_Pharmaceuticals>,
        <https://1145.am/db/2341652/Catabasis_Pharmaceuticals>,
        <https://1145.am/db/2347391/Catabasis_Pharmaceuticals> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2360758/Advanced_Technology_Ventures> a org:Organization ;
    ns1:basedInLowRaw "CAMBRIDGE" ;
    ns1:documentDate "2010-12-08T14:23:07+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Catabasis Pharmaceuticals Secures $14.5 Million Second Tranche in Series A Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/catabasis-pharmaceuticals-secures-14-5-million-second-tranche-series-a-financing-0> ;
    ns1:foundName "Advanced Technology Ventures" ;
    ns1:investor <https://1145.am/db/2360758/Series_A_Investment_Advanced_Technology_Ventures_Catabasis_Pharmaceuticals_Catabasis_Pharmaceuticals_Clarus_Ventures_Medimmune_Ventures_Sv_Life_Sciences_Completed> ;
    ns1:name "Advanced Technology Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/1800080/Advanced_Technology_Ventures>,
        <https://1145.am/db/1830593/Advanced_Technology_Ventures>,
        <https://1145.am/db/1850376/Advanced_Technology_Ventures>,
        <https://1145.am/db/1854846/Advanced_Technology_Ventures>,
        <https://1145.am/db/1861352/Advanced_Technology_Ventures>,
        <https://1145.am/db/1872490/Advanced_Technology_Ventures>,
        <https://1145.am/db/2287777/Advanced_Technology_Ventures>,
        <https://1145.am/db/2291818/Advanced_Technology_Ventures>,
        <https://1145.am/db/2300322/Advanced_Technology_Ventures>,
        <https://1145.am/db/2316391/Advanced_Technology_Ventures>,
        <https://1145.am/db/2317467/Advanced_Technology_Ventures>,
        <https://1145.am/db/2317918/Advanced_Technology_Ventures>,
        <https://1145.am/db/2319874/Advanced_Technology_Ventures>,
        <https://1145.am/db/2322012/Advanced_Technology_Ventures>,
        <https://1145.am/db/2322022/Advanced_Technology_Ventures>,
        <https://1145.am/db/2328599/Advanced_Technology_Ventures>,
        <https://1145.am/db/2336313/Advanced_Technology_Ventures>,
        <https://1145.am/db/2338703/Advanced_Technology_Ventures>,
        <https://1145.am/db/2338704/Advanced_Technology_Ventures>,
        <https://1145.am/db/2341904/Advanced_Technology_Ventures>,
        <https://1145.am/db/2343722/Advanced_Technology_Ventures>,
        <https://1145.am/db/2343737/Advanced_Technology_Ventures>,
        <https://1145.am/db/2347389/Advanced_Technology_Ventures>,
        <https://1145.am/db/2360756/Advanced_Technology_Ventures>,
        <https://1145.am/db/2362553/Advanced_Technology_Ventures>,
        <https://1145.am/db/2362871/Advanced_Technology_Ventures>,
        <https://1145.am/db/2364939/Advanced_Technology_Ventures>,
        <https://1145.am/db/2367204/Advanced_Technology_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2360758/Catabasis_Pharmaceuticals> a org:Organization ;
    ns1:basedInHighGeoName "Cambridge" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/4931972/about.rdf> ;
    ns1:basedInHighRaw "CAMBRIDGE, Mass." ;
    ns1:description "a biopharmaceutical company" ;
    ns1:documentDate "2010-12-08T14:23:07+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Catabasis Pharmaceuticals Secures $14.5 Million Second Tranche in Series A Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/catabasis-pharmaceuticals-secures-14-5-million-second-tranche-series-a-financing-0> ;
    ns1:foundName "Catabasis",
        "Catabasis Pharmaceuticals" ;
    ns1:industry "biopharmaceutical" ;
    ns1:name "Catabasis Pharmaceuticals" ;
    ns1:sameAsHigh <https://1145.am/db/2336296/Catabasis_Pharmaceuticals_Inc>,
        <https://1145.am/db/2336303/Catabasis_Pharmaceuticals>,
        <https://1145.am/db/2343722/Catabasis_Pharmaceuticals>,
        <https://1145.am/db/2343725/Catabasis_Pharmaceuticals>,
        <https://1145.am/db/2343737/Catabasis_Pharmaceuticals>,
        <https://1145.am/db/2347389/Catabasis_Pharmaceuticals>,
        <https://1145.am/db/2347773/Catabasis_Pharmaceuticals>,
        <https://1145.am/db/2353371/Catabasis_Pharmaceuticals>,
        <https://1145.am/db/2353463/Catabasis_Pharmaceuticals>,
        <https://1145.am/db/2354134/Catabasis_Pharmaceuticals_Inc>,
        <https://1145.am/db/2360756/Catabasis_Pharmaceuticals>,
        <https://1145.am/db/2364972/Catabasis_Pharmaceuticals>,
        <https://1145.am/db/2367443/Catabasis_Pharmaceuticals>,
        <https://1145.am/db/2580881/Catabasis_Pharmaceuticals> ;
    ns1:sameAsMedium <https://1145.am/db/2336313/Catabasis_Pharmaceuticals>,
        <https://1145.am/db/2341652/Catabasis_Pharmaceuticals>,
        <https://1145.am/db/2347391/Catabasis_Pharmaceuticals> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2362826/Cypress_Bioscience> a org:Organization ;
    ns1:basedInHighGeoName "New York City",
        "San Diego County" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5128581/about.rdf>,
        <https://sws.geonames.org/5391832/about.rdf> ;
    ns1:basedInHighRaw "SAN DIEGO & NEW YORK" ;
    ns1:description "pharmaceutical company engaged in the development of innovative drugs to treat central nervous system (CNS) disorders" ;
    ns1:documentDate "2010-12-15T13:23:15+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Cypress Bioscience Agrees To Be Acquired by Ramius LLC and Royalty Pharma for $6.50 Per Share in Cash" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cypress-bioscience-agrees-to-be-acquired-by-ramius-llc-and-royalty-pharma-for-6-50-per> ;
    ns1:foundName "Cypress",
        "Cypress Bioscience, Inc" ;
    ns1:industry "pharmaceutical" ;
    ns1:name "Cypress Bioscience" ;
    ns1:sameAsHigh <https://1145.am/db/2311166/Cypress_Bioscience>,
        <https://1145.am/db/2311179/Cypress_Bioscience>,
        <https://1145.am/db/2340402/Cypress_Bioscience_Inc>,
        <https://1145.am/db/2348691/Cypress_Bioscience>,
        <https://1145.am/db/2348695/Cypress_Bioscience>,
        <https://1145.am/db/2353890/Cypress_Bioscience>,
        <https://1145.am/db/2365163/Cypress_Bioscience>,
        <https://1145.am/db/2365716/Cypress_Bioscience>,
        <https://1145.am/db/2560066/Cypress_Pharmaceuticals>,
        <https://1145.am/db/2594304/Cypress_Pharmaceutical> ;
    ns1:sameAsMedium <https://1145.am/db/2319674/Cypress_Bioscience>,
        <https://1145.am/db/2341460/Cypress_Bioscience>,
        <https://1145.am/db/2348694/Cypress_Bioscience>,
        <https://1145.am/db/2350755/Cypress_Bioscience_Inc>,
        <https://1145.am/db/2353869/Cypress_Bioscience>,
        <https://1145.am/db/2361249/Cypress_Bioscience>,
        <https://1145.am/db/2361250/Cypress_Bioscience>,
        <https://1145.am/db/2361775/Cypress_Bioscience>,
        <https://1145.am/db/2361781/Cypress_Bioscience>,
        <https://1145.am/db/2362845/Cypress_Bioscience>,
        <https://1145.am/db/2586232/Cypress_Bioscience> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2363262/Immatics_Biotechnologies_Gmbh> a org:Organization ;
    ns1:basedInLowRaw "Germany" ;
    ns1:description "developing advanced therapeutic vaccines" ;
    ns1:documentDate "2010-09-21T11:15:34+00:00"^^xsd:dateTime ;
    ns1:documentTitle "immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/immatics-raises-eur54-million-to-advance-its-late-stage-clinical-therapeutic-cancer-0> ;
    ns1:foundName "immatics biotechnologies GmbH" ;
    ns1:industry "biopharmaceutical" ;
    ns1:name "immatics biotechnologies GmbH" ;
    ns1:sameAsHigh <https://1145.am/db/1006052/Mbx_Biosciences>,
        <https://1145.am/db/1015442/Peak_Bio>,
        <https://1145.am/db/1016869/Peak_Bio>,
        <https://1145.am/db/1037301/Caladrius_Biosciences>,
        <https://1145.am/db/1099788/Aadi_Bioscience>,
        <https://1145.am/db/1115265/Forte_Biosciences>,
        <https://1145.am/db/1116238/Forte_Biosciences>,
        <https://1145.am/db/1118932/Pharnext_Sa>,
        <https://1145.am/db/1130017/Rubedo_Life_Sciences>,
        <https://1145.am/db/1131675/Rubedo_Life_Sciences>,
        <https://1145.am/db/1142603/Myovant_Sciences>,
        <https://1145.am/db/1143747/Atai_Life_Sciences_Nv>,
        <https://1145.am/db/1218171/Myovant_Sciences>,
        <https://1145.am/db/1229551/Ammax_Bio>,
        <https://1145.am/db/1244653/Rubedo_Life_Sciences>,
        <https://1145.am/db/1245312/Rubedo_Life_Sciences>,
        <https://1145.am/db/1259314/Caladrius_Biosciences>,
        <https://1145.am/db/1263129/Arcus_Biosciences>,
        <https://1145.am/db/1269874/Arcus_Biosciences>,
        <https://1145.am/db/1278059/Atai_Life_Sciences_Nv>,
        <https://1145.am/db/1283749/Myovant_Sciences>,
        <https://1145.am/db/1296375/Pharnext>,
        <https://1145.am/db/1337532/Xenotech>,
        <https://1145.am/db/1349348/Myovant_Sciences>,
        <https://1145.am/db/1352490/Ventyx_Biosciences_Inc>,
        <https://1145.am/db/1389183/Xenetic_Biosciences>,
        <https://1145.am/db/1429987/Myovant_Sciences>,
        <https://1145.am/db/1467264/Peak_Bio>,
        <https://1145.am/db/1470827/Novadip_Biosciences>,
        <https://1145.am/db/1472245/Novadip_Biosciences>,
        <https://1145.am/db/1472731/Peak_Bio>,
        <https://1145.am/db/1475092/Edesa_Biotech>,
        <https://1145.am/db/1475939/Peak_Bio>,
        <https://1145.am/db/1483506/Pharnext_Sa>,
        <https://1145.am/db/1487323/Aadi_Bioscience>,
        <https://1145.am/db/1509766/Xenetic_Biosciences>,
        <https://1145.am/db/1536041/Pharnext_Sa>,
        <https://1145.am/db/1540716/Experic>,
        <https://1145.am/db/1540944/Experic>,
        <https://1145.am/db/1634976/Biontech>,
        <https://1145.am/db/1638497/Ventyx_Biosciences>,
        <https://1145.am/db/1696383/Biontech>,
        <https://1145.am/db/1697281/Biontech>,
        <https://1145.am/db/2033878/Scinopsis>,
        <https://1145.am/db/2035273/Almirall_Sa>,
        <https://1145.am/db/2133694/Interax_Biotech>,
        <https://1145.am/db/2152410/Altasciences>,
        <https://1145.am/db/2152861/Biontech>,
        <https://1145.am/db/2211386/Biospecifics_Technologies_Corp>,
        <https://1145.am/db/2283508/Biontech>,
        <https://1145.am/db/2291327/Bioclinica>,
        <https://1145.am/db/2301832/Abraxis_Bioscience_Inc>,
        <https://1145.am/db/2303018/Profectus_Biosciences>,
        <https://1145.am/db/2304587/Bipar_Sciences>,
        <https://1145.am/db/2307925/Bipar_Sciences>,
        <https://1145.am/db/2309020/Bioprocessors>,
        <https://1145.am/db/2313209/Bipar_Sciences>,
        <https://1145.am/db/2320925/Bipar_Sciences>,
        <https://1145.am/db/2325513/Echelon_Biosciences_Inc>,
        <https://1145.am/db/2336300/Braasch_Biotech>,
        <https://1145.am/db/2338379/Catalyst_Biosciences_Inc>,
        <https://1145.am/db/2338400/Anavex_Life_Sciences_Corp>,
        <https://1145.am/db/2339237/Anavex_Life_Sciences_Corp>,
        <https://1145.am/db/2340127/Knopp_Biosciences_Llc>,
        <https://1145.am/db/2346950/Biolinerx_Ltd>,
        <https://1145.am/db/2348109/Immatics_Biotechnologies_Gmbh>,
        <https://1145.am/db/2348209/Xenetic_Biosciences>,
        <https://1145.am/db/2348970/Biooutsource_Ltd>,
        <https://1145.am/db/2349187/Biospecifics_Technologies_Corp>,
        <https://1145.am/db/2351879/Immatics_Biotechnologies_Gmbh>,
        <https://1145.am/db/2352174/Theravance_Biopharma>,
        <https://1145.am/db/2352362/Ceregene>,
        <https://1145.am/db/2355157/Xenetic_Biosciences>,
        <https://1145.am/db/2355423/Biontech>,
        <https://1145.am/db/2357078/Biospecifics_Technologies_Corp>,
        <https://1145.am/db/2359443/Immatics_Biotechnologies_Gmbh>,
        <https://1145.am/db/2360281/Biotechnology_Industry_Organization>,
        <https://1145.am/db/2362455/Pharnext_Sas>,
        <https://1145.am/db/2363274/Immatics_Biotechnologies_Gmbh>,
        <https://1145.am/db/2366052/Accentia_Biopharmaceuticals_Inc>,
        <https://1145.am/db/2366710/Fidelity_Biosciences>,
        <https://1145.am/db/2367301/Ricerca_Biosciences>,
        <https://1145.am/db/2368362/Anavex_Life_Sciences_Corp>,
        <https://1145.am/db/2370575/Anavex_Life_Sciences_Corp>,
        <https://1145.am/db/2370820/Catalyst_Biosciences>,
        <https://1145.am/db/2537396/Boehringer_Ingelheim>,
        <https://1145.am/db/2540757/Biontech>,
        <https://1145.am/db/2548924/Biontech>,
        <https://1145.am/db/2549913/Biontech>,
        <https://1145.am/db/2554710/Bioanalab>,
        <https://1145.am/db/2557995/Jhl_Biotech>,
        <https://1145.am/db/2578126/Biovest_International_Inc>,
        <https://1145.am/db/2578278/Accentia_Biopharmaceuticals_Inc>,
        <https://1145.am/db/2785879/Dren_Bio>,
        <https://1145.am/db/2797140/Biontech>,
        <https://1145.am/db/432278/Aadi_Bioscience_Inc>,
        <https://1145.am/db/565352/Ventyx_Biosciences_Inc>,
        <https://1145.am/db/573811/Ventyx_Biosciences_Inc>,
        <https://1145.am/db/590165/Aadi_Bioscience>,
        <https://1145.am/db/616870/Kronos_Bio>,
        <https://1145.am/db/624182/Aruvant_Sciences>,
        <https://1145.am/db/643999/Pharnext_Sa>,
        <https://1145.am/db/720091/Pardes_Biosciences>,
        <https://1145.am/db/736423/Biomea>,
        <https://1145.am/db/739368/Iveric_Bio>,
        <https://1145.am/db/766180/Alvotech>,
        <https://1145.am/db/766742/Alvotech>,
        <https://1145.am/db/833022/Coherus_Biosciences>,
        <https://1145.am/db/871264/Pardes_Biosciences_Inc>,
        <https://1145.am/db/914424/Scilex>,
        <https://1145.am/db/926840/Edesa_Biotech>,
        <https://1145.am/db/933046/Edesa_Biotech>,
        <https://1145.am/db/942858/Edesa_Biotech>,
        <https://1145.am/db/972875/Mbx_Biosciences>,
        <https://1145.am/db/984385/Bionova_Scientific>,
        <https://1145.am/db/986224/Bionova_Scientific> ;
    ns1:sameAsMedium <https://1145.am/db/2303093/Immatics_Biotechnologies> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2363274/Immatics_Biotechnologies_Gmbh> a org:Organization ;
    ns1:basedInLowRaw "Germany" ;
    ns1:description "developing advanced therapeutic vaccines" ;
    ns1:documentDate "2010-09-21T12:37:18+00:00"^^xsd:dateTime ;
    ns1:documentTitle "immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/immatics-raises-eur54-million-to-advance-its-late-stage-clinical-therapeutic-cancer-vaccine> ;
    ns1:foundName "immatics biotechnologies GmbH" ;
    ns1:industry "biopharmaceutical" ;
    ns1:name "immatics biotechnologies GmbH" ;
    ns1:sameAsHigh <https://1145.am/db/1006052/Mbx_Biosciences>,
        <https://1145.am/db/1015442/Peak_Bio>,
        <https://1145.am/db/1016869/Peak_Bio>,
        <https://1145.am/db/1037301/Caladrius_Biosciences>,
        <https://1145.am/db/1099788/Aadi_Bioscience>,
        <https://1145.am/db/1115265/Forte_Biosciences>,
        <https://1145.am/db/1116238/Forte_Biosciences>,
        <https://1145.am/db/1118932/Pharnext_Sa>,
        <https://1145.am/db/1130017/Rubedo_Life_Sciences>,
        <https://1145.am/db/1131675/Rubedo_Life_Sciences>,
        <https://1145.am/db/1142603/Myovant_Sciences>,
        <https://1145.am/db/1143747/Atai_Life_Sciences_Nv>,
        <https://1145.am/db/1218171/Myovant_Sciences>,
        <https://1145.am/db/1229551/Ammax_Bio>,
        <https://1145.am/db/1244653/Rubedo_Life_Sciences>,
        <https://1145.am/db/1245312/Rubedo_Life_Sciences>,
        <https://1145.am/db/1259314/Caladrius_Biosciences>,
        <https://1145.am/db/1263129/Arcus_Biosciences>,
        <https://1145.am/db/1269874/Arcus_Biosciences>,
        <https://1145.am/db/1278059/Atai_Life_Sciences_Nv>,
        <https://1145.am/db/1283749/Myovant_Sciences>,
        <https://1145.am/db/1296375/Pharnext>,
        <https://1145.am/db/1337532/Xenotech>,
        <https://1145.am/db/1349348/Myovant_Sciences>,
        <https://1145.am/db/1352490/Ventyx_Biosciences_Inc>,
        <https://1145.am/db/1389183/Xenetic_Biosciences>,
        <https://1145.am/db/1429987/Myovant_Sciences>,
        <https://1145.am/db/1467264/Peak_Bio>,
        <https://1145.am/db/1470827/Novadip_Biosciences>,
        <https://1145.am/db/1472245/Novadip_Biosciences>,
        <https://1145.am/db/1472731/Peak_Bio>,
        <https://1145.am/db/1475092/Edesa_Biotech>,
        <https://1145.am/db/1475939/Peak_Bio>,
        <https://1145.am/db/1483506/Pharnext_Sa>,
        <https://1145.am/db/1487323/Aadi_Bioscience>,
        <https://1145.am/db/1509766/Xenetic_Biosciences>,
        <https://1145.am/db/1536041/Pharnext_Sa>,
        <https://1145.am/db/1540716/Experic>,
        <https://1145.am/db/1540944/Experic>,
        <https://1145.am/db/1634976/Biontech>,
        <https://1145.am/db/1638497/Ventyx_Biosciences>,
        <https://1145.am/db/1696383/Biontech>,
        <https://1145.am/db/1697281/Biontech>,
        <https://1145.am/db/2033878/Scinopsis>,
        <https://1145.am/db/2035273/Almirall_Sa>,
        <https://1145.am/db/2133694/Interax_Biotech>,
        <https://1145.am/db/2152410/Altasciences>,
        <https://1145.am/db/2152861/Biontech>,
        <https://1145.am/db/2211386/Biospecifics_Technologies_Corp>,
        <https://1145.am/db/2283508/Biontech>,
        <https://1145.am/db/2291327/Bioclinica>,
        <https://1145.am/db/2301832/Abraxis_Bioscience_Inc>,
        <https://1145.am/db/2303018/Profectus_Biosciences>,
        <https://1145.am/db/2304587/Bipar_Sciences>,
        <https://1145.am/db/2307925/Bipar_Sciences>,
        <https://1145.am/db/2309020/Bioprocessors>,
        <https://1145.am/db/2313209/Bipar_Sciences>,
        <https://1145.am/db/2320925/Bipar_Sciences>,
        <https://1145.am/db/2325513/Echelon_Biosciences_Inc>,
        <https://1145.am/db/2336300/Braasch_Biotech>,
        <https://1145.am/db/2338379/Catalyst_Biosciences_Inc>,
        <https://1145.am/db/2338400/Anavex_Life_Sciences_Corp>,
        <https://1145.am/db/2339237/Anavex_Life_Sciences_Corp>,
        <https://1145.am/db/2340127/Knopp_Biosciences_Llc>,
        <https://1145.am/db/2346950/Biolinerx_Ltd>,
        <https://1145.am/db/2348109/Immatics_Biotechnologies_Gmbh>,
        <https://1145.am/db/2348209/Xenetic_Biosciences>,
        <https://1145.am/db/2348970/Biooutsource_Ltd>,
        <https://1145.am/db/2349187/Biospecifics_Technologies_Corp>,
        <https://1145.am/db/2351879/Immatics_Biotechnologies_Gmbh>,
        <https://1145.am/db/2352174/Theravance_Biopharma>,
        <https://1145.am/db/2352362/Ceregene>,
        <https://1145.am/db/2355157/Xenetic_Biosciences>,
        <https://1145.am/db/2355423/Biontech>,
        <https://1145.am/db/2357078/Biospecifics_Technologies_Corp>,
        <https://1145.am/db/2359443/Immatics_Biotechnologies_Gmbh>,
        <https://1145.am/db/2360281/Biotechnology_Industry_Organization>,
        <https://1145.am/db/2362455/Pharnext_Sas>,
        <https://1145.am/db/2363262/Immatics_Biotechnologies_Gmbh>,
        <https://1145.am/db/2366052/Accentia_Biopharmaceuticals_Inc>,
        <https://1145.am/db/2366710/Fidelity_Biosciences>,
        <https://1145.am/db/2367301/Ricerca_Biosciences>,
        <https://1145.am/db/2368362/Anavex_Life_Sciences_Corp>,
        <https://1145.am/db/2370575/Anavex_Life_Sciences_Corp>,
        <https://1145.am/db/2370820/Catalyst_Biosciences>,
        <https://1145.am/db/2537396/Boehringer_Ingelheim>,
        <https://1145.am/db/2540757/Biontech>,
        <https://1145.am/db/2548924/Biontech>,
        <https://1145.am/db/2549913/Biontech>,
        <https://1145.am/db/2554710/Bioanalab>,
        <https://1145.am/db/2557995/Jhl_Biotech>,
        <https://1145.am/db/2578126/Biovest_International_Inc>,
        <https://1145.am/db/2578278/Accentia_Biopharmaceuticals_Inc>,
        <https://1145.am/db/2785879/Dren_Bio>,
        <https://1145.am/db/2797140/Biontech>,
        <https://1145.am/db/432278/Aadi_Bioscience_Inc>,
        <https://1145.am/db/565352/Ventyx_Biosciences_Inc>,
        <https://1145.am/db/573811/Ventyx_Biosciences_Inc>,
        <https://1145.am/db/590165/Aadi_Bioscience>,
        <https://1145.am/db/616870/Kronos_Bio>,
        <https://1145.am/db/624182/Aruvant_Sciences>,
        <https://1145.am/db/643999/Pharnext_Sa>,
        <https://1145.am/db/720091/Pardes_Biosciences>,
        <https://1145.am/db/736423/Biomea>,
        <https://1145.am/db/739368/Iveric_Bio>,
        <https://1145.am/db/766180/Alvotech>,
        <https://1145.am/db/766742/Alvotech>,
        <https://1145.am/db/833022/Coherus_Biosciences>,
        <https://1145.am/db/871264/Pardes_Biosciences_Inc>,
        <https://1145.am/db/914424/Scilex>,
        <https://1145.am/db/926840/Edesa_Biotech>,
        <https://1145.am/db/933046/Edesa_Biotech>,
        <https://1145.am/db/942858/Edesa_Biotech>,
        <https://1145.am/db/972875/Mbx_Biosciences>,
        <https://1145.am/db/984385/Bionova_Scientific>,
        <https://1145.am/db/986224/Bionova_Scientific> ;
    ns1:sameAsMedium <https://1145.am/db/2303093/Immatics_Biotechnologies> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2364249/Cytomx_Therapeutics> a org:Organization ;
    ns1:basedInHighGeoName "Santa Barbara County" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5392967/about.rdf> ;
    ns1:basedInHighRaw "SANTA BARBARA, Calif" ;
    ns1:description "Biotechnology" ;
    ns1:documentDate "2010-09-23T11:06:41+00:00"^^xsd:dateTime ;
    ns1:documentTitle "CytomX Therapeutics Completes $30 Million Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cytomx-therapeutics-completes-30-million-series-b-financing-0> ;
    ns1:foundName "CytomX Therapeutics" ;
    ns1:industry "biotechnology" ;
    ns1:name "CytomX Therapeutics" ;
    ns1:sameAsHigh <https://1145.am/db/2151786/Cytomx_Therapeutics>,
        <https://1145.am/db/2154105/Cytomx>,
        <https://1145.am/db/2299752/Cytox>,
        <https://1145.am/db/2337958/Cytomx_Therapeutics>,
        <https://1145.am/db/2337974/Cytomx_Therapeutics>,
        <https://1145.am/db/2339513/Cytomx>,
        <https://1145.am/db/2339908/Cytomx_Therapeutics>,
        <https://1145.am/db/2340913/Cytomx>,
        <https://1145.am/db/2343178/Cytomx_Therapeutics>,
        <https://1145.am/db/2347024/Cytomedix_Inc>,
        <https://1145.am/db/2354469/Cytomx_Therapeutics>,
        <https://1145.am/db/2355041/Cytomx>,
        <https://1145.am/db/2355043/Cytomx>,
        <https://1145.am/db/2356089/Cytomx>,
        <https://1145.am/db/2356791/Cytomx>,
        <https://1145.am/db/2357499/Cytomx>,
        <https://1145.am/db/2358191/Cytovance_Biologics>,
        <https://1145.am/db/2361245/Cytogenix>,
        <https://1145.am/db/2361695/Cytomx>,
        <https://1145.am/db/2364255/Cytomx>,
        <https://1145.am/db/2364283/Cytomx_Therapeutics>,
        <https://1145.am/db/2365825/Cytomx>,
        <https://1145.am/db/2366301/Cytomx_Therapeutics>,
        <https://1145.am/db/2366304/Cytomx>,
        <https://1145.am/db/2369631/Cytomx_Therapeutics>,
        <https://1145.am/db/522087/Cytomx_Therapeutics> ;
    ns1:sameAsMedium <https://1145.am/db/812566/Cytomx_Therapeutics>,
        <https://1145.am/db/926316/Cytomx_Therapeutics>,
        <https://1145.am/db/979386/Cytomx_Therapeutics> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2364249/Series_B_Investment_Cytomx_Therapeutics_Roche_Venture_Fund_Third_Rock_Ventures_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-09-23T11:06:41+00:00"^^xsd:dateTime ;
    ns1:documentExtract "SANTA BARBARA, Calif.- (BUSINESS WIRE) - CytomX Therapeutics, a biotechnology company focused on the development of proteolytically-activated antibodies, today announced it has completed a $ 30 million Series B financing." ;
    ns1:documentTitle "CytomX Therapeutics Completes $30 Million Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cytomx-therapeutics-completes-30-million-series-b-financing-0> ;
    ns1:foundName "financing" ;
    ns1:name "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2364249/Cytomx_Therapeutics> ;
    ns1:targetDetails "Series B" ;
    ns1:valueRaw "$ 30 million" ;
    ns1:whereGeoName "Departamento de Santa Bárbara" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/3601689/about.rdf> ;
    ns1:whereRaw "SANTA BARBARA" .

<https://1145.am/db/2364249/Third_Rock_Ventures> a org:Organization ;
    ns1:basedInLowRaw "SANTA BARBARA" ;
    ns1:documentDate "2010-09-23T11:06:41+00:00"^^xsd:dateTime ;
    ns1:documentTitle "CytomX Therapeutics Completes $30 Million Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cytomx-therapeutics-completes-30-million-series-b-financing-0> ;
    ns1:foundName "Third Rock Ventures" ;
    ns1:investor <https://1145.am/db/2364249/Series_B_Investment_Cytomx_Therapeutics_Roche_Venture_Fund_Third_Rock_Ventures_Completed> ;
    ns1:name "Third Rock Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/1042269/Third_Rock_Ventures>,
        <https://1145.am/db/1086582/Third_Rock_Ventures>,
        <https://1145.am/db/1089269/Third_Rock_Ventures>,
        <https://1145.am/db/1325987/Third_Rock_Ventures>,
        <https://1145.am/db/1326547/Third_Rock_Ventures>,
        <https://1145.am/db/1503058/Third_Rock_Ventures>,
        <https://1145.am/db/159801/Third_Rock_Ventures>,
        <https://1145.am/db/1928208/Third_Rock_Ventures>,
        <https://1145.am/db/2095032/Third_Rock_Ventures>,
        <https://1145.am/db/2152566/Third_Rock_Ventures>,
        <https://1145.am/db/2153763/Third_Rock_Ventures>,
        <https://1145.am/db/2281272/Third_Rock_Ventures>,
        <https://1145.am/db/2291199/Third_Rock_Ventures>,
        <https://1145.am/db/2291940/Third_Rock_Ventures>,
        <https://1145.am/db/2294789/Third_Rock_Ventures>,
        <https://1145.am/db/2298193/Third_Rock_Ventures>,
        <https://1145.am/db/2298844/Third_Rock_Ventures>,
        <https://1145.am/db/2300971/Third_Rock_Ventures>,
        <https://1145.am/db/2303250/Third_Rock_Ventures>,
        <https://1145.am/db/2303251/Third_Rock_Ventures>,
        <https://1145.am/db/2303257/Third_Rock_Ventures>,
        <https://1145.am/db/2303294/Third_Rock_Ventures>,
        <https://1145.am/db/2311551/Third_Rock_Ventures>,
        <https://1145.am/db/2315931/Third_Rock_Ventures>,
        <https://1145.am/db/2315933/Third_Rock_Ventures>,
        <https://1145.am/db/2322522/Third_Rock_Ventures>,
        <https://1145.am/db/2322531/Third_Rock_Ventures>,
        <https://1145.am/db/2327474/Third_Rock_Ventures>,
        <https://1145.am/db/2335531/Third_Rock_Ventures>,
        <https://1145.am/db/2335750/Third_Rock_Ventures>,
        <https://1145.am/db/2335755/Third_Rock_Ventures>,
        <https://1145.am/db/2336126/Third_Rock_Ventures>,
        <https://1145.am/db/2337555/Third_Rock_Ventures>,
        <https://1145.am/db/2337559/Third_Rock_Ventures>,
        <https://1145.am/db/2337889/Third_Rock_Ventures>,
        <https://1145.am/db/2337958/Third_Rock_Ventures>,
        <https://1145.am/db/2337974/Third_Rock_Ventures>,
        <https://1145.am/db/2338625/Third_Rock_Ventures>,
        <https://1145.am/db/2338633/Third_Rock_Ventures>,
        <https://1145.am/db/2339127/Third_Rock_Ventures>,
        <https://1145.am/db/2339128/Third_Rock_Ventures>,
        <https://1145.am/db/2339413/Third_Rock_Ventures>,
        <https://1145.am/db/2339704/Third_Rock_Ventures>,
        <https://1145.am/db/2339925/Third_Rock_Ventures>,
        <https://1145.am/db/2339926/Third_Rock_Ventures>,
        <https://1145.am/db/2341662/Third_Rock_Ventures>,
        <https://1145.am/db/2341792/Third_Rock_Ventures>,
        <https://1145.am/db/2341800/Third_Rock_Ventures>,
        <https://1145.am/db/2342754/Third_Rock_Ventures>,
        <https://1145.am/db/2342768/Third_Rock_Ventures>,
        <https://1145.am/db/2342771/Third_Rock_Ventures>,
        <https://1145.am/db/2344256/Third_Rock_Ventures>,
        <https://1145.am/db/2344912/Third_Rock_Ventures>,
        <https://1145.am/db/2344918/Third_Rock_Ventures>,
        <https://1145.am/db/2345224/Third_Rock_Ventures>,
        <https://1145.am/db/2346212/Third_Rock_Ventures>,
        <https://1145.am/db/2346216/Third_Rock_Ventures>,
        <https://1145.am/db/2346988/Third_Rock_Ventures>,
        <https://1145.am/db/2347885/Third_Rock_Ventures>,
        <https://1145.am/db/2350364/Third_Rock_Ventures>,
        <https://1145.am/db/2351009/Third_Rock_Ventures>,
        <https://1145.am/db/2351011/Third_Rock_Ventures>,
        <https://1145.am/db/2351348/Third_Rock_Ventures>,
        <https://1145.am/db/2351372/Third_Rock_Ventures>,
        <https://1145.am/db/2351520/Third_Rock_Ventures>,
        <https://1145.am/db/2351644/Third_Rock_Ventures>,
        <https://1145.am/db/2354307/Third_Rock_Ventures>,
        <https://1145.am/db/2354314/Third_Rock_Ventures>,
        <https://1145.am/db/2354608/Third_Rock_Ventures>,
        <https://1145.am/db/2354613/Third_Rock_Ventures>,
        <https://1145.am/db/2355043/Third_Rock_Ventures>,
        <https://1145.am/db/2357253/Third_Rock_Ventures>,
        <https://1145.am/db/2357256/Third_Rock_Ventures>,
        <https://1145.am/db/2357722/Third_Rock_Ventures>,
        <https://1145.am/db/2358551/Third_Rock_Ventures>,
        <https://1145.am/db/2358737/Third_Rock_Ventures>,
        <https://1145.am/db/2359321/Third_Rock_Ventures>,
        <https://1145.am/db/2359334/Third_Rock_Ventures>,
        <https://1145.am/db/2359447/Third_Rock_Ventures>,
        <https://1145.am/db/2359575/Third_Rock_Ventures>,
        <https://1145.am/db/2359818/Third_Rock_Ventures>,
        <https://1145.am/db/2359864/Third_Rock_Ventures>,
        <https://1145.am/db/2359873/Third_Rock_Ventures>,
        <https://1145.am/db/2359875/Third_Rock_Ventures>,
        <https://1145.am/db/2359887/Third_Rock_Ventures>,
        <https://1145.am/db/2359984/Third_Rock_Ventures>,
        <https://1145.am/db/2359987/Third_Rock_Ventures>,
        <https://1145.am/db/2360006/Third_Rock_Ventures>,
        <https://1145.am/db/2360169/Third_Rock_Ventures>,
        <https://1145.am/db/2360814/Third_Rock_Ventures>,
        <https://1145.am/db/2360877/Third_Rock_Ventures>,
        <https://1145.am/db/2362102/Third_Rock_Ventures>,
        <https://1145.am/db/2362109/Third_Rock_Ventures>,
        <https://1145.am/db/2362128/Third_Rock_Ventures>,
        <https://1145.am/db/2363422/Third_Rock_Ventures>,
        <https://1145.am/db/2364240/Third_Rock_Ventures>,
        <https://1145.am/db/2364255/Third_Rock_Ventures>,
        <https://1145.am/db/2364283/Third_Rock_Ventures>,
        <https://1145.am/db/2364481/Third_Rock_Ventures>,
        <https://1145.am/db/2365109/Third_Rock_Ventures>,
        <https://1145.am/db/2365111/Third_Rock_Ventures>,
        <https://1145.am/db/2365315/Third_Rock_Ventures>,
        <https://1145.am/db/2366539/Third_Rock_Ventures>,
        <https://1145.am/db/2366641/Third_Rock_Ventures>,
        <https://1145.am/db/2367442/Third_Rock_Ventures>,
        <https://1145.am/db/2367448/Third_Rock_Ventures>,
        <https://1145.am/db/2368166/Third_Rock_Ventures>,
        <https://1145.am/db/2368501/Third_Rock_Ventures>,
        <https://1145.am/db/2369130/Third_Rock_Ventures>,
        <https://1145.am/db/2369202/Third_Rock_Ventures>,
        <https://1145.am/db/2370105/Third_Rock_Ventures_Llc>,
        <https://1145.am/db/2371191/Third_Rock_Ventures>,
        <https://1145.am/db/2580088/Third_Rock_Ventures>,
        <https://1145.am/db/2584533/Third_Rock_Ventures>,
        <https://1145.am/db/441151/Third_Rock_Ventures>,
        <https://1145.am/db/572554/Third_Rock_Ventures>,
        <https://1145.am/db/768794/Third_Rock_Ventures>,
        <https://1145.am/db/769408/Third_Rock_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2364283/Cytomx_Therapeutics> a org:Organization ;
    ns1:description "pharmaceuticals" ;
    ns1:documentDate "2010-09-23T16:24:58+00:00"^^xsd:dateTime ;
    ns1:documentTitle "CytomX Therapeutics Completes $30 Million Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cytomx-therapeutics-completes-30-million-series-b-financing> ;
    ns1:foundName "CytomX Therapeutics" ;
    ns1:industry "biotechnology" ;
    ns1:name "CytomX Therapeutics" ;
    ns1:sameAsHigh <https://1145.am/db/2151786/Cytomx_Therapeutics>,
        <https://1145.am/db/2154105/Cytomx>,
        <https://1145.am/db/2299752/Cytox>,
        <https://1145.am/db/2337958/Cytomx_Therapeutics>,
        <https://1145.am/db/2337974/Cytomx_Therapeutics>,
        <https://1145.am/db/2339513/Cytomx>,
        <https://1145.am/db/2339908/Cytomx_Therapeutics>,
        <https://1145.am/db/2340913/Cytomx>,
        <https://1145.am/db/2343178/Cytomx_Therapeutics>,
        <https://1145.am/db/2347024/Cytomedix_Inc>,
        <https://1145.am/db/2354469/Cytomx_Therapeutics>,
        <https://1145.am/db/2355041/Cytomx>,
        <https://1145.am/db/2355043/Cytomx>,
        <https://1145.am/db/2356089/Cytomx>,
        <https://1145.am/db/2356791/Cytomx>,
        <https://1145.am/db/2357499/Cytomx>,
        <https://1145.am/db/2358191/Cytovance_Biologics>,
        <https://1145.am/db/2361245/Cytogenix>,
        <https://1145.am/db/2361695/Cytomx>,
        <https://1145.am/db/2364249/Cytomx_Therapeutics>,
        <https://1145.am/db/2364255/Cytomx>,
        <https://1145.am/db/2365825/Cytomx>,
        <https://1145.am/db/2366301/Cytomx_Therapeutics>,
        <https://1145.am/db/2366304/Cytomx>,
        <https://1145.am/db/2369631/Cytomx_Therapeutics>,
        <https://1145.am/db/522087/Cytomx_Therapeutics> ;
    ns1:sameAsMedium <https://1145.am/db/812566/Cytomx_Therapeutics>,
        <https://1145.am/db/926316/Cytomx_Therapeutics>,
        <https://1145.am/db/979386/Cytomx_Therapeutics> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2364283/Series_B_Investment_Cytomx_Therapeutics_Roche_Venture_Fund_Third_Rock_Ventures_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-09-23T16:24:58+00:00"^^xsd:dateTime ;
    ns1:documentExtract "CytomX Therapeutics Completes $ 30 Million Series B Financing.",
        "SANTA BARBARA, Calif. - September 23, 2010 - CytomX Therapeutics, a biotechnology company focused on the development of proteolytically-activated antibodies, today announced it has completed a $ 30 million Series B financing." ;
    ns1:documentTitle "CytomX Therapeutics Completes $30 Million Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cytomx-therapeutics-completes-30-million-series-b-financing> ;
    ns1:foundName "financing" ;
    ns1:name "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2364283/Cytomx_Therapeutics> ;
    ns1:targetDetails "Series B" ;
    ns1:valueRaw "$ 30 Million",
        "$ 30 million" ;
    ns1:when "2010-09-23T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "September 23, 2010" ;
    ns1:whereGeoName "Santa Barbara County" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5392967/about.rdf> ;
    ns1:whereRaw "SANTA BARBARA, Calif" .

<https://1145.am/db/2364283/Third_Rock_Ventures> a org:Organization ;
    ns1:basedInLowRaw "SANTA BARBARA" ;
    ns1:documentDate "2010-09-23T16:24:58+00:00"^^xsd:dateTime ;
    ns1:documentTitle "CytomX Therapeutics Completes $30 Million Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cytomx-therapeutics-completes-30-million-series-b-financing> ;
    ns1:foundName "Third Rock Ventures" ;
    ns1:investor <https://1145.am/db/2364283/Series_B_Investment_Cytomx_Therapeutics_Roche_Venture_Fund_Third_Rock_Ventures_Completed> ;
    ns1:name "Third Rock Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/1042269/Third_Rock_Ventures>,
        <https://1145.am/db/1086582/Third_Rock_Ventures>,
        <https://1145.am/db/1089269/Third_Rock_Ventures>,
        <https://1145.am/db/1325987/Third_Rock_Ventures>,
        <https://1145.am/db/1326547/Third_Rock_Ventures>,
        <https://1145.am/db/1503058/Third_Rock_Ventures>,
        <https://1145.am/db/159801/Third_Rock_Ventures>,
        <https://1145.am/db/1928208/Third_Rock_Ventures>,
        <https://1145.am/db/2095032/Third_Rock_Ventures>,
        <https://1145.am/db/2152566/Third_Rock_Ventures>,
        <https://1145.am/db/2153763/Third_Rock_Ventures>,
        <https://1145.am/db/2281272/Third_Rock_Ventures>,
        <https://1145.am/db/2291199/Third_Rock_Ventures>,
        <https://1145.am/db/2291940/Third_Rock_Ventures>,
        <https://1145.am/db/2294789/Third_Rock_Ventures>,
        <https://1145.am/db/2298193/Third_Rock_Ventures>,
        <https://1145.am/db/2298844/Third_Rock_Ventures>,
        <https://1145.am/db/2300971/Third_Rock_Ventures>,
        <https://1145.am/db/2303250/Third_Rock_Ventures>,
        <https://1145.am/db/2303251/Third_Rock_Ventures>,
        <https://1145.am/db/2303257/Third_Rock_Ventures>,
        <https://1145.am/db/2303294/Third_Rock_Ventures>,
        <https://1145.am/db/2311551/Third_Rock_Ventures>,
        <https://1145.am/db/2315931/Third_Rock_Ventures>,
        <https://1145.am/db/2315933/Third_Rock_Ventures>,
        <https://1145.am/db/2322522/Third_Rock_Ventures>,
        <https://1145.am/db/2322531/Third_Rock_Ventures>,
        <https://1145.am/db/2327474/Third_Rock_Ventures>,
        <https://1145.am/db/2335531/Third_Rock_Ventures>,
        <https://1145.am/db/2335750/Third_Rock_Ventures>,
        <https://1145.am/db/2335755/Third_Rock_Ventures>,
        <https://1145.am/db/2336126/Third_Rock_Ventures>,
        <https://1145.am/db/2337555/Third_Rock_Ventures>,
        <https://1145.am/db/2337559/Third_Rock_Ventures>,
        <https://1145.am/db/2337889/Third_Rock_Ventures>,
        <https://1145.am/db/2337958/Third_Rock_Ventures>,
        <https://1145.am/db/2337974/Third_Rock_Ventures>,
        <https://1145.am/db/2338625/Third_Rock_Ventures>,
        <https://1145.am/db/2338633/Third_Rock_Ventures>,
        <https://1145.am/db/2339127/Third_Rock_Ventures>,
        <https://1145.am/db/2339128/Third_Rock_Ventures>,
        <https://1145.am/db/2339413/Third_Rock_Ventures>,
        <https://1145.am/db/2339704/Third_Rock_Ventures>,
        <https://1145.am/db/2339925/Third_Rock_Ventures>,
        <https://1145.am/db/2339926/Third_Rock_Ventures>,
        <https://1145.am/db/2341662/Third_Rock_Ventures>,
        <https://1145.am/db/2341792/Third_Rock_Ventures>,
        <https://1145.am/db/2341800/Third_Rock_Ventures>,
        <https://1145.am/db/2342754/Third_Rock_Ventures>,
        <https://1145.am/db/2342768/Third_Rock_Ventures>,
        <https://1145.am/db/2342771/Third_Rock_Ventures>,
        <https://1145.am/db/2344256/Third_Rock_Ventures>,
        <https://1145.am/db/2344912/Third_Rock_Ventures>,
        <https://1145.am/db/2344918/Third_Rock_Ventures>,
        <https://1145.am/db/2345224/Third_Rock_Ventures>,
        <https://1145.am/db/2346212/Third_Rock_Ventures>,
        <https://1145.am/db/2346216/Third_Rock_Ventures>,
        <https://1145.am/db/2346988/Third_Rock_Ventures>,
        <https://1145.am/db/2347885/Third_Rock_Ventures>,
        <https://1145.am/db/2350364/Third_Rock_Ventures>,
        <https://1145.am/db/2351009/Third_Rock_Ventures>,
        <https://1145.am/db/2351011/Third_Rock_Ventures>,
        <https://1145.am/db/2351348/Third_Rock_Ventures>,
        <https://1145.am/db/2351372/Third_Rock_Ventures>,
        <https://1145.am/db/2351520/Third_Rock_Ventures>,
        <https://1145.am/db/2351644/Third_Rock_Ventures>,
        <https://1145.am/db/2354307/Third_Rock_Ventures>,
        <https://1145.am/db/2354314/Third_Rock_Ventures>,
        <https://1145.am/db/2354608/Third_Rock_Ventures>,
        <https://1145.am/db/2354613/Third_Rock_Ventures>,
        <https://1145.am/db/2355043/Third_Rock_Ventures>,
        <https://1145.am/db/2357253/Third_Rock_Ventures>,
        <https://1145.am/db/2357256/Third_Rock_Ventures>,
        <https://1145.am/db/2357722/Third_Rock_Ventures>,
        <https://1145.am/db/2358551/Third_Rock_Ventures>,
        <https://1145.am/db/2358737/Third_Rock_Ventures>,
        <https://1145.am/db/2359321/Third_Rock_Ventures>,
        <https://1145.am/db/2359334/Third_Rock_Ventures>,
        <https://1145.am/db/2359447/Third_Rock_Ventures>,
        <https://1145.am/db/2359575/Third_Rock_Ventures>,
        <https://1145.am/db/2359818/Third_Rock_Ventures>,
        <https://1145.am/db/2359864/Third_Rock_Ventures>,
        <https://1145.am/db/2359873/Third_Rock_Ventures>,
        <https://1145.am/db/2359875/Third_Rock_Ventures>,
        <https://1145.am/db/2359887/Third_Rock_Ventures>,
        <https://1145.am/db/2359984/Third_Rock_Ventures>,
        <https://1145.am/db/2359987/Third_Rock_Ventures>,
        <https://1145.am/db/2360006/Third_Rock_Ventures>,
        <https://1145.am/db/2360169/Third_Rock_Ventures>,
        <https://1145.am/db/2360814/Third_Rock_Ventures>,
        <https://1145.am/db/2360877/Third_Rock_Ventures>,
        <https://1145.am/db/2362102/Third_Rock_Ventures>,
        <https://1145.am/db/2362109/Third_Rock_Ventures>,
        <https://1145.am/db/2362128/Third_Rock_Ventures>,
        <https://1145.am/db/2363422/Third_Rock_Ventures>,
        <https://1145.am/db/2364240/Third_Rock_Ventures>,
        <https://1145.am/db/2364249/Third_Rock_Ventures>,
        <https://1145.am/db/2364255/Third_Rock_Ventures>,
        <https://1145.am/db/2364481/Third_Rock_Ventures>,
        <https://1145.am/db/2365109/Third_Rock_Ventures>,
        <https://1145.am/db/2365111/Third_Rock_Ventures>,
        <https://1145.am/db/2365315/Third_Rock_Ventures>,
        <https://1145.am/db/2366539/Third_Rock_Ventures>,
        <https://1145.am/db/2366641/Third_Rock_Ventures>,
        <https://1145.am/db/2367442/Third_Rock_Ventures>,
        <https://1145.am/db/2367448/Third_Rock_Ventures>,
        <https://1145.am/db/2368166/Third_Rock_Ventures>,
        <https://1145.am/db/2368501/Third_Rock_Ventures>,
        <https://1145.am/db/2369130/Third_Rock_Ventures>,
        <https://1145.am/db/2369202/Third_Rock_Ventures>,
        <https://1145.am/db/2370105/Third_Rock_Ventures_Llc>,
        <https://1145.am/db/2371191/Third_Rock_Ventures>,
        <https://1145.am/db/2580088/Third_Rock_Ventures>,
        <https://1145.am/db/2584533/Third_Rock_Ventures>,
        <https://1145.am/db/441151/Third_Rock_Ventures>,
        <https://1145.am/db/572554/Third_Rock_Ventures>,
        <https://1145.am/db/768794/Third_Rock_Ventures>,
        <https://1145.am/db/769408/Third_Rock_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2365138/Amgen_Ventures> a org:Organization ;
    ns1:basedInHighGeoName "Cambridgeshire" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2653940/about.rdf> ;
    ns1:basedInHighRaw "CAMBRIDGE" ;
    ns1:documentDate "2010-09-27T13:02:25+00:00"^^xsd:dateTime ;
    ns1:documentTitle "DecImmune Therapeutics Secures $3.2 Million in Development Funding" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/decimmune-therapeutics-secures-3-2-million-development-funding> ;
    ns1:foundName "Amgen Ventures" ;
    ns1:investor <https://1145.am/db/2365138/Sbir_Investment_Amgen_Ventures_Astellas_Venture_Management_Decimmune_Therapeutics_Healthcare_Ventures_Has_Not_Happened> ;
    ns1:name "Amgen Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/1018050/Amgen_Ventures>,
        <https://1145.am/db/1065608/Amgen_Ventures>,
        <https://1145.am/db/1066448/Amgen_Ventures>,
        <https://1145.am/db/1115103/Amgen_Ventures>,
        <https://1145.am/db/1116076/Amgen_Ventures>,
        <https://1145.am/db/1168715/Amgen_Ventures>,
        <https://1145.am/db/1169697/Amgen_Ventures>,
        <https://1145.am/db/1219346/Amgen_Ventures>,
        <https://1145.am/db/1219817/Amgen_Ventures>,
        <https://1145.am/db/1422234/Amgen_Ventures>,
        <https://1145.am/db/1422725/Amgen_Ventures>,
        <https://1145.am/db/1503058/Amgen_Ventures>,
        <https://1145.am/db/2141183/Amgen_Ventures>,
        <https://1145.am/db/2152096/Amgen_Ventures>,
        <https://1145.am/db/2197183/Amgen_Ventures>,
        <https://1145.am/db/2280119/Amgen_Ventures>,
        <https://1145.am/db/2280896/Amgen_Ventures>,
        <https://1145.am/db/2284256/Amgen_Ventures>,
        <https://1145.am/db/2298167/Amgen_Ventures>,
        <https://1145.am/db/2315446/Amgen_Ventures>,
        <https://1145.am/db/2318635/Amgen_Ventures>,
        <https://1145.am/db/2320476/Amgen_Ventures>,
        <https://1145.am/db/2342629/Amgen_Ventures>,
        <https://1145.am/db/2344782/Amgen_Ventures>,
        <https://1145.am/db/2344926/Amgen_Ventures>,
        <https://1145.am/db/2345223/Amgen_Ventures>,
        <https://1145.am/db/2347469/Amgen_Ventures>,
        <https://1145.am/db/2349717/Amgen_Ventures>,
        <https://1145.am/db/2349722/Amgen_Ventures>,
        <https://1145.am/db/2352203/Amgen_Ventures>,
        <https://1145.am/db/2352204/Amgen_Ventures>,
        <https://1145.am/db/2352216/Amgen_Ventures>,
        <https://1145.am/db/2352349/Amgen_Ventures>,
        <https://1145.am/db/2352350/Amgen_Ventures>,
        <https://1145.am/db/2353439/Amgen_Ventures>,
        <https://1145.am/db/2353524/Amgen_Ventures>,
        <https://1145.am/db/2353525/Amgen_Ventures>,
        <https://1145.am/db/2355586/Amgen_Ventures>,
        <https://1145.am/db/2356048/Amgen_Ventures>,
        <https://1145.am/db/2365171/Amgen_Ventures>,
        <https://1145.am/db/2366693/Amgen_Ventures>,
        <https://1145.am/db/2366700/Amgen_Ventures>,
        <https://1145.am/db/2367740/Amgen_Ventures>,
        <https://1145.am/db/2569831/Amgen_Ventures>,
        <https://1145.am/db/2570481/Amgen_Ventures>,
        <https://1145.am/db/2570483/Amgen_Ventures>,
        <https://1145.am/db/770366/Amgen_Ventures>,
        <https://1145.am/db/874503/Amgen_Ventures>,
        <https://1145.am/db/919784/Amgen_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2365163/Cypress_Bioscience> a org:Organization ;
    ns1:basedInHighGeoName "San Diego County" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5391832/about.rdf> ;
    ns1:basedInHighRaw "SAN DIEGO" ;
    ns1:description "pharmaceutical company engaged in the development of innovative drugs to treat central nervous system (CNS) disorders" ;
    ns1:documentDate "2010-09-28T13:04:15+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Cypress Bioscience Board of Directors Unanimously Rejects Ramius' Unsolicited Tender Offer" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cypress-bioscience-board-of-directors-unanimously-rejects-ramius-unsolicited-tender-offer> ;
    ns1:foundName "Cypress",
        "Cypress Bioscience, Inc" ;
    ns1:industry "pharmaceutical" ;
    ns1:name "Cypress Bioscience" ;
    ns1:sameAsHigh <https://1145.am/db/2311166/Cypress_Bioscience>,
        <https://1145.am/db/2311179/Cypress_Bioscience>,
        <https://1145.am/db/2340402/Cypress_Bioscience_Inc>,
        <https://1145.am/db/2348691/Cypress_Bioscience>,
        <https://1145.am/db/2348695/Cypress_Bioscience>,
        <https://1145.am/db/2353890/Cypress_Bioscience>,
        <https://1145.am/db/2362826/Cypress_Bioscience>,
        <https://1145.am/db/2365716/Cypress_Bioscience>,
        <https://1145.am/db/2560066/Cypress_Pharmaceuticals>,
        <https://1145.am/db/2594304/Cypress_Pharmaceutical> ;
    ns1:sameAsMedium <https://1145.am/db/2319674/Cypress_Bioscience>,
        <https://1145.am/db/2341460/Cypress_Bioscience>,
        <https://1145.am/db/2348694/Cypress_Bioscience>,
        <https://1145.am/db/2350755/Cypress_Bioscience_Inc>,
        <https://1145.am/db/2353869/Cypress_Bioscience>,
        <https://1145.am/db/2361249/Cypress_Bioscience>,
        <https://1145.am/db/2361250/Cypress_Bioscience>,
        <https://1145.am/db/2361775/Cypress_Bioscience>,
        <https://1145.am/db/2361781/Cypress_Bioscience>,
        <https://1145.am/db/2362845/Cypress_Bioscience>,
        <https://1145.am/db/2586232/Cypress_Bioscience> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2365171/Amgen_Ventures> a org:Organization ;
    ns1:basedInLowRaw "Pa" ;
    ns1:description "Series C financing" ;
    ns1:documentDate "2010-09-28T13:45:54+00:00"^^xsd:dateTime ;
    ns1:documentTitle "TetraLogic Pharmaceuticals Expands Series C Financing with New Investor Pfizer Ventures with Investment of $5 Million Incrasing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/tetralogic-pharmaceuticals-expands-series-c-financing-new-investor-pfizer-ventures> ;
    ns1:foundName "Amgen Ventures" ;
    ns1:investor <https://1145.am/db/2365171/Series_C_Investment_Amgen_Ventures_Clarus_Ventures_Hatteras_Venture_Partners_Healthcare_Ventures_Latterell_Venture_Partners_Novitas_Capital_Pfizer_Ventures_Quaker_Bioventures_Tetralogic_Pharmaceuticals_Vertical_Group_Completed> ;
    ns1:name "Amgen Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/1018050/Amgen_Ventures>,
        <https://1145.am/db/1065608/Amgen_Ventures>,
        <https://1145.am/db/1066448/Amgen_Ventures>,
        <https://1145.am/db/1115103/Amgen_Ventures>,
        <https://1145.am/db/1116076/Amgen_Ventures>,
        <https://1145.am/db/1168715/Amgen_Ventures>,
        <https://1145.am/db/1169697/Amgen_Ventures>,
        <https://1145.am/db/1219346/Amgen_Ventures>,
        <https://1145.am/db/1219817/Amgen_Ventures>,
        <https://1145.am/db/1422234/Amgen_Ventures>,
        <https://1145.am/db/1422725/Amgen_Ventures>,
        <https://1145.am/db/1503058/Amgen_Ventures>,
        <https://1145.am/db/2141183/Amgen_Ventures>,
        <https://1145.am/db/2152096/Amgen_Ventures>,
        <https://1145.am/db/2197183/Amgen_Ventures>,
        <https://1145.am/db/2280119/Amgen_Ventures>,
        <https://1145.am/db/2280896/Amgen_Ventures>,
        <https://1145.am/db/2284256/Amgen_Ventures>,
        <https://1145.am/db/2298167/Amgen_Ventures>,
        <https://1145.am/db/2315446/Amgen_Ventures>,
        <https://1145.am/db/2318635/Amgen_Ventures>,
        <https://1145.am/db/2320476/Amgen_Ventures>,
        <https://1145.am/db/2342629/Amgen_Ventures>,
        <https://1145.am/db/2344782/Amgen_Ventures>,
        <https://1145.am/db/2344926/Amgen_Ventures>,
        <https://1145.am/db/2345223/Amgen_Ventures>,
        <https://1145.am/db/2347469/Amgen_Ventures>,
        <https://1145.am/db/2349717/Amgen_Ventures>,
        <https://1145.am/db/2349722/Amgen_Ventures>,
        <https://1145.am/db/2352203/Amgen_Ventures>,
        <https://1145.am/db/2352204/Amgen_Ventures>,
        <https://1145.am/db/2352216/Amgen_Ventures>,
        <https://1145.am/db/2352349/Amgen_Ventures>,
        <https://1145.am/db/2352350/Amgen_Ventures>,
        <https://1145.am/db/2353439/Amgen_Ventures>,
        <https://1145.am/db/2353524/Amgen_Ventures>,
        <https://1145.am/db/2353525/Amgen_Ventures>,
        <https://1145.am/db/2355586/Amgen_Ventures>,
        <https://1145.am/db/2356048/Amgen_Ventures>,
        <https://1145.am/db/2365138/Amgen_Ventures>,
        <https://1145.am/db/2366693/Amgen_Ventures>,
        <https://1145.am/db/2366700/Amgen_Ventures>,
        <https://1145.am/db/2367740/Amgen_Ventures>,
        <https://1145.am/db/2569831/Amgen_Ventures>,
        <https://1145.am/db/2570481/Amgen_Ventures>,
        <https://1145.am/db/2570483/Amgen_Ventures>,
        <https://1145.am/db/770366/Amgen_Ventures>,
        <https://1145.am/db/874503/Amgen_Ventures>,
        <https://1145.am/db/919784/Amgen_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2365171/Quaker_Bioventures> a org:Organization ;
    ns1:basedInLowRaw "Pa" ;
    ns1:description "Investing" ;
    ns1:documentDate "2010-09-28T13:45:54+00:00"^^xsd:dateTime ;
    ns1:documentTitle "TetraLogic Pharmaceuticals Expands Series C Financing with New Investor Pfizer Ventures with Investment of $5 Million Incrasing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/tetralogic-pharmaceuticals-expands-series-c-financing-new-investor-pfizer-ventures> ;
    ns1:foundName "Quaker BioVentures" ;
    ns1:investor <https://1145.am/db/2365171/Series_C_Investment_Amgen_Ventures_Clarus_Ventures_Hatteras_Venture_Partners_Healthcare_Ventures_Latterell_Venture_Partners_Novitas_Capital_Pfizer_Ventures_Quaker_Bioventures_Tetralogic_Pharmaceuticals_Vertical_Group_Completed> ;
    ns1:name "Quaker BioVentures" ;
    ns1:sameAsHigh <https://1145.am/db/2302192/Quaker_Bioventures>,
        <https://1145.am/db/2309809/Quaker_Bioventures>,
        <https://1145.am/db/2312792/Quaker_Bioventures>,
        <https://1145.am/db/2320853/Quaker_Bioventures>,
        <https://1145.am/db/2332631/Quaker_Bioventures>,
        <https://1145.am/db/2340429/Quaker_Bioventures>,
        <https://1145.am/db/2349717/Quaker_Bioventures> ;
    ns1:sameAsMedium <https://1145.am/db/2217039/Quaker_Bioventures>,
        <https://1145.am/db/2291872/Quaker_Bioventures>,
        <https://1145.am/db/2303458/Quaker_Bioventures>,
        <https://1145.am/db/2303641/Quaker_Bioventures>,
        <https://1145.am/db/2303642/Quaker_Bioventures>,
        <https://1145.am/db/2305610/Quaker_Bioventures>,
        <https://1145.am/db/2305615/Quaker_Bioventures>,
        <https://1145.am/db/2305625/Quaker_Bioventures>,
        <https://1145.am/db/2310123/Quaker_Bioventures>,
        <https://1145.am/db/2311099/Quaker_Bioventures>,
        <https://1145.am/db/2317849/Quaker_Bioventures>,
        <https://1145.am/db/2317961/Quaker_Bioventures>,
        <https://1145.am/db/2319360/Quaker_Bioventures>,
        <https://1145.am/db/2320852/Quaker_Bioventures>,
        <https://1145.am/db/2330549/Quaker_Bioventures>,
        <https://1145.am/db/2332021/Quaker_Bioventures>,
        <https://1145.am/db/2332626/Quaker_Bioventures>,
        <https://1145.am/db/2340423/Quaker_Bioventures>,
        <https://1145.am/db/2349722/Quaker_Bioventures>,
        <https://1145.am/db/2352808/Quaker_Bioventures>,
        <https://1145.am/db/2355936/Quaker_Bioventures>,
        <https://1145.am/db/2355938/Quaker_Bioventures>,
        <https://1145.am/db/2363464/Quaker_Bioventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2365171/Tetralogic_Pharmaceuticals> a org:Organization ;
    ns1:description "pharmaceuticals" ;
    ns1:documentDate "2010-09-28T13:45:54+00:00"^^xsd:dateTime ;
    ns1:documentTitle "TetraLogic Pharmaceuticals Expands Series C Financing with New Investor Pfizer Ventures with Investment of $5 Million Incrasing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/tetralogic-pharmaceuticals-expands-series-c-financing-new-investor-pfizer-ventures> ;
    ns1:foundName "TetraLogic Pharmaceuticals" ;
    ns1:industry "pharmaceuticals" ;
    ns1:name "TetraLogic Pharmaceuticals" ;
    ns1:sameAsHigh <https://1145.am/db/2070596/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2308022/Tetralogic_Pharmaceuticals>,
        <https://1145.am/db/2311219/Tekmira_Pharmaceuticals>,
        <https://1145.am/db/2314563/Tekmira_Pharmaceuticals>,
        <https://1145.am/db/2319925/Tekmira_Pharmaceuticals_Corporation>,
        <https://1145.am/db/2323263/Teva_Europe>,
        <https://1145.am/db/2339763/Teva_Pharmaceutical>,
        <https://1145.am/db/2349717/Tetralogic_Pharmaceuticals>,
        <https://1145.am/db/2349722/Tetralogic_Pharmaceuticals>,
        <https://1145.am/db/2349999/Tetraphase_Pharmaceuticals_Inc>,
        <https://1145.am/db/2357275/Tetraphase_Pharmaceuticals>,
        <https://1145.am/db/2358420/Tekmira_Pharmaceuticals>,
        <https://1145.am/db/2368702/Teva>,
        <https://1145.am/db/2567583/Teva_Pharmaceuticals>,
        <https://1145.am/db/2578498/Teva_Pharmaceutical_Industries_Sanofi-Aventis>,
        <https://1145.am/db/2594786/Tekmira_Pharmaceuticals_Corporation>,
        <https://1145.am/db/2594787/Tekmira_Pharmaceuticals> ;
    ns1:sameAsMedium <https://1145.am/db/2346197/Tetralogic_Pharmaceuticals>,
        <https://1145.am/db/2346213/Tetralogic_Pharmaceuticals>,
        <https://1145.am/db/2346948/Tetralogic_Pharmaceuticals>,
        <https://1145.am/db/2352302/Tetralogic_Pharmaceuticals_Corporation>,
        <https://1145.am/db/2366291/Tetralogic_Pharmaceuticals> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2366860/New_Leaf_Venture_Partners> a org:Organization ;
    ns1:description "private equity" ;
    ns1:documentDate "2010-10-06T13:04:22+00:00"^^xsd:dateTime ;
    ns1:documentTitle "New Leaf Venture Partners Invests in $35.4 (GBP 22.4) Million Series A Financing of Convergence Pharmaceuticals" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/new-leaf-venture-partners-invests-35-4-gbp-22-4-million-series-a-financing-of-convergence> ;
    ns1:foundName "New Leaf Venture Partners",
        "New Leaf Venture Partners (NLV Partners)" ;
    ns1:industry "private equity" ;
    ns1:investor <https://1145.am/db/2366860/Series_A_Investment_Apposite_Capital_Convergence_Pharmaceuticals_New_Leaf_Venture_Partners_Sv_Life_Sciences_Has_Not_Happened>,
        <https://1145.am/db/2366860/Series_A_Investment_Apposite_Capital_New_Leaf_Venture_Partners_Sv_Life_Sciences_Completed>,
        <https://1145.am/db/2366860/Series_A_Investment_New_Leaf_Venture_Partners_Completed> ;
    ns1:name "New Leaf Venture Partners" ;
    ns1:sameAsHigh <https://1145.am/db/1119554/New_Markets_Venture_Partners>,
        <https://1145.am/db/1232912/Private_Equity_Backers_Nvm>,
        <https://1145.am/db/1847661/New_World_Private_Equity_Partners>,
        <https://1145.am/db/2192699/New_Capital_Partners>,
        <https://1145.am/db/246674/Newquest_Capital_Partners>,
        <https://1145.am/db/456465/New_Capital_Partners>,
        <https://1145.am/db/679562/New_Future_Capital>,
        <https://1145.am/db/787410/Stage>,
        <https://1145.am/db/936422/Newlight_Partners>,
        <https://1145.am/db/938662/Newlight_Partners> ;
    ns1:sameAsMedium <https://1145.am/db/1287338/New_Leaf_Venture_Partners>,
        <https://1145.am/db/1749104/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2151983/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2155668/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2208603/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2289585/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2293765/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2298642/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2300322/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2301824/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2301828/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2305507/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2305514/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2307682/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2311595/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2312792/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2315071/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2315932/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2315934/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2316674/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2317919/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2318656/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2318657/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2325326/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2325398/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2334479/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2334797/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2341003/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2342925/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2342937/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2343298/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2345037/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2345047/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2346532/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2346542/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2347043/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2347571/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2347876/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2347878/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2348149/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2348618/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2349120/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2350164/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2350167/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2350491/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2352059/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2357356/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2359683/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2360174/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2361416/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2362736/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2362737/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2569522/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2594141/New_Leaf_Venture_Partners>,
        <https://1145.am/db/425953/New_Leaf_Venture_Partners>,
        <https://1145.am/db/583528/New_Leaf_Venture_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2367203/Merck_Serono> a org:Organization ;
    ns1:basedInLowRaw "France" ;
    ns1:description "Life Sciences" ;
    ns1:documentDate "2010-07-08T15:01:09+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Bionest Partners Finance Advises Poxel in a Serie A Financing of €16M" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/bionest-partners-finance-advises-poxel-a-serie-a-financing-of-%E2%82%AC16m> ;
    ns1:foundName "Merck Serono" ;
    ns1:industry "Life Sciences" ;
    ns1:name "Merck Serono" ;
    ns1:sameAsHigh <https://1145.am/db/2292667/German_Merck>,
        <https://1145.am/db/2303625/Merck_Manufacturing_Division>,
        <https://1145.am/db/2326224/Merck___Co_Inc>,
        <https://1145.am/db/2340789/Merck_Research_Laboratories>,
        <https://1145.am/db/2341435/Merck>,
        <https://1145.am/db/2344563/Merck>,
        <https://1145.am/db/2344564/Merck>,
        <https://1145.am/db/2348683/Merck>,
        <https://1145.am/db/2362458/Merck_Kgaa>,
        <https://1145.am/db/2367206/Merck_Serono> ;
    ns1:sameAsMedium <https://1145.am/db/2307377/Merck_Kgaa>,
        <https://1145.am/db/2330990/Merck_Kgaa>,
        <https://1145.am/db/2339972/Merck_Serono>,
        <https://1145.am/db/2350594/Merck_Serono>,
        <https://1145.am/db/2359490/Merck_Serono>,
        <https://1145.am/db/2557023/Merck_Serono>,
        <https://1145.am/db/2569029/Merck_Serono>,
        <https://1145.am/db/2596156/Merck_Serono>,
        <https://1145.am/db/2597135/Merck_Serono> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2367203/Poxel> a org:Organization ;
    ns1:basedInLowRaw "France" ;
    ns1:description "Life Sciences" ;
    ns1:documentDate "2010-07-08T15:01:09+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Bionest Partners Finance Advises Poxel in a Serie A Financing of €16M" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/bionest-partners-finance-advises-poxel-a-serie-a-financing-of-%E2%82%AC16m> ;
    ns1:foundName "Poxel" ;
    ns1:industry "Life Sciences" ;
    ns1:name "Poxel" ;
    ns1:sameAsHigh <https://1145.am/db/1260776/Poxel>,
        <https://1145.am/db/1262171/Poxel>,
        <https://1145.am/db/1597904/Poxel>,
        <https://1145.am/db/1598981/Poxel>,
        <https://1145.am/db/1945846/Poxel>,
        <https://1145.am/db/2299902/Poxel>,
        <https://1145.am/db/2301003/Poxel>,
        <https://1145.am/db/2355431/Poxel>,
        <https://1145.am/db/2367206/Poxel>,
        <https://1145.am/db/2562342/Poxel>,
        <https://1145.am/db/447095/Poxel_Sa>,
        <https://1145.am/db/447175/Poxel> ;
    ns1:sameAsMedium <https://1145.am/db/2367201/Poxel> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2367204/Advanced_Technology_Ventures> a org:Organization ;
    ns1:basedInLowRaw "SOUTH SAN FRANCISCO" ;
    ns1:description "Venture capital" ;
    ns1:documentDate "2010-07-08T15:06:02+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Calithera Biosciences Closes $40 Million in Series A Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/calithera-biosciences-closes-40-million-series-a-financing> ;
    ns1:foundName "Advanced Technology Ventures" ;
    ns1:investor <https://1145.am/db/2367204/Series_A_Investment_Advanced_Technology_Ventures_Calithera_Biosciences_Delphi_Ventures_Mission_Bay_Capital_Morgenthaler_Ventures_Us_Venture_Partners_Completed> ;
    ns1:name "Advanced Technology Ventures" ;
    ns1:sameAsHigh <https://1145.am/db/1004004/Kindred_Ventures>,
        <https://1145.am/db/1018112/S3_Ventures>,
        <https://1145.am/db/1018984/S3_Ventures>,
        <https://1145.am/db/1065192/Sevenx_Ventures>,
        <https://1145.am/db/1079459/Obvious_Ventures>,
        <https://1145.am/db/1081175/166_2nd>,
        <https://1145.am/db/1082613/166_2nd>,
        <https://1145.am/db/1086692/468_Capital>,
        <https://1145.am/db/1091554/Switch_Ventures>,
        <https://1145.am/db/1091576/Switch_Ventures>,
        <https://1145.am/db/1138998/First_Rate_Ventures>,
        <https://1145.am/db/1152929/Base_Ventures>,
        <https://1145.am/db/1232111/Upfront_Ventures>,
        <https://1145.am/db/1233008/M12>,
        <https://1145.am/db/1238474/M12>,
        <https://1145.am/db/1287465/Innovation_Endeavors>,
        <https://1145.am/db/1352190/Valar_Ventures>,
        <https://1145.am/db/1381832/Breakout_Ventures>,
        <https://1145.am/db/1381832/Coatue>,
        <https://1145.am/db/1382787/Breakout_Ventures>,
        <https://1145.am/db/1382787/Coatue>,
        <https://1145.am/db/1398917/Upfront_Ventures>,
        <https://1145.am/db/1406168/Kindred_Ventures>,
        <https://1145.am/db/1429403/Venture_Capital_Firm>,
        <https://1145.am/db/1499092/Sourcenext>,
        <https://1145.am/db/1526876/M13>,
        <https://1145.am/db/1528201/M13>,
        <https://1145.am/db/1545833/S3_Ventures>,
        <https://1145.am/db/1546945/S3_Ventures>,
        <https://1145.am/db/1557307/Am_Ventures>,
        <https://1145.am/db/1558854/Am_Ventures>,
        <https://1145.am/db/1575612/Snr_Vc>,
        <https://1145.am/db/1575612/V1_Vc>,
        <https://1145.am/db/1584937/Venture_Catalysts>,
        <https://1145.am/db/1614343/Partners_Group>,
        <https://1145.am/db/1664845/S3_Ventures>,
        <https://1145.am/db/1682224/M13>,
        <https://1145.am/db/1693658/Upfront_Ventures>,
        <https://1145.am/db/1701485/Aum_Ventures>,
        <https://1145.am/db/1705761/Obvious_Ventures>,
        <https://1145.am/db/1711784/Venture_Catalysts>,
        <https://1145.am/db/1712520/Vspring_Capital>,
        <https://1145.am/db/1719240/K3>,
        <https://1145.am/db/1722058/Upfront_Ventures>,
        <https://1145.am/db/1726625/Sourcenext>,
        <https://1145.am/db/1737467/Index>,
        <https://1145.am/db/1739763/Invent>,
        <https://1145.am/db/1743316/Founders_Fund>,
        <https://1145.am/db/1748890/Newgen_Vc>,
        <https://1145.am/db/1749533/Afore_Capital>,
        <https://1145.am/db/1751312/Kindred_Ventures>,
        <https://1145.am/db/1751916/S3_Ventures>,
        <https://1145.am/db/1753024/S28_Capital>,
        <https://1145.am/db/1753730/Strong_Ventures>,
        <https://1145.am/db/1757392/K5_Global>,
        <https://1145.am/db/1757788/Strong_Ventures>,
        <https://1145.am/db/1758221/Valar_Ventures>,
        <https://1145.am/db/1760608/Upfront_Ventures>,
        <https://1145.am/db/1761491/A16z>,
        <https://1145.am/db/1761520/Novator>,
        <https://1145.am/db/1761999/Coatue>,
        <https://1145.am/db/1765092/S28_Capital>,
        <https://1145.am/db/1765372/468_Capital>,
        <https://1145.am/db/1766096/Founders_Fund>,
        <https://1145.am/db/1770139/Morningside>,
        <https://1145.am/db/1788333/Outbound_Ventures>,
        <https://1145.am/db/1790953/Venture_Capital>,
        <https://1145.am/db/1791220/Capital-E>,
        <https://1145.am/db/1795198/K1_Capital>,
        <https://1145.am/db/1796199/Generation_Ventures>,
        <https://1145.am/db/1799113/Upfront_Ventures>,
        <https://1145.am/db/1806746/K2_Global>,
        <https://1145.am/db/1819543/Base_Ventures>,
        <https://1145.am/db/1820422/Valar_Ventures>,
        <https://1145.am/db/1829422/Founders_Fund>,
        <https://1145.am/db/1859652/A16z>,
        <https://1145.am/db/1859806/Strong_Ventures>,
        <https://1145.am/db/1871784/Founders_Fund>,
        <https://1145.am/db/1884049/S3_Ventures>,
        <https://1145.am/db/2008536/Incite_Ventures>,
        <https://1145.am/db/2023596/Building_Ventures>,
        <https://1145.am/db/2023596/Concrete_Ventures>,
        <https://1145.am/db/2058874/Founders_Fund>,
        <https://1145.am/db/2064584/Concrete_Ventures>,
        <https://1145.am/db/2073480/Santé_Ventures>,
        <https://1145.am/db/2100049/K5_Global>,
        <https://1145.am/db/2120116/Capital_T>,
        <https://1145.am/db/2138006/Innovation_Endeavors>,
        <https://1145.am/db/2176223/Sig_Capital>,
        <https://1145.am/db/2183141/Founders_Fund>,
        <https://1145.am/db/219754/Founders_Fund>,
        <https://1145.am/db/2292800/Ws_Investments>,
        <https://1145.am/db/2298916/Breakout_Ventures>,
        <https://1145.am/db/2301736/Santé_Ventures>,
        <https://1145.am/db/2303695/Sigvion_Capital>,
        <https://1145.am/db/2305610/Techno_Venture_Management>,
        <https://1145.am/db/2305615/Techno_Venture_Management>,
        <https://1145.am/db/2310170/Apposite>,
        <https://1145.am/db/2314573/3i>,
        <https://1145.am/db/2317918/Advanced_Technology_Ventures>,
        <https://1145.am/db/2317934/Sr_One>,
        <https://1145.am/db/2319874/Advanced_Technology_Ventures>,
        <https://1145.am/db/2341904/Advanced_Technology_Ventures>,
        <https://1145.am/db/2343722/Advanced_Technology_Ventures>,
        <https://1145.am/db/2343737/Advanced_Technology_Ventures>,
        <https://1145.am/db/2355531/Leerink_Swann>,
        <https://1145.am/db/2355543/Leerink_Swann>,
        <https://1145.am/db/2365104/Sr_One>,
        <https://1145.am/db/2365300/Sr_One>,
        <https://1145.am/db/2595958/Sr_One>,
        <https://1145.am/db/2621506/D1>,
        <https://1145.am/db/336270/Sbi_Investment>,
        <https://1145.am/db/396305/Obvious_Ventures>,
        <https://1145.am/db/435691/Concrete_Ventures>,
        <https://1145.am/db/437556/Founders_Fund>,
        <https://1145.am/db/438632/Founders_Fund>,
        <https://1145.am/db/478867/Founders_Fund>,
        <https://1145.am/db/508145/Snz_Capital>,
        <https://1145.am/db/508161/Snz_Capital>,
        <https://1145.am/db/517818/Strong_Ventures>,
        <https://1145.am/db/539214/Sosv>,
        <https://1145.am/db/571520/G___M_Capital>,
        <https://1145.am/db/606173/Impellent_Ventures>,
        <https://1145.am/db/6743/S28_Capital>,
        <https://1145.am/db/676953/Upfront_Ventures>,
        <https://1145.am/db/678418/Sjf_Ventures>,
        <https://1145.am/db/678978/Inp_Capital>,
        <https://1145.am/db/683067/Lofty_Ventures>,
        <https://1145.am/db/690348/L37_Ventures>,
        <https://1145.am/db/700308/Afore_Capital>,
        <https://1145.am/db/714710/2b_Ahead_Ventures>,
        <https://1145.am/db/731044/Sempervirensvc>,
        <https://1145.am/db/733491/Build_Ventures>,
        <https://1145.am/db/749201/Trust_Ventures>,
        <https://1145.am/db/750485/A16z>,
        <https://1145.am/db/750849/Trust_Ventures>,
        <https://1145.am/db/753541/A16z>,
        <https://1145.am/db/768306/Coatue>,
        <https://1145.am/db/773235/Innovation_Endeavors>,
        <https://1145.am/db/815627/Xyz_Capital>,
        <https://1145.am/db/821222/Afore_Capital>,
        <https://1145.am/db/838181/Addition_Ventures>,
        <https://1145.am/db/840680/Afore_Capital>,
        <https://1145.am/db/846931/Myasiavc>,
        <https://1145.am/db/922498/Founders_Fund> ;
    ns1:sameAsMedium <https://1145.am/db/1800080/Advanced_Technology_Ventures>,
        <https://1145.am/db/1830593/Advanced_Technology_Ventures>,
        <https://1145.am/db/1850376/Advanced_Technology_Ventures>,
        <https://1145.am/db/1854846/Advanced_Technology_Ventures>,
        <https://1145.am/db/1861352/Advanced_Technology_Ventures>,
        <https://1145.am/db/1872490/Advanced_Technology_Ventures>,
        <https://1145.am/db/2287777/Advanced_Technology_Ventures>,
        <https://1145.am/db/2291818/Advanced_Technology_Ventures>,
        <https://1145.am/db/2300322/Advanced_Technology_Ventures>,
        <https://1145.am/db/2316391/Advanced_Technology_Ventures>,
        <https://1145.am/db/2317467/Advanced_Technology_Ventures>,
        <https://1145.am/db/2322012/Advanced_Technology_Ventures>,
        <https://1145.am/db/2322022/Advanced_Technology_Ventures>,
        <https://1145.am/db/2328599/Advanced_Technology_Ventures>,
        <https://1145.am/db/2336313/Advanced_Technology_Ventures>,
        <https://1145.am/db/2338703/Advanced_Technology_Ventures>,
        <https://1145.am/db/2338704/Advanced_Technology_Ventures>,
        <https://1145.am/db/2347389/Advanced_Technology_Ventures>,
        <https://1145.am/db/2360756/Advanced_Technology_Ventures>,
        <https://1145.am/db/2360758/Advanced_Technology_Ventures>,
        <https://1145.am/db/2362553/Advanced_Technology_Ventures>,
        <https://1145.am/db/2362871/Advanced_Technology_Ventures>,
        <https://1145.am/db/2364939/Advanced_Technology_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2367206/Poxel> a org:Organization ;
    ns1:basedInLowRaw "France" ;
    ns1:description "Life Sciences" ;
    ns1:documentDate "2010-07-08T15:10:38+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Bionest Partners Finance Advises Poxel in a Series A Financing of EUR16M" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/bionest-partners-finance-advises-poxel-a-series-a-financing-of-eur16m> ;
    ns1:foundName "Poxel" ;
    ns1:industry "Life Sciences" ;
    ns1:name "Poxel" ;
    ns1:sameAsHigh <https://1145.am/db/1260776/Poxel>,
        <https://1145.am/db/1262171/Poxel>,
        <https://1145.am/db/1597904/Poxel>,
        <https://1145.am/db/1598981/Poxel>,
        <https://1145.am/db/1945846/Poxel>,
        <https://1145.am/db/2299902/Poxel>,
        <https://1145.am/db/2301003/Poxel>,
        <https://1145.am/db/2355431/Poxel>,
        <https://1145.am/db/2367203/Poxel>,
        <https://1145.am/db/2562342/Poxel>,
        <https://1145.am/db/447095/Poxel_Sa>,
        <https://1145.am/db/447175/Poxel> ;
    ns1:sameAsMedium <https://1145.am/db/2367201/Poxel> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2367364/Investment_Cpmg_Inc_Novo_A_S_Reata_Pharmaceuticals_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-07-12T12:27:59+00:00"^^xsd:dateTime ;
    ns1:documentExtract "IRVING, Texas- (BUSINESS WIRE) -Reata Pharmaceuticals, Inc. (\"Reata\") has completed a $ 78 million equity financing led by existing investors CPMG, Inc. and Novo A/S.",
        "Reata Pharmaceuticals Completes $ 78 Million Equity Financing for Second Pivotal Trial of Bardoxolone Methyl." ;
    ns1:documentTitle "Reata Pharmaceuticals Completes $78 Million Equity Financing for Second Pivotal Trial of Bardoxolone Methyl" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/reata-pharmaceuticals-completes-78-million-equity-financing-for-second-pivotal-trial-of> ;
    ns1:foundName "Financing",
        "financing" ;
    ns1:name "Financing",
        "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2367364/Reata_Pharmaceuticals> ;
    ns1:targetDetails "Equity",
        "equity" ;
    ns1:valueRaw "$ 180 million",
        "$ 78 Million",
        "$ 78 million" ;
    ns1:whereGeoName "Texas" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/4736286/about.rdf> ;
    ns1:whereRaw "Texas" .

<https://1145.am/db/2367448/Series_A_Investment_Ninepoint_Medical_Prospect_Venture_Partners_Third_Rock_Ventures_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-10-14T14:30:50+00:00"^^xsd:dateTime ;
    ns1:documentExtract "CAMBRIDGE, Mass.- (BUSINESS WIRE) -NinePoint Medical, Inc., an emerging leader in the development of in vivo pathology devices, today announced it has completed a $ 33 million Series A financing led by Third Rock Ventures and Prospect Venture Partners.",
        "NinePoint Medical Completes $ 33 Million Series A Financing to Develop Innovative Broad - Based Medical Platform for in vivo Pathology Devices." ;
    ns1:documentTitle "NinePoint Medical Completes $33 Million Series A Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/ninepoint-medical-completes-33-million-series-a-financing> ;
    ns1:foundName "financing" ;
    ns1:name "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2367448/Ninepoint_Medical> ;
    ns1:targetDetails "Series A" ;
    ns1:valueRaw "$ 33 Million",
        "$ 33 million" ;
    ns1:whereGeoName "Cambridge" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/4931972/about.rdf> ;
    ns1:whereRaw "Cambridge, Mass" .

<https://1145.am/db/2367448/Third_Rock_Ventures> a org:Organization ;
    ns1:basedInLowRaw "Mass" ;
    ns1:documentDate "2010-10-14T14:30:50+00:00"^^xsd:dateTime ;
    ns1:documentTitle "NinePoint Medical Completes $33 Million Series A Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/ninepoint-medical-completes-33-million-series-a-financing> ;
    ns1:foundName "Third Rock Ventures" ;
    ns1:investor <https://1145.am/db/2367448/Series_A_Investment_Ninepoint_Medical_Prospect_Venture_Partners_Third_Rock_Ventures_Completed> ;
    ns1:name "Third Rock Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/1042269/Third_Rock_Ventures>,
        <https://1145.am/db/1086582/Third_Rock_Ventures>,
        <https://1145.am/db/1089269/Third_Rock_Ventures>,
        <https://1145.am/db/1325987/Third_Rock_Ventures>,
        <https://1145.am/db/1326547/Third_Rock_Ventures>,
        <https://1145.am/db/1503058/Third_Rock_Ventures>,
        <https://1145.am/db/159801/Third_Rock_Ventures>,
        <https://1145.am/db/1928208/Third_Rock_Ventures>,
        <https://1145.am/db/2095032/Third_Rock_Ventures>,
        <https://1145.am/db/2152566/Third_Rock_Ventures>,
        <https://1145.am/db/2153763/Third_Rock_Ventures>,
        <https://1145.am/db/2281272/Third_Rock_Ventures>,
        <https://1145.am/db/2291199/Third_Rock_Ventures>,
        <https://1145.am/db/2291940/Third_Rock_Ventures>,
        <https://1145.am/db/2294789/Third_Rock_Ventures>,
        <https://1145.am/db/2298193/Third_Rock_Ventures>,
        <https://1145.am/db/2298844/Third_Rock_Ventures>,
        <https://1145.am/db/2300971/Third_Rock_Ventures>,
        <https://1145.am/db/2303250/Third_Rock_Ventures>,
        <https://1145.am/db/2303251/Third_Rock_Ventures>,
        <https://1145.am/db/2303257/Third_Rock_Ventures>,
        <https://1145.am/db/2303294/Third_Rock_Ventures>,
        <https://1145.am/db/2311551/Third_Rock_Ventures>,
        <https://1145.am/db/2315931/Third_Rock_Ventures>,
        <https://1145.am/db/2315933/Third_Rock_Ventures>,
        <https://1145.am/db/2322522/Third_Rock_Ventures>,
        <https://1145.am/db/2322531/Third_Rock_Ventures>,
        <https://1145.am/db/2327474/Third_Rock_Ventures>,
        <https://1145.am/db/2335531/Third_Rock_Ventures>,
        <https://1145.am/db/2335750/Third_Rock_Ventures>,
        <https://1145.am/db/2335755/Third_Rock_Ventures>,
        <https://1145.am/db/2336126/Third_Rock_Ventures>,
        <https://1145.am/db/2337555/Third_Rock_Ventures>,
        <https://1145.am/db/2337559/Third_Rock_Ventures>,
        <https://1145.am/db/2337889/Third_Rock_Ventures>,
        <https://1145.am/db/2337958/Third_Rock_Ventures>,
        <https://1145.am/db/2337974/Third_Rock_Ventures>,
        <https://1145.am/db/2338625/Third_Rock_Ventures>,
        <https://1145.am/db/2338633/Third_Rock_Ventures>,
        <https://1145.am/db/2339127/Third_Rock_Ventures>,
        <https://1145.am/db/2339128/Third_Rock_Ventures>,
        <https://1145.am/db/2339413/Third_Rock_Ventures>,
        <https://1145.am/db/2339704/Third_Rock_Ventures>,
        <https://1145.am/db/2339925/Third_Rock_Ventures>,
        <https://1145.am/db/2339926/Third_Rock_Ventures>,
        <https://1145.am/db/2341662/Third_Rock_Ventures>,
        <https://1145.am/db/2341792/Third_Rock_Ventures>,
        <https://1145.am/db/2341800/Third_Rock_Ventures>,
        <https://1145.am/db/2342754/Third_Rock_Ventures>,
        <https://1145.am/db/2342768/Third_Rock_Ventures>,
        <https://1145.am/db/2342771/Third_Rock_Ventures>,
        <https://1145.am/db/2344256/Third_Rock_Ventures>,
        <https://1145.am/db/2344912/Third_Rock_Ventures>,
        <https://1145.am/db/2344918/Third_Rock_Ventures>,
        <https://1145.am/db/2345224/Third_Rock_Ventures>,
        <https://1145.am/db/2346212/Third_Rock_Ventures>,
        <https://1145.am/db/2346216/Third_Rock_Ventures>,
        <https://1145.am/db/2346988/Third_Rock_Ventures>,
        <https://1145.am/db/2347885/Third_Rock_Ventures>,
        <https://1145.am/db/2350364/Third_Rock_Ventures>,
        <https://1145.am/db/2351009/Third_Rock_Ventures>,
        <https://1145.am/db/2351011/Third_Rock_Ventures>,
        <https://1145.am/db/2351348/Third_Rock_Ventures>,
        <https://1145.am/db/2351372/Third_Rock_Ventures>,
        <https://1145.am/db/2351520/Third_Rock_Ventures>,
        <https://1145.am/db/2351644/Third_Rock_Ventures>,
        <https://1145.am/db/2354307/Third_Rock_Ventures>,
        <https://1145.am/db/2354314/Third_Rock_Ventures>,
        <https://1145.am/db/2354608/Third_Rock_Ventures>,
        <https://1145.am/db/2354613/Third_Rock_Ventures>,
        <https://1145.am/db/2355043/Third_Rock_Ventures>,
        <https://1145.am/db/2357253/Third_Rock_Ventures>,
        <https://1145.am/db/2357256/Third_Rock_Ventures>,
        <https://1145.am/db/2357722/Third_Rock_Ventures>,
        <https://1145.am/db/2358551/Third_Rock_Ventures>,
        <https://1145.am/db/2358737/Third_Rock_Ventures>,
        <https://1145.am/db/2359321/Third_Rock_Ventures>,
        <https://1145.am/db/2359334/Third_Rock_Ventures>,
        <https://1145.am/db/2359447/Third_Rock_Ventures>,
        <https://1145.am/db/2359575/Third_Rock_Ventures>,
        <https://1145.am/db/2359818/Third_Rock_Ventures>,
        <https://1145.am/db/2359864/Third_Rock_Ventures>,
        <https://1145.am/db/2359873/Third_Rock_Ventures>,
        <https://1145.am/db/2359875/Third_Rock_Ventures>,
        <https://1145.am/db/2359887/Third_Rock_Ventures>,
        <https://1145.am/db/2359984/Third_Rock_Ventures>,
        <https://1145.am/db/2359987/Third_Rock_Ventures>,
        <https://1145.am/db/2360006/Third_Rock_Ventures>,
        <https://1145.am/db/2360169/Third_Rock_Ventures>,
        <https://1145.am/db/2360814/Third_Rock_Ventures>,
        <https://1145.am/db/2360877/Third_Rock_Ventures>,
        <https://1145.am/db/2362102/Third_Rock_Ventures>,
        <https://1145.am/db/2362109/Third_Rock_Ventures>,
        <https://1145.am/db/2362128/Third_Rock_Ventures>,
        <https://1145.am/db/2363422/Third_Rock_Ventures>,
        <https://1145.am/db/2364240/Third_Rock_Ventures>,
        <https://1145.am/db/2364249/Third_Rock_Ventures>,
        <https://1145.am/db/2364255/Third_Rock_Ventures>,
        <https://1145.am/db/2364283/Third_Rock_Ventures>,
        <https://1145.am/db/2364481/Third_Rock_Ventures>,
        <https://1145.am/db/2365109/Third_Rock_Ventures>,
        <https://1145.am/db/2365111/Third_Rock_Ventures>,
        <https://1145.am/db/2365315/Third_Rock_Ventures>,
        <https://1145.am/db/2366539/Third_Rock_Ventures>,
        <https://1145.am/db/2366641/Third_Rock_Ventures>,
        <https://1145.am/db/2367442/Third_Rock_Ventures>,
        <https://1145.am/db/2368166/Third_Rock_Ventures>,
        <https://1145.am/db/2368501/Third_Rock_Ventures>,
        <https://1145.am/db/2369130/Third_Rock_Ventures>,
        <https://1145.am/db/2369202/Third_Rock_Ventures>,
        <https://1145.am/db/2370105/Third_Rock_Ventures_Llc>,
        <https://1145.am/db/2371191/Third_Rock_Ventures>,
        <https://1145.am/db/2580088/Third_Rock_Ventures>,
        <https://1145.am/db/2584533/Third_Rock_Ventures>,
        <https://1145.am/db/441151/Third_Rock_Ventures>,
        <https://1145.am/db/572554/Third_Rock_Ventures>,
        <https://1145.am/db/768794/Third_Rock_Ventures>,
        <https://1145.am/db/769408/Third_Rock_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2573611/Alcon_Stake_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition",
        "investment" ;
    ns1:documentDate "2010-07-08T14:06:34+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Alcon's (NYSE: ACL) independent directors are upping the ante in their squabble with Novartis.",
        "Novartis agreed to buy Nestle's Alcon stake in a two-stage deal." ;
    ns1:documentTitle "Alcon IDC earmarks $50M for possible Novartis suit" ;
    ns1:documentURL <https://www.fiercepharma.com/pharma/alcon-idc-earmarks-50m-for-possible-novartis-suit> ;
    ns1:foundName "buy",
        "own" ;
    ns1:name "buy",
        "own" ;
    ns1:sourceName "Fierce Pharma" ;
    ns1:status "completed",
        "has not happened",
        "stopped" ;
    ns1:target <https://1145.am/db/2573611/Alcon> ;
    ns1:targetDetails "stake" ;
    ns1:targetName "Alcon" ;
    ns1:valueRaw "$ 39.3 billion" ;
    ns1:vendor <https://1145.am/db/2573611/Nestle> ;
    ns1:whereGeoName "Switzerland" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/2658434/about.rdf> ;
    ns1:whereRaw "Switzerland" .

<https://1145.am/db/2573611/Nestle> a org:Organization ;
    ns1:basedInLowRaw "Switzerland" ;
    ns1:description "eye care company" ;
    ns1:documentDate "2010-07-08T14:06:34+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Alcon IDC earmarks $50M for possible Novartis suit" ;
    ns1:documentURL <https://www.fiercepharma.com/pharma/alcon-idc-earmarks-50m-for-possible-novartis-suit> ;
    ns1:foundName "Nestle'" ;
    ns1:name "Nestle" ;
    ns1:sameAsMedium <https://1145.am/db/102578/Nestle>,
        <https://1145.am/db/107688/Nestle>,
        <https://1145.am/db/107857/Nestle>,
        <https://1145.am/db/135716/Nestle>,
        <https://1145.am/db/1466026/Nestle_Sa>,
        <https://1145.am/db/1527177/Nestle>,
        <https://1145.am/db/156125/Nestle>,
        <https://1145.am/db/1574226/Nestle>,
        <https://1145.am/db/1777197/Nestle>,
        <https://1145.am/db/190820/Nestlé_Sa>,
        <https://1145.am/db/1961632/Nestlé>,
        <https://1145.am/db/2022502/Nestle>,
        <https://1145.am/db/2069033/Nestle>,
        <https://1145.am/db/2106406/Nestle>,
        <https://1145.am/db/2108869/Nestle>,
        <https://1145.am/db/2109377/Nestle>,
        <https://1145.am/db/218697/Nestle_Sa>,
        <https://1145.am/db/2291397/Nestlé>,
        <https://1145.am/db/2292189/Nestlé>,
        <https://1145.am/db/2299847/Nestle>,
        <https://1145.am/db/2325386/Nestle>,
        <https://1145.am/db/2327560/Nestle>,
        <https://1145.am/db/2346208/Nestlé>,
        <https://1145.am/db/237583/Nestle>,
        <https://1145.am/db/2549982/Nestlé>,
        <https://1145.am/db/2558316/Nestle>,
        <https://1145.am/db/2559797/Nestle>,
        <https://1145.am/db/2560477/Nestlé>,
        <https://1145.am/db/2563194/Nestlé>,
        <https://1145.am/db/2563348/Nestlé_Sa>,
        <https://1145.am/db/2566415/Nestlé>,
        <https://1145.am/db/2567953/Nestlé>,
        <https://1145.am/db/2572568/Nestle_Sa>,
        <https://1145.am/db/2574332/Nestlé>,
        <https://1145.am/db/2576962/Nestle>,
        <https://1145.am/db/2579519/Nestle>,
        <https://1145.am/db/2582395/Nestlé>,
        <https://1145.am/db/2582400/Nestlé>,
        <https://1145.am/db/2582402/Nestle>,
        <https://1145.am/db/2588438/Nestlé>,
        <https://1145.am/db/2590095/Nestle>,
        <https://1145.am/db/2591520/Nestle>,
        <https://1145.am/db/2591733/Nestle>,
        <https://1145.am/db/2594249/Nestle>,
        <https://1145.am/db/2596947/Nestle>,
        <https://1145.am/db/2597078/Nestle>,
        <https://1145.am/db/315049/Nestle>,
        <https://1145.am/db/315797/Nestle>,
        <https://1145.am/db/319737/Nestlé>,
        <https://1145.am/db/320746/Nestle>,
        <https://1145.am/db/544750/Nestle>,
        <https://1145.am/db/633223/Nestlé>,
        <https://1145.am/db/680407/Nestle>,
        <https://1145.am/db/681432/Nestle_Sa>,
        <https://1145.am/db/836550/Nestle> ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2573611/Novartis> a org:Organization ;
    ns1:basedInHighGeoName "Switzerland" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2658434/about.rdf> ;
    ns1:basedInHighRaw "Switzerland" ;
    ns1:buyer <https://1145.am/db/2573611/Alcon_Stake_Acquisition> ;
    ns1:description "drugmaker" ;
    ns1:documentDate "2010-07-08T14:06:34+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Alcon IDC earmarks $50M for possible Novartis suit" ;
    ns1:documentURL <https://www.fiercepharma.com/pharma/alcon-idc-earmarks-50m-for-possible-novartis-suit> ;
    ns1:foundName "Novartis" ;
    ns1:industry "drugmaker" ;
    ns1:investor <https://1145.am/db/2573611/Alcon_Stake_Acquisition> ;
    ns1:name "Novartis" ;
    ns1:sameAsHigh <https://1145.am/db/1048908/Johnson___Johnson>,
        <https://1145.am/db/1176158/Novartis>,
        <https://1145.am/db/1177562/Novartis>,
        <https://1145.am/db/1262552/Johnson___Johnson>,
        <https://1145.am/db/1270868/Johnson___Johnson>,
        <https://1145.am/db/131136/Novartis>,
        <https://1145.am/db/132002/Novartis>,
        <https://1145.am/db/1328753/Novartis>,
        <https://1145.am/db/1507918/Novartis_Ag>,
        <https://1145.am/db/156403/Novartis>,
        <https://1145.am/db/1567521/Novartis>,
        <https://1145.am/db/1578114/Novartis>,
        <https://1145.am/db/1628428/Novalgen_Ltd>,
        <https://1145.am/db/1629605/Novartis>,
        <https://1145.am/db/1629663/Novartis>,
        <https://1145.am/db/165056/Novartis>,
        <https://1145.am/db/1673527/Johnson___Johnson>,
        <https://1145.am/db/176334/Novartis>,
        <https://1145.am/db/177096/Novartis>,
        <https://1145.am/db/1822601/Johnson___Johnson>,
        <https://1145.am/db/1986468/Novabay®_Pharmaceuticals_Inc>,
        <https://1145.am/db/2033677/Novartis>,
        <https://1145.am/db/2033933/Novartis>,
        <https://1145.am/db/2036487/Novartis_Ag>,
        <https://1145.am/db/2057335/Johnson___Johnson>,
        <https://1145.am/db/2062728/Novan>,
        <https://1145.am/db/2065993/Novartis_Ag>,
        <https://1145.am/db/2089281/Johnson___Johnson>,
        <https://1145.am/db/2103283/Johnson___Johnson>,
        <https://1145.am/db/2107835/Novartis>,
        <https://1145.am/db/2129754/Novartis>,
        <https://1145.am/db/2152605/Novartis>,
        <https://1145.am/db/2152618/Novartis>,
        <https://1145.am/db/2153059/Novartis>,
        <https://1145.am/db/2153410/Johnson___Johnson>,
        <https://1145.am/db/2154194/Johnson___Johnson>,
        <https://1145.am/db/2154521/Johnson___Johnson>,
        <https://1145.am/db/2154527/Novartis>,
        <https://1145.am/db/2155069/Novartis>,
        <https://1145.am/db/2155665/Novartis>,
        <https://1145.am/db/2190363/Novartis_Ag>,
        <https://1145.am/db/2193661/Johnson___Johnson>,
        <https://1145.am/db/2194161/Novartis>,
        <https://1145.am/db/2279108/Novartis>,
        <https://1145.am/db/2279232/Novartis>,
        <https://1145.am/db/2279829/Novartis>,
        <https://1145.am/db/2280153/Novartis>,
        <https://1145.am/db/2280350/Novartis>,
        <https://1145.am/db/2280422/Johnson___Johnson>,
        <https://1145.am/db/2282888/Johnson_And_Johnson>,
        <https://1145.am/db/2282888/Johnson___Johnson>,
        <https://1145.am/db/2283590/Novartis>,
        <https://1145.am/db/2283645/Novartis>,
        <https://1145.am/db/2285311/Novartis>,
        <https://1145.am/db/2285587/Johnson___Johnson>,
        <https://1145.am/db/2286603/Johnson___Johnson>,
        <https://1145.am/db/2286604/Novartis>,
        <https://1145.am/db/2287377/Johnson___Johnson>,
        <https://1145.am/db/2288851/Novartis>,
        <https://1145.am/db/2289846/Novartis>,
        <https://1145.am/db/2290022/Novartis>,
        <https://1145.am/db/2290342/Johnson___Johnson>,
        <https://1145.am/db/2290894/Johnson___Johnson>,
        <https://1145.am/db/2291777/Johnson___Johnson>,
        <https://1145.am/db/2292345/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2293323/Novartis>,
        <https://1145.am/db/2293342/Novartis>,
        <https://1145.am/db/2293591/Novartis>,
        <https://1145.am/db/2294026/Novartis>,
        <https://1145.am/db/2294585/Novartis>,
        <https://1145.am/db/2296402/Johnson___Johnson>,
        <https://1145.am/db/2296504/Novartis>,
        <https://1145.am/db/2296552/Novartis>,
        <https://1145.am/db/2296598/Johnson___Johnson>,
        <https://1145.am/db/2298037/Johnson___Johnson>,
        <https://1145.am/db/2298501/Johnson___Johnson>,
        <https://1145.am/db/2298606/Novartis>,
        <https://1145.am/db/2301066/Novartis>,
        <https://1145.am/db/2301089/Novartis>,
        <https://1145.am/db/2301705/Novasep>,
        <https://1145.am/db/2301735/Novartis>,
        <https://1145.am/db/2301857/Novartis>,
        <https://1145.am/db/2302724/Novartis>,
        <https://1145.am/db/2302727/Novartis>,
        <https://1145.am/db/2303121/Novartis_Bioventures>,
        <https://1145.am/db/230344/Swiss_Drugmaker_Novartis>,
        <https://1145.am/db/2304113/Novartis>,
        <https://1145.am/db/2304373/Novartis>,
        <https://1145.am/db/2304374/Novartis>,
        <https://1145.am/db/2305192/Novartis>,
        <https://1145.am/db/2305244/Novabay_Pharmaceuticals>,
        <https://1145.am/db/2307228/Novadel_Pharma_Inc>,
        <https://1145.am/db/2307347/Novartis>,
        <https://1145.am/db/2307847/Novartis>,
        <https://1145.am/db/2307851/Novartis>,
        <https://1145.am/db/2307863/Novartis>,
        <https://1145.am/db/2307998/Novartis>,
        <https://1145.am/db/2308010/Novartis>,
        <https://1145.am/db/2308298/Novartis>,
        <https://1145.am/db/2308765/Novartis>,
        <https://1145.am/db/2308812/Novartis>,
        <https://1145.am/db/2308946/Novartis_Ag>,
        <https://1145.am/db/2309065/Novartis_Intercell>,
        <https://1145.am/db/2309930/Johnson___Johnson>,
        <https://1145.am/db/2310118/Johnson___Johnson>,
        <https://1145.am/db/2310150/Novartis>,
        <https://1145.am/db/2312008/Novartis>,
        <https://1145.am/db/2312018/Novartis_International_Ag>,
        <https://1145.am/db/2312088/Novabay_Pharmaceuticals>,
        <https://1145.am/db/2312436/Novartis>,
        <https://1145.am/db/2314331/Johnson___Johnson>,
        <https://1145.am/db/2315481/Johnson___Johnson>,
        <https://1145.am/db/2317181/Johnson___Johnson>,
        <https://1145.am/db/2317639/Johnson___Johnson>,
        <https://1145.am/db/2317845/Novadel>,
        <https://1145.am/db/2317949/Novalar_Pharmaceuticals>,
        <https://1145.am/db/2317951/Novalar_Pharmaceuticals>,
        <https://1145.am/db/2318685/Johnson___Johnson>,
        <https://1145.am/db/2318994/Novadel>,
        <https://1145.am/db/2319412/Novartis>,
        <https://1145.am/db/2319656/Johnson___Johnson>,
        <https://1145.am/db/2320828/Novartis>,
        <https://1145.am/db/2321067/Novartis>,
        <https://1145.am/db/2322024/Johnson___Johnson>,
        <https://1145.am/db/2322266/Novartis>,
        <https://1145.am/db/2323000/Johnson___Johnson>,
        <https://1145.am/db/2323188/Novartis>,
        <https://1145.am/db/2323692/Novabay_Pharmaceuticals>,
        <https://1145.am/db/2324255/Novartis_Bioventures>,
        <https://1145.am/db/2325073/Novartis>,
        <https://1145.am/db/2325869/Novartis>,
        <https://1145.am/db/2326949/Novartis>,
        <https://1145.am/db/2327024/Johnson___Johnson>,
        <https://1145.am/db/2327560/Novartis>,
        <https://1145.am/db/2329413/Novadel_Pharma_Inc>,
        <https://1145.am/db/2329475/Novadel_Pharma>,
        <https://1145.am/db/2329487/Johnson___Johnson>,
        <https://1145.am/db/2329597/Novartis>,
        <https://1145.am/db/2330648/Novartis>,
        <https://1145.am/db/2330734/Johnson___Johnson>,
        <https://1145.am/db/2331875/Novadel>,
        <https://1145.am/db/2332005/Novartis>,
        <https://1145.am/db/2332788/Novartis_Ag>,
        <https://1145.am/db/2332796/Novadel_Pharma_Inc>,
        <https://1145.am/db/2332872/Novartis>,
        <https://1145.am/db/2334206/Novartis>,
        <https://1145.am/db/2334645/Novast>,
        <https://1145.am/db/2336028/Novartis>,
        <https://1145.am/db/2336704/Novartis>,
        <https://1145.am/db/2336790/Johnson___Johnson>,
        <https://1145.am/db/2336797/Johnson___Johnson>,
        <https://1145.am/db/2336990/Novartis>,
        <https://1145.am/db/2339656/Novartis>,
        <https://1145.am/db/2339669/Novartis>,
        <https://1145.am/db/2340071/Johnson___Johnson>,
        <https://1145.am/db/2340615/Novartis>,
        <https://1145.am/db/2340948/Novartis>,
        <https://1145.am/db/2341850/Johnson___Johnson>,
        <https://1145.am/db/2344017/Novartis>,
        <https://1145.am/db/2344434/Novartis>,
        <https://1145.am/db/2344683/Johnson___Johnson>,
        <https://1145.am/db/2346576/Novadel_Pharma_Inc>,
        <https://1145.am/db/2346629/Novartis>,
        <https://1145.am/db/2348176/Novartis>,
        <https://1145.am/db/2349068/Novartis>,
        <https://1145.am/db/2350116/Johnson___Johnson>,
        <https://1145.am/db/2350440/Johnson___Johnson_Inc>,
        <https://1145.am/db/2352045/Novartis>,
        <https://1145.am/db/2352046/Novartis>,
        <https://1145.am/db/2352178/Novartis>,
        <https://1145.am/db/2354148/Novartis>,
        <https://1145.am/db/2354402/Johnson___Johnson>,
        <https://1145.am/db/2358273/Novartis>,
        <https://1145.am/db/2358297/Novartis>,
        <https://1145.am/db/2358579/Novartis>,
        <https://1145.am/db/2358657/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2359165/Novartis>,
        <https://1145.am/db/2359179/Novartis>,
        <https://1145.am/db/2359302/Johnson___Johnson>,
        <https://1145.am/db/2359915/Novadel_Pharma_Inc>,
        <https://1145.am/db/2360309/Novartis_Pharma_Ag>,
        <https://1145.am/db/2360526/Novartis>,
        <https://1145.am/db/2360633/Novartis>,
        <https://1145.am/db/2360754/Johnson___Johnson>,
        <https://1145.am/db/2362448/Novadel_Pharma_Inc>,
        <https://1145.am/db/2363618/Novartis_Uk>,
        <https://1145.am/db/2364457/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2364601/Johnson___Johnson>,
        <https://1145.am/db/2366653/Johnson___Johnson>,
        <https://1145.am/db/2367118/Novabay_Pharmaceuticals>,
        <https://1145.am/db/2367207/Novartis>,
        <https://1145.am/db/2367616/Johnson___Johnson>,
        <https://1145.am/db/2367617/Johnson___Johnson>,
        <https://1145.am/db/2367829/Novartis_International_Ag>,
        <https://1145.am/db/2367836/Novartis_International_Ag>,
        <https://1145.am/db/2367993/Novabay>,
        <https://1145.am/db/2368571/Novartis>,
        <https://1145.am/db/2368646/Novartis>,
        <https://1145.am/db/2368659/Novartis>,
        <https://1145.am/db/2369183/Novartis>,
        <https://1145.am/db/2369449/Novartis_Pharma_Ag>,
        <https://1145.am/db/2369450/Novartis>,
        <https://1145.am/db/2369451/Novartis>,
        <https://1145.am/db/2369555/Swiss_Pharma_Giant_Novartis>,
        <https://1145.am/db/2369718/Novartis>,
        <https://1145.am/db/2370010/Novartis>,
        <https://1145.am/db/2370013/Novartis>,
        <https://1145.am/db/2370259/Johnson___Johnson>,
        <https://1145.am/db/2370615/Novartis>,
        <https://1145.am/db/2370635/Novartis>,
        <https://1145.am/db/2371070/Novartis>,
        <https://1145.am/db/2371077/Novartis>,
        <https://1145.am/db/2371188/Novartis>,
        <https://1145.am/db/2371323/Novartis>,
        <https://1145.am/db/2371326/Novartis>,
        <https://1145.am/db/2434670/Novartis>,
        <https://1145.am/db/2536264/Johnson___Johnson>,
        <https://1145.am/db/2536325/Novartis>,
        <https://1145.am/db/2536882/Novartis>,
        <https://1145.am/db/2536914/Novartis>,
        <https://1145.am/db/2537064/Novartis>,
        <https://1145.am/db/2537477/Novartis>,
        <https://1145.am/db/2537482/Novacea>,
        <https://1145.am/db/2538344/Novartis>,
        <https://1145.am/db/2538791/Novartis>,
        <https://1145.am/db/2539541/Novasep>,
        <https://1145.am/db/2539787/Novartis>,
        <https://1145.am/db/2539925/Novartis>,
        <https://1145.am/db/2540187/Novartis>,
        <https://1145.am/db/2541511/Novartis>,
        <https://1145.am/db/2542938/Novartis>,
        <https://1145.am/db/2543689/Novartis>,
        <https://1145.am/db/2543863/Johnson___Johnson>,
        <https://1145.am/db/2544236/Novartis>,
        <https://1145.am/db/2544326/Novartis>,
        <https://1145.am/db/2545284/Novartis>,
        <https://1145.am/db/2545522/Johnson___Johnson>,
        <https://1145.am/db/2545651/Novartis>,
        <https://1145.am/db/2545966/Novartis>,
        <https://1145.am/db/2545986/Novartis>,
        <https://1145.am/db/2546157/Novartis>,
        <https://1145.am/db/2546170/Novartis>,
        <https://1145.am/db/2546172/Johnson___Johnson>,
        <https://1145.am/db/2546603/Novartis>,
        <https://1145.am/db/2547152/Johnson___Johnson>,
        <https://1145.am/db/2547397/Novartis>,
        <https://1145.am/db/2548223/Novartis>,
        <https://1145.am/db/2548224/Novartis_Group>,
        <https://1145.am/db/2549043/Novartis>,
        <https://1145.am/db/2549631/Novast>,
        <https://1145.am/db/2550855/Novartis>,
        <https://1145.am/db/2551143/Novartis>,
        <https://1145.am/db/2551693/Novartis>,
        <https://1145.am/db/2551694/Novartis>,
        <https://1145.am/db/2552165/Novartis>,
        <https://1145.am/db/2552258/Novartis>,
        <https://1145.am/db/2553024/Johnson___Johnson>,
        <https://1145.am/db/2553024/Novartis>,
        <https://1145.am/db/2553276/Novartis>,
        <https://1145.am/db/2553480/Novartis>,
        <https://1145.am/db/2553740/Novasep>,
        <https://1145.am/db/2553810/Novartis>,
        <https://1145.am/db/2553846/Novartis>,
        <https://1145.am/db/2553852/Johnson___Johnson>,
        <https://1145.am/db/2554060/Novartis>,
        <https://1145.am/db/2554669/Novasep>,
        <https://1145.am/db/2555555/Novartis>,
        <https://1145.am/db/2555561/Novartis>,
        <https://1145.am/db/2556030/Novartis>,
        <https://1145.am/db/2556543/Novartis>,
        <https://1145.am/db/2557204/Novartis>,
        <https://1145.am/db/2557588/Novartis>,
        <https://1145.am/db/2558316/Novartis>,
        <https://1145.am/db/2558415/Novartis>,
        <https://1145.am/db/2558779/Novartis>,
        <https://1145.am/db/2558927/Novartis>,
        <https://1145.am/db/2559306/Novartis>,
        <https://1145.am/db/2559655/Novartis>,
        <https://1145.am/db/2559797/Novartis>,
        <https://1145.am/db/2559802/Novartis>,
        <https://1145.am/db/2559810/Switzerlands_Novartis>,
        <https://1145.am/db/2560023/Novartis>,
        <https://1145.am/db/2560079/Novartis>,
        <https://1145.am/db/2560372/Johnson___Johnson>,
        <https://1145.am/db/2561162/Novasep>,
        <https://1145.am/db/2561268/Novartis>,
        <https://1145.am/db/2561541/Novartis>,
        <https://1145.am/db/2561955/Novartis>,
        <https://1145.am/db/2562202/Novartis>,
        <https://1145.am/db/2562695/Novartis>,
        <https://1145.am/db/2562951/Novartis>,
        <https://1145.am/db/2563497/Novartis>,
        <https://1145.am/db/2563987/Novartis>,
        <https://1145.am/db/2564032/Johnson___Johnson>,
        <https://1145.am/db/2564141/Novartis>,
        <https://1145.am/db/2564268/Novartis>,
        <https://1145.am/db/2564462/Johnson___Johnson_Novartis>,
        <https://1145.am/db/2564695/Novartis>,
        <https://1145.am/db/2565142/Novartis>,
        <https://1145.am/db/2565794/Novartis>,
        <https://1145.am/db/2565844/Novartis>,
        <https://1145.am/db/2566121/Novartis>,
        <https://1145.am/db/2566147/Johnson___Johnson>,
        <https://1145.am/db/2567283/Novartis>,
        <https://1145.am/db/2567300/Novartis>,
        <https://1145.am/db/2567942/Novartis>,
        <https://1145.am/db/2568308/Novartis>,
        <https://1145.am/db/2568734/Novartis>,
        <https://1145.am/db/2568932/Novartis>,
        <https://1145.am/db/2568968/Novartis>,
        <https://1145.am/db/2568973/Novartis>,
        <https://1145.am/db/2569724/Novartis>,
        <https://1145.am/db/2570214/Novartis>,
        <https://1145.am/db/2570721/Novartis>,
        <https://1145.am/db/2570791/Novartis>,
        <https://1145.am/db/2570932/Novartis>,
        <https://1145.am/db/2570937/Novartis_Uk>,
        <https://1145.am/db/2571513/Novartis>,
        <https://1145.am/db/2571519/Novartis>,
        <https://1145.am/db/2571527/Novartis>,
        <https://1145.am/db/2572466/Johnson___Johnson>,
        <https://1145.am/db/2572713/Novartis>,
        <https://1145.am/db/2572904/Novartis_Group>,
        <https://1145.am/db/2572985/Novartis>,
        <https://1145.am/db/2573002/Novartis>,
        <https://1145.am/db/2573373/Johnson___Johnson>,
        <https://1145.am/db/2573473/Novartis>,
        <https://1145.am/db/2573517/Novartis>,
        <https://1145.am/db/2574347/Johnson___Johnson>,
        <https://1145.am/db/2574584/Novartis>,
        <https://1145.am/db/2574958/Novartis>,
        <https://1145.am/db/2575047/Novartis>,
        <https://1145.am/db/2575310/Novartis>,
        <https://1145.am/db/2575313/Novartis>,
        <https://1145.am/db/2575488/Novartis>,
        <https://1145.am/db/2575492/Johnson___Johnson>,
        <https://1145.am/db/2575496/Johnson___Johnson>,
        <https://1145.am/db/2575545/Novartis>,
        <https://1145.am/db/2575625/Novartis>,
        <https://1145.am/db/2575702/Novartis>,
        <https://1145.am/db/2575712/Novartis>,
        <https://1145.am/db/2575810/Novartis_Ag>,
        <https://1145.am/db/2575810/Novartis_Pharma_Ag>,
        <https://1145.am/db/2575813/Novartis>,
        <https://1145.am/db/2576242/Novartis>,
        <https://1145.am/db/2576254/Novartis>,
        <https://1145.am/db/2576439/Johnson___Johnson>,
        <https://1145.am/db/2576547/Novartis>,
        <https://1145.am/db/2576933/Novartis>,
        <https://1145.am/db/2576962/Johnson___Johnson>,
        <https://1145.am/db/2577129/Novartis>,
        <https://1145.am/db/2577419/Novartis>,
        <https://1145.am/db/2577998/Novartis>,
        <https://1145.am/db/2579507/Novartis>,
        <https://1145.am/db/2579519/Novartis>,
        <https://1145.am/db/2580047/Novartis>,
        <https://1145.am/db/2580401/Novartis>,
        <https://1145.am/db/2580963/Novartis>,
        <https://1145.am/db/2581378/Novartis>,
        <https://1145.am/db/2581394/Novartis>,
        <https://1145.am/db/2581397/Novartis>,
        <https://1145.am/db/2581493/Novartis>,
        <https://1145.am/db/2581716/Novartis>,
        <https://1145.am/db/2582355/Novartis>,
        <https://1145.am/db/2582395/Novartis>,
        <https://1145.am/db/2582400/Novartis>,
        <https://1145.am/db/2582402/Novartis>,
        <https://1145.am/db/2582623/Novartis>,
        <https://1145.am/db/2582643/Novartis>,
        <https://1145.am/db/2583067/Novartis>,
        <https://1145.am/db/2583189/Johnson___Johnson>,
        <https://1145.am/db/2584383/Johnson___Johnson>,
        <https://1145.am/db/2584538/Novartis>,
        <https://1145.am/db/2585039/Novartis>,
        <https://1145.am/db/2585121/Novartis>,
        <https://1145.am/db/2585710/Johnson___Johnson>,
        <https://1145.am/db/2586661/Novatis>,
        <https://1145.am/db/2586670/Novartis>,
        <https://1145.am/db/2587047/Novartis>,
        <https://1145.am/db/2587143/Johnson___Johnson>,
        <https://1145.am/db/2587177/Johnson___Johnson>,
        <https://1145.am/db/2587805/Novartis>,
        <https://1145.am/db/2587857/Novartis>,
        <https://1145.am/db/2588074/Johnson___Johnson>,
        <https://1145.am/db/2588196/Novartis>,
        <https://1145.am/db/2589178/Novartis>,
        <https://1145.am/db/2589402/Johnson___Johnson>,
        <https://1145.am/db/2589535/Novartis>,
        <https://1145.am/db/2589799/Novartis>,
        <https://1145.am/db/2591073/Johnson___Johnson>,
        <https://1145.am/db/2591074/Johnson___Johnson>,
        <https://1145.am/db/2591076/Johnson___Johnson>,
        <https://1145.am/db/2591905/Novartis>,
        <https://1145.am/db/2592351/Novartis>,
        <https://1145.am/db/2592505/Novartis>,
        <https://1145.am/db/2592534/Johnson___Johnson>,
        <https://1145.am/db/2592895/Novartis>,
        <https://1145.am/db/2592987/Novartis>,
        <https://1145.am/db/2593443/Novartis>,
        <https://1145.am/db/2593889/Johnson___Johnson>,
        <https://1145.am/db/2594106/Johnson___Johnson>,
        <https://1145.am/db/2594494/Novartis>,
        <https://1145.am/db/2594935/Novartis>,
        <https://1145.am/db/2594940/Novartis>,
        <https://1145.am/db/2595048/Novartis>,
        <https://1145.am/db/2595150/Novartis>,
        <https://1145.am/db/2595688/Novartis>,
        <https://1145.am/db/2595924/Novartis_Ag>,
        <https://1145.am/db/2596344/Novartis>,
        <https://1145.am/db/2597135/Johnson___Johnson>,
        <https://1145.am/db/2597197/Novamed_Pharmaceuticals>,
        <https://1145.am/db/2598439/Johnson___Johnson_Inc>,
        <https://1145.am/db/2598636/Novartis>,
        <https://1145.am/db/2787530/Novartis>,
        <https://1145.am/db/2787550/Johnson___Johnson>,
        <https://1145.am/db/282192/Novartis>,
        <https://1145.am/db/346162/Novartis>,
        <https://1145.am/db/488391/Novartis>,
        <https://1145.am/db/509708/Novabay®_Pharmaceuticals_Inc>,
        <https://1145.am/db/595011/Novartis>,
        <https://1145.am/db/601300/Novabay®_Pharmaceuticals_Inc>,
        <https://1145.am/db/637582/Novartis>,
        <https://1145.am/db/652831/Novartis>,
        <https://1145.am/db/661296/Novartis>,
        <https://1145.am/db/691279/Novartis>,
        <https://1145.am/db/699695/Johnson___Johnson>,
        <https://1145.am/db/712016/Novartis>,
        <https://1145.am/db/895235/Novan> ;
    ns1:sameAsMedium <https://1145.am/db/1151476/Novartis>,
        <https://1145.am/db/1629127/Novartis>,
        <https://1145.am/db/1630421/Novartis>,
        <https://1145.am/db/2076347/Novartis>,
        <https://1145.am/db/2155042/Novartis>,
        <https://1145.am/db/2186148/Novartis>,
        <https://1145.am/db/2290898/Novartis>,
        <https://1145.am/db/2291090/Novartis>,
        <https://1145.am/db/2291713/Novartis>,
        <https://1145.am/db/2293419/Novartis>,
        <https://1145.am/db/2294680/Novartis>,
        <https://1145.am/db/2299847/Novartis>,
        <https://1145.am/db/2309347/Novartis>,
        <https://1145.am/db/2321958/Novartis>,
        <https://1145.am/db/2325386/Novartis>,
        <https://1145.am/db/2332408/Novartis>,
        <https://1145.am/db/2333390/Novartis>,
        <https://1145.am/db/2337976/Novartis>,
        <https://1145.am/db/2342687/Novartis>,
        <https://1145.am/db/2343460/Novartis>,
        <https://1145.am/db/2358559/Novartis>,
        <https://1145.am/db/2361451/Novartis>,
        <https://1145.am/db/2369178/Novartis>,
        <https://1145.am/db/2371165/Novartis>,
        <https://1145.am/db/2371203/Novartis>,
        <https://1145.am/db/2536538/Novartis>,
        <https://1145.am/db/2537155/Novartis>,
        <https://1145.am/db/2544350/Novartis>,
        <https://1145.am/db/2544409/Novartis>,
        <https://1145.am/db/2550764/Novartis>,
        <https://1145.am/db/2551001/Novartis>,
        <https://1145.am/db/2551402/Novartis>,
        <https://1145.am/db/2552856/Novartis>,
        <https://1145.am/db/2553487/Novartis>,
        <https://1145.am/db/2560238/Novartis>,
        <https://1145.am/db/2562442/Novartis>,
        <https://1145.am/db/2565564/Novartis>,
        <https://1145.am/db/2570062/Novartis>,
        <https://1145.am/db/2571462/Novartis>,
        <https://1145.am/db/2573984/Novartis>,
        <https://1145.am/db/2574950/Novartis>,
        <https://1145.am/db/2575947/Novartis>,
        <https://1145.am/db/2576892/Novartis>,
        <https://1145.am/db/2578046/Novartis>,
        <https://1145.am/db/2579890/Novartis>,
        <https://1145.am/db/2581804/Novartis>,
        <https://1145.am/db/2582646/Novartis>,
        <https://1145.am/db/2583163/Novartis>,
        <https://1145.am/db/2584135/Novartis>,
        <https://1145.am/db/2584245/Novartis>,
        <https://1145.am/db/2587048/Novartis>,
        <https://1145.am/db/2588333/Novartis>,
        <https://1145.am/db/2588691/Novartis>,
        <https://1145.am/db/2590887/Novartis>,
        <https://1145.am/db/2593780/Novartis>,
        <https://1145.am/db/619955/Novartis>,
        <https://1145.am/db/623985/Novartis> ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2581397/Alcon_Assets_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition",
        "merger" ;
    ns1:documentDate "2010-08-17T14:53:50+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Novartis AG will be required to sell an injectable eye care drug used in cataract surgery as part of a settlement which resolves Federal Trade Commission charges that Novartis's proposed acquisition of Alcon, Inc., would be anticompetitive.",
        "Novartis Must Sell Assets to Bausch & Lomb After Acquiring Alcon." ;
    ns1:documentTitle "FTC Order Protects Consumers in U.S. Market for Eye Care Drug Used in Cataract Surgery" ;
    ns1:documentURL <https://www.fiercepharma.com/pharma/ftc-order-protects-consumers-u-s-market-for-eye-care-drug-used-cataract-surgery> ;
    ns1:foundName "Sell",
        "acquisition",
        "sell" ;
    ns1:name "Sell",
        "acquisition",
        "sell" ;
    ns1:sourceName "Fierce Pharma" ;
    ns1:status "has not happened",
        "stopped" ;
    ns1:target <https://1145.am/db/2581397/Alcon> ;
    ns1:targetDetails "Assets" ;
    ns1:targetName "Alcon" ;
    ns1:vendor <https://1145.am/db/2581397/Novartis> ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "U.S." .

<https://1145.am/db/2582395/Alcon_Stock> a org:Organization ;
    ns1:basedInLowRaw "Basel" ;
    ns1:description "eye care" ;
    ns1:documentDate "2010-08-26T11:50:28+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Novartis completes 77% majority ownership of Alcon adding new growth platform in eye care to its leading healthcare portfolio" ;
    ns1:documentURL <https://www.fiercepharma.com/pharma/novartis-completes-77-majority-ownership-of-alcon-adding-new-growth-platform-eye-care-to-its> ;
    ns1:foundName "Alcon",
        "Alcon stock" ;
    ns1:industry "Healthcare" ;
    ns1:name "Alcon",
        "Alcon stock" ;
    ns1:sameAsHigh <https://1145.am/db/1077454/Alcon>,
        <https://1145.am/db/1078071/Alcon>,
        <https://1145.am/db/1294499/Alcon>,
        <https://1145.am/db/1294506/Alcon>,
        <https://1145.am/db/1295948/Alcon>,
        <https://1145.am/db/1296487/Alcon>,
        <https://1145.am/db/1520596/Alcon>,
        <https://1145.am/db/1520597/Alcon>,
        <https://1145.am/db/1521695/Alcon>,
        <https://1145.am/db/2291606/Alcon>,
        <https://1145.am/db/2293419/Alcon>,
        <https://1145.am/db/2305192/Alcon>,
        <https://1145.am/db/2314943/Alcon>,
        <https://1145.am/db/2314947/Alcon>,
        <https://1145.am/db/2321067/Alcon_Inc>,
        <https://1145.am/db/2552258/Alcon>,
        <https://1145.am/db/2553276/Alcon>,
        <https://1145.am/db/2553634/Alcon>,
        <https://1145.am/db/2572713/Alcon>,
        <https://1145.am/db/2573611/Alcon>,
        <https://1145.am/db/2575488/Alcon>,
        <https://1145.am/db/2577419/Alcon>,
        <https://1145.am/db/2579507/Alcon>,
        <https://1145.am/db/2579519/Alcon>,
        <https://1145.am/db/2580401/Alcon>,
        <https://1145.am/db/2581378/Alcon>,
        <https://1145.am/db/2581394/Alcon>,
        <https://1145.am/db/2582355/Alcon>,
        <https://1145.am/db/2582400/Alcon>,
        <https://1145.am/db/2584359/Alcon>,
        <https://1145.am/db/2590349/Alcon>,
        <https://1145.am/db/2598636/Alcon>,
        <https://1145.am/db/600939/Alcon>,
        <https://1145.am/db/600941/Alcon>,
        <https://1145.am/db/744985/Alcon> ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2582395/Alcon_Stock_Ownership_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition",
        "investment" ;
    ns1:documentDate "2010-08-26T11:50:28+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Basel, August 26, 2010 - Novartis announced today that it has completed its purchase of Alcon stock from Nestlé resulting in 77 % ownership of Alcon.",
        "Novartis completes 77 % majority ownership of Alcon adding new growth platform in eye care to its leading healthcare portfolio." ;
    ns1:documentTitle "Novartis completes 77% majority ownership of Alcon adding new growth platform in eye care to its leading healthcare portfolio" ;
    ns1:documentURL <https://www.fiercepharma.com/pharma/novartis-completes-77-majority-ownership-of-alcon-adding-new-growth-platform-eye-care-to-its> ;
    ns1:foundName "acquisition",
        "purchase" ;
    ns1:name "acquisition",
        "purchase" ;
    ns1:sourceName "Fierce Pharma" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2582395/Alcon_Stock> ;
    ns1:targetDetails "ownership" ;
    ns1:targetName "Alcon",
        "Alcon stock" ;
    ns1:valueRaw "USD 28.3 billion" ;
    ns1:vendor <https://1145.am/db/2582395/Nestlé> ;
    ns1:when "2010-08-26T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "August 26, 2010" ;
    ns1:whereGeoName "Basel" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/2661604/about.rdf> ;
    ns1:whereRaw "Basel" .

<https://1145.am/db/2582395/Nestlé> a org:Organization ;
    ns1:basedInLowRaw "Basel" ;
    ns1:documentDate "2010-08-26T11:50:28+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Novartis completes 77% majority ownership of Alcon adding new growth platform in eye care to its leading healthcare portfolio" ;
    ns1:documentURL <https://www.fiercepharma.com/pharma/novartis-completes-77-majority-ownership-of-alcon-adding-new-growth-platform-eye-care-to-its> ;
    ns1:foundName "Nestlé" ;
    ns1:name "Nestlé" ;
    ns1:sameAsMedium <https://1145.am/db/102578/Nestle>,
        <https://1145.am/db/107688/Nestle>,
        <https://1145.am/db/107857/Nestle>,
        <https://1145.am/db/135716/Nestle>,
        <https://1145.am/db/1466026/Nestle_Sa>,
        <https://1145.am/db/1527177/Nestle>,
        <https://1145.am/db/156125/Nestle>,
        <https://1145.am/db/1574226/Nestle>,
        <https://1145.am/db/1777197/Nestle>,
        <https://1145.am/db/190820/Nestlé_Sa>,
        <https://1145.am/db/1961632/Nestlé>,
        <https://1145.am/db/2022502/Nestle>,
        <https://1145.am/db/2069033/Nestle>,
        <https://1145.am/db/2106406/Nestle>,
        <https://1145.am/db/2108869/Nestle>,
        <https://1145.am/db/2109377/Nestle>,
        <https://1145.am/db/218697/Nestle_Sa>,
        <https://1145.am/db/2291397/Nestlé>,
        <https://1145.am/db/2292189/Nestlé>,
        <https://1145.am/db/2299847/Nestle>,
        <https://1145.am/db/2325386/Nestle>,
        <https://1145.am/db/2327560/Nestle>,
        <https://1145.am/db/2346208/Nestlé>,
        <https://1145.am/db/237583/Nestle>,
        <https://1145.am/db/2549982/Nestlé>,
        <https://1145.am/db/2558316/Nestle>,
        <https://1145.am/db/2559797/Nestle>,
        <https://1145.am/db/2560477/Nestlé>,
        <https://1145.am/db/2563194/Nestlé>,
        <https://1145.am/db/2563348/Nestlé_Sa>,
        <https://1145.am/db/2566415/Nestlé>,
        <https://1145.am/db/2567953/Nestlé>,
        <https://1145.am/db/2572568/Nestle_Sa>,
        <https://1145.am/db/2573611/Nestle>,
        <https://1145.am/db/2574332/Nestlé>,
        <https://1145.am/db/2576962/Nestle>,
        <https://1145.am/db/2579519/Nestle>,
        <https://1145.am/db/2582400/Nestlé>,
        <https://1145.am/db/2582402/Nestle>,
        <https://1145.am/db/2588438/Nestlé>,
        <https://1145.am/db/2590095/Nestle>,
        <https://1145.am/db/2591520/Nestle>,
        <https://1145.am/db/2591733/Nestle>,
        <https://1145.am/db/2594249/Nestle>,
        <https://1145.am/db/2596947/Nestle>,
        <https://1145.am/db/2597078/Nestle>,
        <https://1145.am/db/315049/Nestle>,
        <https://1145.am/db/315797/Nestle>,
        <https://1145.am/db/319737/Nestlé>,
        <https://1145.am/db/320746/Nestle>,
        <https://1145.am/db/544750/Nestle>,
        <https://1145.am/db/633223/Nestlé>,
        <https://1145.am/db/680407/Nestle>,
        <https://1145.am/db/681432/Nestle_Sa>,
        <https://1145.am/db/836550/Nestle> ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2582395/Novartis> a org:Organization ;
    ns1:basedInLowRaw "Switzerland" ;
    ns1:buyer <https://1145.am/db/2582395/Alcon_Stock_Ownership_Acquisition> ;
    ns1:description "Healthcare" ;
    ns1:documentDate "2010-08-26T11:50:28+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Novartis completes 77% majority ownership of Alcon adding new growth platform in eye care to its leading healthcare portfolio" ;
    ns1:documentURL <https://www.fiercepharma.com/pharma/novartis-completes-77-majority-ownership-of-alcon-adding-new-growth-platform-eye-care-to-its> ;
    ns1:foundName "Novartis" ;
    ns1:industry "Healthcare" ;
    ns1:investor <https://1145.am/db/2582395/Alcon_Stock_Ownership_Acquisition> ;
    ns1:name "Novartis" ;
    ns1:sameAsHigh <https://1145.am/db/1176158/Novartis>,
        <https://1145.am/db/1177562/Novartis>,
        <https://1145.am/db/131136/Novartis>,
        <https://1145.am/db/132002/Novartis>,
        <https://1145.am/db/1328753/Novartis>,
        <https://1145.am/db/1507918/Novartis_Ag>,
        <https://1145.am/db/156403/Novartis>,
        <https://1145.am/db/1567521/Novartis>,
        <https://1145.am/db/1578114/Novartis>,
        <https://1145.am/db/1628428/Novalgen_Ltd>,
        <https://1145.am/db/1629605/Novartis>,
        <https://1145.am/db/1629663/Novartis>,
        <https://1145.am/db/165056/Novartis>,
        <https://1145.am/db/176334/Novartis>,
        <https://1145.am/db/177096/Novartis>,
        <https://1145.am/db/1986468/Novabay®_Pharmaceuticals_Inc>,
        <https://1145.am/db/2033677/Novartis>,
        <https://1145.am/db/2062728/Novan>,
        <https://1145.am/db/2107835/Novartis>,
        <https://1145.am/db/2129754/Novartis>,
        <https://1145.am/db/2152605/Novartis>,
        <https://1145.am/db/2152618/Novartis>,
        <https://1145.am/db/2153059/Novartis>,
        <https://1145.am/db/2154527/Novartis>,
        <https://1145.am/db/2155069/Novartis>,
        <https://1145.am/db/2155665/Novartis>,
        <https://1145.am/db/2190363/Novartis_Ag>,
        <https://1145.am/db/2194161/Novartis>,
        <https://1145.am/db/2279108/Novartis>,
        <https://1145.am/db/2279232/Novartis>,
        <https://1145.am/db/2279829/Novartis>,
        <https://1145.am/db/2280153/Novartis>,
        <https://1145.am/db/2280350/Novartis>,
        <https://1145.am/db/2283590/Novartis>,
        <https://1145.am/db/2283645/Novartis>,
        <https://1145.am/db/2285311/Novartis>,
        <https://1145.am/db/2286604/Novartis>,
        <https://1145.am/db/2288851/Novartis>,
        <https://1145.am/db/2289846/Novartis>,
        <https://1145.am/db/2290022/Novartis>,
        <https://1145.am/db/2293323/Novartis>,
        <https://1145.am/db/2293342/Novartis>,
        <https://1145.am/db/2293591/Novartis>,
        <https://1145.am/db/2294026/Novartis>,
        <https://1145.am/db/2294585/Novartis>,
        <https://1145.am/db/2296504/Novartis>,
        <https://1145.am/db/2296552/Novartis>,
        <https://1145.am/db/2298606/Novartis>,
        <https://1145.am/db/2301066/Novartis>,
        <https://1145.am/db/2301089/Novartis>,
        <https://1145.am/db/2301705/Novasep>,
        <https://1145.am/db/2301735/Novartis>,
        <https://1145.am/db/2301857/Novartis>,
        <https://1145.am/db/2302724/Novartis>,
        <https://1145.am/db/2302727/Novartis>,
        <https://1145.am/db/2303121/Novartis_Bioventures>,
        <https://1145.am/db/230344/Swiss_Drugmaker_Novartis>,
        <https://1145.am/db/2304113/Novartis>,
        <https://1145.am/db/2304373/Novartis>,
        <https://1145.am/db/2304374/Novartis>,
        <https://1145.am/db/2305192/Novartis>,
        <https://1145.am/db/2305244/Novabay_Pharmaceuticals>,
        <https://1145.am/db/2307228/Novadel_Pharma_Inc>,
        <https://1145.am/db/2307347/Novartis>,
        <https://1145.am/db/2307847/Novartis>,
        <https://1145.am/db/2307863/Novartis>,
        <https://1145.am/db/2307998/Novartis>,
        <https://1145.am/db/2308010/Novartis>,
        <https://1145.am/db/2308298/Novartis>,
        <https://1145.am/db/2308765/Novartis>,
        <https://1145.am/db/2308812/Novartis>,
        <https://1145.am/db/2308946/Novartis_Ag>,
        <https://1145.am/db/2309065/Novartis_Intercell>,
        <https://1145.am/db/2310150/Novartis>,
        <https://1145.am/db/2312008/Novartis>,
        <https://1145.am/db/2312018/Novartis_International_Ag>,
        <https://1145.am/db/2312088/Novabay_Pharmaceuticals>,
        <https://1145.am/db/2312436/Novartis>,
        <https://1145.am/db/2317845/Novadel>,
        <https://1145.am/db/2317949/Novalar_Pharmaceuticals>,
        <https://1145.am/db/2317951/Novalar_Pharmaceuticals>,
        <https://1145.am/db/2318994/Novadel>,
        <https://1145.am/db/2319412/Novartis>,
        <https://1145.am/db/2320828/Novartis>,
        <https://1145.am/db/2321067/Novartis>,
        <https://1145.am/db/2322266/Novartis>,
        <https://1145.am/db/2323188/Novartis>,
        <https://1145.am/db/2323692/Novabay_Pharmaceuticals>,
        <https://1145.am/db/2324255/Novartis_Bioventures>,
        <https://1145.am/db/2325073/Novartis>,
        <https://1145.am/db/2325869/Novartis>,
        <https://1145.am/db/2326949/Novartis>,
        <https://1145.am/db/2327560/Novartis>,
        <https://1145.am/db/2329413/Novadel_Pharma_Inc>,
        <https://1145.am/db/2329475/Novadel_Pharma>,
        <https://1145.am/db/2329597/Novartis>,
        <https://1145.am/db/2330648/Novartis>,
        <https://1145.am/db/2331875/Novadel>,
        <https://1145.am/db/2332005/Novartis>,
        <https://1145.am/db/2332788/Novartis_Ag>,
        <https://1145.am/db/2332796/Novadel_Pharma_Inc>,
        <https://1145.am/db/2332872/Novartis>,
        <https://1145.am/db/2334206/Novartis>,
        <https://1145.am/db/2334645/Novast>,
        <https://1145.am/db/2336028/Novartis>,
        <https://1145.am/db/2336704/Novartis>,
        <https://1145.am/db/2339656/Novartis>,
        <https://1145.am/db/2339669/Novartis>,
        <https://1145.am/db/2340615/Novartis>,
        <https://1145.am/db/2340948/Novartis>,
        <https://1145.am/db/2344017/Novartis>,
        <https://1145.am/db/2344434/Novartis>,
        <https://1145.am/db/2346576/Novadel_Pharma_Inc>,
        <https://1145.am/db/2346629/Novartis>,
        <https://1145.am/db/2348176/Novartis>,
        <https://1145.am/db/2349068/Novartis>,
        <https://1145.am/db/2352045/Novartis>,
        <https://1145.am/db/2352046/Novartis>,
        <https://1145.am/db/2354148/Novartis>,
        <https://1145.am/db/2358273/Novartis>,
        <https://1145.am/db/2358297/Novartis>,
        <https://1145.am/db/2359165/Novartis>,
        <https://1145.am/db/2359179/Novartis>,
        <https://1145.am/db/2359915/Novadel_Pharma_Inc>,
        <https://1145.am/db/2360526/Novartis>,
        <https://1145.am/db/2360633/Novartis>,
        <https://1145.am/db/2362448/Novadel_Pharma_Inc>,
        <https://1145.am/db/2363618/Novartis_Uk>,
        <https://1145.am/db/2367118/Novabay_Pharmaceuticals>,
        <https://1145.am/db/2367207/Novartis>,
        <https://1145.am/db/2367829/Novartis_International_Ag>,
        <https://1145.am/db/2367836/Novartis_International_Ag>,
        <https://1145.am/db/2367993/Novabay>,
        <https://1145.am/db/2368571/Novartis>,
        <https://1145.am/db/2368646/Novartis>,
        <https://1145.am/db/2368659/Novartis>,
        <https://1145.am/db/2369183/Novartis>,
        <https://1145.am/db/2369450/Novartis>,
        <https://1145.am/db/2369451/Novartis>,
        <https://1145.am/db/2369555/Swiss_Pharma_Giant_Novartis>,
        <https://1145.am/db/2369718/Novartis>,
        <https://1145.am/db/2370010/Novartis>,
        <https://1145.am/db/2370013/Novartis>,
        <https://1145.am/db/2370615/Novartis>,
        <https://1145.am/db/2370635/Novartis>,
        <https://1145.am/db/2371070/Novartis>,
        <https://1145.am/db/2371077/Novartis>,
        <https://1145.am/db/2371323/Novartis>,
        <https://1145.am/db/2371326/Novartis>,
        <https://1145.am/db/2434670/Novartis>,
        <https://1145.am/db/2536325/Novartis>,
        <https://1145.am/db/2536882/Novartis>,
        <https://1145.am/db/2536914/Novartis>,
        <https://1145.am/db/2537064/Novartis>,
        <https://1145.am/db/2537477/Novartis>,
        <https://1145.am/db/2537482/Novacea>,
        <https://1145.am/db/2538344/Novartis>,
        <https://1145.am/db/2538791/Novartis>,
        <https://1145.am/db/2539541/Novasep>,
        <https://1145.am/db/2539787/Novartis>,
        <https://1145.am/db/2539925/Novartis>,
        <https://1145.am/db/2540187/Novartis>,
        <https://1145.am/db/2541511/Novartis>,
        <https://1145.am/db/2542938/Novartis>,
        <https://1145.am/db/2543689/Novartis>,
        <https://1145.am/db/2544236/Novartis>,
        <https://1145.am/db/2544326/Novartis>,
        <https://1145.am/db/2545284/Novartis>,
        <https://1145.am/db/2545651/Novartis>,
        <https://1145.am/db/2545966/Novartis>,
        <https://1145.am/db/2545986/Novartis>,
        <https://1145.am/db/2546157/Novartis>,
        <https://1145.am/db/2546170/Novartis>,
        <https://1145.am/db/2546603/Novartis>,
        <https://1145.am/db/2547397/Novartis>,
        <https://1145.am/db/2548223/Novartis>,
        <https://1145.am/db/2548224/Novartis_Group>,
        <https://1145.am/db/2549043/Novartis>,
        <https://1145.am/db/2549631/Novast>,
        <https://1145.am/db/2550855/Novartis>,
        <https://1145.am/db/2551143/Novartis>,
        <https://1145.am/db/2551693/Novartis>,
        <https://1145.am/db/2551694/Novartis>,
        <https://1145.am/db/2552165/Novartis>,
        <https://1145.am/db/2552258/Novartis>,
        <https://1145.am/db/2553024/Novartis>,
        <https://1145.am/db/2553276/Novartis>,
        <https://1145.am/db/2553480/Novartis>,
        <https://1145.am/db/2553487/Novartis>,
        <https://1145.am/db/2553740/Novasep>,
        <https://1145.am/db/2553810/Novartis>,
        <https://1145.am/db/2553846/Novartis>,
        <https://1145.am/db/2554060/Novartis>,
        <https://1145.am/db/2554669/Novasep>,
        <https://1145.am/db/2555555/Novartis>,
        <https://1145.am/db/2555561/Novartis>,
        <https://1145.am/db/2556030/Novartis>,
        <https://1145.am/db/2556543/Novartis>,
        <https://1145.am/db/2557588/Novartis>,
        <https://1145.am/db/2558316/Novartis>,
        <https://1145.am/db/2558415/Novartis>,
        <https://1145.am/db/2558779/Novartis>,
        <https://1145.am/db/2558927/Novartis>,
        <https://1145.am/db/2559306/Novartis>,
        <https://1145.am/db/2559655/Novartis>,
        <https://1145.am/db/2559797/Novartis>,
        <https://1145.am/db/2559802/Novartis>,
        <https://1145.am/db/2559810/Switzerlands_Novartis>,
        <https://1145.am/db/2560023/Novartis>,
        <https://1145.am/db/2560079/Novartis>,
        <https://1145.am/db/2561162/Novasep>,
        <https://1145.am/db/2561268/Novartis>,
        <https://1145.am/db/2561541/Novartis>,
        <https://1145.am/db/2561955/Novartis>,
        <https://1145.am/db/2562202/Novartis>,
        <https://1145.am/db/2562695/Novartis>,
        <https://1145.am/db/2562951/Novartis>,
        <https://1145.am/db/2563497/Novartis>,
        <https://1145.am/db/2563987/Novartis>,
        <https://1145.am/db/2564141/Novartis>,
        <https://1145.am/db/2564268/Novartis>,
        <https://1145.am/db/2564695/Novartis>,
        <https://1145.am/db/2565142/Novartis>,
        <https://1145.am/db/2565794/Novartis>,
        <https://1145.am/db/2565844/Novartis>,
        <https://1145.am/db/2567283/Novartis>,
        <https://1145.am/db/2567300/Novartis>,
        <https://1145.am/db/2567942/Novartis>,
        <https://1145.am/db/2568308/Novartis>,
        <https://1145.am/db/2568932/Novartis>,
        <https://1145.am/db/2568968/Novartis>,
        <https://1145.am/db/2568973/Novartis>,
        <https://1145.am/db/2570214/Novartis>,
        <https://1145.am/db/2570791/Novartis>,
        <https://1145.am/db/2570932/Novartis>,
        <https://1145.am/db/2570937/Novartis_Uk>,
        <https://1145.am/db/2571513/Novartis>,
        <https://1145.am/db/2571519/Novartis>,
        <https://1145.am/db/2571527/Novartis>,
        <https://1145.am/db/2572713/Novartis>,
        <https://1145.am/db/2572904/Novartis_Group>,
        <https://1145.am/db/2572985/Novartis>,
        <https://1145.am/db/2573002/Novartis>,
        <https://1145.am/db/2573473/Novartis>,
        <https://1145.am/db/2573517/Novartis>,
        <https://1145.am/db/2573611/Novartis>,
        <https://1145.am/db/2574958/Novartis>,
        <https://1145.am/db/2575047/Novartis>,
        <https://1145.am/db/2575310/Novartis>,
        <https://1145.am/db/2575313/Novartis>,
        <https://1145.am/db/2575488/Novartis>,
        <https://1145.am/db/2575545/Novartis>,
        <https://1145.am/db/2575625/Novartis>,
        <https://1145.am/db/2575702/Novartis>,
        <https://1145.am/db/2575712/Novartis>,
        <https://1145.am/db/2575810/Novartis_Ag>,
        <https://1145.am/db/2575813/Novartis>,
        <https://1145.am/db/2576242/Novartis>,
        <https://1145.am/db/2576254/Novartis>,
        <https://1145.am/db/2576547/Novartis>,
        <https://1145.am/db/2576933/Novartis>,
        <https://1145.am/db/2577129/Novartis>,
        <https://1145.am/db/2577419/Novartis>,
        <https://1145.am/db/2577998/Novartis>,
        <https://1145.am/db/2579507/Novartis>,
        <https://1145.am/db/2579519/Novartis>,
        <https://1145.am/db/2580047/Novartis>,
        <https://1145.am/db/2580401/Novartis>,
        <https://1145.am/db/2580963/Novartis>,
        <https://1145.am/db/2581378/Novartis>,
        <https://1145.am/db/2581394/Novartis>,
        <https://1145.am/db/2581397/Novartis>,
        <https://1145.am/db/2581493/Novartis>,
        <https://1145.am/db/2581716/Novartis>,
        <https://1145.am/db/2582355/Novartis>,
        <https://1145.am/db/2582400/Novartis>,
        <https://1145.am/db/2582402/Novartis>,
        <https://1145.am/db/2582623/Novartis>,
        <https://1145.am/db/2582643/Novartis>,
        <https://1145.am/db/2583067/Novartis>,
        <https://1145.am/db/2584538/Novartis>,
        <https://1145.am/db/2585039/Novartis>,
        <https://1145.am/db/2585121/Novartis>,
        <https://1145.am/db/2586661/Novatis>,
        <https://1145.am/db/2586670/Novartis>,
        <https://1145.am/db/2587047/Novartis>,
        <https://1145.am/db/2587857/Novartis>,
        <https://1145.am/db/2588196/Novartis>,
        <https://1145.am/db/2589178/Novartis>,
        <https://1145.am/db/2589535/Novartis>,
        <https://1145.am/db/2591905/Novartis>,
        <https://1145.am/db/2592351/Novartis>,
        <https://1145.am/db/2592505/Novartis>,
        <https://1145.am/db/2592895/Novartis>,
        <https://1145.am/db/2592987/Novartis>,
        <https://1145.am/db/2593443/Novartis>,
        <https://1145.am/db/2594494/Novartis>,
        <https://1145.am/db/2594935/Novartis>,
        <https://1145.am/db/2594940/Novartis>,
        <https://1145.am/db/2595048/Novartis>,
        <https://1145.am/db/2595150/Novartis>,
        <https://1145.am/db/2595688/Novartis>,
        <https://1145.am/db/2596344/Novartis>,
        <https://1145.am/db/2597197/Novamed_Pharmaceuticals>,
        <https://1145.am/db/2598636/Novartis>,
        <https://1145.am/db/2787530/Novartis>,
        <https://1145.am/db/282192/Novartis>,
        <https://1145.am/db/346162/Novartis>,
        <https://1145.am/db/488391/Novartis>,
        <https://1145.am/db/509708/Novabay®_Pharmaceuticals_Inc>,
        <https://1145.am/db/595011/Novartis>,
        <https://1145.am/db/601300/Novabay®_Pharmaceuticals_Inc>,
        <https://1145.am/db/637582/Novartis>,
        <https://1145.am/db/652831/Novartis>,
        <https://1145.am/db/661296/Novartis>,
        <https://1145.am/db/691279/Novartis>,
        <https://1145.am/db/712016/Novartis>,
        <https://1145.am/db/895235/Novan> ;
    ns1:sameAsMedium <https://1145.am/db/1151476/Novartis>,
        <https://1145.am/db/1629127/Novartis>,
        <https://1145.am/db/1630421/Novartis>,
        <https://1145.am/db/2033933/Novartis>,
        <https://1145.am/db/2036487/Novartis_Ag>,
        <https://1145.am/db/2065993/Novartis_Ag>,
        <https://1145.am/db/2076347/Novartis>,
        <https://1145.am/db/2155042/Novartis>,
        <https://1145.am/db/2186148/Novartis>,
        <https://1145.am/db/2290898/Novartis>,
        <https://1145.am/db/2291090/Novartis>,
        <https://1145.am/db/2291713/Novartis>,
        <https://1145.am/db/2293419/Novartis>,
        <https://1145.am/db/2294680/Novartis>,
        <https://1145.am/db/2299847/Novartis>,
        <https://1145.am/db/2307851/Novartis>,
        <https://1145.am/db/2309347/Novartis>,
        <https://1145.am/db/2321958/Novartis>,
        <https://1145.am/db/2325386/Novartis>,
        <https://1145.am/db/2332408/Novartis>,
        <https://1145.am/db/2333390/Novartis>,
        <https://1145.am/db/2336990/Novartis>,
        <https://1145.am/db/2337976/Novartis>,
        <https://1145.am/db/2342687/Novartis>,
        <https://1145.am/db/2343460/Novartis>,
        <https://1145.am/db/2352178/Novartis>,
        <https://1145.am/db/2358559/Novartis>,
        <https://1145.am/db/2358579/Novartis>,
        <https://1145.am/db/2361451/Novartis>,
        <https://1145.am/db/2369178/Novartis>,
        <https://1145.am/db/2371165/Novartis>,
        <https://1145.am/db/2371188/Novartis>,
        <https://1145.am/db/2371203/Novartis>,
        <https://1145.am/db/2536538/Novartis>,
        <https://1145.am/db/2537155/Novartis>,
        <https://1145.am/db/2544350/Novartis>,
        <https://1145.am/db/2544409/Novartis>,
        <https://1145.am/db/2550764/Novartis>,
        <https://1145.am/db/2551001/Novartis>,
        <https://1145.am/db/2551402/Novartis>,
        <https://1145.am/db/2552856/Novartis>,
        <https://1145.am/db/2557204/Novartis>,
        <https://1145.am/db/2560238/Novartis>,
        <https://1145.am/db/2562442/Novartis>,
        <https://1145.am/db/2565564/Novartis>,
        <https://1145.am/db/2566121/Novartis>,
        <https://1145.am/db/2568734/Novartis>,
        <https://1145.am/db/2569724/Novartis>,
        <https://1145.am/db/2570062/Novartis>,
        <https://1145.am/db/2570721/Novartis>,
        <https://1145.am/db/2571462/Novartis>,
        <https://1145.am/db/2573984/Novartis>,
        <https://1145.am/db/2574584/Novartis>,
        <https://1145.am/db/2574950/Novartis>,
        <https://1145.am/db/2575947/Novartis>,
        <https://1145.am/db/2576892/Novartis>,
        <https://1145.am/db/2578046/Novartis>,
        <https://1145.am/db/2579890/Novartis>,
        <https://1145.am/db/2581804/Novartis>,
        <https://1145.am/db/2582646/Novartis>,
        <https://1145.am/db/2583163/Novartis>,
        <https://1145.am/db/2584135/Novartis>,
        <https://1145.am/db/2584245/Novartis>,
        <https://1145.am/db/2587048/Novartis>,
        <https://1145.am/db/2587805/Novartis>,
        <https://1145.am/db/2588333/Novartis>,
        <https://1145.am/db/2588691/Novartis>,
        <https://1145.am/db/2589799/Novartis>,
        <https://1145.am/db/2590887/Novartis>,
        <https://1145.am/db/2593780/Novartis>,
        <https://1145.am/db/2595924/Novartis_Ag>,
        <https://1145.am/db/619955/Novartis>,
        <https://1145.am/db/623985/Novartis> ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2608966/Abry_Partners> a org:Organization ;
    ns1:buyer <https://1145.am/db/2608966/Rcn_Acquisition> ;
    ns1:documentDate "2010-08-31T14:42:45+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Ridgemont Equity Partners buys big piece of United Private Networks" ;
    ns1:documentURL <https://www.fiercetelecom.com/telecom/ridgemont-equity-partners-buys-big-piece-united-private-networks> ;
    ns1:foundName "ABRY Partners",
        "Abry" ;
    ns1:investor <https://1145.am/db/2608966/Rcn_Acquisition> ;
    ns1:name "ABRY Partners",
        "Abry" ;
    ns1:sameAsMedium <https://1145.am/db/1008666/Abry_Partners>,
        <https://1145.am/db/1023105/Abry_Partners>,
        <https://1145.am/db/1023959/Abry_Partners>,
        <https://1145.am/db/1085084/Abry_Partners>,
        <https://1145.am/db/1411722/Abry_Partners>,
        <https://1145.am/db/1412233/Abry_Partners>,
        <https://1145.am/db/1588064/Abry_Partners>,
        <https://1145.am/db/2017219/Abry_Partners>,
        <https://1145.am/db/2159047/Abry_Partners>,
        <https://1145.am/db/2171577/Abry_Partners>,
        <https://1145.am/db/2598932/Abry_Partners>,
        <https://1145.am/db/2599554/Abry_Partners>,
        <https://1145.am/db/2599816/Abry_Partners>,
        <https://1145.am/db/2603541/Abry_Partners>,
        <https://1145.am/db/2605285/Abry_Partners>,
        <https://1145.am/db/2608284/Abry_Partners>,
        <https://1145.am/db/2608962/Abry_Partners>,
        <https://1145.am/db/2610482/Abry_Partners>,
        <https://1145.am/db/2614178/Abry_Partners>,
        <https://1145.am/db/2615297/Abry_Partners>,
        <https://1145.am/db/2615628/Abry_Partners>,
        <https://1145.am/db/2618622/Abry_Partners>,
        <https://1145.am/db/295281/Abry_Partners>,
        <https://1145.am/db/832/Abry_Partners> ;
    ns1:sourceName "Fierce Telecom" .

<https://1145.am/db/2608966/Fibertech> a org:Organization ;
    ns1:description "regional fiber service provider" ;
    ns1:documentDate "2010-08-31T14:42:45+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Ridgemont Equity Partners buys big piece of United Private Networks" ;
    ns1:documentURL <https://www.fiercetelecom.com/telecom/ridgemont-equity-partners-buys-big-piece-united-private-networks> ;
    ns1:foundName "Fibertech" ;
    ns1:name "Fibertech" ;
    ns1:sameAsHigh <https://1145.am/db/2618315/Network_Usa> ;
    ns1:sameAsMedium <https://1145.am/db/2600044/Fibertech>,
        <https://1145.am/db/2608946/Fibertech>,
        <https://1145.am/db/2615628/Fibertech>,
        <https://1145.am/db/2616286/Fibertech>,
        <https://1145.am/db/2616291/Fibertech>,
        <https://1145.am/db/2616294/Fibertech> ;
    ns1:sourceName "Fierce Telecom" .

<https://1145.am/db/2608966/RCN> a org:Organization ;
    ns1:documentDate "2010-08-31T14:42:45+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Ridgemont Equity Partners buys big piece of United Private Networks" ;
    ns1:documentURL <https://www.fiercetelecom.com/telecom/ridgemont-equity-partners-buys-big-piece-united-private-networks> ;
    ns1:foundName "RCN" ;
    ns1:name "RCN" ;
    ns1:sameAsMedium <https://1145.am/db/2159047/RCN>,
        <https://1145.am/db/2171577/RCN>,
        <https://1145.am/db/2599816/RCN>,
        <https://1145.am/db/2615628/Rcn_Corp>,
        <https://1145.am/db/2616784/RCN>,
        <https://1145.am/db/622344/RCN>,
        <https://1145.am/db/866856/RCN> ;
    ns1:sourceName "Fierce Telecom" .

<https://1145.am/db/2608966/Rcn_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition",
        "investment" ;
    ns1:documentDate "2010-08-31T14:42:45+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Abry partners to acquire RCN for $ 1.2 billion.",
        "Over the past week, ABRY Partners completed its acquisition of RCN, while Court Square bought up regional fiber service provider Fibertech." ;
    ns1:documentTitle "Ridgemont Equity Partners buys big piece of United Private Networks" ;
    ns1:documentURL <https://www.fiercetelecom.com/telecom/ridgemont-equity-partners-buys-big-piece-united-private-networks> ;
    ns1:foundName "acquire",
        "acquisition" ;
    ns1:name "acquire",
        "acquisition" ;
    ns1:sourceName "Fierce Telecom" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2608966/RCN> ;
    ns1:targetName "RCN" ;
    ns1:valueRaw "$ 1.2 billion" .

<https://1145.am/db/2610482/Abry_Partners> a org:Organization ;
    ns1:basedInLowRaw "New York" ;
    ns1:documentDate "2010-09-27T13:40:32+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Iran accuses West of unleashing computer worm; U.S. law enforcement wants Internet regulatory change" ;
    ns1:documentURL <https://www.fiercetelecom.com/telecom/iran-accuses-west-unleashing-computer-worm-u-s-law-enforcement-wants-internet-regulatory> ;
    ns1:foundName "ABRY Partners" ;
    ns1:investor <https://1145.am/db/2610482/Juma_Technology_Acquisition>,
        <https://1145.am/db/2610482/Peter_Aquino_Investment> ;
    ns1:name "ABRY Partners" ;
    ns1:sameAsMedium <https://1145.am/db/1008666/Abry_Partners>,
        <https://1145.am/db/1023105/Abry_Partners>,
        <https://1145.am/db/1023959/Abry_Partners>,
        <https://1145.am/db/1085084/Abry_Partners>,
        <https://1145.am/db/1411722/Abry_Partners>,
        <https://1145.am/db/1412233/Abry_Partners>,
        <https://1145.am/db/1588064/Abry_Partners>,
        <https://1145.am/db/2017219/Abry_Partners>,
        <https://1145.am/db/2159047/Abry_Partners>,
        <https://1145.am/db/2171577/Abry_Partners>,
        <https://1145.am/db/2598932/Abry_Partners>,
        <https://1145.am/db/2599554/Abry_Partners>,
        <https://1145.am/db/2599816/Abry_Partners>,
        <https://1145.am/db/2603541/Abry_Partners>,
        <https://1145.am/db/2605285/Abry_Partners>,
        <https://1145.am/db/2608284/Abry_Partners>,
        <https://1145.am/db/2608962/Abry_Partners>,
        <https://1145.am/db/2608966/Abry_Partners>,
        <https://1145.am/db/2614178/Abry_Partners>,
        <https://1145.am/db/2615297/Abry_Partners>,
        <https://1145.am/db/2615628/Abry_Partners>,
        <https://1145.am/db/2618622/Abry_Partners>,
        <https://1145.am/db/295281/Abry_Partners>,
        <https://1145.am/db/832/Abry_Partners> ;
    ns1:sourceName "Fierce Telecom" .

<https://1145.am/db/2610482/Juma_Technology_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition",
        "investment" ;
    ns1:documentDate "2010-09-27T13:40:32+00:00"^^xsd:dateTime ;
    ns1:documentExtract "> Value added solutions (VAS) provider ConvergeOne will purchase Juma Technology (OTC BB: JUMT) , a New York - based telecommunications and IT systems integrator." ;
    ns1:documentTitle "Iran accuses West of unleashing computer worm; U.S. law enforcement wants Internet regulatory change" ;
    ns1:documentURL <https://www.fiercetelecom.com/telecom/iran-accuses-west-unleashing-computer-worm-u-s-law-enforcement-wants-internet-regulatory> ;
    ns1:foundName "acquisition",
        "purchase" ;
    ns1:name "acquisition",
        "purchase" ;
    ns1:sourceName "Fierce Telecom" ;
    ns1:status "has not happened" ;
    ns1:target <https://1145.am/db/2610482/Juma_Technology> ;
    ns1:targetName "Juma Technology" ;
    ns1:whereGeoName "New York City" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5128581/about.rdf> ;
    ns1:whereRaw "New York" .

<https://1145.am/db/2614889/One_Communications> a org:Organization ;
    ns1:basedInLowRaw "United States" ;
    ns1:description "and see the story." ;
    ns1:documentDate "2010-12-09T15:41:28+00:00"^^xsd:dateTime ;
    ns1:documentTitle "EarthLink wraps up ITC^Deltacom acquisition" ;
    ns1:documentURL <https://www.fiercetelecom.com/telecom/earthlink-wraps-up-itc-deltacom-acquisition> ;
    ns1:foundName "One Communications" ;
    ns1:name "One Communications" ;
    ns1:sameAsMedium <https://1145.am/db/1730294/One_Communications>,
        <https://1145.am/db/2169661/One_Communications>,
        <https://1145.am/db/2600844/One_Communications>,
        <https://1145.am/db/2603731/One_Communications>,
        <https://1145.am/db/2606667/One_Communications>,
        <https://1145.am/db/2608212/One_Communications>,
        <https://1145.am/db/2609709/One_Communications>,
        <https://1145.am/db/2614189/One_Communications>,
        <https://1145.am/db/2614880/One_Communications>,
        <https://1145.am/db/2614893/One_Communications>,
        <https://1145.am/db/2615617/One_Communications> ;
    ns1:sourceName "Fierce Telecom" .

<https://1145.am/db/2614889/One_Communications_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition",
        "merger" ;
    ns1:documentDate "2010-12-09T15:41:28+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Earthlink, Paetec rumored to make bids on One Communications.",
        "Yesterday, rumors emerged that EarthLink and CLEC Paetec were going to make a bid on One Communications, but nothing has officially been announced as of yet." ;
    ns1:documentTitle "EarthLink wraps up ITC^Deltacom acquisition" ;
    ns1:documentURL <https://www.fiercetelecom.com/telecom/earthlink-wraps-up-itc-deltacom-acquisition> ;
    ns1:foundName "bid",
        "bids" ;
    ns1:name "bid",
        "bids" ;
    ns1:sourceName "Fierce Telecom" ;
    ns1:status "unknown" ;
    ns1:target <https://1145.am/db/2614889/One_Communications> ;
    ns1:targetName "One Communications" ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "United States" .

<https://1145.am/db/2614902/Lexent_Metro_Connect> a org:Organization ;
    ns1:basedInLowRaw "United States" ;
    ns1:documentDate "2010-12-13T15:33:12+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Lightower acquires Open Access, increases Long Island fiber footprint" ;
    ns1:documentURL <https://www.fiercetelecom.com/telecom/lightower-acquires-open-access-increases-long-island-fiber-footprint> ;
    ns1:foundName "Lexent",
        "Lexent Metro Connect" ;
    ns1:name "Lexent",
        "Lexent Metro Connect" ;
    ns1:sameAsMedium <https://1145.am/db/2600842/Lexent_Metro_Connect>,
        <https://1145.am/db/2614179/Lexent_Metro_Connect>,
        <https://1145.am/db/2615618/Lexent_Metro_Connect> ;
    ns1:sourceName "Fierce Telecom" .

<https://1145.am/db/2614902/Open_Access> a org:Organization ;
    ns1:basedInHighGeoName "Farmingdale" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5116931/about.rdf> ;
    ns1:basedInHighRaw "Farmingdale, N.Y." ;
    ns1:description "providing network services to area businesses" ;
    ns1:documentDate "2010-12-13T15:33:12+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Lightower acquires Open Access, increases Long Island fiber footprint" ;
    ns1:documentURL <https://www.fiercetelecom.com/telecom/lightower-acquires-open-access-increases-long-island-fiber-footprint> ;
    ns1:foundName "Open Access Inc" ;
    ns1:name "Open Access" ;
    ns1:sameAsMedium <https://1145.am/db/2600842/Open_Access_Inc>,
        <https://1145.am/db/2607363/Open_Access>,
        <https://1145.am/db/2615618/Open_Access> ;
    ns1:sourceName "Fierce Telecom" .

<https://1145.am/db/2615618/Lexent_Metro_Connect> a org:Organization ;
    ns1:basedInLowRaw "United States" ;
    ns1:documentDate "2010-12-20T15:40:15+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Lightower secures $230 million credit from GE Capital" ;
    ns1:documentURL <https://www.fiercetelecom.com/telecom/lightower-secures-230-million-credit-from-ge-capital> ;
    ns1:foundName "Lexent",
        "Lexent Metro Connect" ;
    ns1:name "Lexent",
        "Lexent Metro Connect" ;
    ns1:sameAsMedium <https://1145.am/db/2600842/Lexent_Metro_Connect>,
        <https://1145.am/db/2614179/Lexent_Metro_Connect>,
        <https://1145.am/db/2614902/Lexent_Metro_Connect> ;
    ns1:sourceName "Fierce Telecom" .

<https://1145.am/db/2615618/Open_Access> a org:Organization ;
    ns1:basedInHighGeoName "Long Island" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/3572005/about.rdf> ;
    ns1:basedInHighRaw "Long Island." ;
    ns1:documentDate "2010-12-20T15:40:15+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Lightower secures $230 million credit from GE Capital" ;
    ns1:documentURL <https://www.fiercetelecom.com/telecom/lightower-secures-230-million-credit-from-ge-capital> ;
    ns1:foundName "Open Access" ;
    ns1:name "Open Access" ;
    ns1:sameAsMedium <https://1145.am/db/2600842/Open_Access_Inc>,
        <https://1145.am/db/2607363/Open_Access>,
        <https://1145.am/db/2614902/Open_Access> ;
    ns1:sourceName "Fierce Telecom" .

<https://1145.am/db/2615628/Abry_Partners> a org:Organization ;
    ns1:buyer <https://1145.am/db/2615628/Rcn_Corp_Acquisition> ;
    ns1:documentDate "2010-12-22T04:14:18+00:00"^^xsd:dateTime ;
    ns1:documentTitle "DukeNet becomes joint venture of Duke Energy and Alinda Capital" ;
    ns1:documentURL <https://www.fiercetelecom.com/telecom/dukenet-becomes-joint-venture-duke-energy-and-alinda-capital> ;
    ns1:foundName "ABRY Partners" ;
    ns1:industry "investment companies" ;
    ns1:name "ABRY Partners" ;
    ns1:sameAsMedium <https://1145.am/db/1008666/Abry_Partners>,
        <https://1145.am/db/1023105/Abry_Partners>,
        <https://1145.am/db/1023959/Abry_Partners>,
        <https://1145.am/db/1085084/Abry_Partners>,
        <https://1145.am/db/1411722/Abry_Partners>,
        <https://1145.am/db/1412233/Abry_Partners>,
        <https://1145.am/db/1588064/Abry_Partners>,
        <https://1145.am/db/2017219/Abry_Partners>,
        <https://1145.am/db/2159047/Abry_Partners>,
        <https://1145.am/db/2171577/Abry_Partners>,
        <https://1145.am/db/2598932/Abry_Partners>,
        <https://1145.am/db/2599554/Abry_Partners>,
        <https://1145.am/db/2599816/Abry_Partners>,
        <https://1145.am/db/2603541/Abry_Partners>,
        <https://1145.am/db/2605285/Abry_Partners>,
        <https://1145.am/db/2608284/Abry_Partners>,
        <https://1145.am/db/2608962/Abry_Partners>,
        <https://1145.am/db/2608966/Abry_Partners>,
        <https://1145.am/db/2610482/Abry_Partners>,
        <https://1145.am/db/2614178/Abry_Partners>,
        <https://1145.am/db/2615297/Abry_Partners>,
        <https://1145.am/db/2618622/Abry_Partners>,
        <https://1145.am/db/295281/Abry_Partners>,
        <https://1145.am/db/832/Abry_Partners> ;
    ns1:sourceName "Fierce Telecom" .

<https://1145.am/db/2615628/Fibertech> a org:Organization ;
    ns1:description "- see the release" ;
    ns1:documentDate "2010-12-22T04:14:18+00:00"^^xsd:dateTime ;
    ns1:documentTitle "DukeNet becomes joint venture of Duke Energy and Alinda Capital" ;
    ns1:documentURL <https://www.fiercetelecom.com/telecom/dukenet-becomes-joint-venture-duke-energy-and-alinda-capital> ;
    ns1:foundName "Fibertech" ;
    ns1:name "Fibertech" ;
    ns1:sameAsMedium <https://1145.am/db/2600044/Fibertech>,
        <https://1145.am/db/2608946/Fibertech>,
        <https://1145.am/db/2608966/Fibertech>,
        <https://1145.am/db/2616286/Fibertech>,
        <https://1145.am/db/2616291/Fibertech>,
        <https://1145.am/db/2616294/Fibertech> ;
    ns1:sourceName "Fierce Telecom" .

<https://1145.am/db/2615628/Fibertech_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition",
        "investment" ;
    ns1:documentDate "2010-12-22T04:14:18+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Alinda's purchase of a large stake in DukeNet seems to be representative of a larger trend of investment companies either acquiring a company whole or acquiring a major stake.",
        "Fibertech sold to Court Square for $ 500 million." ;
    ns1:documentTitle "DukeNet becomes joint venture of Duke Energy and Alinda Capital" ;
    ns1:documentURL <https://www.fiercetelecom.com/telecom/dukenet-becomes-joint-venture-duke-energy-and-alinda-capital> ;
    ns1:foundName "purchase" ;
    ns1:name "purchase" ;
    ns1:sourceName "Fierce Telecom" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2615628/Fibertech> ;
    ns1:targetName "Fibertech" ;
    ns1:valueRaw "$ 500 million" .

<https://1145.am/db/2615628/Investment_Alinda_Capital_Partners_Dukenet_Communications_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition",
        "investment" ;
    ns1:documentDate "2010-12-22T04:14:18+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Alinda's purchase of a large stake in DukeNet seems to be representative of a larger trend of investment companies either acquiring a company whole or acquiring a major stake.",
        "DukeNet Communications gets cash infusion from Alinda Capital Partners." ;
    ns1:documentTitle "DukeNet becomes joint venture of Duke Energy and Alinda Capital" ;
    ns1:documentURL <https://www.fiercetelecom.com/telecom/dukenet-becomes-joint-venture-duke-energy-and-alinda-capital> ;
    ns1:foundName "purchase" ;
    ns1:name "purchase" ;
    ns1:sourceName "Fierce Telecom" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2615628/Dukenet_Communications> ;
    ns1:targetName "DukeNet" ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "United States" .

<https://1145.am/db/2615628/Rcn_Corp> a org:Organization ;
    ns1:description "investment" ;
    ns1:documentDate "2010-12-22T04:14:18+00:00"^^xsd:dateTime ;
    ns1:documentTitle "DukeNet becomes joint venture of Duke Energy and Alinda Capital" ;
    ns1:documentURL <https://www.fiercetelecom.com/telecom/dukenet-becomes-joint-venture-duke-energy-and-alinda-capital> ;
    ns1:foundName "RCN Corp." ;
    ns1:name "RCN Corp." ;
    ns1:sameAsHigh <https://1145.am/db/1599579/Abrdn_Plc>,
        <https://1145.am/db/2064619/Abrdn_Inc>,
        <https://1145.am/db/2695792/Aon_Bgn> ;
    ns1:sameAsMedium <https://1145.am/db/2159047/RCN>,
        <https://1145.am/db/2171577/RCN>,
        <https://1145.am/db/2599816/RCN>,
        <https://1145.am/db/2608966/RCN>,
        <https://1145.am/db/2616784/RCN>,
        <https://1145.am/db/622344/RCN>,
        <https://1145.am/db/866856/RCN> ;
    ns1:sourceName "Fierce Telecom" .

<https://1145.am/db/2615628/Rcn_Corp_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition" ;
    ns1:documentDate "2010-12-22T04:14:18+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Alinda's purchase of a large stake in DukeNet seems to be representative of a larger trend of investment companies either acquiring a company whole or acquiring a major stake." ;
    ns1:documentTitle "DukeNet becomes joint venture of Duke Energy and Alinda Capital" ;
    ns1:documentURL <https://www.fiercetelecom.com/telecom/dukenet-becomes-joint-venture-duke-energy-and-alinda-capital> ;
    ns1:foundName "purchase" ;
    ns1:name "purchase" ;
    ns1:sourceName "Fierce Telecom" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2615628/Rcn_Corp> ;
    ns1:targetName "RCN Corp." .

<https://1145.am/db/2208806/Venture_Capital_Investment_Halfpenny_Technologies_Lore_Associates_Milestone_Venture_Partners_Osage_Venture_Partners_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-10-07T17:00:04+00:00"^^xsd:dateTime ;
    ns1:documentExtract "BLUE BELL, Pa.- (BUSINESS WIRE) - Halfpenny Technologies, Inc., a leading provider of clinical data integration solutions specializing in laboratory, pathology and physician electronic medical record (EMR) system interoperability, today announced that it has secured $ 2.6 million in venture capital funding co - led by Pennsylvania - based Osage Venture Partners and New York - based Milestone Venture Partners." ;
    ns1:documentTitle "Halfpenny Technologies Secures $2.6 Million in Capital Investment" ;
    ns1:documentURL <https://www.fiercehealthcare.com/it/halfpenny-technologies-secures-2-6-million-capital-investment> ;
    ns1:foundName "funding" ;
    ns1:name "funding" ;
    ns1:sourceName "Fierce Healthcare" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2208806/Halfpenny_Technologies> ;
    ns1:targetDetails "venture capital" ;
    ns1:valueRaw "$ 2.6 million" ;
    ns1:whereGeoName "Pennsylvania" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6254927/about.rdf> ;
    ns1:whereRaw "Pennsylvania" .

<https://1145.am/db/2242173/Trinity_Health> a org:Organization ;
    ns1:basedInHighGeoName "Novi" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5004062/about.rdf> ;
    ns1:basedInHighRaw "Novi, Mich." ;
    ns1:documentDate "2010-12-15T17:57:28+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Merger will create new Michigan healthcare system" ;
    ns1:documentURL <https://www.fiercehealthcare.com/healthcare/merger-will-create-new-michigan-healthcare-system> ;
    ns1:foundName "Trinity Health of Novi, Mich." ;
    ns1:industry "health care" ;
    ns1:name "Trinity Health" ;
    ns1:sameAsHigh <https://1145.am/db/1232959/Trinity_Family_Health_Care_Center>,
        <https://1145.am/db/1233935/Trinity_Family_Health_Care_Center>,
        <https://1145.am/db/2181061/Trinity_Health>,
        <https://1145.am/db/2181544/Trinity_Health>,
        <https://1145.am/db/2183106/Trinity_Health>,
        <https://1145.am/db/2186408/Trinity_Health>,
        <https://1145.am/db/2188305/Trinity_Health>,
        <https://1145.am/db/2197301/Trinity_Health>,
        <https://1145.am/db/2197692/Trinity_Health>,
        <https://1145.am/db/2237578/Trinity_Medical_Center>,
        <https://1145.am/db/2250618/Trinity_Health>,
        <https://1145.am/db/2269309/Trinity_Health>,
        <https://1145.am/db/2273319/Trinity_Health> ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2242500/Venture_Capital_Investment_Halfpenny_Technologies_Lore_Associates_Milestone_Venture_Partners_Osage_Venture_Partners_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-10-07T17:02:42+00:00"^^xsd:dateTime ;
    ns1:documentExtract "BLUE BELL, Pa.- (BUSINESS WIRE) - Halfpenny Technologies, Inc., a leading provider of clinical data integration solutions specializing in laboratory, pathology and physician electronic medical record (EMR) system interoperability, today announced that it has secured $ 2.6 million in venture capital funding co - led by Pennsylvania - based Osage Venture Partners and New York - based Milestone Venture Partners." ;
    ns1:documentTitle "Halfpenny Technologies Secures $2.6 Million in Capital Investment" ;
    ns1:documentURL <https://www.fiercehealthcare.com/healthcare/halfpenny-technologies-secures-2-6-million-capital-investment> ;
    ns1:foundName "funding" ;
    ns1:name "funding" ;
    ns1:sourceName "Fierce Healthcare" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2242500/Halfpenny_Technologies> ;
    ns1:targetDetails "venture capital" ;
    ns1:valueRaw "$ 2.6 million" ;
    ns1:whereGeoName "Pennsylvania" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6254927/about.rdf> ;
    ns1:whereRaw "Pennsylvania" .

<https://1145.am/db/2343041/Dicerna_Pharmaceuticals> a org:Organization ;
    ns1:description "RNA interference" ;
    ns1:documentDate "2010-10-21T16:07:04+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Dicerna Pharmaceuticals Announces Second Close of Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/dicerna-pharmaceuticals-announces-second-close-of-series-b-financing> ;
    ns1:foundName "Dicerna Pharmaceuticals",
        "Dicerna Pharmaceuticals, Inc",
        "Dicerna Pharmaceuticals, Inc." ;
    ns1:industry "pharmaceuticals" ;
    ns1:name "Dicerna Pharmaceuticals" ;
    ns1:sameAsHigh <https://1145.am/db/1408389/Dice_Therapeutics_Inc>,
        <https://1145.am/db/1414280/Dice_Therapeutics_Inc>,
        <https://1145.am/db/1430935/Dice_Therapeutics_Inc>,
        <https://1145.am/db/2279495/Dicerna_Pharmaceuticals>,
        <https://1145.am/db/2308925/Dicerna_Pharmaceuticals>,
        <https://1145.am/db/2308931/Dicerna_Pharmaceuticals>,
        <https://1145.am/db/2319004/Dicerna_Pharmaceuticals>,
        <https://1145.am/db/2336621/Dicerna_Pharmaceuticals>,
        <https://1145.am/db/2342804/Dicerna_Pharmaceuticals>,
        <https://1145.am/db/2343058/Dicerna_Pharmaceuticals>,
        <https://1145.am/db/2348453/Dicerna_Pharmaceuticals>,
        <https://1145.am/db/2349741/Dicerna_Pharmaceuticals>,
        <https://1145.am/db/2349753/Dicerna_Pharmaceuticals>,
        <https://1145.am/db/2350964/Dicerna_Pharmaceuticals_Inc>,
        <https://1145.am/db/2353604/Dicerna_Pharmaceuticals_Inc>,
        <https://1145.am/db/2362491/Dicerna_Pharmaceuticals_Inc>,
        <https://1145.am/db/2566150/Dicerna_Pharma>,
        <https://1145.am/db/490489/Dicerna_Pharmaceuticals_Inc>,
        <https://1145.am/db/633908/Dicerna_Pharmaceuticals>,
        <https://1145.am/db/635744/Dicerna_Pharmaceuticals>,
        <https://1145.am/db/635895/Dicerna_Pharmaceuticals_Inc>,
        <https://1145.am/db/636407/Dicerna_Pharmaceuticals>,
        <https://1145.am/db/637582/Dicerna_Pharmaceuticals>,
        <https://1145.am/db/718330/Dicerna_Pharmaceuticals>,
        <https://1145.am/db/719216/Dicerna_Pharmaceuticals>,
        <https://1145.am/db/721891/Dicerna_Pharmaceuticals_Inc>,
        <https://1145.am/db/722559/Dicerna_Pharmaceuticals_Inc>,
        <https://1145.am/db/940792/Dice_Therapeutics> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2343058/Dicerna_Pharmaceuticals> a org:Organization ;
    ns1:description "RNA interference" ;
    ns1:documentDate "2010-10-22T14:11:46+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Dicerna Pharmaceuticals Announces Second Close of Series B Financing; Securing Additional $4 Million" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/dicerna-pharmaceuticals-announces-second-close-of-series-b-financing-securing-additional-4> ;
    ns1:foundName "Dicerna Pharmaceuticals",
        "Dicerna Pharmaceuticals, Inc" ;
    ns1:industry "pharmaceuticals" ;
    ns1:name "Dicerna Pharmaceuticals" ;
    ns1:sameAsHigh <https://1145.am/db/1408389/Dice_Therapeutics_Inc>,
        <https://1145.am/db/1414280/Dice_Therapeutics_Inc>,
        <https://1145.am/db/1430935/Dice_Therapeutics_Inc>,
        <https://1145.am/db/2279495/Dicerna_Pharmaceuticals>,
        <https://1145.am/db/2308925/Dicerna_Pharmaceuticals>,
        <https://1145.am/db/2308931/Dicerna_Pharmaceuticals>,
        <https://1145.am/db/2319004/Dicerna_Pharmaceuticals>,
        <https://1145.am/db/2336621/Dicerna_Pharmaceuticals>,
        <https://1145.am/db/2342804/Dicerna_Pharmaceuticals>,
        <https://1145.am/db/2343041/Dicerna_Pharmaceuticals>,
        <https://1145.am/db/2348453/Dicerna_Pharmaceuticals>,
        <https://1145.am/db/2349741/Dicerna_Pharmaceuticals>,
        <https://1145.am/db/2349753/Dicerna_Pharmaceuticals>,
        <https://1145.am/db/2350964/Dicerna_Pharmaceuticals_Inc>,
        <https://1145.am/db/2353604/Dicerna_Pharmaceuticals_Inc>,
        <https://1145.am/db/2362491/Dicerna_Pharmaceuticals_Inc>,
        <https://1145.am/db/2566150/Dicerna_Pharma>,
        <https://1145.am/db/490489/Dicerna_Pharmaceuticals_Inc>,
        <https://1145.am/db/633908/Dicerna_Pharmaceuticals>,
        <https://1145.am/db/635744/Dicerna_Pharmaceuticals>,
        <https://1145.am/db/635895/Dicerna_Pharmaceuticals_Inc>,
        <https://1145.am/db/636407/Dicerna_Pharmaceuticals>,
        <https://1145.am/db/637582/Dicerna_Pharmaceuticals>,
        <https://1145.am/db/718330/Dicerna_Pharmaceuticals>,
        <https://1145.am/db/719216/Dicerna_Pharmaceuticals>,
        <https://1145.am/db/721891/Dicerna_Pharmaceuticals_Inc>,
        <https://1145.am/db/722559/Dicerna_Pharmaceuticals_Inc>,
        <https://1145.am/db/940792/Dice_Therapeutics> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2344565/Working_Capital_Investment_Greenspring_Associates_Inc_Greenspring_Associates_Inc_Oxford_Finance_Corporation_Paul_Capital_Investments_Tethys_Bioscience_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-07-27T18:54:24+00:00"^^xsd:dateTime ;
    ns1:documentExtract "EMERYVILLE, CALIF., - July 21, 2010 - Tethys Bioscience, Inc., a privately held company, announced today that the company has recently raised $ 33 million, comprising $ 23 million of venture financing and a $ 10 million working capital loan." ;
    ns1:documentTitle "Tethys Raises $33 Million" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/tethys-raises-33-million-0> ;
    ns1:foundName "financing",
        "raised" ;
    ns1:name "financing",
        "raised" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2344565/Tethys_Bioscience> ;
    ns1:targetDetails "venture",
        "working capital" ;
    ns1:valueRaw "$ 10 million",
        "$ 23 million",
        "$ 33 million" ;
    ns1:when "2010-07-21T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "July 21, 2010" ;
    ns1:whereGeoName "Emeryville" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5346462/about.rdf> ;
    ns1:whereRaw "EMERYVILLE, CALIF." .

<https://1145.am/db/2349753/Dicerna_Pharmaceuticals> a org:Organization ;
    ns1:basedInHighGeoName "Watertown" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/4954611/about.rdf> ;
    ns1:basedInHighRaw "WATERTOWN, Mass." ;
    ns1:description "RNA interference" ;
    ns1:documentDate "2010-08-11T13:20:47+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Dicerna Closes $25 Million Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/dicerna-closes-25-million-series-b-financing> ;
    ns1:foundName "Dicerna",
        "Dicerna Pharmaceuticals, Inc",
        "Dicerna Pharmaceuticals, Inc." ;
    ns1:industry "Pharmaceuticals" ;
    ns1:name "Dicerna",
        "Dicerna Pharmaceuticals" ;
    ns1:sameAsHigh <https://1145.am/db/1408389/Dice_Therapeutics_Inc>,
        <https://1145.am/db/1414280/Dice_Therapeutics_Inc>,
        <https://1145.am/db/1430935/Dice_Therapeutics_Inc>,
        <https://1145.am/db/2279495/Dicerna_Pharmaceuticals>,
        <https://1145.am/db/2308925/Dicerna_Pharmaceuticals>,
        <https://1145.am/db/2308931/Dicerna_Pharmaceuticals>,
        <https://1145.am/db/2319004/Dicerna_Pharmaceuticals>,
        <https://1145.am/db/2336621/Dicerna_Pharmaceuticals>,
        <https://1145.am/db/2342804/Dicerna_Pharmaceuticals>,
        <https://1145.am/db/2343041/Dicerna_Pharmaceuticals>,
        <https://1145.am/db/2343058/Dicerna_Pharmaceuticals>,
        <https://1145.am/db/2348453/Dicerna_Pharmaceuticals>,
        <https://1145.am/db/2349741/Dicerna_Pharmaceuticals>,
        <https://1145.am/db/2350964/Dicerna_Pharmaceuticals_Inc>,
        <https://1145.am/db/2353604/Dicerna_Pharmaceuticals_Inc>,
        <https://1145.am/db/2362491/Dicerna_Pharmaceuticals_Inc>,
        <https://1145.am/db/2566150/Dicerna_Pharma>,
        <https://1145.am/db/490489/Dicerna_Pharmaceuticals_Inc>,
        <https://1145.am/db/633908/Dicerna_Pharmaceuticals>,
        <https://1145.am/db/635744/Dicerna_Pharmaceuticals>,
        <https://1145.am/db/635895/Dicerna_Pharmaceuticals_Inc>,
        <https://1145.am/db/636407/Dicerna_Pharmaceuticals>,
        <https://1145.am/db/637582/Dicerna_Pharmaceuticals>,
        <https://1145.am/db/718330/Dicerna_Pharmaceuticals>,
        <https://1145.am/db/719216/Dicerna_Pharmaceuticals>,
        <https://1145.am/db/721891/Dicerna_Pharmaceuticals_Inc>,
        <https://1145.am/db/722559/Dicerna_Pharmaceuticals_Inc>,
        <https://1145.am/db/940792/Dice_Therapeutics> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2349753/Domain_Associates> a org:Organization ;
    ns1:basedInLowRaw "WATERTOWN, Mass" ;
    ns1:description "Investing" ;
    ns1:documentDate "2010-08-11T13:20:47+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Dicerna Closes $25 Million Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/dicerna-closes-25-million-series-b-financing> ;
    ns1:foundName "Domain Associates" ;
    ns1:investor <https://1145.am/db/2349753/Series_B_Investment_Abingworth_Dicerna_Pharmaceuticals_Domain_Associates_Oxford_Bioscience_Partners_Skyline_Ventures_Completed> ;
    ns1:name "Domain Associates" ;
    ns1:sameAsHigh <https://1145.am/db/1859331/Domain_Associates>,
        <https://1145.am/db/2155032/Domain_Associates>,
        <https://1145.am/db/2296841/Domain_Associates>,
        <https://1145.am/db/2307644/Domain_Associates>,
        <https://1145.am/db/2309809/Domain_Associates>,
        <https://1145.am/db/2312051/Domain_Associates>,
        <https://1145.am/db/2320925/Domain_Associates>,
        <https://1145.am/db/2356301/Domain_Associates>,
        <https://1145.am/db/2357325/Domain_Associates>,
        <https://1145.am/db/2366187/Domain_Associates> ;
    ns1:sameAsMedium <https://1145.am/db/2153759/Domain_Associates>,
        <https://1145.am/db/2155189/Domain_Associates>,
        <https://1145.am/db/2289515/Domain_Associates>,
        <https://1145.am/db/2289819/Domain_Associates>,
        <https://1145.am/db/2290405/Domain_Associates>,
        <https://1145.am/db/2294753/Domain_Associates>,
        <https://1145.am/db/2297408/Domain_Associates>,
        <https://1145.am/db/2299776/Domain_Associates>,
        <https://1145.am/db/2300270/Domain_Associates>,
        <https://1145.am/db/2300293/Domain_Associates>,
        <https://1145.am/db/2300337/Domain_Associates>,
        <https://1145.am/db/2300455/Domain_Associates>,
        <https://1145.am/db/2302292/Domain_Associates_Llc>,
        <https://1145.am/db/2302508/Domain_Associates>,
        <https://1145.am/db/2303641/Domain_Associates>,
        <https://1145.am/db/2303642/Domain_Associates>,
        <https://1145.am/db/2303793/Domain_Associates>,
        <https://1145.am/db/2304578/Domain_Associates>,
        <https://1145.am/db/2304587/Domain_Associates>,
        <https://1145.am/db/2305524/Domain_Associates>,
        <https://1145.am/db/2305530/Domain_Associates>,
        <https://1145.am/db/2305706/Domain_Associates>,
        <https://1145.am/db/2305713/Domain_Associates>,
        <https://1145.am/db/2305729/Domain_Associates>,
        <https://1145.am/db/2306290/Domain_Associates_Llc>,
        <https://1145.am/db/2306873/Domain_Associates>,
        <https://1145.am/db/2307237/Domain_Associates>,
        <https://1145.am/db/2310073/Domain_Associates>,
        <https://1145.am/db/2311099/Domain_Associates>,
        <https://1145.am/db/2311221/Domain_Associates>,
        <https://1145.am/db/2312120/Domain_Associates>,
        <https://1145.am/db/2312297/Domain_Associates>,
        <https://1145.am/db/2313171/Domain_Associates>,
        <https://1145.am/db/2316210/Domain_Associates>,
        <https://1145.am/db/2316214/Domain_Associates>,
        <https://1145.am/db/2317145/Domain_Associates>,
        <https://1145.am/db/2317951/Domain_Associates>,
        <https://1145.am/db/2318934/Domain_Associates>,
        <https://1145.am/db/2322231/Domain_Associates>,
        <https://1145.am/db/2326423/Domain_Associates>,
        <https://1145.am/db/2326430/Domain_Associates_Llc>,
        <https://1145.am/db/2328030/Domain_Associates_Llc>,
        <https://1145.am/db/2328034/Domain_Associates_Llc>,
        <https://1145.am/db/2330075/Domain_Associates>,
        <https://1145.am/db/2330539/Domain_Associates>,
        <https://1145.am/db/2330549/Domain_Associates>,
        <https://1145.am/db/2331026/Domain_Associates>,
        <https://1145.am/db/2331047/Domain_Associates>,
        <https://1145.am/db/2331784/Domain_Associates>,
        <https://1145.am/db/2336221/Domain_Associates>,
        <https://1145.am/db/2340284/Domain_Associates>,
        <https://1145.am/db/2340634/Domain_Associates>,
        <https://1145.am/db/2341764/Domain_Associates>,
        <https://1145.am/db/2343206/Domain_Associates>,
        <https://1145.am/db/2344090/Domain_Associates>,
        <https://1145.am/db/2344092/Domain_Associates>,
        <https://1145.am/db/2344100/Domain_Associates>,
        <https://1145.am/db/2344782/Domain_Associates>,
        <https://1145.am/db/2347984/Domain_Associates>,
        <https://1145.am/db/2349143/Domain_Associates>,
        <https://1145.am/db/2350044/Domain_Associates>,
        <https://1145.am/db/2352167/Domain_Associates>,
        <https://1145.am/db/2352170/Domain_Associates>,
        <https://1145.am/db/2352808/Domain_Associates>,
        <https://1145.am/db/2354899/Domain_Associates>,
        <https://1145.am/db/2354903/Domain_Associates>,
        <https://1145.am/db/2355936/Domain_Associates>,
        <https://1145.am/db/2355938/Domain_Associates>,
        <https://1145.am/db/2357981/Domain_Associates>,
        <https://1145.am/db/2358541/Domain_Associates>,
        <https://1145.am/db/2358883/Domain_Associates>,
        <https://1145.am/db/2361625/Domain_Associates>,
        <https://1145.am/db/2362278/Domain_Associates>,
        <https://1145.am/db/2365700/Domain_Associates>,
        <https://1145.am/db/2366128/Domain_Associates>,
        <https://1145.am/db/2366133/Domain_Associates> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2350780/Series_C_Investment_Cenerx_Biopharma_Inc_L_Capital_Partners_Pappas_Ventures_Perseus_Soros_Biopharmaceutical_Fund_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-08-13T13:29:08+00:00"^^xsd:dateTime ;
    ns1:documentExtract "CeNeRx BioPharma Completes $ 13 Million Series C Financing.",
        "RESEARCH TRIANGLE PARK, N.C., Aug. 13 /PRNewswire/ - CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing innovative treatments for diseases of the central nervous system (CNS) , today announced completion of a $ 13 million Series C financing." ;
    ns1:documentTitle "CeNeRx BioPharma Completes $13 Million Series C Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cenerx-biopharma-completes-13-million-series-c-financing> ;
    ns1:foundName "Financing",
        "financing" ;
    ns1:name "Financing",
        "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2350780/Cenerx_Biopharma_Inc> ;
    ns1:targetDetails "Series C" ;
    ns1:valueRaw "$ 13 Million",
        "$ 13 million" ;
    ns1:when "2010-08-13T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "Aug. 13" ;
    ns1:whereGeoName "Park County",
        "Research",
        "Triangle" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/2151718/about.rdf>,
        <https://sws.geonames.org/4790025/about.rdf>,
        <https://sws.geonames.org/5834587/about.rdf> ;
    ns1:whereRaw "RESEARCH TRIANGLE PARK" .

<https://1145.am/db/2352808/Domain_Associates> a org:Organization ;
    ns1:basedInLowRaw "Conn" ;
    ns1:documentDate "2010-08-19T15:35:59+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Achillion Announces Private Placement of $50 Million" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/achillion-announces-private-placement-of-50-million> ;
    ns1:foundName "Domain Associates" ;
    ns1:investor <https://1145.am/db/2352808/Investment_Achillion_Pharmaceuticals_Inc_Clarus_Ventures_Domain_Associates_Pappas_Ventures_Quaker_Bioventures_Has_Not_Happened> ;
    ns1:name "Domain Associates" ;
    ns1:sameAsMedium <https://1145.am/db/1859331/Domain_Associates>,
        <https://1145.am/db/2153759/Domain_Associates>,
        <https://1145.am/db/2155032/Domain_Associates>,
        <https://1145.am/db/2155189/Domain_Associates>,
        <https://1145.am/db/2289515/Domain_Associates>,
        <https://1145.am/db/2289819/Domain_Associates>,
        <https://1145.am/db/2290405/Domain_Associates>,
        <https://1145.am/db/2294753/Domain_Associates>,
        <https://1145.am/db/2296841/Domain_Associates>,
        <https://1145.am/db/2297408/Domain_Associates>,
        <https://1145.am/db/2299776/Domain_Associates>,
        <https://1145.am/db/2300270/Domain_Associates>,
        <https://1145.am/db/2300293/Domain_Associates>,
        <https://1145.am/db/2300337/Domain_Associates>,
        <https://1145.am/db/2300455/Domain_Associates>,
        <https://1145.am/db/2302292/Domain_Associates_Llc>,
        <https://1145.am/db/2302508/Domain_Associates>,
        <https://1145.am/db/2303641/Domain_Associates>,
        <https://1145.am/db/2303642/Domain_Associates>,
        <https://1145.am/db/2303793/Domain_Associates>,
        <https://1145.am/db/2304578/Domain_Associates>,
        <https://1145.am/db/2304587/Domain_Associates>,
        <https://1145.am/db/2305524/Domain_Associates>,
        <https://1145.am/db/2305530/Domain_Associates>,
        <https://1145.am/db/2305706/Domain_Associates>,
        <https://1145.am/db/2305713/Domain_Associates>,
        <https://1145.am/db/2305729/Domain_Associates>,
        <https://1145.am/db/2306290/Domain_Associates_Llc>,
        <https://1145.am/db/2306873/Domain_Associates>,
        <https://1145.am/db/2307237/Domain_Associates>,
        <https://1145.am/db/2307644/Domain_Associates>,
        <https://1145.am/db/2309809/Domain_Associates>,
        <https://1145.am/db/2310073/Domain_Associates>,
        <https://1145.am/db/2311099/Domain_Associates>,
        <https://1145.am/db/2311221/Domain_Associates>,
        <https://1145.am/db/2312051/Domain_Associates>,
        <https://1145.am/db/2312120/Domain_Associates>,
        <https://1145.am/db/2312297/Domain_Associates>,
        <https://1145.am/db/2313171/Domain_Associates>,
        <https://1145.am/db/2316210/Domain_Associates>,
        <https://1145.am/db/2316214/Domain_Associates>,
        <https://1145.am/db/2317145/Domain_Associates>,
        <https://1145.am/db/2317951/Domain_Associates>,
        <https://1145.am/db/2318934/Domain_Associates>,
        <https://1145.am/db/2320925/Domain_Associates>,
        <https://1145.am/db/2322231/Domain_Associates>,
        <https://1145.am/db/2326423/Domain_Associates>,
        <https://1145.am/db/2326430/Domain_Associates_Llc>,
        <https://1145.am/db/2328030/Domain_Associates_Llc>,
        <https://1145.am/db/2328034/Domain_Associates_Llc>,
        <https://1145.am/db/2330075/Domain_Associates>,
        <https://1145.am/db/2330539/Domain_Associates>,
        <https://1145.am/db/2330549/Domain_Associates>,
        <https://1145.am/db/2331026/Domain_Associates>,
        <https://1145.am/db/2331047/Domain_Associates>,
        <https://1145.am/db/2331784/Domain_Associates>,
        <https://1145.am/db/2336221/Domain_Associates>,
        <https://1145.am/db/2340284/Domain_Associates>,
        <https://1145.am/db/2340634/Domain_Associates>,
        <https://1145.am/db/2341764/Domain_Associates>,
        <https://1145.am/db/2343206/Domain_Associates>,
        <https://1145.am/db/2344090/Domain_Associates>,
        <https://1145.am/db/2344092/Domain_Associates>,
        <https://1145.am/db/2344100/Domain_Associates>,
        <https://1145.am/db/2344782/Domain_Associates>,
        <https://1145.am/db/2347984/Domain_Associates>,
        <https://1145.am/db/2349143/Domain_Associates>,
        <https://1145.am/db/2349753/Domain_Associates>,
        <https://1145.am/db/2350044/Domain_Associates>,
        <https://1145.am/db/2352167/Domain_Associates>,
        <https://1145.am/db/2352170/Domain_Associates>,
        <https://1145.am/db/2354899/Domain_Associates>,
        <https://1145.am/db/2354903/Domain_Associates>,
        <https://1145.am/db/2355936/Domain_Associates>,
        <https://1145.am/db/2355938/Domain_Associates>,
        <https://1145.am/db/2356301/Domain_Associates>,
        <https://1145.am/db/2357325/Domain_Associates>,
        <https://1145.am/db/2357981/Domain_Associates>,
        <https://1145.am/db/2358541/Domain_Associates>,
        <https://1145.am/db/2358883/Domain_Associates>,
        <https://1145.am/db/2361625/Domain_Associates>,
        <https://1145.am/db/2362278/Domain_Associates>,
        <https://1145.am/db/2365700/Domain_Associates>,
        <https://1145.am/db/2366128/Domain_Associates>,
        <https://1145.am/db/2366133/Domain_Associates>,
        <https://1145.am/db/2366187/Domain_Associates> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352820/Series_B_Investment_Anchor_Therapeutics_Healthcare_Ventures_Novartis_Option_Fund_Tvm_Capital_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-08-20T13:33:44+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Anchor Therapeutics Nabs $ 10M for New Class of Peptide Drugs Against Hard Targets.",
        "CAMBRIDGE, Mass.- (BUSINESS WIRE) -Anchor Therapeutics today announced an initial closing of $ 10 million in a Series B financing." ;
    ns1:documentTitle "Anchor Therapeutics Nabs $10M for New Class of Peptide Drugs Against Hard Targets" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/anchor-therapeutics-nabs-10m-for-new-class-of-peptide-drugs-against-hard-targets> ;
    ns1:foundName "financing" ;
    ns1:name "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2352820/Anchor_Therapeutics> ;
    ns1:targetDetails "Series B" ;
    ns1:valueRaw "$ 10 million",
        "$ 10M" ;
    ns1:whereGeoName "Anchor" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/4883301/about.rdf> ;
    ns1:whereRaw "Anchor Therapeutics" .

<https://1145.am/db/2354899/Domain_Associates> a org:Organization ;
    ns1:basedInLowRaw "SAN DIEGO" ;
    ns1:description "financing" ;
    ns1:documentDate "2010-08-30T13:07:55+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Otonomy Closes $38.5 Million Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/otonomy-closes-38-5-million-series-b-financing> ;
    ns1:foundName "Domain Associates" ;
    ns1:investor <https://1145.am/db/2354899/Series_B_Investment_Domain_Associates_Novo_Ventures_Otonomy_Rivervest_Venture_Partners_Tpg_Biotech_Completed> ;
    ns1:name "Domain Associates" ;
    ns1:sameAsHigh <https://1145.am/db/2289515/Domain_Associates>,
        <https://1145.am/db/2290405/Domain_Associates>,
        <https://1145.am/db/2303642/Domain_Associates>,
        <https://1145.am/db/2304587/Domain_Associates>,
        <https://1145.am/db/2330075/Domain_Associates>,
        <https://1145.am/db/2330539/Domain_Associates>,
        <https://1145.am/db/2352170/Domain_Associates>,
        <https://1145.am/db/2361625/Domain_Associates> ;
    ns1:sameAsMedium <https://1145.am/db/1859331/Domain_Associates>,
        <https://1145.am/db/2153759/Domain_Associates>,
        <https://1145.am/db/2155032/Domain_Associates>,
        <https://1145.am/db/2155189/Domain_Associates>,
        <https://1145.am/db/2289819/Domain_Associates>,
        <https://1145.am/db/2294753/Domain_Associates>,
        <https://1145.am/db/2296841/Domain_Associates>,
        <https://1145.am/db/2297408/Domain_Associates>,
        <https://1145.am/db/2299776/Domain_Associates>,
        <https://1145.am/db/2300270/Domain_Associates>,
        <https://1145.am/db/2300293/Domain_Associates>,
        <https://1145.am/db/2300337/Domain_Associates>,
        <https://1145.am/db/2300455/Domain_Associates>,
        <https://1145.am/db/2302292/Domain_Associates_Llc>,
        <https://1145.am/db/2302508/Domain_Associates>,
        <https://1145.am/db/2303641/Domain_Associates>,
        <https://1145.am/db/2303793/Domain_Associates>,
        <https://1145.am/db/2304578/Domain_Associates>,
        <https://1145.am/db/2305524/Domain_Associates>,
        <https://1145.am/db/2305530/Domain_Associates>,
        <https://1145.am/db/2305706/Domain_Associates>,
        <https://1145.am/db/2305713/Domain_Associates>,
        <https://1145.am/db/2305729/Domain_Associates>,
        <https://1145.am/db/2306290/Domain_Associates_Llc>,
        <https://1145.am/db/2306873/Domain_Associates>,
        <https://1145.am/db/2307237/Domain_Associates>,
        <https://1145.am/db/2307644/Domain_Associates>,
        <https://1145.am/db/2309809/Domain_Associates>,
        <https://1145.am/db/2310073/Domain_Associates>,
        <https://1145.am/db/2311099/Domain_Associates>,
        <https://1145.am/db/2311221/Domain_Associates>,
        <https://1145.am/db/2312051/Domain_Associates>,
        <https://1145.am/db/2312120/Domain_Associates>,
        <https://1145.am/db/2312297/Domain_Associates>,
        <https://1145.am/db/2313171/Domain_Associates>,
        <https://1145.am/db/2316210/Domain_Associates>,
        <https://1145.am/db/2316214/Domain_Associates>,
        <https://1145.am/db/2317145/Domain_Associates>,
        <https://1145.am/db/2317951/Domain_Associates>,
        <https://1145.am/db/2318934/Domain_Associates>,
        <https://1145.am/db/2320925/Domain_Associates>,
        <https://1145.am/db/2322231/Domain_Associates>,
        <https://1145.am/db/2326423/Domain_Associates>,
        <https://1145.am/db/2326430/Domain_Associates_Llc>,
        <https://1145.am/db/2328030/Domain_Associates_Llc>,
        <https://1145.am/db/2328034/Domain_Associates_Llc>,
        <https://1145.am/db/2330549/Domain_Associates>,
        <https://1145.am/db/2331026/Domain_Associates>,
        <https://1145.am/db/2331047/Domain_Associates>,
        <https://1145.am/db/2331784/Domain_Associates>,
        <https://1145.am/db/2336221/Domain_Associates>,
        <https://1145.am/db/2340284/Domain_Associates>,
        <https://1145.am/db/2340634/Domain_Associates>,
        <https://1145.am/db/2341764/Domain_Associates>,
        <https://1145.am/db/2343206/Domain_Associates>,
        <https://1145.am/db/2344090/Domain_Associates>,
        <https://1145.am/db/2344092/Domain_Associates>,
        <https://1145.am/db/2344100/Domain_Associates>,
        <https://1145.am/db/2344782/Domain_Associates>,
        <https://1145.am/db/2347984/Domain_Associates>,
        <https://1145.am/db/2349143/Domain_Associates>,
        <https://1145.am/db/2349753/Domain_Associates>,
        <https://1145.am/db/2350044/Domain_Associates>,
        <https://1145.am/db/2352167/Domain_Associates>,
        <https://1145.am/db/2352808/Domain_Associates>,
        <https://1145.am/db/2354903/Domain_Associates>,
        <https://1145.am/db/2355936/Domain_Associates>,
        <https://1145.am/db/2355938/Domain_Associates>,
        <https://1145.am/db/2356301/Domain_Associates>,
        <https://1145.am/db/2357325/Domain_Associates>,
        <https://1145.am/db/2357981/Domain_Associates>,
        <https://1145.am/db/2358541/Domain_Associates>,
        <https://1145.am/db/2358883/Domain_Associates>,
        <https://1145.am/db/2362278/Domain_Associates>,
        <https://1145.am/db/2365700/Domain_Associates>,
        <https://1145.am/db/2366128/Domain_Associates>,
        <https://1145.am/db/2366133/Domain_Associates>,
        <https://1145.am/db/2366187/Domain_Associates> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2356567/Mp_Healthcare_Venture_Management_Inc> a org:Organization ;
    ns1:description "investing",
        "venture capital" ;
    ns1:documentDate "2010-11-29T16:58:07+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Covagen closes Series A financing round with Seroba Kernel as lead investor" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/covagen-closes-series-a-financing-round-seroba-kernel-as-lead-investor> ;
    ns1:foundName "(MPH)",
        "MP Healthcare Venture Management, Inc",
        "MP Healthcare Venture Management, Inc. (MPH)" ;
    ns1:investor <https://1145.am/db/2356567/Series_A_Investment_Covagen_Edmond_De_Rothschild_Investment_Partners_Mp_Healthcare_Venture_Management_Inc_Mp_Healthcare_Venture_Management_Inc_Novartis_Venture_Fund_Seroba_Kernel_Life_Sciences_Ventech_Completed> ;
    ns1:name "MP Healthcare Venture Management",
        "MP Healthcare Venture Management, Inc" ;
    ns1:sameAsHigh <https://1145.am/db/1335924/Blue_Venture_Fund>,
        <https://1145.am/db/1336552/Blue_Venture_Fund>,
        <https://1145.am/db/1374213/Apollo_Health_Ventures>,
        <https://1145.am/db/1628978/Cvs_Health_Ventures>,
        <https://1145.am/db/2180772/7wireventures>,
        <https://1145.am/db/2281648/Medical_Excellence_Capital_Partners>,
        <https://1145.am/db/2282392/Pioneer_Healthcare_Partners>,
        <https://1145.am/db/2294753/Catalyst_Health_Ventures>,
        <https://1145.am/db/2298897/Healthlink_Capital>,
        <https://1145.am/db/2303251/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2303257/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2305524/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/230667/Red_Tree_Venture_Capital>,
        <https://1145.am/db/2309845/Healthcare_Ventures>,
        <https://1145.am/db/2311069/Healthcare_Ventures>,
        <https://1145.am/db/2311075/Healthcare_Ventures>,
        <https://1145.am/db/2321713/Healthcor_Partners_Management>,
        <https://1145.am/db/2323586/Healthcare_Ventures>,
        <https://1145.am/db/2329533/Essex_Woodlands_Healthcare_Ventures>,
        <https://1145.am/db/2329533/Gilde_Healthcare>,
        <https://1145.am/db/2330876/Healthcare_Venture>,
        <https://1145.am/db/2337166/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2340284/Catalyst_Health_Ventures>,
        <https://1145.am/db/2342611/Healthcap>,
        <https://1145.am/db/2346204/Healthcare_Ventures>,
        <https://1145.am/db/2347469/Healthcare_Ventures>,
        <https://1145.am/db/2347822/Healthcap>,
        <https://1145.am/db/2349717/Healthcare_Ventures>,
        <https://1145.am/db/2352820/Healthcare_Ventures>,
        <https://1145.am/db/2365279/Founders_Fund>,
        <https://1145.am/db/2365296/Mp_Healthcare_Venture_Management>,
        <https://1145.am/db/2367497/Healthcare_Ventures>,
        <https://1145.am/db/2369086/Whitesun_Healthcare_Ventures>,
        <https://1145.am/db/348452/Inflect_Health>,
        <https://1145.am/db/662177/Apollo_Health_Ventures> ;
    ns1:sameAsMedium <https://1145.am/db/2062003/Mp_Healthcare_Venture_Management>,
        <https://1145.am/db/2287244/Mp_Healthcare_Venture_Management>,
        <https://1145.am/db/2327441/Mp_Healthcare_Venture_Management>,
        <https://1145.am/db/2327442/Mp_Healthcare_Venture_Management>,
        <https://1145.am/db/2341904/Mp_Healthcare_Venture_Management>,
        <https://1145.am/db/2364468/Mp_Healthcare_Venture_Management_Inc>,
        <https://1145.am/db/2364471/Mp_Healthcare_Venture_Management>,
        <https://1145.am/db/2367740/Mp_Healthcare_Venture_Management> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2359104/Zymogenetics> a org:Organization ;
    ns1:basedInLowRaw "Boston" ;
    ns1:documentDate "2010-09-09T16:17:38+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Ark restructures; Genentech sees promise in preclinical cancer therapy" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/ark-restructures-genentech-sees-promise-preclinical-cancer-therapy> ;
    ns1:foundName "ZymoGenetics" ;
    ns1:industry "Biotech" ;
    ns1:name "ZymoGenetics" ;
    ns1:sameAsHigh <https://1145.am/db/2305700/Zymogenetics>,
        <https://1145.am/db/2317635/Zymogenetics>,
        <https://1145.am/db/2322515/Zymogenetics>,
        <https://1145.am/db/2324615/Zymogenetics>,
        <https://1145.am/db/2324755/Zymogenetics>,
        <https://1145.am/db/2325221/Zymogenetics>,
        <https://1145.am/db/2340432/Zymogenetics>,
        <https://1145.am/db/2350282/Zymogenetics>,
        <https://1145.am/db/2358044/Zymogenetics>,
        <https://1145.am/db/2365203/Zymogenetics>,
        <https://1145.am/db/2545610/Zymogenetics>,
        <https://1145.am/db/2585238/Zymogenetics> ;
    ns1:sameAsMedium <https://1145.am/db/2358038/Zymogenetics>,
        <https://1145.am/db/2358039/Zymogenetics>,
        <https://1145.am/db/2358078/Zymogenetics>,
        <https://1145.am/db/2359117/Zymogenetics>,
        <https://1145.am/db/2365157/Zymogenetics>,
        <https://1145.am/db/2367078/Zymogenetics>,
        <https://1145.am/db/2367082/Zymogenetics>,
        <https://1145.am/db/2367085/Zymogenetics>,
        <https://1145.am/db/2367306/Zymogenetics>,
        <https://1145.am/db/2584317/Zymogenetics>,
        <https://1145.am/db/2584318/Zymogenetics>,
        <https://1145.am/db/2585263/Zymogenetics>,
        <https://1145.am/db/2589142/Zymogenetics>,
        <https://1145.am/db/2592024/Zymogenetics>,
        <https://1145.am/db/2592993/Zymogenetics> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2359125/Series_A_Investment_Good_Start_Genetics_Orbimed_Advisors_Sv_Life_Sciences_Safeguard_Scientifics_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-09-10T13:16:20+00:00"^^xsd:dateTime ;
    ns1:documentExtract "BOSTON, Sep 10, 2010 (BUSINESS WIRE) - Good Start Genetics, Inc., today announced the completion of an $ 18 million Series A financing.",
        "Good Start Genetics, Inc. Raises $ 18 Million to Develop and Launch Sequencing - Based Pre-Pregnancy Genetic Screening Test." ;
    ns1:documentTitle "Good Start Genetics, Inc. Raises $18 Million to Develop and Launch Sequencing-Based Pre-Pregnancy Genetic Screening Test" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/good-start-genetics-inc-raises-18-million-to-develop-and-launch-sequencing-based-pre> ;
    ns1:foundName "Raises",
        "financing" ;
    ns1:name "Raises",
        "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2359125/Good_Start_Genetics> ;
    ns1:targetDetails "Series A" ;
    ns1:valueRaw "$ 18 Million",
        "$ 18 million" ;
    ns1:when "2010-09-10T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "2010-09-10" ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "United States" .

<https://1145.am/db/2361809/Series_B_Investment_Merieux_Developpement_Paladin_Capital_Group_Quantalife_Vital_Financial_Llc_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-12-13T15:52:16+00:00"^^xsd:dateTime ;
    ns1:documentExtract "QuantaLife, Inc. Closes $ 17.2M Series B Financing to Accelerate Application Development for Its Droplet DigitalTM PCR Platform and Establish Commercial Operations by 2011.",
        "QuantaLife, Inc. announced today that it has closed a $ 17.2M Series B financing." ;
    ns1:documentTitle "QuantaLife, Inc. Closes $17.2M Series B Financing to Accelerate Application Development for Its Droplet DigitalTM PCR Platform" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/quantalife-inc-closes-17-2m-series-b-financing-to-accelerate-application-development-for> ;
    ns1:foundName "financing" ;
    ns1:name "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2361809/Quantalife> ;
    ns1:targetDetails "Series B" ;
    ns1:valueRaw "$ 17.2M" ;
    ns1:whereRaw "QuantaLife, Inc." .

<https://1145.am/db/2365157/Zymogenetics> a org:Organization ;
    ns1:basedInLowRaw "NEW YORK" ;
    ns1:description "Biotechnology" ;
    ns1:documentDate "2010-09-28T12:07:12+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Bristol-Myers Squibb Announces Expiration of Hart-Scott-Rodino Waiting Period for Acquisition of ZymoGenetics, Inc." ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/bristol-myers-squibb-announces-expiration-of-hart-scott-rodino-waiting-period-for-1> ;
    ns1:foundName "ZymoGenetics",
        "ZymoGenetics, Inc" ;
    ns1:name "ZymoGenetics" ;
    ns1:sameAsHigh <https://1145.am/db/2325221/Zymogenetics>,
        <https://1145.am/db/2340432/Zymogenetics>,
        <https://1145.am/db/2585263/Zymogenetics>,
        <https://1145.am/db/2589142/Zymogenetics> ;
    ns1:sameAsMedium <https://1145.am/db/2305700/Zymogenetics>,
        <https://1145.am/db/2317635/Zymogenetics>,
        <https://1145.am/db/2322515/Zymogenetics>,
        <https://1145.am/db/2324615/Zymogenetics>,
        <https://1145.am/db/2324755/Zymogenetics>,
        <https://1145.am/db/2350282/Zymogenetics>,
        <https://1145.am/db/2358038/Zymogenetics>,
        <https://1145.am/db/2358039/Zymogenetics>,
        <https://1145.am/db/2358044/Zymogenetics>,
        <https://1145.am/db/2358078/Zymogenetics>,
        <https://1145.am/db/2359104/Zymogenetics>,
        <https://1145.am/db/2359117/Zymogenetics>,
        <https://1145.am/db/2365203/Zymogenetics>,
        <https://1145.am/db/2367078/Zymogenetics>,
        <https://1145.am/db/2367082/Zymogenetics>,
        <https://1145.am/db/2367085/Zymogenetics>,
        <https://1145.am/db/2367306/Zymogenetics>,
        <https://1145.am/db/2545610/Zymogenetics>,
        <https://1145.am/db/2584317/Zymogenetics>,
        <https://1145.am/db/2584318/Zymogenetics>,
        <https://1145.am/db/2585238/Zymogenetics>,
        <https://1145.am/db/2592024/Zymogenetics>,
        <https://1145.am/db/2592993/Zymogenetics> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2365157/Zymogenetics_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition",
        "merger" ;
    ns1:documentDate "2010-09-28T12:07:12+00:00"^^xsd:dateTime ;
    ns1:documentExtract "NEW YORK- (BUSINESS WIRE) - Bristol-Myers Squibb Company (NYSE: BMY) announced today that the Hart-Scott-Rodino (HSR) waiting period for its tender offer for ZymoGenetics, Inc. (NASDAQ: ZGEN) has expired." ;
    ns1:documentTitle "Bristol-Myers Squibb Announces Expiration of Hart-Scott-Rodino Waiting Period for Acquisition of ZymoGenetics, Inc." ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/bristol-myers-squibb-announces-expiration-of-hart-scott-rodino-waiting-period-for-1> ;
    ns1:foundName "purchase",
        "tender offer" ;
    ns1:name "purchase",
        "tender offer" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "has not happened" ;
    ns1:target <https://1145.am/db/2365157/Zymogenetics> ;
    ns1:targetName "ZymoGenetics" ;
    ns1:whereGeoName "New York City" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5128581/about.rdf> ;
    ns1:whereRaw "New York City" .

<https://1145.am/db/2366187/Domain_Associates> a org:Organization ;
    ns1:basedInLowRaw "N.J" ;
    ns1:description "Investing" ;
    ns1:documentDate "2010-09-30T16:26:17+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Tobira Therapeutics Inc. Raises $31 Million in Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/tobira-therapeutics-inc-raises-31-million-series-b-financing> ;
    ns1:foundName "Domain Associates, L.L.C." ;
    ns1:investor <https://1145.am/db/2366187/Series_B_Investment_Canaan_Partners_Domain_Associates_Frazier_Healthcare_Ventures_Montreux_Equity_Partners_Novo_A_S_Tobira_Therapeutics_Inc_Completed> ;
    ns1:name "Domain Associates" ;
    ns1:sameAsHigh <https://1145.am/db/1859331/Domain_Associates>,
        <https://1145.am/db/2155032/Domain_Associates>,
        <https://1145.am/db/2296841/Domain_Associates>,
        <https://1145.am/db/2307644/Domain_Associates>,
        <https://1145.am/db/2309809/Domain_Associates>,
        <https://1145.am/db/2312051/Domain_Associates>,
        <https://1145.am/db/2320925/Domain_Associates>,
        <https://1145.am/db/2349753/Domain_Associates>,
        <https://1145.am/db/2356301/Domain_Associates>,
        <https://1145.am/db/2357325/Domain_Associates> ;
    ns1:sameAsMedium <https://1145.am/db/2153759/Domain_Associates>,
        <https://1145.am/db/2155189/Domain_Associates>,
        <https://1145.am/db/2289515/Domain_Associates>,
        <https://1145.am/db/2289819/Domain_Associates>,
        <https://1145.am/db/2290405/Domain_Associates>,
        <https://1145.am/db/2294753/Domain_Associates>,
        <https://1145.am/db/2297408/Domain_Associates>,
        <https://1145.am/db/2299776/Domain_Associates>,
        <https://1145.am/db/2300270/Domain_Associates>,
        <https://1145.am/db/2300293/Domain_Associates>,
        <https://1145.am/db/2300337/Domain_Associates>,
        <https://1145.am/db/2300455/Domain_Associates>,
        <https://1145.am/db/2302292/Domain_Associates_Llc>,
        <https://1145.am/db/2302508/Domain_Associates>,
        <https://1145.am/db/2303641/Domain_Associates>,
        <https://1145.am/db/2303642/Domain_Associates>,
        <https://1145.am/db/2303793/Domain_Associates>,
        <https://1145.am/db/2304578/Domain_Associates>,
        <https://1145.am/db/2304587/Domain_Associates>,
        <https://1145.am/db/2305524/Domain_Associates>,
        <https://1145.am/db/2305530/Domain_Associates>,
        <https://1145.am/db/2305706/Domain_Associates>,
        <https://1145.am/db/2305713/Domain_Associates>,
        <https://1145.am/db/2305729/Domain_Associates>,
        <https://1145.am/db/2306290/Domain_Associates_Llc>,
        <https://1145.am/db/2306873/Domain_Associates>,
        <https://1145.am/db/2307237/Domain_Associates>,
        <https://1145.am/db/2310073/Domain_Associates>,
        <https://1145.am/db/2311099/Domain_Associates>,
        <https://1145.am/db/2311221/Domain_Associates>,
        <https://1145.am/db/2312120/Domain_Associates>,
        <https://1145.am/db/2312297/Domain_Associates>,
        <https://1145.am/db/2313171/Domain_Associates>,
        <https://1145.am/db/2316210/Domain_Associates>,
        <https://1145.am/db/2316214/Domain_Associates>,
        <https://1145.am/db/2317145/Domain_Associates>,
        <https://1145.am/db/2317951/Domain_Associates>,
        <https://1145.am/db/2318934/Domain_Associates>,
        <https://1145.am/db/2322231/Domain_Associates>,
        <https://1145.am/db/2326423/Domain_Associates>,
        <https://1145.am/db/2326430/Domain_Associates_Llc>,
        <https://1145.am/db/2328030/Domain_Associates_Llc>,
        <https://1145.am/db/2328034/Domain_Associates_Llc>,
        <https://1145.am/db/2330075/Domain_Associates>,
        <https://1145.am/db/2330539/Domain_Associates>,
        <https://1145.am/db/2330549/Domain_Associates>,
        <https://1145.am/db/2331026/Domain_Associates>,
        <https://1145.am/db/2331047/Domain_Associates>,
        <https://1145.am/db/2331784/Domain_Associates>,
        <https://1145.am/db/2336221/Domain_Associates>,
        <https://1145.am/db/2340284/Domain_Associates>,
        <https://1145.am/db/2340634/Domain_Associates>,
        <https://1145.am/db/2341764/Domain_Associates>,
        <https://1145.am/db/2343206/Domain_Associates>,
        <https://1145.am/db/2344090/Domain_Associates>,
        <https://1145.am/db/2344092/Domain_Associates>,
        <https://1145.am/db/2344100/Domain_Associates>,
        <https://1145.am/db/2344782/Domain_Associates>,
        <https://1145.am/db/2347984/Domain_Associates>,
        <https://1145.am/db/2349143/Domain_Associates>,
        <https://1145.am/db/2350044/Domain_Associates>,
        <https://1145.am/db/2352167/Domain_Associates>,
        <https://1145.am/db/2352170/Domain_Associates>,
        <https://1145.am/db/2352808/Domain_Associates>,
        <https://1145.am/db/2354899/Domain_Associates>,
        <https://1145.am/db/2354903/Domain_Associates>,
        <https://1145.am/db/2355936/Domain_Associates>,
        <https://1145.am/db/2355938/Domain_Associates>,
        <https://1145.am/db/2357981/Domain_Associates>,
        <https://1145.am/db/2358541/Domain_Associates>,
        <https://1145.am/db/2358883/Domain_Associates>,
        <https://1145.am/db/2361625/Domain_Associates>,
        <https://1145.am/db/2362278/Domain_Associates>,
        <https://1145.am/db/2365700/Domain_Associates>,
        <https://1145.am/db/2366128/Domain_Associates>,
        <https://1145.am/db/2366133/Domain_Associates> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2366860/Series_A_Investment_Apposite_Capital_Convergence_Pharmaceuticals_New_Leaf_Venture_Partners_Sv_Life_Sciences_Has_Not_Happened> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-10-06T13:04:22+00:00"^^xsd:dateTime ;
    ns1:documentExtract "NEW YORK & MENLO PARK, Calif., Oct 05, 2010 (BUSINESS WIRE) - New Leaf Venture Partners (NLV Partners) announced today that it is investing with Apposite Capital and SV Life Sciences in a $ 35.4 million Series A private equity financing of Convergence Pharmaceuticals." ;
    ns1:documentTitle "New Leaf Venture Partners Invests in $35.4 (GBP 22.4) Million Series A Financing of Convergence Pharmaceuticals" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/new-leaf-venture-partners-invests-35-4-gbp-22-4-million-series-a-financing-of-convergence> ;
    ns1:foundName "financing",
        "investing" ;
    ns1:name "financing",
        "investing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2366860/Convergence_Pharmaceuticals> ;
    ns1:targetDetails "Series A",
        "private equity" ;
    ns1:valueRaw "$ 35.4 million" ;
    ns1:when "2010-10-05T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "Oct 05, 2010" ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "United States" .

<https://1145.am/db/2366860/Series_A_Investment_Apposite_Capital_New_Leaf_Venture_Partners_Sv_Life_Sciences_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-10-06T13:04:22+00:00"^^xsd:dateTime ;
    ns1:documentExtract "NEW YORK & MENLO PARK, Calif., Oct 05, 2010 (BUSINESS WIRE) - New Leaf Venture Partners (NLV Partners) announced today that it is investing with Apposite Capital and SV Life Sciences in a $ 35.4 million Series A private equity financing of Convergence Pharmaceuticals." ;
    ns1:documentTitle "New Leaf Venture Partners Invests in $35.4 (GBP 22.4) Million Series A Financing of Convergence Pharmaceuticals" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/new-leaf-venture-partners-invests-35-4-gbp-22-4-million-series-a-financing-of-convergence> ;
    ns1:foundName "financing" ;
    ns1:name "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:targetDetails "Series A" ;
    ns1:valueRaw "$ 35.4 million" ;
    ns1:when "2010-10-05T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "Oct 05, 2010" ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "United States" .

<https://1145.am/db/2366953/Alnara_Pharmaceuticals_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition",
        "merger" ;
    ns1:documentDate "2010-07-02T13:00:55+00:00"^^xsd:dateTime ;
    ns1:documentExtract "INDIANAPOLIS and CAMBRIDGE, Mass., July 2 /PRNewswire-FirstCall/ - Eli Lilly and Company (NYSE: LLY) and Alnara Pharmaceuticals, Inc. today announced they have signed a definitive merger agreement whereby Lilly will acquire Alnara, a privately held biotechnology company developing protein therapeutics for the treatment of metabolic diseases." ;
    ns1:documentTitle "Lilly to Acquire Alnara Pharmaceuticals" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/lilly-to-acquire-alnara-pharmaceuticals> ;
    ns1:foundName "acquire",
        "merger" ;
    ns1:name "acquire",
        "merger" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "has not happened" ;
    ns1:target <https://1145.am/db/2366953/Alnara_Pharmaceuticals> ;
    ns1:targetName "Alnara Pharmaceuticals" ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "United States" .

<https://1145.am/db/2367206/Merck_Serono> a org:Organization ;
    ns1:basedInLowRaw "French" ;
    ns1:description "Life Sciences" ;
    ns1:documentDate "2010-07-08T15:10:38+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Bionest Partners Finance Advises Poxel in a Series A Financing of EUR16M" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/bionest-partners-finance-advises-poxel-a-series-a-financing-of-eur16m> ;
    ns1:foundName "Merck Serono" ;
    ns1:industry "Life Sciences" ;
    ns1:name "Merck Serono" ;
    ns1:sameAsHigh <https://1145.am/db/2292667/German_Merck>,
        <https://1145.am/db/2303625/Merck_Manufacturing_Division>,
        <https://1145.am/db/2326224/Merck___Co_Inc>,
        <https://1145.am/db/2340789/Merck_Research_Laboratories>,
        <https://1145.am/db/2341435/Merck>,
        <https://1145.am/db/2344563/Merck>,
        <https://1145.am/db/2344564/Merck>,
        <https://1145.am/db/2348683/Merck>,
        <https://1145.am/db/2362458/Merck_Kgaa>,
        <https://1145.am/db/2367203/Merck_Serono> ;
    ns1:sameAsMedium <https://1145.am/db/2307377/Merck_Kgaa>,
        <https://1145.am/db/2330990/Merck_Kgaa>,
        <https://1145.am/db/2339972/Merck_Serono>,
        <https://1145.am/db/2350594/Merck_Serono>,
        <https://1145.am/db/2359490/Merck_Serono>,
        <https://1145.am/db/2557023/Merck_Serono>,
        <https://1145.am/db/2569029/Merck_Serono>,
        <https://1145.am/db/2596156/Merck_Serono>,
        <https://1145.am/db/2597135/Merck_Serono> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2573611/Alcon> a org:Organization ;
    ns1:basedInLowRaw "Switzerland" ;
    ns1:description "eye care" ;
    ns1:documentDate "2010-07-08T14:06:34+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Alcon IDC earmarks $50M for possible Novartis suit" ;
    ns1:documentURL <https://www.fiercepharma.com/pharma/alcon-idc-earmarks-50m-for-possible-novartis-suit> ;
    ns1:foundName "Alcon",
        "Alcon's" ;
    ns1:industry "drugmaker" ;
    ns1:name "Alcon" ;
    ns1:sameAsHigh <https://1145.am/db/1077454/Alcon>,
        <https://1145.am/db/1078071/Alcon>,
        <https://1145.am/db/1294499/Alcon>,
        <https://1145.am/db/1294506/Alcon>,
        <https://1145.am/db/1295948/Alcon>,
        <https://1145.am/db/1296487/Alcon>,
        <https://1145.am/db/1520596/Alcon>,
        <https://1145.am/db/1520597/Alcon>,
        <https://1145.am/db/1521695/Alcon>,
        <https://1145.am/db/2291606/Alcon>,
        <https://1145.am/db/2293419/Alcon>,
        <https://1145.am/db/2305192/Alcon>,
        <https://1145.am/db/2314943/Alcon>,
        <https://1145.am/db/2314947/Alcon>,
        <https://1145.am/db/2321067/Alcon_Inc>,
        <https://1145.am/db/2367207/Alcon>,
        <https://1145.am/db/2552258/Alcon>,
        <https://1145.am/db/2552998/Aldevron>,
        <https://1145.am/db/2553276/Alcon>,
        <https://1145.am/db/2553634/Alcon>,
        <https://1145.am/db/2572713/Alcon>,
        <https://1145.am/db/2575488/Alcon>,
        <https://1145.am/db/2577419/Alcon>,
        <https://1145.am/db/2579507/Alcon>,
        <https://1145.am/db/2579519/Alcon>,
        <https://1145.am/db/2580401/Alcon>,
        <https://1145.am/db/2581378/Alcon>,
        <https://1145.am/db/2581394/Alcon>,
        <https://1145.am/db/2582355/Alcon>,
        <https://1145.am/db/2582395/Alcon_Stock>,
        <https://1145.am/db/2582400/Alcon>,
        <https://1145.am/db/2584359/Alcon>,
        <https://1145.am/db/2586661/Alcon>,
        <https://1145.am/db/2590349/Alcon>,
        <https://1145.am/db/2598636/Alcon>,
        <https://1145.am/db/600939/Alcon>,
        <https://1145.am/db/600941/Alcon>,
        <https://1145.am/db/744985/Alcon> ;
    ns1:sameAsMedium <https://1145.am/db/1078074/Alcon_Inc>,
        <https://1145.am/db/1084233/Alcon_Inc>,
        <https://1145.am/db/1085993/Alcon_Inc>,
        <https://1145.am/db/1196175/Alcon_Inc>,
        <https://1145.am/db/1371279/Alcon_Inc>,
        <https://1145.am/db/1417348/Alcon_Inc>,
        <https://1145.am/db/1418572/Alcon_Inc>,
        <https://1145.am/db/1430057/Alcon_Inc>,
        <https://1145.am/db/1443334/Alcon>,
        <https://1145.am/db/1540449/Alcon_Inc>,
        <https://1145.am/db/2279276/Alcon>,
        <https://1145.am/db/2279686/Alcon>,
        <https://1145.am/db/2293431/Alcon>,
        <https://1145.am/db/2298871/Alcon>,
        <https://1145.am/db/2298902/Alcon>,
        <https://1145.am/db/2299847/Alcon>,
        <https://1145.am/db/2308298/Alcon>,
        <https://1145.am/db/2311754/Alcon>,
        <https://1145.am/db/2323188/Alcon>,
        <https://1145.am/db/2345114/Alcon_Inc>,
        <https://1145.am/db/2360683/Alcon>,
        <https://1145.am/db/2547283/Alcon>,
        <https://1145.am/db/2549760/Alcon>,
        <https://1145.am/db/2551680/Alcon>,
        <https://1145.am/db/2559797/Alcon>,
        <https://1145.am/db/2561268/Alcon>,
        <https://1145.am/db/2581397/Alcon>,
        <https://1145.am/db/2582402/Alcon>,
        <https://1145.am/db/2587805/Alcon>,
        <https://1145.am/db/2590140/Alcon>,
        <https://1145.am/db/2593443/Alcon>,
        <https://1145.am/db/2594604/Alcon>,
        <https://1145.am/db/2595924/Alcon_Inc>,
        <https://1145.am/db/2597135/Alcon> ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2581397/Alcon> a org:Organization ;
    ns1:description "Pharmaceuticals" ;
    ns1:documentDate "2010-08-17T14:53:50+00:00"^^xsd:dateTime ;
    ns1:documentTitle "FTC Order Protects Consumers in U.S. Market for Eye Care Drug Used in Cataract Surgery" ;
    ns1:documentURL <https://www.fiercepharma.com/pharma/ftc-order-protects-consumers-u-s-market-for-eye-care-drug-used-cataract-surgery> ;
    ns1:foundName "Alcon",
        "Alcon, Inc.",
        "Alcon, Inc.," ;
    ns1:name "Alcon" ;
    ns1:sameAsHigh <https://1145.am/db/1443334/Alcon>,
        <https://1145.am/db/1633105/Amryt>,
        <https://1145.am/db/1633172/Amryt>,
        <https://1145.am/db/1645224/Amryt>,
        <https://1145.am/db/1683116/Amryt>,
        <https://1145.am/db/1975641/Aditxt>,
        <https://1145.am/db/2303588/Innocoll_Inc>,
        <https://1145.am/db/2306705/Aryx>,
        <https://1145.am/db/2306946/Amatsigroup>,
        <https://1145.am/db/2313223/Accera>,
        <https://1145.am/db/2323188/Alcon>,
        <https://1145.am/db/2337999/Akorn>,
        <https://1145.am/db/2340926/Innocoll>,
        <https://1145.am/db/2341615/Forma>,
        <https://1145.am/db/2342626/Affinivax_Inc>,
        <https://1145.am/db/2350800/Aryx>,
        <https://1145.am/db/2537618/Adare_Pharmaceuticals>,
        <https://1145.am/db/2546317/Akorn>,
        <https://1145.am/db/2549982/Aimmune>,
        <https://1145.am/db/2553835/Impax>,
        <https://1145.am/db/2559177/Impax>,
        <https://1145.am/db/2559178/Impax>,
        <https://1145.am/db/2560987/Admedus>,
        <https://1145.am/db/2569024/Akorn_Inc>,
        <https://1145.am/db/2569509/Adare_Pharmaceuticals>,
        <https://1145.am/db/2572248/Agila_Specialties>,
        <https://1145.am/db/2584185/Impax>,
        <https://1145.am/db/2584538/Aduro>,
        <https://1145.am/db/2588918/Akorn>,
        <https://1145.am/db/2597135/Alcon>,
        <https://1145.am/db/566598/Acino> ;
    ns1:sameAsMedium <https://1145.am/db/1077454/Alcon>,
        <https://1145.am/db/1078071/Alcon>,
        <https://1145.am/db/1078074/Alcon_Inc>,
        <https://1145.am/db/1084233/Alcon_Inc>,
        <https://1145.am/db/1085993/Alcon_Inc>,
        <https://1145.am/db/1196175/Alcon_Inc>,
        <https://1145.am/db/1294499/Alcon>,
        <https://1145.am/db/1294506/Alcon>,
        <https://1145.am/db/1295948/Alcon>,
        <https://1145.am/db/1296487/Alcon>,
        <https://1145.am/db/1371279/Alcon_Inc>,
        <https://1145.am/db/1417348/Alcon_Inc>,
        <https://1145.am/db/1418572/Alcon_Inc>,
        <https://1145.am/db/1430057/Alcon_Inc>,
        <https://1145.am/db/1520596/Alcon>,
        <https://1145.am/db/1520597/Alcon>,
        <https://1145.am/db/1521695/Alcon>,
        <https://1145.am/db/1540449/Alcon_Inc>,
        <https://1145.am/db/2279276/Alcon>,
        <https://1145.am/db/2279686/Alcon>,
        <https://1145.am/db/2291606/Alcon>,
        <https://1145.am/db/2293419/Alcon>,
        <https://1145.am/db/2293431/Alcon>,
        <https://1145.am/db/2298871/Alcon>,
        <https://1145.am/db/2298902/Alcon>,
        <https://1145.am/db/2299847/Alcon>,
        <https://1145.am/db/2305192/Alcon>,
        <https://1145.am/db/2308298/Alcon>,
        <https://1145.am/db/2311754/Alcon>,
        <https://1145.am/db/2314943/Alcon>,
        <https://1145.am/db/2314947/Alcon>,
        <https://1145.am/db/2321067/Alcon_Inc>,
        <https://1145.am/db/2345114/Alcon_Inc>,
        <https://1145.am/db/2360683/Alcon>,
        <https://1145.am/db/2367207/Alcon>,
        <https://1145.am/db/2547283/Alcon>,
        <https://1145.am/db/2549760/Alcon>,
        <https://1145.am/db/2551680/Alcon>,
        <https://1145.am/db/2552258/Alcon>,
        <https://1145.am/db/2553276/Alcon>,
        <https://1145.am/db/2553634/Alcon>,
        <https://1145.am/db/2559797/Alcon>,
        <https://1145.am/db/2561268/Alcon>,
        <https://1145.am/db/2572713/Alcon>,
        <https://1145.am/db/2573611/Alcon>,
        <https://1145.am/db/2575488/Alcon>,
        <https://1145.am/db/2577419/Alcon>,
        <https://1145.am/db/2579507/Alcon>,
        <https://1145.am/db/2579519/Alcon>,
        <https://1145.am/db/2580401/Alcon>,
        <https://1145.am/db/2581378/Alcon>,
        <https://1145.am/db/2581394/Alcon>,
        <https://1145.am/db/2582355/Alcon>,
        <https://1145.am/db/2582400/Alcon>,
        <https://1145.am/db/2582402/Alcon>,
        <https://1145.am/db/2584359/Alcon>,
        <https://1145.am/db/2586661/Alcon>,
        <https://1145.am/db/2587805/Alcon>,
        <https://1145.am/db/2590140/Alcon>,
        <https://1145.am/db/2590349/Alcon>,
        <https://1145.am/db/2593443/Alcon>,
        <https://1145.am/db/2594604/Alcon>,
        <https://1145.am/db/2595924/Alcon_Inc>,
        <https://1145.am/db/2598636/Alcon>,
        <https://1145.am/db/600939/Alcon>,
        <https://1145.am/db/600941/Alcon>,
        <https://1145.am/db/744985/Alcon> ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2589142/Zymogenetics> a org:Organization ;
    ns1:basedInLowRaw "NEW YORK" ;
    ns1:description "Biotechnology" ;
    ns1:documentDate "2010-09-28T12:04:31+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Bristol-Myers Squibb Announces Expiration of Hart-Scott-Rodino Waiting Period for Acquisition of ZymoGenetics, Inc." ;
    ns1:documentURL <https://www.fiercepharma.com/pharma/bristol-myers-squibb-announces-expiration-of-hart-scott-rodino-waiting-period-for-2> ;
    ns1:foundName "ZymoGenetics",
        "ZymoGenetics, Inc" ;
    ns1:name "ZymoGenetics" ;
    ns1:sameAsHigh <https://1145.am/db/2325221/Zymogenetics>,
        <https://1145.am/db/2340432/Zymogenetics>,
        <https://1145.am/db/2365157/Zymogenetics>,
        <https://1145.am/db/2585263/Zymogenetics> ;
    ns1:sameAsMedium <https://1145.am/db/2305700/Zymogenetics>,
        <https://1145.am/db/2317635/Zymogenetics>,
        <https://1145.am/db/2322515/Zymogenetics>,
        <https://1145.am/db/2324615/Zymogenetics>,
        <https://1145.am/db/2324755/Zymogenetics>,
        <https://1145.am/db/2350282/Zymogenetics>,
        <https://1145.am/db/2358038/Zymogenetics>,
        <https://1145.am/db/2358039/Zymogenetics>,
        <https://1145.am/db/2358044/Zymogenetics>,
        <https://1145.am/db/2358078/Zymogenetics>,
        <https://1145.am/db/2359104/Zymogenetics>,
        <https://1145.am/db/2359117/Zymogenetics>,
        <https://1145.am/db/2365203/Zymogenetics>,
        <https://1145.am/db/2367078/Zymogenetics>,
        <https://1145.am/db/2367082/Zymogenetics>,
        <https://1145.am/db/2367085/Zymogenetics>,
        <https://1145.am/db/2367306/Zymogenetics>,
        <https://1145.am/db/2545610/Zymogenetics>,
        <https://1145.am/db/2584317/Zymogenetics>,
        <https://1145.am/db/2584318/Zymogenetics>,
        <https://1145.am/db/2585238/Zymogenetics>,
        <https://1145.am/db/2592024/Zymogenetics>,
        <https://1145.am/db/2592993/Zymogenetics> ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2589142/Zymogenetics_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition",
        "merger" ;
    ns1:documentDate "2010-09-28T12:04:31+00:00"^^xsd:dateTime ;
    ns1:documentExtract "NEW YORK- (BUSINESS WIRE) - Bristol-Myers Squibb Company (NYSE: BMY) announced today that the Hart-Scott-Rodino (HSR) waiting period for its tender offer for ZymoGenetics, Inc. (NASDAQ: ZGEN) has expired." ;
    ns1:documentTitle "Bristol-Myers Squibb Announces Expiration of Hart-Scott-Rodino Waiting Period for Acquisition of ZymoGenetics, Inc." ;
    ns1:documentURL <https://www.fiercepharma.com/pharma/bristol-myers-squibb-announces-expiration-of-hart-scott-rodino-waiting-period-for-2> ;
    ns1:foundName "purchase",
        "tender offer" ;
    ns1:name "purchase",
        "tender offer" ;
    ns1:sourceName "Fierce Pharma" ;
    ns1:status "has not happened" ;
    ns1:target <https://1145.am/db/2589142/Zymogenetics> ;
    ns1:targetName "ZymoGenetics" ;
    ns1:whereGeoName "New York City" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5128581/about.rdf> ;
    ns1:whereRaw "New York City" .

<https://1145.am/db/2614893/One_Communications> a org:Organization ;
    ns1:description "telecommunications" ;
    ns1:documentDate "2010-12-09T20:52:24+00:00"^^xsd:dateTime ;
    ns1:documentTitle "nTelos breaks up wireless and wireline holdings into separate units" ;
    ns1:documentURL <https://www.fiercetelecom.com/telecom/ntelos-breaks-up-wireless-and-wireline-holdings-into-separate-units> ;
    ns1:foundName "One Communications" ;
    ns1:name "One Communications" ;
    ns1:sameAsHigh <https://1145.am/db/1730294/One_Communications>,
        <https://1145.am/db/2608212/One_Communications>,
        <https://1145.am/db/2609709/One_Communications>,
        <https://1145.am/db/2609788/Onelink_Communications>,
        <https://1145.am/db/2614189/One_Communications> ;
    ns1:sameAsMedium <https://1145.am/db/2169661/One_Communications>,
        <https://1145.am/db/2600844/One_Communications>,
        <https://1145.am/db/2603731/One_Communications>,
        <https://1145.am/db/2606667/One_Communications>,
        <https://1145.am/db/2614880/One_Communications>,
        <https://1145.am/db/2614889/One_Communications>,
        <https://1145.am/db/2615617/One_Communications> ;
    ns1:sourceName "Fierce Telecom" .

<https://1145.am/db/2203459/Ingenix> a org:Organization ;
    ns1:basedInHighGeoName "Eden Prairie" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5025219/about.rdf> ;
    ns1:basedInHighRaw "EDEN PRAIRIE, Minn." ;
    ns1:buyer <https://1145.am/db/2203459/Picis_Acquisition> ;
    ns1:description "health intelligence and analytics" ;
    ns1:documentDate "2010-07-22T14:00:07+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Ingenix to Acquire Picis" ;
    ns1:documentURL <https://www.fiercehealthcare.com/it/ingenix-to-acquire-picis-0> ;
    ns1:foundName "Ingenix" ;
    ns1:industry "health information technology and services" ;
    ns1:name "Ingenix" ;
    ns1:sameAsHigh <https://1145.am/db/2199924/Ingenix>,
        <https://1145.am/db/2203473/Ingenix>,
        <https://1145.am/db/2203476/Ingenix>,
        <https://1145.am/db/2204518/Ingenix>,
        <https://1145.am/db/2204532/Ingenix>,
        <https://1145.am/db/2205570/Ingenix>,
        <https://1145.am/db/2225094/Ingenix>,
        <https://1145.am/db/2227885/Ingenix>,
        <https://1145.am/db/2227908/Ingenix>,
        <https://1145.am/db/2231160/Ingenix>,
        <https://1145.am/db/2239159/Ingenix>,
        <https://1145.am/db/2239161/Ingenix>,
        <https://1145.am/db/2250964/Ingenix>,
        <https://1145.am/db/2251336/Ingenix>,
        <https://1145.am/db/2252305/Ingenix>,
        <https://1145.am/db/2252311/Ingenix>,
        <https://1145.am/db/2252318/Ingenix>,
        <https://1145.am/db/2262219/Ingenix>,
        <https://1145.am/db/2262258/Ingenix> ;
    ns1:sameAsMedium <https://1145.am/db/2205543/Ingenix>,
        <https://1145.am/db/2217392/Ingenix>,
        <https://1145.am/db/2218433/Ingenix>,
        <https://1145.am/db/2224570/Ingenix>,
        <https://1145.am/db/2237749/Ingenix>,
        <https://1145.am/db/2249263/Ingenix>,
        <https://1145.am/db/2251157/Ingenix>,
        <https://1145.am/db/2338799/Ingenix>,
        <https://1145.am/db/2344145/Ingenix>,
        <https://1145.am/db/2355125/Ingenix>,
        <https://1145.am/db/2581316/Ingenix>,
        <https://1145.am/db/2595379/Ingenix> ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2203476/Ingenix> a org:Organization ;
    ns1:basedInHighGeoName "Minnesota" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5037779/about.rdf> ;
    ns1:basedInHighRaw "Minn." ;
    ns1:buyer <https://1145.am/db/2203476/Picis_Acquisition> ;
    ns1:description "health intelligence and analytics throughout the health care system" ;
    ns1:documentDate "2010-07-26T18:43:07+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Ingenix to Acquire Picis" ;
    ns1:documentURL <https://www.fiercehealthcare.com/it/ingenix-to-acquire-picis> ;
    ns1:foundName "Ingenix" ;
    ns1:industry "health information technology and services" ;
    ns1:name "Ingenix" ;
    ns1:sameAsHigh <https://1145.am/db/2199924/Ingenix>,
        <https://1145.am/db/2203459/Ingenix>,
        <https://1145.am/db/2203473/Ingenix>,
        <https://1145.am/db/2204518/Ingenix>,
        <https://1145.am/db/2204532/Ingenix>,
        <https://1145.am/db/2205570/Ingenix>,
        <https://1145.am/db/2225094/Ingenix>,
        <https://1145.am/db/2227885/Ingenix>,
        <https://1145.am/db/2227908/Ingenix>,
        <https://1145.am/db/2231160/Ingenix>,
        <https://1145.am/db/2239159/Ingenix>,
        <https://1145.am/db/2239161/Ingenix>,
        <https://1145.am/db/2250964/Ingenix>,
        <https://1145.am/db/2251336/Ingenix>,
        <https://1145.am/db/2252305/Ingenix>,
        <https://1145.am/db/2252311/Ingenix>,
        <https://1145.am/db/2252318/Ingenix>,
        <https://1145.am/db/2262219/Ingenix>,
        <https://1145.am/db/2262258/Ingenix> ;
    ns1:sameAsMedium <https://1145.am/db/2205543/Ingenix>,
        <https://1145.am/db/2217392/Ingenix>,
        <https://1145.am/db/2218433/Ingenix>,
        <https://1145.am/db/2224570/Ingenix>,
        <https://1145.am/db/2237749/Ingenix>,
        <https://1145.am/db/2249263/Ingenix>,
        <https://1145.am/db/2251157/Ingenix>,
        <https://1145.am/db/2338799/Ingenix>,
        <https://1145.am/db/2344145/Ingenix>,
        <https://1145.am/db/2355125/Ingenix>,
        <https://1145.am/db/2581316/Ingenix>,
        <https://1145.am/db/2595379/Ingenix> ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2227885/Ingenix> a org:Organization ;
    ns1:basedInHighGeoName "Eden Prairie" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5025219/about.rdf> ;
    ns1:basedInHighRaw "EDEN PRAIRIE, Minn." ;
    ns1:buyer <https://1145.am/db/2227885/Picis_Acquisition> ;
    ns1:description "health intelligence and analytics" ;
    ns1:documentDate "2010-07-22T14:02:01+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Ingenix to Acquire Picis" ;
    ns1:documentURL <https://www.fiercehealthcare.com/practices/ingenix-to-acquire-picis> ;
    ns1:foundName "Ingenix" ;
    ns1:industry "health information technology and services" ;
    ns1:name "Ingenix" ;
    ns1:sameAsHigh <https://1145.am/db/2199924/Ingenix>,
        <https://1145.am/db/2203459/Ingenix>,
        <https://1145.am/db/2203473/Ingenix>,
        <https://1145.am/db/2203476/Ingenix>,
        <https://1145.am/db/2204518/Ingenix>,
        <https://1145.am/db/2204532/Ingenix>,
        <https://1145.am/db/2205570/Ingenix>,
        <https://1145.am/db/2225094/Ingenix>,
        <https://1145.am/db/2227908/Ingenix>,
        <https://1145.am/db/2231160/Ingenix>,
        <https://1145.am/db/2239159/Ingenix>,
        <https://1145.am/db/2239161/Ingenix>,
        <https://1145.am/db/2250964/Ingenix>,
        <https://1145.am/db/2251336/Ingenix>,
        <https://1145.am/db/2252305/Ingenix>,
        <https://1145.am/db/2252311/Ingenix>,
        <https://1145.am/db/2252318/Ingenix>,
        <https://1145.am/db/2262219/Ingenix>,
        <https://1145.am/db/2262258/Ingenix> ;
    ns1:sameAsMedium <https://1145.am/db/2205543/Ingenix>,
        <https://1145.am/db/2217392/Ingenix>,
        <https://1145.am/db/2218433/Ingenix>,
        <https://1145.am/db/2224570/Ingenix>,
        <https://1145.am/db/2237749/Ingenix>,
        <https://1145.am/db/2249263/Ingenix>,
        <https://1145.am/db/2251157/Ingenix>,
        <https://1145.am/db/2338799/Ingenix>,
        <https://1145.am/db/2344145/Ingenix>,
        <https://1145.am/db/2355125/Ingenix>,
        <https://1145.am/db/2581316/Ingenix>,
        <https://1145.am/db/2595379/Ingenix> ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2250964/Ingenix> a org:Organization ;
    ns1:basedInHighGeoName "Eden Prairie" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5025219/about.rdf> ;
    ns1:basedInHighRaw "EDEN PRAIRIE, Minn." ;
    ns1:buyer <https://1145.am/db/2250964/Picis_Acquisition> ;
    ns1:description "health intelligence and analytics" ;
    ns1:documentDate "2010-07-22T14:01:39+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Ingenix to Acquire Picis" ;
    ns1:documentURL <https://www.fiercehealthcare.com/healthcare/ingenix-to-acquire-picis-0> ;
    ns1:foundName "Ingenix" ;
    ns1:industry "health information technology and services" ;
    ns1:name "Ingenix" ;
    ns1:sameAsHigh <https://1145.am/db/2199924/Ingenix>,
        <https://1145.am/db/2203459/Ingenix>,
        <https://1145.am/db/2203473/Ingenix>,
        <https://1145.am/db/2203476/Ingenix>,
        <https://1145.am/db/2204518/Ingenix>,
        <https://1145.am/db/2204532/Ingenix>,
        <https://1145.am/db/2205570/Ingenix>,
        <https://1145.am/db/2225094/Ingenix>,
        <https://1145.am/db/2227885/Ingenix>,
        <https://1145.am/db/2227908/Ingenix>,
        <https://1145.am/db/2231160/Ingenix>,
        <https://1145.am/db/2239159/Ingenix>,
        <https://1145.am/db/2239161/Ingenix>,
        <https://1145.am/db/2251336/Ingenix>,
        <https://1145.am/db/2252305/Ingenix>,
        <https://1145.am/db/2252311/Ingenix>,
        <https://1145.am/db/2252318/Ingenix>,
        <https://1145.am/db/2262219/Ingenix>,
        <https://1145.am/db/2262258/Ingenix> ;
    ns1:sameAsMedium <https://1145.am/db/2205543/Ingenix>,
        <https://1145.am/db/2217392/Ingenix>,
        <https://1145.am/db/2218433/Ingenix>,
        <https://1145.am/db/2224570/Ingenix>,
        <https://1145.am/db/2237749/Ingenix>,
        <https://1145.am/db/2249263/Ingenix>,
        <https://1145.am/db/2251157/Ingenix>,
        <https://1145.am/db/2338799/Ingenix>,
        <https://1145.am/db/2344145/Ingenix>,
        <https://1145.am/db/2355125/Ingenix>,
        <https://1145.am/db/2581316/Ingenix>,
        <https://1145.am/db/2595379/Ingenix> ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2262219/Ingenix> a org:Organization ;
    ns1:basedInHighGeoName "Eden Prairie" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5025219/about.rdf> ;
    ns1:basedInHighRaw "EDEN PRAIRIE, Minn." ;
    ns1:buyer <https://1145.am/db/2262219/Picis_Acquisition> ;
    ns1:description "health intelligence and analytics" ;
    ns1:documentDate "2010-07-22T15:10:34+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Ingenix to Acquire Picis" ;
    ns1:documentURL <https://www.fiercehealthcare.com/payer/ingenix-to-acquire-picis> ;
    ns1:foundName "Ingenix" ;
    ns1:industry "health information technology and services" ;
    ns1:name "Ingenix" ;
    ns1:sameAsHigh <https://1145.am/db/2199924/Ingenix>,
        <https://1145.am/db/2203459/Ingenix>,
        <https://1145.am/db/2203473/Ingenix>,
        <https://1145.am/db/2203476/Ingenix>,
        <https://1145.am/db/2204518/Ingenix>,
        <https://1145.am/db/2204532/Ingenix>,
        <https://1145.am/db/2205570/Ingenix>,
        <https://1145.am/db/2225094/Ingenix>,
        <https://1145.am/db/2227885/Ingenix>,
        <https://1145.am/db/2227908/Ingenix>,
        <https://1145.am/db/2231160/Ingenix>,
        <https://1145.am/db/2239159/Ingenix>,
        <https://1145.am/db/2239161/Ingenix>,
        <https://1145.am/db/2250964/Ingenix>,
        <https://1145.am/db/2251336/Ingenix>,
        <https://1145.am/db/2252305/Ingenix>,
        <https://1145.am/db/2252311/Ingenix>,
        <https://1145.am/db/2252318/Ingenix>,
        <https://1145.am/db/2262258/Ingenix> ;
    ns1:sameAsMedium <https://1145.am/db/2205543/Ingenix>,
        <https://1145.am/db/2217392/Ingenix>,
        <https://1145.am/db/2218433/Ingenix>,
        <https://1145.am/db/2224570/Ingenix>,
        <https://1145.am/db/2237749/Ingenix>,
        <https://1145.am/db/2249263/Ingenix>,
        <https://1145.am/db/2251157/Ingenix>,
        <https://1145.am/db/2338799/Ingenix>,
        <https://1145.am/db/2344145/Ingenix>,
        <https://1145.am/db/2355125/Ingenix>,
        <https://1145.am/db/2581316/Ingenix>,
        <https://1145.am/db/2595379/Ingenix> ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2341003/Series_C_Investment_5am_Ventures_Clarus_Ventures_New_Leaf_Venture_Partners_Pearl_Therapeutics_Inc_Vatera_Healthcare_Partners_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-10-19T14:00:23+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Pearl Therapeutics Raises $ 69 Million Series C Financing.",
        "REDWOOD CITY, Calif., Oct. 19 /PRNewswire/ - Pearl Therapeutics Inc., a privately held company developing clinically differentiated combination therapies for the treatment of highly prevalent chronic respiratory diseases, including chronic obstructive pulmonary disease (COPD) , today announced a $ 69 million Series C financing." ;
    ns1:documentTitle "Pearl Therapeutics Raises $69 Million Series C Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/pearl-therapeutics-raises-69-million-series-c-financing> ;
    ns1:foundName "financing" ;
    ns1:name "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2341003/Pearl_Therapeutics_Inc> ;
    ns1:targetDetails "Series C" ;
    ns1:valueRaw "$ 69 Million",
        "$ 69 million" ;
    ns1:when "2010-10-19T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "Oct. 19" ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "United States" .

<https://1145.am/db/2343486/Series_A_Investment_Euthymics_Bioscience_Gbs_Venture_Partners_Hambrecht___Quist_Capital_Management_Novartis_Venture_Funds_State_Of_Wisconsin_Investment_Board_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-07-22T13:15:02+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Euthymics Bioscience, Inc., a clinical-stage company developing next-generation antidepressants, today announced the completion of a Series A financing - led by Novartis Venture Funds and Venture Investors - for a total investment commitment of $ 24 million in milestone-conditioned tranches." ;
    ns1:documentTitle "Euthymics Bioscience, Inc. Closes $24 Million Series A Financing and Completes Acquisition of DOV Pharmaceutical" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/euthymics-bioscience-inc-closes-24-million-series-a-financing-and-completes-acquisition-of> ;
    ns1:foundName "financing" ;
    ns1:name "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2343486/Euthymics_Bioscience> ;
    ns1:targetDetails "Series A" ;
    ns1:valueRaw "$ 24 million" ;
    ns1:whereGeoName "Wisconsin" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5279468/about.rdf> ;
    ns1:whereRaw "Wisconsin" .

<https://1145.am/db/2349753/Series_B_Investment_Abingworth_Dicerna_Pharmaceuticals_Domain_Associates_Oxford_Bioscience_Partners_Skyline_Ventures_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-08-11T13:20:47+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Dicerna Closes $ 25 Million Series B Financing.",
        "WATERTOWN, Mass.- (BUSINESS WIRE) -Dicerna Pharmaceuticals, Inc. (Dicerna) , a second generation RNA interference (RNAi) company developing novel therapeutics utilizing its proprietary Dicer Substrate TechnologyTM and Dicer Substrate siRNA (DsiRNA) molecules, today announced that it has closed a $ 25 million Series B round of financing." ;
    ns1:documentTitle "Dicerna Closes $25 Million Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/dicerna-closes-25-million-series-b-financing> ;
    ns1:foundName "financing" ;
    ns1:name "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2349753/Dicerna_Pharmaceuticals> ;
    ns1:targetDetails "Series B" ;
    ns1:valueRaw "$ 25 Million",
        "$ 25 million" ;
    ns1:whereGeoName "Watertown" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/4954611/about.rdf> ;
    ns1:whereRaw "WATERTOWN, Mass" .

<https://1145.am/db/2352382/Sv_Life_Sciences> a org:Organization ;
    ns1:basedInLowRaw "Switzerland" ;
    ns1:description "venture capital firms in the biotech industry" ;
    ns1:documentDate "2010-11-12T14:21:30+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Delenex Therapeutics Secures CHF 13.5 Million Series A Venture Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/delenex-therapeutics-secures-chf-13-5-million-series-a-venture-financing> ;
    ns1:foundName "SV Life Sciences" ;
    ns1:industry "biotech" ;
    ns1:investor <https://1145.am/db/2352382/Series_A_Investment_Biomedinvest_Delenex_Therapeutics_Ag_Hbm_Biocapital_Hbm_Bioventures_Sv_Life_Sciences_Vi_Partners_Completed> ;
    ns1:name "SV Life Sciences" ;
    ns1:sameAsHigh <https://1145.am/db/1009450/Biocompare>,
        <https://1145.am/db/1023985/Orgenesis_Inc>,
        <https://1145.am/db/1051761/Curative_Biotechnology_Inc>,
        <https://1145.am/db/1066819/Biocentriq_Inc>,
        <https://1145.am/db/1088717/Biosynth>,
        <https://1145.am/db/1089921/Biosynth>,
        <https://1145.am/db/1116501/Alvotech_Sa>,
        <https://1145.am/db/1117630/Alvotech_Sa>,
        <https://1145.am/db/1124798/Accustem_Sciences>,
        <https://1145.am/db/1130652/Cogent_Biosciences>,
        <https://1145.am/db/1132106/Cogent_Biosciences>,
        <https://1145.am/db/1140693/Curative_Biotechnology_Inc>,
        <https://1145.am/db/1142391/Cogent_Biosciences_Inc>,
        <https://1145.am/db/1143081/Bioinvent_International_Ab>,
        <https://1145.am/db/1154042/Applied_Biology>,
        <https://1145.am/db/1167874/Ensysce_Biosciences>,
        <https://1145.am/db/1174373/Biosynth>,
        <https://1145.am/db/1175242/Biosynth>,
        <https://1145.am/db/1179100/Ensysce_Biosciences>,
        <https://1145.am/db/1216524/Forbion>,
        <https://1145.am/db/1216997/180_Life_Sciences>,
        <https://1145.am/db/1222768/180_Life_Sciences_Corp>,
        <https://1145.am/db/1229517/Enveric_Biosciences>,
        <https://1145.am/db/1236975/Enveric_Biosciences>,
        <https://1145.am/db/1252190/Forbion>,
        <https://1145.am/db/1271538/Ensysce_Biosciences>,
        <https://1145.am/db/1278078/Monod_Bio>,
        <https://1145.am/db/1278479/Monod_Bio>,
        <https://1145.am/db/1293677/Biosion>,
        <https://1145.am/db/1295884/Brii_Biosciences_Limited>,
        <https://1145.am/db/1320133/Hc_Bioscience>,
        <https://1145.am/db/1336573/Hc_Bioscience>,
        <https://1145.am/db/1354619/Biogen>,
        <https://1145.am/db/1382711/Solid_Biosciences_Inc>,
        <https://1145.am/db/1386738/Vergent_Bioscience>,
        <https://1145.am/db/1387057/Vergent_Bioscience>,
        <https://1145.am/db/1408611/Alvotech>,
        <https://1145.am/db/1490000/Enavate_Sciences>,
        <https://1145.am/db/1506505/Biodesix>,
        <https://1145.am/db/1509205/Biodesix>,
        <https://1145.am/db/1522275/Stagezero_Life_Sciences_Ltd>,
        <https://1145.am/db/1534347/Enveric_Biosciences>,
        <https://1145.am/db/1536048/Replicel_Life_Sciences_Inc>,
        <https://1145.am/db/1537082/Vergent_Bioscience>,
        <https://1145.am/db/1537788/Vergent_Bioscience>,
        <https://1145.am/db/1547927/Solid_Biosciences_Inc>,
        <https://1145.am/db/1548092/Innoforce>,
        <https://1145.am/db/1548093/Alvotech>,
        <https://1145.am/db/1553518/Solid_Biosciences_Inc>,
        <https://1145.am/db/1556387/Avalon_Bioventures>,
        <https://1145.am/db/1562950/Ensysce_Biosciences>,
        <https://1145.am/db/1577542/Bioasis>,
        <https://1145.am/db/1585988/Alvotech>,
        <https://1145.am/db/1585992/Alvotech>,
        <https://1145.am/db/1586236/Alvotech>,
        <https://1145.am/db/1586786/Bioasis>,
        <https://1145.am/db/1619665/Bioversys_Ag>,
        <https://1145.am/db/1630753/Solid_Biosciences_Inc>,
        <https://1145.am/db/1639462/Forte_Biosciences>,
        <https://1145.am/db/1640582/Forte_Biosciences>,
        <https://1145.am/db/1664988/Upstream_Bio>,
        <https://1145.am/db/1668597/Verily>,
        <https://1145.am/db/1685433/Enveric_Biosciences>,
        <https://1145.am/db/1696213/Genentech>,
        <https://1145.am/db/1728598/Life_Technologies_Corporation>,
        <https://1145.am/db/1787025/Verily>,
        <https://1145.am/db/1821833/Verily>,
        <https://1145.am/db/1945850/Puretech>,
        <https://1145.am/db/2000772/Biosynth>,
        <https://1145.am/db/2010010/Iveric_Bio_Inc>,
        <https://1145.am/db/2019705/Eqt_Life_Sciences>,
        <https://1145.am/db/2023773/Genentech>,
        <https://1145.am/db/2032047/Enavate_Sciences>,
        <https://1145.am/db/2032047/Upstream_Bio>,
        <https://1145.am/db/2053399/Univercells_Technologies>,
        <https://1145.am/db/2061027/Roivant_Sciences>,
        <https://1145.am/db/2073555/Puretech_Scientific>,
        <https://1145.am/db/209111/Bioage>,
        <https://1145.am/db/2113176/Genentech>,
        <https://1145.am/db/2115362/2seventy_Bio>,
        <https://1145.am/db/2123899/Biosynth>,
        <https://1145.am/db/2152786/Aruvant_Sciences>,
        <https://1145.am/db/2152862/Therachon>,
        <https://1145.am/db/2152961/Arcus_Biosciences>,
        <https://1145.am/db/2153083/Arcus_Biosciences>,
        <https://1145.am/db/2153509/Or>,
        <https://1145.am/db/2154521/Baergic_Bio>,
        <https://1145.am/db/2154848/Brii_Biosciences>,
        <https://1145.am/db/2155108/Roivant_Sciences>,
        <https://1145.am/db/2155252/Bioagilytix>,
        <https://1145.am/db/2156304/Puretech>,
        <https://1145.am/db/2181432/Verily>,
        <https://1145.am/db/2188567/Verily_Life_Sciences>,
        <https://1145.am/db/2189613/Genapsys>,
        <https://1145.am/db/2198949/Cellectricon>,
        <https://1145.am/db/222920/Genapsys_Inc>,
        <https://1145.am/db/2230848/Bioohio>,
        <https://1145.am/db/2280215/Concentra_Biosciences>,
        <https://1145.am/db/2280734/Forte_Biosciences>,
        <https://1145.am/db/2281285/Locus_Biosciences>,
        <https://1145.am/db/2281875/Solid_Biosciences>,
        <https://1145.am/db/2282549/Coave>,
        <https://1145.am/db/2282760/Bioreliance>,
        <https://1145.am/db/2282760/Inotiv>,
        <https://1145.am/db/2283032/Morningside_Ventures>,
        <https://1145.am/db/2283398/Sab>,
        <https://1145.am/db/2283480/Hcbioscience>,
        <https://1145.am/db/2285390/Cellarity>,
        <https://1145.am/db/2285399/Solid_Biosciences>,
        <https://1145.am/db/2285897/Hologic>,
        <https://1145.am/db/2285963/Iveric_Bio>,
        <https://1145.am/db/2286634/Therachon>,
        <https://1145.am/db/2286677/Roivant_Sciences>,
        <https://1145.am/db/2287185/Brii_Biosciences>,
        <https://1145.am/db/2290342/Biotech_Sector>,
        <https://1145.am/db/2290381/Life_Sciences>,
        <https://1145.am/db/2292237/Bioinvent>,
        <https://1145.am/db/2293367/Ascentage>,
        <https://1145.am/db/2293654/Eleven_Bio>,
        <https://1145.am/db/2293662/Sv_Life_Sciences>,
        <https://1145.am/db/2295596/Roivant_Sciences>,
        <https://1145.am/db/2295654/Sv>,
        <https://1145.am/db/2295929/Life_Technologies>,
        <https://1145.am/db/2296584/Enterin>,
        <https://1145.am/db/2296692/Tp>,
        <https://1145.am/db/2297083/Biogen_Idec>,
        <https://1145.am/db/2297978/Ocugen>,
        <https://1145.am/db/2298237/Life_Technologies>,
        <https://1145.am/db/2298404/Bioz>,
        <https://1145.am/db/2298499/Inthera_Bioscience>,
        <https://1145.am/db/2298505/Inventisbio>,
        <https://1145.am/db/2298709/Life_Technologies>,
        <https://1145.am/db/2298866/Biosafe_Group>,
        <https://1145.am/db/2298948/Bioverativ>,
        <https://1145.am/db/2299124/Life_Technologies>,
        <https://1145.am/db/2299472/Aadi_Bioscience>,
        <https://1145.am/db/2300786/Axovant_Sciences>,
        <https://1145.am/db/2300790/Axovant_Sciences>,
        <https://1145.am/db/2301003/Roivant_Sciences>,
        <https://1145.am/db/2301684/Biogen_Idec_Inc>,
        <https://1145.am/db/2301979/Biogen_Idec_Inc>,
        <https://1145.am/db/2301983/Biogen_Idec>,
        <https://1145.am/db/2302002/Biogen_Idec>,
        <https://1145.am/db/2303130/Bioreliance_Corporation>,
        <https://1145.am/db/2303317/Applied_Biosystems>,
        <https://1145.am/db/2303604/Biogen_Idec>,
        <https://1145.am/db/2304650/Bioprocessors_Corp>,
        <https://1145.am/db/2304650/Life>,
        <https://1145.am/db/2305210/Biogen_Idec>,
        <https://1145.am/db/2306250/Bioadvance>,
        <https://1145.am/db/2306259/Bioanalab>,
        <https://1145.am/db/2306288/Bioanalab>,
        <https://1145.am/db/2308142/Biogen_Idec>,
        <https://1145.am/db/2310216/Biogen_Idec>,
        <https://1145.am/db/2310216/Genentech>,
        <https://1145.am/db/2310979/Cogenics>,
        <https://1145.am/db/2311995/Biovitrum>,
        <https://1145.am/db/2312238/Prometic_Life_Sciences>,
        <https://1145.am/db/2313533/Biosource_International>,
        <https://1145.am/db/2313760/Sistemic_Ltd>,
        <https://1145.am/db/2313762/Sistemic_Ltd>,
        <https://1145.am/db/2313763/Biomarin>,
        <https://1145.am/db/2314526/Bio-Rad>,
        <https://1145.am/db/2315615/Anormed>,
        <https://1145.am/db/2316066/Biogen_Idec>,
        <https://1145.am/db/2317136/Biogen_Idec_Inc>,
        <https://1145.am/db/2318537/Genomics>,
        <https://1145.am/db/2319551/Medevol>,
        <https://1145.am/db/2319959/Progentech>,
        <https://1145.am/db/2320138/Biogen_Idec>,
        <https://1145.am/db/2320164/Anaptys_Biosciences>,
        <https://1145.am/db/2320435/Ym_Biosciences_Inc>,
        <https://1145.am/db/2322209/Genentech>,
        <https://1145.am/db/2322417/Bio-Quant>,
        <https://1145.am/db/2322417/Biotox_Sciences>,
        <https://1145.am/db/2323003/Bioadvance>,
        <https://1145.am/db/2324015/Alta_Partners>,
        <https://1145.am/db/2325377/Celmed_Biosciences>,
        <https://1145.am/db/2325387/Bioadvance>,
        <https://1145.am/db/2326063/Biooutsource>,
        <https://1145.am/db/2327677/Fundamental_Applied_Biology>,
        <https://1145.am/db/2327982/Biovex_Inc>,
        <https://1145.am/db/2328028/Biotrove>,
        <https://1145.am/db/2328815/Fundamental_Applied_Biology>,
        <https://1145.am/db/2329870/Complex_Biosystems_Gmbh>,
        <https://1145.am/db/2330058/Bio-Quant>,
        <https://1145.am/db/2330348/Blaze_Bioscience>,
        <https://1145.am/db/2332771/S_*_Bio>,
        <https://1145.am/db/2333005/Genizon_Biosciences>,
        <https://1145.am/db/2334156/Genizon>,
        <https://1145.am/db/2335943/Genentech>,
        <https://1145.am/db/2336178/Biocon_Limited>,
        <https://1145.am/db/2336178/Biocon_Ltd>,
        <https://1145.am/db/2336383/Biocrates_Life_Sciences_Ag>,
        <https://1145.am/db/2336736/Coherus_Biosciences>,
        <https://1145.am/db/2336983/Biogen_Idec>,
        <https://1145.am/db/2337110/Bioutah>,
        <https://1145.am/db/2337412/Blaze_Bioscience>,
        <https://1145.am/db/2337664/Advent_Life_Sciences>,
        <https://1145.am/db/2338193/Sv_Life_Sciences>,
        <https://1145.am/db/2338837/Coherus_Biosciences>,
        <https://1145.am/db/2340502/Massbio>,
        <https://1145.am/db/2340513/Massbio>,
        <https://1145.am/db/2340560/Puretech>,
        <https://1145.am/db/2341443/Biosystems_International>,
        <https://1145.am/db/2341509/Epic_Sciences>,
        <https://1145.am/db/2341676/Bioforward>,
        <https://1145.am/db/2342754/Fidelity_Biosciences>,
        <https://1145.am/db/2342768/Fidelity_Biosciences>,
        <https://1145.am/db/2342862/Sv_Life_Sciences>,
        <https://1145.am/db/2343761/Ovascience>,
        <https://1145.am/db/2343777/Ovascience>,
        <https://1145.am/db/2343791/Bioniche_Life_Sciences_Inc>,
        <https://1145.am/db/2344638/Coherus_Biosciences>,
        <https://1145.am/db/2345112/Med_Biogene_Inc>,
        <https://1145.am/db/2345132/Biocon>,
        <https://1145.am/db/2345999/Biogen_Idec>,
        <https://1145.am/db/2346485/Pracinostat>,
        <https://1145.am/db/2347467/Theraclone_Sciences>,
        <https://1145.am/db/2347950/Epic_Sciences>,
        <https://1145.am/db/2348109/Immatics_Biotechnologies_Gmbh>,
        <https://1145.am/db/2349436/Ovascience>,
        <https://1145.am/db/2350267/Harvard_Bioscience_Inc>,
        <https://1145.am/db/2350471/Biovex>,
        <https://1145.am/db/2350645/Biochrom_Ag>,
        <https://1145.am/db/2351192/Genticel>,
        <https://1145.am/db/2351312/Themis_Bioscience>,
        <https://1145.am/db/2351397/Sv_Life_Sciences>,
        <https://1145.am/db/2351472/Mymetics>,
        <https://1145.am/db/2351853/Life_Technologies>,
        <https://1145.am/db/2351921/Ovascience>,
        <https://1145.am/db/2352069/Biogen_Idec>,
        <https://1145.am/db/2354537/Fidelity_Biosciences>,
        <https://1145.am/db/2354835/Biovex>,
        <https://1145.am/db/2355219/Stellar_Biotechnologies_Inc>,
        <https://1145.am/db/2355236/Stellar_Biotechnologies_Inc>,
        <https://1145.am/db/2356064/Frontline_Bioventures>,
        <https://1145.am/db/2356509/Inq_Biosciences_Corporation>,
        <https://1145.am/db/2357079/Techne_Corporation>,
        <https://1145.am/db/2358271/Sv_Life_Sciences>,
        <https://1145.am/db/2358296/Biogen_Idec>,
        <https://1145.am/db/2359227/Fidelity_Biosciences>,
        <https://1145.am/db/2360075/Bionomics>,
        <https://1145.am/db/2360313/Engene>,
        <https://1145.am/db/2361502/Ovascience>,
        <https://1145.am/db/2362647/Bioqual>,
        <https://1145.am/db/2362737/Life_Sciences>,
        <https://1145.am/db/2363484/Bioscale>,
        <https://1145.am/db/2363485/Bioscale_Inc>,
        <https://1145.am/db/2363668/Ovasciencesm>,
        <https://1145.am/db/2364681/Biogen_Idec>,
        <https://1145.am/db/2366915/Biogen_Idec>,
        <https://1145.am/db/2368129/V-Bio_Ventures>,
        <https://1145.am/db/2368752/Replicel_Life_Sciences_Inc>,
        <https://1145.am/db/2369498/Genentech>,
        <https://1145.am/db/2370383/Prometic_Life_Sciences>,
        <https://1145.am/db/2370548/Bionovion>,
        <https://1145.am/db/2370549/Bionovion>,
        <https://1145.am/db/2370806/Alvotech>,
        <https://1145.am/db/2538197/Orgenesis>,
        <https://1145.am/db/2542617/Core_Biogenesis>,
        <https://1145.am/db/2542993/Biogen_Idec>,
        <https://1145.am/db/2550495/Bioatla>,
        <https://1145.am/db/2552636/Ark_Biosciences>,
        <https://1145.am/db/2553773/Mabxience>,
        <https://1145.am/db/2563996/Biocnd>,
        <https://1145.am/db/256464/Atai_Life_Sciences>,
        <https://1145.am/db/2566932/Exosomics>,
        <https://1145.am/db/2567231/Genentech>,
        <https://1145.am/db/2568479/Subintro>,
        <https://1145.am/db/2569491/Forbion_Capital_Partners>,
        <https://1145.am/db/2571023/Biochrom_Ag>,
        <https://1145.am/db/2577183/Biogen_Idec>,
        <https://1145.am/db/2577644/Presage_Biosciences>,
        <https://1145.am/db/2578308/Intermune>,
        <https://1145.am/db/2578528/Biogen_Idec>,
        <https://1145.am/db/2580665/Themis_Bioscience>,
        <https://1145.am/db/2580671/Themis_Bioscience>,
        <https://1145.am/db/2584538/Bionovion>,
        <https://1145.am/db/2594353/S_*_Bio_Pte_Ltd>,
        <https://1145.am/db/2797140/Biotheus>,
        <https://1145.am/db/322594/Roivant_Sciences>,
        <https://1145.am/db/356493/Atai_Life_Sciences_Bv>,
        <https://1145.am/db/396787/Biotheryx>,
        <https://1145.am/db/417096/Solid_Biosciences_Inc>,
        <https://1145.am/db/417543/180_Life_Sciences_Corp>,
        <https://1145.am/db/417568/Ultivue>,
        <https://1145.am/db/425981/180_Life_Sciences_Corp>,
        <https://1145.am/db/436937/Triad_Life_Sciences>,
        <https://1145.am/db/471380/Insidescientific>,
        <https://1145.am/db/481671/Biolegend>,
        <https://1145.am/db/482988/Biolegend>,
        <https://1145.am/db/486391/Biolife_Solutions>,
        <https://1145.am/db/505292/Ensysce_Biosciences>,
        <https://1145.am/db/520363/Biohive>,
        <https://1145.am/db/521860/Tosoh_Bioscience_Llc>,
        <https://1145.am/db/523221/Biohive>,
        <https://1145.am/db/540091/Curative_Biotechnology_Inc>,
        <https://1145.am/db/540784/Coherus_Biosciences_Inc>,
        <https://1145.am/db/544370/Replicel_Life_Sciences_Inc>,
        <https://1145.am/db/591563/180_Life_Sciences>,
        <https://1145.am/db/624546/Ensysce_Biosciences>,
        <https://1145.am/db/730321/Biosion>,
        <https://1145.am/db/739185/Sqz_Biotechnologies>,
        <https://1145.am/db/767994/Biotech_Prokidney_Lp>,
        <https://1145.am/db/818850/Ensysce_Biosciences>,
        <https://1145.am/db/877317/Accustem_Sciences>,
        <https://1145.am/db/922807/Biolabs>,
        <https://1145.am/db/941576/Orgenesis_Inc>,
        <https://1145.am/db/948136/Ensysce_Biosciences_Inc>,
        <https://1145.am/db/958575/Biocompare>,
        <https://1145.am/db/958575/Scilan>,
        <https://1145.am/db/968301/Ansa_Biotechnologies>,
        <https://1145.am/db/972968/Ansa_Biotechnologies>,
        <https://1145.am/db/979663/Biostrand>,
        <https://1145.am/db/979842/Biostrand_Bv>,
        <https://1145.am/db/986828/Ensysce_Biosciences>,
        <https://1145.am/db/991347/Genovac> ;
    ns1:sameAsMedium <https://1145.am/db/2236188/Sv_Life_Sciences>,
        <https://1145.am/db/2246177/Sv_Life_Sciences>,
        <https://1145.am/db/2293765/Sv_Life_Sciences>,
        <https://1145.am/db/2297439/Sv_Life_Sciences>,
        <https://1145.am/db/2297604/Sv_Life_Sciences>,
        <https://1145.am/db/2298869/Sv_Life_Sciences>,
        <https://1145.am/db/2300322/Sv_Life_Sciences>,
        <https://1145.am/db/2302994/Sv_Life_Sciences>,
        <https://1145.am/db/2302995/Sv_Life_Sciences>,
        <https://1145.am/db/2305587/Sv_Life_Sciences>,
        <https://1145.am/db/2310485/Sv_Life_Sciences>,
        <https://1145.am/db/2311540/Sv_Life_Sciences>,
        <https://1145.am/db/2312831/Sv_Life_Sciences>,
        <https://1145.am/db/2312833/Sv_Life_Sciences>,
        <https://1145.am/db/2313287/Sv_Life_Sciences>,
        <https://1145.am/db/2313322/Sv_Life_Sciences>,
        <https://1145.am/db/2313438/Sv_Life_Sciences>,
        <https://1145.am/db/2314515/Sv_Life_Sciences>,
        <https://1145.am/db/2314625/Sv_Life_Sciences>,
        <https://1145.am/db/2316038/Sv_Life_Sciences>,
        <https://1145.am/db/2317635/Sv_Life_Sciences>,
        <https://1145.am/db/2319338/Sv_Life_Sciences>,
        <https://1145.am/db/2321713/Sv_Life_Sciences>,
        <https://1145.am/db/2321861/Sv_Life_Sciences>,
        <https://1145.am/db/2321870/Sv_Life_Sciences>,
        <https://1145.am/db/2327405/Sv_Life_Sciences>,
        <https://1145.am/db/2327677/Sv_Life_Sciences>,
        <https://1145.am/db/2328815/Sv_Life_Sciences>,
        <https://1145.am/db/2329550/Sv_Life_Sciences>,
        <https://1145.am/db/2336313/Sv_Life_Sciences>,
        <https://1145.am/db/2336890/Sv_Life_Sciences>,
        <https://1145.am/db/2337166/Sv_Life_Sciences>,
        <https://1145.am/db/2338196/Sv_Life_Sciences>,
        <https://1145.am/db/2339295/Sv_Life_Sciences>,
        <https://1145.am/db/2342260/Sv_Life_Sciences>,
        <https://1145.am/db/2342261/Sv_Life_Sciences>,
        <https://1145.am/db/2342266/Sv_Life_Sciences>,
        <https://1145.am/db/2342284/Sv_Life_Sciences>,
        <https://1145.am/db/2342445/Sv_Life_Sciences>,
        <https://1145.am/db/2343467/Sv_Life_Sciences>,
        <https://1145.am/db/2343722/Sv_Life_Sciences>,
        <https://1145.am/db/2343725/Sv_Life_Sciences>,
        <https://1145.am/db/2343737/Sv_Life_Sciences>,
        <https://1145.am/db/2346832/Sv_Life_Sciences>,
        <https://1145.am/db/2347389/Sv_Life_Sciences>,
        <https://1145.am/db/2349406/Sv_Life_Sciences>,
        <https://1145.am/db/2349426/Sv_Life_Sciences>,
        <https://1145.am/db/2350034/Sv_Life_Sciences>,
        <https://1145.am/db/2350720/Sv_Life_Sciences>,
        <https://1145.am/db/2351394/Sv_Life_Sciences>,
        <https://1145.am/db/2352383/Sv_Life_Sciences>,
        <https://1145.am/db/2353098/Sv_Life_Sciences>,
        <https://1145.am/db/2353439/Sv_Life_Sciences>,
        <https://1145.am/db/2355586/Sv_Life_Sciences>,
        <https://1145.am/db/2356861/Sv_Life_Sciences>,
        <https://1145.am/db/2356876/Sv_Life_Sciences>,
        <https://1145.am/db/2358272/Sv_Life_Sciences>,
        <https://1145.am/db/2359125/Sv_Life_Sciences>,
        <https://1145.am/db/2360756/Sv_Life_Sciences>,
        <https://1145.am/db/2360758/Sv_Life_Sciences>,
        <https://1145.am/db/2361065/Sv_Life_Sciences>,
        <https://1145.am/db/2365315/Sv_Life_Sciences>,
        <https://1145.am/db/2366519/Sv_Life_Sciences>,
        <https://1145.am/db/2366860/Sv_Life_Sciences>,
        <https://1145.am/db/2368251/Sv_Life_Sciences>,
        <https://1145.am/db/2368572/Sv_Life_Sciences> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2354899/Series_B_Investment_Domain_Associates_Novo_Ventures_Otonomy_Rivervest_Venture_Partners_Tpg_Biotech_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-08-30T13:07:55+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Otonomy Closes $ 38.5 Million Series B Financing.",
        "SAN DIEGO, Aug. 30 /PRNewswire/ - Otonomy, Inc. announced today that it has closed a $ 38.5 million Series B financing co - led by Novo Ventures and RiverVest Venture Partners, and joined by Domain Associates and TPG Biotech." ;
    ns1:documentTitle "Otonomy Closes $38.5 Million Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/otonomy-closes-38-5-million-series-b-financing> ;
    ns1:foundName "financing" ;
    ns1:name "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2354899/Otonomy> ;
    ns1:targetDetails "Series B" ;
    ns1:valueRaw "$ 38.5 Million",
        "$ 38.5 million" ;
    ns1:when "2010-08-30T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "Aug. 30" ;
    ns1:whereGeoName "San Diego County" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5391832/about.rdf> ;
    ns1:whereRaw "SAN DIEGO" .

<https://1145.am/db/2357626/Series_A_Investment_Angus_Mitchell_Histogen_Leonard_Lavin_Lordship_Ventures_Secure_Medical_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-12-01T15:12:33+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Histogen Announces Completion of Series A Financing.",
        "SAN DIEGO, December 1, 2010 - Histogen, Inc., a regenerative medicine company developing solutions based on the products of newborn cells grown under embryonic conditions, today announced the successful completion of its Series A financing at $ 10 million." ;
    ns1:documentTitle "Histogen Announces Completion of Series A Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/histogen-announces-completion-of-series-a-financing-0> ;
    ns1:foundName "Financing",
        "financing" ;
    ns1:name "Financing",
        "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2357626/Histogen> ;
    ns1:targetDetails "Series A" ;
    ns1:valueRaw "$ 10 million" ;
    ns1:when "2010-12-01T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "December 1, 2010" ;
    ns1:whereGeoName "San Diego County" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5391832/about.rdf> ;
    ns1:whereRaw "SAN DIEGO" .

<https://1145.am/db/2357628/Series_A_Investment_Angus_Mitchell_Histogen_Leonard_Lavin_Lordship_Ventures_Secure_Medical_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-12-01T15:20:17+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Histogen, Inc., a regenerative medicine company developing solutions based on the products of newborn cells grown under embryonic conditions, today announced the successful completion of its Series A financing at $ 10 million." ;
    ns1:documentTitle "Histogen Announces Completion of Series A Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/histogen-announces-completion-of-series-a-financing> ;
    ns1:foundName "financing" ;
    ns1:name "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2357628/Histogen> ;
    ns1:targetDetails "Series A",
        "Series B" ;
    ns1:valueRaw "$ 10 million" ;
    ns1:whereGeoName "San Diego County" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5391832/about.rdf> ;
    ns1:whereRaw "San Diego" .

<https://1145.am/db/2358030/Investment_Kfw_Mig_Fonds_Nrwbank_Protagen_Ag_S-Venture_Capital_Dortmund_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-09-07T15:33:08+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Dortmund, Germany, September 7, 2010 / b3c newswire / - Protagen AG, a specialist for in-vitro diagnostics and GMP-compliant protein analysis announced today a second round of finance totalling a volume of € 10.0 Million.",
        "Protagen Raises € 10.0 Million For Diagnostic Developments." ;
    ns1:documentTitle "Protagen Raises € 10.0 Million For Diagnostic Developments" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/protagen-raises-%E2%82%AC-10-0-million-for-diagnostic-developments> ;
    ns1:foundName "Raises",
        "finance" ;
    ns1:name "Raises",
        "finance" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2358030/Protagen_Ag> ;
    ns1:valueRaw "€ 10.0 Million" ;
    ns1:when "2010-09-07T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "September 7, 2010" ;
    ns1:whereGeoName "Europe" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6255148/about.rdf> ;
    ns1:whereRaw "Europe" .

<https://1145.am/db/2358031/Series_A_Investment_Agechem_Venture_Fund_Alethia_Biotherapeutics_Inc_Bdc_Venture_Capital_Epicentre_Technologies_Corporation_Of_Wisconsin_Go_Capital_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-09-07T15:34:11+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Alethia Biotherapeutics Secures C $ 9.6 Million in Series A Financing to Fund Its Therapeutic Monoclonal Antibody Product Pipeline.",
        "MONTREAL, QUEBEC- (Marketwire - Sept. 7, 2010) - Alethia Biotherapeutics Inc., a privately held Montreal - based biopharmaceutical company focused on the development of monoclonal antibodies (\"mAbs\") against therapeutic targets emanating from its STAR proprietary target discovery platform, announced today it has closed a C $ 9.6M Series A round of financing." ;
    ns1:documentTitle "Alethia Biotherapeutics Secures C$9.6 Million in Series A Financing to Fund Its Therapeutic Monoclonal Antibody Product Pipeline" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/alethia-biotherapeutics-secures-c-9-6-million-series-a-financing-to-fund-its-therapeutic> ;
    ns1:foundName "financing" ;
    ns1:name "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2358031/Alethia_Biotherapeutics_Inc> ;
    ns1:targetDetails "Series A" ;
    ns1:valueRaw "C $ 9.6 Million",
        "C $ 9.6M" ;
    ns1:when "2010-09-07T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "2010-September-7" ;
    ns1:whereGeoName "Canada" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6251999/about.rdf> ;
    ns1:whereRaw "Canada" .

<https://1145.am/db/2359125/Sv_Life_Sciences> a org:Organization ;
    ns1:basedInLowRaw "BOSTON" ;
    ns1:documentDate "2010-09-10T13:16:20+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Good Start Genetics, Inc. Raises $18 Million to Develop and Launch Sequencing-Based Pre-Pregnancy Genetic Screening Test" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/good-start-genetics-inc-raises-18-million-to-develop-and-launch-sequencing-based-pre> ;
    ns1:foundName "SV Life Sciences" ;
    ns1:investor <https://1145.am/db/2359125/Series_A_Investment_Good_Start_Genetics_Orbimed_Advisors_Sv_Life_Sciences_Safeguard_Scientifics_Completed> ;
    ns1:name "SV Life Sciences" ;
    ns1:sameAsMedium <https://1145.am/db/2236188/Sv_Life_Sciences>,
        <https://1145.am/db/2246177/Sv_Life_Sciences>,
        <https://1145.am/db/2293662/Sv_Life_Sciences>,
        <https://1145.am/db/2293765/Sv_Life_Sciences>,
        <https://1145.am/db/2297439/Sv_Life_Sciences>,
        <https://1145.am/db/2297604/Sv_Life_Sciences>,
        <https://1145.am/db/2298869/Sv_Life_Sciences>,
        <https://1145.am/db/2300322/Sv_Life_Sciences>,
        <https://1145.am/db/2302994/Sv_Life_Sciences>,
        <https://1145.am/db/2302995/Sv_Life_Sciences>,
        <https://1145.am/db/2305587/Sv_Life_Sciences>,
        <https://1145.am/db/2310485/Sv_Life_Sciences>,
        <https://1145.am/db/2311540/Sv_Life_Sciences>,
        <https://1145.am/db/2312831/Sv_Life_Sciences>,
        <https://1145.am/db/2312833/Sv_Life_Sciences>,
        <https://1145.am/db/2313287/Sv_Life_Sciences>,
        <https://1145.am/db/2313322/Sv_Life_Sciences>,
        <https://1145.am/db/2313438/Sv_Life_Sciences>,
        <https://1145.am/db/2314515/Sv_Life_Sciences>,
        <https://1145.am/db/2314625/Sv_Life_Sciences>,
        <https://1145.am/db/2316038/Sv_Life_Sciences>,
        <https://1145.am/db/2317635/Sv_Life_Sciences>,
        <https://1145.am/db/2319338/Sv_Life_Sciences>,
        <https://1145.am/db/2321713/Sv_Life_Sciences>,
        <https://1145.am/db/2321861/Sv_Life_Sciences>,
        <https://1145.am/db/2321870/Sv_Life_Sciences>,
        <https://1145.am/db/2327405/Sv_Life_Sciences>,
        <https://1145.am/db/2327677/Sv_Life_Sciences>,
        <https://1145.am/db/2328815/Sv_Life_Sciences>,
        <https://1145.am/db/2329550/Sv_Life_Sciences>,
        <https://1145.am/db/2336313/Sv_Life_Sciences>,
        <https://1145.am/db/2336890/Sv_Life_Sciences>,
        <https://1145.am/db/2337166/Sv_Life_Sciences>,
        <https://1145.am/db/2338193/Sv_Life_Sciences>,
        <https://1145.am/db/2338196/Sv_Life_Sciences>,
        <https://1145.am/db/2339295/Sv_Life_Sciences>,
        <https://1145.am/db/2342260/Sv_Life_Sciences>,
        <https://1145.am/db/2342261/Sv_Life_Sciences>,
        <https://1145.am/db/2342266/Sv_Life_Sciences>,
        <https://1145.am/db/2342284/Sv_Life_Sciences>,
        <https://1145.am/db/2342445/Sv_Life_Sciences>,
        <https://1145.am/db/2342862/Sv_Life_Sciences>,
        <https://1145.am/db/2343467/Sv_Life_Sciences>,
        <https://1145.am/db/2343722/Sv_Life_Sciences>,
        <https://1145.am/db/2343725/Sv_Life_Sciences>,
        <https://1145.am/db/2343737/Sv_Life_Sciences>,
        <https://1145.am/db/2346832/Sv_Life_Sciences>,
        <https://1145.am/db/2347389/Sv_Life_Sciences>,
        <https://1145.am/db/2349406/Sv_Life_Sciences>,
        <https://1145.am/db/2349426/Sv_Life_Sciences>,
        <https://1145.am/db/2350034/Sv_Life_Sciences>,
        <https://1145.am/db/2350720/Sv_Life_Sciences>,
        <https://1145.am/db/2351394/Sv_Life_Sciences>,
        <https://1145.am/db/2351397/Sv_Life_Sciences>,
        <https://1145.am/db/2352382/Sv_Life_Sciences>,
        <https://1145.am/db/2352383/Sv_Life_Sciences>,
        <https://1145.am/db/2353098/Sv_Life_Sciences>,
        <https://1145.am/db/2353439/Sv_Life_Sciences>,
        <https://1145.am/db/2355586/Sv_Life_Sciences>,
        <https://1145.am/db/2356861/Sv_Life_Sciences>,
        <https://1145.am/db/2356876/Sv_Life_Sciences>,
        <https://1145.am/db/2358271/Sv_Life_Sciences>,
        <https://1145.am/db/2358272/Sv_Life_Sciences>,
        <https://1145.am/db/2360756/Sv_Life_Sciences>,
        <https://1145.am/db/2360758/Sv_Life_Sciences>,
        <https://1145.am/db/2361065/Sv_Life_Sciences>,
        <https://1145.am/db/2365315/Sv_Life_Sciences>,
        <https://1145.am/db/2366519/Sv_Life_Sciences>,
        <https://1145.am/db/2366860/Sv_Life_Sciences>,
        <https://1145.am/db/2368251/Sv_Life_Sciences>,
        <https://1145.am/db/2368572/Sv_Life_Sciences> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2360756/Series_A_Investment_Advanced_Technology_Ventures_Catabasis_Pharmaceuticals_Catabasis_Pharmaceuticals_Clarus_Ventures_Medimmune_Ventures_Sv_Life_Sciences_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-12-08T14:42:10+00:00"^^xsd:dateTime ;
    ns1:documentExtract "CAMBRIDGE, Mass.- (BUSINESS WIRE) -Catabasis Pharmaceuticals, a biopharmaceutical company leveraging the therapeutic potential of omega-3 fatty acids and other well-characterized compounds to create dual action medicines for the treatment of inflammatory and metabolic diseases, today announced that it has achieved important development milestones in advancing its lead compound toward human clinical trials, triggering a second tranche of $ 14.5 million in its Series A financing from its current investors." ;
    ns1:documentTitle "Catabasis Pharmaceuticals Secures $14.5 Million Second Tranche in Series A Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/catabasis-pharmaceuticals-secures-14-5-million-second-tranche-series-a-financing> ;
    ns1:foundName "financing" ;
    ns1:name "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2360756/Catabasis_Pharmaceuticals> ;
    ns1:targetDetails "Series A" ;
    ns1:valueRaw "$ 14.5 million",
        "$ 39.6 million" ;
    ns1:whereGeoName "Cambridgeshire" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/2653940/about.rdf> ;
    ns1:whereRaw "CAMBRIDGE" .

<https://1145.am/db/2360756/Sv_Life_Sciences> a org:Organization ;
    ns1:basedInLowRaw "CAMBRIDGE" ;
    ns1:description "a biopharmaceutical company" ;
    ns1:documentDate "2010-12-08T14:42:10+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Catabasis Pharmaceuticals Secures $14.5 Million Second Tranche in Series A Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/catabasis-pharmaceuticals-secures-14-5-million-second-tranche-series-a-financing> ;
    ns1:foundName "SV Life Sciences" ;
    ns1:investor <https://1145.am/db/2360756/Series_A_Investment_Advanced_Technology_Ventures_Catabasis_Pharmaceuticals_Catabasis_Pharmaceuticals_Clarus_Ventures_Medimmune_Ventures_Sv_Life_Sciences_Completed> ;
    ns1:name "SV Life Sciences" ;
    ns1:sameAsMedium <https://1145.am/db/2236188/Sv_Life_Sciences>,
        <https://1145.am/db/2246177/Sv_Life_Sciences>,
        <https://1145.am/db/2293662/Sv_Life_Sciences>,
        <https://1145.am/db/2293765/Sv_Life_Sciences>,
        <https://1145.am/db/2297439/Sv_Life_Sciences>,
        <https://1145.am/db/2297604/Sv_Life_Sciences>,
        <https://1145.am/db/2298869/Sv_Life_Sciences>,
        <https://1145.am/db/2300322/Sv_Life_Sciences>,
        <https://1145.am/db/2302994/Sv_Life_Sciences>,
        <https://1145.am/db/2302995/Sv_Life_Sciences>,
        <https://1145.am/db/2305587/Sv_Life_Sciences>,
        <https://1145.am/db/2310485/Sv_Life_Sciences>,
        <https://1145.am/db/2311540/Sv_Life_Sciences>,
        <https://1145.am/db/2312831/Sv_Life_Sciences>,
        <https://1145.am/db/2312833/Sv_Life_Sciences>,
        <https://1145.am/db/2313287/Sv_Life_Sciences>,
        <https://1145.am/db/2313322/Sv_Life_Sciences>,
        <https://1145.am/db/2313438/Sv_Life_Sciences>,
        <https://1145.am/db/2314515/Sv_Life_Sciences>,
        <https://1145.am/db/2314625/Sv_Life_Sciences>,
        <https://1145.am/db/2316038/Sv_Life_Sciences>,
        <https://1145.am/db/2317635/Sv_Life_Sciences>,
        <https://1145.am/db/2319338/Sv_Life_Sciences>,
        <https://1145.am/db/2321713/Sv_Life_Sciences>,
        <https://1145.am/db/2321861/Sv_Life_Sciences>,
        <https://1145.am/db/2321870/Sv_Life_Sciences>,
        <https://1145.am/db/2327405/Sv_Life_Sciences>,
        <https://1145.am/db/2327677/Sv_Life_Sciences>,
        <https://1145.am/db/2328815/Sv_Life_Sciences>,
        <https://1145.am/db/2329550/Sv_Life_Sciences>,
        <https://1145.am/db/2336313/Sv_Life_Sciences>,
        <https://1145.am/db/2336890/Sv_Life_Sciences>,
        <https://1145.am/db/2337166/Sv_Life_Sciences>,
        <https://1145.am/db/2338193/Sv_Life_Sciences>,
        <https://1145.am/db/2338196/Sv_Life_Sciences>,
        <https://1145.am/db/2339295/Sv_Life_Sciences>,
        <https://1145.am/db/2342260/Sv_Life_Sciences>,
        <https://1145.am/db/2342261/Sv_Life_Sciences>,
        <https://1145.am/db/2342266/Sv_Life_Sciences>,
        <https://1145.am/db/2342284/Sv_Life_Sciences>,
        <https://1145.am/db/2342445/Sv_Life_Sciences>,
        <https://1145.am/db/2342862/Sv_Life_Sciences>,
        <https://1145.am/db/2343467/Sv_Life_Sciences>,
        <https://1145.am/db/2343722/Sv_Life_Sciences>,
        <https://1145.am/db/2343725/Sv_Life_Sciences>,
        <https://1145.am/db/2343737/Sv_Life_Sciences>,
        <https://1145.am/db/2346832/Sv_Life_Sciences>,
        <https://1145.am/db/2347389/Sv_Life_Sciences>,
        <https://1145.am/db/2349406/Sv_Life_Sciences>,
        <https://1145.am/db/2349426/Sv_Life_Sciences>,
        <https://1145.am/db/2350034/Sv_Life_Sciences>,
        <https://1145.am/db/2350720/Sv_Life_Sciences>,
        <https://1145.am/db/2351394/Sv_Life_Sciences>,
        <https://1145.am/db/2351397/Sv_Life_Sciences>,
        <https://1145.am/db/2352382/Sv_Life_Sciences>,
        <https://1145.am/db/2352383/Sv_Life_Sciences>,
        <https://1145.am/db/2353098/Sv_Life_Sciences>,
        <https://1145.am/db/2353439/Sv_Life_Sciences>,
        <https://1145.am/db/2355586/Sv_Life_Sciences>,
        <https://1145.am/db/2356861/Sv_Life_Sciences>,
        <https://1145.am/db/2356876/Sv_Life_Sciences>,
        <https://1145.am/db/2358271/Sv_Life_Sciences>,
        <https://1145.am/db/2358272/Sv_Life_Sciences>,
        <https://1145.am/db/2359125/Sv_Life_Sciences>,
        <https://1145.am/db/2360758/Sv_Life_Sciences>,
        <https://1145.am/db/2361065/Sv_Life_Sciences>,
        <https://1145.am/db/2365315/Sv_Life_Sciences>,
        <https://1145.am/db/2366519/Sv_Life_Sciences>,
        <https://1145.am/db/2366860/Sv_Life_Sciences>,
        <https://1145.am/db/2368251/Sv_Life_Sciences>,
        <https://1145.am/db/2368572/Sv_Life_Sciences> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2360758/Series_A_Investment_Advanced_Technology_Ventures_Catabasis_Pharmaceuticals_Catabasis_Pharmaceuticals_Clarus_Ventures_Medimmune_Ventures_Sv_Life_Sciences_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-12-08T14:23:07+00:00"^^xsd:dateTime ;
    ns1:documentExtract "CAMBRIDGE, Mass.- (BUSINESS WIRE) - Catabasis Pharmaceuticals, a biopharmaceutical company leveraging the therapeutic potential of omega-3 fatty acids and other well-characterized compounds to create dual action medicines for the treatment of inflammatory and metabolic diseases, today announced that it has achieved important development milestones in advancing its lead compound toward human clinical trials, triggering a second tranche of $ 14.5 million in its Series A financing from its current investors." ;
    ns1:documentTitle "Catabasis Pharmaceuticals Secures $14.5 Million Second Tranche in Series A Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/catabasis-pharmaceuticals-secures-14-5-million-second-tranche-series-a-financing-0> ;
    ns1:foundName "financing" ;
    ns1:name "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2360758/Catabasis_Pharmaceuticals> ;
    ns1:targetDetails "Series A" ;
    ns1:valueRaw "$ 14.5 million",
        "$ 39.6 million" ;
    ns1:whereGeoName "Cambridgeshire" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/2653940/about.rdf> ;
    ns1:whereRaw "CAMBRIDGE" .

<https://1145.am/db/2360758/Sv_Life_Sciences> a org:Organization ;
    ns1:basedInLowRaw "CAMBRIDGE" ;
    ns1:documentDate "2010-12-08T14:23:07+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Catabasis Pharmaceuticals Secures $14.5 Million Second Tranche in Series A Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/catabasis-pharmaceuticals-secures-14-5-million-second-tranche-series-a-financing-0> ;
    ns1:foundName "SV Life Sciences" ;
    ns1:investor <https://1145.am/db/2360758/Series_A_Investment_Advanced_Technology_Ventures_Catabasis_Pharmaceuticals_Catabasis_Pharmaceuticals_Clarus_Ventures_Medimmune_Ventures_Sv_Life_Sciences_Completed> ;
    ns1:name "SV Life Sciences" ;
    ns1:sameAsMedium <https://1145.am/db/2236188/Sv_Life_Sciences>,
        <https://1145.am/db/2246177/Sv_Life_Sciences>,
        <https://1145.am/db/2293662/Sv_Life_Sciences>,
        <https://1145.am/db/2293765/Sv_Life_Sciences>,
        <https://1145.am/db/2297439/Sv_Life_Sciences>,
        <https://1145.am/db/2297604/Sv_Life_Sciences>,
        <https://1145.am/db/2298869/Sv_Life_Sciences>,
        <https://1145.am/db/2300322/Sv_Life_Sciences>,
        <https://1145.am/db/2302994/Sv_Life_Sciences>,
        <https://1145.am/db/2302995/Sv_Life_Sciences>,
        <https://1145.am/db/2305587/Sv_Life_Sciences>,
        <https://1145.am/db/2310485/Sv_Life_Sciences>,
        <https://1145.am/db/2311540/Sv_Life_Sciences>,
        <https://1145.am/db/2312831/Sv_Life_Sciences>,
        <https://1145.am/db/2312833/Sv_Life_Sciences>,
        <https://1145.am/db/2313287/Sv_Life_Sciences>,
        <https://1145.am/db/2313322/Sv_Life_Sciences>,
        <https://1145.am/db/2313438/Sv_Life_Sciences>,
        <https://1145.am/db/2314515/Sv_Life_Sciences>,
        <https://1145.am/db/2314625/Sv_Life_Sciences>,
        <https://1145.am/db/2316038/Sv_Life_Sciences>,
        <https://1145.am/db/2317635/Sv_Life_Sciences>,
        <https://1145.am/db/2319338/Sv_Life_Sciences>,
        <https://1145.am/db/2321713/Sv_Life_Sciences>,
        <https://1145.am/db/2321861/Sv_Life_Sciences>,
        <https://1145.am/db/2321870/Sv_Life_Sciences>,
        <https://1145.am/db/2327405/Sv_Life_Sciences>,
        <https://1145.am/db/2327677/Sv_Life_Sciences>,
        <https://1145.am/db/2328815/Sv_Life_Sciences>,
        <https://1145.am/db/2329550/Sv_Life_Sciences>,
        <https://1145.am/db/2336313/Sv_Life_Sciences>,
        <https://1145.am/db/2336890/Sv_Life_Sciences>,
        <https://1145.am/db/2337166/Sv_Life_Sciences>,
        <https://1145.am/db/2338193/Sv_Life_Sciences>,
        <https://1145.am/db/2338196/Sv_Life_Sciences>,
        <https://1145.am/db/2339295/Sv_Life_Sciences>,
        <https://1145.am/db/2342260/Sv_Life_Sciences>,
        <https://1145.am/db/2342261/Sv_Life_Sciences>,
        <https://1145.am/db/2342266/Sv_Life_Sciences>,
        <https://1145.am/db/2342284/Sv_Life_Sciences>,
        <https://1145.am/db/2342445/Sv_Life_Sciences>,
        <https://1145.am/db/2342862/Sv_Life_Sciences>,
        <https://1145.am/db/2343467/Sv_Life_Sciences>,
        <https://1145.am/db/2343722/Sv_Life_Sciences>,
        <https://1145.am/db/2343725/Sv_Life_Sciences>,
        <https://1145.am/db/2343737/Sv_Life_Sciences>,
        <https://1145.am/db/2346832/Sv_Life_Sciences>,
        <https://1145.am/db/2347389/Sv_Life_Sciences>,
        <https://1145.am/db/2349406/Sv_Life_Sciences>,
        <https://1145.am/db/2349426/Sv_Life_Sciences>,
        <https://1145.am/db/2350034/Sv_Life_Sciences>,
        <https://1145.am/db/2350720/Sv_Life_Sciences>,
        <https://1145.am/db/2351394/Sv_Life_Sciences>,
        <https://1145.am/db/2351397/Sv_Life_Sciences>,
        <https://1145.am/db/2352382/Sv_Life_Sciences>,
        <https://1145.am/db/2352383/Sv_Life_Sciences>,
        <https://1145.am/db/2353098/Sv_Life_Sciences>,
        <https://1145.am/db/2353439/Sv_Life_Sciences>,
        <https://1145.am/db/2355586/Sv_Life_Sciences>,
        <https://1145.am/db/2356861/Sv_Life_Sciences>,
        <https://1145.am/db/2356876/Sv_Life_Sciences>,
        <https://1145.am/db/2358271/Sv_Life_Sciences>,
        <https://1145.am/db/2358272/Sv_Life_Sciences>,
        <https://1145.am/db/2359125/Sv_Life_Sciences>,
        <https://1145.am/db/2360756/Sv_Life_Sciences>,
        <https://1145.am/db/2361065/Sv_Life_Sciences>,
        <https://1145.am/db/2365315/Sv_Life_Sciences>,
        <https://1145.am/db/2366519/Sv_Life_Sciences>,
        <https://1145.am/db/2366860/Sv_Life_Sciences>,
        <https://1145.am/db/2368251/Sv_Life_Sciences>,
        <https://1145.am/db/2368572/Sv_Life_Sciences> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2362826/Cypress_Bioscience_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition",
        "merger" ;
    ns1:documentDate "2010-12-15T13:23:15+00:00"^^xsd:dateTime ;
    ns1:documentExtract "SAN DIEGO & NEW YORK- (BUSINESS WIRE) - Cypress Bioscience, Inc. (Nasdaq: CYPB) (\"Cypress\") , a pharmaceutical company engaged in the development of innovative drugs to treat central nervous system (CNS) disorders, announced today that it has entered into a definitive merger agreement with Ramius V & O Acquisition LLC, an affiliate of Ramius LLC (collectively, \"Ramius\") and affiliates of Royalty Pharma (\"Royalty Pharma\") , providing for the acquisition of Cypress by Ramius and Royalty Pharma." ;
    ns1:documentTitle "Cypress Bioscience Agrees To Be Acquired by Ramius LLC and Royalty Pharma for $6.50 Per Share in Cash" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cypress-bioscience-agrees-to-be-acquired-by-ramius-llc-and-royalty-pharma-for-6-50-per> ;
    ns1:foundName "acquire",
        "acquisition",
        "merger" ;
    ns1:name "acquire",
        "acquisition",
        "merger" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "has not happened" ;
    ns1:target <https://1145.am/db/2362826/Cypress_Bioscience> ;
    ns1:targetName "Cypress Bioscience" ;
    ns1:valueRaw "approximately $ 255 million" ;
    ns1:whereGeoName "New York City",
        "San Diego County" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5128581/about.rdf>,
        <https://sws.geonames.org/5391832/about.rdf> ;
    ns1:whereRaw "SAN DIEGO & NEW YORK" .

<https://1145.am/db/2363262/Series_C_Investment_At_Impf_Gmbh_Mig_Wellington_Partners_Dievini_Hopp_Biotech_Holding_Immatics_Biotechnologies_Gmbh_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-09-21T11:15:34+00:00"^^xsd:dateTime ;
    ns1:documentExtract "immatics biotechnologies GmbH, a biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, announced today that it has raised EUR53.8million in a Series C financing round." ;
    ns1:documentTitle "immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/immatics-raises-eur54-million-to-advance-its-late-stage-clinical-therapeutic-cancer-0> ;
    ns1:foundName "financing",
        "raised" ;
    ns1:name "financing",
        "raised" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2363262/Immatics_Biotechnologies_Gmbh> ;
    ns1:targetDetails "Series C" ;
    ns1:valueRaw "EUR53.8million" .

<https://1145.am/db/2363274/Series_C_Investment_At_Impf_Gmbh_Mig_Wellington_Partners_Dievini_Hopp_Biotech_Holding_Immatics_Biotechnologies_Gmbh_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-09-21T12:37:18+00:00"^^xsd:dateTime ;
    ns1:documentExtract "immatics biotechnologies GmbH, a biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, announced today that it has raised EUR53.8million in a Series C financing round." ;
    ns1:documentTitle "immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/immatics-raises-eur54-million-to-advance-its-late-stage-clinical-therapeutic-cancer-vaccine> ;
    ns1:foundName "financing",
        "raised" ;
    ns1:name "financing",
        "raised" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2363274/Immatics_Biotechnologies_Gmbh> ;
    ns1:targetDetails "Series C" ;
    ns1:valueRaw "EUR53.8million" .

<https://1145.am/db/2365138/Healthcare_Ventures> a org:Organization ;
    ns1:basedInLowRaw "CAMBRIDGE" ;
    ns1:documentDate "2010-09-27T13:02:25+00:00"^^xsd:dateTime ;
    ns1:documentTitle "DecImmune Therapeutics Secures $3.2 Million in Development Funding" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/decimmune-therapeutics-secures-3-2-million-development-funding> ;
    ns1:foundName "HealthCare Ventures" ;
    ns1:investor <https://1145.am/db/2365138/Sbir_Investment_Amgen_Ventures_Astellas_Venture_Management_Decimmune_Therapeutics_Healthcare_Ventures_Has_Not_Happened> ;
    ns1:name "HealthCare Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/2235852/Healthcare_Ventures>,
        <https://1145.am/db/2304650/Healthcare_Ventures>,
        <https://1145.am/db/2308148/Healthcare_Ventures>,
        <https://1145.am/db/2308887/Healthcare_Ventures>,
        <https://1145.am/db/2309845/Healthcare_Ventures>,
        <https://1145.am/db/2311069/Healthcare_Ventures>,
        <https://1145.am/db/2311075/Healthcare_Ventures>,
        <https://1145.am/db/2312192/Healthcare_Ventures>,
        <https://1145.am/db/2313405/Healthcare_Ventures>,
        <https://1145.am/db/2316601/Healthcare_Ventures>,
        <https://1145.am/db/2316605/Healthcare_Ventures>,
        <https://1145.am/db/2316823/Healthcare_Ventures>,
        <https://1145.am/db/2318657/Healthcare_Ventures>,
        <https://1145.am/db/2321097/Healthcare_Ventures>,
        <https://1145.am/db/2323586/Healthcare_Ventures>,
        <https://1145.am/db/2331639/Healthcare_Ventures>,
        <https://1145.am/db/2338373/Healthcare_Ventures>,
        <https://1145.am/db/2342269/Healthcare_Ventures>,
        <https://1145.am/db/2343202/Healthcare_Ventures>,
        <https://1145.am/db/2343210/Healthcare_Ventures>,
        <https://1145.am/db/2346204/Healthcare_Ventures>,
        <https://1145.am/db/2347469/Healthcare_Ventures>,
        <https://1145.am/db/2348486/Healthcare_Ventures>,
        <https://1145.am/db/2349717/Healthcare_Ventures>,
        <https://1145.am/db/2349722/Healthcare_Ventures>,
        <https://1145.am/db/2352814/Healthcare_Ventures>,
        <https://1145.am/db/2352820/Healthcare_Ventures>,
        <https://1145.am/db/2363510/Healthcare_Ventures>,
        <https://1145.am/db/2365171/Healthcare_Ventures>,
        <https://1145.am/db/2367497/Healthcare_Ventures>,
        <https://1145.am/db/2443170/Healthcare_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2365138/Sbir_Investment_Amgen_Ventures_Astellas_Venture_Management_Decimmune_Therapeutics_Healthcare_Ventures_Has_Not_Happened> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-09-27T13:02:25+00:00"^^xsd:dateTime ;
    ns1:documentExtract "CAMBRIDGE, Mass.- (BUSINESS WIRE) - DecImmune Therapeutics announced today that it has received a $ 1 million equity investment from Astellas Venture Management and has additionally been awarded $ 2.2 million in Phase II SBIR funding from the National Institutes of Health." ;
    ns1:documentTitle "DecImmune Therapeutics Secures $3.2 Million in Development Funding" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/decimmune-therapeutics-secures-3-2-million-development-funding> ;
    ns1:foundName "funding",
        "investment" ;
    ns1:name "funding",
        "investment" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2365138/Decimmune_Therapeutics> ;
    ns1:targetDetails "SBIR" ;
    ns1:valueRaw "$ 1 million",
        "$ 2.2 million" ;
    ns1:whereGeoName "Cambridge" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/4931972/about.rdf> ;
    ns1:whereRaw "CAMBRIDGE, Mass" .

<https://1145.am/db/2366860/Sv_Life_Sciences> a org:Organization ;
    ns1:basedInLowRaw "UK" ;
    ns1:documentDate "2010-10-06T13:04:22+00:00"^^xsd:dateTime ;
    ns1:documentTitle "New Leaf Venture Partners Invests in $35.4 (GBP 22.4) Million Series A Financing of Convergence Pharmaceuticals" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/new-leaf-venture-partners-invests-35-4-gbp-22-4-million-series-a-financing-of-convergence> ;
    ns1:foundName "SV Life Sciences" ;
    ns1:investor <https://1145.am/db/2366860/Series_A_Investment_Apposite_Capital_Convergence_Pharmaceuticals_New_Leaf_Venture_Partners_Sv_Life_Sciences_Has_Not_Happened>,
        <https://1145.am/db/2366860/Series_A_Investment_Apposite_Capital_New_Leaf_Venture_Partners_Sv_Life_Sciences_Completed> ;
    ns1:name "SV Life Sciences" ;
    ns1:sameAsMedium <https://1145.am/db/2236188/Sv_Life_Sciences>,
        <https://1145.am/db/2246177/Sv_Life_Sciences>,
        <https://1145.am/db/2293662/Sv_Life_Sciences>,
        <https://1145.am/db/2293765/Sv_Life_Sciences>,
        <https://1145.am/db/2297439/Sv_Life_Sciences>,
        <https://1145.am/db/2297604/Sv_Life_Sciences>,
        <https://1145.am/db/2298869/Sv_Life_Sciences>,
        <https://1145.am/db/2300322/Sv_Life_Sciences>,
        <https://1145.am/db/2302994/Sv_Life_Sciences>,
        <https://1145.am/db/2302995/Sv_Life_Sciences>,
        <https://1145.am/db/2305587/Sv_Life_Sciences>,
        <https://1145.am/db/2310485/Sv_Life_Sciences>,
        <https://1145.am/db/2311540/Sv_Life_Sciences>,
        <https://1145.am/db/2312831/Sv_Life_Sciences>,
        <https://1145.am/db/2312833/Sv_Life_Sciences>,
        <https://1145.am/db/2313287/Sv_Life_Sciences>,
        <https://1145.am/db/2313322/Sv_Life_Sciences>,
        <https://1145.am/db/2313438/Sv_Life_Sciences>,
        <https://1145.am/db/2314515/Sv_Life_Sciences>,
        <https://1145.am/db/2314625/Sv_Life_Sciences>,
        <https://1145.am/db/2316038/Sv_Life_Sciences>,
        <https://1145.am/db/2317635/Sv_Life_Sciences>,
        <https://1145.am/db/2319338/Sv_Life_Sciences>,
        <https://1145.am/db/2321713/Sv_Life_Sciences>,
        <https://1145.am/db/2321861/Sv_Life_Sciences>,
        <https://1145.am/db/2321870/Sv_Life_Sciences>,
        <https://1145.am/db/2327405/Sv_Life_Sciences>,
        <https://1145.am/db/2327677/Sv_Life_Sciences>,
        <https://1145.am/db/2328815/Sv_Life_Sciences>,
        <https://1145.am/db/2329550/Sv_Life_Sciences>,
        <https://1145.am/db/2336313/Sv_Life_Sciences>,
        <https://1145.am/db/2336890/Sv_Life_Sciences>,
        <https://1145.am/db/2337166/Sv_Life_Sciences>,
        <https://1145.am/db/2338193/Sv_Life_Sciences>,
        <https://1145.am/db/2338196/Sv_Life_Sciences>,
        <https://1145.am/db/2339295/Sv_Life_Sciences>,
        <https://1145.am/db/2342260/Sv_Life_Sciences>,
        <https://1145.am/db/2342261/Sv_Life_Sciences>,
        <https://1145.am/db/2342266/Sv_Life_Sciences>,
        <https://1145.am/db/2342284/Sv_Life_Sciences>,
        <https://1145.am/db/2342445/Sv_Life_Sciences>,
        <https://1145.am/db/2342862/Sv_Life_Sciences>,
        <https://1145.am/db/2343467/Sv_Life_Sciences>,
        <https://1145.am/db/2343722/Sv_Life_Sciences>,
        <https://1145.am/db/2343725/Sv_Life_Sciences>,
        <https://1145.am/db/2343737/Sv_Life_Sciences>,
        <https://1145.am/db/2346832/Sv_Life_Sciences>,
        <https://1145.am/db/2347389/Sv_Life_Sciences>,
        <https://1145.am/db/2349406/Sv_Life_Sciences>,
        <https://1145.am/db/2349426/Sv_Life_Sciences>,
        <https://1145.am/db/2350034/Sv_Life_Sciences>,
        <https://1145.am/db/2350720/Sv_Life_Sciences>,
        <https://1145.am/db/2351394/Sv_Life_Sciences>,
        <https://1145.am/db/2351397/Sv_Life_Sciences>,
        <https://1145.am/db/2352382/Sv_Life_Sciences>,
        <https://1145.am/db/2352383/Sv_Life_Sciences>,
        <https://1145.am/db/2353098/Sv_Life_Sciences>,
        <https://1145.am/db/2353439/Sv_Life_Sciences>,
        <https://1145.am/db/2355586/Sv_Life_Sciences>,
        <https://1145.am/db/2356861/Sv_Life_Sciences>,
        <https://1145.am/db/2356876/Sv_Life_Sciences>,
        <https://1145.am/db/2358271/Sv_Life_Sciences>,
        <https://1145.am/db/2358272/Sv_Life_Sciences>,
        <https://1145.am/db/2359125/Sv_Life_Sciences>,
        <https://1145.am/db/2360756/Sv_Life_Sciences>,
        <https://1145.am/db/2360758/Sv_Life_Sciences>,
        <https://1145.am/db/2361065/Sv_Life_Sciences>,
        <https://1145.am/db/2365315/Sv_Life_Sciences>,
        <https://1145.am/db/2366519/Sv_Life_Sciences>,
        <https://1145.am/db/2368251/Sv_Life_Sciences>,
        <https://1145.am/db/2368572/Sv_Life_Sciences> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2581397/Novartis> a org:Organization ;
    ns1:basedInLowRaw "Switzerland" ;
    ns1:buyer <https://1145.am/db/2581397/Alcon_Assets_Acquisition> ;
    ns1:description "pharmaceuticals" ;
    ns1:documentDate "2010-08-17T14:53:50+00:00"^^xsd:dateTime ;
    ns1:documentTitle "FTC Order Protects Consumers in U.S. Market for Eye Care Drug Used in Cataract Surgery" ;
    ns1:documentURL <https://www.fiercepharma.com/pharma/ftc-order-protects-consumers-u-s-market-for-eye-care-drug-used-cataract-surgery> ;
    ns1:foundName "Novartis",
        "Novartis AG" ;
    ns1:industry "pharmaceutical" ;
    ns1:name "Novartis" ;
    ns1:sameAsHigh <https://1145.am/db/1048908/Johnson___Johnson>,
        <https://1145.am/db/1176158/Novartis>,
        <https://1145.am/db/1177562/Novartis>,
        <https://1145.am/db/1262552/Johnson___Johnson>,
        <https://1145.am/db/1270868/Johnson___Johnson>,
        <https://1145.am/db/131136/Novartis>,
        <https://1145.am/db/132002/Novartis>,
        <https://1145.am/db/1328753/Novartis>,
        <https://1145.am/db/1507918/Novartis_Ag>,
        <https://1145.am/db/156403/Novartis>,
        <https://1145.am/db/1567521/Novartis>,
        <https://1145.am/db/1578114/Novartis>,
        <https://1145.am/db/1628428/Novalgen_Ltd>,
        <https://1145.am/db/1629605/Novartis>,
        <https://1145.am/db/1629663/Novartis>,
        <https://1145.am/db/165056/Novartis>,
        <https://1145.am/db/1673527/Johnson___Johnson>,
        <https://1145.am/db/176334/Novartis>,
        <https://1145.am/db/177096/Novartis>,
        <https://1145.am/db/1822601/Johnson___Johnson>,
        <https://1145.am/db/1986468/Novabay®_Pharmaceuticals_Inc>,
        <https://1145.am/db/2033677/Novartis>,
        <https://1145.am/db/2033933/Novartis>,
        <https://1145.am/db/2036487/Novartis_Ag>,
        <https://1145.am/db/2057335/Johnson___Johnson>,
        <https://1145.am/db/2062728/Novan>,
        <https://1145.am/db/2065993/Novartis_Ag>,
        <https://1145.am/db/2089281/Johnson___Johnson>,
        <https://1145.am/db/2103283/Johnson___Johnson>,
        <https://1145.am/db/2107835/Novartis>,
        <https://1145.am/db/2129754/Novartis>,
        <https://1145.am/db/2152605/Novartis>,
        <https://1145.am/db/2152618/Novartis>,
        <https://1145.am/db/2153059/Novartis>,
        <https://1145.am/db/2153410/Johnson___Johnson>,
        <https://1145.am/db/2154194/Johnson___Johnson>,
        <https://1145.am/db/2154521/Johnson___Johnson>,
        <https://1145.am/db/2154527/Novartis>,
        <https://1145.am/db/2155069/Novartis>,
        <https://1145.am/db/2155665/Novartis>,
        <https://1145.am/db/2190363/Novartis_Ag>,
        <https://1145.am/db/2193661/Johnson___Johnson>,
        <https://1145.am/db/2194161/Novartis>,
        <https://1145.am/db/2279108/Novartis>,
        <https://1145.am/db/2279232/Novartis>,
        <https://1145.am/db/2279829/Novartis>,
        <https://1145.am/db/2280153/Novartis>,
        <https://1145.am/db/2280350/Novartis>,
        <https://1145.am/db/2280422/Johnson___Johnson>,
        <https://1145.am/db/2282888/Johnson_And_Johnson>,
        <https://1145.am/db/2282888/Johnson___Johnson>,
        <https://1145.am/db/2283590/Novartis>,
        <https://1145.am/db/2283645/Novartis>,
        <https://1145.am/db/2285311/Novartis>,
        <https://1145.am/db/2285587/Johnson___Johnson>,
        <https://1145.am/db/2286603/Johnson___Johnson>,
        <https://1145.am/db/2286604/Novartis>,
        <https://1145.am/db/2287377/Johnson___Johnson>,
        <https://1145.am/db/2288851/Novartis>,
        <https://1145.am/db/2289846/Novartis>,
        <https://1145.am/db/2290022/Novartis>,
        <https://1145.am/db/2290342/Johnson___Johnson>,
        <https://1145.am/db/2290894/Johnson___Johnson>,
        <https://1145.am/db/2291777/Johnson___Johnson>,
        <https://1145.am/db/2292345/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2293323/Novartis>,
        <https://1145.am/db/2293342/Novartis>,
        <https://1145.am/db/2293591/Novartis>,
        <https://1145.am/db/2294026/Novartis>,
        <https://1145.am/db/2294585/Novartis>,
        <https://1145.am/db/2296402/Johnson___Johnson>,
        <https://1145.am/db/2296504/Novartis>,
        <https://1145.am/db/2296552/Novartis>,
        <https://1145.am/db/2296598/Johnson___Johnson>,
        <https://1145.am/db/2298037/Johnson___Johnson>,
        <https://1145.am/db/2298501/Johnson___Johnson>,
        <https://1145.am/db/2298606/Novartis>,
        <https://1145.am/db/2301066/Novartis>,
        <https://1145.am/db/2301089/Novartis>,
        <https://1145.am/db/2301705/Novasep>,
        <https://1145.am/db/2301735/Novartis>,
        <https://1145.am/db/2301857/Novartis>,
        <https://1145.am/db/2302724/Novartis>,
        <https://1145.am/db/2302727/Novartis>,
        <https://1145.am/db/2303121/Novartis_Bioventures>,
        <https://1145.am/db/230344/Swiss_Drugmaker_Novartis>,
        <https://1145.am/db/2304113/Novartis>,
        <https://1145.am/db/2304373/Novartis>,
        <https://1145.am/db/2304374/Novartis>,
        <https://1145.am/db/2305192/Novartis>,
        <https://1145.am/db/2305244/Novabay_Pharmaceuticals>,
        <https://1145.am/db/2307228/Novadel_Pharma_Inc>,
        <https://1145.am/db/2307347/Novartis>,
        <https://1145.am/db/2307847/Novartis>,
        <https://1145.am/db/2307851/Novartis>,
        <https://1145.am/db/2307863/Novartis>,
        <https://1145.am/db/2307998/Novartis>,
        <https://1145.am/db/2308010/Novartis>,
        <https://1145.am/db/2308298/Novartis>,
        <https://1145.am/db/2308765/Novartis>,
        <https://1145.am/db/2308812/Novartis>,
        <https://1145.am/db/2308946/Novartis_Ag>,
        <https://1145.am/db/2309065/Novartis_Intercell>,
        <https://1145.am/db/2309930/Johnson___Johnson>,
        <https://1145.am/db/2310118/Johnson___Johnson>,
        <https://1145.am/db/2310150/Novartis>,
        <https://1145.am/db/2312008/Novartis>,
        <https://1145.am/db/2312018/Novartis_International_Ag>,
        <https://1145.am/db/2312088/Novabay_Pharmaceuticals>,
        <https://1145.am/db/2312436/Novartis>,
        <https://1145.am/db/2314331/Johnson___Johnson>,
        <https://1145.am/db/2315481/Johnson___Johnson>,
        <https://1145.am/db/2317181/Johnson___Johnson>,
        <https://1145.am/db/2317639/Johnson___Johnson>,
        <https://1145.am/db/2317845/Novadel>,
        <https://1145.am/db/2317949/Novalar_Pharmaceuticals>,
        <https://1145.am/db/2317951/Novalar_Pharmaceuticals>,
        <https://1145.am/db/2318685/Johnson___Johnson>,
        <https://1145.am/db/2318994/Novadel>,
        <https://1145.am/db/2319412/Novartis>,
        <https://1145.am/db/2319656/Johnson___Johnson>,
        <https://1145.am/db/2320828/Novartis>,
        <https://1145.am/db/2321067/Novartis>,
        <https://1145.am/db/2322024/Johnson___Johnson>,
        <https://1145.am/db/2322266/Novartis>,
        <https://1145.am/db/2323000/Johnson___Johnson>,
        <https://1145.am/db/2323188/Novartis>,
        <https://1145.am/db/2323692/Novabay_Pharmaceuticals>,
        <https://1145.am/db/2324255/Novartis_Bioventures>,
        <https://1145.am/db/2325073/Novartis>,
        <https://1145.am/db/2325869/Novartis>,
        <https://1145.am/db/2326949/Novartis>,
        <https://1145.am/db/2327024/Johnson___Johnson>,
        <https://1145.am/db/2327560/Novartis>,
        <https://1145.am/db/2329413/Novadel_Pharma_Inc>,
        <https://1145.am/db/2329475/Novadel_Pharma>,
        <https://1145.am/db/2329487/Johnson___Johnson>,
        <https://1145.am/db/2329597/Novartis>,
        <https://1145.am/db/2330648/Novartis>,
        <https://1145.am/db/2330734/Johnson___Johnson>,
        <https://1145.am/db/2331875/Novadel>,
        <https://1145.am/db/2332005/Novartis>,
        <https://1145.am/db/2332788/Novartis_Ag>,
        <https://1145.am/db/2332796/Novadel_Pharma_Inc>,
        <https://1145.am/db/2332872/Novartis>,
        <https://1145.am/db/2334206/Novartis>,
        <https://1145.am/db/2334645/Novast>,
        <https://1145.am/db/2336028/Novartis>,
        <https://1145.am/db/2336704/Novartis>,
        <https://1145.am/db/2336790/Johnson___Johnson>,
        <https://1145.am/db/2336797/Johnson___Johnson>,
        <https://1145.am/db/2336990/Novartis>,
        <https://1145.am/db/2339656/Novartis>,
        <https://1145.am/db/2339669/Novartis>,
        <https://1145.am/db/2340071/Johnson___Johnson>,
        <https://1145.am/db/2340615/Novartis>,
        <https://1145.am/db/2340948/Novartis>,
        <https://1145.am/db/2341850/Johnson___Johnson>,
        <https://1145.am/db/2344017/Novartis>,
        <https://1145.am/db/2344434/Novartis>,
        <https://1145.am/db/2344683/Johnson___Johnson>,
        <https://1145.am/db/2346576/Novadel_Pharma_Inc>,
        <https://1145.am/db/2346629/Novartis>,
        <https://1145.am/db/2348176/Novartis>,
        <https://1145.am/db/2349068/Novartis>,
        <https://1145.am/db/2350116/Johnson___Johnson>,
        <https://1145.am/db/2350440/Johnson___Johnson_Inc>,
        <https://1145.am/db/2352045/Novartis>,
        <https://1145.am/db/2352046/Novartis>,
        <https://1145.am/db/2352178/Novartis>,
        <https://1145.am/db/2354148/Novartis>,
        <https://1145.am/db/2354402/Johnson___Johnson>,
        <https://1145.am/db/2358273/Novartis>,
        <https://1145.am/db/2358297/Novartis>,
        <https://1145.am/db/2358579/Novartis>,
        <https://1145.am/db/2358657/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2359165/Novartis>,
        <https://1145.am/db/2359179/Novartis>,
        <https://1145.am/db/2359302/Johnson___Johnson>,
        <https://1145.am/db/2359915/Novadel_Pharma_Inc>,
        <https://1145.am/db/2360309/Novartis_Pharma_Ag>,
        <https://1145.am/db/2360526/Novartis>,
        <https://1145.am/db/2360633/Novartis>,
        <https://1145.am/db/2360754/Johnson___Johnson>,
        <https://1145.am/db/2362448/Novadel_Pharma_Inc>,
        <https://1145.am/db/2363618/Novartis_Uk>,
        <https://1145.am/db/2364457/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2364601/Johnson___Johnson>,
        <https://1145.am/db/2366653/Johnson___Johnson>,
        <https://1145.am/db/2367118/Novabay_Pharmaceuticals>,
        <https://1145.am/db/2367207/Novartis>,
        <https://1145.am/db/2367616/Johnson___Johnson>,
        <https://1145.am/db/2367617/Johnson___Johnson>,
        <https://1145.am/db/2367829/Novartis_International_Ag>,
        <https://1145.am/db/2367836/Novartis_International_Ag>,
        <https://1145.am/db/2367993/Novabay>,
        <https://1145.am/db/2368571/Novartis>,
        <https://1145.am/db/2368646/Novartis>,
        <https://1145.am/db/2368659/Novartis>,
        <https://1145.am/db/2369183/Novartis>,
        <https://1145.am/db/2369449/Novartis_Pharma_Ag>,
        <https://1145.am/db/2369450/Novartis>,
        <https://1145.am/db/2369451/Novartis>,
        <https://1145.am/db/2369555/Swiss_Pharma_Giant_Novartis>,
        <https://1145.am/db/2369718/Novartis>,
        <https://1145.am/db/2370010/Novartis>,
        <https://1145.am/db/2370013/Novartis>,
        <https://1145.am/db/2370259/Johnson___Johnson>,
        <https://1145.am/db/2370615/Novartis>,
        <https://1145.am/db/2370635/Novartis>,
        <https://1145.am/db/2371070/Novartis>,
        <https://1145.am/db/2371077/Novartis>,
        <https://1145.am/db/2371188/Novartis>,
        <https://1145.am/db/2371323/Novartis>,
        <https://1145.am/db/2371326/Novartis>,
        <https://1145.am/db/2434670/Novartis>,
        <https://1145.am/db/2536264/Johnson___Johnson>,
        <https://1145.am/db/2536325/Novartis>,
        <https://1145.am/db/2536882/Novartis>,
        <https://1145.am/db/2536914/Novartis>,
        <https://1145.am/db/2537064/Novartis>,
        <https://1145.am/db/2537477/Novartis>,
        <https://1145.am/db/2537482/Novacea>,
        <https://1145.am/db/2538344/Novartis>,
        <https://1145.am/db/2538791/Novartis>,
        <https://1145.am/db/2539541/Novasep>,
        <https://1145.am/db/2539787/Novartis>,
        <https://1145.am/db/2539925/Novartis>,
        <https://1145.am/db/2540187/Novartis>,
        <https://1145.am/db/2541511/Novartis>,
        <https://1145.am/db/2542938/Novartis>,
        <https://1145.am/db/2543689/Novartis>,
        <https://1145.am/db/2543863/Johnson___Johnson>,
        <https://1145.am/db/2544236/Novartis>,
        <https://1145.am/db/2544326/Novartis>,
        <https://1145.am/db/2545284/Novartis>,
        <https://1145.am/db/2545522/Johnson___Johnson>,
        <https://1145.am/db/2545651/Novartis>,
        <https://1145.am/db/2545966/Novartis>,
        <https://1145.am/db/2545986/Novartis>,
        <https://1145.am/db/2546157/Novartis>,
        <https://1145.am/db/2546170/Novartis>,
        <https://1145.am/db/2546172/Johnson___Johnson>,
        <https://1145.am/db/2546603/Novartis>,
        <https://1145.am/db/2547152/Johnson___Johnson>,
        <https://1145.am/db/2547397/Novartis>,
        <https://1145.am/db/2548223/Novartis>,
        <https://1145.am/db/2548224/Novartis_Group>,
        <https://1145.am/db/2549043/Novartis>,
        <https://1145.am/db/2549631/Novast>,
        <https://1145.am/db/2550855/Novartis>,
        <https://1145.am/db/2551143/Novartis>,
        <https://1145.am/db/2551693/Novartis>,
        <https://1145.am/db/2551694/Novartis>,
        <https://1145.am/db/2552165/Novartis>,
        <https://1145.am/db/2552258/Novartis>,
        <https://1145.am/db/2553024/Johnson___Johnson>,
        <https://1145.am/db/2553024/Novartis>,
        <https://1145.am/db/2553276/Novartis>,
        <https://1145.am/db/2553480/Novartis>,
        <https://1145.am/db/2553740/Novasep>,
        <https://1145.am/db/2553810/Novartis>,
        <https://1145.am/db/2553846/Novartis>,
        <https://1145.am/db/2553852/Johnson___Johnson>,
        <https://1145.am/db/2554060/Novartis>,
        <https://1145.am/db/2554669/Novasep>,
        <https://1145.am/db/2555555/Novartis>,
        <https://1145.am/db/2555561/Novartis>,
        <https://1145.am/db/2556030/Novartis>,
        <https://1145.am/db/2556543/Novartis>,
        <https://1145.am/db/2557204/Novartis>,
        <https://1145.am/db/2557588/Novartis>,
        <https://1145.am/db/2558316/Novartis>,
        <https://1145.am/db/2558415/Novartis>,
        <https://1145.am/db/2558779/Novartis>,
        <https://1145.am/db/2558927/Novartis>,
        <https://1145.am/db/2559306/Novartis>,
        <https://1145.am/db/2559655/Novartis>,
        <https://1145.am/db/2559797/Novartis>,
        <https://1145.am/db/2559802/Novartis>,
        <https://1145.am/db/2559810/Switzerlands_Novartis>,
        <https://1145.am/db/2560023/Novartis>,
        <https://1145.am/db/2560079/Novartis>,
        <https://1145.am/db/2560372/Johnson___Johnson>,
        <https://1145.am/db/2561162/Novasep>,
        <https://1145.am/db/2561268/Novartis>,
        <https://1145.am/db/2561541/Novartis>,
        <https://1145.am/db/2561955/Novartis>,
        <https://1145.am/db/2562202/Novartis>,
        <https://1145.am/db/2562695/Novartis>,
        <https://1145.am/db/2562951/Novartis>,
        <https://1145.am/db/2563497/Novartis>,
        <https://1145.am/db/2563987/Novartis>,
        <https://1145.am/db/2564032/Johnson___Johnson>,
        <https://1145.am/db/2564141/Novartis>,
        <https://1145.am/db/2564268/Novartis>,
        <https://1145.am/db/2564462/Johnson___Johnson_Novartis>,
        <https://1145.am/db/2564695/Novartis>,
        <https://1145.am/db/2565142/Novartis>,
        <https://1145.am/db/2565794/Novartis>,
        <https://1145.am/db/2565844/Novartis>,
        <https://1145.am/db/2566121/Novartis>,
        <https://1145.am/db/2566147/Johnson___Johnson>,
        <https://1145.am/db/2567283/Novartis>,
        <https://1145.am/db/2567300/Novartis>,
        <https://1145.am/db/2567942/Novartis>,
        <https://1145.am/db/2568308/Novartis>,
        <https://1145.am/db/2568734/Novartis>,
        <https://1145.am/db/2568932/Novartis>,
        <https://1145.am/db/2568968/Novartis>,
        <https://1145.am/db/2568973/Novartis>,
        <https://1145.am/db/2569724/Novartis>,
        <https://1145.am/db/2570214/Novartis>,
        <https://1145.am/db/2570721/Novartis>,
        <https://1145.am/db/2570791/Novartis>,
        <https://1145.am/db/2570932/Novartis>,
        <https://1145.am/db/2570937/Novartis_Uk>,
        <https://1145.am/db/2571513/Novartis>,
        <https://1145.am/db/2571519/Novartis>,
        <https://1145.am/db/2571527/Novartis>,
        <https://1145.am/db/2572466/Johnson___Johnson>,
        <https://1145.am/db/2572713/Novartis>,
        <https://1145.am/db/2572904/Novartis_Group>,
        <https://1145.am/db/2572985/Novartis>,
        <https://1145.am/db/2573002/Novartis>,
        <https://1145.am/db/2573373/Johnson___Johnson>,
        <https://1145.am/db/2573473/Novartis>,
        <https://1145.am/db/2573517/Novartis>,
        <https://1145.am/db/2573611/Novartis>,
        <https://1145.am/db/2574347/Johnson___Johnson>,
        <https://1145.am/db/2574584/Novartis>,
        <https://1145.am/db/2574958/Novartis>,
        <https://1145.am/db/2575047/Novartis>,
        <https://1145.am/db/2575310/Novartis>,
        <https://1145.am/db/2575313/Novartis>,
        <https://1145.am/db/2575488/Novartis>,
        <https://1145.am/db/2575492/Johnson___Johnson>,
        <https://1145.am/db/2575496/Johnson___Johnson>,
        <https://1145.am/db/2575545/Novartis>,
        <https://1145.am/db/2575625/Novartis>,
        <https://1145.am/db/2575702/Novartis>,
        <https://1145.am/db/2575712/Novartis>,
        <https://1145.am/db/2575810/Novartis_Ag>,
        <https://1145.am/db/2575810/Novartis_Pharma_Ag>,
        <https://1145.am/db/2575813/Novartis>,
        <https://1145.am/db/2576242/Novartis>,
        <https://1145.am/db/2576254/Novartis>,
        <https://1145.am/db/2576439/Johnson___Johnson>,
        <https://1145.am/db/2576547/Novartis>,
        <https://1145.am/db/2576933/Novartis>,
        <https://1145.am/db/2576962/Johnson___Johnson>,
        <https://1145.am/db/2577129/Novartis>,
        <https://1145.am/db/2577419/Novartis>,
        <https://1145.am/db/2577998/Novartis>,
        <https://1145.am/db/2579507/Novartis>,
        <https://1145.am/db/2579519/Novartis>,
        <https://1145.am/db/2580047/Novartis>,
        <https://1145.am/db/2580401/Novartis>,
        <https://1145.am/db/2580963/Novartis>,
        <https://1145.am/db/2581378/Novartis>,
        <https://1145.am/db/2581394/Novartis>,
        <https://1145.am/db/2581493/Novartis>,
        <https://1145.am/db/2581716/Novartis>,
        <https://1145.am/db/2582355/Novartis>,
        <https://1145.am/db/2582395/Novartis>,
        <https://1145.am/db/2582400/Novartis>,
        <https://1145.am/db/2582402/Novartis>,
        <https://1145.am/db/2582623/Novartis>,
        <https://1145.am/db/2582643/Novartis>,
        <https://1145.am/db/2583067/Novartis>,
        <https://1145.am/db/2583189/Johnson___Johnson>,
        <https://1145.am/db/2584383/Johnson___Johnson>,
        <https://1145.am/db/2584538/Novartis>,
        <https://1145.am/db/2585039/Novartis>,
        <https://1145.am/db/2585121/Novartis>,
        <https://1145.am/db/2585710/Johnson___Johnson>,
        <https://1145.am/db/2586661/Novatis>,
        <https://1145.am/db/2586670/Novartis>,
        <https://1145.am/db/2587047/Novartis>,
        <https://1145.am/db/2587143/Johnson___Johnson>,
        <https://1145.am/db/2587177/Johnson___Johnson>,
        <https://1145.am/db/2587805/Novartis>,
        <https://1145.am/db/2587857/Novartis>,
        <https://1145.am/db/2588074/Johnson___Johnson>,
        <https://1145.am/db/2588196/Novartis>,
        <https://1145.am/db/2589178/Novartis>,
        <https://1145.am/db/2589402/Johnson___Johnson>,
        <https://1145.am/db/2589535/Novartis>,
        <https://1145.am/db/2589799/Novartis>,
        <https://1145.am/db/2591073/Johnson___Johnson>,
        <https://1145.am/db/2591074/Johnson___Johnson>,
        <https://1145.am/db/2591076/Johnson___Johnson>,
        <https://1145.am/db/2591905/Novartis>,
        <https://1145.am/db/2592351/Novartis>,
        <https://1145.am/db/2592505/Novartis>,
        <https://1145.am/db/2592534/Johnson___Johnson>,
        <https://1145.am/db/2592895/Novartis>,
        <https://1145.am/db/2592987/Novartis>,
        <https://1145.am/db/2593443/Novartis>,
        <https://1145.am/db/2593889/Johnson___Johnson>,
        <https://1145.am/db/2594106/Johnson___Johnson>,
        <https://1145.am/db/2594494/Novartis>,
        <https://1145.am/db/2594935/Novartis>,
        <https://1145.am/db/2594940/Novartis>,
        <https://1145.am/db/2595048/Novartis>,
        <https://1145.am/db/2595150/Novartis>,
        <https://1145.am/db/2595688/Novartis>,
        <https://1145.am/db/2595924/Novartis_Ag>,
        <https://1145.am/db/2596344/Novartis>,
        <https://1145.am/db/2597135/Johnson___Johnson>,
        <https://1145.am/db/2597197/Novamed_Pharmaceuticals>,
        <https://1145.am/db/2598439/Johnson___Johnson_Inc>,
        <https://1145.am/db/2598636/Novartis>,
        <https://1145.am/db/2787530/Novartis>,
        <https://1145.am/db/2787550/Johnson___Johnson>,
        <https://1145.am/db/282192/Novartis>,
        <https://1145.am/db/346162/Novartis>,
        <https://1145.am/db/488391/Novartis>,
        <https://1145.am/db/509708/Novabay®_Pharmaceuticals_Inc>,
        <https://1145.am/db/595011/Novartis>,
        <https://1145.am/db/601300/Novabay®_Pharmaceuticals_Inc>,
        <https://1145.am/db/637582/Novartis>,
        <https://1145.am/db/652831/Novartis>,
        <https://1145.am/db/661296/Novartis>,
        <https://1145.am/db/691279/Novartis>,
        <https://1145.am/db/699695/Johnson___Johnson>,
        <https://1145.am/db/712016/Novartis>,
        <https://1145.am/db/895235/Novan> ;
    ns1:sameAsMedium <https://1145.am/db/1151476/Novartis>,
        <https://1145.am/db/1629127/Novartis>,
        <https://1145.am/db/1630421/Novartis>,
        <https://1145.am/db/2076347/Novartis>,
        <https://1145.am/db/2155042/Novartis>,
        <https://1145.am/db/2186148/Novartis>,
        <https://1145.am/db/2290898/Novartis>,
        <https://1145.am/db/2291090/Novartis>,
        <https://1145.am/db/2291713/Novartis>,
        <https://1145.am/db/2293419/Novartis>,
        <https://1145.am/db/2294680/Novartis>,
        <https://1145.am/db/2299847/Novartis>,
        <https://1145.am/db/2309347/Novartis>,
        <https://1145.am/db/2321958/Novartis>,
        <https://1145.am/db/2325386/Novartis>,
        <https://1145.am/db/2332408/Novartis>,
        <https://1145.am/db/2333390/Novartis>,
        <https://1145.am/db/2337976/Novartis>,
        <https://1145.am/db/2342687/Novartis>,
        <https://1145.am/db/2343460/Novartis>,
        <https://1145.am/db/2358559/Novartis>,
        <https://1145.am/db/2361451/Novartis>,
        <https://1145.am/db/2369178/Novartis>,
        <https://1145.am/db/2371165/Novartis>,
        <https://1145.am/db/2371203/Novartis>,
        <https://1145.am/db/2536538/Novartis>,
        <https://1145.am/db/2537155/Novartis>,
        <https://1145.am/db/2544350/Novartis>,
        <https://1145.am/db/2544409/Novartis>,
        <https://1145.am/db/2550764/Novartis>,
        <https://1145.am/db/2551001/Novartis>,
        <https://1145.am/db/2551402/Novartis>,
        <https://1145.am/db/2552856/Novartis>,
        <https://1145.am/db/2553487/Novartis>,
        <https://1145.am/db/2560238/Novartis>,
        <https://1145.am/db/2562442/Novartis>,
        <https://1145.am/db/2565564/Novartis>,
        <https://1145.am/db/2570062/Novartis>,
        <https://1145.am/db/2571462/Novartis>,
        <https://1145.am/db/2573984/Novartis>,
        <https://1145.am/db/2574950/Novartis>,
        <https://1145.am/db/2575947/Novartis>,
        <https://1145.am/db/2576892/Novartis>,
        <https://1145.am/db/2578046/Novartis>,
        <https://1145.am/db/2579890/Novartis>,
        <https://1145.am/db/2581804/Novartis>,
        <https://1145.am/db/2582646/Novartis>,
        <https://1145.am/db/2583163/Novartis>,
        <https://1145.am/db/2584135/Novartis>,
        <https://1145.am/db/2584245/Novartis>,
        <https://1145.am/db/2587048/Novartis>,
        <https://1145.am/db/2588333/Novartis>,
        <https://1145.am/db/2588691/Novartis>,
        <https://1145.am/db/2590887/Novartis>,
        <https://1145.am/db/2593780/Novartis>,
        <https://1145.am/db/619955/Novartis>,
        <https://1145.am/db/623985/Novartis> ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2203459/Picis> a org:Organization ;
    ns1:basedInHighGeoName "Eden Prairie" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5025219/about.rdf> ;
    ns1:basedInHighRaw "EDEN PRAIRIE, Minn." ;
    ns1:description "health information solutions" ;
    ns1:documentDate "2010-07-22T14:00:07+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Ingenix to Acquire Picis" ;
    ns1:documentURL <https://www.fiercehealthcare.com/it/ingenix-to-acquire-picis-0> ;
    ns1:foundName "Picis®, Inc." ;
    ns1:industry "health information technology and services" ;
    ns1:name "Picis" ;
    ns1:sameAsHigh <https://1145.am/db/2203473/Picis>,
        <https://1145.am/db/2203476/Picis>,
        <https://1145.am/db/2227885/Picis>,
        <https://1145.am/db/2250964/Picis>,
        <https://1145.am/db/2251336/Picis>,
        <https://1145.am/db/2262219/Picis>,
        <https://1145.am/db/440636/Picis_Clinical_Solutions>,
        <https://1145.am/db/662006/Picis_Clinical_Solutions> ;
    ns1:sameAsMedium <https://1145.am/db/2204532/Picis> ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2203476/Picis> a org:Organization ;
    ns1:basedInHighGeoName "Eden Prairie" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5025219/about.rdf> ;
    ns1:basedInHighRaw "EDEN PRAIRIE, Minn." ;
    ns1:description "health information solutions" ;
    ns1:documentDate "2010-07-26T18:43:07+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Ingenix to Acquire Picis" ;
    ns1:documentURL <https://www.fiercehealthcare.com/it/ingenix-to-acquire-picis> ;
    ns1:foundName "Picis®, Inc." ;
    ns1:industry "health information technology and services" ;
    ns1:name "Picis" ;
    ns1:sameAsHigh <https://1145.am/db/2203459/Picis>,
        <https://1145.am/db/2203473/Picis>,
        <https://1145.am/db/2227885/Picis>,
        <https://1145.am/db/2250964/Picis>,
        <https://1145.am/db/2251336/Picis>,
        <https://1145.am/db/2262219/Picis>,
        <https://1145.am/db/440636/Picis_Clinical_Solutions>,
        <https://1145.am/db/662006/Picis_Clinical_Solutions> ;
    ns1:sameAsMedium <https://1145.am/db/2204532/Picis> ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2227885/Picis> a org:Organization ;
    ns1:basedInHighGeoName "Eden Prairie" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5025219/about.rdf> ;
    ns1:basedInHighRaw "EDEN PRAIRIE, Minn." ;
    ns1:description "health information solutions" ;
    ns1:documentDate "2010-07-22T14:02:01+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Ingenix to Acquire Picis" ;
    ns1:documentURL <https://www.fiercehealthcare.com/practices/ingenix-to-acquire-picis> ;
    ns1:foundName "Picis®, Inc." ;
    ns1:industry "health information technology and services" ;
    ns1:name "Picis" ;
    ns1:sameAsHigh <https://1145.am/db/2203459/Picis>,
        <https://1145.am/db/2203473/Picis>,
        <https://1145.am/db/2203476/Picis>,
        <https://1145.am/db/2250964/Picis>,
        <https://1145.am/db/2251336/Picis>,
        <https://1145.am/db/2262219/Picis>,
        <https://1145.am/db/440636/Picis_Clinical_Solutions>,
        <https://1145.am/db/662006/Picis_Clinical_Solutions> ;
    ns1:sameAsMedium <https://1145.am/db/2204532/Picis> ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2250964/Picis> a org:Organization ;
    ns1:basedInHighGeoName "Eden Prairie" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5025219/about.rdf> ;
    ns1:basedInHighRaw "EDEN PRAIRIE, Minn." ;
    ns1:description "health information solutions" ;
    ns1:documentDate "2010-07-22T14:01:39+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Ingenix to Acquire Picis" ;
    ns1:documentURL <https://www.fiercehealthcare.com/healthcare/ingenix-to-acquire-picis-0> ;
    ns1:foundName "Picis®, Inc." ;
    ns1:industry "health information technology and services" ;
    ns1:name "Picis" ;
    ns1:sameAsHigh <https://1145.am/db/2203459/Picis>,
        <https://1145.am/db/2203473/Picis>,
        <https://1145.am/db/2203476/Picis>,
        <https://1145.am/db/2227885/Picis>,
        <https://1145.am/db/2251336/Picis>,
        <https://1145.am/db/2262219/Picis>,
        <https://1145.am/db/440636/Picis_Clinical_Solutions>,
        <https://1145.am/db/662006/Picis_Clinical_Solutions> ;
    ns1:sameAsMedium <https://1145.am/db/2204532/Picis> ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2262219/Picis> a org:Organization ;
    ns1:basedInHighGeoName "Eden Prairie" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5025219/about.rdf> ;
    ns1:basedInHighRaw "EDEN PRAIRIE, Minn." ;
    ns1:description "health information solutions" ;
    ns1:documentDate "2010-07-22T15:10:34+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Ingenix to Acquire Picis" ;
    ns1:documentURL <https://www.fiercehealthcare.com/payer/ingenix-to-acquire-picis> ;
    ns1:foundName "Picis®, Inc." ;
    ns1:industry "health information technology and services" ;
    ns1:name "Picis" ;
    ns1:sameAsHigh <https://1145.am/db/2203459/Picis>,
        <https://1145.am/db/2203473/Picis>,
        <https://1145.am/db/2203476/Picis>,
        <https://1145.am/db/2227885/Picis>,
        <https://1145.am/db/2250964/Picis>,
        <https://1145.am/db/2251336/Picis>,
        <https://1145.am/db/440636/Picis_Clinical_Solutions>,
        <https://1145.am/db/662006/Picis_Clinical_Solutions> ;
    ns1:sameAsMedium <https://1145.am/db/2204532/Picis> ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2341003/Clarus_Ventures> a org:Organization ;
    ns1:basedInLowRaw "Calif" ;
    ns1:documentDate "2010-10-19T14:00:23+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Pearl Therapeutics Raises $69 Million Series C Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/pearl-therapeutics-raises-69-million-series-c-financing> ;
    ns1:foundName "Clarus Ventures" ;
    ns1:investor <https://1145.am/db/2341003/Series_C_Investment_5am_Ventures_Clarus_Ventures_New_Leaf_Venture_Partners_Pearl_Therapeutics_Inc_Vatera_Healthcare_Partners_Completed> ;
    ns1:name "Clarus Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/2289229/Clarus_Ventures>,
        <https://1145.am/db/2302292/Clarus_Ventures>,
        <https://1145.am/db/2302994/Clarus_Ventures>,
        <https://1145.am/db/2303563/Clarus_Ventures>,
        <https://1145.am/db/2303581/Clarus_Ventures>,
        <https://1145.am/db/2304261/Clarus_Ventures>,
        <https://1145.am/db/2305745/Clarus_Ventures>,
        <https://1145.am/db/2306754/Clarus_Ventures>,
        <https://1145.am/db/2311011/Clarus_Ventures>,
        <https://1145.am/db/2311595/Clarus_Ventures>,
        <https://1145.am/db/2312277/Clarus_Ventures>,
        <https://1145.am/db/2312288/Clarus_Ventures>,
        <https://1145.am/db/2312945/Clarus_Ventures>,
        <https://1145.am/db/2313322/Clarus_Ventures>,
        <https://1145.am/db/2313438/Clarus_Ventures>,
        <https://1145.am/db/2315059/Clarus_Ventures>,
        <https://1145.am/db/2317145/Clarus_Ventures>,
        <https://1145.am/db/2318851/Clarus_Ventures>,
        <https://1145.am/db/2321137/Clarus_Ventures>,
        <https://1145.am/db/2324936/Clarus_Ventures>,
        <https://1145.am/db/2325880/Clarus_Ventures>,
        <https://1145.am/db/2327405/Clarus_Ventures>,
        <https://1145.am/db/2329773/Clarus_Ventures>,
        <https://1145.am/db/2332748/Clarus_Ventures>,
        <https://1145.am/db/2335928/Clarus_Ventures>,
        <https://1145.am/db/2336313/Clarus_Ventures>,
        <https://1145.am/db/2336944/Clarus_Ventures>,
        <https://1145.am/db/2341600/Clarus_Ventures>,
        <https://1145.am/db/2342624/Clarus_Ventures>,
        <https://1145.am/db/2342629/Clarus_Ventures_Llc>,
        <https://1145.am/db/2343722/Clarus_Ventures>,
        <https://1145.am/db/2343725/Clarus_Ventures>,
        <https://1145.am/db/2343737/Clarus_Ventures>,
        <https://1145.am/db/2347389/Clarus_Ventures>,
        <https://1145.am/db/2347876/Clarus_Ventures>,
        <https://1145.am/db/2349120/Clarus_Ventures>,
        <https://1145.am/db/2349717/Clarus_Ventures>,
        <https://1145.am/db/2349722/Clarus_Ventures>,
        <https://1145.am/db/2350004/Clarus_Ventures>,
        <https://1145.am/db/2351958/Clarus_Ventures>,
        <https://1145.am/db/2352808/Clarus_Ventures>,
        <https://1145.am/db/2352831/Clarus_Ventures>,
        <https://1145.am/db/2353771/Clarus_Ventures>,
        <https://1145.am/db/2353789/Clarus_Ventures>,
        <https://1145.am/db/2354295/Clarus_Ventures>,
        <https://1145.am/db/2355435/Clarus_Ventures>,
        <https://1145.am/db/2356084/Clarus_Ventures>,
        <https://1145.am/db/2357858/Clarus_Ventures>,
        <https://1145.am/db/2359654/Clarus_Ventures>,
        <https://1145.am/db/2360756/Clarus_Ventures>,
        <https://1145.am/db/2360758/Clarus_Ventures>,
        <https://1145.am/db/2364468/Clarus_Ventures>,
        <https://1145.am/db/2364471/Clarus_Ventures>,
        <https://1145.am/db/2365171/Clarus_Ventures>,
        <https://1145.am/db/2365184/Clarus_Ventures>,
        <https://1145.am/db/2366049/Clarus_Ventures>,
        <https://1145.am/db/2366055/Clarus_Ventures>,
        <https://1145.am/db/2368297/Clarus_Ventures>,
        <https://1145.am/db/2370240/Clarus_Ventures>,
        <https://1145.am/db/2584561/Clarus_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2349717/Clarus_Ventures> a org:Organization ;
    ns1:basedInLowRaw "Pa" ;
    ns1:documentDate "2010-08-10T15:41:02+00:00"^^xsd:dateTime ;
    ns1:documentTitle "TetraLogic Pharmaceuticals Completes $32 Million Series C Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/tetralogic-pharmaceuticals-completes-32-million-series-c-financing> ;
    ns1:foundName "Clarus Ventures" ;
    ns1:investor <https://1145.am/db/2349717/Series_C_Investment_Amgen_Ventures_Clarus_Ventures_Hatteras_Venture_Partners_Healthcare_Ventures_Latterell_Venture_Partners_Novitas_Capital_Quaker_Bioventures_Tetralogic_Pharmaceuticals_Vertical_Group_Completed> ;
    ns1:name "Clarus Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/2289229/Clarus_Ventures>,
        <https://1145.am/db/2302292/Clarus_Ventures>,
        <https://1145.am/db/2302994/Clarus_Ventures>,
        <https://1145.am/db/2303563/Clarus_Ventures>,
        <https://1145.am/db/2303581/Clarus_Ventures>,
        <https://1145.am/db/2304261/Clarus_Ventures>,
        <https://1145.am/db/2305745/Clarus_Ventures>,
        <https://1145.am/db/2306754/Clarus_Ventures>,
        <https://1145.am/db/2311011/Clarus_Ventures>,
        <https://1145.am/db/2311595/Clarus_Ventures>,
        <https://1145.am/db/2312277/Clarus_Ventures>,
        <https://1145.am/db/2312288/Clarus_Ventures>,
        <https://1145.am/db/2312945/Clarus_Ventures>,
        <https://1145.am/db/2313322/Clarus_Ventures>,
        <https://1145.am/db/2313438/Clarus_Ventures>,
        <https://1145.am/db/2315059/Clarus_Ventures>,
        <https://1145.am/db/2317145/Clarus_Ventures>,
        <https://1145.am/db/2318851/Clarus_Ventures>,
        <https://1145.am/db/2321137/Clarus_Ventures>,
        <https://1145.am/db/2324936/Clarus_Ventures>,
        <https://1145.am/db/2325880/Clarus_Ventures>,
        <https://1145.am/db/2327405/Clarus_Ventures>,
        <https://1145.am/db/2329773/Clarus_Ventures>,
        <https://1145.am/db/2332748/Clarus_Ventures>,
        <https://1145.am/db/2335928/Clarus_Ventures>,
        <https://1145.am/db/2336313/Clarus_Ventures>,
        <https://1145.am/db/2336944/Clarus_Ventures>,
        <https://1145.am/db/2341003/Clarus_Ventures>,
        <https://1145.am/db/2341600/Clarus_Ventures>,
        <https://1145.am/db/2342624/Clarus_Ventures>,
        <https://1145.am/db/2342629/Clarus_Ventures_Llc>,
        <https://1145.am/db/2343722/Clarus_Ventures>,
        <https://1145.am/db/2343725/Clarus_Ventures>,
        <https://1145.am/db/2343737/Clarus_Ventures>,
        <https://1145.am/db/2347389/Clarus_Ventures>,
        <https://1145.am/db/2347876/Clarus_Ventures>,
        <https://1145.am/db/2349120/Clarus_Ventures>,
        <https://1145.am/db/2349722/Clarus_Ventures>,
        <https://1145.am/db/2350004/Clarus_Ventures>,
        <https://1145.am/db/2351958/Clarus_Ventures>,
        <https://1145.am/db/2352808/Clarus_Ventures>,
        <https://1145.am/db/2352831/Clarus_Ventures>,
        <https://1145.am/db/2353771/Clarus_Ventures>,
        <https://1145.am/db/2353789/Clarus_Ventures>,
        <https://1145.am/db/2354295/Clarus_Ventures>,
        <https://1145.am/db/2355435/Clarus_Ventures>,
        <https://1145.am/db/2356084/Clarus_Ventures>,
        <https://1145.am/db/2357858/Clarus_Ventures>,
        <https://1145.am/db/2359654/Clarus_Ventures>,
        <https://1145.am/db/2360756/Clarus_Ventures>,
        <https://1145.am/db/2360758/Clarus_Ventures>,
        <https://1145.am/db/2364468/Clarus_Ventures>,
        <https://1145.am/db/2364471/Clarus_Ventures>,
        <https://1145.am/db/2365171/Clarus_Ventures>,
        <https://1145.am/db/2365184/Clarus_Ventures>,
        <https://1145.am/db/2366049/Clarus_Ventures>,
        <https://1145.am/db/2366055/Clarus_Ventures>,
        <https://1145.am/db/2368297/Clarus_Ventures>,
        <https://1145.am/db/2370240/Clarus_Ventures>,
        <https://1145.am/db/2584561/Clarus_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2349717/Healthcare_Ventures> a org:Organization ;
    ns1:basedInLowRaw "Pa" ;
    ns1:description "investing" ;
    ns1:documentDate "2010-08-10T15:41:02+00:00"^^xsd:dateTime ;
    ns1:documentTitle "TetraLogic Pharmaceuticals Completes $32 Million Series C Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/tetralogic-pharmaceuticals-completes-32-million-series-c-financing> ;
    ns1:foundName "HealthCare Ventures" ;
    ns1:investor <https://1145.am/db/2349717/Series_C_Investment_Amgen_Ventures_Clarus_Ventures_Hatteras_Venture_Partners_Healthcare_Ventures_Latterell_Venture_Partners_Novitas_Capital_Quaker_Bioventures_Tetralogic_Pharmaceuticals_Vertical_Group_Completed> ;
    ns1:name "HealthCare Ventures" ;
    ns1:sameAsHigh <https://1145.am/db/1335924/Blue_Venture_Fund>,
        <https://1145.am/db/1336552/Blue_Venture_Fund>,
        <https://1145.am/db/1374213/Apollo_Health_Ventures>,
        <https://1145.am/db/1628978/Cvs_Health_Ventures>,
        <https://1145.am/db/2180772/7wireventures>,
        <https://1145.am/db/2281648/Medical_Excellence_Capital_Partners>,
        <https://1145.am/db/2282392/Pioneer_Healthcare_Partners>,
        <https://1145.am/db/2294753/Catalyst_Health_Ventures>,
        <https://1145.am/db/2298897/Healthlink_Capital>,
        <https://1145.am/db/2303251/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2303257/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2305524/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/230667/Red_Tree_Venture_Capital>,
        <https://1145.am/db/2309845/Healthcare_Ventures>,
        <https://1145.am/db/2311069/Healthcare_Ventures>,
        <https://1145.am/db/2311075/Healthcare_Ventures>,
        <https://1145.am/db/2321713/Healthcor_Partners_Management>,
        <https://1145.am/db/2323586/Healthcare_Ventures>,
        <https://1145.am/db/2329533/Essex_Woodlands_Healthcare_Ventures>,
        <https://1145.am/db/2329533/Gilde_Healthcare>,
        <https://1145.am/db/2330876/Healthcare_Venture>,
        <https://1145.am/db/2337166/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2340284/Catalyst_Health_Ventures>,
        <https://1145.am/db/2342611/Healthcap>,
        <https://1145.am/db/2346204/Healthcare_Ventures>,
        <https://1145.am/db/2347469/Healthcare_Ventures>,
        <https://1145.am/db/2347822/Healthcap>,
        <https://1145.am/db/2352820/Healthcare_Ventures>,
        <https://1145.am/db/2356567/Mp_Healthcare_Venture_Management_Inc>,
        <https://1145.am/db/2365279/Founders_Fund>,
        <https://1145.am/db/2365296/Mp_Healthcare_Venture_Management>,
        <https://1145.am/db/2367497/Healthcare_Ventures>,
        <https://1145.am/db/2369086/Whitesun_Healthcare_Ventures>,
        <https://1145.am/db/348452/Inflect_Health>,
        <https://1145.am/db/662177/Apollo_Health_Ventures> ;
    ns1:sameAsMedium <https://1145.am/db/2235852/Healthcare_Ventures>,
        <https://1145.am/db/2304650/Healthcare_Ventures>,
        <https://1145.am/db/2308148/Healthcare_Ventures>,
        <https://1145.am/db/2308887/Healthcare_Ventures>,
        <https://1145.am/db/2312192/Healthcare_Ventures>,
        <https://1145.am/db/2313405/Healthcare_Ventures>,
        <https://1145.am/db/2316601/Healthcare_Ventures>,
        <https://1145.am/db/2316605/Healthcare_Ventures>,
        <https://1145.am/db/2316823/Healthcare_Ventures>,
        <https://1145.am/db/2318657/Healthcare_Ventures>,
        <https://1145.am/db/2321097/Healthcare_Ventures>,
        <https://1145.am/db/2331639/Healthcare_Ventures>,
        <https://1145.am/db/2338373/Healthcare_Ventures>,
        <https://1145.am/db/2342269/Healthcare_Ventures>,
        <https://1145.am/db/2343202/Healthcare_Ventures>,
        <https://1145.am/db/2343210/Healthcare_Ventures>,
        <https://1145.am/db/2348486/Healthcare_Ventures>,
        <https://1145.am/db/2349722/Healthcare_Ventures>,
        <https://1145.am/db/2352814/Healthcare_Ventures>,
        <https://1145.am/db/2363510/Healthcare_Ventures>,
        <https://1145.am/db/2365138/Healthcare_Ventures>,
        <https://1145.am/db/2365171/Healthcare_Ventures>,
        <https://1145.am/db/2443170/Healthcare_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352382/Series_A_Investment_Biomedinvest_Delenex_Therapeutics_Ag_Hbm_Biocapital_Hbm_Bioventures_Sv_Life_Sciences_Vi_Partners_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-11-12T14:21:30+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Delenex Therapeutics AG, a Swiss biotech company developing therapeutic antibody fragments targeting serious medical diseases with high unmet need, has announced the closing of its Series A venture equity investment round securing CHF 13.5 million (USD 14 million, EUR 10 million) .",
        "Delenex Therapeutics Secures CHF 13.5 Million Series A Venture Financing." ;
    ns1:documentTitle "Delenex Therapeutics Secures CHF 13.5 Million Series A Venture Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/delenex-therapeutics-secures-chf-13-5-million-series-a-venture-financing> ;
    ns1:foundName "investment" ;
    ns1:name "investment" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2352382/Delenex_Therapeutics_Ag> ;
    ns1:targetDetails "Series A",
        "Venture" ;
    ns1:valueRaw "CHF 13.5 Million",
        "CHF 13.5 million",
        "EUR 10 million",
        "USD 14 million" ;
    ns1:whereGeoName "Switzerland" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/2658434/about.rdf> ;
    ns1:whereRaw "Switzerland" .

<https://1145.am/db/2352414/Series_C_Investment_Bessemer_Venture_Partners_Cerulean_Pharma_Inc_Lilly_Ventures_Lux_Capital_Polaris_Venture_Partners_Venrock_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-11-15T14:49:42+00:00"^^xsd:dateTime ;
    ns1:documentExtract "CAMBRIDGE, Mass.- (BUSINESS WIRE) -Cerulean Pharma Inc., a leader in designing and developing nanopharmaceuticals, today announced that the Company has closed a $ 24 million Series C financing led by Lilly Ventures, with participation from all other existing investors including Polaris Venture Partners, Venrock, Lux Capital, and Bessemer Venture Partners.",
        "Cerulean Pharma Inc. Closes $ 24 Million in Series C Financing." ;
    ns1:documentTitle "Cerulean Pharma Inc. Closes $24 Million in Series C Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cerulean-pharma-inc-closes-24-million-series-c-financing> ;
    ns1:foundName "financing" ;
    ns1:name "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2352414/Cerulean_Pharma_Inc> ;
    ns1:targetDetails "Series C" ;
    ns1:valueRaw "$ 24 Million",
        "$ 24 million" ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "United States" .

<https://1145.am/db/2352808/Clarus_Ventures> a org:Organization ;
    ns1:basedInLowRaw "Conn" ;
    ns1:documentDate "2010-08-19T15:35:59+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Achillion Announces Private Placement of $50 Million" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/achillion-announces-private-placement-of-50-million> ;
    ns1:foundName "Clarus Ventures" ;
    ns1:investor <https://1145.am/db/2352808/Investment_Achillion_Pharmaceuticals_Inc_Clarus_Ventures_Domain_Associates_Pappas_Ventures_Quaker_Bioventures_Has_Not_Happened> ;
    ns1:name "Clarus Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/2289229/Clarus_Ventures>,
        <https://1145.am/db/2302292/Clarus_Ventures>,
        <https://1145.am/db/2302994/Clarus_Ventures>,
        <https://1145.am/db/2303563/Clarus_Ventures>,
        <https://1145.am/db/2303581/Clarus_Ventures>,
        <https://1145.am/db/2304261/Clarus_Ventures>,
        <https://1145.am/db/2305745/Clarus_Ventures>,
        <https://1145.am/db/2306754/Clarus_Ventures>,
        <https://1145.am/db/2311011/Clarus_Ventures>,
        <https://1145.am/db/2311595/Clarus_Ventures>,
        <https://1145.am/db/2312277/Clarus_Ventures>,
        <https://1145.am/db/2312288/Clarus_Ventures>,
        <https://1145.am/db/2312945/Clarus_Ventures>,
        <https://1145.am/db/2313322/Clarus_Ventures>,
        <https://1145.am/db/2313438/Clarus_Ventures>,
        <https://1145.am/db/2315059/Clarus_Ventures>,
        <https://1145.am/db/2317145/Clarus_Ventures>,
        <https://1145.am/db/2318851/Clarus_Ventures>,
        <https://1145.am/db/2321137/Clarus_Ventures>,
        <https://1145.am/db/2324936/Clarus_Ventures>,
        <https://1145.am/db/2325880/Clarus_Ventures>,
        <https://1145.am/db/2327405/Clarus_Ventures>,
        <https://1145.am/db/2329773/Clarus_Ventures>,
        <https://1145.am/db/2332748/Clarus_Ventures>,
        <https://1145.am/db/2335928/Clarus_Ventures>,
        <https://1145.am/db/2336313/Clarus_Ventures>,
        <https://1145.am/db/2336944/Clarus_Ventures>,
        <https://1145.am/db/2341003/Clarus_Ventures>,
        <https://1145.am/db/2341600/Clarus_Ventures>,
        <https://1145.am/db/2342624/Clarus_Ventures>,
        <https://1145.am/db/2342629/Clarus_Ventures_Llc>,
        <https://1145.am/db/2343722/Clarus_Ventures>,
        <https://1145.am/db/2343725/Clarus_Ventures>,
        <https://1145.am/db/2343737/Clarus_Ventures>,
        <https://1145.am/db/2347389/Clarus_Ventures>,
        <https://1145.am/db/2347876/Clarus_Ventures>,
        <https://1145.am/db/2349120/Clarus_Ventures>,
        <https://1145.am/db/2349717/Clarus_Ventures>,
        <https://1145.am/db/2349722/Clarus_Ventures>,
        <https://1145.am/db/2350004/Clarus_Ventures>,
        <https://1145.am/db/2351958/Clarus_Ventures>,
        <https://1145.am/db/2352831/Clarus_Ventures>,
        <https://1145.am/db/2353771/Clarus_Ventures>,
        <https://1145.am/db/2353789/Clarus_Ventures>,
        <https://1145.am/db/2354295/Clarus_Ventures>,
        <https://1145.am/db/2355435/Clarus_Ventures>,
        <https://1145.am/db/2356084/Clarus_Ventures>,
        <https://1145.am/db/2357858/Clarus_Ventures>,
        <https://1145.am/db/2359654/Clarus_Ventures>,
        <https://1145.am/db/2360756/Clarus_Ventures>,
        <https://1145.am/db/2360758/Clarus_Ventures>,
        <https://1145.am/db/2364468/Clarus_Ventures>,
        <https://1145.am/db/2364471/Clarus_Ventures>,
        <https://1145.am/db/2365171/Clarus_Ventures>,
        <https://1145.am/db/2365184/Clarus_Ventures>,
        <https://1145.am/db/2366049/Clarus_Ventures>,
        <https://1145.am/db/2366055/Clarus_Ventures>,
        <https://1145.am/db/2368297/Clarus_Ventures>,
        <https://1145.am/db/2370240/Clarus_Ventures>,
        <https://1145.am/db/2584561/Clarus_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352808/Investment_Achillion_Pharmaceuticals_Inc_Clarus_Ventures_Domain_Associates_Pappas_Ventures_Quaker_Bioventures_Has_Not_Happened> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-08-19T15:35:59+00:00"^^xsd:dateTime ;
    ns1:documentExtract "NEW HAVEN, Conn., Aug. 18, 2010 (GLOBE NEWSWIRE) - Achillion Pharmaceuticals, Inc., /quotes/comstock/15 *! achn/quotes/nls/achn (ACHN 2.65, +0.04, +1.53 %) a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that it has entered into definitive agreements for the purchase of $ 50.1 million of Achillion's common stock and warrants in a private placement financing with a select group of institutional and accredited investors, namely Domain Associates, Clarus Ventures, Quaker BioVentures and Pappas Ventures." ;
    ns1:documentTitle "Achillion Announces Private Placement of $50 Million" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/achillion-announces-private-placement-of-50-million> ;
    ns1:foundName "private placement",
        "purchase" ;
    ns1:name "private placement",
        "purchase" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2352808/Achillion_Pharmaceuticals_Inc> ;
    ns1:valueRaw "$ 50.1 million" ;
    ns1:whereGeoName "New Haven County" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/4839373/about.rdf> ;
    ns1:whereRaw "NEW HAVEN" .

<https://1145.am/db/2352820/Healthcare_Ventures> a org:Organization ;
    ns1:basedInLowRaw "CAMBRIDGE" ;
    ns1:description "investing" ;
    ns1:documentDate "2010-08-20T13:33:44+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Anchor Therapeutics Nabs $10M for New Class of Peptide Drugs Against Hard Targets" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/anchor-therapeutics-nabs-10m-for-new-class-of-peptide-drugs-against-hard-targets> ;
    ns1:foundName "HealthCare Ventures" ;
    ns1:investor <https://1145.am/db/2352820/Series_B_Investment_Anchor_Therapeutics_Healthcare_Ventures_Novartis_Option_Fund_Tvm_Capital_Completed> ;
    ns1:name "HealthCare Ventures" ;
    ns1:sameAsHigh <https://1145.am/db/1335924/Blue_Venture_Fund>,
        <https://1145.am/db/1336552/Blue_Venture_Fund>,
        <https://1145.am/db/1374213/Apollo_Health_Ventures>,
        <https://1145.am/db/1628978/Cvs_Health_Ventures>,
        <https://1145.am/db/2180772/7wireventures>,
        <https://1145.am/db/2281648/Medical_Excellence_Capital_Partners>,
        <https://1145.am/db/2282392/Pioneer_Healthcare_Partners>,
        <https://1145.am/db/2294753/Catalyst_Health_Ventures>,
        <https://1145.am/db/2298897/Healthlink_Capital>,
        <https://1145.am/db/2303251/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2303257/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2305524/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/230667/Red_Tree_Venture_Capital>,
        <https://1145.am/db/2309845/Healthcare_Ventures>,
        <https://1145.am/db/2311069/Healthcare_Ventures>,
        <https://1145.am/db/2311075/Healthcare_Ventures>,
        <https://1145.am/db/2321713/Healthcor_Partners_Management>,
        <https://1145.am/db/2323586/Healthcare_Ventures>,
        <https://1145.am/db/2329533/Essex_Woodlands_Healthcare_Ventures>,
        <https://1145.am/db/2329533/Gilde_Healthcare>,
        <https://1145.am/db/2330876/Healthcare_Venture>,
        <https://1145.am/db/2337166/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2340284/Catalyst_Health_Ventures>,
        <https://1145.am/db/2342611/Healthcap>,
        <https://1145.am/db/2346204/Healthcare_Ventures>,
        <https://1145.am/db/2347469/Healthcare_Ventures>,
        <https://1145.am/db/2347822/Healthcap>,
        <https://1145.am/db/2349717/Healthcare_Ventures>,
        <https://1145.am/db/2356567/Mp_Healthcare_Venture_Management_Inc>,
        <https://1145.am/db/2365279/Founders_Fund>,
        <https://1145.am/db/2365296/Mp_Healthcare_Venture_Management>,
        <https://1145.am/db/2367497/Healthcare_Ventures>,
        <https://1145.am/db/2369086/Whitesun_Healthcare_Ventures>,
        <https://1145.am/db/348452/Inflect_Health>,
        <https://1145.am/db/662177/Apollo_Health_Ventures> ;
    ns1:sameAsMedium <https://1145.am/db/2235852/Healthcare_Ventures>,
        <https://1145.am/db/2304650/Healthcare_Ventures>,
        <https://1145.am/db/2308148/Healthcare_Ventures>,
        <https://1145.am/db/2308887/Healthcare_Ventures>,
        <https://1145.am/db/2312192/Healthcare_Ventures>,
        <https://1145.am/db/2313405/Healthcare_Ventures>,
        <https://1145.am/db/2316601/Healthcare_Ventures>,
        <https://1145.am/db/2316605/Healthcare_Ventures>,
        <https://1145.am/db/2316823/Healthcare_Ventures>,
        <https://1145.am/db/2318657/Healthcare_Ventures>,
        <https://1145.am/db/2321097/Healthcare_Ventures>,
        <https://1145.am/db/2331639/Healthcare_Ventures>,
        <https://1145.am/db/2338373/Healthcare_Ventures>,
        <https://1145.am/db/2342269/Healthcare_Ventures>,
        <https://1145.am/db/2343202/Healthcare_Ventures>,
        <https://1145.am/db/2343210/Healthcare_Ventures>,
        <https://1145.am/db/2348486/Healthcare_Ventures>,
        <https://1145.am/db/2349722/Healthcare_Ventures>,
        <https://1145.am/db/2352814/Healthcare_Ventures>,
        <https://1145.am/db/2363510/Healthcare_Ventures>,
        <https://1145.am/db/2365138/Healthcare_Ventures>,
        <https://1145.am/db/2365171/Healthcare_Ventures>,
        <https://1145.am/db/2443170/Healthcare_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2355511/Series_D_Investment_Btg_International_Crédit_Agricole_Private_Equity_Forbion_Capital_Partners_Mvm_Seroba-Kernel_Life_Sciences_Ltd_Xention_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-11-23T15:57:00+00:00"^^xsd:dateTime ;
    ns1:documentExtract "> The UK's Xention closed an £8 million series D financing to fund the clinical development of its experimental therapies for atrial fibrillation." ;
    ns1:documentTitle "Xention raises £8M; Maxygen distributes Codexis shares; Insurer counts costs of diabetes;" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/xention-raises-%C2%A38m-maxygen-distributes-codexis-shares-insurer-counts-costs-of-diabetes> ;
    ns1:foundName "financing" ;
    ns1:name "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2355511/Xention> ;
    ns1:targetDetails "series D" ;
    ns1:valueRaw "£8 million" ;
    ns1:whereGeoName "United Kingdom of Great Britain and Northern Ireland" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/2635167/about.rdf> ;
    ns1:whereRaw "UK" .

<https://1145.am/db/2355512/Series_D_Investment_Btg_International_Cambridge_Crédit_Agricole_Private_Equity_Forbion_Capital_Partners_Mvm_Seroba-Kernel_Life_Sciences_Ltd_Xention_Ltd_Xention_Ltd_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-11-23T16:11:46+00:00"^^xsd:dateTime ;
    ns1:documentExtract "CAMBRIDGE, UK - XENTION LTD, the Cambridge - based biopharmaceutical company specialising in the discovery and development of ion channel-modulating drugs, announced today that it had closed an £8 million series D financing to fund the clinical development of Xention's novel drugs for the treatment of atrial fibrillation." ;
    ns1:documentTitle "Xention Raises £8 Million in Private Equity Placement" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/xention-raises-%C2%A38-million-private-equity-placement> ;
    ns1:foundName "financing" ;
    ns1:name "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2355512/Cambridge>,
        <https://1145.am/db/2355512/Xention_Ltd> ;
    ns1:targetDetails "series D" ;
    ns1:valueRaw "£8 million" ;
    ns1:whereGeoName "United Kingdom of Great Britain and Northern Ireland" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/2635167/about.rdf> ;
    ns1:whereRaw "UK" .

<https://1145.am/db/2356567/Series_A_Investment_Covagen_Edmond_De_Rothschild_Investment_Partners_Mp_Healthcare_Venture_Management_Inc_Mp_Healthcare_Venture_Management_Inc_Novartis_Venture_Fund_Seroba_Kernel_Life_Sciences_Ventech_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-11-29T16:58:07+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Covagen closes Series A financing round with Seroba Kernel as lead investor.",
        "Covagen, an ETH Zurich spin-off company pioneering the development of a novel class of protein therapeutics (Fynomers) , announced today the closing of a Series A financing round in which CHF 6.3 million was raised." ;
    ns1:documentTitle "Covagen closes Series A financing round with Seroba Kernel as lead investor" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/covagen-closes-series-a-financing-round-seroba-kernel-as-lead-investor> ;
    ns1:foundName "financing" ;
    ns1:name "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2356567/Covagen> ;
    ns1:targetDetails "Series A" ;
    ns1:valueRaw "CHF 6.3 million" ;
    ns1:when "2010-11-29T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "November 29, 2010" ;
    ns1:whereGeoName "Switzerland" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/2658434/about.rdf> ;
    ns1:whereRaw "Switzerland" .

<https://1145.am/db/2360756/Clarus_Ventures> a org:Organization ;
    ns1:basedInLowRaw "CAMBRIDGE" ;
    ns1:documentDate "2010-12-08T14:42:10+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Catabasis Pharmaceuticals Secures $14.5 Million Second Tranche in Series A Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/catabasis-pharmaceuticals-secures-14-5-million-second-tranche-series-a-financing> ;
    ns1:foundName "Clarus Ventures" ;
    ns1:investor <https://1145.am/db/2360756/Series_A_Investment_Advanced_Technology_Ventures_Catabasis_Pharmaceuticals_Catabasis_Pharmaceuticals_Clarus_Ventures_Medimmune_Ventures_Sv_Life_Sciences_Completed> ;
    ns1:name "Clarus Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/2289229/Clarus_Ventures>,
        <https://1145.am/db/2302292/Clarus_Ventures>,
        <https://1145.am/db/2302994/Clarus_Ventures>,
        <https://1145.am/db/2303563/Clarus_Ventures>,
        <https://1145.am/db/2303581/Clarus_Ventures>,
        <https://1145.am/db/2304261/Clarus_Ventures>,
        <https://1145.am/db/2305745/Clarus_Ventures>,
        <https://1145.am/db/2306754/Clarus_Ventures>,
        <https://1145.am/db/2311011/Clarus_Ventures>,
        <https://1145.am/db/2311595/Clarus_Ventures>,
        <https://1145.am/db/2312277/Clarus_Ventures>,
        <https://1145.am/db/2312288/Clarus_Ventures>,
        <https://1145.am/db/2312945/Clarus_Ventures>,
        <https://1145.am/db/2313322/Clarus_Ventures>,
        <https://1145.am/db/2313438/Clarus_Ventures>,
        <https://1145.am/db/2315059/Clarus_Ventures>,
        <https://1145.am/db/2317145/Clarus_Ventures>,
        <https://1145.am/db/2318851/Clarus_Ventures>,
        <https://1145.am/db/2321137/Clarus_Ventures>,
        <https://1145.am/db/2324936/Clarus_Ventures>,
        <https://1145.am/db/2325880/Clarus_Ventures>,
        <https://1145.am/db/2327405/Clarus_Ventures>,
        <https://1145.am/db/2329773/Clarus_Ventures>,
        <https://1145.am/db/2332748/Clarus_Ventures>,
        <https://1145.am/db/2335928/Clarus_Ventures>,
        <https://1145.am/db/2336313/Clarus_Ventures>,
        <https://1145.am/db/2336944/Clarus_Ventures>,
        <https://1145.am/db/2341003/Clarus_Ventures>,
        <https://1145.am/db/2341600/Clarus_Ventures>,
        <https://1145.am/db/2342624/Clarus_Ventures>,
        <https://1145.am/db/2342629/Clarus_Ventures_Llc>,
        <https://1145.am/db/2343722/Clarus_Ventures>,
        <https://1145.am/db/2343725/Clarus_Ventures>,
        <https://1145.am/db/2343737/Clarus_Ventures>,
        <https://1145.am/db/2347389/Clarus_Ventures>,
        <https://1145.am/db/2347876/Clarus_Ventures>,
        <https://1145.am/db/2349120/Clarus_Ventures>,
        <https://1145.am/db/2349717/Clarus_Ventures>,
        <https://1145.am/db/2349722/Clarus_Ventures>,
        <https://1145.am/db/2350004/Clarus_Ventures>,
        <https://1145.am/db/2351958/Clarus_Ventures>,
        <https://1145.am/db/2352808/Clarus_Ventures>,
        <https://1145.am/db/2352831/Clarus_Ventures>,
        <https://1145.am/db/2353771/Clarus_Ventures>,
        <https://1145.am/db/2353789/Clarus_Ventures>,
        <https://1145.am/db/2354295/Clarus_Ventures>,
        <https://1145.am/db/2355435/Clarus_Ventures>,
        <https://1145.am/db/2356084/Clarus_Ventures>,
        <https://1145.am/db/2357858/Clarus_Ventures>,
        <https://1145.am/db/2359654/Clarus_Ventures>,
        <https://1145.am/db/2360758/Clarus_Ventures>,
        <https://1145.am/db/2364468/Clarus_Ventures>,
        <https://1145.am/db/2364471/Clarus_Ventures>,
        <https://1145.am/db/2365171/Clarus_Ventures>,
        <https://1145.am/db/2365184/Clarus_Ventures>,
        <https://1145.am/db/2366049/Clarus_Ventures>,
        <https://1145.am/db/2366055/Clarus_Ventures>,
        <https://1145.am/db/2368297/Clarus_Ventures>,
        <https://1145.am/db/2370240/Clarus_Ventures>,
        <https://1145.am/db/2584561/Clarus_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2360758/Clarus_Ventures> a org:Organization ;
    ns1:basedInLowRaw "CAMBRIDGE" ;
    ns1:documentDate "2010-12-08T14:23:07+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Catabasis Pharmaceuticals Secures $14.5 Million Second Tranche in Series A Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/catabasis-pharmaceuticals-secures-14-5-million-second-tranche-series-a-financing-0> ;
    ns1:foundName "Clarus Ventures" ;
    ns1:investor <https://1145.am/db/2360758/Series_A_Investment_Advanced_Technology_Ventures_Catabasis_Pharmaceuticals_Catabasis_Pharmaceuticals_Clarus_Ventures_Medimmune_Ventures_Sv_Life_Sciences_Completed> ;
    ns1:name "Clarus Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/2289229/Clarus_Ventures>,
        <https://1145.am/db/2302292/Clarus_Ventures>,
        <https://1145.am/db/2302994/Clarus_Ventures>,
        <https://1145.am/db/2303563/Clarus_Ventures>,
        <https://1145.am/db/2303581/Clarus_Ventures>,
        <https://1145.am/db/2304261/Clarus_Ventures>,
        <https://1145.am/db/2305745/Clarus_Ventures>,
        <https://1145.am/db/2306754/Clarus_Ventures>,
        <https://1145.am/db/2311011/Clarus_Ventures>,
        <https://1145.am/db/2311595/Clarus_Ventures>,
        <https://1145.am/db/2312277/Clarus_Ventures>,
        <https://1145.am/db/2312288/Clarus_Ventures>,
        <https://1145.am/db/2312945/Clarus_Ventures>,
        <https://1145.am/db/2313322/Clarus_Ventures>,
        <https://1145.am/db/2313438/Clarus_Ventures>,
        <https://1145.am/db/2315059/Clarus_Ventures>,
        <https://1145.am/db/2317145/Clarus_Ventures>,
        <https://1145.am/db/2318851/Clarus_Ventures>,
        <https://1145.am/db/2321137/Clarus_Ventures>,
        <https://1145.am/db/2324936/Clarus_Ventures>,
        <https://1145.am/db/2325880/Clarus_Ventures>,
        <https://1145.am/db/2327405/Clarus_Ventures>,
        <https://1145.am/db/2329773/Clarus_Ventures>,
        <https://1145.am/db/2332748/Clarus_Ventures>,
        <https://1145.am/db/2335928/Clarus_Ventures>,
        <https://1145.am/db/2336313/Clarus_Ventures>,
        <https://1145.am/db/2336944/Clarus_Ventures>,
        <https://1145.am/db/2341003/Clarus_Ventures>,
        <https://1145.am/db/2341600/Clarus_Ventures>,
        <https://1145.am/db/2342624/Clarus_Ventures>,
        <https://1145.am/db/2342629/Clarus_Ventures_Llc>,
        <https://1145.am/db/2343722/Clarus_Ventures>,
        <https://1145.am/db/2343725/Clarus_Ventures>,
        <https://1145.am/db/2343737/Clarus_Ventures>,
        <https://1145.am/db/2347389/Clarus_Ventures>,
        <https://1145.am/db/2347876/Clarus_Ventures>,
        <https://1145.am/db/2349120/Clarus_Ventures>,
        <https://1145.am/db/2349717/Clarus_Ventures>,
        <https://1145.am/db/2349722/Clarus_Ventures>,
        <https://1145.am/db/2350004/Clarus_Ventures>,
        <https://1145.am/db/2351958/Clarus_Ventures>,
        <https://1145.am/db/2352808/Clarus_Ventures>,
        <https://1145.am/db/2352831/Clarus_Ventures>,
        <https://1145.am/db/2353771/Clarus_Ventures>,
        <https://1145.am/db/2353789/Clarus_Ventures>,
        <https://1145.am/db/2354295/Clarus_Ventures>,
        <https://1145.am/db/2355435/Clarus_Ventures>,
        <https://1145.am/db/2356084/Clarus_Ventures>,
        <https://1145.am/db/2357858/Clarus_Ventures>,
        <https://1145.am/db/2359654/Clarus_Ventures>,
        <https://1145.am/db/2360756/Clarus_Ventures>,
        <https://1145.am/db/2364468/Clarus_Ventures>,
        <https://1145.am/db/2364471/Clarus_Ventures>,
        <https://1145.am/db/2365171/Clarus_Ventures>,
        <https://1145.am/db/2365184/Clarus_Ventures>,
        <https://1145.am/db/2366049/Clarus_Ventures>,
        <https://1145.am/db/2366055/Clarus_Ventures>,
        <https://1145.am/db/2368297/Clarus_Ventures>,
        <https://1145.am/db/2370240/Clarus_Ventures>,
        <https://1145.am/db/2584561/Clarus_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2365135/Series_B_Equity_Investment_Chl_Medical_Partners_Highland_Capital_Partners_Mason_Wells_Biomedical_Opgen_Versant_Ventures_Jven_Capital_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-09-27T12:37:38+00:00"^^xsd:dateTime ;
    ns1:documentExtract "GAITHERSBURG, Md.- (BUSINESS WIRE) -OpGen, Inc., a commercial phase genomics company, today announced the successful completion of a $ 17 million Series B equity financing.",
        "OpGen Completes $ 17 Million Series B Financing." ;
    ns1:documentTitle "OpGen Completes $17 Million Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/opgen-completes-17-million-series-b-financing> ;
    ns1:foundName "Financing",
        "financing" ;
    ns1:name "Financing",
        "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2365135/Opgen> ;
    ns1:targetDetails "Series B",
        "equity" ;
    ns1:valueRaw "$ 17 Million",
        "$ 17 million" ;
    ns1:whereGeoName "Gaithersburg" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/4355843/about.rdf> ;
    ns1:whereRaw "GAITHERSBURG, Md." .

<https://1145.am/db/2365171/Clarus_Ventures> a org:Organization ;
    ns1:basedInLowRaw "Pa" ;
    ns1:documentDate "2010-09-28T13:45:54+00:00"^^xsd:dateTime ;
    ns1:documentTitle "TetraLogic Pharmaceuticals Expands Series C Financing with New Investor Pfizer Ventures with Investment of $5 Million Incrasing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/tetralogic-pharmaceuticals-expands-series-c-financing-new-investor-pfizer-ventures> ;
    ns1:foundName "Clarus Ventures" ;
    ns1:investor <https://1145.am/db/2365171/Series_C_Investment_Amgen_Ventures_Clarus_Ventures_Hatteras_Venture_Partners_Healthcare_Ventures_Latterell_Venture_Partners_Novitas_Capital_Pfizer_Ventures_Quaker_Bioventures_Tetralogic_Pharmaceuticals_Vertical_Group_Completed> ;
    ns1:name "Clarus Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/2289229/Clarus_Ventures>,
        <https://1145.am/db/2302292/Clarus_Ventures>,
        <https://1145.am/db/2302994/Clarus_Ventures>,
        <https://1145.am/db/2303563/Clarus_Ventures>,
        <https://1145.am/db/2303581/Clarus_Ventures>,
        <https://1145.am/db/2304261/Clarus_Ventures>,
        <https://1145.am/db/2305745/Clarus_Ventures>,
        <https://1145.am/db/2306754/Clarus_Ventures>,
        <https://1145.am/db/2311011/Clarus_Ventures>,
        <https://1145.am/db/2311595/Clarus_Ventures>,
        <https://1145.am/db/2312277/Clarus_Ventures>,
        <https://1145.am/db/2312288/Clarus_Ventures>,
        <https://1145.am/db/2312945/Clarus_Ventures>,
        <https://1145.am/db/2313322/Clarus_Ventures>,
        <https://1145.am/db/2313438/Clarus_Ventures>,
        <https://1145.am/db/2315059/Clarus_Ventures>,
        <https://1145.am/db/2317145/Clarus_Ventures>,
        <https://1145.am/db/2318851/Clarus_Ventures>,
        <https://1145.am/db/2321137/Clarus_Ventures>,
        <https://1145.am/db/2324936/Clarus_Ventures>,
        <https://1145.am/db/2325880/Clarus_Ventures>,
        <https://1145.am/db/2327405/Clarus_Ventures>,
        <https://1145.am/db/2329773/Clarus_Ventures>,
        <https://1145.am/db/2332748/Clarus_Ventures>,
        <https://1145.am/db/2335928/Clarus_Ventures>,
        <https://1145.am/db/2336313/Clarus_Ventures>,
        <https://1145.am/db/2336944/Clarus_Ventures>,
        <https://1145.am/db/2341003/Clarus_Ventures>,
        <https://1145.am/db/2341600/Clarus_Ventures>,
        <https://1145.am/db/2342624/Clarus_Ventures>,
        <https://1145.am/db/2342629/Clarus_Ventures_Llc>,
        <https://1145.am/db/2343722/Clarus_Ventures>,
        <https://1145.am/db/2343725/Clarus_Ventures>,
        <https://1145.am/db/2343737/Clarus_Ventures>,
        <https://1145.am/db/2347389/Clarus_Ventures>,
        <https://1145.am/db/2347876/Clarus_Ventures>,
        <https://1145.am/db/2349120/Clarus_Ventures>,
        <https://1145.am/db/2349717/Clarus_Ventures>,
        <https://1145.am/db/2349722/Clarus_Ventures>,
        <https://1145.am/db/2350004/Clarus_Ventures>,
        <https://1145.am/db/2351958/Clarus_Ventures>,
        <https://1145.am/db/2352808/Clarus_Ventures>,
        <https://1145.am/db/2352831/Clarus_Ventures>,
        <https://1145.am/db/2353771/Clarus_Ventures>,
        <https://1145.am/db/2353789/Clarus_Ventures>,
        <https://1145.am/db/2354295/Clarus_Ventures>,
        <https://1145.am/db/2355435/Clarus_Ventures>,
        <https://1145.am/db/2356084/Clarus_Ventures>,
        <https://1145.am/db/2357858/Clarus_Ventures>,
        <https://1145.am/db/2359654/Clarus_Ventures>,
        <https://1145.am/db/2360756/Clarus_Ventures>,
        <https://1145.am/db/2360758/Clarus_Ventures>,
        <https://1145.am/db/2364468/Clarus_Ventures>,
        <https://1145.am/db/2364471/Clarus_Ventures>,
        <https://1145.am/db/2365184/Clarus_Ventures>,
        <https://1145.am/db/2366049/Clarus_Ventures>,
        <https://1145.am/db/2366055/Clarus_Ventures>,
        <https://1145.am/db/2368297/Clarus_Ventures>,
        <https://1145.am/db/2370240/Clarus_Ventures>,
        <https://1145.am/db/2584561/Clarus_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2365171/Healthcare_Ventures> a org:Organization ;
    ns1:basedInLowRaw "Pa" ;
    ns1:description "Venture Capital" ;
    ns1:documentDate "2010-09-28T13:45:54+00:00"^^xsd:dateTime ;
    ns1:documentTitle "TetraLogic Pharmaceuticals Expands Series C Financing with New Investor Pfizer Ventures with Investment of $5 Million Incrasing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/tetralogic-pharmaceuticals-expands-series-c-financing-new-investor-pfizer-ventures> ;
    ns1:foundName "HealthCare Ventures" ;
    ns1:investor <https://1145.am/db/2365171/Series_C_Investment_Amgen_Ventures_Clarus_Ventures_Hatteras_Venture_Partners_Healthcare_Ventures_Latterell_Venture_Partners_Novitas_Capital_Pfizer_Ventures_Quaker_Bioventures_Tetralogic_Pharmaceuticals_Vertical_Group_Completed> ;
    ns1:name "HealthCare Ventures" ;
    ns1:sameAsHigh <https://1145.am/db/1223133/Bioadvance>,
        <https://1145.am/db/1223149/Bioadvance>,
        <https://1145.am/db/1422234/Forbion_Ventures>,
        <https://1145.am/db/1422725/Forbion_Ventures>,
        <https://1145.am/db/1867543/Tpg_Biotech>,
        <https://1145.am/db/1926411/Bioqube_Ventures>,
        <https://1145.am/db/1990861/Bioqube_Ventures>,
        <https://1145.am/db/2060484/Healthtech_Capital>,
        <https://1145.am/db/2155146/Biomatics_Capital_Partners>,
        <https://1145.am/db/2280492/Biovision_Ventures>,
        <https://1145.am/db/2285038/Time_Bioventures>,
        <https://1145.am/db/2286671/Forbion>,
        <https://1145.am/db/2298954/Biossom_Investment_Management>,
        <https://1145.am/db/2298978/Advent_Life_Sciences>,
        <https://1145.am/db/2301741/Bio_*_One_Capital>,
        <https://1145.am/db/2301792/Fonds_Bio-Innovation_Sec>,
        <https://1145.am/db/2302351/Medimmune_Ventures>,
        <https://1145.am/db/2305587/Medimmune_Ventures>,
        <https://1145.am/db/2309840/Bio_Fund>,
        <https://1145.am/db/2310285/Medventure_Associates>,
        <https://1145.am/db/2313322/Biomedinvest>,
        <https://1145.am/db/2313322/Hbm_Bioventures>,
        <https://1145.am/db/2313401/Biogen_Idec_New_Ventures>,
        <https://1145.am/db/2313438/Biomedinvest>,
        <https://1145.am/db/2313438/Hbm_Biocapital>,
        <https://1145.am/db/2313438/Hbm_Bioventures>,
        <https://1145.am/db/2313438/Sv_Life_Sciences>,
        <https://1145.am/db/2314400/Hbm_Biocapital>,
        <https://1145.am/db/2314515/Sv_Life_Sciences>,
        <https://1145.am/db/2314573/Avlar_Bioventures>,
        <https://1145.am/db/2316709/Bioadvance_Ventures>,
        <https://1145.am/db/2317737/Mc_Life_Sciences_Ventures>,
        <https://1145.am/db/2317779/Bio_*_One_Capital>,
        <https://1145.am/db/2319360/Medimmune_Ventures>,
        <https://1145.am/db/2321097/Healthcare_Ventures>,
        <https://1145.am/db/2323785/Medimmune_Ventures>,
        <https://1145.am/db/2324015/Medsciences_Capital>,
        <https://1145.am/db/2324195/Lotus_Bioscience_Ventures>,
        <https://1145.am/db/2325831/Bb_Biotech>,
        <https://1145.am/db/2325831/Hbm_Bioventures>,
        <https://1145.am/db/2336109/Biomed_Ventures>,
        <https://1145.am/db/2338673/Hopen_Life_Science_Ventures>,
        <https://1145.am/db/2339295/Biomedinvest>,
        <https://1145.am/db/2345037/Biomed_Ventures>,
        <https://1145.am/db/2347571/Advent_Life_Sciences>,
        <https://1145.am/db/2352382/Biomedinvest>,
        <https://1145.am/db/2352633/Advanced_Biotechnologies_Venture_Fund>,
        <https://1145.am/db/2354295/Biomed_Ventures>,
        <https://1145.am/db/2359240/Frontline_Bioventures>,
        <https://1145.am/db/2364853/Medimmune_Ventures>,
        <https://1145.am/db/2366049/Biomed_Ventures>,
        <https://1145.am/db/2366055/Biomed_Ventures>,
        <https://1145.am/db/2366133/Biopacificventures>,
        <https://1145.am/db/2368251/Sv_Life_Sciences>,
        <https://1145.am/db/2369916/Biomed_Ventures>,
        <https://1145.am/db/363714/Palliare>,
        <https://1145.am/db/564585/Bioqube_Ventures>,
        <https://1145.am/db/566971/Bioqube_Ventures>,
        <https://1145.am/db/684123/Biourja_Ventures>,
        <https://1145.am/db/938108/Bioeconomy_Capital>,
        <https://1145.am/db/971939/I___I_Biotech_Fund>,
        <https://1145.am/db/975114/I___I_Biotech_Fund> ;
    ns1:sameAsMedium <https://1145.am/db/2235852/Healthcare_Ventures>,
        <https://1145.am/db/2304650/Healthcare_Ventures>,
        <https://1145.am/db/2308148/Healthcare_Ventures>,
        <https://1145.am/db/2308887/Healthcare_Ventures>,
        <https://1145.am/db/2309845/Healthcare_Ventures>,
        <https://1145.am/db/2311069/Healthcare_Ventures>,
        <https://1145.am/db/2311075/Healthcare_Ventures>,
        <https://1145.am/db/2312192/Healthcare_Ventures>,
        <https://1145.am/db/2313405/Healthcare_Ventures>,
        <https://1145.am/db/2316601/Healthcare_Ventures>,
        <https://1145.am/db/2316605/Healthcare_Ventures>,
        <https://1145.am/db/2316823/Healthcare_Ventures>,
        <https://1145.am/db/2318657/Healthcare_Ventures>,
        <https://1145.am/db/2323586/Healthcare_Ventures>,
        <https://1145.am/db/2331639/Healthcare_Ventures>,
        <https://1145.am/db/2338373/Healthcare_Ventures>,
        <https://1145.am/db/2342269/Healthcare_Ventures>,
        <https://1145.am/db/2343202/Healthcare_Ventures>,
        <https://1145.am/db/2343210/Healthcare_Ventures>,
        <https://1145.am/db/2346204/Healthcare_Ventures>,
        <https://1145.am/db/2347469/Healthcare_Ventures>,
        <https://1145.am/db/2348486/Healthcare_Ventures>,
        <https://1145.am/db/2349717/Healthcare_Ventures>,
        <https://1145.am/db/2349722/Healthcare_Ventures>,
        <https://1145.am/db/2352814/Healthcare_Ventures>,
        <https://1145.am/db/2352820/Healthcare_Ventures>,
        <https://1145.am/db/2363510/Healthcare_Ventures>,
        <https://1145.am/db/2365138/Healthcare_Ventures>,
        <https://1145.am/db/2367497/Healthcare_Ventures>,
        <https://1145.am/db/2443170/Healthcare_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2366187/Series_B_Investment_Canaan_Partners_Domain_Associates_Frazier_Healthcare_Ventures_Montreux_Equity_Partners_Novo_A_S_Tobira_Therapeutics_Inc_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-09-30T16:26:17+00:00"^^xsd:dateTime ;
    ns1:documentExtract "MANALAPAN, N.J.- (BUSINESS WIRE) -Tobira Therapeutics Inc., a biopharmaceutical company focused on developing and commercializing innovative antiviral compounds to treat HIV disease, today announced the completion of a $ 31 million Series B financing.",
        "Tobira Therapeutics Inc. Raises $ 31 Million in Series B Financing." ;
    ns1:documentTitle "Tobira Therapeutics Inc. Raises $31 Million in Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/tobira-therapeutics-inc-raises-31-million-series-b-financing> ;
    ns1:foundName "Financing",
        "financing" ;
    ns1:name "Financing",
        "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2366187/Tobira_Therapeutics_Inc> ;
    ns1:targetDetails "Series B" ;
    ns1:valueRaw "$ 31 Million",
        "$ 31 million" ;
    ns1:whereRaw "Tobira Therapeutics Inc." .

<https://1145.am/db/2367204/Series_A_Investment_Advanced_Technology_Ventures_Calithera_Biosciences_Delphi_Ventures_Mission_Bay_Capital_Morgenthaler_Ventures_Us_Venture_Partners_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-07-08T15:06:02+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Calithera Biosciences Closes $ 40 Million in Series A Financing.",
        "SOUTH SAN FRANCISCO, Calif., July 8 /PRNewswire/ - Calithera Biosciences, a company developing novel oncology therapeutics, today announced the completion of a Series A financing totaling $ 40 million." ;
    ns1:documentTitle "Calithera Biosciences Closes $40 Million in Series A Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/calithera-biosciences-closes-40-million-series-a-financing> ;
    ns1:foundName "Financing",
        "financing" ;
    ns1:name "Financing",
        "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2367204/Calithera_Biosciences> ;
    ns1:targetDetails "Series A" ;
    ns1:valueRaw "$ 40 Million",
        "$ 40 million" ;
    ns1:when "2010-07-08T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "July 8" ;
    ns1:whereGeoName "South San Francisco" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5397765/about.rdf> ;
    ns1:whereRaw "SOUTH SAN FRANCISCO" .

<https://1145.am/db/2367475/Series_C_Investment_Aurelia_Private_Equity_Bio_*_One_Capital_Heidelbergcapital_Merlion_Pharmaceuticals_Pte_Ltd_Venture_Incubator_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-07-13T16:13:01+00:00"^^xsd:dateTime ;
    ns1:documentExtract "MerLion Pharmaceuticals Completes US $ 7 Million Series C.",
        "Singapore, 13th July 2010 - MerLion Pharmaceuticals Pte Ltd (MerLion) , a biotechnology company focused on the discovery and development of novel antiinfectives and with a leading position in offering natural product research services, today announced the completion of a US $ 7 million Series C round of financing." ;
    ns1:documentTitle "MerLion Pharmaceuticals Completes US$7 Million Series C" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/merlion-pharmaceuticals-completes-us-7-million-series-c> ;
    ns1:foundName "financing" ;
    ns1:name "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2367475/Merlion_Pharmaceuticals_Pte_Ltd> ;
    ns1:targetDetails "Series C" ;
    ns1:valueRaw "US $ 7 Million",
        "US $ 7 million" ;
    ns1:when "2010-07-13T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "13th July 2010" ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "US" .

<https://1145.am/db/2367497/Healthcare_Ventures> a org:Organization ;
    ns1:description "financing" ;
    ns1:documentDate "2010-07-14T12:04:54+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Trevena Secures $35 Million in Series B Funding" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/trevena-secures-35-million-series-b-funding> ;
    ns1:foundName "Healthcare Ventures" ;
    ns1:investor <https://1145.am/db/2367497/Series_B_Investment_Alta_Partners_Healthcare_Ventures_New_Enterprise_Associates_Polaris_Venture_Partners_Trevena_Yasuda_Enterprise_Development_Company_Completed> ;
    ns1:name "Healthcare Ventures" ;
    ns1:sameAsHigh <https://1145.am/db/1335924/Blue_Venture_Fund>,
        <https://1145.am/db/1336552/Blue_Venture_Fund>,
        <https://1145.am/db/1374213/Apollo_Health_Ventures>,
        <https://1145.am/db/1628978/Cvs_Health_Ventures>,
        <https://1145.am/db/2180772/7wireventures>,
        <https://1145.am/db/2281648/Medical_Excellence_Capital_Partners>,
        <https://1145.am/db/2282392/Pioneer_Healthcare_Partners>,
        <https://1145.am/db/2294753/Catalyst_Health_Ventures>,
        <https://1145.am/db/2298897/Healthlink_Capital>,
        <https://1145.am/db/2303251/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2303257/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2305524/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/230667/Red_Tree_Venture_Capital>,
        <https://1145.am/db/2309845/Healthcare_Ventures>,
        <https://1145.am/db/2311069/Healthcare_Ventures>,
        <https://1145.am/db/2311075/Healthcare_Ventures>,
        <https://1145.am/db/2321713/Healthcor_Partners_Management>,
        <https://1145.am/db/2323586/Healthcare_Ventures>,
        <https://1145.am/db/2329533/Essex_Woodlands_Healthcare_Ventures>,
        <https://1145.am/db/2329533/Gilde_Healthcare>,
        <https://1145.am/db/2330876/Healthcare_Venture>,
        <https://1145.am/db/2337166/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2340284/Catalyst_Health_Ventures>,
        <https://1145.am/db/2342611/Healthcap>,
        <https://1145.am/db/2346204/Healthcare_Ventures>,
        <https://1145.am/db/2347469/Healthcare_Ventures>,
        <https://1145.am/db/2347822/Healthcap>,
        <https://1145.am/db/2349717/Healthcare_Ventures>,
        <https://1145.am/db/2352820/Healthcare_Ventures>,
        <https://1145.am/db/2356567/Mp_Healthcare_Venture_Management_Inc>,
        <https://1145.am/db/2365279/Founders_Fund>,
        <https://1145.am/db/2365296/Mp_Healthcare_Venture_Management>,
        <https://1145.am/db/2369086/Whitesun_Healthcare_Ventures>,
        <https://1145.am/db/348452/Inflect_Health>,
        <https://1145.am/db/662177/Apollo_Health_Ventures> ;
    ns1:sameAsMedium <https://1145.am/db/2235852/Healthcare_Ventures>,
        <https://1145.am/db/2304650/Healthcare_Ventures>,
        <https://1145.am/db/2308148/Healthcare_Ventures>,
        <https://1145.am/db/2308887/Healthcare_Ventures>,
        <https://1145.am/db/2312192/Healthcare_Ventures>,
        <https://1145.am/db/2313405/Healthcare_Ventures>,
        <https://1145.am/db/2316601/Healthcare_Ventures>,
        <https://1145.am/db/2316605/Healthcare_Ventures>,
        <https://1145.am/db/2316823/Healthcare_Ventures>,
        <https://1145.am/db/2318657/Healthcare_Ventures>,
        <https://1145.am/db/2321097/Healthcare_Ventures>,
        <https://1145.am/db/2331639/Healthcare_Ventures>,
        <https://1145.am/db/2338373/Healthcare_Ventures>,
        <https://1145.am/db/2342269/Healthcare_Ventures>,
        <https://1145.am/db/2343202/Healthcare_Ventures>,
        <https://1145.am/db/2343210/Healthcare_Ventures>,
        <https://1145.am/db/2348486/Healthcare_Ventures>,
        <https://1145.am/db/2349722/Healthcare_Ventures>,
        <https://1145.am/db/2352814/Healthcare_Ventures>,
        <https://1145.am/db/2363510/Healthcare_Ventures>,
        <https://1145.am/db/2365138/Healthcare_Ventures>,
        <https://1145.am/db/2365171/Healthcare_Ventures>,
        <https://1145.am/db/2443170/Healthcare_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2367497/Series_B_Investment_Alta_Partners_Healthcare_Ventures_New_Enterprise_Associates_Polaris_Venture_Partners_Trevena_Yasuda_Enterprise_Development_Company_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-07-14T12:04:54+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Trevena Secures $ 35 Million in Series B Funding to Progress Portfolio of GPCR Biased Ligands and to Complete Phase 2 Study of TRV120027 for Acute Heart Failure.",
        "Trevena, Inc., the leader in discovery and development of G-protein coupled receptor (GPCR) biased ligands, announced today that it has completed a $ 35 million Series B financing." ;
    ns1:documentTitle "Trevena Secures $35 Million in Series B Funding" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/trevena-secures-35-million-series-b-funding> ;
    ns1:foundName "Funding",
        "financing" ;
    ns1:name "Funding",
        "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2367497/Trevena> ;
    ns1:targetDetails "Series B" ;
    ns1:valueRaw "$ 35 Million",
        "$ 35 million" .

<https://1145.am/db/2360174/Series_B_Investment_5am_Ventures_Delphi_Ventures_Mediphase_Venture_Partners_New_Leaf_Venture_Partners_Orbimed_Advisors_Llc_Relypsa_Sprout_Group_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-09-13T14:04:48+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Relypsa Raises $ 70 Million in Series B Financing.",
        "SANTA CLARA, Calif.- (BUSINESS WIRE) -Relypsa, Inc., a biopharmaceutical company developing non-absorbed polymeric drugs, today announced the completion of a Series B financing totaling $ 70 million." ;
    ns1:documentTitle "Relypsa Raises $70 Million in Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/relypsa-raises-70-million-series-b-financing> ;
    ns1:foundName "financing" ;
    ns1:name "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2360174/Relypsa> ;
    ns1:targetDetails "Series B" ;
    ns1:valueRaw "$ 70 Million",
        "$ 70 million" ;
    ns1:whereGeoName "Santa Clara" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/3537906/about.rdf> ;
    ns1:whereRaw "SANTA CLARA" .

<https://1145.am/db/2364301/Investment_Bioventures_Investors_Cylene_Pharmaceuticals_Hbm_Bioventures_(cayman)_Ltd_Lilly_Ventures_Mitsui___Co_Morningside_Venture_Investments_Ltd_Novartis_Bioventure_Fund_Sanderling_Ventures_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-09-24T13:02:10+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Cylene also announced the simultaneous closing of a $ 12 million financing with participation from existing investors including Sanderling Ventures, HBM BioVentures (Cayman) Ltd., Novartis BioVenture Fund, BioVentures Investors, Lilly Ventures, Mitsui & Co. and Morningside Venture Investments Ltd.",
        "SAN DIEGO, Sept. 24 /PRNewswire/ - Cylene Pharmaceuticals, Inc. announced today the initiation of a Phase I clinical trial of their first-in-class, oral CK2 inhibitor CX-4945 in patients with multiple myeloma." ;
    ns1:documentTitle "Cylene Initiates Phase I Trial in Multiple Myeloma With CX-4945 Inhibitor of CK2 and Closes Accompanying Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cylene-initiates-phase-i-trial-multiple-myeloma-cx-4945-inhibitor-ck2-and-closes> ;
    ns1:foundName "financing" ;
    ns1:name "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2364301/Cylene_Pharmaceuticals> ;
    ns1:valueRaw "$ 12 million" ;
    ns1:whereGeoName "San Diego County" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5391832/about.rdf> ;
    ns1:whereRaw "SAN DIEGO" .

<https://1145.am/db/2342488/Series_D_Investment_Alta_Biopharma_Ascent_Biomedical_Ventures_Ct_Innovations_Cara_Therapeutics_Devon_Park_Bioventures_Healthcare_Private_Equity_Mvm_Life_Science_Partners_Mitsubishi_International_Corporation_Rho_Ventures_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-07-21T12:57:52+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Cara Therapeutics Secures $ 15 Million Series D Financing to Continue Clinical Development of CR845.",
        "SHELTON, Conn., July 21 /PRNewswire/ - Cara Therapeutics, Inc. announced today that it had closed on a Series D financing of $ 15 million." ;
    ns1:documentTitle "Cara Therapeutics Secures $15 Million Series D Financing to Continue Clinical Development of CR845" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cara-therapeutics-secures-15-million-series-d-financing-to-continue-clinical-development-0> ;
    ns1:foundName "financing" ;
    ns1:name "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2342488/Cara_Therapeutics> ;
    ns1:targetDetails "Series D" ;
    ns1:valueRaw "$ 15 Million",
        "$ 15 million" ;
    ns1:when "2010-07-21T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "July 21" ;
    ns1:whereGeoName "Shelton" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/4842898/about.rdf> ;
    ns1:whereRaw "SHELTON, Conn" .

<https://1145.am/db/2342498/Series_D_Investment_Alta_Biopharma_Ascent_Biomedical_Ventures_Ct_Innovations_Cara_Therapeutics_Devon_Park_Bioventures_Healthcare_Private_Equity_Mvm_Life_Science_Partners_Mitsubishi_International_Corporation_Rho_Ventures_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-07-21T15:31:17+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Cara Therapeutics Secures $ 15 Million Series D Financing to Continue Clinical Development of CR845.",
        "SHELTON, Conn., July 21 /PRNewswire/ - Cara Therapeutics, Inc. announced today that it had closed on a Series D financing of $ 15 million." ;
    ns1:documentTitle "Cara Therapeutics Secures $15 Million Series D Financing to Continue Clinical Development of CR845" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cara-therapeutics-secures-15-million-series-d-financing-to-continue-clinical-development-of> ;
    ns1:foundName "financing" ;
    ns1:name "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2342498/Cara_Therapeutics> ;
    ns1:targetDetails "Series D" ;
    ns1:valueRaw "$ 15 Million",
        "$ 15 million" ;
    ns1:when "2010-07-21T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "July 21" ;
    ns1:whereGeoName "Shelton" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/4842898/about.rdf> ;
    ns1:whereRaw "SHELTON, Conn" .

<https://1145.am/db/2343545/Series_C_Investment_Alta_Partners_And_Tvm_Capital_Cerenis_Therapeutics_Sa_Daiwa_Corporate_Investment_Edf_Ventures_Fund_For_Strategic_Investment_Healthcap_Orbimed_Sofinnova_Partners_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-07-26T13:03:59+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Cerenis Therapeutics raises EUR 40 million in series C financingJean-Pierre Garnier appointed as non-executive director to the board.",
        "Toulouse, France and Ann Arbor, MI, USA July 26, 2010 - Cerenis Therapeutics SA (Cerenis) , a biopharmaceutical company specializing in the research and development of novel therapies based on the metabolism of HDL (the \"good\" cholesterol) to treat cardiovascular and other metabolic diseases, announced today it has raised €40 million in the first close of its series C financing." ;
    ns1:documentTitle "Cerenis Therapeutics raises EUR 40 million in series C financingJean-Pierre Garnier appointed as non-executive director to the" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cerenis-therapeutics-raises-eur-40-million-series-c-financingjean-pierre-garnier-appointed> ;
    ns1:foundName "financing" ;
    ns1:name "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2343545/Cerenis_Therapeutics_Sa> ;
    ns1:targetDetails "series C" ;
    ns1:valueRaw "EUR 40 million",
        "€20 million",
        "€40 million" ;
    ns1:when "2010-07-26T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "July 26, 2010" ;
    ns1:whereGeoName "Republic of France" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/3017382/about.rdf> ;
    ns1:whereRaw "France" .

<https://1145.am/db/2352807/Series_E_Investment_Complete_Genomics_Enterprise_Partners_Essex_Woodlands_Highland_Capital_Ovp_Venture_Partners_Orbimed_Advisors_Prospect_Venture_Partners_Sands_Capital_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-08-19T15:28:58+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Complete Genomics, Inc. Announces Completion of $ 39 Million Series E Financing and Addresses Illumina Patent Infringement Lawsuit.",
        "MOUNTAIN VIEW, Calif. - Aug. 19, 2010 - Complete Genomics announced today that it has raised $ 39 million in its Series E funding round." ;
    ns1:documentTitle "Complete Genomics, Inc. Announces Completion of $39 Million Series E Financing and Addresses Illumina Patent Infringement Lawsui" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/complete-genomics-inc-announces-completion-of-39-million-series-e-financing-and-addresses> ;
    ns1:foundName "funding" ;
    ns1:name "funding" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2352807/Complete_Genomics> ;
    ns1:targetDetails "Series E" ;
    ns1:valueRaw "$ 39 Million",
        "$ 39 million" ;
    ns1:when "2010-08-19T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "Aug. 19, 2010" ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "United States" .

<https://1145.am/db/2349717/Series_C_Investment_Amgen_Ventures_Clarus_Ventures_Hatteras_Venture_Partners_Healthcare_Ventures_Latterell_Venture_Partners_Novitas_Capital_Quaker_Bioventures_Tetralogic_Pharmaceuticals_Vertical_Group_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-08-10T15:41:02+00:00"^^xsd:dateTime ;
    ns1:documentExtract "MALVERN, Pa.- (BUSINESS WIRE) -TetraLogic Pharmaceuticals, a biopharmaceutical company developing novel small molecule drugs to treat cancer, today announced it has completed a $ 32 million Series C financing with new investor Clarus Ventures leading the round.",
        "TetraLogic Pharmaceuticals Completes $ 32 Million Series C Financing." ;
    ns1:documentTitle "TetraLogic Pharmaceuticals Completes $32 Million Series C Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/tetralogic-pharmaceuticals-completes-32-million-series-c-financing> ;
    ns1:foundName "Financing",
        "financing" ;
    ns1:name "Financing",
        "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2349717/Tetralogic_Pharmaceuticals> ;
    ns1:targetDetails "Series C" ;
    ns1:valueRaw "$ 32 Million",
        "$ 32 million" ;
    ns1:whereGeoName "Malvern" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/11495083/about.rdf> ;
    ns1:whereRaw "MALVERN" .

<https://1145.am/db/2365171/Series_C_Investment_Amgen_Ventures_Clarus_Ventures_Hatteras_Venture_Partners_Healthcare_Ventures_Latterell_Venture_Partners_Novitas_Capital_Pfizer_Ventures_Quaker_Bioventures_Tetralogic_Pharmaceuticals_Vertical_Group_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2010-09-28T13:45:54+00:00"^^xsd:dateTime ;
    ns1:documentExtract "MALVERN, Pa.- (BUSINESS WIRE) -TetraLogic Pharmaceuticals, a biopharmaceutical company developing novel small molecule drugs to treat cancer, today announced that Pfizer Ventures has joined the syndicate of Series C investors with an investment of $ 5 million, increasing the amount of the Series C financing to $ 37 million.",
        "TetraLogic Pharmaceuticals Expands Series C Financing with New Investor Pfizer Ventures with Investment of $ 5 Million Incrasing Total Series C Financing to $ 32 Million." ;
    ns1:documentTitle "TetraLogic Pharmaceuticals Expands Series C Financing with New Investor Pfizer Ventures with Investment of $5 Million Incrasing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/tetralogic-pharmaceuticals-expands-series-c-financing-new-investor-pfizer-ventures> ;
    ns1:foundName "investment" ;
    ns1:name "investment" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2365171/Tetralogic_Pharmaceuticals> ;
    ns1:targetDetails "Series C" ;
    ns1:valueRaw "$ 32 Million",
        "$ 37 million",
        "$ 5 million" ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "United States" .

